diff --git a/README.md b/README.md index 41da7ee1..b22b74ad 100644 --- a/README.md +++ b/README.md @@ -36,7 +36,15 @@ This project contains the released versions of the JSON-LD schemas for the [Cancer Complexity Knowledge Portal] (CCKP), and more broadly, MC2 Center. You can learn more about the schemas/data models and other aspects of this project in our portal documentation - coming soon! The MC2 Center data model -is in both CSV and JSON-LD format. +is in both CSV and JSON-LD format, and individual entity schemas are also +exported as standalone JSON Schemas in `./json_schemas`. + +Beyond the original entity types (Dataset, Study, Publication, Grant, +Educational Resource, File, Tool, Person), the model also covers Biospecimen, +Individual, and Model (non-human organism/cell line) entities, as well as +assay-level metadata for imaging (multiplexed/single-channel imaging), +NanoString GeoMx Digital Spatial Profiler (DSP) spatial transcriptomics, +bulk/single-cell sequencing, and 10x Genomics Visium spatial transcriptomics. ## Folder Structure diff --git a/all_valid_values.csv b/all_valid_values.csv index fc921c63..2e65425b 100644 --- a/all_valid_values.csv +++ b/all_valid_values.csv @@ -7939,6 +7939,7 @@ treatmentType,Brachytherapy, treatmentType,Cellular Therapy, treatmentType,Chemotherapy, treatmentType,Concurrent Chemoradiation, +treatmentType,Control, treatmentType,Conventional Radiotherapy, treatmentType,Electron Beam Radiation Therapy, treatmentType,External Beam Radiation Therapy, @@ -10836,30 +10837,30 @@ rtPrimer,Poly-dT, rtPrimer,Feature barcoding, rtPrimer,Random, duo,Pending Annotation, -duo,GRU, -duo,PS, -duo,GSO, -duo,RTN, -duo,CC, -duo,NMDS, -duo,NRES, -duo,NPU, -duo,DUM, -duo,POA, -duo,NCU, -duo,NPUNCU, -duo,NPOA, -duo,IRB, -duo,HMB, -duo,PUB, -duo,USE, -duo,COL, -duo,RST, -duo,TSM, -duo,MOR, -duo,IST, -duo,GSR, -duo,DSR, +duo,DUO:0000042, +duo,DUO:0000027, +duo,DUO:0000016, +duo,DUO:0000029, +duo,DUO:0000043, +duo,DUO:0000015, +duo,DUO:0000004, +duo,DUO:0000045, +duo,DUO:0000017, +duo,DUO:0000011, +duo,DUO:0000046, +duo,DUO:0000018, +duo,DUO:0000044, +duo,DUO:0000021, +duo,DUO:0000006, +duo,DUO:0000019, +duo,DUO:0000026, +duo,DUO:0000020, +duo,DUO:0000012, +duo,DUO:0000025, +duo,DUO:0000024, +duo,DUO:0000028, +duo,DUO:0000022, +duo,DUO:0000007, duo,DUOPlus1, duo,DUOPlus2, duo,DUOPlus3, diff --git a/docs/index.md b/docs/index.md index 74818eaa..9bedd0c9 100644 --- a/docs/index.md +++ b/docs/index.md @@ -26,6 +26,12 @@ The platform supports the documentation and upload of a variety of resource type | **Files** | Individual research files to organize and reference within projects. | | **Tools** | Software applications used for data analysis, visualization, and workflow automation. | | **Persons** | Profiles of key individuals involved in research projects, including investigators and contributors. | +| **Biospecimens** | Tissue, tumor, fluid, and other physical samples, including acquisition, preservation, and pathology details. | +| **Individuals & Models** | Human participants and the non-human organisms, cell lines, or organoids used as experimental models. | +| **Imaging** | Multiplexed and single-channel imaging data, from raw images through channel, segmentation, and summary statistic levels. | +| **NanoString GeoMx** | Digital Spatial Profiler (DSP) spatial transcriptomics data, including ROI/segment annotations and processed expression levels. | +| **Sequencing** | Bulk and single-cell sequencing data, including RNA-specific library metadata and processed matrices. | +| **10x Visium** | 10x Genomics Visium spatial transcriptomics data, from slide/capture-area metadata through processed levels. | By documenting your resources here, you make your work more discoverable, reproducible, and impactful. @@ -81,4 +87,4 @@ You can also read our [contribution guidelines] if you'd like to submit updates [contribution guidelines]: https://mc2-center.github.io/data-models/contributing/ -[let us know]: https://github.com/mc2-center/data-models/issues/new?assignees=aditigopalan&labels=bug&projects=&template=bug-report.md&title=%5Bbug%5D+ \ No newline at end of file +[let us know]: https://github.com/mc2-center/data-models/issues/new?assignees=data-ingress-team&labels=bug&projects=&template=bug-report.md&title=%5Bbug%5D+ \ No newline at end of file diff --git a/docs/model/DataDSP.md b/docs/model/DataDSP.md index 5cbb5a62..6ba36baa 100644 --- a/docs/model/DataDSP.md +++ b/docs/model/DataDSP.md @@ -43,4 +43,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('sharingPlans/reference.csv') }} \ No newline at end of file +{{ read_csv('sharingPlans/reference.csv', keep_default_na=False) }} \ No newline at end of file diff --git a/docs/model/biospecimen.md b/docs/model/biospecimen.md new file mode 100644 index 00000000..75d19711 --- /dev/null +++ b/docs/model/biospecimen.md @@ -0,0 +1,28 @@ +A **Biospecimen** entry documents a tissue, tumor, fluid, or other physical sample collected from an individual or a model organism/cell line for use in MC2 Center-supported research. Biospecimen metadata captures how and when a specimen was acquired, its composition and preservation, and clinically relevant context such as disease type, tumor grade, morphology, and treatment history at the time of collection. + +This model outlines the key attributes needed to track a biospecimen from acquisition through processing, including its relationship to a parent individual, model, or another biospecimen (for derived specimens), as well as the pathology and preservation details that downstream assays depend on. + + +## Why You Should Contribute Biospecimen Entries + +Contributing biospecimen entries ensures that every downstream dataset (imaging, sequencing, spatial transcriptomics, etc.) can be traced back to a well-documented physical sample. Complete biospecimen metadata makes it possible to reproduce experiments, correctly interpret assay results in their clinical context, and avoid ambiguity when the same specimen is used across multiple studies or assay types. + + +### Who Should Be Contributing Biospecimen Entries? + +1. **Biobank and Specimen Coordinators** – Ensure specimens are consistently tracked from acquisition through distribution to assay cores. +2. **Pathologists and Histology Staff** – Provide accurate morphology, tumor status, and preservation details that inform downstream analysis. +3. **Research Staff and Lab Managers** – Maintain the link between specimens, the individuals/models they were derived from, and the assays performed on them. +4. **Data Managers** – Ensure biospecimen records are complete before associated assay-level data (imaging, sequencing, etc.) is submitted. + + +## Download Template + +You can download the [Biospecimen entry template](https://github.com/mc2-center/data-models/raw/main/templates/Biospecimen.csv), which includes all required fields, to streamline the data entry process. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('biospecimen/reference.csv', keep_default_na=False) }} diff --git a/docs/model/dataset.md b/docs/model/dataset.md index 94df61b3..5071ec8b 100644 --- a/docs/model/dataset.md +++ b/docs/model/dataset.md @@ -47,4 +47,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('dataset/reference.csv') }} +{{ read_csv('dataset/reference.csv', keep_default_na=False) }} diff --git a/docs/model/education.md b/docs/model/education.md index aa4114c5..a1648b20 100644 --- a/docs/model/education.md +++ b/docs/model/education.md @@ -49,4 +49,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('education/reference.csv') }} +{{ read_csv('education/reference.csv', keep_default_na=False) }} diff --git a/docs/model/file.md b/docs/model/file.md index 178f37a0..e5e218e4 100644 --- a/docs/model/file.md +++ b/docs/model/file.md @@ -49,4 +49,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('file/reference.csv') }} \ No newline at end of file +{{ read_csv('file/reference.csv', keep_default_na=False) }} \ No newline at end of file diff --git a/docs/model/geomxAux.md b/docs/model/geomxAux.md new file mode 100644 index 00000000..1fbcc7a7 --- /dev/null +++ b/docs/model/geomxAux.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx Auxiliary Files** entry documents the supporting, non-image and non-count files that accompany a NanoString GeoMx Digital Spatial Profiler (DSP) experiment. Rather than describing the imaging or expression data itself, this module tracks the auxiliary artifacts needed to fully interpret and reproduce a GeoMx run: the ROI/segment annotation file, the PKC probe kit configuration file, the lab worksheet(s) generated during the run, and the DSP `config.ini` file. + +These files are typically produced automatically by the GeoMx DSP instrument and software alongside the imaging and sequencing/count data, but they are easy to overlook when depositing a dataset. Capturing their Synapse identifiers here ensures that anyone reusing the imaging or expression data (Levels 1–3) can also locate the exact probe configuration, worksheet, and run settings that produced it. + + +## Why You Should Contribute NanoString GeoMx Auxiliary Files Entries + +Contributing auxiliary file entries ensures that the configuration and worksheet files needed to interpret or reproduce a GeoMx DSP run are not lost or disconnected from the primary imaging and expression data, making the full experiment traceable and reusable by others. + + +### Who Should Be Contributing NanoString GeoMx Auxiliary Files Entries? + +1. **Core Facility Staff** – Deposit the PKC, config, and worksheet files generated directly by the GeoMx DSP instrument. +2. **Spatial Biology Researchers** – Ensure auxiliary files are linked to the correct experiment and biospecimens they support. +3. **Computational Analysts** – Confirm that the probe kit and configuration files needed to reprocess or validate results are available and correctly referenced. +4. **Data Managers** – Track auxiliary file completeness alongside the imaging and expression data deposited for a study. + + +## Download Template + +You can download the [NanoStringGeoMxAuxiliaryFiles CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMxAuxiliaryFiles.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxAux/reference.csv', keep_default_na=False) }} diff --git a/docs/model/geomxImaging.md b/docs/model/geomxImaging.md new file mode 100644 index 00000000..c60e3e90 --- /dev/null +++ b/docs/model/geomxImaging.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx Imaging** entry documents the images acquired directly by the GeoMx Digital Spatial Profiler (DSP) instrument during a spatial profiling run. This includes the standard file-level descriptors (format, species, design, assay) shared across the data model, along with GeoMx-specific attributes such as the imaging channel names captured and the Synapse ID(s) of tabular files containing the coordinate points for each Area of Illumination (AOI) found in the image. + +Because GeoMx images can vary widely in acquisition hardware and configuration, this module also captures detailed instrument- and file-format-level imaging metadata: platform model and manufacturer, acquisition software, objective and magnification, working distance, immersion type, field-of-view size and index, physical pixel size and dimension order, bit depth, plane count, and timepoint/z-stack structure. Imaging entries link forward to the sequencing outputs derived from the same run (Level 1 and Level 2) and to the ROI/segment annotations and biospecimen that were imaged, anchoring the full GeoMx data provenance chain. + + +## Why You Should Contribute NanoString GeoMx Imaging Entries + +Contributing imaging entries ensures that the raw scan images underlying a GeoMx DSP experiment are properly cataloged with the acquisition and instrument details needed to interpret them, and are traceable to the ROIs, segments, and downstream expression data they informed. + + +### Who Should Be Contributing NanoString GeoMx Imaging Entries? + +1. **Core Facility Staff** – Record the instrument, software, and acquisition settings used to capture GeoMx scan images. +2. **Spatial Biology Researchers** – Confirm imaging metadata accurately reflects the tissue, channels, and regions profiled. +3. **Computational Imaging Analysts** – Ensure channel names and AOI coordinate files are correctly linked so downstream expression data can be traced back to specific image regions. +4. **Data Managers** – Track imaging files as they are deposited alongside sequencing and annotation data for a study. + + +## Download Template + +You can download the [NanoStringGeoMxDSPImaging CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMxDSPImaging.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxImaging/reference.csv', keep_default_na=False) }} diff --git a/docs/model/geomxLevel1.md b/docs/model/geomxLevel1.md new file mode 100644 index 00000000..9ed515bc --- /dev/null +++ b/docs/model/geomxLevel1.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx Level 1** entry describes the raw sequencing files produced from a GeoMx Digital Spatial Profiler (DSP) experiment, prior to alignment or count conversion. This includes the assay type used in the DSP pipeline (RNA or Protein, run via nCounter or NGS) along with detailed next-generation sequencing (NGS) library metadata: library strategy, source material and molecule, selection method, layout, sequencing platform, read length, raw read counts, unique bases, sequencing coverage, and the library preparation kit name, vendor, and version. + +Level 1 entries represent the earliest and most complete record of what was sequenced during a GeoMx run, and they anchor the full data provenance chain — every downstream processed file (Level 2 count conversions and Level 3 processed counts) traces back to the raw reads documented here. + + +## Why You Should Contribute NanoString GeoMx Level 1 Entries + +Contributing Level 1 entries ensures that raw GeoMx sequencing outputs are properly cataloged with the library preparation and sequencing details needed to interpret them, and are traceable back to the biospecimen and ROI/segment they were derived from. + + +### Who Should Be Contributing NanoString GeoMx Level 1 Entries? + +1. **Core Facility Staff** – Document the library preparation kit, sequencing platform, and run parameters used to generate raw reads. +2. **Spatial Biology Researchers** – Confirm that raw sequencing files are correctly linked to the biospecimen and segments profiled. +3. **Computational Analysts** – Ensure sequencing metadata is complete so raw files can be correctly processed into Level 2 and Level 3 outputs. +4. **Data Managers** – Track raw sequencing files as they are deposited to ensure completeness of the GeoMx data provenance chain. + + +## Download Template + +You can download the [NanoStringGeoMxDSPLevel1 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMxDSPLevel1.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxLevel1/reference.csv', keep_default_na=False) }} diff --git a/docs/model/geomxLevel2.md b/docs/model/geomxLevel2.md new file mode 100644 index 00000000..fcecbfee --- /dev/null +++ b/docs/model/geomxLevel2.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx Level 2** entry documents processed count conversion files (DCC/RCC) derived from a GeoMx Level 1 raw sequencing file. This level captures the same core library preparation and sequencing platform metadata as Level 1, along with the read-processing metrics generated during count conversion: stitched reads, aligned reads, deduplicated reads, trimmed reads, percent reads mapping at Q30 (MapQ30), unique bases, sequencing coverage, the genomic reference used, and the software and version that performed the conversion. + +Level 2 entries represent the intermediate step between raw sequencing reads and analysis-ready processed counts, preserving a clear lineage back to the Level 1 raw reads that produced them while capturing the alignment and deduplication metrics needed to assess data quality. + + +## Why You Should Contribute NanoString GeoMx Level 2 Entries + +Contributing Level 2 entries ensures that the read-processing and alignment steps between raw reads and final count data are documented with enough detail for others to assess data quality and trace processed counts back to their source reads. + + +### Who Should Be Contributing NanoString GeoMx Level 2 Entries? + +1. **Computational Analysts** – Document the software, genomic reference, and alignment/deduplication metrics used to generate count conversion files. +2. **Core Facility Staff** – Provide the sequencing platform and library details carried through from Level 1. +3. **Bioinformatics Pipeline Developers** – Record workflow and software versions to support reproducibility of the count conversion step. +4. **Data Managers** – Maintain consistent, portal-ready metadata linking Level 1 raw reads to Level 2 processed outputs. + + +## Download Template + +You can download the [NanoStringGeoMxDSPLevel2 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMxDSPLevel2.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxLevel2/reference.csv', keep_default_na=False) }} diff --git a/docs/model/geomxLevel3.md b/docs/model/geomxLevel3.md new file mode 100644 index 00000000..ee5ca95e --- /dev/null +++ b/docs/model/geomxLevel3.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx Level 3** entry documents the fully processed count data produced by the NanoString GeoMx DSP pipeline, such as final probe- or target-level expression matrices. This level captures the unique probe and unique target counts represented in the file, the matrix type (e.g. raw, normalized, or background-subtracted counts), and the software, workflow, and parameters used to generate the processed output, including a link to the workflow for reproducibility. + +Level 3 entries represent the analysis-ready data products most commonly used for downstream statistical analysis, while still preserving a clear lineage back to the Level 2 count conversion and Level 1 raw reads that produced them. + + +## Why You Should Contribute NanoString GeoMx Level 3 Entries + +Contributing Level 3 entries ensures that processed count data is documented with enough workflow and provenance detail for others to understand exactly how it was derived, and to confidently reuse it in downstream analyses shared through the CCKP. + + +### Who Should Be Contributing NanoString GeoMx Level 3 Entries? + +1. **Computational Analysts** – Document the workflow, parameters, and matrix type used to generate processed count data. +2. **Bioinformatics Pipeline Developers** – Record the software and workflow versions that produced the processed outputs, supporting reproducibility. +3. **Spatial Biology Researchers** – Track which processed data products correspond to which raw reads and ROI/segments. +4. **Data Managers** – Maintain consistent, portal-ready metadata for processed GeoMx outputs shared through the CCKP. + + +## Download Template + +You can download the [NanoStringGeoMxDSPLevel3 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMxDSPLevel3.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxLevel3/reference.csv', keep_default_na=False) }} diff --git a/docs/model/geomxRoi.md b/docs/model/geomxRoi.md new file mode 100644 index 00000000..fa24926e --- /dev/null +++ b/docs/model/geomxRoi.md @@ -0,0 +1,28 @@ +A **NanoString GeoMx ROI Segment Annotation** entry documents the Region of Interest (ROI) and Area of Illumination (AOI)/segment metadata generated during a GeoMx Digital Spatial Profiler (DSP) run. Each entry reports one assayed biospecimen per row, together with the ROI and AOI names and coordinates, scan- and slide-level identifiers, and quality control status as reported by the GeoMx DSP application. + +Beyond spatial location, this module captures the segment-level quality metrics used to assess and normalize GeoMx data: binding density, positive normalization factor, surface area, nuclei count, tissue stain used to select ROI boundaries, and the negative control, no-template-control, and limit-of-quantification values used for background correction. It also carries the sequencing quality metrics (raw, stitched, aligned, deduplicated, and trimmed read counts, coverage, and MapQ30) associated with each segment, linking spatial and sequencing quality control together in a single record. + + +## Why You Should Contribute NanoString GeoMx ROI Segment Annotation Entries + +Contributing ROI/segment annotation entries ensures that the spatial location, quality control metrics, and normalization factors behind every GeoMx expression measurement are documented and traceable back to the specific biospecimen, ROI, and AOI that produced them. + + +### Who Should Be Contributing NanoString GeoMx ROI Segment Annotation Entries? + +1. **Spatial Biology Researchers** – Confirm that ROI and AOI selections accurately reflect the biological regions of interest being studied. +2. **Core Facility Staff** – Record the scan, slide, and segment QC metrics reported directly by the GeoMx DSP application. +3. **Computational Analysts** – Ensure normalization factors and QC metrics are complete and correctly linked so downstream expression data can be properly background-corrected and interpreted. +4. **Data Managers** – Track ROI/segment annotations alongside the imaging and sequencing data deposited for a study. + + +## Download Template + +You can download the [NanoStringGeoMXROISegmentAnnotation CSV template](https://github.com/mc2-center/data-models/raw/main/templates/NanoStringGeoMXROISegmentAnnotation.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('geomxRoi/reference.csv', keep_default_na=False) }} diff --git a/docs/model/grant.md b/docs/model/grant.md index 3cdd94c5..23c196fe 100644 --- a/docs/model/grant.md +++ b/docs/model/grant.md @@ -53,4 +53,4 @@ It is important to note that where these examples can generally guide you on the Below is the full field reference table with attributes and their descriptions. -{{ read_csv('grant/reference.csv') }} +{{ read_csv('grant/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingChannel.md b/docs/model/imagingChannel.md new file mode 100644 index 00000000..a0c9c0e1 --- /dev/null +++ b/docs/model/imagingChannel.md @@ -0,0 +1,28 @@ +An **Imaging Channel** entry describes the channel-level metadata for a single detection channel within a multiplexed or multi-channel imaging experiment, such as a cycle in CODEX/CyCIF, a fluorescence channel in MxIF, or a metal-tagged channel in Imaging Mass Cytometry (IMC). Rather than describing an image file itself, this module captures the reagents, targets, and physical detection parameters (fluorophore, metal isotope, oligo barcode, excitation/emission wavelengths) associated with one channel, along with the antibody or probe used to generate signal in that channel. + +Because a single imaging experiment can involve dozens of channels across multiple staining cycles, Imaging Channel entries are typically submitted as a table with one row per channel per assay, and are then linked from the imaging file-level modules (Imaging Level 1 and Imaging Level 2) via the `ImagingChannel Key`. This separation keeps channel/antibody metadata reusable and consistent across the many image files that share the same channel configuration. + + +## Why You Should Contribute Imaging Channel Entries + +Contributing Imaging Channel entries ensures that the antibodies, probes, and detection parameters behind each signal in a multiplexed image are fully traceable — which is essential for reproducing staining panels, troubleshooting failed channels, and enabling downstream re-analysis of multiplexed imaging data by other groups. + + +### Who Should Be Contributing Imaging Channel Entries? + +1. **Imaging Scientists** – Document the antibody panel, fluorophore, or isotope assignments used to generate each channel of a multiplexed imaging experiment. +2. **Core Facility Staff** – Record the reagent lot numbers, vendors, and detection settings applied during acquisition on shared imaging instrumentation. +3. **Computational Imaging Analysts** – Ensure channel metadata is complete and consistent so that channel-to-marker mappings can be programmatically resolved during analysis. +4. **Lab Managers** – Maintain a durable record of antibody clones, dilutions, and QC outcomes across staining cycles and experiments. + + +## Download Template + +You can download the [ImagingChannel CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingChannel.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingChannel/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingLevel1.md b/docs/model/imagingLevel1.md new file mode 100644 index 00000000..d06f4e36 --- /dev/null +++ b/docs/model/imagingLevel1.md @@ -0,0 +1,28 @@ +An **Imaging Level 1** entry describes a raw imaging data file — the unprocessed output of a microscope, scanner, or other imaging platform, prior to any quality control, co-registration, or downstream processing. This is the earliest and most complete record of what was captured during an imaging experiment, and includes the acquisition context (assay type, platform model and manufacturer, acquisition software, protocol link) along with standard file-level descriptors such as file format, species, and design. + +Because raw images are typically generated per-channel or per-acquisition, Imaging Level 1 entries link back to the corresponding channel metadata via the `ImagingChannel Key`, and forward to the biospecimen that was imaged via `Biospecimen Key`. This level anchors the full imaging data provenance chain: every downstream processed image, segmentation, or feature array (Imaging Levels 2–4) traces back to the raw file(s) documented here. + + +## Why You Should Contribute Imaging Level 1 Entries + +Contributing Imaging Level 1 entries ensures that raw imaging outputs are properly cataloged, discoverable, and traceable back to the specimen and acquisition settings that produced them — the foundation that all subsequent image processing and analysis depends on. + + +### Who Should Be Contributing Imaging Level 1 Entries? + +1. **Imaging Scientists** – Document raw image files and the acquisition settings used to generate them. +2. **Core Facility Staff** – Record platform, instrument, and software details at the point of image acquisition. +3. **Computational Imaging Analysts** – Ensure raw file metadata is complete so it can be correctly linked to downstream processed and derived imaging products. +4. **Data Managers** – Track raw imaging files as they are deposited to ensure completeness of the imaging data provenance chain. + + +## Download Template + +You can download the [ImagingLevel1 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingLevel1.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingLevel1/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingLevel2.md b/docs/model/imagingLevel2.md new file mode 100644 index 00000000..6110369d --- /dev/null +++ b/docs/model/imagingLevel2.md @@ -0,0 +1,28 @@ +An **Imaging Level 2** entry describes raw or pre-processed image data that carries detailed image-format and acquisition metadata beyond what is captured at Level 1 — including optical parameters (objective, magnification, numerical aperture, working distance, immersion type), pixel and physical dimensions (X/Y/Z size, pixel type, plane count, channel size), and structural properties of the image file (whether it is pyramidal, contains a Z-stack, or a time series). This level is intended to describe the image as a technical object in detail, capturing everything needed to correctly interpret its pixel data. + +Imaging Level 2 entries link to the corresponding raw file via `ImagingLevel1 Key` and to channel metadata via `ImagingChannel Key`, tying detailed image structure back to both its originating acquisition and the channel(s) it contains. This level is a key input for any downstream co-registration, segmentation, or feature extraction that depends on precise knowledge of image geometry and pixel encoding. + + +## Why You Should Contribute Imaging Level 2 Entries + +Contributing Imaging Level 2 entries ensures that the technical structure of each image file — its dimensions, pixel encoding, and optical acquisition parameters — is fully documented, which is essential for correctly loading, interpreting, and reprocessing multi-dimensional imaging data. + + +### Who Should Be Contributing Imaging Level 2 Entries? + +1. **Imaging Scientists** – Document detailed acquisition and optical parameters associated with each image file. +2. **Core Facility Staff** – Record instrument-specific settings such as objective, magnification, and immersion type at time of capture. +3. **Computational Imaging Analysts** – Ensure image geometry and pixel encoding metadata is accurate so images can be correctly parsed and processed downstream. +4. **Data Managers** – Track pre-processed image files and their associated technical metadata for reproducibility. + + +## Download Template + +You can download the [ImagingLevel2 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingLevel2.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingLevel2/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingLevel3Image.md b/docs/model/imagingLevel3Image.md new file mode 100644 index 00000000..51757a77 --- /dev/null +++ b/docs/model/imagingLevel3Image.md @@ -0,0 +1,28 @@ +An **Imaging Level 3 (Image)** entry describes quality-controlled or co-registered image data — imagery that has been processed beyond the raw and pre-processed stages to correct artifacts, align channels or cycles, and confirm suitability for downstream analysis. It carries the same detailed image-format metadata as Imaging Level 2 (optical parameters, pixel dimensions, pyramid/Z-stack/timeseries flags, and pixel encoding), reflecting the state of the image after QC and/or co-registration have been applied. + +Imaging Level 3 (Image) entries link back to the pre-processed image via `ImagingLevel2 Key` and to the relevant channel via `ImagingChannel Key`, preserving a clear processing lineage from raw acquisition through to analysis-ready imagery. This level typically serves as the direct input to segmentation (Imaging Level 3 Segments) and downstream feature extraction (Imaging Level 4). + + +## Why You Should Contribute Imaging Level 3 (Image) Entries + +Contributing Imaging Level 3 (Image) entries ensures that quality-controlled and co-registered imagery is clearly distinguished from raw data, with full traceability back to its source image — supporting confident reuse of processed images in downstream segmentation and analysis. + + +### Who Should Be Contributing Imaging Level 3 (Image) Entries? + +1. **Computational Imaging Analysts** – Document QC and co-registration outcomes and the resulting processed image files. +2. **Imaging Scientists** – Verify that processing steps applied to raw images are accurately reflected in the metadata. +3. **Core Facility Staff** – Confirm image quality metrics and processing parameters used prior to downstream analysis. +4. **Data Managers** – Track processed image files to maintain a complete and auditable imaging data lineage. + + +## Download Template + +You can download the [ImagingLevel3Image CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingLevel3Image.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingLevel3Image/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingLevel3Segments.md b/docs/model/imagingLevel3Segments.md new file mode 100644 index 00000000..79fab716 --- /dev/null +++ b/docs/model/imagingLevel3Segments.md @@ -0,0 +1,28 @@ +An **Imaging Level 3 (Segments)** entry describes image segmentation mask information — the output of algorithms that delineate objects of interest (such as nuclei, cytoplasm, plasma membrane, or whole cells) within a processed image. Rather than pixel intensity data, this module captures how segmentation results are stored (mask, outline, polygon, probability map, or point representation), the object class being segmented, the number of objects identified, and a pointer to the parameter file needed to reproduce the segmentation. + +Imaging Level 3 (Segments) entries link to both the pre-processed image (`ImagingLevel2 Key`) and the QC'd/co-registered image (`ImagingLevel3Image Key`) that the segmentation was derived from. Segmentation results documented here are typically the direct input to object-level feature extraction and summary statistics captured in Imaging Level 4. + + +## Why You Should Contribute Imaging Level 3 (Segments) Entries + +Contributing Imaging Level 3 (Segments) entries ensures that segmentation outputs — and the parameters used to generate them — are documented clearly enough for others to reproduce, validate, or build on object-level analyses without re-running segmentation from scratch. + + +### Who Should Be Contributing Imaging Level 3 (Segments) Entries? + +1. **Computational Imaging Analysts** – Document segmentation algorithms, parameters, and resulting object classes and counts. +2. **Imaging Scientists** – Confirm that the object classes and segmentation representations accurately reflect the underlying biology. +3. **Core Facility Staff** – Provide context on the imaging assay driving segmentation choices (e.g. nuclear vs. whole-cell masks). +4. **Data Managers** – Track segmentation output files and their associated parameter files for reproducibility. + + +## Download Template + +You can download the [ImagingLevel3Segments CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingLevel3Segments.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingLevel3Segments/reference.csv', keep_default_na=False) }} diff --git a/docs/model/imagingLevel4.md b/docs/model/imagingLevel4.md new file mode 100644 index 00000000..929c8cb2 --- /dev/null +++ b/docs/model/imagingLevel4.md @@ -0,0 +1,28 @@ +An **Imaging Level 4** entry describes derived imaging data in the form of an object-by-feature array — the quantitative output produced after segmented objects (e.g. cells) have had their features (e.g. per-channel marker intensities, morphology) extracted and summarized. Rather than image or mask files, this module captures tabular, analysis-ready data: the number of objects and features described, the object class involved, and the summary statistic (mean, median, or otherwise) used to aggregate feature values per object. + +Imaging Level 4 entries reference the full processing lineage that produced them, linking back to the pre-processed image (`ImagingLevel2 Key`), the QC'd/co-registered image (`ImagingLevel3Image Key`), and the segmentation used (`ImagingLevel3Segments Key`). This level typically represents the final, most analysis-ready product of the imaging pipeline, suitable for downstream statistical or machine learning analyses. + + +## Why You Should Contribute Imaging Level 4 Entries + +Contributing Imaging Level 4 entries ensures that derived, object-level feature data is documented with a clear link back to the images and segmentations that produced it, making quantitative imaging results reusable and interpretable by other researchers. + + +### Who Should Be Contributing Imaging Level 4 Entries? + +1. **Computational Imaging Analysts** – Document feature extraction pipelines and the resulting object-by-feature arrays. +2. **Imaging Scientists** – Confirm that extracted features and summary statistics align with the biological question being addressed. +3. **Data Scientists** – Ensure derived feature data is complete and well-annotated for downstream statistical or machine learning analyses. +4. **Data Managers** – Track derived data files to maintain a complete record from raw image through to final quantitative output. + + +## Download Template + +You can download the [ImagingLevel4 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/ImagingLevel4.csv) to streamline data entry. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('imagingLevel4/reference.csv', keep_default_na=False) }} diff --git a/docs/model/individual.md b/docs/model/individual.md new file mode 100644 index 00000000..fc11eb08 --- /dev/null +++ b/docs/model/individual.md @@ -0,0 +1,28 @@ +An **Individual** entry documents a human participant (or the source patient behind a derived model) from whom biospecimens were collected for MC2 Center-supported research. Individual metadata captures demographic information (sex, gender), diagnosis and staging at the individual level, and longitudinal clinical outcomes such as treatment history, recurrence, and vital status. + +This model outlines the key attributes needed to describe an individual independent of any single specimen or assay, so that clinical context collected once can be linked across every biospecimen, model, and dataset derived from that individual. + + +## Why You Should Contribute Individual Entries + +Contributing individual entries ensures that clinical and demographic context is recorded once and consistently reused across every biospecimen and downstream dataset tied to that person, rather than being duplicated or left out of assay-level metadata. This supports accurate cohort analysis, reduces re-collection of the same clinical details, and helps ensure patient privacy is respected through consistent de-identified identifiers. + + +### Who Should Be Contributing Individual Entries? + +1. **Clinical Research Coordinators** – Ensure demographic and diagnosis information is accurately captured at enrollment. +2. **Data Managers** – Maintain the individual-level record that biospecimen and model entries key off of. +3. **Principal Investigators (PIs)** – Ensure longitudinal outcomes (treatment response, recurrence, vital status) are kept up to date as a study progresses. +4. **Biobank Coordinators** – Link individuals to the biospecimens collected from them. + + +## Download Template + +You can download the [Individual entry template](https://github.com/mc2-center/data-models/raw/main/templates/Individual.csv), which includes all required fields, to streamline the data entry process. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('individual/reference.csv', keep_default_na=False) }} diff --git a/docs/model/model.md b/docs/model/model.md new file mode 100644 index 00000000..5d9cb670 --- /dev/null +++ b/docs/model/model.md @@ -0,0 +1,28 @@ +A **Model** entry documents a non-human organism (e.g. mouse, zebrafish) or a cell line/organoid used as an experimental stand-in for human disease in MC2 Center-supported research. Model metadata captures how the model was derived or acquired (e.g. patient-derived xenograft, cell line, genetically engineered model), its genotype, and the treatment history applied to it during experiments. + +This model outlines the key attributes needed to describe a model system, including its link back to the individual it was derived from (when applicable), so that biospecimens and assay data collected from the model can be traced to both the model itself and its clinical origin. + + +## Why You Should Contribute Model Entries + +Contributing model entries ensures that experimental findings generated from mouse models, cell lines, organoids, and other model systems can be correctly attributed to a well-documented source, including how faithfully the model represents the original patient disease. This supports reproducibility and allows other researchers to evaluate whether a given model system is appropriate for their own experiments. + + +### Who Should Be Contributing Model Entries? + +1. **Model System Core Staff** – Document how a model was generated, acquired, and maintained (e.g. PDX, cell line, genetically engineered model). +2. **Research Staff and Lab Managers** – Track treatment and experimental history applied to a model over time. +3. **Principal Investigators (PIs)** – Ensure model provenance and its relationship to the source individual is properly documented. +4. **Data Managers** – Maintain the model-level record that biospecimen entries derived from the model key off of. + + +## Download Template + +You can download the [Model entry template](https://github.com/mc2-center/data-models/raw/main/templates/Model.csv), which includes all required fields, to streamline the data entry process. + + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('model/reference.csv', keep_default_na=False) }} diff --git a/docs/model/person.md b/docs/model/person.md index 32349960..c1f515a9 100644 --- a/docs/model/person.md +++ b/docs/model/person.md @@ -53,4 +53,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('person/reference.csv') }} \ No newline at end of file +{{ read_csv('person/reference.csv', keep_default_na=False) }} \ No newline at end of file diff --git a/docs/model/publication.md b/docs/model/publication.md index 5b288a14..88cd9ed0 100644 --- a/docs/model/publication.md +++ b/docs/model/publication.md @@ -48,4 +48,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('publication/reference.csv') }} \ No newline at end of file +{{ read_csv('publication/reference.csv', keep_default_na=False) }} \ No newline at end of file diff --git a/docs/model/sequencingLevel1.md b/docs/model/sequencingLevel1.md new file mode 100644 index 00000000..4f4a27bd --- /dev/null +++ b/docs/model/sequencingLevel1.md @@ -0,0 +1,24 @@ +A **Sequencing Level 1** entry documents the raw, unaligned sequencing reads produced directly by a sequencer, before any downstream processing or alignment has been applied. This level captures the file itself (e.g., a FASTQ file) alongside the biospecimen, dataset, and study context it belongs to, along with next-generation sequencing (NGS) library and platform metadata such as library strategy, selection method, read length, raw read counts, and sequencing coverage. + +Because Level 1 files represent the earliest, most foundational data product of a sequencing experiment, complete and accurate metadata at this level is what makes every downstream processing step (alignment, quantification, variant calling) traceable back to its source. Missing or incomplete library and platform details at this stage are difficult to reconstruct later. + +## Why You Should Contribute Sequencing Level 1 Entries + +Contributing Sequencing Level 1 entries ensures that raw sequencing outputs are properly linked to their originating biospecimens and are described with enough library preparation and platform detail to support reproducible reprocessing, reanalysis, and integration with other datasets on the Cancer Complexity Knowledge Portal (CCKP). + +### Who Should Be Contributing Sequencing Level 1 Entries? + +1. **Sequencing Core Staff** – Capture library preparation and instrument run details at the point of generation, when they are most accurate. +2. **Computational Genomics Analysts** – Ensure raw file metadata is complete before it feeds into alignment and processing pipelines. +3. **Research Staff and Lab Managers** – Track which raw sequencing files correspond to which biospecimens and studies. +4. **Data Managers** – Maintain consistent, portal-ready metadata for raw sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [SequencingLevel1 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/SequencingLevel1.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('sequencingLevel1/reference.csv', keep_default_na=False) }} diff --git a/docs/model/sequencingLevel2.md b/docs/model/sequencingLevel2.md new file mode 100644 index 00000000..70bc9a2d --- /dev/null +++ b/docs/model/sequencingLevel2.md @@ -0,0 +1,24 @@ +A **Sequencing Level 2** entry documents sequencing data that has been aligned to a reference genome. This level builds directly on a Sequencing Level 1 file and adds alignment-specific metrics, such as aligned reads, deduplicated reads, trimmed reads, mapping quality (MapQ30), and the genomic reference and software version used to perform the alignment. + +Level 2 entries make explicit the connection between a raw sequencing file and the processed alignment derived from it, while also capturing the tools and parameters that produced the alignment, which is essential for evaluating data quality and reproducing analyses. + +## Why You Should Contribute Sequencing Level 2 Entries + +Contributing Sequencing Level 2 entries ensures that alignment outputs are traceable to their raw source files and are documented with the quality metrics and software versions needed for others to assess, reproduce, or build on the analysis. + +### Who Should Be Contributing Sequencing Level 2 Entries? + +1. **Computational Genomics Analysts** – Record alignment metrics and software versions immediately after processing pipelines complete. +2. **Sequencing Core Staff** – Confirm that aligned outputs are correctly linked back to the raw files and biospecimens they originated from. +3. **Bioinformatics Pipeline Developers** – Document the genomic reference and workflow versions used, supporting reproducibility across pipeline updates. +4. **Data Managers** – Maintain consistent, portal-ready metadata for aligned sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [SequencingLevel2 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/SequencingLevel2.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('sequencingLevel2/reference.csv', keep_default_na=False) }} diff --git a/docs/model/sequencingLevel3.md b/docs/model/sequencingLevel3.md new file mode 100644 index 00000000..12c82260 --- /dev/null +++ b/docs/model/sequencingLevel3.md @@ -0,0 +1,24 @@ +A **Sequencing Level 3** entry documents further-processed sequencing data derived from a Sequencing Level 2 alignment, such as count matrices or probe-level summaries. This level captures matrix-type metadata (raw, normalized, scaled, or batch-corrected counts), unique probe and target counts, and the workflow, software, and parameters used to generate the processed output. + +Level 3 entries represent the analysis-ready data products most commonly used for downstream statistical analysis, while still preserving a clear lineage back to the Level 2 alignment and Level 1 raw reads that produced them. + +## Why You Should Contribute Sequencing Level 3 Entries + +Contributing Sequencing Level 3 entries ensures that processed count data is documented with enough workflow and provenance detail for others to understand exactly how it was derived, and to confidently reuse it in downstream analyses shared through the CCKP. + +### Who Should Be Contributing Sequencing Level 3 Entries? + +1. **Computational Genomics Analysts** – Document the workflow, parameters, and matrix type used to generate processed count data. +2. **Bioinformatics Pipeline Developers** – Record the software and workflow versions that produced the processed outputs, supporting reproducibility. +3. **Research Staff** – Track which processed data products correspond to which raw and aligned files. +4. **Data Managers** – Maintain consistent, portal-ready metadata for processed sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [SequencingLevel3 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/SequencingLevel3.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('sequencingLevel3/reference.csv', keep_default_na=False) }} diff --git a/docs/model/sequencingRNALevel1.md b/docs/model/sequencingRNALevel1.md new file mode 100644 index 00000000..3295ebc6 --- /dev/null +++ b/docs/model/sequencingRNALevel1.md @@ -0,0 +1,24 @@ +A **Sequencing RNA Level 1** entry documents raw, unaligned RNA sequencing data, extending the general Sequencing Level 1 structure with RNA-specific library metadata. In addition to standard NGS library and platform fields, this level captures RNA-specific details such as end bias (3 prime, 5 prime, or full-length transcript coverage), reverse transcription primer type, RNA integrity number (RIN), and DV200, which describe the quality and construction of the RNA library before sequencing. + +These RNA-specific quality metrics are critical for interpreting downstream expression results, since RNA degradation or library construction choices can significantly affect quantification accuracy. + +## Why You Should Contribute Sequencing RNA Level 1 Entries + +Contributing Sequencing RNA Level 1 entries ensures that raw RNA sequencing outputs carry the library construction and RNA quality metadata needed to properly interpret and reproduce downstream expression analyses shared through the CCKP. + +### Who Should Be Contributing Sequencing RNA Level 1 Entries? + +1. **Sequencing Core Staff** – Record RNA library preparation details and quality metrics (RIN, DV200) at the point of library construction. +2. **Computational Genomics Analysts** – Ensure RNA-specific metadata is available before it is used in expression quantification pipelines. +3. **Research Staff and Lab Managers** – Track which raw RNA sequencing files correspond to which biospecimens and studies. +4. **Data Managers** – Maintain consistent, portal-ready metadata for raw RNA sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [SequencingRNALevel1 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/SequencingRNALevel1.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('sequencingRNALevel1/reference.csv', keep_default_na=False) }} diff --git a/docs/model/study.md b/docs/model/study.md index f3888169..79842b68 100644 --- a/docs/model/study.md +++ b/docs/model/study.md @@ -44,14 +44,14 @@ The table below includes sample values to demonstrate proper attribute usage. | Study De-identification Method Software | Safe Harbor Privacy Software | | Study dbGaP Accession Id | phs000424.v7.p2 | | Study License | CC BY-NC 4.0 | -| Study Data Use Codes | IRB, PUB, HMB | +| Study Data Use Codes | DUO:0000021, DUO:0000019, DUO:0000006 | ## Full Field Reference Below is the full field reference table with attributes and their descriptions. -{{ read_csv('study/reference.csv') }} +{{ read_csv('study/reference.csv', keep_default_na=False) }} ## Test diff --git a/docs/model/tool.md b/docs/model/tool.md index 621385cb..a3dcfa44 100644 --- a/docs/model/tool.md +++ b/docs/model/tool.md @@ -46,4 +46,4 @@ The table below includes sample values to demonstrate proper attribute usage. Below is the full field reference table with attributes and their descriptions. -{{ read_csv('tool/reference.csv') }} +{{ read_csv('tool/reference.csv', keep_default_na=False) }} diff --git a/docs/model/visiumRNAAux.md b/docs/model/visiumRNAAux.md new file mode 100644 index 00000000..9384b228 --- /dev/null +++ b/docs/model/visiumRNAAux.md @@ -0,0 +1,24 @@ +A **10x Visium Auxiliary Files** entry documents supporting data associated with 10x Genomics Visium spatial transcriptomics experiments, such as aligned tissue images, quality control reports, and other files that accompany the primary sequencing and expression outputs of a Visium run. Rather than representing a sequencing or expression level itself, this module links auxiliary artifacts, such as slide images, scale factor files, and QC reports, back to the Visium RNA Level 1 through 4 files, biospecimen, and study they belong to, along with the run, slide, and capture area they were generated from. + +Auxiliary files are often what make a Visium dataset interpretable and reusable: tissue images and QC reports give downstream users the context needed to evaluate spot detection, alignment quality, and tissue morphology alongside the expression data. + +## Why You Should Contribute 10x Visium Auxiliary Files Entries + +Contributing 10x Visium Auxiliary Files entries ensures that the images, scale factors, and quality control artifacts generated during a Visium run are discoverable and properly linked to the sequencing and expression data they support, giving downstream users full context for interpreting spatial results shared through the CCKP. + +### Who Should Be Contributing 10x Visium Auxiliary Files Entries? + +1. **Spatial Biology Researchers** – Document tissue images and slide/capture area context generated during a Visium experiment. +2. **Computational Genomics Analysts** – Record QC reports and scale factor files produced alongside spatial expression processing. +3. **Sequencing Core Staff** – Track which auxiliary files correspond to which Visium run and biospecimen. +4. **Data Managers** – Maintain consistent, portal-ready metadata for auxiliary spatial transcriptomics files shared through the CCKP. + +## Download Template + +You can download the [VisiumAuxiliaryFiles CSV template](https://github.com/mc2-center/data-models/raw/main/templates/VisiumAuxiliaryFiles.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('visiumRNAAux/reference.csv', keep_default_na=False) }} diff --git a/docs/model/visiumRNALevel1.md b/docs/model/visiumRNALevel1.md new file mode 100644 index 00000000..3592f07b --- /dev/null +++ b/docs/model/visiumRNALevel1.md @@ -0,0 +1,24 @@ +A **10x Visium RNA Level 1** entry documents raw RNA sequencing data associated with a Visium spatial transcriptomics spot/slide experiment. In addition to standard NGS library and platform fields, this level captures Visium-specific slide and library metadata, including the Visium run ID, spatial read content (spatial barcode and UMI vs. cDNA), spatial library construction method, capture area, slide version and ID, image re-orientation, and permeabilization time, along with RNA quality metrics such as RIN and DV200. + +Because Visium data links sequencing reads to a specific physical location on a slide, accurate capture of the slide, capture area, and read-structure metadata at this level is essential for correctly reconstructing the spatial context of the data in downstream processing. + +## Why You Should Contribute 10x Visium RNA Level 1 Entries + +Contributing 10x Visium RNA Level 1 entries ensures that raw spatial sequencing reads are documented with the slide, capture area, and library metadata needed to correctly reconstruct spatial context in downstream alignment and analysis shared through the CCKP. + +### Who Should Be Contributing 10x Visium RNA Level 1 Entries? + +1. **Spatial Biology Researchers** – Record slide, capture area, and permeabilization details from the Visium experiment. +2. **Sequencing Core Staff** – Capture library preparation and platform metadata for the spatial sequencing run. +3. **Computational Genomics Analysts** – Ensure raw file and slide metadata is complete before spatial alignment pipelines are run. +4. **Data Managers** – Maintain consistent, portal-ready metadata for raw Visium sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [VisiumRNALevel1 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/VisiumRNALevel1.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('visiumRNALevel1/reference.csv', keep_default_na=False) }} diff --git a/docs/model/visiumRNALevel2.md b/docs/model/visiumRNALevel2.md new file mode 100644 index 00000000..5d35fcf1 --- /dev/null +++ b/docs/model/visiumRNALevel2.md @@ -0,0 +1,24 @@ +A **10x Visium RNA Level 2** entry documents the alignment workflow outputs downstream of a 10x Visium RNA Level 1 file. This level captures the SAM tags used for the unique molecular identifier (UMI) and spatial barcode fields, a link to the spatial barcode whitelist file, whether hard trimming was applied, and the genomic reference, genome annotation, and workflow version used to perform the alignment. + +Level 2 entries make explicit how raw spatial reads were mapped and tagged with their spatial barcodes, preserving the technical details needed to reproduce or audit the alignment step before expression quantification. + +## Why You Should Contribute 10x Visium RNA Level 2 Entries + +Contributing 10x Visium RNA Level 2 entries ensures that the alignment and barcode-tagging workflow applied to spatial sequencing reads is documented with enough detail for others to reproduce or evaluate the analysis shared through the CCKP. + +### Who Should Be Contributing 10x Visium RNA Level 2 Entries? + +1. **Computational Genomics Analysts** – Record alignment tags, genomic reference, and workflow versions used to process spatial reads. +2. **Bioinformatics Pipeline Developers** – Document the spatial barcode whitelist and trimming parameters applied during alignment. +3. **Spatial Biology Researchers** – Confirm that aligned outputs are correctly linked back to the raw Visium run they originated from. +4. **Data Managers** – Maintain consistent, portal-ready metadata for aligned Visium sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [VisiumRNALevel2 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/VisiumRNALevel2.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('visiumRNALevel2/reference.csv', keep_default_na=False) }} diff --git a/docs/model/visiumRNALevel3.md b/docs/model/visiumRNALevel3.md new file mode 100644 index 00000000..58f4a989 --- /dev/null +++ b/docs/model/visiumRNALevel3.md @@ -0,0 +1,24 @@ +A **10x Visium RNA Level 3** entry documents processed spatial transcriptomics data built from a 10x Visium RNA Level 2 alignment together with its associated auxiliary files. This level captures per-spot summary statistics such as spots under tissue, mean reads per spatial spot, median genes and UMI counts per spot, sequencing coverage, and the proportion of reads mapped overall and to the transcriptome, along with the workflow version and file type generated. + +These per-spot quality and summary metrics are what allow downstream users to assess the technical performance of a Visium run (e.g., tissue coverage, sequencing depth per spot) before interpreting the underlying biology. + +## Why You Should Contribute 10x Visium RNA Level 3 Entries + +Contributing 10x Visium RNA Level 3 entries ensures that per-spot quality and summary metrics from a Visium run are documented, giving downstream users the information needed to assess data quality before further spatial analysis shared through the CCKP. + +### Who Should Be Contributing 10x Visium RNA Level 3 Entries? + +1. **Computational Genomics Analysts** – Record per-spot summary statistics and workflow versions produced by processing pipelines. +2. **Spatial Biology Researchers** – Confirm that spot-level quality metrics accurately reflect the tissue and capture area analyzed. +3. **Bioinformatics Pipeline Developers** – Document the file types and workflows used to generate processed spatial outputs. +4. **Data Managers** – Maintain consistent, portal-ready metadata for processed Visium sequencing outputs shared through the CCKP. + +## Download Template + +You can download the [VisiumRNALevel3 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/VisiumRNALevel3.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('visiumRNALevel3/reference.csv', keep_default_na=False) }} diff --git a/docs/model/visiumRNALevel4.md b/docs/model/visiumRNALevel4.md new file mode 100644 index 00000000..454e9c37 --- /dev/null +++ b/docs/model/visiumRNALevel4.md @@ -0,0 +1,24 @@ +A **10x Visium RNA Level 4** entry documents further-processed data built from a 10x Visium RNA Level 3 output, capturing the generic workflow type and workflow parameters used to derive higher-order analysis products (e.g., spatial clustering, differential expression, or other downstream spatial analyses) from the per-spot summary data. + +As the most highly processed level in the Visium cluster, Level 4 entries emphasize workflow provenance, ensuring that the analysis choices behind a derived spatial result remain traceable back through Level 3, Level 2, and Level 1 to the original tissue and sequencing run. + +## Why You Should Contribute 10x Visium RNA Level 4 Entries + +Contributing 10x Visium RNA Level 4 entries ensures that downstream spatial analysis outputs remain traceable to the workflow and parameters that produced them, supporting reproducibility for results shared through the CCKP. + +### Who Should Be Contributing 10x Visium RNA Level 4 Entries? + +1. **Computational Genomics Analysts** – Document the workflow type and parameters used to generate derived spatial analysis products. +2. **Spatial Biology Researchers** – Confirm that derived results are correctly linked back to the Level 3 data they were built from. +3. **Bioinformatics Pipeline Developers** – Track workflow versions to support reproducibility across pipeline updates. +4. **Data Managers** – Maintain consistent, portal-ready metadata for derived Visium analysis outputs shared through the CCKP. + +## Download Template + +You can download the [VisiumRNALevel4 CSV template](https://github.com/mc2-center/data-models/raw/main/templates/VisiumRNALevel4.csv) to streamline data entry. + +## Full Field Reference + +Below is the full field reference table with attributes and their descriptions. + +{{ read_csv('visiumRNALevel4/reference.csv', keep_default_na=False) }} diff --git a/json_schemas/10xVisiumRNALevel2.json b/json_schemas/10xVisiumRNALevel2.json new file mode 100644 index 00000000..5250fa61 --- /dev/null +++ b/json_schemas/10xVisiumRNALevel2.json @@ -0,0 +1,704 @@ +{ + "$id": "http://example.com/10xVisiumRNALevel2", + "$schema": "http://json-schema.org/draft-07/schema#", + "description": "Alignment workflows downstream of Spatial Transcriptomics RNA-seq Level 1.", + "properties": { + "10xVisiumRNALevel1Key": { + "description": "Unique 10xVisiumRNALevel1_id foreign key(s) that link metadata entries as part of the same Dataset. Please provide multiple values as a comma-separate list.", + "title": "10xVisiumRNALevel1 Key", + "type": "string" + }, + "10xVisiumRNALevel2Id": { + "description": "Unique row identifier, used as a primary key for record updates. This should be equivalent to the file Synapse Id unless otherwise indicated.", + "pattern": "^syn\\d{7,8}$", + "title": "10xVisiumRNALevel2_id", + "type": "string" + }, + "BiospecimenKey": { + "description": "Unique Biospecimen_id foreign key(s) that link metadata entries as part of the same collection. Please provide multiple values as a comma-separated list.", + "pattern": "-B\\d{1,9}", + "title": "Biospecimen Key", + "type": "string" + }, + "DatasetViewKey": { + "description": "Unique DatasetView_id foreign key(s) that link metadata entries as part of the same collection. Please provide multiple values as a comma-separated list.", + "title": "DatasetView Key", + "type": "string" + }, + "FileAlias": { + "description": "A string identifier associated with the file. Must be unique. Can be the repository accesssion number (e.g., Synapse ID, GEO identifier such as GSE12345). No Greek Letters or DOIs.", + "title": "File Alias", + "type": "string" + }, + "FileAssay": { + "description": "The assay the file is representative of.", + "enum": [ + "10-cellRNASequencing", + "10xMultiome", + "16SRibosomalGeneSequencingAssay", + "3'RNA-seq", + "3C", + "3C-qPCR", + "3DATAC-PALM", + "3DBioprinting", + "3DCellCulture", + "4C", + "5C", + "ATAC-Seq", + "ATPBioluminescenceAssay", + "AffinityPurificationMassSpectrometry", + "AlcianBlueStainingMethod", + "Allograft", + "AmpliconSequencing", + "AngiogenesisAssay", + "AntitumorDrugScreeningAssay", + "ApoptosisAssay", + "ArtificialIntelligence", + "AtomicAbsorptionSpectrophotometry", + "AtomicAbsorptionSpectroscopy", + "AtomicForceMicroscopy", + "Autoradiography", + "Barcode-Seq", + "BicinchoninicAcidAssay", + "BindingAssay", + "Bio-LayerInterferometry", + "BioelectrochemicalAnalysis", + "BioluminescenceImaging", + "BisulfiteSequencing", + "BrightfieldMicroscopy", + "BrillouinMicroscopy", + "CASFISH", + "CDNAArray", + "CITE-seq", + "CLIP-qPCR", + "CODEX", + "CRISPR", + "CUT&RUN", + "CUT&Tag-Sequencing", + "Cell-freeCirculatingTumorDNAAssay", + "Cell-spreadingAssay", + "CellAdhesionAssay", + "CellCulture", + "CellCycleAssay", + "CellFractionation", + "CellProliferationAssay", + "CellTiter-GloLuminescentCellViabilityAssay", + "CellViabilityAssay", + "CerenkovLuminescenceImaging", + "ChIA-PET", + "ChIP-PCR", + "ChIP-Seq", + "ChIP-qPCRassay", + "ChemiluminescentAssay", + "ChemotaxisAssay", + "ChimericAntigenReceptorT-CellTherapy", + "CircularDichroismSpectroscopy", + "ClinicalStudy", + "ClonalityAnalysis", + "Co-Immunoprecipitation", + "Co-ImmunoprecipitationMassSpectrometry", + "Co-cultureAssay", + "Collision-InducedDissociation", + "ColorimetricCellViabilityAssay", + "ComparativeGenomicHybridization", + "ComputationalModeling", + "ComputationalTool", + "ComputedTomography", + "ConfocalMicroscopy", + "ConfocalReflectanceQuantitativePhaseMicroscopy", + "Cross-LinkingImmunoprecipitationHigh-throughputSequencing", + "Cross-LinkingMassSpectrometry", + "Cryo-ElectronMicroscopy", + "Cryo-ElectronTomography", + "CyclicImmunofluorescence", + "CytochemicalStain", + "CytokineExpressionProfile", + "CytometricBeadArrayAssay", + "CytotoxicityAssay", + "DBiT-Seq", + "DNAGene-ExpressionMicroarray", + "DNAMethylationArray", + "DNASequencing", + "DNase-Seq", + "DRIP-seq", + "DarkFieldMicroscopy", + "DataIntegration", + "DeepLearning", + "DeepMutationalScanning", + "DesorptionElectrosprayIonization", + "DideoxyChainTerminationDNASequencing", + "DifferentialInterferenceContrastMicroscopy", + "DifferentialScanningFluorimetry", + "DiffusionWeightedImaging", + "DirectLong-ReadRNASequencing", + "Drop-Seq", + "DropletDigitalPCR", + "Dual-LuciferaseReporterAssay", + "DyeEndocytosisAssay", + "DynamicContrast-EnhancedMagneticResonanceImaging", + "DynamicForceSpectroscopy", + "DynamicLightScattering", + "DynamicSusceptibilityContrast-EnhancedMagneticResonanceImaging", + "ECLIP-Seq", + "ELISA", + "EfferocytosisAssay", + "ElectronDiffraction", + "ElectronMicroscopy", + "ElectronParamagneticResonanceSpectroscopy", + "ElectrophoreticMobilityShiftAssay", + "ElectrosprayIonizationTime-of-FlightMassSpectrometry", + "EndotoxinAssay", + "Energy-DispersiveX-RaySpectroscopy", + "Enzyme-LinkedImmunospotAssay", + "EnzymeActivityAssay", + "EpidemiologicalMethod", + "FAIRE-Seq", + "FISH", + "Field-EmissionScanningElectronMicroscopy", + "FlowCytometry", + "FluorescenceActivatedCellSorting", + "FluorescenceCorrelationSpectroscopy", + "FluorescenceImaging", + "FluorescenceLifetimeImagingMicroscopy", + "FluorescenceMicroscopy", + "FluorescenceRecoveryAfterPhoto-Bleaching", + "FluorescentAntibodyProcedure", + "FluorescentCellBarcoding", + "FluorescentInSituSequencing", + "FocusedIonBeamScanningElectronMicroscopy", + "ForsterResonanceEnergyTransfer", + "Fourier-TransformInfraredSpectroscopy", + "FourierTransformIonCyclotronResonanceMassSpectrometry", + "GasChromatographyMassSpectrometry", + "GelatinZymography", + "GeneOntologyEnrichmentAnalysis", + "GeneSetEnrichmentAnalysis", + "GeneSilencing", + "Genotyping", + "GlobalChromatinProfiling", + "GlobalRun-OnSequencing", + "GraphiteFurnaceAtomicAbsorptionSpectrometry", + "HL-Chip", + "HPLC-MSMS", + "HematoxylinandEosinStainingMethod", + "Hi-C", + "HiChIP", + "High-ContentScreen", + "HighThroughputScreening", + "HumanInducedPluripotentStemCell-derivedCardiomyocytesCulture", + "Hydrogels", + "HydrophilicInteractionChromatography", + "ImageCytometry", + "Imaging", + "ImagingMassCytometry", + "ImmobilizedMetalAffinityChromatography", + "ImmunoFISH", + "Immunoassay", + "Immunocytochemistry", + "ImmunofluorescentStainingMethod", + "ImmunohistochemistryStainingMethod", + "Immunoprecipitation", + "Immunotherapy", + "In-CellWesternAssay", + "InSituHybridization", + "InVitroCellKillingAssay", + "InVitroModel", + "InVitroSelection", + "InVitroTranslation", + "InVivoBioluminescence", + "Inductively-CoupledPlasmaMassSpectrometry", + "InterferenceReflectionMicroscopy", + "IntravitalMicroscopy", + "InvasionAssay", + "IsothermalTitrationCalorimetry", + "Karyotyping", + "Knife-EdgeScanningMicroscopy", + "L1000mRNAProfilingAssay", + "Label-freeProteinQuantificationbyLC/MS", + "LatticeLightSheetMicroscopy", + "LightSheetMicroscopy", + "LiquidChromatography/TandemMassSpectrometry", + "LiquidChromatographyMassSpectrometry", + "Low-VacuumScanningElectronMicroscopy", + "LuciferaseReporterAssay", + "LuminescentCellViabilityAssay", + "MALDI-TOFMassSpectrometry", + "MEMACellGrowthAssay", + "MNase-Seq", + "MRNASequencing", + "MULTI-Seq", + "MacrophagePolarizationAssay", + "MagneticResonanceImaging", + "MagneticTweezers", + "MagneticTwistingCytometry", + "MagneticallyActivatedCellSorting", + "MammosphereFormationAssay", + "MassCytometry", + "MassSpectrometry", + "MathematicalModeling", + "MeDIP", + "MeRIP-Seq", + "MetaboliteProfilingAssay", + "MetastaticColonizationAssay", + "MethylBindingDomainSequencing", + "Methylation-SpecificPCR", + "Micro-computedTomography", + "MicroRNAExpressionArray", + "MicroRNASequencing", + "MicrocontactPrinting", + "Microfluidics", + "MicropipetteAdhesionAssay", + "MicropipetteAspiration", + "Microscopy", + "MigrationAssay", + "Mint-ChIP", + "Modeling", + "MolecularSimulations", + "MonolayerStressMicroscopy", + "Multi-AngleLightScattering", + "Multi-IsotopeMassSpectrometry", + "MultiparametricMagneticResonanceImaging", + "MultiphotonMicroscopy", + "MultiplexedError-RobustFluorescenceInSituHybridization", + "MultiplexedImmunofluorescence", + "MultiplexedImmunohistochemistry", + "MultiplexedIonBeamImaging", + "MultiscaleLightSheetMicroscopy", + "MurineModel", + "Nano-hmC-Seal", + "NanoStringDigitalSpatialProfiling", + "Nanopatterning", + "NanoporeSequencing", + "Nanowire", + "NestedPCR", + "NextGenerationSequencing", + "Nm-seq", + "NotApplicable", + "NuclearMagneticResonance", + "OpticalCoherenceTomography", + "OpticalEmissionSpectroscopy", + "OpticalMapping", + "OpticalStretcher", + "OpticalTweezers", + "OptogeneticAssay", + "Organoid", + "PCR", + "PET-CT", + "ParaquatSurvivalAssay", + "PartialWaveSpectroscopy", + "PatientDerivedXenograft", + "PendingAnnotation", + "PermeabilityAssay", + "PhagocytosisAssay", + "PhotoacousticImaging", + "Photolithography", + "PhylogeneticAnalysis", + "PicrosiriusStaining", + "PlasmidConstruction", + "PlateSeq", + "PointAccumulationforImaginginNanoscaleTopography", + "PositronEmissionTomography", + "PrecisionRun-OnSequencing", + "ProteomicsAssay", + "ProximityLigationAssay", + "Pull-DownAssay", + "QFISH", + "QPCR", + "QuantitativeMultiplexImmunofluorescence", + "QuantitativePointAccumulationforImaginginNanoscaleTopography", + "Questionnaire", + "RASProteinFamilyActivationAssay", + "RIP", + "RIP-Seq", + "RNASequencing", + "RNAiScreen", + "RT-PCR", + "RT-qPCR", + "RamanSpectroscopy", + "ReducedRepresentationBisulfiteSequencing", + "ReporterGeneAssay", + "Reverse-PhaseHigh-PerformanceliquidChromatography", + "ReversePhaseProteinArray", + "Rheometry", + "Ribo-Seq", + "RibosomalPProteinAntibodyMeasurement", + "SDS-PAGE", + "ScCGI-seq", + "ScNT-Seq", + "ScSLAM-seq", + "ScanningAngleInterferenceMicroscopy", + "ScanningElectronMicroscopy", + "ScratchAssay", + "Second-HarmonicImagingMicroscopy", + "SeqFISH", + "ShRNA", + "ShotgunMassSpectrometry", + "SiRNA", + "Single-CellBCRSequencing", + "Single-CellBarcodeChip", + "Single-CellTCRSequencing", + "Single-MoleculeLocalizationMicroscopy", + "Single-MoleculeTracking", + "SingleCellATAC-Seq", + "SingleCellCytokineDetectionChipAssay", + "SingleCellDNASequencing", + "SingleCellGelElectrophoresis", + "SingleCellRNA-Sequencing", + "SingleMoleculeForsterResonanceEnergyTransfer", + "SingleNucleotidePolymorphismArray", + "SingleNucleusRNA-Sequencing", + "SiriusRedStaining", + "SizeExclusionChromatography", + "SmFISH", + "SmRNA-seq", + "Small-AngleX-rayScattering", + "SnRNA-seq", + "SoftAgarAssay", + "SouthernBlotting", + "Spectroscopy", + "StatisticalModeling", + "StimulatedEmissionDepletionMicroscopy", + "StimulatedRamanScattering", + "StochasticOpticalReconstructionMicroscopy", + "StructuralVariantAnalysis", + "Super-ResolutionMicroscopy", + "SurfacePlasmonResonance", + "SurveyorNucleaseAssay", + "SurvivalAnalysis", + "SuspendedMicrochannelResonator", + "SynaptophysinStainingMethod", + "Synthesis", + "SyntheticGeneticArray", + "TAB-Seq", + "TCRSequencing", + "TIRFMicroscopy", + "TRAPStaining", + "TUNELassay", + "TandemMassSpectrometry", + "TandemMassTagging", + "TargetEngagementAssay", + "TargetedErrorCorrectionSequencing", + "TargetedGenomeSequencing", + "TargetedTherapyAgent", + "TargetedTranscriptomeSequencing", + "ThermalShiftAssay", + "Thin-LayerChromatography", + "TilingArray", + "Time-CorrelatedSinglePhotonCounting", + "TimeLapseMicroscopy", + "TissueEngineering", + "TissueMicroarray", + "TotalInternalReflectionFluorescenceMicroscopy", + "TractionForceMicroscopy", + "TranscriptionprofilingbyNanoString", + "TransmissionElectronMicroscopy", + "TranswellAssay", + "TrichromeStainingMethod", + "Tuba-Seq", + "UPLC-MSMS", + "UVPhotocrosslinking", + "UltrasoundImaging", + "Unspecified", + "VibrationalSpectroscopy", + "ViralTransduction", + "VirusPlaqueAssay", + "VisiumSpatialGeneExpression", + "VonKossaStaining", + "WesternBlotting", + "WholeExomeSequencing", + "WholeGenomeBisulfiteSequencing", + "WholeGenomeSequencing", + "WidefieldFluorescenceMicroscopy", + "Wound-HealingAssay", + "X-RayCrystallography", + "X-RayDiffraction", + "X-RayMicro-ComputedTomography", + "Xenograft" + ], + "title": "File Assay" + }, + "FileDataUseCodes": { + "description": "DUO code - A data item that is used to indicate consent permissions for datasets and/or materials, and relates to the purposes for which datasets and/or material might be removed, stored or used. Available DUO code definitions can be found here: https://mc2-center.github.io/data-models/valid_values/study/#attribute-study-data-use-codes", + "items": { + "type": "string" + }, + "title": "File Data Use Codes", + "type": "array" + }, + "FileDescription": { + "description": "Description of the file.", + "title": "File Description", + "type": "string" + }, + "FileDesign": { + "description": "The overall design of the dataset or file, including a batch identifier, if applicable.", + "title": "File Design", + "type": "string" + }, + "FileFormat": { + "description": "The format of the file described by this entry.", + "enum": [ + "AVI", + "BAI", + "BAM", + "BED", + "BIGWIG", + "BPM", + "Bed12", + "Bedgraph", + "CDS", + "CHP", + "CLS", + "COOL", + "CSV", + "Cel", + "Cloupe", + "DAE", + "DB", + "DCC", + "DSStore", + "Docx", + "FASTA", + "FASTQ", + "FCS", + "FIG", + "FREQ", + "GCG", + "GCT", + "GCTx", + "GFF3", + "GTF", + "GZIPFormat", + "H5", + "H5AD", + "HDF", + "HDF5", + "HTML", + "IDAT", + "JPG", + "JSON", + "LIF", + "MAP", + "MAT", + "MATLABscript", + "MGF", + "MSF", + "MTX", + "Maf", + "MzIdentML", + "MzXML", + "PDF", + "PKL", + "PNG", + "PZFX", + "PendingAnnotation", + "Pptx", + "PythonScript", + "RAW", + "RDS", + "RFileFormat", + "ROUT", + "RPROJ", + "RTF", + "Rcc", + "SCN", + "SF", + "SGI", + "SRA", + "STAT", + "SVS", + "TARFormat", + "TDF", + "TIFF", + "TSV", + "TXT", + "Unspecified", + "VCF", + "WIG", + "XML", + "Xls", + "Xlsx", + "ZIP" + ], + "title": "File Format" + }, + "FileLevel": { + "description": "The processing level the file can be mapped to.", + "enum": [ + "Auxiliary", + "Level1", + "Level2", + "Level3", + "Level4", + "Metadata", + "NotApplicable" + ], + "title": "File Level" + }, + "FileLongitudinalEventType": { + "description": "The type of event to which File Longitudinal Total Time Elapsed is related", + "enum": [ + "Baseline", + "Enrollment" + ], + "title": "File Longitudinal Event Type" + }, + "FileLongitudinalGroup": { + "description": "A label that can be used to identify groups of files from the same longitudinal/time-resolved experiment", + "title": "File Longitudinal Group", + "type": "string" + }, + "FileLongitudinalSequenceIdentifier": { + "description": "The order in which this file was collected with respect to the longitudinal experiment (e.g., 1, 2, etc.). Integer.", + "title": "File Longitudinal Sequence Identifier", + "type": "number" + }, + "FileLongitudinalTimeElapsedUnit": { + "description": "The unit of time associated with Sequential and Total Time Elapsed attributes.", + "title": "File Longitudinal Time Elapsed Unit", + "type": "string" + }, + "FileLongitudinalTotalTimeElapsed": { + "description": "The total time elapsed between the first and current files contained this longitudinal group.", + "title": "File Longitudinal Total Time Elapsed", + "type": "number" + }, + "FileSpecies": { + "description": "The species the data was collected on.", + "enum": [ + "AfricanBushElephant", + "Armadillo", + "AsianElephant", + "Boar", + "Cat", + "Chicken", + "Cow", + "Dog", + "Escherichiacoli", + "FruitFly", + "GuineaPig", + "Horse", + "Human", + "HumanCellLine", + "HumanPatient", + "Mouse", + "Multispecies", + "NotApplicable", + "Opossum", + "Rabbit", + "Rat", + "Rhesusmonkey", + "Sheep", + "Trichoplaxadhaerens", + "Unknown", + "Unspecified", + "Worm", + "Yeast", + "Zebrafish" + ], + "title": "File Species" + }, + "FileUrl": { + "description": "The url of where the file is stored.", + "format": "uri", + "title": "File Url", + "type": "string" + }, + "Filename": { + "description": "The path of a file in Synapse, relative to the project. The file associated with the path will be annotated with attributes contained in this sheet.", + "title": "Filename", + "type": "string" + }, + "GenomeAnnotationURL": { + "description": "Link to the human genome annotation (GTF) file; ftp or reference URL will be accepted.", + "format": "uri", + "title": "Genome Annotation URL", + "type": "string" + }, + "GenomicReference": { + "description": "Exact version of the human genome reference used in the alignment of reads (e.g. GCF_000001405.39)", + "title": "Genomic Reference", + "type": "string" + }, + "GenomicReferenceURL": { + "description": "Link to human genome sequence; ftp or reference URL will be accepted.", + "format": "uri", + "title": "Genomic Reference URL", + "type": "string" + }, + "StudyKey": { + "description": "The unique Study_id foreign keys associated with the resource, found in the grant Study information. Used to group the resource with other components. Please provide multiple values as a comma-separated list.", + "title": "Study Key", + "type": "string" + }, + "VisiumAppliedHardTrimming": { + "description": "Was Hard Trimming applied", + "enum": [ + "False", + "True" + ], + "title": "Visium Applied Hard Trimming" + }, + "VisiumCaptureArea": { + "description": "Area (or Capture Area) - One of the either four or two active regions where tissue can be placed on a Visium slide. Each area is intended to contain only one tissue sample. Slide areas are named consecutively from top to bottom: A1, B1, C1, D1 for Visium slides with 6.5 mm Capture Area and A, B for CytAssist slides with 11 mm Capture Area. Both CytAssist slides with 6.5 mm Capture Area and Gateway Slides contain only two slide areas, A1 and D1.", + "enum": [ + "A", + "A1", + "B", + "B1", + "C", + "C1", + "D", + "D1" + ], + "title": "Visium Capture Area" + }, + "VisiumRunID": { + "description": "A unique identifier for this individual run (typically associated with a single slide) of the spatial transcriptomic processing workflow.", + "title": "Visium Run ID", + "type": "string" + }, + "VisiumSpatialBarcodeTag": { + "description": "SAM tag for spot barcode field; please provide a valid tag-type pair, consisting of a tag (e.g. CB or CR) and type (e.g. Z) separated by a colon.", + "title": "Visium Spatial Barcode Tag", + "type": "string" + }, + "VisiumUMITag": { + "description": "SAM tag for the UMI field; please provide a valid tag-type pair, consisting of a tag (e.g. UB or UR) and type (e.g. Z) separated by a colon.", + "title": "Visium UMI Tag", + "type": "string" + }, + "VisiumWhitelistSpatialBarcodeFileLink": { + "description": "Link to file listing all possible spatial barcodes. URL", + "title": "Visium Whitelist Spatial Barcode File Link", + "type": "string" + }, + "WorkflowLink": { + "description": "Link to documentation or webpage associated with the computational workflow used to generate the file.", + "format": "uri", + "title": "Workflow Link", + "type": "string" + }, + "WorkflowVersion": { + "description": "Major version of the workflow (e.g. Cell Ranger v3.1)", + "title": "Workflow Version", + "type": "string" + } + }, + "required": [ + "10xVisiumRNALevel2Id", + "FileAlias", + "FileAssay", + "FileFormat", + "FileLevel", + "FileSpecies", + "FileUrl", + "VisiumAppliedHardTrimming", + "VisiumRunID", + "VisiumSpatialBarcodeTag", + "VisiumUMITag", + "VisiumWhitelistSpatialBarcodeFileLink" + ], + "title": "10xVisiumRNALevel2", + "type": "object" +} \ No newline at end of file diff --git a/json_schemas/Biospecimen.json b/json_schemas/Biospecimen.json index 82799354..0d0fe3a3 100644 --- a/json_schemas/Biospecimen.json +++ b/json_schemas/Biospecimen.json @@ -7830,6 +7830,7 @@ "CellularTherapy", "Chemotherapy", "ConcurrentChemoradiation", + "Control", "ConventionalRadiotherapy", "ElectronBeamRadiationTherapy", "ExternalBeamRadiationTherapy", diff --git a/json_schemas/Individual.json b/json_schemas/Individual.json index 7cf47eff..eb28391a 100644 --- a/json_schemas/Individual.json +++ b/json_schemas/Individual.json @@ -6742,6 +6742,7 @@ "CellularTherapy", "Chemotherapy", "ConcurrentChemoradiation", + "Control", "ConventionalRadiotherapy", "ElectronBeamRadiationTherapy", "ExternalBeamRadiationTherapy", diff --git a/json_schemas/Model.json b/json_schemas/Model.json index d006003c..18f66253 100644 --- a/json_schemas/Model.json +++ b/json_schemas/Model.json @@ -6351,6 +6351,7 @@ "CellularTherapy", "Chemotherapy", "ConcurrentChemoradiation", + "Control", "ConventionalRadiotherapy", "ElectronBeamRadiationTherapy", "ExternalBeamRadiationTherapy", diff --git a/mc2.model.csv b/mc2.model.csv index 07e13570..3849f1d2 100644 --- a/mc2.model.csv +++ b/mc2.model.csv @@ -35,7 +35,7 @@ Biospecimen Primary Site,Primary site in the body associated with the primary di Biospecimen Primary Diagnosis,"Text term used to describe the histologic diagnosis relevant to the model system, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).","Head and Neck Squamous Cell Carcinoma, Astroblastoma; Other; Other CNS Tumor; NOS Or NEC, Medulloblastoma; Hypercellular Lesion With Marked Atypia, Ependymoma; NOS; Posterior Fossa Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Neuroma; NOS, Precursor Cell Lymphoblastic Leukemia; NOS, Hypercellular Neuroepithelial Tumor With Some Features Of Glioma; Possibly High Grade, Acute Leukemia; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Papillary Glioneuronal Tumor, High-grade serous carcinoma, Myeloid Leukemia; NOS, Choriocarcinoma; NOS, Embryonal Carcinoma; NOS; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Giant Cell Tumor Of Bone; NOS, Adenocarcinoma; Intestinal Type, Not Specified In Data, Neoplasm; Uncertain Whether Benign Or Malignant; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ductal Carcinoma NOS, Renal Cell Carcinoma; NOS, B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Myelodysplastic Syndrome; NOS, Low Grade Fibromyxoid Sarcoma, Benign Cystic Nephroma, Glial Neoplasm, Papillary Adenocarcinoma; NOS, Telangiectatic Osteosarcoma, Ganglioglioma; NOS; Malignant Peripheral Nerve Sheath Tumor; NOS, Central Neurocytoma, Giant Cell Tumor Of Soft Parts; NOS, Giant Cell Tumor Of Bone; Malignant, Sertoli-Leydig Cell Tumor; Poorly Differentiated, Glioma; Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Acute Megakaryoblastic Leukemia, Germinoma; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia; WHO Grade 1, Supratentorial Ependymoma; NOS, Myxoid Liposarcoma, Acute Lymphoblastic Leukemia, Combined Small Cell-Squamous Cell Carcinoma, High Grade Spindle Cell Sarcoma, Medulloblastoma; Group 3 Subtype (WHO Grade 4), Acute Monocytic Leukemia, Neoplasm; NOS, Retinoblastoma; Grade 3, Yolk Sac Tumor; NOS; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Myofibroblastic Tumor; NOS, Sex Cord-Gonadal Stromal Tumor; Mixed Forms, Adamantinomatous Craniopharyngioma, Mesoblastic Nephroma, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Astrocytoma; NOS; High-Grade Glioma; Infant-Type Hemispheric Glioma, Rhabdomyosarcoma; NOS, Mucinous Adenocarcinoma; Endocervical Type, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ganglioglioma; NOS; Glioneuronal And Neuronal Tumors, Dermoid Cyst, Adenocarcinoma Combined With Other Types Of Carcinoma, Precursor Cell Lymphoblastic Lymphoma; NOS, Posterior Fossa Ependymoma; CNS WHO Grade 2, Pituitary Adenoma; NOS, Neoplasm; Malignant; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Sex Cord-Gonadal Stromal Tumor; Incompletely Differentiated, High Grade Follicular Derived Thyroid Carcinoma, Desmoplastic Fibroma, Perineuroma, Diffuse Midline Glioma; H3K27M-Mutant; CNS WHO Grade 4, Ganglioglioma, Pancreatobiliary-Type Carcinoma, Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia, Hemangioblastoma, Colorectal Carcinoma, Acute Myelomonocytic Leukemia, Diffuse Midline Glioma; H3 K27-Altered, T-Lymphoblastic Lymphoma, Lymphangioma; NOS, Neoplasm; Benign, Papillary Intralymphatic Angioendothelioma, Ependymoma; NOS; Supratentorial Ependymoma; ZFTA Fusion-Positive, Unclassified Sarcoma With Round Cell Morphology, Glioma, Medulloblastoma; Classic (Biphasic) Histologic Type; Non-SHH/Non-WNT Molecular Group; CNS WHO Grade 4, Soft Tissue Sarcoma, Xanthogranuloma, Neoplasm; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Bronchio-Alveolar Carcinoma; Mucinous, Hepatocellular Carcinoma; Fibrolamellar, Pancreatic Neuroendocrine Tumor; Nonfunctioning, Myxopapillary Ependymoma, Chondrosarcoma; NOS, Favor Ganglioglioma, Papillary Tumor Of Pineal Region, Acute Myeloid Leukemia With Mutated NPM1, Epithelioid Hemangioendothelioma; NOS, Neuroblastoma; NOS, Chondroid Chordoma, Infiltrating Duct And Lobular Carcinoma, Mitotically Active Glial/ Glioneuronal Neoplasm, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, CPNET, Mycosis Fungoides; Langerhans Cell Histiocytosis; NOS, T-Lymphoblastic Leukemia, Medulloblastoma; NOS; Medulloblastoma; Non-WNT/Non-SHH, Clear Cell Meningioma; Meningioma; Other, Ameloblastic Carcinosarcoma, Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Meningothelial Meningioma, Epithelioid Cell Melanoma, Prostate Cancer, Paraganglioma; Malignant, Small Cell Sarcoma, Cystosarcoma Phyllodes; NOS, Seminoma; NOS, Yolk Sac Tumor; NOS, Intraductal Carcinoma NOS, Adenocarcinoma; Endocervical Type, Neurofibroma; NOS, Astroblastoma; Astroblastoma; MN1-Altered; High-Grade Glioma, Meningothelial Meningioma; Grade 1, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Unknown, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Sarcoma; Ewing Sarcoma, Glioma; Malignant; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Endometrioid Adenocarcinoma; NOS, Pancreas-Adenocarcinoma Ductal Type, Giant Cell Glioblastoma; Glioblastoma; IDH-Wildtype; High-Grade Glioma, Angiomyosarcoma, Carcinoid Tumor, Adenosquamous Carcinoma, Metastatic Neuroblastoma, Clear Cell Sarcoma Of Kidney, Infiltrating Duct Mixed With Other Types Of Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Embryonal Carcinoma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Germ Cell Tumors; CNS Germinoma, Astrocytoma; NOS; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Low Cumulative Sun Damage Melanoma, Supratentorial Ependymoma, Ossifying Fibromyxoid Tumor; NOS, Diffuse Large B-Cell Lymphoma; NOS, Adenocarcinoma With Neuroendocrine Differentiation, Atypical Meningioma, Pineoblastoma, Chronic Myeloid Leukemia; NOS, Atypical Choroid Plexus Papilloma, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFB, Pleomorphic Xanthoastrocytoma; NOS; High-Grade Glioma, Oxyphilic Adenocarcinoma, Favor Pilocytic Astrocytoma; CNS WHO Grade 1, Poorly Differentiated; Intermediate Mitotic-Karyorrhectic Index, Clear Cell Meningioma, Medulloblastoma; Classic Histologic Type; CNS WHO Grade 4, Appearances Consistent With Alveolar Soft Part Sarcoma, Dedifferentiated Liposarcoma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Tubular Adenocarcinoma, Rhabdomyosarcoma; Most Likely An Embryonal Carcinoma, Adenocarcinoma; NOS, Pleuropulmonary Blastoma, Basaloid Squamous Cell Carcinoma, Oligodendroglioma; Anaplastic; NOS, Pilocytic Astrocytoma; WHO Grade 1, Not Applicable, Abdominal Fibromatosis, Hamartoma, Neoplasm; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Choroid Plexus Papilloma; NOS; Choroid Plexus Tumors, Burkitt Lymphoma; NOS, Lymphoepithelial Carcinoma, Bronchiolo-Alveolar Carcinoma; Non-Mucinous, Kidney Clear Cell Renal Carcinoma, Pilocytic Astrocytoma; Low-Grade Glioma, Adenocarcinoma In Situ In Adenomatous Polyp, Neoplasm; Uncertain Whether Benign Or Malignant, Small Blue Cell Tumor. Favor Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma; NOS, Embryonal Tumor With Multi-Layered Rosettes, Chronic Eosinophilic Leukemia, Mixed Glioma, Basal Cell Adenocarcinoma, Olfactory Neuroblastoma, Transitional Cell Carcinoma; NOS, Clear Cell Sarcoma; NOS, Embryonal Rhabdomyosarcoma; High-Grade, Angiocentric Glioma, Diffuse Midline Glioma; H3 K27 Altered; WHO Grade 4, Osteoblastoma; NOS, Malignant Neoplasm With Rhabdomyoblastic Differentiation; High Grade, Myxopapillary Ependymoma (CNS WHO Grade II), Melanoma In Situ, Secretory Carcinoma, Pilocytic Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Rhabdomyosarcoma; Favor Alveolar Type, Adenocarcinoma; Metastatic NOS, Fibrosarcoma; NOS, Glioblastoma, Atypical Choroid Plexus Papilloma; Choroid Plexus Tumors, Ganglioneuroma; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Desmoplastic Melanoma; NOS, Choroid Plexus Carcinoma, Soft Tissue Tumor; Benign, Medulloblastoma; NOS, Glioblastoma; NOS; Medulloblastoma; NOS, Residual Astrocytoma, B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged, Extra Adrenal Paraganglioma, Mucoepidermoid Carcinoma, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Choroid Plexus Papilloma; NOS, Glioma; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, B-Lymphoblastic Leukemia/Lymphoma; NOS, Hodgkin Lymphoma; Nodular Sclerosis; NOS, Fibroma, Craniopharyngioma; NOS; Adamantinomatous Craniopharyngioma, T-Cell/Histiocyte Rich Large B-Cell Lymphoma, Astrocytoma; IDH-Mutant; CNS WHO Grade 4, Acute Erythroid Leukemia, Glioma; Histologically Low Grade, Mucous Adenocarcinoma, Glioma; Malignant; Ganglioglioma; Glioneuronal And Neuronal Tumors, Nodular Melanoma, Synovial Sarcoma; Biphasic, Neoplasm; Metastatic, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Thymoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Posterior Fossa Ependymoma; Group PFA, Desmoplastic/Nodular Medulloblastoma, Papillary Glioneuronal Tumor, Mixed Phenotype Acute Leukemia; T/Myeloid; NOS, Cholangiocarcinoma, Astroblastoma; MN1-Altered. Histologically High-Grade, Sertoli-Leydig Cell Tumor; Poorly Differentiated; With Heterologous Elements, Glioma; Malignant; High-Grade Glioma; Infant-Type Hemispheric Glioma, Juvenile Myelomonocytic Leukemia; NOS, Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry, Myeloid Leukemia With Myelodysplasia-Related Changes, Primary Cutaneous Follicle Center Lymphoma, Choroid Plexus Carcinoma; WHO Grade 3, Infiltrating Duct Carcinoma NOS, T Lymphoblastic Leukemia/Lymphoma, Glioma; Malignant; Other; Other CNS Tumor; NOS Or NEC, Mixed Germ Cell Tumor; Myelodysplastic Syndrome With Excess Blasts, Clear Cell Adenocarcinoma; NOS, Cutaneous T-Cell Lymphoma; NOS, Germinoma, Neoplasm; Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Meningeal Melanocytoma, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Acute Promyelocytic Leukemia; T(15;17)(Q22;Q11-12), Alveolar Soft Part Sarcoma, Astrocytoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Mixed Epithelioid And Spindle Cell Melanoma, CNS Embryonal Tumor; NOS; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Malignant Tumor; Spindle Cell Type, Glioma; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Glioma; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Endometrioid Carcinoma; NOS, Lung Squamous Cell Carcinoma; NOS, Papillary Urothelial Carcinoma; Non-Invasive, Neuroblastoma; Undifferentiated Type, Periosteal Osteosarcoma, Mixed Phenotype Acute Leukemia; B/Myeloid; NOS, Inflammatory Carcinoma, Glioblastoma; NOS, Carcinoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Squamous Cell Carcinoma; NOS, Hypocellular Low Grade Lesion, Glioblastoma Multiforme, Pancreas-Undifferentiated Carcinoma, Differentiating Neuroblastoma, Myxoid Spindle Cell Tumor, Merkel Cell Tumor, Malignant Peripheral Nerve Sheath Tumor; NOS; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Hemangioma; NOS, Acute Myeloid Leukemia With Abnormal Marrow Eosinophils, Well Differentiated Neuroendocrince Tumor; Grade 1, Ganglioglioma; Anaplastic, Ependymoma WHO Grade 2, Synovial Sarcoma; NOS, Thymic Carcinoma; NOS, Tumor Cells; Malignant, Pilomyxoid Astrocytoma, Papillary Carcinoma; Columnar Cell, Plexiform Fibrohistiocytic Tumor, Astrocytoma; NOS; Angiocentric Glioma; Low-Grade Glioma, Carcinoma; Undifferentiated; NOS, Dermatofibrosarcoma Protuberans; NOS, High Grade Glioma With Necrosis; WHO Grade 4, Infiltrating ductular carcinoma, Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Juvenile Myelomonocytic Leukemia; NOS, Infiltrating Duct And Mucinous Carcinoma, Intraductal Papillary Carcinoma, Serous Surface Papillary Carcinoma, Invasive Carcinoma, High Grade Malignant Epithelioid Neoplasm, Favor Pilocytic Astrocytoma With Increased Proliferation Indices, Medulloblastoma; Classic Morphology; CNS WHO Grade 4; NON-WNT/NON-SHH; Group 4 Subtype By Methylation, Composite Hodgkin And Non-Hodgkin Lymphoma, Atypical Teratoid/Rhabdoid Tumor; ATRT; NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor; ATRT-TYR, Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder, Hemangioendothelioma; NOS, Hypercellular Lesion With Atypia, Embryonal Carcinoma; NOS, Subependymoma; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Germ Cell Tumor; Nonseminomatous, Adrenal Cortical Carcinoma, Olfactory Neurocytoma, Large Cell Medulloblastoma; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Nuclear Protein In Testis (NUT)-Associated Carcinoma, Epithelial-Myoepithelial Carcinoma, Squamous Cell Carcinoma; Keratinizing; NOS, Ganglioneuroma; Other; Schwannoma, Glomus Tumor; Malignant, Neoplasm; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Malignant Lymphoma; Non-Hodgkin; NOS, Embryonal Rhabdomyosarcoma; NOS; CNS Embryonal Tumor; NOS, Tenosynovial Giant Cell Tumor; NOS, Histologically Low-Grade Glioma, Chordoma; NOS; Ganglioneuroblastoma, Ependymoma; NOS, Invasive Mammary Carcinoma, Rhabdoid Tumor; Malignant, Medulloblastoma; Classic Histology, Adenocarcinoma In Villous Adenoma, Undifferentiated Sarcoma, Papillary Thyroid Carcinoma, Renal Cell Adenocarcinoma, Hodgkin Lymphoma; NOS, Malignant Histiocytosis, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Solid Pseudopapillary Tumor Of Ovary, Astrocytic Glioma; Histologically Low-Grade; Most Compatible With Pilocytic Astrocytoma, Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst, Myofibromatosis, Small Round Blue Cell Tumor, Meningioma; Atypical; CNS WHO Grade 2, Neoplasm; Uncertain Whether Benign Or Malignant; Adamantinomatous Craniopharyngioma; Craniopharyngioma, Pilocytic Astrocytoma, Lobular And Ductal Carcinoma, Desmoplastic/Nodular Medulloblastoma (Histologically Defined); CNS WHO Grade 4, Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation, Tumor Cells; Malignant; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Malignant Tumor, Brain Tumor, Gastrointestinal Stromal Tumor; Benign, Rasmussen Encephalitis, Medulloblastoma; NOS; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Adenocarcinoma;NOS; Glioblastoma; NOS, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Embryonal Sarcoma, Neoplasm; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Anaplastic Large Cell Lymphoma; T-Cell And Null-Cell Type, Teratoma; NOS, Pleomorphic Xanthoastrocytoma; NOS, Infiltrating duct and lobular carcinoma, Sclerosing Stromal Tumor, Tumor Cells; Uncertain Whether Benign Or Malignant, Acute Myeloid Leukemia; NOS; Juvenile Myelomonocytic Leukemia; NOS, Lobular Carcinoma; NOS, Schwannoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Sarcoma; NOS, CNS Embryonal Tumor With Rhabdoid Features, Glial Neoplasm; Astrocytoma, Pancreas-Adenosquamous Carcinoma, Mesenchymal Lesion, Serous Adenocarcinoma; NOS, Hepatoblastoma; NOS, Astrocytoma; NOS; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Sex Cord-Gonadal Stromal Tumor; NOS, Adenoid Cystic Carcinoma, Embryonal Tumor, Acute Myeloid Leukemia; T(8;21)(Q22;Q22), Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor, Cavernoma, Malignant Tumor; Small Cell Type, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Germinoma, Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma., Neoplasm; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Serous Carcinoma; NOS, Metastatic Secondary Tumors, Yolk Sac Tumor, Morphologically Consistent With Pilocytic Astrocytoma; WHO Grade 1, Neuroendocrine Tumor; NOS, Mixed Germ Cell Tumor; Acute Megakaryoblastic Leukemia, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL, Glioma; Malignant; High-Grade Glioma; Pleomorphic Xanthoastrocytoma, Papillary Glioneuronal Tumor; WHO Grade 1, Central Neuroblastoma, Dysembryoplastic Neuroepithelial Tumor, Mixed Adenocarcinoma And Squamous Cell Carcinoma; Pancreatobiliary-Type Carcinoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Myofibroblastic Tumor, Nephroblastoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Malignant Melanoma; NOS; Meningeal Melanocytic Neoplasms (Includes Melanoma); Other, Carcinoma; Metastatic; NOS, Follicular Carcinoma; Minimally Invasive, Angiomyofibroblastoma, Classic Medulloblastoma; CNS WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Atypical Teratoid/Rhabdoid Tumor; ATRT-MYC, Astroblastoma, Meningothelial Meningioma; Meningioma; Other, Poorly Differentiated Chordoma, Chronic Myelogenous Leukemia, Pleomorphic Sarcoma, Supratentorial Ependymoma CNS WHO Grade 3, Leydig Cell Tumor; NOS, Adenosarcoma, Pigmented Dermatofibrosarcoma Protuberans, Astrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Astrocytoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Astrocytoma; NOS; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Myxofibrosarcoma, Precursor T-Cell Lymphoblastic Leukemia, Neurocytoma, Adrenal Cortical Tumor; NOS, Neoplasm; Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1, Neoplasm; Malignant; CNS Neuroblastoma; FOXR2-Activated; Other CNS Embryonal Tumors, Infiltrating duct and mucinous carcinoma, Adenocarcinoma In Situ; NOS, Mucinous Adenocarcinoma, Retinoblastoma; NOS, Anaplastic Ependymoma, Germ Cell Tumor; Nonseminomatous; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Acute Monoblastic And Monocytic Leukemia, Hemangioblastoma; CNS WHO Grade 1, Alveolar Rhabdomyosarcoma, Medullary Carcinoma; NOS, Adult Granulosa Cell Tumor Of Testis, Medulloblastoma; WHO Grade 4, Craniopharyngioma; Adamantinomatous, High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor), Spindle Cell Rhabdomyosaroma, Diffuse Midline Glioma; H3 K27M-Mutant, Epithelioid Sarcoma; NOS, Myoepithelial Carcinoma, Multiple Myeloma, Triple-Negative Breast Carcinoma, Hepatocellular Carcinoma; NOS; Nephroblastoma; NOS, Neuroblastoma; Schwannian Stroma Poor; Poorly Differentiated; Low MKI; Favorable Histology, Sertoli Cell Tumor; NOS, Ossifying Fibroma, Pleomorphic Liposarcoma, Amelanotic Melanoma, Liposarcoma; NOS, Non-Germinomatous Germ Cell Tumor, Lactotroph Adenoma, Transient Abnormal Myelopoiesis, Favor Posterior Fossa Ependymoma; WHO GRADE 3, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Carcinoma In Situ; NOS, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ependymoma; Anaplastic, Glial Neoplasm; Favor Pilocytic Astrocytoma, Gastrointestinal Stromal Tumor; NOS, Serous Cystadenocarcinoma; NOS, Papillary Lesion With Atypical/High Grade Features, Spinal Ependymoma; WHO Grade 2, Ductal Carcinoma In Situ; NOS, Infiltrating Ductal Carcinoma, Mixed Type Rhabdomyosarcoma, Medulloblastoma; SHH-Activated And TP53-Mutant, Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy, Mesenchymal Chondrosarcoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Cribriform Carcinoma; NOS, Myxopapillary Ependymoma; Anaplastic, Ependymoma; Anaplastic; Supratentorial Ependymoma; NOS Or NEC, Astrocytoma; IDH-Mutant; WHO Grade 2, Meningioangiomatosis, Acute Myeloid Leukemia; NOS; Myeloproliferative Neoplasm; Unclassifiable, Endometrioid carcinoma; NOS, Adenocarcinoma In Situ; Non-Mucinous, Medulloblastoma; NOS; Medulloblastoma; Group 4, Papillary Carcinoma; Follicular Variant, Metaplastic Carcinoma; NOS, Choroid Plexus Carcinoma; Choroid Plexus Tumors, Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation, Low Grade Glioma, Sex Cord Stromal Tumor NOS, Stroma Poor; Poorly Differentiated Neuroblastoma With Low MKI; Favorable Histology, Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid), Melanotic Neuroectodermal Tumor, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Angiocentric Glioma; Low-Grade Glioma, Malignant Lymphoma; NOS, Medulloblastoma WHO Grade 4, Choroid Plexus Papillary Tumor, Follicular Adenocarcinoma; Well Differentiated; Neuroblastoma; NOS, Neuroepithelial Tumor, Myelodysplastic Syndrome With Multilineage Dysplasia, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Mast Cell Leukemia, Ganglioneuroblastoma, Pheochromocytoma; NOS, Papillary Serous Adenocarcinoma, Mixed Germ Cell Tumor, Lymphoid Leukemia; NOS, Ependymoma NOS, Smooth Muscle Tumor Of Uncertain Malignant Potential, Combined Small Cell-Large Carcinoma, Sertoli Leydig Cell Tumor, Anaplastic Large Cell Lymphoma; ALK Positive, Meningioma; Malignant, Rhabdoid Tumor; NOS, Merkel Cell Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Meningioma; Other, Lymphoma; NOS, Gangliocytoma; NOS, Glioblastoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Mucinous Non-Cystic Carcinoma, Mucinous Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Pilocytic Astrocytoma, Ganglioglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, High Grade Carcinosarcoma, Subependymal Giant Cell Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Squamous Cell Carcinoma; Metastatic; NOS, Myeloid Leukemia Associated With Down Syndrome, Meningeal Melanomatosis, Neuroepithelial Tumor With Glioneuronal-Like Features, Squamous Cell Carcinoma; Large Cell; Nonkeratinizing; NOS, Meningiomatosis; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Oligodendroglioma; NOS; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFA, CNS Embryonal Tumor; NOS, Favor Anaplastic Ependymoma, Diffuse Glioma, Adamantinomatous Craniopharyngioma (CNS WHO Grade 1), Medulloblastoma; Classic Variant; WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Glioneuronal Tumor With Focal Increased Atypia, High Grade Neuroepithelial Tumor, Squamous Cell Carcinoma; Small Cell; Nonkeratinizing, Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged, Acute Myeloid Leukemia; Minimal Differentiation, Fibrillary Astrocytoma, Chordoma; NOS, Undifferentiated Leukemia, Myofibroma, Neoplasm; Malignant, Pleomorphic Xanthoastrocytoma; NOS; Low-Grade Glioma, Invasive Ductal Carcinoma, Subependymal Giant Cell Astrocytoma, Embryonal Rhabdomyosarcoma With Anaplastic Features, High-Grade Neuroepithelial Tumor, Low Grade Glioneuronal Tumor, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Acute Myeloid Leukemia Without Maturation, Adenocarcinoma With Mixed Subtypes, B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy, Malignant Peripheral Nerve Sheath Tumor; NOS, Hemangiosarcoma, Paraganglioma; NOS, Medulloblastoma; Nodular/Desmoplastic With Anaplastic/Large Cell Features; Non-WNT/Non-SHH; WHO Grade 4, Signet Ring Cell Carcinoma, Spindle Cell Melanoma; NOS, Lobular Adenocarcinoma, Undiagnosed Spindle Cell Tumor, Pilocytic Astrocytoma; WHO Grade 1; KIAA1549-BRAF Fusion, Meningioma, Hepatosplenic T-Cell Lymphoma; Precursor Cell Lymphoblastic Leukemia; NOS, Mesenchymal Chondrosarcoma, Anaplastic Ganglioglioma, Osteosarcoma; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Ependymoma WHO Grade 3, Lung Adenocarcinoma; NOS, Lymphoproliferative Disorder; NOS, Atypical Lymphoid Infiltrate, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Wildtype, Genital Rhabdomyoma, Chondroblastic Osteosarcoma, Neuroepithelioma; NOS, Malignant Epithelioid And Myxoid Neoplasm, Pancreatoblastoma, Nephroblastoma (Wilms Tumor), Malignant Glioma, Ewing Sarcoma, Atypical Smooth Muscle Neoplasm, Acute Myelomonocytic Leukemia; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Epithelial Tumor; Benign, Favor Teratoma, Malignant Neoplasm Of Prostate, Non-Clear Cell Renal Cell Carcinoma, Meningioma; NOS; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Melanotic Schwannoma; Other, Medulloblastoma; NOS; Medulloblastoma; WNT-Activated, Carcinosarcoma NOS, Plasmacytoma; Extramedullary, Infantile Fibrosarcoma, Glioma; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, CNS Primative Neuroectodermal Tumor (PNET), Infiltrating duct carcinoma; NOS, Precursor B-Cell Lymphoblastic Leukemia, Squamous Cell Carcinoma In Situ; NOS, Acute Myeloid Leukemia; T(16;16)(P 13;Q 11), Papillary Transitional Cell Carcinoma, Atypical Teratoid/Rhabdoid Tumor, Low-Grade Glioneuronal; Neuronal Tumor, Combined Small Cell-Adenocarcinoma, Hepatocellular Carcinoma; NOS, Spindle Cell Carcinoma; NOS, Carcinoma; Diffuse Type, Lentiginous Melanocytic Nevus, Glioma; Malignant; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Solitary Fibrous Tumor; NOS, Glioma; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Granulosa Cell Tumor; Malignant, Ganglioneuroma; Maturing Type; Favorable Histology, Invasive Lobular Carcinoma, Ganglioglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation, Medulloblastoma, Hepatoblastoma, Low Grade Glial/ Glioneuronal Tumor, Atypical Teratoid Rhabdoid Tumor; CNS WHO Grade 4, Oligoastrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Diffuse Glioma; Favor High Grade, Reactive Connective Tissue, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Mutant, Tumor Cells; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Malignant Peripheral Nerve Sheath Tumor; NOS, Melanoma; NOS, Malignant Melanocytic Neoplasm, Chronic Myelogenous Leukemia; BCR/ABL Positive, Vascular Lesion; Consistent With Hemangioma, Small Cell Neuroendocrine Carcinoma, Medullary Carcinoma, Anaplastic Astrocytoma; IDH-Wildtype; Glioblastoma; IDH Wildtype, Rhabdomyosarcoma; Embryonal Subtype, Medulloblastoma By Morphology; NON-WNT By Immunohistochemistry, Glioma; Malignant; Astrocytoma; IDH-Mutant; High-Grade Glioma, Ganglioglioma; NOS, Dysembryoplastic Neuroepithelial Tumor; Angiocentric Glioma; Low-Grade Glioma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Angiomatoid Fibrous Histiocytoma, Micropapillary Carcinoma; NOS, Infiltrating Lobular Carcinoma; NOS, Gastrointestinal Stromal Tumor, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; Group 4, Craniopharyngioma, Sertoli-Leydig Cell Tumor; Intermediate Differentiation; With Heterologous Elements, Acute Myeloid Leukemia; Inv(16)(P13;Q22), Subependymoma, Gliomatosis Cerebri, Infiltrating lobular carcinoma; NOS, Schwannoma; NOS, Oligodendroglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dysplasia, Malignant Rhabdoid Tumor, Blue Nevus; Malignant, Adenocarcinoma; Pancreatobiliary Type, Ependymoma; NOS; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ganglioneuroblastoma; Nodular Type, Granulosa Cell Tumor; Juvenile, Juvenile Granulosa Cell Tumor, Chronic Myeloid Leukemia; BCR-ABL1-Positive, Head & Neck Squamous Cell Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Medulloblastoma; SHH-Activated And TP53-Wildtype, Ganglioglioma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma, Adrenal Cortical Adenoma; NOS, Adenocarcinoma; Pancreatobiliary Type; Pancreatobiliary-Type Carcinoma, Lipoblastomatosis, Central Neurocytoma; Glioneuronal And Neuronal Tumors, Control, HHV8 Positive Diffuse Large B-Cell Lymphoma, Pilocytic Astrocytoma; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Group 4, Large Cell Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1), Central Osteosarcoma; NOS, Chordoma, Pilocytic Astrocytoma; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Pilocytic Astrocytoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dermatofibrosarcoma Protuberans; Fibrosarcomatous, Neuroendocrine Carcinoma; NOS, Glioma; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Oligodendroglioma; NOS, Acute Monoblastic Leukemia, Glioma; Malignant; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Neoplasm, Medulloepithelioma; NOS, Oligodendroglioma; NOS; High-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Not Reported, Aggressive Fibromatosis, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Langerhans Cell Histiocytosis; Disseminated, Glioma; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Oligoastrocytoma; NOS, Undifferentiated Nasopharyngeal Carcinoma, Small Cell Carcinoma; NOS, Chordoma; NOS; Chordoma (Including Poorly Differentiated Chordoma); Other, Mesothelioma; Biphasic; Malignant; B Lymphoblastic Leukemia/Lymphoma; NOS, Central Neurocytoma; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Undifferentiated Small Round Cell Sarcoma, Rhabdomyoma; NOS, Glioblastoma; IDH Wildtype, Neoplasm; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Therapy Related Myeloid Neoplasm, Acute Myeloid Leukemia; NOS, Malignant Tumor; Spindle Cell Type; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Leydig Cell Tumor; Benign, Myelodysplastic Syndrome With Single Lineage Dysplasia, Germinoma; CNS Germ Cell Tumors; CNS Germinoma, Glial Tumor, Synovial Sarcoma; Spindle Cell, Spindle Cell Melanoma; Type B, Familial Adenomatous Polyposis, Giant Cell Glioblastoma, Teratocarcinoma, Adenoma; NOS, Acral Lentiginous Melanoma; Malignant, Carcinoma NOS, Papillary Carcinoma; NOS, Poorly Differentiated Neuroblastoma, Solid Pseudopapillary Neoplasm Of Pancreas, Nasopharyngeal Carcinoma, Adenocarcinoma In Adenomatous Polyposis Coli, Leiomyoma; NOS, Embryonal Rhabdomyosarcoma; NOS, Choroid Plexus Papilloma; NOS; Other CNS Embryonal Tumors; Pineoblastoma, Tumor Cells; Benign, Marginal Zone B-Cell Lymphoma; NOS, Tumor Cells; Malignant; Other; Pineal Parenchymal Tumor Of Intermediate Differentiation, Pinealoma, Atypical Teratoid/Rhabdoid Tumor; INI1/SMARCB1-Altered; WHO Grade 4, Metastatic Signet Ring Cell Carcinoma, Astrocytoma, Desmoplastic Infantile Astrocytoma, Malignant Sarcoma With DICER1 Mutation; Favor Primary Intracranial Sarcoma; DICER1 Mutant, B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy, Colon Adenocarcinoma, Ependymoma; NOS; Supratentorial Ependymoma; NOS Or NEC, Proliferative Dermal Lesion In Congenital Nevus, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; WNT-Activated, Arteriovenous Malformation, Glioma; Malignant, Acinar Cell Carcinoma, Spinal Ependymoma; Histologically Low Grade (CNS WHO Grade 2), Leukemia; NOS, Hemangioblastoma; Other, High-Grade Serous Carcinoma, Medulloblastoma; NOS; Medulloblastoma; Group 3, Schwannian Stroma Poor Peripheral Neuroblastic Tumor; Consistent With Neuroblastoma, Acute Myeloid Leukemia With Mutated CEBPA, Parosteal Osteosarcoma, Epithelioid Mesothelioma; Malignant, Meningioma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Choriocarcinoma Combined With Other Germ Cell Elements, Brain Tumor; Low Grade Glioma, Ganglioglioma; NOS; Diffuse Astrocytoma; MYB- Or MYBL1-Altered; Low-Grade Glioma, Embryonal Tumor With Multilayered Rosettes C19MC-Altered, Neoplasm; Malignant; Uncertain Whether Primary Or Metastatic, Desmoplastic Small Round Cell Tumor, Embryonal Rhabdomyosarcoma, Langerhans Cell Histiocytosis, Glial Neoplasm Showing High-Grade Features, Oligodendroglioma, Malignant Melanoma; NOS, Myxopapillary Ependymoma; Ependymoma, Medulloblastoma; NOS; Medulloblastoma; NOS Or NEC, Neoplasm; Malignant; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Adenocarcinoma, B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1, Hemangioendothelioma; Malignant, Choroid Plexus Neoplasm, Craniopharyngioma; Adamantinomatous; Adamantinomatous Craniopharyngioma, Pinealoblastoma, Large Cell Medulloblastoma; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Spindle Cell Sarcoma, Gliosarcoma, Central Primitive Neuroectodermal Tumor, Astrocytoma; IDH-Mutant; CNS WHO Grade 3, Astrocytoma; Benign, Pleomorphic Rhabdomyosarcoma; Adult Type, Myeloid Sarcoma, Glioma; Malignant; Other; Other Low-Grade B-Cell Lymphomas Of The CNS, Ganglioneuroma, Neoplasm; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Clear Cell Renal Cell Carcinoma, Ependymoma; NOS; Atypical Meningioma, Oligodendroglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Malignant Peripheral Nerve Sheath Tumor, Glioma; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Sertoli-Leydig Cell Tumor Of Intermediate Differentiation; NOS, Desmoplastic Nodular Medulloblastoma, Papillary Microcarcinoma, Craniopharyngioma; NOS, Low Grade Glial Neoplasm, Leiomyosarcoma; NOS, Follicular Adenocarcinoma; NOS",,,CDE:14714127,,string,,,,,, Biospecimen Treatment Response,Text term that describes the treatment response of a model or patient from which this specimen was derived.,"Complete Response, No Evidence of Disease, No Response, Not Applicable, Not Evaluable, Not Reported, Partial Response, Persistent Disease, Progressive Disease, Stable Disease, Unknown",,,CDE:13383448,,string,,,,,, Biospecimen Incidence Type,Text term describing a change in disease status associated with the collection of this specimen. ,"Primary, Progression, Recurrence, Metastasis, Remission, No Disease",,,CDE:0002002,,string,,,,,, -Biospecimen Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string_list,,,,,, +Biospecimen Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string_list,,,,,, Collection,The set of metadata entries associated with a Study. A collection defines which resources should be grouped for sharing and reuse.,,"Collection_id, GrantView Key, Study Key, PublicationView Key, DatasetView Key, ToolView Key, EducationalResource Key, Biospecimen Table Id, Model Table Id, Individual Table Id, Imaging Channel Table Id, GeoMx ROI Table Id",,,,,,,,,True, Collection_id,"Unique ID associated with a collection, used as a key for record linking and updates.",,,True,primary_key,,string,,"^C-\d{2,9}$",,,, Biospecimen Table Id,The Synapse Id corresponding to a Biospecimen metadata table associated with the Dataset(s),,,,,,string,,"^syn\d{7,8}$",,,, @@ -302,7 +302,7 @@ Individual Primary Tumor Stage,Extent of the primary cancer based on evidence ob Individual Tumor Lymph Node Stage,Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.,"N0, N0 (i+), N0 (i-), N0 (mol+), N0 (mol-), N1, N1a, N1b, N1bI, N1bII, N1bIII, N1bIV, N1c, N1mi, N2, N2a, N2b, N2c, N3, N3a, N3b, N3c, N4, NX, Unknown, Not Reported",,,CDE:3440330,,string,,,,,, Individual Days To Recurrence,Number of days between the date used for index and the date the patient's disease recurred,,,,,,number,,,,,, Individual Days to Last Known Disease Status,"Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days.",,,,,,number,,,,,, -Individual Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, +Individual Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, Individual Days to Treatment,Number of days between the date used for index and the date the treatment started.,,,,,,number,,,,,, Individual Therapeutic Agent,Text identification of the individual agent(s) used as part of a treatment regimen.,"10-Deacetyltaxol, 11C Topotecan, 11D10 AluGel Anti-Idiotype Monoclonal Antibody, 12-Allyldeoxoartemisinin, 13-Deoxydoxorubicin, 14C BMS-275183, 17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521, 2-Deoxy-D-glucose, 2-Ethylhydrazide, 2-Fluoroadenine, 2-Fluorofucose-containing SGN-2FF, 2-Hydroxyestradiol, 2-Hydroxyestrone, 2-Hydroxyflutamide Depot, 2-Hydroxyoleic Acid, 2-Methoxyestradiol, 2-Methoxyestradiol Nanocrystal Colloidal Dispersion, 2-Methoxyestrone, 2-O; 3-O Desulfated Heparin, 2;6-Diaminopurine, 2;6-Dimethoxyquinone, 2'-F-ara-deoxyuridine, 3'-C-ethynylcytidine, 3'-dA Phosphoramidate NUC-7738, 4-Nitroestrone 3-Methyl Ether, 4-Thio-2-deoxycytidine, 4'-Iodo-4'-Deoxydoxorubicin, 5-Aza-4'-thio-2'-deoxycytidine, 5-Fluoro-2-Deoxycytidine, 6-Phosphofructo-2-kinase/fructose-2;6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158, 7-Cyanoquinocarcinol, 7-Ethyl-10-Hydroxycamptothecin, 7-Hydroxystaurosporine, 8-Azaguanine, 9-Ethyl 6-Mercaptopurine, 9H-Purine-6Thio-98D, A2A Receptor Antagonist EOS100850, Abagovomab, Abarelix, Abemaciclib, Abemaciclib Mesylate, Abexinostat, Abexinostat Tosylate, Abiraterone, Abiraterone Acetate, Abituzumab, Acai Berry Juice, Acalabrutinib, Acalisib, Aceglatone, Acetylcysteine, Acitretin, Acivicin, Aclacinomycin B, Aclarubicin, Acodazole, Acodazole Hydrochloride, Acolbifene Hydrochloride, Acridine, Acridine Carboxamide, Acronine, Actinium Ac 225 Lintuzumab, Actinium Ac 225-FPI-1434, Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591, Actinomycin C2, Actinomycin C3, Actinomycin F1, Activin Type 2B Receptor Fc Fusion Protein STM 434, Acyclic Nucleoside Phosphonate Prodrug ABI-1968, Ad-RTS-hIL-12, Adagloxad Simolenin, Adavosertib, Adecatumumab, Adenosine A2A Receptor Antagonist AZD4635, Adenosine A2A Receptor Antagonist CS3005, Adenosine A2A Receptor Antagonist NIR178, Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999, Adenosine A2A/A2B Receptor Antagonist AB928, Adenosine A2B Receptor Antagonist PBF-1129, Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201, Adenoviral Brachyury Vaccine ETBX-051, Adenoviral Cancer Vaccine PF-06936308, Adenoviral MUC1 Vaccine ETBX-061, Adenoviral PSA Vaccine ETBX-071, Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001, Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901, Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE, Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918, Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931, Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3, Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001, Aderbasib, ADH-1, AE37 Peptide/GM-CSF Vaccine, AEE788, Aerosol Gemcitabine, Aerosolized Aldesleukin, Aerosolized Liposomal Rubitecan, Afatinib, Afatinib Dimaleate, Afimoxifene, Afuresertib, Agatolimod Sodium, Agerafenib, Aglatimagene Besadenovec, Agonistic Anti-CD40 Monoclonal Antibody ADC-1013, Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Agonistic Anti-OX40 Monoclonal Antibody MEDI6469, AKR1C3-activated Prodrug OBI-3424, AKT 1/2 Inhibitor BAY1125976, AKT Inhibitor ARQ 092, Akt Inhibitor LY2780301, Akt Inhibitor MK2206, Akt Inhibitor SR13668, Akt/ERK Inhibitor ONC201, Alacizumab Pegol, Alanosine, Albumin-binding Cisplatin Prodrug BTP-114, Aldesleukin, Aldoxorubicin, Alectinib, Alefacept, Alemtuzumab, Alestramustine, Alflutinib Mesylate, Algenpantucel-L, Alisertib, Alitretinoin, ALK Inhibitor, ALK Inhibitor ASP3026, ALK Inhibitor PLB 1003, ALK Inhibitor RO5424802, ALK Inhibitor TAE684, ALK Inhibitor WX-0593, ALK-2 Inhibitor TP-0184, ALK-FAK Inhibitor CEP-37440, ALK/c-Met Inhibitor TQ-B3139, ALK/FAK/Pyk2 Inhibitor CT-707, ALK/ROS1/Met Inhibitor TQ-B3101, ALK/TRK Inhibitor TSR-011, Alkotinib, Allodepleted T Cell Immunotherapeutic ATIR101, Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715, Allogeneic Anti-BCMA-CAR T-cells PBCAR269A, Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells, Allogeneic Anti-CD19 CAR T-cells ALLO-501A, Allogeneic Anti-CD19 Universal CAR-T Cells CTA101, Allogeneic Anti-CD19-CAR T-cells PBCAR0191, Allogeneic Anti-CD20 CAR T-cells LUCAR-20S, Allogeneic Anti-CD20-CAR T-cells PBCAR20A, Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22, Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100, Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001, Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Allogeneic Cellular Vaccine 1650-G, Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120, Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130, Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine, Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo, Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2, Allogeneic Irradiated Melanoma Cell Vaccine CSF470, Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307, Allogeneic Melanoma Vaccine AGI-101H, Allogeneic Natural Killer Cell Line MG4101, Allogeneic Natural Killer Cell Line NK-92, Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01, Allogeneic Renal Cell Carcinoma Vaccine MGN1601, Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19, Allosteric ErbB Inhibitor BDTX-189, Allovectin-7, Almurtide, Alobresib, Alofanib, Alpelisib, Alpha Galactosylceramide, Alpha V Beta 1 Inhibitor ATN-161, Alpha V Beta 8 Antagonist PF-06940434, alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801, Alpha-Gal AGI-134, Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H, Alpha-Thioguanine Deoxyriboside, Alpha-tocopheryloxyacetic Acid, Alsevalimab, Altiratinib, Altretamine, Alvespimycin, Alvespimycin Hydrochloride, Alvocidib, Alvocidib Hydrochloride, Alvocidib Prodrug TP-1287, Amatuximab, Ambamustine, Ambazone, Amblyomin-X, Amcasertib, Ametantrone, Amifostine, Amino Acid Injection, Aminocamptothecin, Aminocamptothecin Colloidal Dispersion, Aminoflavone Prodrug AFP464, Aminopterin, Aminopterin Sodium, Amivantamab, Amolimogene Bepiplasmid, Amonafide L-Malate, Amrubicin, Amrubicin Hydrochloride, Amsacrine, Amsacrine Lactate, Amsilarotene, Amustaline, Amustaline Dihydrochloride, Amuvatinib, Amuvatinib Hydrochloride, Anakinra, Anastrozole, Anaxirone, Ancitabine, Ancitabine Hydrochloride, Andecaliximab, Androgen Antagonist APC-100, Androgen Receptor Antagonist BAY 1161116, Androgen Receptor Antagonist SHR3680, Androgen Receptor Antagonist TAS3681, Androgen Receptor Antagonist TRC253, Androgen Receptor Antisense Oligonucleotide AZD5312, Androgen Receptor Antisense Oligonucleotide EZN-4176, Androgen Receptor Degrader ARV-110, Androgen Receptor Degrader CC-94676, Androgen Receptor Downregulator AZD3514, Androgen Receptor Inhibitor EPI-7386, Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118, Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10, Andrographolide, Androstane Steroid HE3235, Anetumab Ravtansine, Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241, Angiogenesis Inhibitor GT-111, Angiogenesis Inhibitor JI-101, Angiogenesis/Heparanase Inhibitor PG545, Angiopoietin-2-specific Fusion Protein PF-04856884, Anhydrous Enol-oxaloacetate, Anhydrovinblastine, Aniline Mustard, Anlotinib Hydrochloride, Annamycin, Annamycin Liposomal, Annonaceous Acetogenins, Ansamitomicin P-3, Anthramycin, Anthrapyrazole, Anti c-KIT Antibody-drug Conjugate LOP628, Anti-5T4 Antibody-drug Conjugate ASN004, Anti-5T4 Antibody-Drug Conjugate PF-06263507, Anti-5T4 Antibody-drug Conjugate SYD1875, Anti-A33 Monoclonal Antibody KRN330, Anti-A5B1 Integrin Monoclonal Antibody PF-04605412, Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087, Anti-AG7 Antibody Drug Conjugate AbGn-107, Anti-AGS-16 Monoclonal Antibody AGS-16M18, Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME, Anti-AGS-8 Monoclonal Antibody AGS-8M4, Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B, Anti-alpha5beta1 Integrin Antibody MINT1526A, Anti-ANG2 Monoclonal Antibody MEDI-3617, Anti-angiopoietin Monoclonal Antibody AMG 780, Anti-APRIL Monoclonal Antibody BION-1301, Anti-AXL Fusion Protein AVB-S6-500, Anti-AXL/PBD Antibody-drug Conjugate ADCT-601, Anti-B7-H3 Antibody DS-5573a, Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a, Anti-B7-H4 Monoclonal Antibody FPA150, Anti-B7H3 Antibody-drug Conjugate MGC018, Anti-BCMA Antibody SEA-BCMA, Anti-BCMA Antibody-drug Conjugate AMG 224, Anti-BCMA Antibody-drug Conjugate CC-99712, Anti-BCMA Antibody-drug Conjugate GSK2857916, Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA, Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459, Anti-BCMA/CD3 BiTE Antibody AMG 420, Anti-BCMA/CD3 BiTE Antibody AMG 701, Anti-BCMA/CD3 BiTE Antibody REGN5458, Anti-BCMA/PBD ADC MEDI2228, Anti-BTLA Monoclonal Antibody TAB004, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, Anti-c-fms Monoclonal Antibody AMG 820, Anti-c-KIT Monoclonal Antibody CDX 0158, Anti-c-Met Antibody-drug Conjugate HTI-1066, Anti-c-Met Antibody-drug Conjugate TR1801, Anti-c-Met Monoclonal Antibody ABT-700, Anti-c-Met Monoclonal Antibody ARGX-111, Anti-c-Met Monoclonal Antibody HLX55, Anti-c-MET Monoclonal Antibody LY2875358, Anti-C-met Monoclonal Antibody SAIT301, Anti-C4.4a Antibody-Drug Conjugate BAY1129980, Anti-C5aR Monoclonal Antibody IPH5401, Anti-CA19-9 Monoclonal Antibody 5B1, Anti-CA6-DM4 Immunoconjugate SAR566658, Anti-CCR7 Antibody-drug Conjugate JBH492, Anti-CD117 Monoclonal Antibody JSP191, Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1, Anti-CD123 ADC IMGN632, Anti-CD123 Monoclonal Antibody CSL360, Anti-CD123 Monoclonal Antibody KHK2823, Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404, Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A, Anti-CD123/CD3 Bispecific Antibody APVO436, Anti-CD123/CD3 Bispecific Antibody JNJ-63709178, Anti-CD123/CD3 BiTE Antibody SAR440234, Anti-CD137 Agonistic Monoclonal Antibody ADG106, Anti-CD137 Agonistic Monoclonal Antibody AGEN2373, Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017, Anti-CD137 Agonistic Monoclonal Antibody CTX-471, Anti-CD137 Agonistic Monoclonal Antibody LVGN6051, Anti-CD157 Monoclonal Antibody MEN1112, Anti-CD166 Probody-drug Conjugate CX-2009, Anti-CD19 Antibody-drug Conjugate SGN-CD19B, Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003, Anti-CD19 iCAR NK Cells, Anti-CD19 Monoclonal Antibody DI-B4, Anti-CD19 Monoclonal Antibody MDX-1342, Anti-CD19 Monoclonal Antibody MEDI-551, Anti-CD19 Monoclonal Antibody XmAb5574, Anti-CD19-DM4 Immunoconjugate SAR3419, Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL, Anti-CD19/CD22 CAR NK Cells, Anti-CD19/CD3 BiTE Antibody AMG 562, Anti-CD19/CD3 Tetravalent Antibody AFM11, Anti-CD20 Monoclonal Antibody B001, Anti-CD20 Monoclonal Antibody BAT4306F, Anti-CD20 Monoclonal Antibody MIL62, Anti-CD20 Monoclonal Antibody PRO131921, Anti-CD20 Monoclonal Antibody SCT400, Anti-CD20 Monoclonal Antibody TL011, Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002, Anti-CD20-engineered Toxin Body MT-3724, Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323, Anti-CD20/CD3 Monoclonal Antibody REGN1979, Anti-CD20/CD3 Monoclonal Antibody XmAb13676, Anti-CD205 Antibody-drug Conjugate OBT076, Anti-CD22 ADC TRPH-222, Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S, Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A, Anti-CD25 Monoclonal Antibody RO7296682, Anti-CD25-PBD Antibody-drug Conjugate ADCT-301, Anti-CD26 Monoclonal Antibody YS110, Anti-CD27 Agonistic Monoclonal Antibody MK-5890, Anti-CD27L Antibody-Drug Conjugate AMG 172, Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1), Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135, Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119, Anti-CD3/CD20 Bispecific Antibody GEN3013, Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424, Anti-CD3/CD7-Ricin Toxin A Immunotoxin, Anti-CD30 Monoclonal Antibody MDX-1401, Anti-CD30 Monoclonal Antibody XmAb2513, Anti-CD30/CD16A Monoclonal Antibody AFM13, Anti-CD30/DM1 Antibody-drug Conjugate F0002, Anti-CD32B Monoclonal Antibody BI-1206, Anti-CD33 Antibody-drug Conjugate IMGN779, Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564, Anti-CD33 Monoclonal Antibody BI 836858, Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633, Anti-CD33/CD3 Bispecific Antibody GEM 333, Anti-CD33/CD3 Bispecific Antibody JNJ-67571244, Anti-CD33/CD3 BiTE Antibody AMG 330, Anti-CD33/CD3 BiTE Antibody AMG 673, Anti-CD352 Antibody-drug Conjugate SGN-CD352A, Anti-CD37 Antibody-Drug Conjugate IMGN529, Anti-CD37 Bispecific Monoclonal Antibody GEN3009, Anti-CD37 MMAE Antibody-drug Conjugate AGS67E, Anti-CD37 Monoclonal Antibody BI 836826, Anti-CD38 Antibody-drug Conjugate STI-6129, Anti-CD38 Monoclonal Antibody MOR03087, Anti-CD38 Monoclonal Antibody SAR442085, Anti-CD38 Monoclonal Antibody TAK-079, Anti-CD38-targeted IgG4-attenuated IFNa TAK-573, Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257, Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342, Anti-CD39 Monoclonal Antibody SRF617, Anti-CD39 Monoclonal Antibody TTX-030, Anti-CD40 Agonist Monoclonal Antibody ABBV-927, Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Anti-CD40 Monoclonal Antibody Chi Lob 7/4, Anti-CD40 Monoclonal Antibody SEA-CD40, Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042, Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428, Anti-CD40L Fc-Fusion Protein BMS-986004, Anti-CD44 Monoclonal Antibody RO5429083, Anti-CD45 Monoclonal Antibody AHN-12, Anti-CD46 Antibody-drug Conjugate FOR46, Anti-CD47 ADC SGN-CD47M, Anti-CD47 Monoclonal Antibody AO-176, Anti-CD47 Monoclonal Antibody CC-90002, Anti-CD47 Monoclonal Antibody Hu5F9-G4, Anti-CD47 Monoclonal Antibody IBI188, Anti-CD47 Monoclonal Antibody IMC-002, Anti-CD47 Monoclonal Antibody SHR-1603, Anti-CD47 Monoclonal Antibody SRF231, Anti-CD47 Monoclonal Antibody TJC4, Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801, Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A, Anti-CD52 Monoclonal Antibody ALLO-647, Anti-CD70 Antibody-Drug Conjugate MDX-1203, Anti-CD70 Antibody-drug Conjugate SGN-CD70A, Anti-CD70 CAR-expressing T Lymphocytes, Anti-CD70 Monoclonal Antibody MDX-1411, Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029, Anti-CD73 Monoclonal Antibody BMS-986179, Anti-CD73 Monoclonal Antibody CPI-006, Anti-CD73 Monoclonal Antibody NZV930, Anti-CD73 Monoclonal Antibody TJ4309, Anti-CD74 Antibody-drug Conjugate STRO-001, Anti-CD98 Monoclonal Antibody IGN523, Anti-CDH6 Antibody-drug Conjugate HKT288, Anti-CEA BiTE Monoclonal Antibody AMG211, Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody, Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2, Anti-CEACAM1 Monoclonal Antibody CM-24, Anti-CEACAM5 Antibody-Drug Conjugate SAR408701, Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47, Anti-CEACAM6 Antibody BAY1834942, Anti-claudin18.2 Monoclonal Antibody AB011, Anti-Claudin18.2 Monoclonal Antibody TST001, Anti-CLDN6 Monoclonal Antibody ASP1650, Anti-CLEC12A/CD3 Bispecific Antibody MCLA117, Anti-CLEVER-1 Monoclonal Antibody FP-1305, Anti-CSF1 Monoclonal Antibody PD-0360324, Anti-CSF1R Monoclonal Antibody IMC-CS4, Anti-CSF1R Monoclonal Antibody SNDX-6352, Anti-CTGF Monoclonal Antibody FG-3019, Anti-CTLA-4 Monoclonal Antibody ADG116, Anti-CTLA-4 Monoclonal Antibody ADU-1604, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Anti-CTLA-4 Monoclonal Antibody BCD-145, Anti-CTLA-4 Monoclonal Antibody HBM4003, Anti-CTLA-4 Monoclonal Antibody MK-1308, Anti-CTLA-4 Monoclonal Antibody ONC-392, Anti-CTLA-4 Monoclonal Antibody REGN4659, Anti-CTLA-4 Probody BMS-986288, Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217, Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841, Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015, Anti-CTLA4 Antibody Fc Fusion Protein KN044, Anti-CTLA4 Monoclonal Antibody BMS-986218, Anti-CXCR4 Monoclonal Antibody PF-06747143, Anti-Denatured Collagen Monoclonal Antibody TRC093, Anti-DKK-1 Monoclonal Antibody LY2812176, Anti-DKK1 Monoclonal Antibody BHQ880, Anti-DLL3/CD3 BiTE Antibody AMG 757, Anti-DLL4 Monoclonal Antibody MEDI0639, Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83, Anti-DR5 Agonist Monoclonal Antibody TRA-8, Anti-DR5 Agonistic Antibody DS-8273a, Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Anti-EGFR Monoclonal Antibody CPGJ 602, Anti-EGFR Monoclonal Antibody EMD 55900, Anti-EGFR Monoclonal Antibody GC1118, Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX, Anti-EGFR Monoclonal Antibody HLX-07, Anti-EGFR Monoclonal Antibody Mixture MM-151, Anti-EGFR Monoclonal Antibody RO5083945, Anti-EGFR Monoclonal Antibody SCT200, Anti-EGFR Monoclonal Antibody SYN004, Anti-EGFR TAP Antibody-drug Conjugate IMGN289, Anti-EGFR/c-Met Bispecific Antibody EMB-01, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, Anti-EGFR/CD16A Bispecific Antibody AFM24, Anti-EGFR/DM1 Antibody-drug Conjugate AVID100, Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013, Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321, Anti-EGFRvIII Antibody Drug Conjugate AMG 595, Anti-EGFRvIII Immunotoxin MR1-1, Anti-EGFRvIII/CD3 BiTE Antibody AMG 596, Anti-EGP-2 Immunotoxin MOC31-PE, Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F, Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F, Anti-Ep-CAM Monoclonal Antibody ING-1, Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310, Anti-EphA2 Monoclonal Antibody DS-8895a, Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547, Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111, Anti-ErbB3 Antibody ISU104, Anti-ErbB3 Monoclonal Antibody AV-203, Anti-ErbB3 Monoclonal Antibody CDX-3379, Anti-ErbB3 Monoclonal Antibody REGN1400, Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141, Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A, Anti-FAP/Interleukin-2 Fusion Protein RO6874281, Anti-FCRH5/CD3 BiTE Antibody BFCR4350A, Anti-FGFR2 Antibody BAY1179470, Anti-FGFR3 Antibody-drug Conjugate LY3076226, Anti-FGFR4 Monoclonal Antibody U3-1784, Anti-FLT3 Antibody-drug Conjugate AGS62P1, Anti-FLT3 Monoclonal Antibody 4G8-SDIEM, Anti-FLT3 Monoclonal Antibody IMC-EB10, Anti-FLT3/CD3 BiTE Antibody AMG 427, Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002, Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202, Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012, Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962, Anti-GARP Monoclonal Antibody ABBV-151, Anti-GCC Antibody-Drug Conjugate MLN0264, Anti-GCC Antibody-Drug Conjugate TAK-164, Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody, Anti-GD2 Monoclonal Antibody hu14.18K322A, Anti-GD2 Monoclonal Antibody MORAb-028, Anti-GD3 Antibody-drug Conjugate PF-06688992, Anti-GITR Agonistic Monoclonal Antibody ASP1951, Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Anti-GITR Agonistic Monoclonal Antibody INCAGN01876, Anti-GITR Monoclonal Antibody GWN 323, Anti-GITR Monoclonal Antibody MK-4166, Anti-Globo H Monoclonal Antibody OBI-888, Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999, Anti-Glypican 3/CD3 Bispecific Antibody ERY974, Anti-GnRH Vaccine PEP223, Anti-gpA33/CD3 Monoclonal Antibody MGD007, Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a, Anti-gremlin-1 Monoclonal Antibody UCB6114, Anti-GRP78 Monoclonal Antibody PAT-SM6, Anti-HA Epitope Monoclonal Antibody MEDI8852, Anti-HB-EGF Monoclonal Antibody KHK2866, Anti-HBEGF Monoclonal Antibody U3-1565, Anti-hepcidin Monoclonal Antibody LY2787106, Anti-HER-2 Bispecific Antibody KN026, Anti-HER2 ADC DS-8201a, Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702, Anti-HER2 Antibody-drug Conjugate A166, Anti-HER2 Antibody-drug Conjugate ARX788, Anti-HER2 Antibody-drug Conjugate BAT8001, Anti-HER2 Antibody-drug Conjugate DP303c, Anti-HER2 Antibody-drug Conjugate MEDI4276, Anti-HER2 Antibody-drug Conjugate RC48, Anti-HER2 Bi-specific Monoclonal Antibody ZW25, Anti-HER2 Bispecific Antibody-drug Conjugate ZW49, Anti-HER2 Immune Stimulator-antibody Conjugate NJH395, Anti-HER2 Monoclonal Antibody B002, Anti-HER2 Monoclonal Antibody CT-P6, Anti-HER2 Monoclonal Antibody HLX22, Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343, Anti-HER2-DM1 ADC B003, Anti-HER2-DM1 Antibody-drug Conjugate GQ1001, Anti-HER2-vc0101 ADC PF-06804103, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302, Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522, Anti-HER2/MMAE Antibody-drug Conjugate MRG002, Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A, Anti-HER3 Antibody-drug Conjugate U3 1402, Anti-HER3 Monoclonal Antibody GSK2849330, Anti-HGF Monoclonal Antibody TAK-701, Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968, Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1, Anti-HLA-DR Monoclonal Antibody IMMU-114, Anti-HLA-G Antibody TTX-080, Anti-human GITR Monoclonal Antibody AMG 228, Anti-human GITR Monoclonal Antibody TRX518, Anti-ICAM-1 Monoclonal Antibody BI-505, Anti-ICOS Agonist Antibody GSK3359609, Anti-ICOS Agonist Monoclonal Antibody BMS-986226, Anti-ICOS Monoclonal Antibody KY1044, Anti-ICOS Monoclonal Antibody MEDI-570, Anti-IGF-1R Monoclonal Antibody AVE1642, Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, Anti-IL-1 alpha Monoclonal Antibody MABp1, Anti-IL-13 Humanized Monoclonal Antibody TNX-650, Anti-IL-15 Monoclonal Antibody AMG 714, Anti-IL-8 Monoclonal Antibody BMS-986253, Anti-IL-8 Monoclonal Antibody HuMax-IL8, Anti-ILDR2 Monoclonal Antibody BAY 1905254, Anti-ILT4 Monoclonal Antibody MK-4830, Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A, Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388, Anti-IRF4 Antisense Oligonucleotide ION251, Anti-KIR Monoclonal Antibody IPH 2101, Anti-KSP/Anti-VEGF siRNAs ALN-VSP02, Anti-LAG-3 Monoclonal Antibody IBI-110, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG-3 Monoclonal Antibody LAG525, Anti-LAG-3 Monoclonal Antibody REGN3767, Anti-LAG-3/PD-L1 Bispecific Antibody FS118, Anti-LAG3 Monoclonal Antibody BI 754111, Anti-LAG3 Monoclonal Antibody MK-4280, Anti-LAG3 Monoclonal Antibody TSR-033, Anti-LAMP1 Antibody-drug Conjugate SAR428926, Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181, Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102, Anti-LGR5 Monoclonal Antibody BNC101, Anti-LIF Monoclonal Antibody MSC-1, Anti-LILRB4 Monoclonal Antibody IO-202, Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A, Anti-Ly6E Antibody-Drug Conjugate RG 7841, Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C, Anti-Melanin Monoclonal Antibody PTI-6D2, Anti-mesothelin Antibody-drug Conjugate BMS-986148, Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100, Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A, Anti-mesothelin/MMAE Antibody-drug Conjugate RC88, Anti-Met Monoclonal Antibody Mixture Sym015, Anti-Met/EGFR Monoclonal Antibody LY3164530, Anti-MMP-9 Monoclonal Antibody GS-5745, Anti-MUC1 Monoclonal Antibody BTH1704, Anti-MUC16/CD3 Bispecific Antibody REGN4018, Anti-MUC16/CD3 BiTE Antibody REGN4018, Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A, Anti-MUC17/CD3 BiTE Antibody AMG 199, Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062, Anti-myostatin Monoclonal Antibody LY2495655, Anti-NaPi2b Antibody-drug Conjugate XMT-1592, Anti-NaPi2b Monoclonal Antibody XMT-1535, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A, Anti-nf-P2X7 Antibody Ointment BIL-010t, Anti-NRP1 Antibody ASP1948, Anti-Nucleolin Aptamer AS1411, Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A, Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso, Anti-OFA Immunotherapeutic BB-MPI-03, Anti-OX40 Agonist Monoclonal Antibody ABBV-368, Anti-OX40 Agonist Monoclonal Antibody BGB-A445, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Anti-OX40 Antibody BMS 986178, Anti-OX40 Hexavalent Agonist Antibody INBRX-106, Anti-OX40 Monoclonal Antibody GSK3174998, Anti-OX40 Monoclonal Antibody IBI101, Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256, Anti-PD-1 Checkpoint Inhibitor PF-06801591, Anti-PD-1 Fusion Protein AMP-224, Anti-PD-1 Monoclonal Antibody 609A, Anti-PD-1 Monoclonal Antibody AK105, Anti-PD-1 Monoclonal Antibody AMG 404, Anti-PD-1 Monoclonal Antibody BAT1306, Anti-PD-1 Monoclonal Antibody BCD-100, Anti-PD-1 Monoclonal Antibody BI 754091, Anti-PD-1 Monoclonal Antibody CS1003, Anti-PD-1 Monoclonal Antibody F520, Anti-PD-1 Monoclonal Antibody GLS-010, Anti-PD-1 Monoclonal Antibody HLX10, Anti-PD-1 Monoclonal Antibody HX008, Anti-PD-1 Monoclonal Antibody JTX-4014, Anti-PD-1 Monoclonal Antibody LZM009, Anti-PD-1 Monoclonal Antibody MEDI0680, Anti-PD-1 Monoclonal Antibody MGA012, Anti-PD-1 Monoclonal Antibody SCT-I10A, Anti-PD-1 Monoclonal Antibody Sym021, Anti-PD-1 Monoclonal Antibody TSR-042, Anti-PD-1/Anti-CTLA4 DART Protein MGD019, Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315, Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669, Anti-PD-1/Anti-LAG-3 DART Protein MGD013, Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318, Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172, Anti-PD-1/CD47 Infusion Protein HX009, Anti-PD-1/CTLA-4 Bispecific Antibody AK104, Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752, Anti-PD-1/TIM-3 Bispecific Antibody RO7121661, Anti-PD-1/VEGF Bispecific Antibody AK112, Anti-PD-L1 Monoclonal Antibody A167, Anti-PD-L1 Monoclonal Antibody BCD-135, Anti-PD-L1 Monoclonal Antibody BGB-A333, Anti-PD-L1 Monoclonal Antibody CBT-502, Anti-PD-L1 Monoclonal Antibody CK-301, Anti-PD-L1 Monoclonal Antibody CS1001, Anti-PD-L1 Monoclonal Antibody FAZ053, Anti-PD-L1 Monoclonal Antibody GR1405, Anti-PD-L1 Monoclonal Antibody HLX20, Anti-PD-L1 Monoclonal Antibody IMC-001, Anti-PD-L1 Monoclonal Antibody LY3300054, Anti-PD-L1 Monoclonal Antibody MDX-1105, Anti-PD-L1 Monoclonal Antibody MSB2311, Anti-PD-L1 Monoclonal Antibody RC98, Anti-PD-L1 Monoclonal Antibody SHR-1316, Anti-PD-L1 Monoclonal Antibody TG-1501, Anti-PD-L1 Monoclonal Antibody ZKAB001, Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105, Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046, Anti-PD-L1/CD137 Bispecific Antibody MCLA-145, Anti-PD-L1/IL-15 Fusion Protein KD033, Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244, Anti-PD1 Monoclonal Antibody AGEN2034, Anti-PD1/CTLA4 Bispecific Antibody XmAb20717, Anti-PGF Monoclonal Antibody RO5323441, Anti-PKN3 siRNA Atu027, Anti-PLGF Monoclonal Antibody TB-403, Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Anti-PRAME Immunotherapeutic GSK2302032A, Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Anti-PRL-3 Monoclonal Antibody PRL3-zumab, Anti-prolactin Receptor Antibody LFA102, Anti-PSCA Monoclonal Antibody AGS-1C4D4, Anti-PSMA Monoclonal Antibody MDX1201-A488, Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704, Anti-PSMA Monoclonal Antibody-MMAE Conjugate, Anti-PSMA/CD28 Bispecific Antibody REGN5678, Anti-PSMA/CD3 Bispecific Antibody CCW702, Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081, Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414, Anti-PSMA/PBD ADC MEDI3726, Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020, Anti-PVRIG Monoclonal Antibody COM701, Anti-RANKL Monoclonal Antibody GB-223, Anti-RANKL Monoclonal Antibody JMT103, Anti-Ribonucleoprotein Antibody ATRC-101, Anti-ROR1 ADC VLS-101, Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002, Anti-S15 Monoclonal Antibody NC318, Anti-sCLU Monoclonal Antibody AB-16B5, Anti-SIRPa Monoclonal Antibody CC-95251, Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E, Anti-TAG-72 Monoclonal Antibody scFV CC-49/218, Anti-TF Monoclonal Antibody ALT-836, Anti-TGF-beta Monoclonal Antibody NIS793, Anti-TGF-beta Monoclonal Antibody SAR-439459, Anti-TGF-beta RII Monoclonal Antibody IMC-TR1, Anti-TIGIT Monoclonal Antibody AB154, Anti-TIGIT Monoclonal Antibody BGB-A1217, Anti-TIGIT Monoclonal Antibody BMS-986207, Anti-TIGIT Monoclonal Antibody COM902, Anti-TIGIT Monoclonal Antibody OMP-313M32, Anti-TIGIT Monoclonal Antibody SGN-TGT, Anti-TIM-3 Antibody BMS-986258, Anti-TIM-3 Monoclonal Antibody BGB-A425, Anti-TIM-3 Monoclonal Antibody INCAGN02390, Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM-3 Monoclonal Antibody Sym023, Anti-TIM-3 Monoclonal Antibody TSR-022, Anti-TIM3 Monoclonal Antibody LY3321367, Anti-TIM3 Monoclonal Antibody SHR-1702, Anti-Tissue Factor Monoclonal Antibody MORAb-066, Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711, Anti-TROP2 Antibody-drug Conjugate BAT8003, Anti-TROP2 Antibody-drug Conjugate SKB264, Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a, Anti-TWEAK Monoclonal Antibody RG7212, Anti-VEGF Anticalin PRS-050-PEG40, Anti-VEGF Monoclonal Antibody hPV19, Anti-VEGF/ANG2 Nanobody BI 836880, Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T, Anti-VEGFC Monoclonal Antibody VGX-100, Anti-VEGFR2 Monoclonal Antibody HLX06, Anti-VEGFR2 Monoclonal Antibody MSB0254, Anti-VEGFR3 Monoclonal Antibody IMC-3C5, Anti-VISTA Monoclonal Antibody JNJ 61610588, Antiangiogenic Drug Combination TL-118, Antibody-drug Conjugate ABBV-011, Antibody-drug Conjugate ABBV-085, Antibody-drug Conjugate ABBV-155, Antibody-drug Conjugate ABBV-176, Antibody-drug Conjugate ABBV-838, Antibody-drug Conjugate ADC XMT-1536, Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014, Antibody-Drug Conjugate DFRF4539A, Antibody-drug Conjugate MEDI7247, Antibody-drug Conjugate PF-06647263, Antibody-drug Conjugate PF-06664178, Antibody-drug Conjugate SC-002, Antibody-drug Conjugate SC-003, Antibody-drug Conjugate SC-004, Antibody-drug Conjugate SC-005, Antibody-drug Conjugate SC-006, Antibody-drug Conjugate SC-007, Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008, Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV, Antimetabolite FF-10502, Antineoplastic Agent Combination SM-88, Antineoplastic Vaccine, Antineoplastic Vaccine GV-1301, Antineoplaston A10, Antineoplaston AS2-1, Antisense Oligonucleotide GTI-2040, Antisense Oligonucleotide QR-313, Antitumor B Key Active Component-alpha, Antrodia cinnamomea Supplement, Antroquinonol Capsule, Apalutamide, Apatorsen, Apaziquone, APC8015F, APE1/Ref-1 Redox Inhibitor APX3330, Aphidicoline Glycinate, Apilimod Dimesylate Capsule, Apitolisib, Apolizumab, Apomab, Apomine, Apoptosis Inducer BZL101, Apoptosis Inducer GCS-100, Apoptosis Inducer MPC-2130, Apricoxib, Aprinocarsen, Aprutumab, Aprutumab Ixadotin, AR Antagonist BMS-641988, Arabinoxylan Compound MGN3, Aranose, ARC Fusion Protein SL-279252, Archexin, Arcitumomab, Arfolitixorin, Arginase Inhibitor INCB001158, Arginine Butyrate, Arnebia Indigo Jade Pearl Topical Cream, Arsenic Trioxide, Arsenic Trioxide Capsule Formulation ORH 2014, Artemether Sublingual Spray, Artemisinin Dimer, Artesunate, Arugula Seed Powder, Aryl Hydrocarbon Receptor Antagonist BAY2416964, Aryl Hydrocarbon Receptor Inhibitor IK-175, Asaley, Asciminib, Ascrinvacumab, Ashwagandha Root Powder Extract, ASP4132, Aspacytarabine, Asparaginase, Asparaginase Erwinia chrysanthemi, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astuprotimut-R, Asulacrine, Asulacrine Isethionate, Asunercept, At 211 Monoclonal Antibody 81C6, Atamestane, Atezolizumab, Atiprimod, Atiprimod Dihydrochloride, Atiprimod Dimaleate, ATM Inhibitor M 3541, ATM Kinase Inhibitor AZD0156, ATM Kinase Inhibitor AZD1390, Atorvastatin Calcium, Atorvastatin Sodium, ATR Inhibitor RP-3500, ATR Kinase Inhibitor BAY1895344, ATR Kinase Inhibitor M1774, ATR Kinase Inhibitor M6620, ATR Kinase Inhibitor VX-803, Atrasentan Hydrochloride, Attenuated Listeria monocytogenes CRS-100, Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Attenuated Measles Virus Encoding SCD Transgene TMV-018, Atuveciclib, Audencel, Auranofin, Aurora A Kinase Inhibitor LY3295668, Aurora A Kinase Inhibitor LY3295668 Erbumine, Aurora A Kinase Inhibitor MK5108, Aurora A Kinase Inhibitor TAS-119, Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076, Aurora B Serine/Threonine Kinase Inhibitor TAK-901, Aurora B/C Kinase Inhibitor GSK1070916A, Aurora kinase A/B inhibitor TT-00420, Aurora Kinase Inhibitor AMG 900, Aurora Kinase Inhibitor BI 811283, Aurora Kinase Inhibitor MLN8054, Aurora Kinase Inhibitor PF-03814735, Aurora Kinase Inhibitor SNS-314, Aurora Kinase Inhibitor TTP607, Aurora Kinase/VEGFR2 Inhibitor CYC116, Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707, Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055, Autologous Anti-BCMA CAR T-cells PHE885, Autologous Anti-BCMA CAR-transduced T-cells KITE-585, Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11, Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053, Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Autologous Anti-CD123 CAR-T Cells, Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx, Autologous Anti-CD19 CAR T-cells IM19, Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19, Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19, Autologous Anti-CD19 CAR-CD28 T-cells ET019002, Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01, Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19, Autologous Anti-CD19 T-cell Receptor T cells ET190L1, Autologous Anti-CD19 TAC-T cells TAC01-CD19, Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells, Autologous Anti-CD19/CD22 CAR T-cells AUTO3, Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells, Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1, Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s, Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes, Autologous Anti-FLT3 CAR T Cells AMG 553, Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202, Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1, Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100, Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes, Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794, Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes, Autologous Anti-PSMA CAR-T Cells P-PSMA-101, Autologous AXL-targeted CAR T-cells CCT301-38, Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B, Autologous BCMA-targeted CAR T Cells CC-98633, Autologous BCMA-targeted CAR T Cells LCAR-B4822M, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022, Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006, Autologous CD123-4SCAR-expressing T-cells 4SCAR123, Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1, Autologous CD19-targeted CAR T Cells CC-97540, Autologous CD19-targeted CAR T Cells JWCAR029, Autologous CD19-targeted CAR-T Cells GC007F, Autologous CD19/PD-1 Bispecific CAR-T Cells, Autologous CD20-4SCAR-expressing T-cells 4SCAR20, Autologous CD22-4SCAR-expressing T-cells 4SCAR22, Autologous CD38-4SCAR-expressing T-cells 4SCAR38, Autologous Clonal Neoantigen T Cells ATL001, Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19, Autologous Deep IL-15 Primed T-cells TRQ15-01, Autologous Dendritic Cell Vaccine ACT2001, Autologous Dendritic Cell-based Immunotherapeutic AV0113, Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa, Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells, Autologous Genetically-modified MAGE-A4 C1032 T Cells, Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858, Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439, Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001, Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718, Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous Mesenchymal Stem Cells Apceth_101, Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11, Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC, Autologous Multi-lineage Potential Cells, Autologous Nectin-4/FAP-targeted CAR-T Cells, Autologous NKG2D CAR T-cells CYAD-02, Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01, Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine, Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001, Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101, Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601, Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201, Autologous ROR2-targeted CAR T-cells CCT301-59, Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1, Autologous TCR-engineered T-cells IMA201, Autologous TCR-engineered T-cells IMA202, Autologous TCR-engineered T-cells IMA203, Autologous TCRm-expressing T-cells ET140203, Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG, Autologous Tumor Infiltrating Lymphocytes LN-144, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T, Avadomide, Avadomide Hydrochloride, Avapritinib, Avdoralimab, Avelumab, Aviscumine, Avitinib Maleate, Axalimogene Filolisbac, Axatilimab, Axicabtagene Ciloleucel, Axitinib, AXL Inhibitor DS-1205c, AXL Inhibitor SLC-391, AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M, AXL/ FLT3/VEGFR2 Inhibitor KC1036, Axl/Mer Inhibitor INCB081776, Axl/Mer Inhibitor PF-07265807, Azacitidine, Azapicyl, Azaribine, Azaserine, Azathioprine, Azimexon, Azintuxizumab Vedotin, Aziridinylbenzoquinone RH1, Azotomycin, Azurin:50-77 Cell Penetrating Peptide p28, B-Raf/VEGFR-2 Inhibitor RAF265, Babaodan Capsule, Bacillus Calmette-Guerin Substrain Connaught Live Antigen, Bactobolin, Bafetinib, Balixafortide, Balstilimab, Baltaleucel-T, Banoxantrone, Barasertib, Bardoxolone, Bardoxolone Methyl, Baricitinib, Batabulin, Batabulin Sodium, Batimastat, Bavituximab, Bazedoxifene, Bazlitoran, BC-819 Plasmid/Polyethylenimine Complex, BCG Solution, BCG Tokyo-172 Strain Solution, BCG Vaccine, Bcl-2 Inhibitor APG 2575, Bcl-2 Inhibitor BCL201, Bcl-2 Inhibitor BGB-11417, Bcl-2 Inhibitor LP-108, Bcl-2 Inhibitor S65487, Bcl-Xs Adenovirus Vaccine, BCMA x CD3 T-cell Engaging Antibody CC-93269, BCMA-CD19 Compound CAR T Cells, BCMA/CD3e Tri-specific T-cell Activating Construct HPN217, Bcr-Abl Kinase Inhibitor K0706, Bcr-Abl Kinase Inhibitor PF-114, BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351, Beauvericin, Becatecarin, Belagenpumatucel-L, Belantamab Mafodotin, Belapectin, Belimumab, Belinostat, Belotecan Hydrochloride, Belvarafenib, Belzutifan, Bemarituzumab, Bemcentinib, Bempegaldesleukin, Benaxibine, Bendamustine, Bendamustine Hydrochloride, Bendamustine-containing Nanoparticle-based Formulation RXDX-107, Benzaldehyde Dimethane Sulfonate, Benzoylphenylurea, Berberine Chloride, Bermekimab, Bersanlimab, Berubicin Hydrochloride, Berzosertib, BET Bromodomain Inhibitor ZEN-3694, BET Inhibitor ABBV-744, BET Inhibitor BAY1238097, BET inhibitor BI 894999, BET Inhibitor BMS-986158, BET Inhibitor CC-90010, BET Inhibitor CPI-0610, BET Inhibitor FT-1101, BET Inhibitor GS-5829, BET Inhibitor GSK2820151, BET Inhibitor INCB054329, BET Inhibitor INCB057643, BET Inhibitor RO6870810, BET-bromodomain Inhibitor ODM-207, Beta Alethine, Beta-Carotene, Beta-elemene, Beta-Glucan, Beta-Glucan MM-10-001, Beta-lapachone Prodrug ARQ 761, Beta-Thioguanine Deoxyriboside, Betaglucin Gel, Betulinic Acid, Bevacizumab, Bexarotene, Bexmarilimab, BF-200 Gel Formulation, BH3 Mimetic ABT-737, Bi-functional Alkylating Agent VAL-083, Bicalutamide, Bimiralisib, Binetrakin, Binimetinib, Bintrafusp Alfa, Birabresib, Birinapant, Bis(choline)tetrathiomolybdate, Bisantrene, Bisantrene Hydrochloride, Bisnafide, Bisnafide Dimesylate, Bispecific Antibody 2B1, Bispecific Antibody AGEN1223, Bispecific Antibody AMG 509, Bispecific Antibody GS-1423, Bispecific Antibody MDX-H210, Bispecific Antibody MDX447, Bisthianostat, BiTE Antibody AMG 910, Bivalent BRD4 Inhibitor AZD5153, Bizalimogene Ralaplasmid, Bizelesin, BL22 Immunotoxin, Black Cohosh, Black Raspberry Nectar, Bleomycin, Bleomycin A2, Bleomycin B2, Bleomycin Sulfate, Blinatumomab, Blueberry Powder Supplement, BMI1 Inhibitor PTC596, BMS-184476, BMS-188797, BMS-214662, BMS-275183, Boanmycin Hydrochloride, Bomedemstat, Boronophenylalanine-Fructose Complex, Bortezomib, Bosutinib, Bosutinib Monohydrate, Botanical Agent BEL-X-HG, Botanical Agent LEAC-102, Bovine Cartilage, Bozitinib, BP-Cx1-Platinum Complex BP-C1, BR96-Doxorubicin Immunoconjugate, Brachyury-expressing Yeast Vaccine GI-6301, BRAF Inhibitor, BRAF Inhibitor ARQ 736, BRAF Inhibitor BGB-3245, BRAF Inhibitor PLX8394, BRAF(V600E) Kinase Inhibitor ABM-1310, BRAF(V600E) Kinase Inhibitor RO5212054, BRAF/EGFR Inhibitor BGB-283, BRAFV600/PI3K Inhibitor ASN003, BRD4 Inhibitor PLX2853, BRD4 Inhibitor PLX51107, Breflate, Brentuximab, Brentuximab Vedotin, Brequinar, Brequinar Sodium, Briciclib Sodium, Brigatinib, Brilanestrant, Brimonidine Tartrate Nanoemulsion OCU-300, Brivanib, Brivanib Alaninate, Brivudine, Brivudine Phosphoramidate, Broad-Spectrum Human Papillomavirus Vaccine V505, Broccoli Sprout/Broccoli Seed Extract Supplement, Bromacrylide, Bromebric Acid, Bromocriptine Mesylate, Brontictuzumab, Brostacillin Hydrochloride, Brostallicin, Broxuridine, Bruceanol A, Bruceanol B, Bruceanol C, Bruceanol D, Bruceanol E, Bruceanol F, Bruceanol G, Bruceanol H, Bruceantin, Bryostatin 1, BTK Inhibitor ARQ 531, BTK Inhibitor CT-1530, BTK Inhibitor DTRMWXHS-12, BTK Inhibitor HZ-A-018, BTK Inhibitor ICP-022, BTK Inhibitor LOXO-305, BTK Inhibitor M7583, BTK inhibitor TG-1701, Budigalimab, Budotitane, Bufalin, Buparlisib, Burixafor, Burixafor Hydrobromide, Burosumab, Buserelin, Bushen Culuan Decoction, Bushen-Jianpi Decoction, Busulfan, Buthionine Sulfoximine, BXQ-350 Nanovesicle Formulation, c-Kit Inhibitor PLX9486, c-Met Inhibitor ABN401, c-Met Inhibitor AL2846, c-Met Inhibitor AMG 208, c-Met Inhibitor AMG 337, c-Met Inhibitor GST-HG161, c-Met Inhibitor HS-10241, c-Met Inhibitor JNJ-38877605, c-Met Inhibitor MK2461, c-Met Inhibitor MK8033, c-Met Inhibitor MSC2156119J, C-myb Antisense Oligonucleotide G4460, c-raf Antisense Oligonucleotide ISIS 5132, C-VISA BikDD:Liposome, C/EBP Beta Antagonist ST101, CAB-ROR2-ADC BA3021, Cabazitaxel, Cabiralizumab, Cabozantinib, Cabozantinib S-malate, Cactinomycin, Caffeic Acid Phenethyl Ester, CAIX Inhibitor DTP348, CAIX Inhibitor SLC-0111, Calaspargase Pegol-mknl, Calcitriol, Calcium Release-activated Channel Inhibitor CM4620, Calcium Release-activated Channels Inhibitor RP4010, Calcium Saccharate, Calculus bovis/Moschus/Olibanum/Myrrha Capsule, Calicheamicin Gamma 1I, Camidanlumab Tesirine, Camptothecin, Camptothecin Analogue TLC388, Camptothecin Glycoconjugate BAY 38-3441, Camptothecin Sodium, Camptothecin-20(S)-O-Propionate Hydrate, Camrelizumab, Camsirubicin, Cancell, Cancer Peptide Vaccine S-588410, Canerpaturev, Canertinib Dihydrochloride, Canfosfamide, Canfosfamide Hydrochloride, Cannabidiol, Cantrixil, Cantuzumab Ravtansine, Capecitabine, Capecitabine Rapidly Disintegrating Tablet, Capivasertib, Capmatinib, Captopril, CAR T-Cells AMG 119, Caracemide, Carbendazim, Carbetimer, Carbogen, Carbon C 14-pamiparib, Carboplatin, Carboquone, Carboxyamidotriazole, Carboxyamidotriazole Orotate, Carboxyphenyl Retinamide, Carfilzomib, Caricotamide/Tretazicar, Carlumab, Carmofur, Carmustine, Carmustine Implant, Carmustine in Ethanol, Carmustine Sustained-Release Implant Wafer, Carotuximab, Carubicin, Carubicin Hydrochloride, Carzelesin, Carzinophilin, Cathelicidin LL-37, Cationic Liposome-Encapsulated Paclitaxel, Cationic Peptide Cream Cypep-1, Catumaxomab, CBP/beta-catenin Antagonist PRI-724, CBP/beta-catenin Modulator E7386, CCR2 Antagonist CCX872-B, CCR2 Antagonist PF-04136309, CCR2/CCR5 Antagonist BMS-813160, CCR4 Inhibitor FLX475, CD11b Agonist GB1275, CD123-CD33 Compound CAR T Cells, CD123-specific Targeting Module TM123, CD20-CD19 Compound CAR T Cells, CD28/ICOS Antagonist ALPN-101, CD4-specific Telomerase Peptide Vaccine UCPVax, CD40 Agonist Monoclonal Antibody CP-870;893, CD40 Agonistic Monoclonal Antibody APX005M, CD44 Targeted Agent SPL-108, CD44v6-specific CAR T-cells, CD47 Antagonist ALX148, CD73 Inhibitor AB680, CD73 Inhibitor LY3475070, CD80-Fc Fusion Protein ALPN-202, CD80-Fc Fusion Protein FPT155, CDC7 Inhibitor TAK-931, CDC7 Kinase Inhibitor BMS-863233, CDC7 Kinase Inhibitor LY3143921 Hydrate, CDC7 Kinase Inhibitor NMS-1116354, CDK Inhibitor AT7519, CDK Inhibitor R547, CDK Inhibitor SNS-032, CDK/JAK2/FLT3 Inhibitor TG02 Citrate, CDK1 Inhibitor BEY1107, CDK1/2/4 Inhibitor AG-024322, CDK2 Inhibitor PF-07104091, CDK2/4/6/FLT3 Inhibitor FN-1501, CDK2/5/9 Inhibitor CYC065, CDK4 Inhibitor P1446A-05, CDK4/6 Inhibitor, CDK4/6 Inhibitor BPI-16350, CDK4/6 Inhibitor CS3002, CDK4/6 Inhibitor FCN-437, CDK4/6 Inhibitor G1T38, CDK4/6 Inhibitor HS-10342, CDK4/6 Inhibitor SHR6390, CDK4/6 Inhibitor TQB3616, CDK7 Inhibitor CT7001, CDK7 Inhibitor SY-1365, CDK7 Inhibitor SY-5609, CDK8/19 Inhibitor SEL 120, CDK9 Inhibitor AZD4573, CEA-MUC-1-TRICOM Vaccine CV301, CEA-targeting Agent RG6123, CEBPA-targeting saRNA MTL-CEBPA Liposome, Cedazuridine, Cedazuridine/Azacitidine Combination Agent ASTX030, Cedazuridine/Decitabine Combination Agent ASTX727, Cedefingol, Cediranib, Cediranib Maleate, Celecoxib, Cell Cycle Checkpoint/DNA Repair Antagonist IC83, Cemadotin, Cemadotin Hydrochloride, Cemiplimab, Cenersen, Cenisertib, CENP-E Inhibitor GSK-923295, Ceralasertib, Ceramide Nanoliposome, Cerdulatinib, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282, Cereblon Modulator CC-90009, Cergutuzumab Amunaleukin, Ceritinib, Cesalin, cEt KRAS Antisense Oligonucleotide AZD4785, Cetrelimab, Cetuximab, Cetuximab Sarotalocan, Cetuximab-IR700 Conjugate RM-1929, Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY), Cevipabulin, Cevipabulin Fumarate, Cevipabulin Succinate, Cevostamab, cFMS Tyrosine Kinase Inhibitor ARRY-382, Chaparrin, Chaparrinone, Checkpoint Kinase Inhibitor AZD7762, Checkpoint Kinase Inhibitor XL844, Chemotherapy, Chiauranib, Chimeric Monoclonal Antibody 81C6, ChiNing Decoction, Chk1 Inhibitor CCT245737, Chk1 Inhibitor GDC-0425, Chk1 Inhibitor GDC-0575, CHK1 Inhibitor MK-8776, CHK1 Inhibitor PF-477736, Chlorambucil, Chlorodihydropyrimidine, Chloroquine, Chloroquinoxaline Sulfonamide, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, Chlorozotocin, Choline Kinase Alpha Inhibitor TCD-717, CHP-NY-ESO-1 Peptide Vaccine IMF-001, Chromomycin A3, Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement, Cibisatamab, Ciclopirox Prodrug CPX-POM, Cidan Herbal Capsule, Ciforadenant, Cilengitide, Ciltacabtagene Autoleucel, Cimetidine, Cinacalcet Hydrochloride, Cinobufagin, Cinobufotalin, Cinrebafusp Alfa, Cintirorgon, Cintredekin Besudotox, Cirmtuzumab, cis-Urocanic Acid, Cisplatin, Cisplatin Liposomal, Cisplatin-E Therapeutic Implant, Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6, Citarinostat, Citatuzumab Bogatox, Cixutumumab, CK1alpha/CDK7/CDK9 Inhibitor BTX-A51, CK2-targeting Synthetic Peptide CIGB-300, CL 246738, Cladribine, Clanfenur, Clarithromycin, Class 1/4 Histone Deacetylase Inhibitor OKI-179, Clinical Trial, Clinical Trial Agent, Clioquinol, Clivatuzumab, Clodronate Disodium, Clodronic Acid, Clofarabine, Clomesone, Clomiphene, Clomiphene Citrate, Clostridium Novyi-NT Spores, Cobimetinib, Cobolimab, Cobomarsen, Codrituzumab, Coenzyme Q10, Cofetuzumab Pelidotin, Colchicine-Site Binding Agent ABT-751, Cold Contaminant-free Iobenguane I-131, Colloidal Gold-Bound Tumor Necrosis Factor, Colorectal Cancer Peptide Vaccine PolyPEPI1018, Colorectal Tumor-Associated Peptides Vaccine IMA910, Coltuximab Ravtansine, Combretastatin, Combretastatin A-1, Combretastatin A1 Diphosphate, Commensal Bacterial Strain Formulation VE800, Compound Kushen Injection, Conatumumab, Conbercept, Concentrated Lingzhi Mushroom Extract, Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011, Copanlisib, Copanlisib Hydrochloride, Copper Cu 64-ATSM, Copper Cu 67 Tyr3-octreotate, Copper Gluconate, Cord Blood Derived CAR T-Cells, Cord Blood-derived Expanded Natural Killer Cells PNK-007, Cordycepin, Cordycepin Triphosphate, Coriolus Versicolor Extract, Corticorelin Acetate, Cortisone Acetate, Cosibelimab, Cositecan, Coxsackievirus A21, Coxsackievirus V937, CpG Oligodeoxynucleotide GNKG168, Crenolanib, Crenolanib Besylate, Crizotinib, Crolibulin, Cryptophycin, Cryptophycin 52, Crystalline Genistein Formulation AXP107-11, CSF-1R Inhibitor BLZ945, CSF1R Inhibitor ABSK021, CSF1R Inhibitor DCC-3014, CSF1R Inhibitor PLX73086, CT2584 HMS, CTLA-4-directed Probody BMS-986249, Curcumin, Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110, Cusatuzumab, Custirsen Sodium, CXC Chemokine Receptor 2 Antagonist AZD5069, CXCR1/2 Inhibitor SX-682, CXCR2 Antagonist QBM076, CXCR4 Antagonist BL-8040, CXCR4 Antagonist USL311, CXCR4 Inhibitor Q-122, CXCR4 Peptide Antagonist LY2510924, CXCR4/E-selectin Antagonist GMI-1359, Cyclin-dependent Kinase 8/19 Inhibitor BCD 115, Cyclin-dependent Kinase Inhibitor PF-06873600, Cyclodextrin-Based Polymer-Camptothecin CRLX101, Cyclodisone, Cycloleucine, Cyclopentenyl Cytosine, Cyclophosphamide, Cyclophosphamide Anhydrous, Cyclosporine, CYL-02 Plasmid DNA, CYP11A1 inhibitor ODM-208, CYP11A1 Inhibitor ODM-209, CYP17 Inhibitor CFG920, CYP17 Lyase Inhibitor ASN001, CYP17/Androgen Receptor Inhibitor ODM 204, CYP17/CYP11B2 Inhibitor LAE001, Cyproterone, Cyproterone Acetate, Cytarabine, Cytarabine Monophosphate Prodrug MB07133, Cytarabine-asparagine Prodrug BST-236, Cytidine Analog RX-3117, Cytochlor, Cytokine-based Biologic Agent IRX-2, D-methionine Formulation MRX-1024, DAB389 Epidermal Growth Factor, Dabrafenib, Dabrafenib Mesylate, Dacarbazine, Dacetuzumab, DACH Polymer Platinate AP5346, DACH-Platin Micelle NC-4016, Daclizumab, Dacomitinib, Dacplatinum, Dactinomycin, Dactolisib, Dactolisib Tosylate, Dalantercept, Dalotuzumab, Daniquidone, Danusertib, Danvatirsen, Daporinad, Daratumumab, Daratumumab and Hyaluronidase-fihj, Daratumumab/rHuPH20, Darinaparsin, Darleukin, Darolutamide, Daromun, Dasatinib, Daunorubicin, Daunorubicin Citrate, Daunorubicin Hydrochloride, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Decitabine and Cedazuridine, Defactinib, Defactinib Hydrochloride, Deferoxamine, Deferoxamine Mesylate, Degarelix, Degarelix Acetate, Delanzomib, Delolimogene Mupadenorepvec, Demcizumab, Demecolcine, Demplatin Pegraglumer, Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466, Dendritic Cell Vaccine, Dendritic Cell-Autologous Lung Tumor Vaccine, Dendritic Cell-targeting Lentiviral Vector ID-LV305, Denenicokin, Dengue Virus Adjuvant PV-001-DV, Denibulin, Denibulin Hydrochloride, Denileukin Diftitox, Denintuzumab Mafodotin, Denosumab, Deoxycytidine Analogue TAS-109, Deoxycytidine Analogue TAS-109 Hydrochloride, Depatuxizumab, Depatuxizumab Mafodotin, Derazantinib, Deslorelin, Deslorelin Acetate, Detirelix, Detorubicin, Deuteporfin, Deuterated Enzalutamide, Devimistat, Dexamethason, Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, Dexanabinol, Dexrazoxane, Dexrazoxane Hydrochloride, Dezaguanine, Dezaguanine Mesylate, Dezapelisib, DHA-Paclitaxel, DHEA Mustard, DI-Leu16-IL2 Immunocytokine, Dianhydrogalactitol, Diarylsulfonylurea Compound ILX-295501, Diazepinomicin, Diaziquone, Diazooxonorleucine, Dibrospidium Chloride, Dichloroallyl Lawsone, Dicycloplatin, Didox, Dienogest, Diethylnorspermine, Digitoxin, Digoxin, Dihydro-5-Azacytidine, Dihydrolenperone, Dihydroorotate Dehydrogenase Inhibitor AG-636, Dihydroorotate Dehydrogenase Inhibitor BAY2402234, Diindolylmethane, Dilpacimab, Dimethylmyleran, Dinaciclib, Dinutuximab, Dioscorea nipponica Makino Extract DNE3, Diphencyprone, Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777, Ditiocarb, DKK1-Neutralizing Monoclonal Antibody DKN-01, DM-CHOC-PEN, DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015, DNA Interference Oligonucleotide PNT2258, DNA Minor Groove Binding Agent SG2000, DNA Plasmid Encoding Interleukin-12 INO-9012, DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151, DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, DNA Vaccine VB10.16, DNA-dependent Protein Kinase Inhibitor VX-984, DNA-PK inhibitor AZD7648, DNA-PK/PI3K-delta Inhibitor BR101801, DNA-PK/TOR Kinase Inhibitor CC-115, DNMT1 Inhibitor NTX-301, DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98, Docetaxel, Docetaxel Anhydrous, Docetaxel Emulsion ANX-514, Docetaxel Formulation CKD-810, Docetaxel Lipid Microspheres, Docetaxel Nanoparticle CPC634, Docetaxel Polymeric Micelles, Docetaxel-loaded Nanopharmaceutical CRLX301, Docetaxel-PNP, Docetaxel/Ritonavir, Dociparstat sodium, Dolastatin 10, Dolastatin 15, Domatinostat, Donafenib, Dopamine-Somatostatin Chimeric Molecule BIM-23A760, Dostarlimab, Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703, Dovitinib, Dovitinib Lactate, Doxazosin, Doxercalciferol, Doxifluridine, Doxorubicin, Doxorubicin Hydrochloride, Doxorubicin Prodrug L-377;202, Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370, Doxorubicin-Eluting Beads, Doxorubicin-HPMA Conjugate, Doxorubicin-loaded EGFR-targeting Nanocells, Doxorubicin-Magnetic Targeted Carrier Complex, DPT/BCG/Measles/Serratia/Pneumococcus Vaccine, DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine, DPX-E7 HPV Vaccine, DR5 HexaBody Agonist GEN1029, DR5-targeting Tetrameric Nanobody Agonist TAS266, Dromostanolone Propionate, Drozitumab, DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555, Dual IGF-1R/InsR Inhibitor BMS-754807, Dual Variable Domain Immunoglobulin ABT-165, Dual-affinity B7-H3/CD3-targeted Protein MGD009, Dubermatinib, Duborimycin, Dulanermin, Duligotuzumab, Dupilumab, Durvalumab, Dusigitumab, dUTPase/DPD Inhibitor TAS-114, Duvelisib, Duvortuxizumab, Dynemicin, Dynemicin A, E2F1 Pathway Activator ARQ 171, EBNA-1 inhibitor VK-2019, Echinomycin, Ecromeximab, Edatrexate, Edelfosine, Edicotinib, Edodekin alfa, Edotecarin, Edrecolomab, EED Inhibitor MAK683, Efatutazone, Efatutazone Dihydrochloride, Efizonerimod, Eflornithine, Eflornithine Hydrochloride, Eftilagimod Alpha, Eftozanermin Alfa, Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205, Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621, EGb761, EGFR Antagonist Hemay022, EGFR Antisense DNA BB-401, EGFR Inhibitor AZD3759, EGFR Inhibitor BIBX 1382, EGFR Inhibitor DBPR112, EGFR Inhibitor PD-168393, EGFR Inhibitor TY-9591, EGFR Mutant-selective Inhibitor TQB3804, EGFR Mutant-specific Inhibitor BPI-7711, EGFR Mutant-specific Inhibitor CK-101, EGFR Mutant-specific Inhibitor D-0316, EGFR Mutant-specific Inhibitor ZN-e4, EGFR T790M Antagonist BPI-15086, EGFR T790M Inhibitor HS-10296, EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR/FLT3/Abl Inhibitor SKLB1028, EGFR/HER1/HER2 Inhibitor PKI166, EGFR/HER2 Inhibitor AP32788, EGFR/HER2 Inhibitor AV-412, EGFR/HER2 Inhibitor DZD9008, EGFR/HER2 Kinase Inhibitor TAK-285, EGFR/TGFb Fusion Monoclonal Antibody BCA101, EGFR/VEGFR/RET Inhibitor HA121-28, Eicosapentaenoic Acid, eIF4E Antisense Oligonucleotide ISIS 183750, Elacestrant, Elacytarabine, Elagolix, Elbasvir/Grazoprevir, Elesclomol, Elesclomol Sodium, Elgemtumab, Elinafide, Elisidepsin, Elliptinium, Elliptinium Acetate, Elmustine, Elotuzumab, Elpamotide, Elsamitrucin, Eltanexor, Emactuzumab, Emapalumab, Emepepimut-S, Emibetuzumab, Emitefur, Emofolin Sodium, Empesertib, Enadenotucirev, Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A, Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641, Enasidenib, Enasidenib Mesylate, Enavatuzumab, Encapsulated Rapamycin, Encelimab, Enclomiphene, Enclomiphene Citrate, Encorafenib, Endothelin B Receptor Blocker ENB 003, Endothelin Receptor Type A Antagonist YM598, Enfortumab Vedotin, Engineered Human Umbilical Vein Endothelial Cells AB-205, Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240, Engineered Toxin Body Targeting CD38 TAK-169, Engineered Toxin Body Targeting HER2 MT-5111, Eniluracil/5-FU Combination Tablet, Enloplatin, Enoblituzumab, Enobosarm, Enoticumab, Enpromate, Ensartinib, Ensituximab, Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride, Enterococcus gallinarum Strain MRx0518, Entinostat, Entolimod, Entospletinib, Entrectinib, Envafolimab, Enzalutamide, Enzastaurin, Enzastaurin Hydrochloride, EP2/EP4 Antagonist TPST-1495, EP4 Antagonist INV-1120, EP4 Antagonist ONO-4578, Epacadostat, Epcoritamab, EphA2-targeting Bicycle Toxin Conjugate BT5528, Epipodophyllotoxin Analog GL331, Epipropidine, Epirubicin, Epirubicin Hydrochloride, Epitinib Succinate, Epitiostanol, Epothilone Analog UTD1, Epothilone KOS-1584, Epratuzumab, Epratuzumab-cys-tesirine, ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471, ERa36 Modulator Icaritin, Erastin Analogue PRLX 93936, Erbulozole, Erdafitinib, Eribulin, Eribulin Mesylate, ERK 1/2 Inhibitor ASTX029, ERK Inhibitor CC-90003, ERK Inhibitor GDC-0994, ERK Inhibitor LTT462, ERK Inhibitor MK-8353, ERK1/2 Inhibitor ASN007, ERK1/2 Inhibitor HH2710, ERK1/2 Inhibitor JSI-1187, ERK1/2 Inhibitor KO-947, ERK1/2 Inhibitor LY3214996, Erlotinib, Erlotinib Hydrochloride, Ertumaxomab, Erythrocyte-encapsulated L-asparaginase Suspension, Esorubicin, Esorubicin Hydrochloride, Esperamicin A1, Essiac, Esterified Estrogens, Estradiol Valerate, Estramustine, Estramustine Phosphate Sodium, Estrogen Receptor Agonist GTx-758, Estrogens; Conjugated, Etalocib, Etanercept, Etanidazole, Etaracizumab, Etarotene, Ethaselen, Ethinyl Estradiol, Ethyleneimine, Ethylnitrosourea, Etidronate-Cytarabine Conjugate MBC-11, Etigilimab, Etirinotecan Pegol, Etoglucid, Etoposide, Etoposide Phosphate, Etoposide Toniribate, Etoprine, Etoricoxib, Ets-family Transcription Factor Inhibitor TK216, Everolimus, Everolimus Tablets for Oral Suspension, Evofosfamide, Ex Vivo-expanded Autologous T Cells IMA101, Exatecan Mesylate, Exatecan Mesylate Anhydrous, Exemestane, Exicorilant, Exisulind, Extended Release Flucytosine, Extended Release Metformin Hydrochloride, Extended-release Onapristone, Ezabenlimab, EZH1/2 Inhibitor DS-3201, EZH1/2 Inhibitor HH2853, EZH2 inhibitor CPI-0209, EZH2 Inhibitor CPI-1205, EZH2 Inhibitor PF-06821497, EZH2 Inhibitor SHR2554, F16-IL2 Fusion Protein, FACT Complex-targeting Curaxin CBL0137, Factor VII-targeting Immunoconjugate Protein ICON-1, Factor VIIa Inhibitor PCI-27483, Fadraciclib, Fadrozole Hydrochloride, FAK Inhibitor GSK2256098, FAK Inhibitor PF-00562271, FAK Inhibitor VS-4718, FAK/ALK/ROS1 Inhibitor APG-2449, Falimarev, Famitinib, FAP/4-1BB-targeting DARPin MP0310, FAP/4-1BB-targeting Fusion Protein RO7122290, Farletuzumab, Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778;123, Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells, Fas Receptor Agonist APO010, Fascin Inhibitor NP-G2-044, FASN Inhibitor TVB-2640, Favezelimab, Fazarabine, Fc-engineered Anti-CD40 Agonist Antibody 2141-V11, Febuxostat, Fedratinib, Fedratinib Hydrochloride, Feladilimab, Felzartamab, Fenebrutinib, Fenretinide, Fenretinide Lipid Matrix, Fenretinide Phospholipid Suspension ST-001, FGF Receptor Antagonist HGS1036, FGF/FGFR Pathway Inhibitor E7090, FGFR Inhibitor ASP5878, FGFR Inhibitor AZD4547, FGFR Inhibitor CPL304110, FGFR Inhibitor Debio 1347, FGFR Inhibitor TAS-120, FGFR/CSF-1R Inhibitor 3D185, FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999, FGFR1/2/3 Inhibitor HMPL-453, FGFR2 Inhibitor RLY-4008, FGFR4 Antagonist INCB062079, FGFR4 Inhibitor BLU 9931, FGFR4 Inhibitor FGF401, FGFR4 Inhibitor H3B-6527, FGFR4 Inhibitor ICP-105, Fianlimab, Fibromun, Ficlatuzumab, Figitumumab, Filanesib, Filgotinib, Filgrastim, Fimaporfin A, Fimepinostat, Firtecan Pegol, Fisogatinib, Flanvotumab, Flotetuzumab, Floxuridine, FLT3 Inhibitor FF-10101 Succinate, FLT3 Inhibitor HM43239, FLT3 Inhibitor SKI-G-801, Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01, FLT3 Tyrosine Kinase Inhibitor TTT-3002, FLT3/ABL/Aurora Kinase Inhibitor KW-2449, FLT3/CDK4/6 Inhibitor FLX925, FLT3/FGFR Dual Kinase Inhibitor MAX-40279, FLT3/KIT Kinase Inhibitor AKN-028, FLT3/KIT/CSF1R Inhibitor NMS-03592088, Flt3/MerTK Inhibitor MRX-2843, Fludarabine, Fludarabine Phosphate, Flumatinib, Flumatinib Mesylate, Fluorine F 18 Ara-G, Fluorodopan, Fluorouracil, Fluorouracil Implant, Fluorouracil-E Therapeutic Implant, Fluoxymesterone, Flutamide, Fluvastatin, Fluvastatin Sodium, Fluzoparib, FMS Inhibitor JNJ-40346527, Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate, Folate Receptor Targeted Epothilone BMS753493, Folate Receptor-Targeted Tubulysin Conjugate EC1456, Folate Receptor-Targeted Vinca Alkaloid EC0489, Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225, Folate-FITC, Folic Acid, Folitixorin, Foretinib, Foritinib Succinate, Formestane, Forodesine Hydrochloride, Fosaprepitant, Fosbretabulin, Fosbretabulin Disodium, Fosbretabulin Tromethamine, Fosgemcitabine Palabenamide, Fosifloxuridine Nafalbenamide, Foslinanib, Foslinanib Disodium, Fosquidone, Fostriecin, Fotemustine, Fotretamine, FPV Vaccine CV301, FPV-Brachyury-TRICOM Vaccine, Fresolimumab, Fruquintinib, Fulvestrant, Fumagillin-Derived Polymer Conjugate XMT-1107, Fursultiamine, Futibatinib, Futuximab, Futuximab/Modotuximab Mixture, G Protein-coupled Estrogen Receptor Agonist LNS8801, G-Quadruplex Stabilizer BMVC, Galamustine, Galarubicin, Galectin Inhibitor GR-MD-02, Galectin-1 Inhibitor OTX008, Galeterone, Galiximab, Gallium-based Bone Resorption Inhibitor AP-002, Galocitabine, Galunisertib, Gamboge Resin Extract TSB-9-W1, Gamma-delta Tocotrienol, Gamma-Secretase Inhibitor LY3039478, Gamma-Secretase Inhibitor RO4929097, Gandotinib, Ganetespib, Ganglioside GD2, Ganglioside GM2, Ganitumab, Ganoderma lucidum Spores Powder Capsule, Garlic, Gastrin Immunotoxin, Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360, Gataparsen Sodium, Gatipotuzumab, GBM Antigens and Alloantigens Immunotherapeutic Vaccine, Gedatolisib, Gefitinib, Geldanamycin, Gelonin, Gemcitabine, Gemcitabine Elaidate, Gemcitabine Hydrochloride, Gemcitabine Hydrochloride Emulsion, Gemcitabine Prodrug LY2334737, Gemcitabine-Phosphoramidate Hydrochloride NUC-1031, Gemcitabine-Releasing Intravesical System, Gemtuzumab Ozogamicin, Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum, Genistein, Gentuximab, Geranylgeranyltransferase I Inhibitor, GI-4000 Vaccine, Giloralimab, Gilteritinib, Gilteritinib Fumarate, Gimatecan, Gimeracil, Ginsenoside Rg3 Capsule, Giredestrant, Girentuximab, Girodazole, GITR Agonist MEDI1873, Givinostat, Glasdegib, Glasdegib Maleate, Glaucarubolone, Glecaprevir/Pibrentasvir, Glembatumumab Vedotin, Glesatinib, Glioblastoma Cancer Vaccine ERC1671, Glioblastoma Multiforme Multipeptide Vaccine IMA950, Glioma Lysate Vaccine GBM6-AD, Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701, Globo H-DT Vaccine OBI-833, Glofitamab, Glucarpidase, Glucocorticoid Receptor Antagonist ORIC-101, Glufosfamide, Glumetinib, Glutaminase Inhibitor CB-839, Glutaminase Inhibitor CB-839 Hydrochloride, Glutaminase Inhibitor IPN60090, Glutamine Antagonist DRP-104, Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101, Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01, Glycooptimized Trastuzumab-GEX, GM-CSF-encoding Oncolytic Adenovirus CGTG-102, Gold Sodium Thiomalate, Golnerminogene Pradenovec, Golotimod, Golvatinib, Gonadotropin-releasing Hormone Analog, Goserelin, Goserelin Acetate, Goserelin Acetate Extended-release Microspheres LY01005, Gossypol, Gossypol Acetic Acid, Grapiprant, Green Tea Extract-based Antioxidant Supplement, GS/pan-Notch Inhibitor AL101, GS/pan-Notch Inhibitor BMS-986115, GSK-3 Inhibitor 9-ING-41, GSK-3 Inhibitor LY2090314, Guadecitabine, Guanabenz Acetate, Guselkumab, Gusperimus Trihydrochloride, Gutolactone, H-ras Antisense Oligodeoxynucleotide ISIS 2503, H1299 Tumor Cell Lysate Vaccine, HAAH Lambda phage Vaccine SNS-301, Hafnium Oxide-containing Nanoparticles NBTXR3, Halichondrin Analogue E7130, Halichondrin B, Halofuginone, Halofuginone Hydrobromide, HCV DNA Vaccine INO-8000, HDAC Class I/IIb Inhibitor HG146, HDAC Inhibitor AR-42, HDAC inhibitor CG200745, HDAC Inhibitor CHR-2845, HDAC Inhibitor CKD-581, HDAC Inhibitor CXD101, HDAC Inhibitor MPT0E028, HDAC Inhibitor OBP-801, HDAC/EGFR/HER2 Inhibitor CUDC-101, HDAC6 Inhibitor KA2507, HDAC8 Inhibitor NBM-BMX, HDM2 Inhibitor HDM201, HDM2 Inhibitor MK-8242, Hedgehog Inhibitor IPI-609, Hematoporphyrin Derivative, Hemiasterlin Analog E7974, Henatinib Maleate, Heparan Sulfate Glycosaminoglycan Mimetic M402, Heparin Derivative SST0001, HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131, HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901, HER2 Inhibitor CP-724;714, HER2 Inhibitor DZD1516, HER2 Inhibitor TAS0728, HER2 Tri-specific Natural Killer Cell Engager DF1001, HER2-directed TLR8 Agonist SBT6050, HER2-targeted DARPin MP0274, HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302, HER2-targeting Antibody Fc Fragment FS102, Herba Scutellaria Barbata, Herbimycin, Heterodimeric Interleukin-15, Hexamethylene Bisacetamide, Hexaminolevulinate, Hexylresorcinol, HIF-1alpha Inhibitor PX-478, HIF-2alpha Inhibitor PT2385, HIF-2alpha Inhibitor PT2977, HIF2a RNAi ARO-HIF2, Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126, Histrelin Acetate, HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001, HLA-A*2402-Restricted Multipeptide Vaccine S-488410, HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201, HM2/MMAE Antibody-Drug Conjugate ALT-P7, Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine, Holmium Ho 166 Poly(L-Lactic Acid) Microspheres, Hormone Therapy, HPPH, HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202, HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, HPV E6/E7 DNA Vaccine GX-188E, HPV E6/E7-encoding Arenavirus Vaccine HB-201, HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C, HPV-16 E6 Peptides Vaccine/Candida albicans Extract, HPV-6-targeting Immunotherapeutic Vaccine INO-3106, HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101, HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN, HPV6/11-targeted DNA Plasmid Vaccine INO-3107, Hsp90 Antagonist KW-2478, Hsp90 Inhibitor AB-010, Hsp90 Inhibitor BIIB021, Hsp90 Inhibitor BIIB028, Hsp90 Inhibitor Debio 0932, Hsp90 Inhibitor DS-2248, Hsp90 Inhibitor HSP990, Hsp90 Inhibitor MPC-3100, Hsp90 Inhibitor PU-H71, Hsp90 Inhibitor SNX-5422 Mesylate, Hsp90 Inhibitor SNX-5542 Mesylate, Hsp90 Inhibitor TQB3474, Hsp90 Inhibitor XL888, Hsp90-targeted Photosensitizer HS-201, HSP90-targeted SN-38 Conjugate PEN-866, HSP90alpha/beta Inhibitor TAS-116, hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301, hTERT Vaccine V934/V935, hTERT-encoding DNA Vaccine INVAC-1, Hu14.18-IL2 Fusion Protein EMD 273063, HuaChanSu, Huaier Extract Granule, Huang Lian, huBC1-huIL12 Fusion Protein AS1409, Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736, Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104, Human MOAB LICO 28a32, Human Monoclonal Antibody 216, Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307, Human Papillomavirus 16 E7 Peptide/Padre 965.10, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Hycanthone, Hydralazine Hydrochloride, Hydrocortisone Sodium Succinate, Hydroxychloroquine, Hydroxyprogesterone Caproate, Hydroxytyrosol, Hydroxyurea, Hypericin, Hypoxia-activated Prodrug TH-4000, I 131 Antiferritin Immunoglobulin, I 131 Monoclonal Antibody A33, I 131 Monoclonal Antibody CC49, I 131 Monoclonal Antibody F19, I 131 Monoclonal Antibody Lym-1, Iadademstat, Ianalumab, IAP Inhibitor APG-1387, IAP Inhibitor AT-406, IAP Inhibitor HGS1029, Ibandronate Sodium, Iberdomide, Iboctadekin, Ibritumomab Tiuxetan, Ibrutinib, Icotinib Hydrochloride, Icrucumab, ICT-121 Dendritic Cell Vaccine, Idarubicin, Idarubicin Hydrochloride, Idarubicin-Eluting Beads, Idasanutlin, Idecabtagene Vicleucel, Idelalisib, Idetrexed, IDH1 Mutant Inhibitor LY3410738, IDH1(R132) Inhibitor IDH305, IDH1R132H-Specific Peptide Vaccine PEPIDH1M, Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020, IDO Peptide Vaccine IO102, IDO-1 Inhibitor LY3381916, IDO/TDO Inhibitor HTI-1090, IDO/TDO Inhibitor LY-01013, IDO1 Inhibitor KHK2455, IDO1 Inhibitor MK-7162, IDO1 Inhibitor PF-06840003, IDO1/TDO2 Inhibitor DN1406131, IDO1/TDO2 Inhibitor M4112, Idronoxil, Idronoxil Suppository NOX66, Ieramilimab, Ifabotuzumab, Ifetroban, Ifosfamide, IGF-1R Inhibitor, IGF-1R Inhibitor PL225B, IGF-1R/IR Inhibitor KW-2450, IGF-methotrexate Conjugate, IL-10 Immunomodulator MK-1966, IL-12-expressing HSV-1 NSC 733972, IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051, IL-12sc; IL-15sushi; IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000, IL-2 Recombinant Fusion Protein ALT-801, IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1, IL4-Pseudomonas Exotoxin Fusion Protein MDNA55, Ilginatinib, Ilixadencel, Iloprost, Ilorasertib, Imalumab, Imaradenant, Imatinib, Imatinib Mesylate, Imetelstat, Imetelstat Sodium, Imexon, Imgatuzumab, Imidazole Mustard, Imidazole-Pyrazole, Imifoplatin, Imipramine Blue, Imiquimod, Immediate-release Onapristone, Immediate-release Tablet Afuresertib, Immune Checkpoint Inhibitor ASP8374, Immunoconjugate RO5479599, Immunocytokine NHS-IL12, Immunocytokine NHS-IL2-LT, Immunomodulator LAM-003, Immunomodulator OHR/AVR118, Immunomodulatory Agent CC-11006, Immunomodulatory Oligonucleotide HYB2055, Immunotherapeutic Combination Product CMB305, Immunotherapeutic GSK1572932A, Immunotherapy Regimen MKC-1106-MT, Immunotoxin CMD-193, IMT-1012 Immunotherapeutic Vaccine, Inactivated Oncolytic Virus Particle GEN0101, Inalimarev, Incyclinide, Indatuximab Ravtansine, Indibulin, Indicine-N-Oxide, Indisulam, Individualized MVA-based Vaccine TG4050, Indocyanine Green-labeled Polymeric Micelles ONM-100, Indole-3-Carbinol, Indomethacin, Indoximod, Indoximod Prodrug NLG802, Indusatumab Vedotin, Inebilizumab, Inecalcitol, Infigratinib, Infigratinib Mesylate, Infliximab, Ingenol Mebutate, Ingenol Mebutate Gel, Iniparib, iNKT Cell Agonist ABX196, Innate Immunostimulator rBBX-01, INO-1001, Inodiftagene Vixteplasmid, iNOS Dimerization Inhibitor ASP9853, Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01, Inosine Monophosphate Dehydrogenase Inhibitor AVN944, Inositol, Inotuzumab Ozogamicin, Inproquone, Integrin alpha-2 Inhibitor E7820, Integrin Receptor Antagonist GLPG0187, Interferon, Interferon Alfa-2B, Interferon Alfa-N1, Interferon Alfa-N3, Interferon Alfacon-1, Interferon Beta-1A, Interferon Gamma-1b, Interferon-gamma-expressing Adenovirus Vaccine ASN-002, Interleukin Therapy, Interleukin-12-Fc Fusion Protein DF6002, Interleukin-15 Agonist Fusion Protein SHR1501, Interleukin-15 Fusion Protein BJ-001, Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306, Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101, Interleukin-2 Liposome, Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230, Intetumumab, Intiquinatine, Intoplicine, Inulin, Iobenguane I-131, Iodine I 124 Monoclonal Antibody A33, Iodine I 124 Monoclonal Antibody M5A, Iodine I 125-Anti-EGFR-425 Monoclonal Antibody, Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP, Iodine I 131 Apamistamab, Iodine I 131 Derlotuximab Biotin, Iodine I 131 Ethiodized Oil, Iodine I 131 IPA, Iodine I 131 MIP-1095, Iodine I 131 Monoclonal Antibody 81C6, Iodine I 131 Monoclonal Antibody BC8, Iodine I 131 Monoclonal Antibody CC49-deltaCH2, Iodine I 131 Monoclonal Antibody F16SIP, Iodine I 131 Monoclonal Antibody G-250, Iodine I 131 Monoclonal Antibody muJ591, Iodine I 131 Omburtamab, Iodine I 131 Rituximab, Iodine I 131 Tenatumomab, Iodine I 131 TM-601, Iodine I 131 Tositumomab, Iodine I-131, Ioflubenzamide I-131, Ionomycin, Ipafricept, Ipatasertib, Ipilimumab, Ipomeanol, Iproplatin, iPSC-derived CD16-expressing Natural Killer Cells FT516, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596, iPSC-derived Natural Killer Cells FT500, IRAK4 Inhibitor CA-4948, Iratumumab, Iridium Ir 192, Irinotecan, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Irinotecan-Eluting Beads, Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet, Irofulven, Iroplact, Irosustat, Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130, Isatuximab, Iso-fludelone, Isobrucein B, Isocoumarin NM-3, Isotretinoin, Ispinesib, Ispinesib Mesylate, ISS 1018 CpG Oligodeoxynucleotide, Istiratumab, Itacitinib, Itacitinib Adipate, ITK Inhibitor CPI-818, Itraconazole, Itraconazole Dispersion In Polymer Matrix, Ivaltinostat, Ivosidenib, Ivuxolimab, Ixabepilone, Ixazomib, Ixazomib Citrate, JAK Inhibitor, JAK Inhibitor INCB047986, JAK1 Inhibitor AZD4205, JAK1 Inhibitor INCB052793, JAK2 Inhibitor AZD1480, JAK2 Inhibitor BMS-911543, JAK2 Inhibitor XL019, JAK2/Src Inhibitor NS-018, Jin Fu Kang, JNK Inhibitor CC-401, Kanglaite, Kanitinib, Ketoconazole, Ketotrexate, KRAS G12C Inhibitor GDC-6036, KRAS G12C Inhibitor LY3499446, KRAS G12C Inhibitor MRTX849, KRAS Mutant-targeting AMG 510, KRAS-MAPK Signaling Pathway Inhibitor JAB-3312, KRASG12C Inhibitor JNJ-74699157, KRN5500, KSP Inhibitor AZD4877, KSP Inhibitor SB-743921, Kunecatechins Ointment, L-Gossypol, L-methylfolate, Labetuzumab Govitecan, Lactoferrin-derived Lytic Peptide LTX-315, Lacutamab, Ladiratuzumab Vedotin, Ladirubicin, Laetrile, LAIR-2 Fusion Protein NC410, Landogrozumab, Laniquidar, Lanreotide Acetate, Lapachone, Lapatinib, Lapatinib Ditosylate, Laprituximab Emtansine, Lapuleucel-T, Laromustine, Larotaxel, Larotinib Mesylate, Larotrectinib, Larotrectinib Sulfate, Lavendustin A, Lazertinib, Lead Pb 212 TCMC-trastuzumab, Lefitolimod, Leflunomide, Lenalidomide, Lenalidomide Analog KPG-121, Lentinan, Lenvatinib, Lenvatinib Mesylate, Lenzilumab, Lerociclib, Lestaurtinib, Letetresgene Autoleucel, Letolizumab, Letrozole, Leucovorin, Leucovorin Calcium, Leuprolide, Leuprolide Acetate, Leuprolide Mesylate Injectable Suspension, Leurubicin, Levetiracetam, Levoleucovorin Calcium, Levothyroxine, Levothyroxine Sodium, Lexatumumab, Lexibulin, Liarozole, Liarozole Fumarate, Liarozole Hydrochloride, Licartin, Licorice, Lifastuzumab Vedotin, Lifileucel, Lifirafenib, Light-activated AU-011, Light-Emitting Oncolytic Vaccinia Virus GL-ONC1, Lilotomab, Limonene; (+)-, Limonene; (+/-)-, Linifanib, Linoleyl Carbonate-Paclitaxel, Linperlisib, Linrodostat, Linsitinib, Lintuzumab, Liothyronine I-131, Liothyronine Sodium, Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1, Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191, Lipid Nanoparticle Encapsulated OX40L mRNA-2416, Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006, Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752, Liposomal Bcl-2 Antisense Oligonucleotide BP1002, Liposomal c-raf Antisense Oligonucleotide, Liposomal Curcumin, Liposomal Cytarabine, Liposomal Daunorubicin Citrate, Liposomal Docetaxel, Liposomal Eribulin Mesylate, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Liposomal Irinotecan, Liposomal Mitoxantrone Hydrochloride, Liposomal MUC1/PET-lipid A Vaccine ONT-10, Liposomal NDDP, Liposomal Rhenium Re 186, Liposomal SN-38, Liposomal Topotecan FF-10850, Liposomal Vinorelbine, Liposomal Vinorelbine Tartrate, Liposome, Liposome-encapsulated Daunorubicin-Cytarabine, Liposome-Encapsulated Doxorubicin Citrate, Liposome-encapsulated miR-34 Mimic MRX34, Liposome-encapsulated OSI-7904, Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94, Liposome-encapsulated TAAs mRNA Vaccine W_ova1, Lirilumab, Lisavanbulin, Lisocabtagene Maraleucel, Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142, Litronesib, Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809, Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207, Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623, Liver X Receptor beta Agonist RGX-104, Lm-tLLO-neoantigens Vaccine ADXS-NEO, LMB-1 Immunotoxin, LMB-2 Immunotoxin, LMB-7 Immunotoxin, LMB-9 Immunotoxin, LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164, LMP-2:340-349 Peptide Vaccine, LMP-2:419-427 Peptide Vaccine, LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes, LMP7 Inhibitor M3258, Lobaplatin, Lodapolimab, Lometrexol, Lometrexol Sodium, Lomustine, Lonafarnib, Loncastuximab Tesirine, Long Peptide Vaccine 7, Long-acting Release Pasireotide, Lontucirev, Lorlatinib, Lorukafusp alfa, Lorvotuzumab Mertansine, Losatuxizumab Vedotin, Losoxantrone, Losoxantrone Hydrochloride, Lovastatin, LOXL2 Inhibitor PAT-1251, LRP5 Antagonist BI 905681, LRP5/6 Antagonist BI 905677, LSD1 Inhibitor CC-90011, LSD1 Inhibitor GSK2879552, LSD1 Inhibitor IMG-7289, LSD1 Inhibitor RO7051790, LSD1 Inhibitor SYHA1807, Lucanthone, Lucatumumab, Lucitanib, Luminespib, Luminespib Mesylate, Lumretuzumab, Lung-targeted Immunomodulator QBKPN, Lupartumab Amadotin, Lurbinectedin, Lurtotecan, Lurtotecan Liposome, Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1, Lutetium Lu 177 DOTA-biotin, Lutetium Lu 177 DOTA-N3-CTT1403, Lutetium Lu 177 DOTA-Tetulomab, Lutetium Lu 177 Dotatate, Lutetium Lu 177 Lilotomab-satetraxetan, Lutetium Lu 177 Monoclonal Antibody CC49, Lutetium Lu 177 Monoclonal Antibody J591, Lutetium Lu 177 PP-F11N, Lutetium Lu 177 Satoreotide Tetraxetan, Lutetium Lu 177-DOTA-EB-TATE, Lutetium Lu 177-DTPA-omburtamab, Lutetium Lu 177-Edotreotide, Lutetium Lu 177-NeoB, Lutetium Lu 177-PSMA-617, Lutetium Lu-177 Capromab, Lutetium Lu-177 Girentuximab, Lutetium Lu-177 PSMA-R2, Lutetium Lu-177 Rituximab, LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1, Lyophilized Black Raspberry Lozenge, Lyophilized Black Raspberry Saliva Substitute, Lysine-specific Demethylase 1 Inhibitor INCB059872, Lyso-Thermosensitive Liposome Doxorubicin, Maackia amurensis Seed Lectin, Macimorelin, Macitentan, Macrocycle-bridged STING Agonist E7766, Maekmoondong-tang, Mafosfamide, MAGE-10.A2, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, MAGE-A3 Multipeptide Vaccine GL-0817, MAGE-A3 Peptide Vaccine, MAGE-A3-specific Immunotherapeutic GSK 2132231A, MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201, Magnesium Valproate, Magrolimab, MALT1 Inhibitor JNJ-67856633, Manelimab, Mannosulfan, Mannosylerythritol Lipid, Mapatumumab, Maraba Oncolytic Virus Expressing Mutant HPV E6/E7, Marcellomycin, MARCKS Protein Inhibitor BIO-11006, Margetuximab, Marimastat, Marizomib, Masitinib Mesylate, Masoprocol, MAT2A Inhibitor AG-270, Matrix Metalloproteinase Inhibitor MMI270, Matuzumab, Mavelertinib, Mavorixafor, Maytansine, MCL-1 Inhibitor ABBV-467, MCL-1 Inhibitor AMG 176, MCL-1 inhibitor AMG 397, Mcl-1 Inhibitor AZD5991, Mcl-1 Inhibitor MIK665, MDM2 Antagonist ASTX295, MDM2 Antagonist RO5045337, MDM2 Antagonist RO6839921, MDM2 Inhibitor AMG-232, MDM2 Inhibitor AMGMDS3, MDM2 Inhibitor BI 907828, MDM2 Inhibitor KRT-232, MDM2/MDMX Inhibitor ALRN-6924, MDR Modulator CBT-1, Mechlorethamine, Mechlorethamine Hydrochloride, Mechlorethamine Hydrochloride Gel, Medorubicin, Medroxyprogesterone, Medroxyprogesterone Acetate, Megestrol Acetate, MEK 1/2 Inhibitor AS703988/MSC2015103B, MEK 1/2 Inhibitor FCN-159, MEK Inhibitor AZD8330, MEK Inhibitor CI-1040, MEK inhibitor CS3006, MEK Inhibitor GDC-0623, MEK Inhibitor HL-085, MEK Inhibitor PD0325901, MEK Inhibitor RO4987655, MEK Inhibitor SHR 7390, MEK Inhibitor TAK-733, MEK Inhibitor WX-554, MEK-1/MEKK-1 Inhibitor E6201, MEK/Aurora Kinase Inhibitor BI 847325, Melanoma Monoclonal Antibody hIgG2A, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Melapuldencel-T, MELK Inhibitor OTS167, Melphalan, Melphalan Flufenamide, Melphalan Hydrochloride, Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex, Membrane-Disrupting Peptide EP-100, Menatetrenone, Menin-MLL Interaction Inhibitor SNDX-5613, Menogaril, Merbarone, Mercaptopurine, Mercaptopurine Anhydrous, Mercaptopurine Oral Suspension, Merestinib, Mesna, Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536, MET Kinase Inhibitor OMO-1, MET Tyrosine Kinase Inhibitor BMS-777607, MET Tyrosine Kinase Inhibitor EMD 1204831, MET Tyrosine Kinase Inhibitor PF-04217903, MET Tyrosine Kinase Inhibitor SAR125844, MET Tyrosine Kinase Inhibitor SGX523, MET x MET Bispecific Antibody REGN5093, Metamelfalan, MetAP2 Inhibitor APL-1202, MetAP2 Inhibitor SDX-7320, Metarrestin, Metatinib Tromethamine, Metformin, Metformin Hydrochloride, Methanol Extraction Residue of BCG, Methazolamide, Methionine Aminopeptidase 2 Inhibitor M8891, Methionine Aminopeptidase 2 Inhibitor PPI-2458, Methotrexate, Methotrexate Sodium, Methotrexate-E Therapeutic Implant, Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles, Methoxsalen, Methoxyamine, Methoxyamine Hydrochloride, Methyl-5-Aminolevulinate Hydrochloride Cream, Methylcantharidimide, Methylmercaptopurine Riboside, Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, Methylselenocysteine, Methyltestosterone, Metoprine, Mevociclib, Mezagitamab, Mibefradil, Mibefradil Dihydrochloride, Micellar Nanoparticle-encapsulated Epirubicin, Micro Needle Array-Doxorubicin, Microbiome GEN-001, Microbiome-derived Peptide Vaccine EO2401, Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300, Microtubule Inhibitor SCB01A, Midostaurin, Mifamurtide, Mifepristone, Milademetan Tosylate, Milataxel, Milatuzumab, Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110, Milciclib Maleate, Milk Thistle, Miltefosine, Minretumomab, Mipsagargin, Miptenalimab, Mirabegron, Miransertib, Mirdametinib, Mirvetuximab Soravtansine, Mirzotamab Clezutoclax, Misonidazole, Mistletoe Extract, Mitazalimab, Mitindomide, Mitobronitol, Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101, Mitoclomine, Mitoflaxone, Mitoguazone, Mitoguazone Dihydrochloride, Mitolactol, Mitomycin, Mitomycin A, Mitomycin B, Mitomycin C Analog KW-2149, Mitosis Inhibitor T 1101 Tosylate, Mitotane, Mitotenamine, Mitoxantrone, Mitoxantrone Hydrochloride, Mitozolomide, Mivavotinib, Mivebresib, Mivobulin, Mivobulin Isethionate, Mixed Bacteria Vaccine, MK0731, MKC-1, MKNK1 Inhibitor BAY 1143269, MMP Inhibitor S-3304, MNK1/2 Inhibitor ETC-1907206, Mobocertinib, Mocetinostat, Modakafusp Alfa, Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208, Modified Vitamin D Binding Protein Macrophage Activator EF-022, Modotuximab, MOF Compound RiMO-301, Mofarotene, Mogamulizumab, Molibresib, Molibresib Besylate, Momelotinib, Monalizumab, Monocarboxylate Transporter 1 Inhibitor AZD3965, Monoclonal Antibody 105AD7 Anti-idiotype Vaccine, Monoclonal Antibody 11D10, Monoclonal Antibody 11D10 Anti-Idiotype Vaccine, Monoclonal Antibody 14G2A, Monoclonal Antibody 1F5, Monoclonal Antibody 3622W94, Monoclonal Antibody 3F8, Monoclonal Antibody 3H1 Anti-Idiotype Vaccine, Monoclonal Antibody 4B5 Anti-Idiotype Vaccine, Monoclonal Antibody 7C11, Monoclonal Antibody 81C6, Monoclonal Antibody A1G4 Anti-Idiotype Vaccine, Monoclonal Antibody A27.15, Monoclonal Antibody A33, Monoclonal Antibody AbGn-7, Monoclonal Antibody AK002, Monoclonal Antibody ASP1948, Monoclonal Antibody CAL, Monoclonal Antibody CC49-delta CH2, Monoclonal Antibody CEP-37250/KHK2804, Monoclonal Antibody D6.12, Monoclonal Antibody E2.3, Monoclonal Antibody F19, Monoclonal Antibody GD2 Anti-Idiotype Vaccine, Monoclonal Antibody HeFi-1, Monoclonal Antibody Hu3S193, Monoclonal Antibody HuAFP31, Monoclonal Antibody HuHMFG1, Monoclonal Antibody huJ591, Monoclonal Antibody HuPAM4, Monoclonal Antibody IMMU-14, Monoclonal Antibody L6, Monoclonal Antibody Lym-1, Monoclonal Antibody m170, Monoclonal Antibody Me1-14 F(ab')2, Monoclonal Antibody muJ591, Monoclonal Antibody MX35 F(ab')2, Monoclonal Antibody NEO-201, Monoclonal Antibody R24, Monoclonal Antibody RAV12, Monoclonal Antibody SGN-14, Monoclonal Antibody TRK-950, Monoclonal Microbial EDP1503, Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100, Monomethyl Auristatin E, Morinda Citrifolia Fruit Extract, Morpholinodoxorubicin, Mosedipimod, Mosunetuzumab, Motesanib, Motesanib Diphosphate, Motexafin Gadolinium, Motexafin Lutetium, Motixafortide, Motolimod, MOv-gamma Chimeric Receptor Gene, Moxetumomab Pasudotox, Mps1 Inhibitor BAY 1217389, Mps1 Inhibitor BOS172722, mRNA-based Personalized Cancer Vaccine mRNA-4157, mRNA-based Personalized Cancer Vaccine NCI-4650, mRNA-based TriMix Melanoma Vaccine ECI-006, mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902, mRNA-derived KRAS-targeted Vaccine V941, mRNA-derived Lung Cancer Vaccine BI 1361849, mRNA-Derived Prostate Cancer Vaccine CV9103, mRNA-derived Prostate Cancer Vaccine CV9104, MTF-1 Inhibitor APTO-253 HCl, mTOR Inhibitor GDC-0349, mTOR Kinase Inhibitor AZD8055, mTOR Kinase Inhibitor CC-223, mTOR Kinase Inhibitor OSI-027, mTOR Kinase Inhibitor PP242, mTOR1/2 Kinase Inhibitor ME-344, mTORC 1/2 Inhibitor LXI-15029, mTORC1/2 Kinase Inhibitor BI 860585, mTORC1/mTORC2/DHFR Inhibitor ABTL0812, MUC-1/WT1 Peptide-primed Autologous Dendritic Cells, MUC1-targeted Peptide GO-203-2C, Mucoadhesive Paclitaxel Formulation, Multi-AGC Kinase Inhibitor AT13148, Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200, Multi-epitope HER2 Peptide Vaccine H2NVAC, Multi-epitope HER2 Peptide Vaccine TPIV100, Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107, Multi-kinase Inhibitor TPX-0022, Multi-kinase Inhibitor XL092, Multi-mode Kinase Inhibitor EOC317, Multi-neo-epitope Vaccine OSE 2101, Multifunctional/Multitargeted Anticancer Agent OMN54, Multikinase Inhibitor 4SC-203, Multikinase Inhibitor AEE788, Multikinase Inhibitor AT9283, Multikinase Inhibitor SAR103168, Multipeptide Vaccine S-588210, Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327, Muparfostat, Mureletecan, Murizatoclax, Muscadine Grape Extract, Mutant IDH1 Inhibitor DS-1001, Mutant p53 Activator COTI-2, Mutant-selective EGFR Inhibitor PF-06459988, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-BN Smallpox Vaccine, MVA-FCU1 TG4023, MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1, MYC-targeting siRNA DCR-MYC, Mycobacterium tuberculosis Arabinomannan Z-100, Mycobacterium w, Mycophenolic Acid, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea, N-dihydrogalactochitosan, N-Methylformamide, N;N-Dibenzyl Daunomycin, NA17-A Antigen, NA17.A2 Peptide Vaccine, Nab-paclitaxel, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Nadofaragene Firadenovec, Nagrestipen, Namirotene, Namodenoson, NAMPT Inhibitor OT-82, Nanafrocin, Nanatinostat, Nanocell-encapsulated miR-16-based microRNA Mimic, Nanoparticle Albumin-Bound Docetaxel, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404, Nanoparticle Paclitaxel Ointment SOR007, Nanoparticle-based Paclitaxel Suspension, Nanoparticle-encapsulated Doxorubicin Hydrochloride, Nanoscale Coordination Polymer Nanoparticles CPI-100, Nanosomal Docetaxel Lipid Suspension, Napabucasin, Naphthalimide Analogue UNBS5162, Naptumomab Estafenatox, Naquotinib, Naratuximab Emtansine, Narnatumab, Natalizumab, Natural IFN-alpha OPC-18, Natural Killer Cells ZRx101, Navarixin, Navicixizumab, Navitoclax, Navoximod, Navy Bean Powder, Naxitamab, Nazartinib, ncmtRNA Oligonucleotide Andes-1537, Necitumumab, Nedaplatin, NEDD8 Activating Enzyme E1 Inhibitor TAS4464, Nedisertib, Nelarabine, Nelipepimut-S, Nelipepimut-S Plus GM-CSF Vaccine, Nemorubicin, Nemorubicin Hydrochloride, Neoantigen Vaccine GEN-009, Neoantigen-based Glioblastoma Vaccine, Neoantigen-based Melanoma-Poly-ICLC Vaccine, Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine, Neoantigen-based Therapeutic Cancer Vaccine GRT-C903, Neoantigen-based Therapeutic Cancer Vaccine GRT-R904, Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017, Neratinib, Neratinib Maleate, Nesvacumab, NG-nitro-L-arginine, Niacinamide, Niclosamide, Nicotinamide Riboside, Nidanilimab, Nifurtimox, Nilotinib, Nilotinib Hydrochloride Anhydrous, Nilotinib Hydrochloride Monohydrate, Nilutamide, Nimesulide-Hyaluronic Acid Conjugate CA102N, Nimodipine, Nimotuzumab, Nimustine, Nimustine Hydrochloride, Ningetinib Tosylate, Nintedanib, Niraparib, Niraparib Tosylate Monohydrate, Nirogacestat, Nitric Oxide-Releasing Acetylsalicylic Acid Derivative, Nitrogen Mustard Prodrug PR-104, Nitroglycerin Transdermal Patch, Nivolumab, NLRP3 Agonist BMS-986299, Nocodazole, Nogalamycin, Nogapendekin Alfa, Nolatrexed Dihydrochloride, Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201, Norgestrel, North American Ginseng Extract AFX-2, Nortopixantrone, Noscapine, Noscapine Hydrochloride, Not Otherwise Specified, Notch Signaling Inhibitor PF-06650808, Notch Signaling Pathway Inhibitor MK0752, NTRK/ROS1 Inhibitor DS-6051b, Nucleolin Antagonist IPP-204106N, Nucleoside Analog DFP-10917, Nucleotide Analog Prodrug NUC-3373, Nucleotide Analogue GS 9219, Numidargistat, Nurulimab, Nutlin-3a, Nutraceutical TBL-12, NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611, NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301, NY-ESO-1/GLA-SE Vaccine ID-G305, NY-ESO-B, O-Chloroacetylcarbamoylfumagillol, O6-Benzylguanine, Obatoclax Mesylate, Obinutuzumab, Oblimersen Sodium, Ocaratuzumab, Ocrelizumab, Octreotide, Octreotide Acetate, Octreotide Pamoate, Odronextamab, Ofatumumab, Ofranergene Obadenovec, Oglufanide Disodium, Olaparib, Olaptesed Pegol, Olaratumab, Oleandrin, Oleclumab, Oligo-fucoidan, Oligonucleotide SPC2996, Olinvacimab, Olivomycin, Olmutinib, Oltipraz, Olutasidenib, Olvimulogene Nanivacirepvec, Omacetaxine Mepesuccinate, Ombrabulin, Omipalisib, Onalespib, Onalespib Lactate, Onartuzumab, Onatasertib, Oncolytic Adenovirus Ad5-DNX-2401, Oncolytic Adenovirus ORCA-010, Oncolytic Herpes Simplex Virus-1 ONCR-177, Oncolytic HSV-1 C134, Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011, Oncolytic HSV-1 G207, Oncolytic HSV-1 NV1020, Oncolytic HSV-1 rQNestin34.5v.2, Oncolytic HSV-1 rRp450, Oncolytic HSV1716, Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Oncolytic Newcastle Disease Virus MEDI5395, Oncolytic Newcastle Disease Virus MTH-68H, Oncolytic Newcastle Disease Virus Strain PV701, Oncolytic Virus ASP9801, Oncolytic Virus RP1, Ondansetron Hydrochloride, Ontorpacept, Ontuxizumab, Onvansertib, Onvatilimab, Opaganib, OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule, Opioid Growth Factor, Opolimogene Capmilisbac, Oportuzumab Monatox, Oprozomib, Opucolimab, Oral Aminolevulinic Acid Hydrochloride, Oral Azacitidine, Oral Cancer Vaccine V3-OVA, Oral Docetaxel, Oral Fludarabine Phosphate, Oral Hsp90 Inhibitor IPI-493, Oral Ixabepilone, Oral Microencapsulated Diindolylmethane, Oral Milataxel, Oral Myoma Vaccine V3-myoma, Oral Pancreatic Cancer Vaccine V3-P, Oral Picoplatin, Oral Sodium Phenylbutyrate, Oral Topotecan Hydrochloride, Orantinib, Oraxol, Oregovomab, Orelabrutinib, Ormaplatin, Ortataxel, Orteronel, Orvacabtagene Autoleucel, Osilodrostat, Osimertinib, Other, Otlertuzumab, Ovapuldencel-T, Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006, Ovine Submaxillary Mucin, OX40L-expressing Oncolytic Adenovirus DNX-2440, Oxaliplatin, Oxaliplatin Eluting Beads, Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome, Oxcarbazepine, Oxeclosporin, Oxidative Phosphorylation Inhibitor IACS-010759, Oxidative Phosphorylation Inhibitor IM156, Oxidopamine, OxPhos Inhibitor VLX600, Ozarelix, P-cadherin Antagonist PF-03732010, P-cadherin Inhibitor PCA062, P-cadherin-targeting Agent PF-06671008, P-p68 Inhibitor RX-5902, P-TEFb Inhibitor BAY1143572, p300/CBP Bromodomain Inhibitor CCS1477, p38 MAPK Inhibitor LY3007113, p53 Peptide Vaccine MPS-128, p53-HDM2 Interaction Inhibitor MI-773, p53-HDM2 Protein-protein Interaction Inhibitor APG-115, p53/HDM2 Interaction Inhibitor CGM097, p70S6K Inhibitor LY2584702, p70S6K/Akt Inhibitor MSC2363318A, p97 Inhibitor CB-5083, p97 Inhibitor CB-5339, p97 Inhibitor CB-5339 Tosylate, Paclitaxel, Paclitaxel Ceribate, Paclitaxel Injection Concentrate for Nanodispersion, Paclitaxel Liposome, Paclitaxel Poliglumex, Paclitaxel Polymeric Micelle Formulation NANT-008, Paclitaxel PPE Microspheres, Paclitaxel Trevatide, Paclitaxel Vitamin E-Based Emulsion, Paclitaxel-Loaded Polymeric Micelle, Pacmilimab, Pacritinib, Padeliporfin, Padoporfin, PAK4 Inhibitor PF-03758309, PAK4/NAMPT Inhibitor KPT-9274, Palbociclib, Palbociclib Isethionate, Palifosfamide, Palifosfamide Tromethamine, Palladium Pd-103, Palonosetron Hydrochloride, Pamidronate Disodium, Pamidronic Acid, Pamiparib, Pamrevlumab, pan FGFR Inhibitor PRN1371, Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514, Pan-AKT Inhibitor ARQ751, Pan-AKT Kinase Inhibitor GSK690693, Pan-FGFR Inhibitor LY2874455, Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806, pan-HER Kinase Inhibitor AC480, Pan-IDH Mutant Inhibitor AG-881, Pan-KRAS Inhibitor BI 1701963, Pan-Mutant-IDH1 Inhibitor Bay-1436032, Pan-mutation-selective EGFR Inhibitor CLN-081, pan-PI3K Inhibitor CLR457, pan-PI3K/mTOR Inhibitor SF1126, Pan-PIM Inhibitor INCB053914, pan-PIM Kinase Inhibitor AZD1208, pan-PIM Kinase Inhibitor NVP-LGB-321, pan-RAF Inhibitor LXH254, Pan-RAF Inhibitor LY3009120, pan-RAF Kinase Inhibitor CCT3833, pan-RAF Kinase Inhibitor TAK-580, Pan-RAR Agonist/AP-1 Inhibitor LGD 1550, Pan-TRK Inhibitor NOV1601, Pan-TRK Inhibitor ONO-7579, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Pancratistatin, Panitumumab, Panobinostat, Panobinostat Nanoparticle Formulation MTX110, Panulisib, Paricalcitol, PARP 1/2 Inhibitor IMP4297, PARP 1/2 Inhibitor NOV1401, PARP Inhibitor AZD2461, PARP Inhibitor CEP-9722, PARP Inhibitor E7016, PARP Inhibitor NMS-03305293, PARP-1/2 Inhibitor ABT-767, PARP/Tankyrase Inhibitor 2X-121, PARP7 Inhibitor RBN-2397, Parsaclisib, Parsaclisib Hydrochloride, Parsatuzumab, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Parvovirus H-1, Pasireotide, Pasotuxizumab, Patidegib, Patidegib Topical Gel, Patritumab, Patritumab Deruxtecan, Patupilone, Paxalisib, Pazopanib, Pazopanib Hydrochloride, pbi-shRNA STMN1 Lipoplex, PBN Derivative OKN-007, PCNU, PD-1 Directed Probody CX-188, PD-1 Inhibitor, PD-L1 Inhibitor GS-4224, PD-L1 Inhibitor INCB086550, PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480, PD-L1/PD-L2/VISTA Antagonist CA-170, PDK1 Inhibitor AR-12, pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0, PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1, PEG-interleukin-2, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, PEG-Proline-Interferon Alfa-2b, Pegargiminase, Pegaspargase, Pegdinetanib, Pegfilgrastim, Pegilodecakin, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Pegvisomant, Pegvorhyaluronidase Alfa, Pegylated Deoxycytidine Analogue DFP-14927, Pegylated Interferon Alfa, Pegylated Liposomal Belotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Pegylated Liposomal Irinotecan, Pegylated Liposomal Mitomycin C Lipid-based Prodrug, Pegylated Liposomal Mitoxantrone Hydrochloride, Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010, Pegylated Paclitaxel, Pegylated Recombinant Human Arginase I BCT-100, Pegylated Recombinant Human Hyaluronidase PH20, Pegylated Recombinant Interleukin-2 THOR-707, Pegylated Recombinant L-asparaginase Erwinia chrysanthemi, Pegylated SN-38 Conjugate PLX038, Pegzilarginase, Pelabresib, Pelareorep, Peldesine, Pelitinib, Pelitrexol, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Pemigatinib, Pemlimogene Merolisbac, Penberol, Penclomedine, Penicillamine, Pentamethylmelamine, Pentamustine, Pentostatin, Pentoxifylline, PEOX-based Polymer Encapsulated Paclitaxel FID-007, PEP-3-KLH Conjugate Vaccine, Pepinemab, Peplomycin, Peplomycin Sulfate, Peposertib, Peptichemio, Peptide 946 Melanoma Vaccine, Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine, Peretinoin, Perflenapent Emulsion, Perfosfamide, Perifosine, Perillyl Alcohol, Personalized ALL-specific Multi-HLA-binding Peptide Vaccine, Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC, Personalized Cancer Vaccine RO7198457, Personalized Neoantigen DNA Vaccine GNOS-PV01, Personalized Neoantigen DNA Vaccine GNOS-PVO2, Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01, Personalized Neoepitope Yeast Vaccine YE-NEO-001, Personalized Peptide Cancer Vaccine NEO-PV-01, Pertuzumab, Pevonedistat, Pexastimogene Devacirepvec, Pexidartinib, Pexmetinib, PGG Beta-Glucan, PGLA/PEG Copolymer-Based Paclitaxel, PH20 Hyaluronidase-expressing Adenovirus VCN-01, Phaleria macrocarpa Extract DLBS-1425, Pharmacological Ascorbate, Phellodendron amurense Bark Extract, Phenesterin, Phenethyl Isothiocyanate, Phenethyl Isothiocyanate-containing Watercress Juice, Phenyl Acetate, Phenytoin Sodium, Phosphaplatin PT-112, Phosphatidylcholine-Bound Silybin, Phospholipid Ether-drug Conjugate CLR 131, Phosphoramide Mustard, Phosphorodiamidate Morpholino Oligomer AVI-4126, Phosphorus P-32, Photodynamic Compound TLD-1433, Photosensitizer LUZ 11, Phytochlorin Sodium-Polyvinylpyrrolidone Complex, PI3K Alpha/Beta Inhibitor BAY1082439, PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate, PI3K Inhibitor ACP-319, PI3K Inhibitor BGT226, PI3K Inhibitor GDC-0084, PI3K Inhibitor GDC0077, PI3K Inhibitor GSK1059615, PI3K Inhibitor WX-037, PI3K Inhibitor ZSTK474, PI3K p110beta/delta Inhibitor KA2237, PI3K-alpha Inhibitor MEN1611, PI3K-beta Inhibitor GSK2636771, PI3K-beta Inhibitor SAR260301, PI3K-delta Inhibitor AMG 319, PI3K-delta Inhibitor HMPL 689, PI3K-delta Inhibitor INCB050465, PI3K-delta Inhibitor PWT143, PI3K-delta Inhibitor SHC014748M, PI3K-delta Inhibitor YY-20394, PI3K-gamma Inhibitor IPI-549, PI3K/BET Inhibitor LY294002, PI3K/mTOR Kinase Inhibitor DS-7423, PI3K/mTOR Kinase Inhibitor PF-04691502, PI3K/mTOR Kinase Inhibitor VS-5584, PI3K/mTOR Kinase Inhibitor WXFL10030390, PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170, PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901, PI3Ka/mTOR Inhibitor PKI-179, PI3Kalpha Inhibitor AZD8835, PI3Kbeta Inhibitor AZD8186, PI3Kdelta Inhibitor GS-9901, Pibenzimol, Pibrozelesin, Pibrozelesin Hydrobromide, Picibanil, Picoplatin, Picrasinoside H, Picropodophyllin, Pictilisib, Pictilisib Bismesylate, Pidilizumab, Pilaralisib, PIM Kinase Inhibitor LGH447, PIM Kinase Inhibitor SGI-1776, PIM Kinase Inhibitor TP-3654, PIM/FLT3 Kinase Inhibitor SEL24, Pimasertib, Pimitespib, Pimurutamab, Pinatuzumab Vedotin, Pingyangmycin, Pinometostat, Pioglitazone, Pioglitazone Hydrochloride, Pipendoxifene, Piperazinedione, Piperine Extract (Standardized), Pipobroman, Piposulfan, Pirarubicin, Pirarubicin Hydrochloride, Pirfenidone, Piritrexim, Piritrexim Isethionate, Pirotinib, Piroxantrone, Piroxantrone Hydrochloride, Pixantrone, Pixantrone Dimaleate, Pixatimod, PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231, PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521, PKC-beta Inhibitor MS-553, Placebo, Pladienolide Derivative E7107, Plamotamab, Plasmid DNA Vaccine pING-hHER3FL, Platinum, Platinum Acetylacetonate-Titanium Dioxide Nanoparticles, Platinum Compound, Plevitrexed, Plicamycin, Plinabulin, Plitidepsin, Plk1 Inhibitor BI 2536, PLK1 Inhibitor CYC140, PLK1 Inhibitor TAK-960, Plocabulin, Plozalizumab, pNGVL4a-CRT-E6E7L2 DNA Vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2, Pol I Inhibitor CX5461, Polatuzumab Vedotin, Polidocanol, Poliglusam, Polo-like Kinase 1 Inhibitor GSK461364, Polo-like Kinase 1 Inhibitor MK1496, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate, Poly-alendronate Dextran-Guanidine Conjugate, Poly-gamma Glutamic Acid, Polyamine Analog SL11093, Polyamine Analogue PG11047, Polyamine Analogue SBP-101, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Polyandrol, Polyethylene Glycol Recombinant Endostatin, Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, Polymer-encapsulated Luteolin Nanoparticle, Polymeric Camptothecin Prodrug XMT-1001, Polypodium leucotomos Extract, Polysaccharide-K, Polysialic Acid, Polyunsaturated Fatty Acid, Polyvalent Melanoma Vaccine, Pomalidomide, Pomegranate Juice, Pomegranate Liquid Extract, Ponatinib, Ponatinib Hydrochloride, Porcupine Inhibitor CGX1321, Porcupine Inhibitor ETC-1922159, Porcupine Inhibitor RXC004, Porcupine Inhibitor WNT974, Porcupine Inhibitor XNW7201, Porfimer Sodium, Porfiromycin, Poziotinib, PPAR Alpha Antagonist TPST-1120, PR1 Leukemia Peptide Vaccine, Pracinostat, Pralatrexate, Pralsetinib, Praluzatamab Ravtansine, PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701, Pravastatin Sodium, Prednimustine, Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, Prednisone, Prexasertib, Prexigebersen, PRIMA-1 Analog APR-246, Prime Cancer Vaccine MVA-BN-CV301, Prinomastat, PRMT1 Inhibitor GSK3368715, PRMT5 Inhibitor JNJ-64619178, PRMT5 Inhibitor PRT811, Proapoptotic Sulindac Analog CP-461, Procarbazine, Procarbazine Hydrochloride, Procaspase Activating Compound-1 VO-100, Progestational IUD, Prohibitin-Targeting Peptide 1, Prolgolimab, Prostaglandin E2 EP4 Receptor Inhibitor AN0025, Prostaglandin E2 EP4 Receptor Inhibitor E7046, Prostate Cancer Vaccine ONY-P1, Prostate Health Cocktail Dietary Supplement, Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024, Protease-activated Anti-PD-L1 Antibody Prodrug CX-072, Protein Arginine Methyltransferase 5 Inhibitor GSK3326595, Protein Arginine Methyltransferase 5 Inhibitor PF-06939999, Protein Arginine Methyltransferase 5 Inhibitor PRT543, Protein Kinase C Inhibitor IDE196, Protein Phosphatase 2A Inhibitor LB-100, Protein Stabilized Liposomal Docetaxel Nanoparticles, Protein Tyrosine Kinase 2 Inhibitor IN10018, Proxalutamide, PSA/IL-2/GM-CSF Vaccine, PSA/PSMA DNA Plasmid INO-5150, Pseudoisocytidine, PSMA-targeted Docetaxel Nanoparticles BIND-014, PSMA-targeted Tubulysin B-containing Conjugate EC1169, PSMA/CD3 Tri-specific T-cell Activating Construct HPN424, PTEF-b/CDK9 Inhibitor BAY1251152, Pterostilbene, Pumitepa, Puquitinib, Puquitinib Mesylate, Puromycin, Puromycin Hydrochloride, PV-10, PVA Microporous Hydrospheres/Doxorubicin Hydrochloride, Pyrazinamide, Pyrazoloacridine, Pyridyl Cyanoguanidine CHS 828, Pyrotinib, Pyrotinib Dimaleate, Pyroxamide, Pyruvate Kinase Inhibitor TLN-232, Pyruvate Kinase M2 Isoform Activator TP-1454, Qilisheng Immunoregulatory Oral Solution, Quadrivalent Human Papillomavirus (types 6; 11; 16; 18) Recombinant Vaccine, Quarfloxin, Quinacrine Hydrochloride, Quinine, Quisinostat, Quizartinib, R-(-)-Gossypol Acetic Acid, Rabusertib, Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88, Racotumomab, RAD51 Inhibitor CYT-0851, Radgocitabine, Radgocitabine Hydrochloride, Radioactive Iodine, Radiolabeled CC49, Radium Ra 223 Dichloride, Radium Ra 224-labeled Calcium Carbonate Microparticles, Radix Angelicae Sinensis/Radix Astragali Herbal Supplement, Radotinib Hydrochloride, Raf Kinase Inhibitor HM95573, RAF Kinase Inhibitor L-779450, RAF Kinase Inhibitor XL281, Ragifilimab, Ralaniten Acetate, Ralimetinib Mesylate, Raloxifene, Raloxifene Hydrochloride, Raltitrexed, Ramucirumab, Ranibizumab, Ranimustine, Ranolazine, Ranpirnase, RARalpha Agonist IRX5183, Ras Inhibitor, Ras Peptide ASP, Ras Peptide CYS, Ras Peptide VAL, Razoxane, Realgar-Indigo naturalis Formulation, Rebastinib Tosylate, Rebeccamycin, Rebimastat, Receptor Tyrosine Kinase Inhibitor R1530, Recombinant Adenovirus-p53 SCH-58500, Recombinant Anti-WT1 Immunotherapeutic GSK2302024A, Recombinant Bacterial Minicells VAX014, Recombinant Bispecific Single-Chain Antibody rM28, Recombinant CD40-Ligand, Recombinant Erwinia asparaginase JZP-458, Recombinant Erythropoietin, Recombinant Fas Ligand, Recombinant Fractalkine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human 6Ckine, Recombinant Human Adenovirus Type 5 H101, Recombinant Human Angiotensin Converting Enzyme 2 APN01, Recombinant Human Apolipoprotein(a) Kringle V MG1102, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Recombinant Human Endostatin, Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Recombinant Human Papillomavirus 11-valent Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Recombinant Human Plasminogen Kringle 5 Domain ABT 828, Recombinant Human TRAIL-Trimer Fusion Protein SCB-313, Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301, Recombinant Interferon, Recombinant Interferon Alfa, Recombinant Interferon Alfa-1b, Recombinant Interferon Alfa-2a, Recombinant Interferon Alfa-2b, Recombinant Interferon Alpha 2b-like Protein, Recombinant Interferon Beta, Recombinant Interferon Gamma, Recombinant Interleukin-12, Recombinant Interleukin-13, Recombinant Interleukin-18, Recombinant Interleukin-2, Recombinant Interleukin-6, Recombinant KSA Glycoprotein CO17-1A, Recombinant Leukocyte Interleukin, Recombinant Leukoregulin, Recombinant Luteinizing Hormone, Recombinant Macrophage Colony-Stimulating Factor, Recombinant MAGE-3.1 Antigen, Recombinant MIP1-alpha Variant ECI301, Recombinant Modified Vaccinia Ankara-5T4 Vaccine, Recombinant Oncolytic Poliovirus PVS-RIPO, Recombinant Platelet Factor 4, Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A, Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207, Recombinant Super-compound Interferon, Recombinant Thyroglobulin, Recombinant Thyrotropin Alfa, Recombinant Transforming Growth Factor-Beta, Recombinant Transforming Growth Factor-Beta-2, Recombinant Tumor Necrosis Factor-Alpha, Recombinant Tyrosinase-Related Protein-2, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Redaporfin, Refametinib, Regorafenib, Relacorilant, Relatlimab, Relugolix, Remetinostat, Renal Cell Carcinoma Peptides Vaccine IMA901, Reparixin, Repotrectinib, Resiquimod, Resiquimod Topical Gel, Resistant Starch, Resminostat, Resveratrol, Resveratrol Formulation SRT501, RET Inhibitor DS-5010, RET Mutation/Fusion Inhibitor BLU-667, RET/SRC Inhibitor TPX-0046, Retaspimycin, Retaspimycin Hydrochloride, Retelliptine, Retifanlimab, Retinoic Acid Agent Ro 16-9100, Retinoid 9cUAB30, Retinol, Retinyl Acetate, Retinyl Palmitate, Retrovector Encoding Mutant Anti-Cyclin G1, Revdofilimab, Rexinoid NRX 194204, Rezivertinib, RFT5-dgA Immunotoxin IMTOX25, Rhenium Re 188 BMEDA-labeled Liposomes, Rhenium Re-186 Hydroxyethylidene Diphosphonate, Rhenium Re-188 Ethiodized Oil, Rhenium Re-188 Etidronate, Rhizoxin, RhoC Peptide Vaccine RV001V, Ribociclib, Ribociclib/Letrozole, Ribonuclease QBI-139, Ribosome-Inactivating Protein CY503, Ribozyme RPI.4610, Rice Bran, Ricolinostat, Ridaforolimus, Rigosertib, Rigosertib Sodium, Rilimogene Galvacirepvec, Rilimogene Galvacirepvec/Rilimogene Glafolivec, Rilimogene Glafolivec, Rilotumumab, Rindopepimut, Ripertamab, RIPK1 Inhibitor GSK3145095, Ripretinib, Risperidone Formulation in Rumenic Acid, Ritrosulfan, Rituximab, Rituximab and Hyaluronidase Human, Rituximab Conjugate CON-4619, Riviciclib, Rivoceranib, Rivoceranib Mesylate, RNR Inhibitor COH29, Robatumumab, Roblitinib, ROBO1-targeted BiCAR-NKT Cells, Rocakinogene Sifuplasmid, Rocapuldencel-T, Rociletinib, Rodorubicin, Roducitabine, Rofecoxib, Roflumilast, Rogaratinib, Rogletimide, Rolinsatamab Talirine, Romidepsin, Roneparstat, Roniciclib, Ropeginterferon Alfa-2B, Ropidoxuridine, Ropocamptide, Roquinimex, RORgamma Agonist LYC-55716, Rosabulin, Rose Bengal Solution PV-10, Rosiglitazone Maleate, Rosmantuzumab, Rosopatamab, Rosuvastatin, Rovalpituzumab Tesirine, RSK1-4 Inhibitor PMD-026, Rubitecan, Rucaparib, Rucaparib Camsylate, Rucaparib Phosphate, Ruthenium Ru-106, Ruthenium-based Small Molecule Therapeutic BOLD-100, Ruthenium-based Transferrin Targeting Agent NKP-1339, Ruxolitinib, Ruxolitinib Phosphate, Ruxotemitide, S-Adenosylmethionine, S-equol, S1P Receptor Agonist KRP203, Sabarubicin, Sabatolimab, Sacituzumab Govitecan, Sacubitril/Valsartan, Safingol, Sagopilone, Salirasib, Salmonella VNP20009, Sam68 Modulator CWP232291, Samalizumab, Samarium Sm 153-DOTMP, Samotolisib, Samrotamab Vedotin, Samuraciclib, Sapacitabine, Sapanisertib, Sapitinib, Saracatinib, Saracatinib Difumarate, SarCNU, Sardomozide, Sargramostim, Sasanlimab, Satraplatin, Savolitinib, SBIL-2, Scopoletin, SDF-1 Receptor Antagonist PTX-9908, Seclidemstat, Sedoxantrone Trihydrochloride, Selatinib Ditosilate, Selective Androgen Receptor Modulator RAD140, Selective Cytokine Inhibitory Drug CC-1088, Selective Estrogen Receptor Degrader AZD9496, Selective Estrogen Receptor Degrader AZD9833, Selective Estrogen Receptor Degrader LSZ102, Selective Estrogen Receptor Degrader LX-039, Selective Estrogen Receptor Degrader LY3484356, Selective Estrogen Receptor Degrader SRN-927, Selective Estrogen Receptor Modulator CC-8490, Selective Estrogen Receptor Modulator TAS-108, Selective Glucocorticoid Receptor Antagonist CORT125281, Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352, Seliciclib, Selicrelumab, Selinexor, Selitrectinib, Selonsertib, Selpercatinib, Selumetinib, Selumetinib Sulfate, Semaxanib, Semuloparin, Semustine, Seneca Valley Virus-001, Seocalcitol, Sepantronium Bromide, Serabelisib, Serclutamab Talirine, SERD D-0502, SERD G1T48, SERD GDC-9545, SERD SAR439859, SERD SHR9549, SERD ZN-c5, Serdemetan, Sergiolide, Seribantumab, Serine/Threonine Kinase Inhibitor CBP501, Serine/Threonine Kinase Inhibitor XL418, Serplulimab, Sevacizumab, Seviteronel, Shared Anti-Idiotype-AB-S006, Shared Anti-Idiotype-AB-S024A, Shark Cartilage, Shark Cartilage Extract AE-941, Shenqi Fuzheng Injection SQ001, Sho-Saiko-To, Short Chain Fatty Acid HQK-1004, SHP-1 Agonist SC-43, SHP2 Inhibitor JAB-3068, SHP2 Inhibitor RLY-1971, SHP2 Inhibitor RMC-4630, SHP2 Inhibitor TNO155, Shu Yu Wan Formula, Sialyl Tn Antigen, Sialyl Tn-KLH Vaccine, Sibrotuzumab, siG12D LODER, Silatecan AR-67, Silibinin, Silicon Phthalocyanine 4, Silmitasertib Sodium, Siltuximab, Simalikalactone D, Simeprevir, Simlukafusp Alfa, Simmitinib, Simotaxel, Simtuzumab, Simurosertib, Sintilimab, Siplizumab, Sipuleucel-T, Siremadlin, siRNA-transfected Peripheral Blood Mononuclear Cells APN401, Sirolimus, SIRPa-4-1BBL Fusion Protein DSP107, SIRPa-Fc Fusion Protein TTI-621, SIRPa-Fc-CD40L Fusion Protein SL-172154, SIRPa-IgG4-Fc Fusion Protein TTI-622, Sitimagene Ceradenovec, Sitravatinib, Sivifene, Sizofiran, SLC6A8 Inhibitor RGX-202, SLCT Inhibitor GNS561, SMAC Mimetic BI 891065, Smac Mimetic GDC-0152, Smac Mimetic GDC-0917, Smac Mimetic LCL161, SMO Protein Inhibitor ZSP1602, Smoothened Antagonist BMS-833923, Smoothened Antagonist LDE225 Topical, Smoothened Antagonist LEQ506, Smoothened Antagonist TAK-441, SN-38-Loaded Polymeric Micelles NK012, SNS01-T Nanoparticles, Sobuzoxane, Sodium Borocaptate, Sodium Butyrate, Sodium Dichloroacetate, Sodium Iodide I-131, Sodium Metaarsenite, Sodium Phenylbutyrate, Sodium Salicylate, Sodium Selenite, Sodium Stibogluconate, Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108, Sofituzumab Vedotin, Solitomab, Sonepcizumab, Sonidegib, Sonolisib, Sorafenib, Sorafenib Tosylate, Sorghum bicolor Supplement, Sotigalimab, Sotorasib, Sotrastaurin, Sotrastaurin Acetate, Soy Isoflavones, Soy Protein Isolate, Spanlecortemlocel, Sparfosate Sodium, Sparfosic Acid, Spartalizumab, Spebrutinib, Spherical Nucleic Acid Nanoparticle NU-0129, Spirogermanium, Spiromustine, Spiroplatin, Splicing Inhibitor H3B-8800, Spongistatin, Squalamine Lactate, SR-BP1/HSI Inhibitor SR31747A, SR-T100 Gel, Src Kinase Inhibitor AP 23846, Src Kinase Inhibitor KX2-391, Src Kinase Inhibitor KX2-391 Ointment, Src Kinase Inhibitor M475271, Src/Abl Kinase Inhibitor AZD0424, Src/tubulin Inhibitor KX02, SRPK1/ABCG2 Inhibitor SCO-101, ssRNA-based Immunomodulator CV8102, SSTR2-targeting Protein/DM1 Conjugate PEN-221, St. John's Wort, Stallimycin, Staphylococcal Enterotoxin A, Staphylococcal Enterotoxin B, STAT Inhibitor OPB-111077, STAT3 Inhibitor DSP-0337, STAT3 Inhibitor OPB-31121, STAT3 Inhibitor OPB-51602, STAT3 Inhibitor TTI-101, STAT3 Inhibitor WP1066, Staurosporine, STING Agonist BMS-986301, STING Agonist GSK3745417, STING Agonist IMSA101, STING Agonist MK-1454, STING Agonist SB 11285, STING Agonist TAK-676, STING-activating Cyclic Dinucleotide Agonist MIW815, STING-expressing E. coli SYNB1891, Streptonigrin, Streptozocin, Strontium Chloride Sr-89, Submicron Particle Paclitaxel Sterile Suspension, Sugemalimab, Sulfatinib, Sulforaphane, Sulindac, Sulofenur, Sumoylation Inhibitor TAK-981, Sunitinib, Sunitinib Malate, Super Enhancer Inhibitor GZ17-6.02, Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803, Superoxide Dismutase Mimetic GC4711, Suramin, Suramin Sodium, Survivin Antigen, Survivin Antigen Vaccine DPX-Survivac, Survivin mRNA Antagonist EZN-3042, Survivin-expressing CVD908ssb-TXSVN Vaccine, Sustained-release Lipid Inhaled Cisplatin, Sustained-release Mitomycin C Hydrogel Formulation UGN-101, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, Syk Inhibitor HMPL-523, Synchrotope TA2M Plasmid DNA Vaccine, Synchrovax SEM Plasmid DNA Vaccine, Synthetic Alkaloid PM00104, Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2, Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1, Synthetic hTERT DNA Vaccine INO-1400, Synthetic hTERT DNA Vaccine INO-1401, Synthetic Hypericin, Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201, Synthetic Long E6/E7 Peptides Vaccine HPV-01, Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b, Synthetic Plumbagin PCUR-101, T900607, Tabalumab, Tabelecleucel, Tacedinaline, Tafasitamab, Tagraxofusp-erzs, Talabostat, Talabostat Mesylate, Talacotuzumab, Talactoferrin Alfa, Taladegib, Talampanel, Talaporfin Sodium, Talazoparib, Taletrectinib, Talimogene Laherparepvec, Tallimustine, Talmapimod, Talotrexin, Talotrexin Ammonium, Taltobulin, TAM/c-Met Inhibitor RXDX-106, Tamibarotene, Taminadenant, Tamoxifen, Tamoxifen Citrate, Tamrintamab Pamozirine, Tandutinib, Tanespimycin, Tanibirumab, Tankyrase Inhibitor STP1002, Tanomastat, Tapotoclax, Tarenflurbil, Tarextumab, Tariquidar, Tasadenoturev, Taselisib, Tasidotin, Tasisulam, Tasisulam Sodium, Tasquinimod, Taurolidine, Tauromustine, Taurultam, Taurultam Analogue GP-2250, Tavokinogene Telseplasmid, Tavolimab, Taxane Analogue TPI 287, Taxane Compound, Taxol Analogue SID 530, Tazarotene, Tazemetostat, Tebentafusp, Teclistamab, Tecogalan Sodium, Tefinostat, Tegafur, Tegafur-gimeracil-oteracil Potassium, Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation, Tegafur-Uracil, Tegavivint, Teglarinad, Teglarinad Chloride, Telaglenastat, Telaglenastat Hydrochloride, Telapristone, Telapristone Acetate, Telatinib Mesylate, Telisotuzumab, Telisotuzumab Vedotin, Telomerase Inhibitor FJ5002, Telomerase-specific Type 5 Adenovirus OBP-301, Teloxantrone, Teloxantrone Hydrochloride, Telratolimod, Temarotene, Temoporfin, Temozolomide, Temsirolimus, Tenalisib, Tenifatecan, Teniposide, Tepoditamab, Tepotinib, Teprotumumab, Terameprocol, Terfluranol, Tergenpumatucel-L, Teroxirone, Tertomotide, Tesetaxel, Tesevatinib, Tesidolumab, Testolactone, Testosterone Enanthate, Tetanus Toxoid Vaccine, Tetradecanoylphorbol Acetate, Tetrahydrouridine, Tetraphenyl Chlorin Disulfonate, Tetrathiomolybdate, Tezacitabine, Tezacitabine Anhydrous, TGF-beta Receptor 1 Inhibitor PF-06952229, TGF-beta Receptor 1 Kinase Inhibitor SH3051, TGF-beta Receptor 1 Kinase Inhibitor YL-13027, TGFa-PE38 Immunotoxin, TGFbeta Inhibitor LY3200882, TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200, Thalicarpine, Thalidomide, Theliatinib, Theramide, Therapeutic Angiotensin-(1-7), Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907, Therapeutic Cancer Vaccine ATP128, Therapeutic Estradiol, Therapeutic Hydrocortisone, Therapeutic Liver Cancer Peptide Vaccine IMA970A, Thiarabine, Thiodiglycol, Thioguanine, Thioguanine Anhydrous, Thioinosine, Thioredoxin-1 Inhibitor PX-12, Thiotepa, Thioureidobutyronitrile, THL-P, Thorium Th 227 Anetumab, Thorium Th 227 Anetumab Corixetan, Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439, Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497, Threonine Tyrosine Kinase Inhibitor CFI-402257, Thymidylate Synthase Inhibitor CX1106, Thymidylate Synthase Inhibitor DFP-11207, Thymopentin, Thyroid Extract, Tiazofurin, Tidutamab, Tigapotide, Tigatuzumab, TIGIT Inhibitor M6223, TIGIT-targeting Agent MK-7684, Tilarginine, Tilogotamab, Tilsotolimod Sodium, Timonacic, Tin Ethyl Etiopurpurin, Tinostamustine, Tinzaparin Sodium, Tiomolibdate Choline, Tiomolibdate Diammonium, Tipapkinogene Sovacivec, Tipifarnib, Tipiracil, Tipiracil Hydrochloride, Tirabrutinib, Tiragolumab, Tirapazamine, Tirbanibulin, Tisagenlecleucel, Tislelizumab, Tisotumab Vedotin, Tivantinib, Tivozanib, TLC ELL-12, TLR Agonist BDB001, TLR Agonist BSG-001, TLR Agonist CADI-05, TLR-Directed Cationic Lipid-DNA Complex JVRS-100, TLR7 Agonist 852A, TLR7 agonist BNT411, TLR7 Agonist LHC165, TLR7/8/9 Antagonist IMO-8400, TLR8 Agonist DN1508052, TLR9 Agonist AST-008, TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells, Tocilizumab, Tocladesine, Tocotrienol, Tocotrienol-rich Fraction, Tolebrutinib, Toll-like Receptor 7 Agonist DSP-0509, Tolnidamine, Tomaralimab, Tomato-Soy Juice, Tomivosertib, Topical Betulinic Acid, Topical Celecoxib, Topical Fluorouracil, Topical Gemcitabine Hydrochloride, Topical Potassium Dobesilate, Topical Trichloroacetic Acid, Topixantrone, Topoisomerase I Inhibitor Genz-644282, Topoisomerase I Inhibitor LMP400, Topoisomerase I Inhibitor LMP776, Topoisomerase I/II Inhibitor NEV-801, Topoisomerase-1 Inhibitor LMP744, Topoisomerase-II Inhibitor Racemic XK469, Topoisomerase-II-beta Inhibitor Racemic XK469, Topotecan, Topotecan Hydrochloride, Topotecan Hydrochloride Liposomes, Topotecan Sustained-release Episcleral Plaque, Topsalysin, TORC1/2 Kinase Inhibitor DS-3078a, Toremifene, Toremifene Citrate, Toripalimab, Tosedostat, Tositumomab, Total Androgen Blockade, Tovetumab, Tozasertib Lactate, TP40 Immunotoxin, Trabectedin, Trabedersen, TRAIL Receptor Agonist ABBV-621, Trametinib, Trametinib Dimethyl Sulfoxide, Trans Sodium Crocetinate, Transdermal 17beta-Estradiol Gel BHR-200, Transdermal 4-Hydroxytestosterone, Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01, Transferrin Receptor-Targeted Liposomal p53 cDNA, Transferrin-CRM107, Tranylcypromine Sulfate, Trapoxin, Trastuzumab, Trastuzumab Conjugate BI-CON-02, Trastuzumab Deruxtecan, Trastuzumab Duocarmazine, Trastuzumab Emtansine, Trastuzumab Monomethyl Auristatin F, Trastuzumab-TLR 7/8 Agonist BDC-1001, Trastuzumab/Hyaluronidase-oysk, Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502, Trebananib, Tremelimumab, Treosulfan, Tretazicar, Tretinoin, Tretinoin Liposome, Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triapine, Triazene Derivative CB10-277, Triazene Derivative TriN2755, Triazinate, Triaziquone, Tributyrin, Triciribine Phosphate, Trientine Hydrochloride, Triethylenemelamine, Trifluridine, Trifluridine and Tipiracil Hydrochloride, Trigriluzole, Trilaciclib, Trimelamol, Trimeric GITRL-Fc OMP-336B11, Trimethylcolchicinic Acid, Trimetrexate, Trimetrexate Glucuronate, Trioxifene, Triplatin Tetranitrate, Triptolide Analog, Triptorelin, Triptorelin Pamoate, Tris-acryl Gelatin Microspheres, Tritylcysteine, TRK Inhibitor AZD6918, TRK Inhibitor TQB3558, TrkA Inhibitor VMD-928, Trodusquemine, Trofosfamide, Troglitazone, Tropomyosin Receptor Kinase Inhibitor AZD7451, Troriluzole, Troxacitabine, Troxacitabine Nucleotide Prodrug MIV-818, TRPM8 Agonist D-3263, TRPV6 Calcium Channel Inhibitor SOR-C13, TSP-1 Mimetic ABT-510, TSP-1 Mimetic Fusion Protein CVX-045, Tubercidin, Tubulin Binding Agent TTI-237, Tubulin Inhibitor ALB 109564 Dihydrochloride, Tubulin Inhibitor ALB-109564, Tubulin Polymerization Inhibitor AEZS 112, Tubulin Polymerization Inhibitor CKD-516, Tubulin Polymerization Inhibitor VERU-111, Tubulin-Binding Agent SSR97225, Tucatinib, Tucidinostat, Tucotuzumab Celmoleukin, Tyroserleutide, Tyrosinase Peptide, Tyrosinase-KLH, Tyrosinase:146-156 Peptide, Tyrosine Kinase Inhibitor, Tyrosine Kinase Inhibitor OSI-930, Tyrosine Kinase Inhibitor SU5402, Tyrosine Kinase Inhibitor TL-895, Tyrosine Kinase Inhibitor XL228, UAE Inhibitor TAK-243, Ubenimex, Ubidecarenone Nanodispersion BPM31510n, Ublituximab, Ulinastatin, Ulixertinib, Ulocuplumab, Umbralisib, Uncaria tomentosa Extract, Upamostat, Upifitamab, Uproleselan, Uprosertib, Urabrelimab, Uracil Ointment, Urelumab, Uroacitides, Urokinase-Derived Peptide A6, Ursolic Acid, USP14/UCHL5 Inhibitor VLX1570, Utomilumab, Uzansertib, V930 Vaccine, Vaccine-Sensitized Draining Lymph Node Cells, Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules, Vactosertib, Vadacabtagene Leraleucel, Vadastuximab Talirine, Vadimezan, Valecobulin, Valemetostat, Valproic Acid, Valrubicin, Valspodar, Vandetanib, Vandetanib-eluting Radiopaque Bead BTG-002814, Vandortuzumab Vedotin, Vantictumab, Vanucizumab, Vapreotide, Varlilumab, Varlitinib, Varlitinib Tosylate, Vascular Disrupting Agent BNC105, Vascular Disrupting Agent BNC105P, Vascular Disrupting Agent ZD6126, Vatalanib, Vatalanib Succinate, Vecabrutinib, Vector-peptide Conjugated Paclitaxel, Vedolizumab, VEGF Inhibitor PTC299, VEGF/HGF-targeting DARPin MP0250, VEGFR Inhibitor KRN951, VEGFR-2 DNA Vaccine VXM01, VEGFR/FGFR Inhibitor ODM-203, VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593, VEGFR2 Tyrosine Kinase Inhibitor PF-00337210, VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813, Veliparib, Veltuzumab, Vemurafenib, Venetoclax, Verapamil, Verpasep Caltespen, Verubulin, Verubulin Hydrochloride, Vesencumab, Vesigenurtucel-L, VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220, VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820, Viagenpumatucel-L, Vibecotamab, Vibostolimab, Vilaprisan, Vinblastine, Vinblastine Sulfate, Vincristine, Vincristine Liposomal, Vincristine Sulfate, Vincristine Sulfate Liposome, Vindesine, Vinepidine, Vinflunine, Vinflunine Ditartrate, Vinfosiltine, Vinorelbine, Vinorelbine Tartrate, Vinorelbine Tartrate Emulsion, Vinorelbine Tartrate Oral, Vintafolide, Vinzolidine, Vinzolidine Sulfate, Virulizin, Vismodegib, Vistusertib, Vitamin D3 Analogue ILX23-7553, Vitamin E Compound, Vitespen, VLP-encapsulated TLR9 Agonist CMP-001, Vocimagene Amiretrorepvec, Vofatamab, Volasertib, Volociximab, Vonlerolizumab, Vopratelimab, Vorasidenib, Vorinostat, Vorolanib, Vorsetzumab Mafodotin, Vosaroxin, Vosilasarm, Voxtalisib, Vulinacimab, Warfarin Sodium, Wee1 Inhibitor ZN-c3, Wee1 Kinase Inhibitor Debio 0123, White Carrot, Wnt Signaling Inhibitor SM04755, Wnt Signaling Pathway Inhibitor SM08502, Wnt-5a Mimic Hexapeptide Foxy-5, Wobe-Mugos E, WT1 Peptide Vaccine OCV-501, WT1 Peptide Vaccine WT2725, WT1 Protein-derived Peptide Vaccine DSP-7888, WT1-A10/AS01B Immunotherapeutic GSK2130579A, WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401, Xanthohumol, XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410, Xeloda, Xentuzumab, Xevinapant, Xiaoai Jiedu Decoction, XIAP Antisense Oligonucleotide AEG35156, XIAP/cIAP1 Antagonist ASTX660, Xiliertinib, Xisomab 3G3, XPO1 Inhibitor SL-801, Y 90 Monoclonal Antibody CC49, Y 90 Monoclonal Antibody HMFG1, Y 90 Monoclonal Antibody Lym-1, Y 90 Monoclonal Antibody m170, Y 90 Monoclonal Antibody M195, Yang Yin Fu Zheng, Yangzheng Xiaoji Extract, Yiqi-yangyin-jiedu Herbal Decoction, Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8, Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101, Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66, Yttrium Y 90 Basiliximab, Yttrium Y 90 Colloid, Yttrium Y 90 Daclizumab, Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A, Yttrium Y 90 Glass Microspheres, Yttrium Y 90 Monoclonal Antibody B3, Yttrium Y 90 Monoclonal Antibody BrE-3, Yttrium Y 90 Monoclonal Antibody Hu3S193, Yttrium Y 90 Monoclonal Antibody MN-14, Yttrium Y 90 Resin Microspheres, Yttrium Y 90 Tabituximab Barzuxetan, Yttrium Y 90-DOTA-Biotin, Yttrium Y 90-DOTA-di-HSG Peptide IMP-288, Yttrium Y 90-Edotreotide, Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101, Yttrium Y-90 Clivatuzumab Tetraxetan, Yttrium Y-90 Epratuzumab Tetraxetan, Yttrium Y-90 Ibritumomab Tiuxetan, Yttrium Y-90 Tacatuzumab Tetraxetan, Yttrium-90 Polycarbonate Brachytherapy Plaque, Z-Endoxifen Hydrochloride, Zalcitabine, Zalifrelimab, Zalutumumab, Zandelisib, Zanidatamab, Zanolimumab, Zanubrutinib, Zebularine, Zelavespib, Zibotentan, Zinc Finger Nuclease ZFN-603, Zinc Finger Nuclease ZFN-758, Zinostatin, Zinostatin Stimalamer, Zirconium Zr 89 Panitumumab, Ziv-Aflibercept, Zolbetuximab, Zoledronic Acid, Zoptarelin Doxorubicin, Zorifertinib, Zorubicin, Zorubicin Hydrochloride, Zotatifin, Zotiraciclib Citrate, Zuclomiphene Citrate, Unknown, Not Reported",,,CDE:13579886,,string,,,,,, Individual Metastasis Stage,Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.,"M0, M1, M1a, M1b, M1c, MX, cM0 (i+), Unknown, Not Reported",,,CDE:3440331,,string,,,,,, @@ -330,7 +330,7 @@ Model Source,"The reference organism from which the model was derived, if applic Model Acquisition Type,"The method by which the model was obtained. If applicable, please provide a link to the supplier of the model source.",,,,,,string,,,,,, Model Graft Source,"If the model is an allograft or xenograft, as indicated by Model Type, please provide a unique identifier associated with the source of the graft material (e.g., RRID, Individual Key, Model Key, Biospecimen Key)",,,,,,string,,,,,, Model Genotype,"The relevant genotype information associated with the model, including markers, background, etc.",,,,,,string,,,,,, -Model Treatment Type,Text term that describes the kind of treatment applied to the model.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, +Model Treatment Type,Text term that describes the kind of treatment applied to the model.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, Model Therapeutic Agent,Text identification of the individual agent(s) used as part of an experimental protocol performed using the model.,"10-Deacetyltaxol, 11C Topotecan, 11D10 AluGel Anti-Idiotype Monoclonal Antibody, 12-Allyldeoxoartemisinin, 13-Deoxydoxorubicin, 14C BMS-275183, 17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521, 2-Deoxy-D-glucose, 2-Ethylhydrazide, 2-Fluoroadenine, 2-Fluorofucose-containing SGN-2FF, 2-Hydroxyestradiol, 2-Hydroxyestrone, 2-Hydroxyflutamide Depot, 2-Hydroxyoleic Acid, 2-Methoxyestradiol, 2-Methoxyestradiol Nanocrystal Colloidal Dispersion, 2-Methoxyestrone, 2-O; 3-O Desulfated Heparin, 2;6-Diaminopurine, 2;6-Dimethoxyquinone, 2'-F-ara-deoxyuridine, 3'-C-ethynylcytidine, 3'-dA Phosphoramidate NUC-7738, 4-Nitroestrone 3-Methyl Ether, 4-Thio-2-deoxycytidine, 4'-Iodo-4'-Deoxydoxorubicin, 5-Aza-4'-thio-2'-deoxycytidine, 5-Fluoro-2-Deoxycytidine, 6-Phosphofructo-2-kinase/fructose-2;6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158, 7-Cyanoquinocarcinol, 7-Ethyl-10-Hydroxycamptothecin, 7-Hydroxystaurosporine, 8-Azaguanine, 9-Ethyl 6-Mercaptopurine, 9H-Purine-6Thio-98D, A2A Receptor Antagonist EOS100850, Abagovomab, Abarelix, Abemaciclib, Abemaciclib Mesylate, Abexinostat, Abexinostat Tosylate, Abiraterone, Abiraterone Acetate, Abituzumab, Acai Berry Juice, Acalabrutinib, Acalisib, Aceglatone, Acetylcysteine, Acitretin, Acivicin, Aclacinomycin B, Aclarubicin, Acodazole, Acodazole Hydrochloride, Acolbifene Hydrochloride, Acridine, Acridine Carboxamide, Acronine, Actinium Ac 225 Lintuzumab, Actinium Ac 225-FPI-1434, Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591, Actinomycin C2, Actinomycin C3, Actinomycin F1, Activin Type 2B Receptor Fc Fusion Protein STM 434, Acyclic Nucleoside Phosphonate Prodrug ABI-1968, Ad-RTS-hIL-12, Adagloxad Simolenin, Adavosertib, Adecatumumab, Adenosine A2A Receptor Antagonist AZD4635, Adenosine A2A Receptor Antagonist CS3005, Adenosine A2A Receptor Antagonist NIR178, Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999, Adenosine A2A/A2B Receptor Antagonist AB928, Adenosine A2B Receptor Antagonist PBF-1129, Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201, Adenoviral Brachyury Vaccine ETBX-051, Adenoviral Cancer Vaccine PF-06936308, Adenoviral MUC1 Vaccine ETBX-061, Adenoviral PSA Vaccine ETBX-071, Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001, Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901, Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE, Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918, Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931, Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3, Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001, Aderbasib, ADH-1, AE37 Peptide/GM-CSF Vaccine, AEE788, Aerosol Gemcitabine, Aerosolized Aldesleukin, Aerosolized Liposomal Rubitecan, Afatinib, Afatinib Dimaleate, Afimoxifene, Afuresertib, Agatolimod Sodium, Agerafenib, Aglatimagene Besadenovec, Agonistic Anti-CD40 Monoclonal Antibody ADC-1013, Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Agonistic Anti-OX40 Monoclonal Antibody MEDI6469, AKR1C3-activated Prodrug OBI-3424, AKT 1/2 Inhibitor BAY1125976, AKT Inhibitor ARQ 092, Akt Inhibitor LY2780301, Akt Inhibitor MK2206, Akt Inhibitor SR13668, Akt/ERK Inhibitor ONC201, Alacizumab Pegol, Alanosine, Albumin-binding Cisplatin Prodrug BTP-114, Aldesleukin, Aldoxorubicin, Alectinib, Alefacept, Alemtuzumab, Alestramustine, Alflutinib Mesylate, Algenpantucel-L, Alisertib, Alitretinoin, ALK Inhibitor, ALK Inhibitor ASP3026, ALK Inhibitor PLB 1003, ALK Inhibitor RO5424802, ALK Inhibitor TAE684, ALK Inhibitor WX-0593, ALK-2 Inhibitor TP-0184, ALK-FAK Inhibitor CEP-37440, ALK/c-Met Inhibitor TQ-B3139, ALK/FAK/Pyk2 Inhibitor CT-707, ALK/ROS1/Met Inhibitor TQ-B3101, ALK/TRK Inhibitor TSR-011, Alkotinib, Allodepleted T Cell Immunotherapeutic ATIR101, Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715, Allogeneic Anti-BCMA-CAR T-cells PBCAR269A, Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells, Allogeneic Anti-CD19 CAR T-cells ALLO-501A, Allogeneic Anti-CD19 Universal CAR-T Cells CTA101, Allogeneic Anti-CD19-CAR T-cells PBCAR0191, Allogeneic Anti-CD20 CAR T-cells LUCAR-20S, Allogeneic Anti-CD20-CAR T-cells PBCAR20A, Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22, Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100, Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001, Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Allogeneic Cellular Vaccine 1650-G, Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120, Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130, Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine, Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo, Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2, Allogeneic Irradiated Melanoma Cell Vaccine CSF470, Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307, Allogeneic Melanoma Vaccine AGI-101H, Allogeneic Natural Killer Cell Line MG4101, Allogeneic Natural Killer Cell Line NK-92, Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01, Allogeneic Renal Cell Carcinoma Vaccine MGN1601, Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19, Allosteric ErbB Inhibitor BDTX-189, Allovectin-7, Almurtide, Alobresib, Alofanib, Alpelisib, Alpha Galactosylceramide, Alpha V Beta 1 Inhibitor ATN-161, Alpha V Beta 8 Antagonist PF-06940434, alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801, Alpha-Gal AGI-134, Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H, Alpha-Thioguanine Deoxyriboside, Alpha-tocopheryloxyacetic Acid, Alsevalimab, Altiratinib, Altretamine, Alvespimycin, Alvespimycin Hydrochloride, Alvocidib, Alvocidib Hydrochloride, Alvocidib Prodrug TP-1287, Amatuximab, Ambamustine, Ambazone, Amblyomin-X, Amcasertib, Ametantrone, Amifostine, Amino Acid Injection, Aminocamptothecin, Aminocamptothecin Colloidal Dispersion, Aminoflavone Prodrug AFP464, Aminopterin, Aminopterin Sodium, Amivantamab, Amolimogene Bepiplasmid, Amonafide L-Malate, Amrubicin, Amrubicin Hydrochloride, Amsacrine, Amsacrine Lactate, Amsilarotene, Amustaline, Amustaline Dihydrochloride, Amuvatinib, Amuvatinib Hydrochloride, Anakinra, Anastrozole, Anaxirone, Ancitabine, Ancitabine Hydrochloride, Andecaliximab, Androgen Antagonist APC-100, Androgen Receptor Antagonist BAY 1161116, Androgen Receptor Antagonist SHR3680, Androgen Receptor Antagonist TAS3681, Androgen Receptor Antagonist TRC253, Androgen Receptor Antisense Oligonucleotide AZD5312, Androgen Receptor Antisense Oligonucleotide EZN-4176, Androgen Receptor Degrader ARV-110, Androgen Receptor Degrader CC-94676, Androgen Receptor Downregulator AZD3514, Androgen Receptor Inhibitor EPI-7386, Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118, Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10, Andrographolide, Androstane Steroid HE3235, Anetumab Ravtansine, Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241, Angiogenesis Inhibitor GT-111, Angiogenesis Inhibitor JI-101, Angiogenesis/Heparanase Inhibitor PG545, Angiopoietin-2-specific Fusion Protein PF-04856884, Anhydrous Enol-oxaloacetate, Anhydrovinblastine, Aniline Mustard, Anlotinib Hydrochloride, Annamycin, Annamycin Liposomal, Annonaceous Acetogenins, Ansamitomicin P-3, Anthramycin, Anthrapyrazole, Anti c-KIT Antibody-drug Conjugate LOP628, Anti-5T4 Antibody-drug Conjugate ASN004, Anti-5T4 Antibody-Drug Conjugate PF-06263507, Anti-5T4 Antibody-drug Conjugate SYD1875, Anti-A33 Monoclonal Antibody KRN330, Anti-A5B1 Integrin Monoclonal Antibody PF-04605412, Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087, Anti-AG7 Antibody Drug Conjugate AbGn-107, Anti-AGS-16 Monoclonal Antibody AGS-16M18, Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME, Anti-AGS-8 Monoclonal Antibody AGS-8M4, Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B, Anti-alpha5beta1 Integrin Antibody MINT1526A, Anti-ANG2 Monoclonal Antibody MEDI-3617, Anti-angiopoietin Monoclonal Antibody AMG 780, Anti-APRIL Monoclonal Antibody BION-1301, Anti-AXL Fusion Protein AVB-S6-500, Anti-AXL/PBD Antibody-drug Conjugate ADCT-601, Anti-B7-H3 Antibody DS-5573a, Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a, Anti-B7-H4 Monoclonal Antibody FPA150, Anti-B7H3 Antibody-drug Conjugate MGC018, Anti-BCMA Antibody SEA-BCMA, Anti-BCMA Antibody-drug Conjugate AMG 224, Anti-BCMA Antibody-drug Conjugate CC-99712, Anti-BCMA Antibody-drug Conjugate GSK2857916, Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA, Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459, Anti-BCMA/CD3 BiTE Antibody AMG 420, Anti-BCMA/CD3 BiTE Antibody AMG 701, Anti-BCMA/CD3 BiTE Antibody REGN5458, Anti-BCMA/PBD ADC MEDI2228, Anti-BTLA Monoclonal Antibody TAB004, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, Anti-c-fms Monoclonal Antibody AMG 820, Anti-c-KIT Monoclonal Antibody CDX 0158, Anti-c-Met Antibody-drug Conjugate HTI-1066, Anti-c-Met Antibody-drug Conjugate TR1801, Anti-c-Met Monoclonal Antibody ABT-700, Anti-c-Met Monoclonal Antibody ARGX-111, Anti-c-Met Monoclonal Antibody HLX55, Anti-c-MET Monoclonal Antibody LY2875358, Anti-C-met Monoclonal Antibody SAIT301, Anti-C4.4a Antibody-Drug Conjugate BAY1129980, Anti-C5aR Monoclonal Antibody IPH5401, Anti-CA19-9 Monoclonal Antibody 5B1, Anti-CA6-DM4 Immunoconjugate SAR566658, Anti-CCR7 Antibody-drug Conjugate JBH492, Anti-CD117 Monoclonal Antibody JSP191, Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1, Anti-CD123 ADC IMGN632, Anti-CD123 Monoclonal Antibody CSL360, Anti-CD123 Monoclonal Antibody KHK2823, Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404, Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A, Anti-CD123/CD3 Bispecific Antibody APVO436, Anti-CD123/CD3 Bispecific Antibody JNJ-63709178, Anti-CD123/CD3 BiTE Antibody SAR440234, Anti-CD137 Agonistic Monoclonal Antibody ADG106, Anti-CD137 Agonistic Monoclonal Antibody AGEN2373, Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017, Anti-CD137 Agonistic Monoclonal Antibody CTX-471, Anti-CD137 Agonistic Monoclonal Antibody LVGN6051, Anti-CD157 Monoclonal Antibody MEN1112, Anti-CD166 Probody-drug Conjugate CX-2009, Anti-CD19 Antibody-drug Conjugate SGN-CD19B, Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003, Anti-CD19 iCAR NK Cells, Anti-CD19 Monoclonal Antibody DI-B4, Anti-CD19 Monoclonal Antibody MDX-1342, Anti-CD19 Monoclonal Antibody MEDI-551, Anti-CD19 Monoclonal Antibody XmAb5574, Anti-CD19-DM4 Immunoconjugate SAR3419, Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL, Anti-CD19/CD22 CAR NK Cells, Anti-CD19/CD3 BiTE Antibody AMG 562, Anti-CD19/CD3 Tetravalent Antibody AFM11, Anti-CD20 Monoclonal Antibody B001, Anti-CD20 Monoclonal Antibody BAT4306F, Anti-CD20 Monoclonal Antibody MIL62, Anti-CD20 Monoclonal Antibody PRO131921, Anti-CD20 Monoclonal Antibody SCT400, Anti-CD20 Monoclonal Antibody TL011, Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002, Anti-CD20-engineered Toxin Body MT-3724, Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323, Anti-CD20/CD3 Monoclonal Antibody REGN1979, Anti-CD20/CD3 Monoclonal Antibody XmAb13676, Anti-CD205 Antibody-drug Conjugate OBT076, Anti-CD22 ADC TRPH-222, Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S, Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A, Anti-CD25 Monoclonal Antibody RO7296682, Anti-CD25-PBD Antibody-drug Conjugate ADCT-301, Anti-CD26 Monoclonal Antibody YS110, Anti-CD27 Agonistic Monoclonal Antibody MK-5890, Anti-CD27L Antibody-Drug Conjugate AMG 172, Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1), Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135, Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119, Anti-CD3/CD20 Bispecific Antibody GEN3013, Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424, Anti-CD3/CD7-Ricin Toxin A Immunotoxin, Anti-CD30 Monoclonal Antibody MDX-1401, Anti-CD30 Monoclonal Antibody XmAb2513, Anti-CD30/CD16A Monoclonal Antibody AFM13, Anti-CD30/DM1 Antibody-drug Conjugate F0002, Anti-CD32B Monoclonal Antibody BI-1206, Anti-CD33 Antibody-drug Conjugate IMGN779, Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564, Anti-CD33 Monoclonal Antibody BI 836858, Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633, Anti-CD33/CD3 Bispecific Antibody GEM 333, Anti-CD33/CD3 Bispecific Antibody JNJ-67571244, Anti-CD33/CD3 BiTE Antibody AMG 330, Anti-CD33/CD3 BiTE Antibody AMG 673, Anti-CD352 Antibody-drug Conjugate SGN-CD352A, Anti-CD37 Antibody-Drug Conjugate IMGN529, Anti-CD37 Bispecific Monoclonal Antibody GEN3009, Anti-CD37 MMAE Antibody-drug Conjugate AGS67E, Anti-CD37 Monoclonal Antibody BI 836826, Anti-CD38 Antibody-drug Conjugate STI-6129, Anti-CD38 Monoclonal Antibody MOR03087, Anti-CD38 Monoclonal Antibody SAR442085, Anti-CD38 Monoclonal Antibody TAK-079, Anti-CD38-targeted IgG4-attenuated IFNa TAK-573, Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257, Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342, Anti-CD39 Monoclonal Antibody SRF617, Anti-CD39 Monoclonal Antibody TTX-030, Anti-CD40 Agonist Monoclonal Antibody ABBV-927, Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Anti-CD40 Monoclonal Antibody Chi Lob 7/4, Anti-CD40 Monoclonal Antibody SEA-CD40, Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042, Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428, Anti-CD40L Fc-Fusion Protein BMS-986004, Anti-CD44 Monoclonal Antibody RO5429083, Anti-CD45 Monoclonal Antibody AHN-12, Anti-CD46 Antibody-drug Conjugate FOR46, Anti-CD47 ADC SGN-CD47M, Anti-CD47 Monoclonal Antibody AO-176, Anti-CD47 Monoclonal Antibody CC-90002, Anti-CD47 Monoclonal Antibody Hu5F9-G4, Anti-CD47 Monoclonal Antibody IBI188, Anti-CD47 Monoclonal Antibody IMC-002, Anti-CD47 Monoclonal Antibody SHR-1603, Anti-CD47 Monoclonal Antibody SRF231, Anti-CD47 Monoclonal Antibody TJC4, Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801, Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A, Anti-CD52 Monoclonal Antibody ALLO-647, Anti-CD70 Antibody-Drug Conjugate MDX-1203, Anti-CD70 Antibody-drug Conjugate SGN-CD70A, Anti-CD70 CAR-expressing T Lymphocytes, Anti-CD70 Monoclonal Antibody MDX-1411, Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029, Anti-CD73 Monoclonal Antibody BMS-986179, Anti-CD73 Monoclonal Antibody CPI-006, Anti-CD73 Monoclonal Antibody NZV930, Anti-CD73 Monoclonal Antibody TJ4309, Anti-CD74 Antibody-drug Conjugate STRO-001, Anti-CD98 Monoclonal Antibody IGN523, Anti-CDH6 Antibody-drug Conjugate HKT288, Anti-CEA BiTE Monoclonal Antibody AMG211, Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody, Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2, Anti-CEACAM1 Monoclonal Antibody CM-24, Anti-CEACAM5 Antibody-Drug Conjugate SAR408701, Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47, Anti-CEACAM6 Antibody BAY1834942, Anti-claudin18.2 Monoclonal Antibody AB011, Anti-Claudin18.2 Monoclonal Antibody TST001, Anti-CLDN6 Monoclonal Antibody ASP1650, Anti-CLEC12A/CD3 Bispecific Antibody MCLA117, Anti-CLEVER-1 Monoclonal Antibody FP-1305, Anti-CSF1 Monoclonal Antibody PD-0360324, Anti-CSF1R Monoclonal Antibody IMC-CS4, Anti-CSF1R Monoclonal Antibody SNDX-6352, Anti-CTGF Monoclonal Antibody FG-3019, Anti-CTLA-4 Monoclonal Antibody ADG116, Anti-CTLA-4 Monoclonal Antibody ADU-1604, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Anti-CTLA-4 Monoclonal Antibody BCD-145, Anti-CTLA-4 Monoclonal Antibody HBM4003, Anti-CTLA-4 Monoclonal Antibody MK-1308, Anti-CTLA-4 Monoclonal Antibody ONC-392, Anti-CTLA-4 Monoclonal Antibody REGN4659, Anti-CTLA-4 Probody BMS-986288, Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217, Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841, Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015, Anti-CTLA4 Antibody Fc Fusion Protein KN044, Anti-CTLA4 Monoclonal Antibody BMS-986218, Anti-CXCR4 Monoclonal Antibody PF-06747143, Anti-Denatured Collagen Monoclonal Antibody TRC093, Anti-DKK-1 Monoclonal Antibody LY2812176, Anti-DKK1 Monoclonal Antibody BHQ880, Anti-DLL3/CD3 BiTE Antibody AMG 757, Anti-DLL4 Monoclonal Antibody MEDI0639, Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83, Anti-DR5 Agonist Monoclonal Antibody TRA-8, Anti-DR5 Agonistic Antibody DS-8273a, Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Anti-EGFR Monoclonal Antibody CPGJ 602, Anti-EGFR Monoclonal Antibody EMD 55900, Anti-EGFR Monoclonal Antibody GC1118, Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX, Anti-EGFR Monoclonal Antibody HLX-07, Anti-EGFR Monoclonal Antibody Mixture MM-151, Anti-EGFR Monoclonal Antibody RO5083945, Anti-EGFR Monoclonal Antibody SCT200, Anti-EGFR Monoclonal Antibody SYN004, Anti-EGFR TAP Antibody-drug Conjugate IMGN289, Anti-EGFR/c-Met Bispecific Antibody EMB-01, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, Anti-EGFR/CD16A Bispecific Antibody AFM24, Anti-EGFR/DM1 Antibody-drug Conjugate AVID100, Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013, Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321, Anti-EGFRvIII Antibody Drug Conjugate AMG 595, Anti-EGFRvIII Immunotoxin MR1-1, Anti-EGFRvIII/CD3 BiTE Antibody AMG 596, Anti-EGP-2 Immunotoxin MOC31-PE, Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F, Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F, Anti-Ep-CAM Monoclonal Antibody ING-1, Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310, Anti-EphA2 Monoclonal Antibody DS-8895a, Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547, Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111, Anti-ErbB3 Antibody ISU104, Anti-ErbB3 Monoclonal Antibody AV-203, Anti-ErbB3 Monoclonal Antibody CDX-3379, Anti-ErbB3 Monoclonal Antibody REGN1400, Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141, Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A, Anti-FAP/Interleukin-2 Fusion Protein RO6874281, Anti-FCRH5/CD3 BiTE Antibody BFCR4350A, Anti-FGFR2 Antibody BAY1179470, Anti-FGFR3 Antibody-drug Conjugate LY3076226, Anti-FGFR4 Monoclonal Antibody U3-1784, Anti-FLT3 Antibody-drug Conjugate AGS62P1, Anti-FLT3 Monoclonal Antibody 4G8-SDIEM, Anti-FLT3 Monoclonal Antibody IMC-EB10, Anti-FLT3/CD3 BiTE Antibody AMG 427, Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002, Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202, Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012, Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962, Anti-GARP Monoclonal Antibody ABBV-151, Anti-GCC Antibody-Drug Conjugate MLN0264, Anti-GCC Antibody-Drug Conjugate TAK-164, Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody, Anti-GD2 Monoclonal Antibody hu14.18K322A, Anti-GD2 Monoclonal Antibody MORAb-028, Anti-GD3 Antibody-drug Conjugate PF-06688992, Anti-GITR Agonistic Monoclonal Antibody ASP1951, Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Anti-GITR Agonistic Monoclonal Antibody INCAGN01876, Anti-GITR Monoclonal Antibody GWN 323, Anti-GITR Monoclonal Antibody MK-4166, Anti-Globo H Monoclonal Antibody OBI-888, Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999, Anti-Glypican 3/CD3 Bispecific Antibody ERY974, Anti-GnRH Vaccine PEP223, Anti-gpA33/CD3 Monoclonal Antibody MGD007, Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a, Anti-gremlin-1 Monoclonal Antibody UCB6114, Anti-GRP78 Monoclonal Antibody PAT-SM6, Anti-HA Epitope Monoclonal Antibody MEDI8852, Anti-HB-EGF Monoclonal Antibody KHK2866, Anti-HBEGF Monoclonal Antibody U3-1565, Anti-hepcidin Monoclonal Antibody LY2787106, Anti-HER-2 Bispecific Antibody KN026, Anti-HER2 ADC DS-8201a, Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702, Anti-HER2 Antibody-drug Conjugate A166, Anti-HER2 Antibody-drug Conjugate ARX788, Anti-HER2 Antibody-drug Conjugate BAT8001, Anti-HER2 Antibody-drug Conjugate DP303c, Anti-HER2 Antibody-drug Conjugate MEDI4276, Anti-HER2 Antibody-drug Conjugate RC48, Anti-HER2 Bi-specific Monoclonal Antibody ZW25, Anti-HER2 Bispecific Antibody-drug Conjugate ZW49, Anti-HER2 Immune Stimulator-antibody Conjugate NJH395, Anti-HER2 Monoclonal Antibody B002, Anti-HER2 Monoclonal Antibody CT-P6, Anti-HER2 Monoclonal Antibody HLX22, Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343, Anti-HER2-DM1 ADC B003, Anti-HER2-DM1 Antibody-drug Conjugate GQ1001, Anti-HER2-vc0101 ADC PF-06804103, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302, Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522, Anti-HER2/MMAE Antibody-drug Conjugate MRG002, Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A, Anti-HER3 Antibody-drug Conjugate U3 1402, Anti-HER3 Monoclonal Antibody GSK2849330, Anti-HGF Monoclonal Antibody TAK-701, Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968, Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1, Anti-HLA-DR Monoclonal Antibody IMMU-114, Anti-HLA-G Antibody TTX-080, Anti-human GITR Monoclonal Antibody AMG 228, Anti-human GITR Monoclonal Antibody TRX518, Anti-ICAM-1 Monoclonal Antibody BI-505, Anti-ICOS Agonist Antibody GSK3359609, Anti-ICOS Agonist Monoclonal Antibody BMS-986226, Anti-ICOS Monoclonal Antibody KY1044, Anti-ICOS Monoclonal Antibody MEDI-570, Anti-IGF-1R Monoclonal Antibody AVE1642, Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, Anti-IL-1 alpha Monoclonal Antibody MABp1, Anti-IL-13 Humanized Monoclonal Antibody TNX-650, Anti-IL-15 Monoclonal Antibody AMG 714, Anti-IL-8 Monoclonal Antibody BMS-986253, Anti-IL-8 Monoclonal Antibody HuMax-IL8, Anti-ILDR2 Monoclonal Antibody BAY 1905254, Anti-ILT4 Monoclonal Antibody MK-4830, Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A, Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388, Anti-IRF4 Antisense Oligonucleotide ION251, Anti-KIR Monoclonal Antibody IPH 2101, Anti-KSP/Anti-VEGF siRNAs ALN-VSP02, Anti-LAG-3 Monoclonal Antibody IBI-110, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG-3 Monoclonal Antibody LAG525, Anti-LAG-3 Monoclonal Antibody REGN3767, Anti-LAG-3/PD-L1 Bispecific Antibody FS118, Anti-LAG3 Monoclonal Antibody BI 754111, Anti-LAG3 Monoclonal Antibody MK-4280, Anti-LAG3 Monoclonal Antibody TSR-033, Anti-LAMP1 Antibody-drug Conjugate SAR428926, Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181, Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102, Anti-LGR5 Monoclonal Antibody BNC101, Anti-LIF Monoclonal Antibody MSC-1, Anti-LILRB4 Monoclonal Antibody IO-202, Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A, Anti-Ly6E Antibody-Drug Conjugate RG 7841, Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C, Anti-Melanin Monoclonal Antibody PTI-6D2, Anti-mesothelin Antibody-drug Conjugate BMS-986148, Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100, Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A, Anti-mesothelin/MMAE Antibody-drug Conjugate RC88, Anti-Met Monoclonal Antibody Mixture Sym015, Anti-Met/EGFR Monoclonal Antibody LY3164530, Anti-MMP-9 Monoclonal Antibody GS-5745, Anti-MUC1 Monoclonal Antibody BTH1704, Anti-MUC16/CD3 Bispecific Antibody REGN4018, Anti-MUC16/CD3 BiTE Antibody REGN4018, Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A, Anti-MUC17/CD3 BiTE Antibody AMG 199, Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062, Anti-myostatin Monoclonal Antibody LY2495655, Anti-NaPi2b Antibody-drug Conjugate XMT-1592, Anti-NaPi2b Monoclonal Antibody XMT-1535, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A, Anti-nf-P2X7 Antibody Ointment BIL-010t, Anti-NRP1 Antibody ASP1948, Anti-Nucleolin Aptamer AS1411, Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A, Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso, Anti-OFA Immunotherapeutic BB-MPI-03, Anti-OX40 Agonist Monoclonal Antibody ABBV-368, Anti-OX40 Agonist Monoclonal Antibody BGB-A445, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Anti-OX40 Antibody BMS 986178, Anti-OX40 Hexavalent Agonist Antibody INBRX-106, Anti-OX40 Monoclonal Antibody GSK3174998, Anti-OX40 Monoclonal Antibody IBI101, Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256, Anti-PD-1 Checkpoint Inhibitor PF-06801591, Anti-PD-1 Fusion Protein AMP-224, Anti-PD-1 Monoclonal Antibody 609A, Anti-PD-1 Monoclonal Antibody AK105, Anti-PD-1 Monoclonal Antibody AMG 404, Anti-PD-1 Monoclonal Antibody BAT1306, Anti-PD-1 Monoclonal Antibody BCD-100, Anti-PD-1 Monoclonal Antibody BI 754091, Anti-PD-1 Monoclonal Antibody CS1003, Anti-PD-1 Monoclonal Antibody F520, Anti-PD-1 Monoclonal Antibody GLS-010, Anti-PD-1 Monoclonal Antibody HLX10, Anti-PD-1 Monoclonal Antibody HX008, Anti-PD-1 Monoclonal Antibody JTX-4014, Anti-PD-1 Monoclonal Antibody LZM009, Anti-PD-1 Monoclonal Antibody MEDI0680, Anti-PD-1 Monoclonal Antibody MGA012, Anti-PD-1 Monoclonal Antibody SCT-I10A, Anti-PD-1 Monoclonal Antibody Sym021, Anti-PD-1 Monoclonal Antibody TSR-042, Anti-PD-1/Anti-CTLA4 DART Protein MGD019, Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315, Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669, Anti-PD-1/Anti-LAG-3 DART Protein MGD013, Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318, Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172, Anti-PD-1/CD47 Infusion Protein HX009, Anti-PD-1/CTLA-4 Bispecific Antibody AK104, Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752, Anti-PD-1/TIM-3 Bispecific Antibody RO7121661, Anti-PD-1/VEGF Bispecific Antibody AK112, Anti-PD-L1 Monoclonal Antibody A167, Anti-PD-L1 Monoclonal Antibody BCD-135, Anti-PD-L1 Monoclonal Antibody BGB-A333, Anti-PD-L1 Monoclonal Antibody CBT-502, Anti-PD-L1 Monoclonal Antibody CK-301, Anti-PD-L1 Monoclonal Antibody CS1001, Anti-PD-L1 Monoclonal Antibody FAZ053, Anti-PD-L1 Monoclonal Antibody GR1405, Anti-PD-L1 Monoclonal Antibody HLX20, Anti-PD-L1 Monoclonal Antibody IMC-001, Anti-PD-L1 Monoclonal Antibody LY3300054, Anti-PD-L1 Monoclonal Antibody MDX-1105, Anti-PD-L1 Monoclonal Antibody MSB2311, Anti-PD-L1 Monoclonal Antibody RC98, Anti-PD-L1 Monoclonal Antibody SHR-1316, Anti-PD-L1 Monoclonal Antibody TG-1501, Anti-PD-L1 Monoclonal Antibody ZKAB001, Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105, Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046, Anti-PD-L1/CD137 Bispecific Antibody MCLA-145, Anti-PD-L1/IL-15 Fusion Protein KD033, Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244, Anti-PD1 Monoclonal Antibody AGEN2034, Anti-PD1/CTLA4 Bispecific Antibody XmAb20717, Anti-PGF Monoclonal Antibody RO5323441, Anti-PKN3 siRNA Atu027, Anti-PLGF Monoclonal Antibody TB-403, Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Anti-PRAME Immunotherapeutic GSK2302032A, Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Anti-PRL-3 Monoclonal Antibody PRL3-zumab, Anti-prolactin Receptor Antibody LFA102, Anti-PSCA Monoclonal Antibody AGS-1C4D4, Anti-PSMA Monoclonal Antibody MDX1201-A488, Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704, Anti-PSMA Monoclonal Antibody-MMAE Conjugate, Anti-PSMA/CD28 Bispecific Antibody REGN5678, Anti-PSMA/CD3 Bispecific Antibody CCW702, Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081, Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414, Anti-PSMA/PBD ADC MEDI3726, Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020, Anti-PVRIG Monoclonal Antibody COM701, Anti-RANKL Monoclonal Antibody GB-223, Anti-RANKL Monoclonal Antibody JMT103, Anti-Ribonucleoprotein Antibody ATRC-101, Anti-ROR1 ADC VLS-101, Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002, Anti-S15 Monoclonal Antibody NC318, Anti-sCLU Monoclonal Antibody AB-16B5, Anti-SIRPa Monoclonal Antibody CC-95251, Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E, Anti-TAG-72 Monoclonal Antibody scFV CC-49/218, Anti-TF Monoclonal Antibody ALT-836, Anti-TGF-beta Monoclonal Antibody NIS793, Anti-TGF-beta Monoclonal Antibody SAR-439459, Anti-TGF-beta RII Monoclonal Antibody IMC-TR1, Anti-TIGIT Monoclonal Antibody AB154, Anti-TIGIT Monoclonal Antibody BGB-A1217, Anti-TIGIT Monoclonal Antibody BMS-986207, Anti-TIGIT Monoclonal Antibody COM902, Anti-TIGIT Monoclonal Antibody OMP-313M32, Anti-TIGIT Monoclonal Antibody SGN-TGT, Anti-TIM-3 Antibody BMS-986258, Anti-TIM-3 Monoclonal Antibody BGB-A425, Anti-TIM-3 Monoclonal Antibody INCAGN02390, Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM-3 Monoclonal Antibody Sym023, Anti-TIM-3 Monoclonal Antibody TSR-022, Anti-TIM3 Monoclonal Antibody LY3321367, Anti-TIM3 Monoclonal Antibody SHR-1702, Anti-Tissue Factor Monoclonal Antibody MORAb-066, Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711, Anti-TROP2 Antibody-drug Conjugate BAT8003, Anti-TROP2 Antibody-drug Conjugate SKB264, Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a, Anti-TWEAK Monoclonal Antibody RG7212, Anti-VEGF Anticalin PRS-050-PEG40, Anti-VEGF Monoclonal Antibody hPV19, Anti-VEGF/ANG2 Nanobody BI 836880, Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T, Anti-VEGFC Monoclonal Antibody VGX-100, Anti-VEGFR2 Monoclonal Antibody HLX06, Anti-VEGFR2 Monoclonal Antibody MSB0254, Anti-VEGFR3 Monoclonal Antibody IMC-3C5, Anti-VISTA Monoclonal Antibody JNJ 61610588, Antiangiogenic Drug Combination TL-118, Antibody-drug Conjugate ABBV-011, Antibody-drug Conjugate ABBV-085, Antibody-drug Conjugate ABBV-155, Antibody-drug Conjugate ABBV-176, Antibody-drug Conjugate ABBV-838, Antibody-drug Conjugate ADC XMT-1536, Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014, Antibody-Drug Conjugate DFRF4539A, Antibody-drug Conjugate MEDI7247, Antibody-drug Conjugate PF-06647263, Antibody-drug Conjugate PF-06664178, Antibody-drug Conjugate SC-002, Antibody-drug Conjugate SC-003, Antibody-drug Conjugate SC-004, Antibody-drug Conjugate SC-005, Antibody-drug Conjugate SC-006, Antibody-drug Conjugate SC-007, Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008, Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV, Antimetabolite FF-10502, Antineoplastic Agent Combination SM-88, Antineoplastic Vaccine, Antineoplastic Vaccine GV-1301, Antineoplaston A10, Antineoplaston AS2-1, Antisense Oligonucleotide GTI-2040, Antisense Oligonucleotide QR-313, Antitumor B Key Active Component-alpha, Antrodia cinnamomea Supplement, Antroquinonol Capsule, Apalutamide, Apatorsen, Apaziquone, APC8015F, APE1/Ref-1 Redox Inhibitor APX3330, Aphidicoline Glycinate, Apilimod Dimesylate Capsule, Apitolisib, Apolizumab, Apomab, Apomine, Apoptosis Inducer BZL101, Apoptosis Inducer GCS-100, Apoptosis Inducer MPC-2130, Apricoxib, Aprinocarsen, Aprutumab, Aprutumab Ixadotin, AR Antagonist BMS-641988, Arabinoxylan Compound MGN3, Aranose, ARC Fusion Protein SL-279252, Archexin, Arcitumomab, Arfolitixorin, Arginase Inhibitor INCB001158, Arginine Butyrate, Arnebia Indigo Jade Pearl Topical Cream, Arsenic Trioxide, Arsenic Trioxide Capsule Formulation ORH 2014, Artemether Sublingual Spray, Artemisinin Dimer, Artesunate, Arugula Seed Powder, Aryl Hydrocarbon Receptor Antagonist BAY2416964, Aryl Hydrocarbon Receptor Inhibitor IK-175, Asaley, Asciminib, Ascrinvacumab, Ashwagandha Root Powder Extract, ASP4132, Aspacytarabine, Asparaginase, Asparaginase Erwinia chrysanthemi, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astuprotimut-R, Asulacrine, Asulacrine Isethionate, Asunercept, At 211 Monoclonal Antibody 81C6, Atamestane, Atezolizumab, Atiprimod, Atiprimod Dihydrochloride, Atiprimod Dimaleate, ATM Inhibitor M 3541, ATM Kinase Inhibitor AZD0156, ATM Kinase Inhibitor AZD1390, Atorvastatin Calcium, Atorvastatin Sodium, ATR Inhibitor RP-3500, ATR Kinase Inhibitor BAY1895344, ATR Kinase Inhibitor M1774, ATR Kinase Inhibitor M6620, ATR Kinase Inhibitor VX-803, Atrasentan Hydrochloride, Attenuated Listeria monocytogenes CRS-100, Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Attenuated Measles Virus Encoding SCD Transgene TMV-018, Atuveciclib, Audencel, Auranofin, Aurora A Kinase Inhibitor LY3295668, Aurora A Kinase Inhibitor LY3295668 Erbumine, Aurora A Kinase Inhibitor MK5108, Aurora A Kinase Inhibitor TAS-119, Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076, Aurora B Serine/Threonine Kinase Inhibitor TAK-901, Aurora B/C Kinase Inhibitor GSK1070916A, Aurora kinase A/B inhibitor TT-00420, Aurora Kinase Inhibitor AMG 900, Aurora Kinase Inhibitor BI 811283, Aurora Kinase Inhibitor MLN8054, Aurora Kinase Inhibitor PF-03814735, Aurora Kinase Inhibitor SNS-314, Aurora Kinase Inhibitor TTP607, Aurora Kinase/VEGFR2 Inhibitor CYC116, Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707, Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055, Autologous Anti-BCMA CAR T-cells PHE885, Autologous Anti-BCMA CAR-transduced T-cells KITE-585, Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11, Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053, Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Autologous Anti-CD123 CAR-T Cells, Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx, Autologous Anti-CD19 CAR T-cells IM19, Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19, Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19, Autologous Anti-CD19 CAR-CD28 T-cells ET019002, Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01, Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19, Autologous Anti-CD19 T-cell Receptor T cells ET190L1, Autologous Anti-CD19 TAC-T cells TAC01-CD19, Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells, Autologous Anti-CD19/CD22 CAR T-cells AUTO3, Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells, Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1, Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s, Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes, Autologous Anti-FLT3 CAR T Cells AMG 553, Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202, Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1, Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100, Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes, Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794, Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes, Autologous Anti-PSMA CAR-T Cells P-PSMA-101, Autologous AXL-targeted CAR T-cells CCT301-38, Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B, Autologous BCMA-targeted CAR T Cells CC-98633, Autologous BCMA-targeted CAR T Cells LCAR-B4822M, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022, Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006, Autologous CD123-4SCAR-expressing T-cells 4SCAR123, Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1, Autologous CD19-targeted CAR T Cells CC-97540, Autologous CD19-targeted CAR T Cells JWCAR029, Autologous CD19-targeted CAR-T Cells GC007F, Autologous CD19/PD-1 Bispecific CAR-T Cells, Autologous CD20-4SCAR-expressing T-cells 4SCAR20, Autologous CD22-4SCAR-expressing T-cells 4SCAR22, Autologous CD38-4SCAR-expressing T-cells 4SCAR38, Autologous Clonal Neoantigen T Cells ATL001, Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19, Autologous Deep IL-15 Primed T-cells TRQ15-01, Autologous Dendritic Cell Vaccine ACT2001, Autologous Dendritic Cell-based Immunotherapeutic AV0113, Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa, Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells, Autologous Genetically-modified MAGE-A4 C1032 T Cells, Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858, Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439, Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001, Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718, Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous Mesenchymal Stem Cells Apceth_101, Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11, Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC, Autologous Multi-lineage Potential Cells, Autologous Nectin-4/FAP-targeted CAR-T Cells, Autologous NKG2D CAR T-cells CYAD-02, Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01, Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine, Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001, Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101, Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601, Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201, Autologous ROR2-targeted CAR T-cells CCT301-59, Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1, Autologous TCR-engineered T-cells IMA201, Autologous TCR-engineered T-cells IMA202, Autologous TCR-engineered T-cells IMA203, Autologous TCRm-expressing T-cells ET140203, Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG, Autologous Tumor Infiltrating Lymphocytes LN-144, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T, Avadomide, Avadomide Hydrochloride, Avapritinib, Avdoralimab, Avelumab, Aviscumine, Avitinib Maleate, Axalimogene Filolisbac, Axatilimab, Axicabtagene Ciloleucel, Axitinib, AXL Inhibitor DS-1205c, AXL Inhibitor SLC-391, AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M, AXL/ FLT3/VEGFR2 Inhibitor KC1036, Axl/Mer Inhibitor INCB081776, Axl/Mer Inhibitor PF-07265807, Azacitidine, Azapicyl, Azaribine, Azaserine, Azathioprine, Azimexon, Azintuxizumab Vedotin, Aziridinylbenzoquinone RH1, Azotomycin, Azurin:50-77 Cell Penetrating Peptide p28, B-Raf/VEGFR-2 Inhibitor RAF265, Babaodan Capsule, Bacillus Calmette-Guerin Substrain Connaught Live Antigen, Bactobolin, Bafetinib, Balixafortide, Balstilimab, Baltaleucel-T, Banoxantrone, Barasertib, Bardoxolone, Bardoxolone Methyl, Baricitinib, Batabulin, Batabulin Sodium, Batimastat, Bavituximab, Bazedoxifene, Bazlitoran, BC-819 Plasmid/Polyethylenimine Complex, BCG Solution, BCG Tokyo-172 Strain Solution, BCG Vaccine, Bcl-2 Inhibitor APG 2575, Bcl-2 Inhibitor BCL201, Bcl-2 Inhibitor BGB-11417, Bcl-2 Inhibitor LP-108, Bcl-2 Inhibitor S65487, Bcl-Xs Adenovirus Vaccine, BCMA x CD3 T-cell Engaging Antibody CC-93269, BCMA-CD19 Compound CAR T Cells, BCMA/CD3e Tri-specific T-cell Activating Construct HPN217, Bcr-Abl Kinase Inhibitor K0706, Bcr-Abl Kinase Inhibitor PF-114, BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351, Beauvericin, Becatecarin, Belagenpumatucel-L, Belantamab Mafodotin, Belapectin, Belimumab, Belinostat, Belotecan Hydrochloride, Belvarafenib, Belzutifan, Bemarituzumab, Bemcentinib, Bempegaldesleukin, Benaxibine, Bendamustine, Bendamustine Hydrochloride, Bendamustine-containing Nanoparticle-based Formulation RXDX-107, Benzaldehyde Dimethane Sulfonate, Benzoylphenylurea, Berberine Chloride, Bermekimab, Bersanlimab, Berubicin Hydrochloride, Berzosertib, BET Bromodomain Inhibitor ZEN-3694, BET Inhibitor ABBV-744, BET Inhibitor BAY1238097, BET inhibitor BI 894999, BET Inhibitor BMS-986158, BET Inhibitor CC-90010, BET Inhibitor CPI-0610, BET Inhibitor FT-1101, BET Inhibitor GS-5829, BET Inhibitor GSK2820151, BET Inhibitor INCB054329, BET Inhibitor INCB057643, BET Inhibitor RO6870810, BET-bromodomain Inhibitor ODM-207, Beta Alethine, Beta-Carotene, Beta-elemene, Beta-Glucan, Beta-Glucan MM-10-001, Beta-lapachone Prodrug ARQ 761, Beta-Thioguanine Deoxyriboside, Betaglucin Gel, Betulinic Acid, Bevacizumab, Bexarotene, Bexmarilimab, BF-200 Gel Formulation, BH3 Mimetic ABT-737, Bi-functional Alkylating Agent VAL-083, Bicalutamide, Bimiralisib, Binetrakin, Binimetinib, Bintrafusp Alfa, Birabresib, Birinapant, Bis(choline)tetrathiomolybdate, Bisantrene, Bisantrene Hydrochloride, Bisnafide, Bisnafide Dimesylate, Bispecific Antibody 2B1, Bispecific Antibody AGEN1223, Bispecific Antibody AMG 509, Bispecific Antibody GS-1423, Bispecific Antibody MDX-H210, Bispecific Antibody MDX447, Bisthianostat, BiTE Antibody AMG 910, Bivalent BRD4 Inhibitor AZD5153, Bizalimogene Ralaplasmid, Bizelesin, BL22 Immunotoxin, Black Cohosh, Black Raspberry Nectar, Bleomycin, Bleomycin A2, Bleomycin B2, Bleomycin Sulfate, Blinatumomab, Blueberry Powder Supplement, BMI1 Inhibitor PTC596, BMS-184476, BMS-188797, BMS-214662, BMS-275183, Boanmycin Hydrochloride, Bomedemstat, Boronophenylalanine-Fructose Complex, Bortezomib, Bosutinib, Bosutinib Monohydrate, Botanical Agent BEL-X-HG, Botanical Agent LEAC-102, Bovine Cartilage, Bozitinib, BP-Cx1-Platinum Complex BP-C1, BR96-Doxorubicin Immunoconjugate, Brachyury-expressing Yeast Vaccine GI-6301, BRAF Inhibitor, BRAF Inhibitor ARQ 736, BRAF Inhibitor BGB-3245, BRAF Inhibitor PLX8394, BRAF(V600E) Kinase Inhibitor ABM-1310, BRAF(V600E) Kinase Inhibitor RO5212054, BRAF/EGFR Inhibitor BGB-283, BRAFV600/PI3K Inhibitor ASN003, BRD4 Inhibitor PLX2853, BRD4 Inhibitor PLX51107, Breflate, Brentuximab, Brentuximab Vedotin, Brequinar, Brequinar Sodium, Briciclib Sodium, Brigatinib, Brilanestrant, Brimonidine Tartrate Nanoemulsion OCU-300, Brivanib, Brivanib Alaninate, Brivudine, Brivudine Phosphoramidate, Broad-Spectrum Human Papillomavirus Vaccine V505, Broccoli Sprout/Broccoli Seed Extract Supplement, Bromacrylide, Bromebric Acid, Bromocriptine Mesylate, Brontictuzumab, Brostacillin Hydrochloride, Brostallicin, Broxuridine, Bruceanol A, Bruceanol B, Bruceanol C, Bruceanol D, Bruceanol E, Bruceanol F, Bruceanol G, Bruceanol H, Bruceantin, Bryostatin 1, BTK Inhibitor ARQ 531, BTK Inhibitor CT-1530, BTK Inhibitor DTRMWXHS-12, BTK Inhibitor HZ-A-018, BTK Inhibitor ICP-022, BTK Inhibitor LOXO-305, BTK Inhibitor M7583, BTK inhibitor TG-1701, Budigalimab, Budotitane, Bufalin, Buparlisib, Burixafor, Burixafor Hydrobromide, Burosumab, Buserelin, Bushen Culuan Decoction, Bushen-Jianpi Decoction, Busulfan, Buthionine Sulfoximine, BXQ-350 Nanovesicle Formulation, c-Kit Inhibitor PLX9486, c-Met Inhibitor ABN401, c-Met Inhibitor AL2846, c-Met Inhibitor AMG 208, c-Met Inhibitor AMG 337, c-Met Inhibitor GST-HG161, c-Met Inhibitor HS-10241, c-Met Inhibitor JNJ-38877605, c-Met Inhibitor MK2461, c-Met Inhibitor MK8033, c-Met Inhibitor MSC2156119J, C-myb Antisense Oligonucleotide G4460, c-raf Antisense Oligonucleotide ISIS 5132, C-VISA BikDD:Liposome, C/EBP Beta Antagonist ST101, CAB-ROR2-ADC BA3021, Cabazitaxel, Cabiralizumab, Cabozantinib, Cabozantinib S-malate, Cactinomycin, Caffeic Acid Phenethyl Ester, CAIX Inhibitor DTP348, CAIX Inhibitor SLC-0111, Calaspargase Pegol-mknl, Calcitriol, Calcium Release-activated Channel Inhibitor CM4620, Calcium Release-activated Channels Inhibitor RP4010, Calcium Saccharate, Calculus bovis/Moschus/Olibanum/Myrrha Capsule, Calicheamicin Gamma 1I, Camidanlumab Tesirine, Camptothecin, Camptothecin Analogue TLC388, Camptothecin Glycoconjugate BAY 38-3441, Camptothecin Sodium, Camptothecin-20(S)-O-Propionate Hydrate, Camrelizumab, Camsirubicin, Cancell, Cancer Peptide Vaccine S-588410, Canerpaturev, Canertinib Dihydrochloride, Canfosfamide, Canfosfamide Hydrochloride, Cannabidiol, Cantrixil, Cantuzumab Ravtansine, Capecitabine, Capecitabine Rapidly Disintegrating Tablet, Capivasertib, Capmatinib, Captopril, CAR T-Cells AMG 119, Caracemide, Carbendazim, Carbetimer, Carbogen, Carbon C 14-pamiparib, Carboplatin, Carboquone, Carboxyamidotriazole, Carboxyamidotriazole Orotate, Carboxyphenyl Retinamide, Carfilzomib, Caricotamide/Tretazicar, Carlumab, Carmofur, Carmustine, Carmustine Implant, Carmustine in Ethanol, Carmustine Sustained-Release Implant Wafer, Carotuximab, Carubicin, Carubicin Hydrochloride, Carzelesin, Carzinophilin, Cathelicidin LL-37, Cationic Liposome-Encapsulated Paclitaxel, Cationic Peptide Cream Cypep-1, Catumaxomab, CBP/beta-catenin Antagonist PRI-724, CBP/beta-catenin Modulator E7386, CCR2 Antagonist CCX872-B, CCR2 Antagonist PF-04136309, CCR2/CCR5 Antagonist BMS-813160, CCR4 Inhibitor FLX475, CD11b Agonist GB1275, CD123-CD33 Compound CAR T Cells, CD123-specific Targeting Module TM123, CD20-CD19 Compound CAR T Cells, CD28/ICOS Antagonist ALPN-101, CD4-specific Telomerase Peptide Vaccine UCPVax, CD40 Agonist Monoclonal Antibody CP-870;893, CD40 Agonistic Monoclonal Antibody APX005M, CD44 Targeted Agent SPL-108, CD44v6-specific CAR T-cells, CD47 Antagonist ALX148, CD73 Inhibitor AB680, CD73 Inhibitor LY3475070, CD80-Fc Fusion Protein ALPN-202, CD80-Fc Fusion Protein FPT155, CDC7 Inhibitor TAK-931, CDC7 Kinase Inhibitor BMS-863233, CDC7 Kinase Inhibitor LY3143921 Hydrate, CDC7 Kinase Inhibitor NMS-1116354, CDK Inhibitor AT7519, CDK Inhibitor R547, CDK Inhibitor SNS-032, CDK/JAK2/FLT3 Inhibitor TG02 Citrate, CDK1 Inhibitor BEY1107, CDK1/2/4 Inhibitor AG-024322, CDK2 Inhibitor PF-07104091, CDK2/4/6/FLT3 Inhibitor FN-1501, CDK2/5/9 Inhibitor CYC065, CDK4 Inhibitor P1446A-05, CDK4/6 Inhibitor, CDK4/6 Inhibitor BPI-16350, CDK4/6 Inhibitor CS3002, CDK4/6 Inhibitor FCN-437, CDK4/6 Inhibitor G1T38, CDK4/6 Inhibitor HS-10342, CDK4/6 Inhibitor SHR6390, CDK4/6 Inhibitor TQB3616, CDK7 Inhibitor CT7001, CDK7 Inhibitor SY-1365, CDK7 Inhibitor SY-5609, CDK8/19 Inhibitor SEL 120, CDK9 Inhibitor AZD4573, CEA-MUC-1-TRICOM Vaccine CV301, CEA-targeting Agent RG6123, CEBPA-targeting saRNA MTL-CEBPA Liposome, Cedazuridine, Cedazuridine/Azacitidine Combination Agent ASTX030, Cedazuridine/Decitabine Combination Agent ASTX727, Cedefingol, Cediranib, Cediranib Maleate, Celecoxib, Cell Cycle Checkpoint/DNA Repair Antagonist IC83, Cemadotin, Cemadotin Hydrochloride, Cemiplimab, Cenersen, Cenisertib, CENP-E Inhibitor GSK-923295, Ceralasertib, Ceramide Nanoliposome, Cerdulatinib, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282, Cereblon Modulator CC-90009, Cergutuzumab Amunaleukin, Ceritinib, Cesalin, cEt KRAS Antisense Oligonucleotide AZD4785, Cetrelimab, Cetuximab, Cetuximab Sarotalocan, Cetuximab-IR700 Conjugate RM-1929, Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY), Cevipabulin, Cevipabulin Fumarate, Cevipabulin Succinate, Cevostamab, cFMS Tyrosine Kinase Inhibitor ARRY-382, Chaparrin, Chaparrinone, Checkpoint Kinase Inhibitor AZD7762, Checkpoint Kinase Inhibitor XL844, Chemotherapy, Chiauranib, Chimeric Monoclonal Antibody 81C6, ChiNing Decoction, Chk1 Inhibitor CCT245737, Chk1 Inhibitor GDC-0425, Chk1 Inhibitor GDC-0575, CHK1 Inhibitor MK-8776, CHK1 Inhibitor PF-477736, Chlorambucil, Chlorodihydropyrimidine, Chloroquine, Chloroquinoxaline Sulfonamide, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, Chlorozotocin, Choline Kinase Alpha Inhibitor TCD-717, CHP-NY-ESO-1 Peptide Vaccine IMF-001, Chromomycin A3, Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement, Cibisatamab, Ciclopirox Prodrug CPX-POM, Cidan Herbal Capsule, Ciforadenant, Cilengitide, Ciltacabtagene Autoleucel, Cimetidine, Cinacalcet Hydrochloride, Cinobufagin, Cinobufotalin, Cinrebafusp Alfa, Cintirorgon, Cintredekin Besudotox, Cirmtuzumab, cis-Urocanic Acid, Cisplatin, Cisplatin Liposomal, Cisplatin-E Therapeutic Implant, Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6, Citarinostat, Citatuzumab Bogatox, Cixutumumab, CK1alpha/CDK7/CDK9 Inhibitor BTX-A51, CK2-targeting Synthetic Peptide CIGB-300, CL 246738, Cladribine, Clanfenur, Clarithromycin, Class 1/4 Histone Deacetylase Inhibitor OKI-179, Clinical Trial, Clinical Trial Agent, Clioquinol, Clivatuzumab, Clodronate Disodium, Clodronic Acid, Clofarabine, Clomesone, Clomiphene, Clomiphene Citrate, Clostridium Novyi-NT Spores, Cobimetinib, Cobolimab, Cobomarsen, Codrituzumab, Coenzyme Q10, Cofetuzumab Pelidotin, Colchicine-Site Binding Agent ABT-751, Cold Contaminant-free Iobenguane I-131, Colloidal Gold-Bound Tumor Necrosis Factor, Colorectal Cancer Peptide Vaccine PolyPEPI1018, Colorectal Tumor-Associated Peptides Vaccine IMA910, Coltuximab Ravtansine, Combretastatin, Combretastatin A-1, Combretastatin A1 Diphosphate, Commensal Bacterial Strain Formulation VE800, Compound Kushen Injection, Conatumumab, Conbercept, Concentrated Lingzhi Mushroom Extract, Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011, Copanlisib, Copanlisib Hydrochloride, Copper Cu 64-ATSM, Copper Cu 67 Tyr3-octreotate, Copper Gluconate, Cord Blood Derived CAR T-Cells, Cord Blood-derived Expanded Natural Killer Cells PNK-007, Cordycepin, Cordycepin Triphosphate, Coriolus Versicolor Extract, Corticorelin Acetate, Cortisone Acetate, Cosibelimab, Cositecan, Coxsackievirus A21, Coxsackievirus V937, CpG Oligodeoxynucleotide GNKG168, Crenolanib, Crenolanib Besylate, Crizotinib, Crolibulin, Cryptophycin, Cryptophycin 52, Crystalline Genistein Formulation AXP107-11, CSF-1R Inhibitor BLZ945, CSF1R Inhibitor ABSK021, CSF1R Inhibitor DCC-3014, CSF1R Inhibitor PLX73086, CT2584 HMS, CTLA-4-directed Probody BMS-986249, Curcumin, Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110, Cusatuzumab, Custirsen Sodium, CXC Chemokine Receptor 2 Antagonist AZD5069, CXCR1/2 Inhibitor SX-682, CXCR2 Antagonist QBM076, CXCR4 Antagonist BL-8040, CXCR4 Antagonist USL311, CXCR4 Inhibitor Q-122, CXCR4 Peptide Antagonist LY2510924, CXCR4/E-selectin Antagonist GMI-1359, Cyclin-dependent Kinase 8/19 Inhibitor BCD 115, Cyclin-dependent Kinase Inhibitor PF-06873600, Cyclodextrin-Based Polymer-Camptothecin CRLX101, Cyclodisone, Cycloleucine, Cyclopentenyl Cytosine, Cyclophosphamide, Cyclophosphamide Anhydrous, Cyclosporine, CYL-02 Plasmid DNA, CYP11A1 inhibitor ODM-208, CYP11A1 Inhibitor ODM-209, CYP17 Inhibitor CFG920, CYP17 Lyase Inhibitor ASN001, CYP17/Androgen Receptor Inhibitor ODM 204, CYP17/CYP11B2 Inhibitor LAE001, Cyproterone, Cyproterone Acetate, Cytarabine, Cytarabine Monophosphate Prodrug MB07133, Cytarabine-asparagine Prodrug BST-236, Cytidine Analog RX-3117, Cytochlor, Cytokine-based Biologic Agent IRX-2, D-methionine Formulation MRX-1024, DAB389 Epidermal Growth Factor, Dabrafenib, Dabrafenib Mesylate, Dacarbazine, Dacetuzumab, DACH Polymer Platinate AP5346, DACH-Platin Micelle NC-4016, Daclizumab, Dacomitinib, Dacplatinum, Dactinomycin, Dactolisib, Dactolisib Tosylate, Dalantercept, Dalotuzumab, Daniquidone, Danusertib, Danvatirsen, Daporinad, Daratumumab, Daratumumab and Hyaluronidase-fihj, Daratumumab/rHuPH20, Darinaparsin, Darleukin, Darolutamide, Daromun, Dasatinib, Daunorubicin, Daunorubicin Citrate, Daunorubicin Hydrochloride, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Decitabine and Cedazuridine, Defactinib, Defactinib Hydrochloride, Deferoxamine, Deferoxamine Mesylate, Degarelix, Degarelix Acetate, Delanzomib, Delolimogene Mupadenorepvec, Demcizumab, Demecolcine, Demplatin Pegraglumer, Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466, Dendritic Cell Vaccine, Dendritic Cell-Autologous Lung Tumor Vaccine, Dendritic Cell-targeting Lentiviral Vector ID-LV305, Denenicokin, Dengue Virus Adjuvant PV-001-DV, Denibulin, Denibulin Hydrochloride, Denileukin Diftitox, Denintuzumab Mafodotin, Denosumab, Deoxycytidine Analogue TAS-109, Deoxycytidine Analogue TAS-109 Hydrochloride, Depatuxizumab, Depatuxizumab Mafodotin, Derazantinib, Deslorelin, Deslorelin Acetate, Detirelix, Detorubicin, Deuteporfin, Deuterated Enzalutamide, Devimistat, Dexamethason, Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, Dexanabinol, Dexrazoxane, Dexrazoxane Hydrochloride, Dezaguanine, Dezaguanine Mesylate, Dezapelisib, DHA-Paclitaxel, DHEA Mustard, DI-Leu16-IL2 Immunocytokine, Dianhydrogalactitol, Diarylsulfonylurea Compound ILX-295501, Diazepinomicin, Diaziquone, Diazooxonorleucine, Dibrospidium Chloride, Dichloroallyl Lawsone, Dicycloplatin, Didox, Dienogest, Diethylnorspermine, Digitoxin, Digoxin, Dihydro-5-Azacytidine, Dihydrolenperone, Dihydroorotate Dehydrogenase Inhibitor AG-636, Dihydroorotate Dehydrogenase Inhibitor BAY2402234, Diindolylmethane, Dilpacimab, Dimethylmyleran, Dinaciclib, Dinutuximab, Dioscorea nipponica Makino Extract DNE3, Diphencyprone, Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777, Ditiocarb, DKK1-Neutralizing Monoclonal Antibody DKN-01, DM-CHOC-PEN, DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015, DNA Interference Oligonucleotide PNT2258, DNA Minor Groove Binding Agent SG2000, DNA Plasmid Encoding Interleukin-12 INO-9012, DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151, DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, DNA Vaccine VB10.16, DNA-dependent Protein Kinase Inhibitor VX-984, DNA-PK inhibitor AZD7648, DNA-PK/PI3K-delta Inhibitor BR101801, DNA-PK/TOR Kinase Inhibitor CC-115, DNMT1 Inhibitor NTX-301, DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98, Docetaxel, Docetaxel Anhydrous, Docetaxel Emulsion ANX-514, Docetaxel Formulation CKD-810, Docetaxel Lipid Microspheres, Docetaxel Nanoparticle CPC634, Docetaxel Polymeric Micelles, Docetaxel-loaded Nanopharmaceutical CRLX301, Docetaxel-PNP, Docetaxel/Ritonavir, Dociparstat sodium, Dolastatin 10, Dolastatin 15, Domatinostat, Donafenib, Dopamine-Somatostatin Chimeric Molecule BIM-23A760, Dostarlimab, Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703, Dovitinib, Dovitinib Lactate, Doxazosin, Doxercalciferol, Doxifluridine, Doxorubicin, Doxorubicin Hydrochloride, Doxorubicin Prodrug L-377;202, Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370, Doxorubicin-Eluting Beads, Doxorubicin-HPMA Conjugate, Doxorubicin-loaded EGFR-targeting Nanocells, Doxorubicin-Magnetic Targeted Carrier Complex, DPT/BCG/Measles/Serratia/Pneumococcus Vaccine, DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine, DPX-E7 HPV Vaccine, DR5 HexaBody Agonist GEN1029, DR5-targeting Tetrameric Nanobody Agonist TAS266, Dromostanolone Propionate, Drozitumab, DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555, Dual IGF-1R/InsR Inhibitor BMS-754807, Dual Variable Domain Immunoglobulin ABT-165, Dual-affinity B7-H3/CD3-targeted Protein MGD009, Dubermatinib, Duborimycin, Dulanermin, Duligotuzumab, Dupilumab, Durvalumab, Dusigitumab, dUTPase/DPD Inhibitor TAS-114, Duvelisib, Duvortuxizumab, Dynemicin, Dynemicin A, E2F1 Pathway Activator ARQ 171, EBNA-1 inhibitor VK-2019, Echinomycin, Ecromeximab, Edatrexate, Edelfosine, Edicotinib, Edodekin alfa, Edotecarin, Edrecolomab, EED Inhibitor MAK683, Efatutazone, Efatutazone Dihydrochloride, Efizonerimod, Eflornithine, Eflornithine Hydrochloride, Eftilagimod Alpha, Eftozanermin Alfa, Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205, Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621, EGb761, EGFR Antagonist Hemay022, EGFR Antisense DNA BB-401, EGFR Inhibitor AZD3759, EGFR Inhibitor BIBX 1382, EGFR Inhibitor DBPR112, EGFR Inhibitor PD-168393, EGFR Inhibitor TY-9591, EGFR Mutant-selective Inhibitor TQB3804, EGFR Mutant-specific Inhibitor BPI-7711, EGFR Mutant-specific Inhibitor CK-101, EGFR Mutant-specific Inhibitor D-0316, EGFR Mutant-specific Inhibitor ZN-e4, EGFR T790M Antagonist BPI-15086, EGFR T790M Inhibitor HS-10296, EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR/FLT3/Abl Inhibitor SKLB1028, EGFR/HER1/HER2 Inhibitor PKI166, EGFR/HER2 Inhibitor AP32788, EGFR/HER2 Inhibitor AV-412, EGFR/HER2 Inhibitor DZD9008, EGFR/HER2 Kinase Inhibitor TAK-285, EGFR/TGFb Fusion Monoclonal Antibody BCA101, EGFR/VEGFR/RET Inhibitor HA121-28, Eicosapentaenoic Acid, eIF4E Antisense Oligonucleotide ISIS 183750, Elacestrant, Elacytarabine, Elagolix, Elbasvir/Grazoprevir, Elesclomol, Elesclomol Sodium, Elgemtumab, Elinafide, Elisidepsin, Elliptinium, Elliptinium Acetate, Elmustine, Elotuzumab, Elpamotide, Elsamitrucin, Eltanexor, Emactuzumab, Emapalumab, Emepepimut-S, Emibetuzumab, Emitefur, Emofolin Sodium, Empesertib, Enadenotucirev, Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A, Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641, Enasidenib, Enasidenib Mesylate, Enavatuzumab, Encapsulated Rapamycin, Encelimab, Enclomiphene, Enclomiphene Citrate, Encorafenib, Endothelin B Receptor Blocker ENB 003, Endothelin Receptor Type A Antagonist YM598, Enfortumab Vedotin, Engineered Human Umbilical Vein Endothelial Cells AB-205, Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240, Engineered Toxin Body Targeting CD38 TAK-169, Engineered Toxin Body Targeting HER2 MT-5111, Eniluracil/5-FU Combination Tablet, Enloplatin, Enoblituzumab, Enobosarm, Enoticumab, Enpromate, Ensartinib, Ensituximab, Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride, Enterococcus gallinarum Strain MRx0518, Entinostat, Entolimod, Entospletinib, Entrectinib, Envafolimab, Enzalutamide, Enzastaurin, Enzastaurin Hydrochloride, EP2/EP4 Antagonist TPST-1495, EP4 Antagonist INV-1120, EP4 Antagonist ONO-4578, Epacadostat, Epcoritamab, EphA2-targeting Bicycle Toxin Conjugate BT5528, Epipodophyllotoxin Analog GL331, Epipropidine, Epirubicin, Epirubicin Hydrochloride, Epitinib Succinate, Epitiostanol, Epothilone Analog UTD1, Epothilone KOS-1584, Epratuzumab, Epratuzumab-cys-tesirine, ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471, ERa36 Modulator Icaritin, Erastin Analogue PRLX 93936, Erbulozole, Erdafitinib, Eribulin, Eribulin Mesylate, ERK 1/2 Inhibitor ASTX029, ERK Inhibitor CC-90003, ERK Inhibitor GDC-0994, ERK Inhibitor LTT462, ERK Inhibitor MK-8353, ERK1/2 Inhibitor ASN007, ERK1/2 Inhibitor HH2710, ERK1/2 Inhibitor JSI-1187, ERK1/2 Inhibitor KO-947, ERK1/2 Inhibitor LY3214996, Erlotinib, Erlotinib Hydrochloride, Ertumaxomab, Erythrocyte-encapsulated L-asparaginase Suspension, Esorubicin, Esorubicin Hydrochloride, Esperamicin A1, Essiac, Esterified Estrogens, Estradiol Valerate, Estramustine, Estramustine Phosphate Sodium, Estrogen Receptor Agonist GTx-758, Estrogens; Conjugated, Etalocib, Etanercept, Etanidazole, Etaracizumab, Etarotene, Ethaselen, Ethinyl Estradiol, Ethyleneimine, Ethylnitrosourea, Etidronate-Cytarabine Conjugate MBC-11, Etigilimab, Etirinotecan Pegol, Etoglucid, Etoposide, Etoposide Phosphate, Etoposide Toniribate, Etoprine, Etoricoxib, Ets-family Transcription Factor Inhibitor TK216, Everolimus, Everolimus Tablets for Oral Suspension, Evofosfamide, Ex Vivo-expanded Autologous T Cells IMA101, Exatecan Mesylate, Exatecan Mesylate Anhydrous, Exemestane, Exicorilant, Exisulind, Extended Release Flucytosine, Extended Release Metformin Hydrochloride, Extended-release Onapristone, Ezabenlimab, EZH1/2 Inhibitor DS-3201, EZH1/2 Inhibitor HH2853, EZH2 inhibitor CPI-0209, EZH2 Inhibitor CPI-1205, EZH2 Inhibitor PF-06821497, EZH2 Inhibitor SHR2554, F16-IL2 Fusion Protein, FACT Complex-targeting Curaxin CBL0137, Factor VII-targeting Immunoconjugate Protein ICON-1, Factor VIIa Inhibitor PCI-27483, Fadraciclib, Fadrozole Hydrochloride, FAK Inhibitor GSK2256098, FAK Inhibitor PF-00562271, FAK Inhibitor VS-4718, FAK/ALK/ROS1 Inhibitor APG-2449, Falimarev, Famitinib, FAP/4-1BB-targeting DARPin MP0310, FAP/4-1BB-targeting Fusion Protein RO7122290, Farletuzumab, Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778;123, Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells, Fas Receptor Agonist APO010, Fascin Inhibitor NP-G2-044, FASN Inhibitor TVB-2640, Favezelimab, Fazarabine, Fc-engineered Anti-CD40 Agonist Antibody 2141-V11, Febuxostat, Fedratinib, Fedratinib Hydrochloride, Feladilimab, Felzartamab, Fenebrutinib, Fenretinide, Fenretinide Lipid Matrix, Fenretinide Phospholipid Suspension ST-001, FGF Receptor Antagonist HGS1036, FGF/FGFR Pathway Inhibitor E7090, FGFR Inhibitor ASP5878, FGFR Inhibitor AZD4547, FGFR Inhibitor CPL304110, FGFR Inhibitor Debio 1347, FGFR Inhibitor TAS-120, FGFR/CSF-1R Inhibitor 3D185, FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999, FGFR1/2/3 Inhibitor HMPL-453, FGFR2 Inhibitor RLY-4008, FGFR4 Antagonist INCB062079, FGFR4 Inhibitor BLU 9931, FGFR4 Inhibitor FGF401, FGFR4 Inhibitor H3B-6527, FGFR4 Inhibitor ICP-105, Fianlimab, Fibromun, Ficlatuzumab, Figitumumab, Filanesib, Filgotinib, Filgrastim, Fimaporfin A, Fimepinostat, Firtecan Pegol, Fisogatinib, Flanvotumab, Flotetuzumab, Floxuridine, FLT3 Inhibitor FF-10101 Succinate, FLT3 Inhibitor HM43239, FLT3 Inhibitor SKI-G-801, Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01, FLT3 Tyrosine Kinase Inhibitor TTT-3002, FLT3/ABL/Aurora Kinase Inhibitor KW-2449, FLT3/CDK4/6 Inhibitor FLX925, FLT3/FGFR Dual Kinase Inhibitor MAX-40279, FLT3/KIT Kinase Inhibitor AKN-028, FLT3/KIT/CSF1R Inhibitor NMS-03592088, Flt3/MerTK Inhibitor MRX-2843, Fludarabine, Fludarabine Phosphate, Flumatinib, Flumatinib Mesylate, Fluorine F 18 Ara-G, Fluorodopan, Fluorouracil, Fluorouracil Implant, Fluorouracil-E Therapeutic Implant, Fluoxymesterone, Flutamide, Fluvastatin, Fluvastatin Sodium, Fluzoparib, FMS Inhibitor JNJ-40346527, Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate, Folate Receptor Targeted Epothilone BMS753493, Folate Receptor-Targeted Tubulysin Conjugate EC1456, Folate Receptor-Targeted Vinca Alkaloid EC0489, Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225, Folate-FITC, Folic Acid, Folitixorin, Foretinib, Foritinib Succinate, Formestane, Forodesine Hydrochloride, Fosaprepitant, Fosbretabulin, Fosbretabulin Disodium, Fosbretabulin Tromethamine, Fosgemcitabine Palabenamide, Fosifloxuridine Nafalbenamide, Foslinanib, Foslinanib Disodium, Fosquidone, Fostriecin, Fotemustine, Fotretamine, FPV Vaccine CV301, FPV-Brachyury-TRICOM Vaccine, Fresolimumab, Fruquintinib, Fulvestrant, Fumagillin-Derived Polymer Conjugate XMT-1107, Fursultiamine, Futibatinib, Futuximab, Futuximab/Modotuximab Mixture, G Protein-coupled Estrogen Receptor Agonist LNS8801, G-Quadruplex Stabilizer BMVC, Galamustine, Galarubicin, Galectin Inhibitor GR-MD-02, Galectin-1 Inhibitor OTX008, Galeterone, Galiximab, Gallium-based Bone Resorption Inhibitor AP-002, Galocitabine, Galunisertib, Gamboge Resin Extract TSB-9-W1, Gamma-delta Tocotrienol, Gamma-Secretase Inhibitor LY3039478, Gamma-Secretase Inhibitor RO4929097, Gandotinib, Ganetespib, Ganglioside GD2, Ganglioside GM2, Ganitumab, Ganoderma lucidum Spores Powder Capsule, Garlic, Gastrin Immunotoxin, Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360, Gataparsen Sodium, Gatipotuzumab, GBM Antigens and Alloantigens Immunotherapeutic Vaccine, Gedatolisib, Gefitinib, Geldanamycin, Gelonin, Gemcitabine, Gemcitabine Elaidate, Gemcitabine Hydrochloride, Gemcitabine Hydrochloride Emulsion, Gemcitabine Prodrug LY2334737, Gemcitabine-Phosphoramidate Hydrochloride NUC-1031, Gemcitabine-Releasing Intravesical System, Gemtuzumab Ozogamicin, Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum, Genistein, Gentuximab, Geranylgeranyltransferase I Inhibitor, GI-4000 Vaccine, Giloralimab, Gilteritinib, Gilteritinib Fumarate, Gimatecan, Gimeracil, Ginsenoside Rg3 Capsule, Giredestrant, Girentuximab, Girodazole, GITR Agonist MEDI1873, Givinostat, Glasdegib, Glasdegib Maleate, Glaucarubolone, Glecaprevir/Pibrentasvir, Glembatumumab Vedotin, Glesatinib, Glioblastoma Cancer Vaccine ERC1671, Glioblastoma Multiforme Multipeptide Vaccine IMA950, Glioma Lysate Vaccine GBM6-AD, Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701, Globo H-DT Vaccine OBI-833, Glofitamab, Glucarpidase, Glucocorticoid Receptor Antagonist ORIC-101, Glufosfamide, Glumetinib, Glutaminase Inhibitor CB-839, Glutaminase Inhibitor CB-839 Hydrochloride, Glutaminase Inhibitor IPN60090, Glutamine Antagonist DRP-104, Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101, Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01, Glycooptimized Trastuzumab-GEX, GM-CSF-encoding Oncolytic Adenovirus CGTG-102, Gold Sodium Thiomalate, Golnerminogene Pradenovec, Golotimod, Golvatinib, Gonadotropin-releasing Hormone Analog, Goserelin, Goserelin Acetate, Goserelin Acetate Extended-release Microspheres LY01005, Gossypol, Gossypol Acetic Acid, Grapiprant, Green Tea Extract-based Antioxidant Supplement, GS/pan-Notch Inhibitor AL101, GS/pan-Notch Inhibitor BMS-986115, GSK-3 Inhibitor 9-ING-41, GSK-3 Inhibitor LY2090314, Guadecitabine, Guanabenz Acetate, Guselkumab, Gusperimus Trihydrochloride, Gutolactone, H-ras Antisense Oligodeoxynucleotide ISIS 2503, H1299 Tumor Cell Lysate Vaccine, HAAH Lambda phage Vaccine SNS-301, Hafnium Oxide-containing Nanoparticles NBTXR3, Halichondrin Analogue E7130, Halichondrin B, Halofuginone, Halofuginone Hydrobromide, HCV DNA Vaccine INO-8000, HDAC Class I/IIb Inhibitor HG146, HDAC Inhibitor AR-42, HDAC inhibitor CG200745, HDAC Inhibitor CHR-2845, HDAC Inhibitor CKD-581, HDAC Inhibitor CXD101, HDAC Inhibitor MPT0E028, HDAC Inhibitor OBP-801, HDAC/EGFR/HER2 Inhibitor CUDC-101, HDAC6 Inhibitor KA2507, HDAC8 Inhibitor NBM-BMX, HDM2 Inhibitor HDM201, HDM2 Inhibitor MK-8242, Hedgehog Inhibitor IPI-609, Hematoporphyrin Derivative, Hemiasterlin Analog E7974, Henatinib Maleate, Heparan Sulfate Glycosaminoglycan Mimetic M402, Heparin Derivative SST0001, HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131, HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901, HER2 Inhibitor CP-724;714, HER2 Inhibitor DZD1516, HER2 Inhibitor TAS0728, HER2 Tri-specific Natural Killer Cell Engager DF1001, HER2-directed TLR8 Agonist SBT6050, HER2-targeted DARPin MP0274, HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302, HER2-targeting Antibody Fc Fragment FS102, Herba Scutellaria Barbata, Herbimycin, Heterodimeric Interleukin-15, Hexamethylene Bisacetamide, Hexaminolevulinate, Hexylresorcinol, HIF-1alpha Inhibitor PX-478, HIF-2alpha Inhibitor PT2385, HIF-2alpha Inhibitor PT2977, HIF2a RNAi ARO-HIF2, Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126, Histrelin Acetate, HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001, HLA-A*2402-Restricted Multipeptide Vaccine S-488410, HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201, HM2/MMAE Antibody-Drug Conjugate ALT-P7, Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine, Holmium Ho 166 Poly(L-Lactic Acid) Microspheres, Hormone Therapy, HPPH, HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202, HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, HPV E6/E7 DNA Vaccine GX-188E, HPV E6/E7-encoding Arenavirus Vaccine HB-201, HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C, HPV-16 E6 Peptides Vaccine/Candida albicans Extract, HPV-6-targeting Immunotherapeutic Vaccine INO-3106, HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101, HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN, HPV6/11-targeted DNA Plasmid Vaccine INO-3107, Hsp90 Antagonist KW-2478, Hsp90 Inhibitor AB-010, Hsp90 Inhibitor BIIB021, Hsp90 Inhibitor BIIB028, Hsp90 Inhibitor Debio 0932, Hsp90 Inhibitor DS-2248, Hsp90 Inhibitor HSP990, Hsp90 Inhibitor MPC-3100, Hsp90 Inhibitor PU-H71, Hsp90 Inhibitor SNX-5422 Mesylate, Hsp90 Inhibitor SNX-5542 Mesylate, Hsp90 Inhibitor TQB3474, Hsp90 Inhibitor XL888, Hsp90-targeted Photosensitizer HS-201, HSP90-targeted SN-38 Conjugate PEN-866, HSP90alpha/beta Inhibitor TAS-116, hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301, hTERT Vaccine V934/V935, hTERT-encoding DNA Vaccine INVAC-1, Hu14.18-IL2 Fusion Protein EMD 273063, HuaChanSu, Huaier Extract Granule, Huang Lian, huBC1-huIL12 Fusion Protein AS1409, Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736, Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104, Human MOAB LICO 28a32, Human Monoclonal Antibody 216, Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307, Human Papillomavirus 16 E7 Peptide/Padre 965.10, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Hycanthone, Hydralazine Hydrochloride, Hydrocortisone Sodium Succinate, Hydroxychloroquine, Hydroxyprogesterone Caproate, Hydroxytyrosol, Hydroxyurea, Hypericin, Hypoxia-activated Prodrug TH-4000, I 131 Antiferritin Immunoglobulin, I 131 Monoclonal Antibody A33, I 131 Monoclonal Antibody CC49, I 131 Monoclonal Antibody F19, I 131 Monoclonal Antibody Lym-1, Iadademstat, Ianalumab, IAP Inhibitor APG-1387, IAP Inhibitor AT-406, IAP Inhibitor HGS1029, Ibandronate Sodium, Iberdomide, Iboctadekin, Ibritumomab Tiuxetan, Ibrutinib, Icotinib Hydrochloride, Icrucumab, ICT-121 Dendritic Cell Vaccine, Idarubicin, Idarubicin Hydrochloride, Idarubicin-Eluting Beads, Idasanutlin, Idecabtagene Vicleucel, Idelalisib, Idetrexed, IDH1 Mutant Inhibitor LY3410738, IDH1(R132) Inhibitor IDH305, IDH1R132H-Specific Peptide Vaccine PEPIDH1M, Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020, IDO Peptide Vaccine IO102, IDO-1 Inhibitor LY3381916, IDO/TDO Inhibitor HTI-1090, IDO/TDO Inhibitor LY-01013, IDO1 Inhibitor KHK2455, IDO1 Inhibitor MK-7162, IDO1 Inhibitor PF-06840003, IDO1/TDO2 Inhibitor DN1406131, IDO1/TDO2 Inhibitor M4112, Idronoxil, Idronoxil Suppository NOX66, Ieramilimab, Ifabotuzumab, Ifetroban, Ifosfamide, IGF-1R Inhibitor, IGF-1R Inhibitor PL225B, IGF-1R/IR Inhibitor KW-2450, IGF-methotrexate Conjugate, IL-10 Immunomodulator MK-1966, IL-12-expressing HSV-1 NSC 733972, IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051, IL-12sc; IL-15sushi; IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000, IL-2 Recombinant Fusion Protein ALT-801, IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1, IL4-Pseudomonas Exotoxin Fusion Protein MDNA55, Ilginatinib, Ilixadencel, Iloprost, Ilorasertib, Imalumab, Imaradenant, Imatinib, Imatinib Mesylate, Imetelstat, Imetelstat Sodium, Imexon, Imgatuzumab, Imidazole Mustard, Imidazole-Pyrazole, Imifoplatin, Imipramine Blue, Imiquimod, Immediate-release Onapristone, Immediate-release Tablet Afuresertib, Immune Checkpoint Inhibitor ASP8374, Immunoconjugate RO5479599, Immunocytokine NHS-IL12, Immunocytokine NHS-IL2-LT, Immunomodulator LAM-003, Immunomodulator OHR/AVR118, Immunomodulatory Agent CC-11006, Immunomodulatory Oligonucleotide HYB2055, Immunotherapeutic Combination Product CMB305, Immunotherapeutic GSK1572932A, Immunotherapy Regimen MKC-1106-MT, Immunotoxin CMD-193, IMT-1012 Immunotherapeutic Vaccine, Inactivated Oncolytic Virus Particle GEN0101, Inalimarev, Incyclinide, Indatuximab Ravtansine, Indibulin, Indicine-N-Oxide, Indisulam, Individualized MVA-based Vaccine TG4050, Indocyanine Green-labeled Polymeric Micelles ONM-100, Indole-3-Carbinol, Indomethacin, Indoximod, Indoximod Prodrug NLG802, Indusatumab Vedotin, Inebilizumab, Inecalcitol, Infigratinib, Infigratinib Mesylate, Infliximab, Ingenol Mebutate, Ingenol Mebutate Gel, Iniparib, iNKT Cell Agonist ABX196, Innate Immunostimulator rBBX-01, INO-1001, Inodiftagene Vixteplasmid, iNOS Dimerization Inhibitor ASP9853, Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01, Inosine Monophosphate Dehydrogenase Inhibitor AVN944, Inositol, Inotuzumab Ozogamicin, Inproquone, Integrin alpha-2 Inhibitor E7820, Integrin Receptor Antagonist GLPG0187, Interferon, Interferon Alfa-2B, Interferon Alfa-N1, Interferon Alfa-N3, Interferon Alfacon-1, Interferon Beta-1A, Interferon Gamma-1b, Interferon-gamma-expressing Adenovirus Vaccine ASN-002, Interleukin Therapy, Interleukin-12-Fc Fusion Protein DF6002, Interleukin-15 Agonist Fusion Protein SHR1501, Interleukin-15 Fusion Protein BJ-001, Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306, Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101, Interleukin-2 Liposome, Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230, Intetumumab, Intiquinatine, Intoplicine, Inulin, Iobenguane I-131, Iodine I 124 Monoclonal Antibody A33, Iodine I 124 Monoclonal Antibody M5A, Iodine I 125-Anti-EGFR-425 Monoclonal Antibody, Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP, Iodine I 131 Apamistamab, Iodine I 131 Derlotuximab Biotin, Iodine I 131 Ethiodized Oil, Iodine I 131 IPA, Iodine I 131 MIP-1095, Iodine I 131 Monoclonal Antibody 81C6, Iodine I 131 Monoclonal Antibody BC8, Iodine I 131 Monoclonal Antibody CC49-deltaCH2, Iodine I 131 Monoclonal Antibody F16SIP, Iodine I 131 Monoclonal Antibody G-250, Iodine I 131 Monoclonal Antibody muJ591, Iodine I 131 Omburtamab, Iodine I 131 Rituximab, Iodine I 131 Tenatumomab, Iodine I 131 TM-601, Iodine I 131 Tositumomab, Iodine I-131, Ioflubenzamide I-131, Ionomycin, Ipafricept, Ipatasertib, Ipilimumab, Ipomeanol, Iproplatin, iPSC-derived CD16-expressing Natural Killer Cells FT516, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596, iPSC-derived Natural Killer Cells FT500, IRAK4 Inhibitor CA-4948, Iratumumab, Iridium Ir 192, Irinotecan, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Irinotecan-Eluting Beads, Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet, Irofulven, Iroplact, Irosustat, Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130, Isatuximab, Iso-fludelone, Isobrucein B, Isocoumarin NM-3, Isotretinoin, Ispinesib, Ispinesib Mesylate, ISS 1018 CpG Oligodeoxynucleotide, Istiratumab, Itacitinib, Itacitinib Adipate, ITK Inhibitor CPI-818, Itraconazole, Itraconazole Dispersion In Polymer Matrix, Ivaltinostat, Ivosidenib, Ivuxolimab, Ixabepilone, Ixazomib, Ixazomib Citrate, JAK Inhibitor, JAK Inhibitor INCB047986, JAK1 Inhibitor AZD4205, JAK1 Inhibitor INCB052793, JAK2 Inhibitor AZD1480, JAK2 Inhibitor BMS-911543, JAK2 Inhibitor XL019, JAK2/Src Inhibitor NS-018, Jin Fu Kang, JNK Inhibitor CC-401, Kanglaite, Kanitinib, Ketoconazole, Ketotrexate, KRAS G12C Inhibitor GDC-6036, KRAS G12C Inhibitor LY3499446, KRAS G12C Inhibitor MRTX849, KRAS Mutant-targeting AMG 510, KRAS-MAPK Signaling Pathway Inhibitor JAB-3312, KRASG12C Inhibitor JNJ-74699157, KRN5500, KSP Inhibitor AZD4877, KSP Inhibitor SB-743921, Kunecatechins Ointment, L-Gossypol, L-methylfolate, Labetuzumab Govitecan, Lactoferrin-derived Lytic Peptide LTX-315, Lacutamab, Ladiratuzumab Vedotin, Ladirubicin, Laetrile, LAIR-2 Fusion Protein NC410, Landogrozumab, Laniquidar, Lanreotide Acetate, Lapachone, Lapatinib, Lapatinib Ditosylate, Laprituximab Emtansine, Lapuleucel-T, Laromustine, Larotaxel, Larotinib Mesylate, Larotrectinib, Larotrectinib Sulfate, Lavendustin A, Lazertinib, Lead Pb 212 TCMC-trastuzumab, Lefitolimod, Leflunomide, Lenalidomide, Lenalidomide Analog KPG-121, Lentinan, Lenvatinib, Lenvatinib Mesylate, Lenzilumab, Lerociclib, Lestaurtinib, Letetresgene Autoleucel, Letolizumab, Letrozole, Leucovorin, Leucovorin Calcium, Leuprolide, Leuprolide Acetate, Leuprolide Mesylate Injectable Suspension, Leurubicin, Levetiracetam, Levoleucovorin Calcium, Levothyroxine, Levothyroxine Sodium, Lexatumumab, Lexibulin, Liarozole, Liarozole Fumarate, Liarozole Hydrochloride, Licartin, Licorice, Lifastuzumab Vedotin, Lifileucel, Lifirafenib, Light-activated AU-011, Light-Emitting Oncolytic Vaccinia Virus GL-ONC1, Lilotomab, Limonene; (+)-, Limonene; (+/-)-, Linifanib, Linoleyl Carbonate-Paclitaxel, Linperlisib, Linrodostat, Linsitinib, Lintuzumab, Liothyronine I-131, Liothyronine Sodium, Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1, Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191, Lipid Nanoparticle Encapsulated OX40L mRNA-2416, Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006, Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752, Liposomal Bcl-2 Antisense Oligonucleotide BP1002, Liposomal c-raf Antisense Oligonucleotide, Liposomal Curcumin, Liposomal Cytarabine, Liposomal Daunorubicin Citrate, Liposomal Docetaxel, Liposomal Eribulin Mesylate, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Liposomal Irinotecan, Liposomal Mitoxantrone Hydrochloride, Liposomal MUC1/PET-lipid A Vaccine ONT-10, Liposomal NDDP, Liposomal Rhenium Re 186, Liposomal SN-38, Liposomal Topotecan FF-10850, Liposomal Vinorelbine, Liposomal Vinorelbine Tartrate, Liposome, Liposome-encapsulated Daunorubicin-Cytarabine, Liposome-Encapsulated Doxorubicin Citrate, Liposome-encapsulated miR-34 Mimic MRX34, Liposome-encapsulated OSI-7904, Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94, Liposome-encapsulated TAAs mRNA Vaccine W_ova1, Lirilumab, Lisavanbulin, Lisocabtagene Maraleucel, Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142, Litronesib, Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809, Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207, Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623, Liver X Receptor beta Agonist RGX-104, Lm-tLLO-neoantigens Vaccine ADXS-NEO, LMB-1 Immunotoxin, LMB-2 Immunotoxin, LMB-7 Immunotoxin, LMB-9 Immunotoxin, LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164, LMP-2:340-349 Peptide Vaccine, LMP-2:419-427 Peptide Vaccine, LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes, LMP7 Inhibitor M3258, Lobaplatin, Lodapolimab, Lometrexol, Lometrexol Sodium, Lomustine, Lonafarnib, Loncastuximab Tesirine, Long Peptide Vaccine 7, Long-acting Release Pasireotide, Lontucirev, Lorlatinib, Lorukafusp alfa, Lorvotuzumab Mertansine, Losatuxizumab Vedotin, Losoxantrone, Losoxantrone Hydrochloride, Lovastatin, LOXL2 Inhibitor PAT-1251, LRP5 Antagonist BI 905681, LRP5/6 Antagonist BI 905677, LSD1 Inhibitor CC-90011, LSD1 Inhibitor GSK2879552, LSD1 Inhibitor IMG-7289, LSD1 Inhibitor RO7051790, LSD1 Inhibitor SYHA1807, Lucanthone, Lucatumumab, Lucitanib, Luminespib, Luminespib Mesylate, Lumretuzumab, Lung-targeted Immunomodulator QBKPN, Lupartumab Amadotin, Lurbinectedin, Lurtotecan, Lurtotecan Liposome, Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1, Lutetium Lu 177 DOTA-biotin, Lutetium Lu 177 DOTA-N3-CTT1403, Lutetium Lu 177 DOTA-Tetulomab, Lutetium Lu 177 Dotatate, Lutetium Lu 177 Lilotomab-satetraxetan, Lutetium Lu 177 Monoclonal Antibody CC49, Lutetium Lu 177 Monoclonal Antibody J591, Lutetium Lu 177 PP-F11N, Lutetium Lu 177 Satoreotide Tetraxetan, Lutetium Lu 177-DOTA-EB-TATE, Lutetium Lu 177-DTPA-omburtamab, Lutetium Lu 177-Edotreotide, Lutetium Lu 177-NeoB, Lutetium Lu 177-PSMA-617, Lutetium Lu-177 Capromab, Lutetium Lu-177 Girentuximab, Lutetium Lu-177 PSMA-R2, Lutetium Lu-177 Rituximab, LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1, Lyophilized Black Raspberry Lozenge, Lyophilized Black Raspberry Saliva Substitute, Lysine-specific Demethylase 1 Inhibitor INCB059872, Lyso-Thermosensitive Liposome Doxorubicin, Maackia amurensis Seed Lectin, Macimorelin, Macitentan, Macrocycle-bridged STING Agonist E7766, Maekmoondong-tang, Mafosfamide, MAGE-10.A2, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, MAGE-A3 Multipeptide Vaccine GL-0817, MAGE-A3 Peptide Vaccine, MAGE-A3-specific Immunotherapeutic GSK 2132231A, MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201, Magnesium Valproate, Magrolimab, MALT1 Inhibitor JNJ-67856633, Manelimab, Mannosulfan, Mannosylerythritol Lipid, Mapatumumab, Maraba Oncolytic Virus Expressing Mutant HPV E6/E7, Marcellomycin, MARCKS Protein Inhibitor BIO-11006, Margetuximab, Marimastat, Marizomib, Masitinib Mesylate, Masoprocol, MAT2A Inhibitor AG-270, Matrix Metalloproteinase Inhibitor MMI270, Matuzumab, Mavelertinib, Mavorixafor, Maytansine, MCL-1 Inhibitor ABBV-467, MCL-1 Inhibitor AMG 176, MCL-1 inhibitor AMG 397, Mcl-1 Inhibitor AZD5991, Mcl-1 Inhibitor MIK665, MDM2 Antagonist ASTX295, MDM2 Antagonist RO5045337, MDM2 Antagonist RO6839921, MDM2 Inhibitor AMG-232, MDM2 Inhibitor AMGMDS3, MDM2 Inhibitor BI 907828, MDM2 Inhibitor KRT-232, MDM2/MDMX Inhibitor ALRN-6924, MDR Modulator CBT-1, Mechlorethamine, Mechlorethamine Hydrochloride, Mechlorethamine Hydrochloride Gel, Medorubicin, Medroxyprogesterone, Medroxyprogesterone Acetate, Megestrol Acetate, MEK 1/2 Inhibitor AS703988/MSC2015103B, MEK 1/2 Inhibitor FCN-159, MEK Inhibitor AZD8330, MEK Inhibitor CI-1040, MEK inhibitor CS3006, MEK Inhibitor GDC-0623, MEK Inhibitor HL-085, MEK Inhibitor PD0325901, MEK Inhibitor RO4987655, MEK Inhibitor SHR 7390, MEK Inhibitor TAK-733, MEK Inhibitor WX-554, MEK-1/MEKK-1 Inhibitor E6201, MEK/Aurora Kinase Inhibitor BI 847325, Melanoma Monoclonal Antibody hIgG2A, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Melapuldencel-T, MELK Inhibitor OTS167, Melphalan, Melphalan Flufenamide, Melphalan Hydrochloride, Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex, Membrane-Disrupting Peptide EP-100, Menatetrenone, Menin-MLL Interaction Inhibitor SNDX-5613, Menogaril, Merbarone, Mercaptopurine, Mercaptopurine Anhydrous, Mercaptopurine Oral Suspension, Merestinib, Mesna, Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536, MET Kinase Inhibitor OMO-1, MET Tyrosine Kinase Inhibitor BMS-777607, MET Tyrosine Kinase Inhibitor EMD 1204831, MET Tyrosine Kinase Inhibitor PF-04217903, MET Tyrosine Kinase Inhibitor SAR125844, MET Tyrosine Kinase Inhibitor SGX523, MET x MET Bispecific Antibody REGN5093, Metamelfalan, MetAP2 Inhibitor APL-1202, MetAP2 Inhibitor SDX-7320, Metarrestin, Metatinib Tromethamine, Metformin, Metformin Hydrochloride, Methanol Extraction Residue of BCG, Methazolamide, Methionine Aminopeptidase 2 Inhibitor M8891, Methionine Aminopeptidase 2 Inhibitor PPI-2458, Methotrexate, Methotrexate Sodium, Methotrexate-E Therapeutic Implant, Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles, Methoxsalen, Methoxyamine, Methoxyamine Hydrochloride, Methyl-5-Aminolevulinate Hydrochloride Cream, Methylcantharidimide, Methylmercaptopurine Riboside, Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, Methylselenocysteine, Methyltestosterone, Metoprine, Mevociclib, Mezagitamab, Mibefradil, Mibefradil Dihydrochloride, Micellar Nanoparticle-encapsulated Epirubicin, Micro Needle Array-Doxorubicin, Microbiome GEN-001, Microbiome-derived Peptide Vaccine EO2401, Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300, Microtubule Inhibitor SCB01A, Midostaurin, Mifamurtide, Mifepristone, Milademetan Tosylate, Milataxel, Milatuzumab, Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110, Milciclib Maleate, Milk Thistle, Miltefosine, Minretumomab, Mipsagargin, Miptenalimab, Mirabegron, Miransertib, Mirdametinib, Mirvetuximab Soravtansine, Mirzotamab Clezutoclax, Misonidazole, Mistletoe Extract, Mitazalimab, Mitindomide, Mitobronitol, Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101, Mitoclomine, Mitoflaxone, Mitoguazone, Mitoguazone Dihydrochloride, Mitolactol, Mitomycin, Mitomycin A, Mitomycin B, Mitomycin C Analog KW-2149, Mitosis Inhibitor T 1101 Tosylate, Mitotane, Mitotenamine, Mitoxantrone, Mitoxantrone Hydrochloride, Mitozolomide, Mivavotinib, Mivebresib, Mivobulin, Mivobulin Isethionate, Mixed Bacteria Vaccine, MK0731, MKC-1, MKNK1 Inhibitor BAY 1143269, MMP Inhibitor S-3304, MNK1/2 Inhibitor ETC-1907206, Mobocertinib, Mocetinostat, Modakafusp Alfa, Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208, Modified Vitamin D Binding Protein Macrophage Activator EF-022, Modotuximab, MOF Compound RiMO-301, Mofarotene, Mogamulizumab, Molibresib, Molibresib Besylate, Momelotinib, Monalizumab, Monocarboxylate Transporter 1 Inhibitor AZD3965, Monoclonal Antibody 105AD7 Anti-idiotype Vaccine, Monoclonal Antibody 11D10, Monoclonal Antibody 11D10 Anti-Idiotype Vaccine, Monoclonal Antibody 14G2A, Monoclonal Antibody 1F5, Monoclonal Antibody 3622W94, Monoclonal Antibody 3F8, Monoclonal Antibody 3H1 Anti-Idiotype Vaccine, Monoclonal Antibody 4B5 Anti-Idiotype Vaccine, Monoclonal Antibody 7C11, Monoclonal Antibody 81C6, Monoclonal Antibody A1G4 Anti-Idiotype Vaccine, Monoclonal Antibody A27.15, Monoclonal Antibody A33, Monoclonal Antibody AbGn-7, Monoclonal Antibody AK002, Monoclonal Antibody ASP1948, Monoclonal Antibody CAL, Monoclonal Antibody CC49-delta CH2, Monoclonal Antibody CEP-37250/KHK2804, Monoclonal Antibody D6.12, Monoclonal Antibody E2.3, Monoclonal Antibody F19, Monoclonal Antibody GD2 Anti-Idiotype Vaccine, Monoclonal Antibody HeFi-1, Monoclonal Antibody Hu3S193, Monoclonal Antibody HuAFP31, Monoclonal Antibody HuHMFG1, Monoclonal Antibody huJ591, Monoclonal Antibody HuPAM4, Monoclonal Antibody IMMU-14, Monoclonal Antibody L6, Monoclonal Antibody Lym-1, Monoclonal Antibody m170, Monoclonal Antibody Me1-14 F(ab')2, Monoclonal Antibody muJ591, Monoclonal Antibody MX35 F(ab')2, Monoclonal Antibody NEO-201, Monoclonal Antibody R24, Monoclonal Antibody RAV12, Monoclonal Antibody SGN-14, Monoclonal Antibody TRK-950, Monoclonal Microbial EDP1503, Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100, Monomethyl Auristatin E, Morinda Citrifolia Fruit Extract, Morpholinodoxorubicin, Mosedipimod, Mosunetuzumab, Motesanib, Motesanib Diphosphate, Motexafin Gadolinium, Motexafin Lutetium, Motixafortide, Motolimod, MOv-gamma Chimeric Receptor Gene, Moxetumomab Pasudotox, Mps1 Inhibitor BAY 1217389, Mps1 Inhibitor BOS172722, mRNA-based Personalized Cancer Vaccine mRNA-4157, mRNA-based Personalized Cancer Vaccine NCI-4650, mRNA-based TriMix Melanoma Vaccine ECI-006, mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902, mRNA-derived KRAS-targeted Vaccine V941, mRNA-derived Lung Cancer Vaccine BI 1361849, mRNA-Derived Prostate Cancer Vaccine CV9103, mRNA-derived Prostate Cancer Vaccine CV9104, MTF-1 Inhibitor APTO-253 HCl, mTOR Inhibitor GDC-0349, mTOR Kinase Inhibitor AZD8055, mTOR Kinase Inhibitor CC-223, mTOR Kinase Inhibitor OSI-027, mTOR Kinase Inhibitor PP242, mTOR1/2 Kinase Inhibitor ME-344, mTORC 1/2 Inhibitor LXI-15029, mTORC1/2 Kinase Inhibitor BI 860585, mTORC1/mTORC2/DHFR Inhibitor ABTL0812, MUC-1/WT1 Peptide-primed Autologous Dendritic Cells, MUC1-targeted Peptide GO-203-2C, Mucoadhesive Paclitaxel Formulation, Multi-AGC Kinase Inhibitor AT13148, Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200, Multi-epitope HER2 Peptide Vaccine H2NVAC, Multi-epitope HER2 Peptide Vaccine TPIV100, Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107, Multi-kinase Inhibitor TPX-0022, Multi-kinase Inhibitor XL092, Multi-mode Kinase Inhibitor EOC317, Multi-neo-epitope Vaccine OSE 2101, Multifunctional/Multitargeted Anticancer Agent OMN54, Multikinase Inhibitor 4SC-203, Multikinase Inhibitor AEE788, Multikinase Inhibitor AT9283, Multikinase Inhibitor SAR103168, Multipeptide Vaccine S-588210, Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327, Muparfostat, Mureletecan, Murizatoclax, Muscadine Grape Extract, Mutant IDH1 Inhibitor DS-1001, Mutant p53 Activator COTI-2, Mutant-selective EGFR Inhibitor PF-06459988, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-BN Smallpox Vaccine, MVA-FCU1 TG4023, MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1, MYC-targeting siRNA DCR-MYC, Mycobacterium tuberculosis Arabinomannan Z-100, Mycobacterium w, Mycophenolic Acid, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea, N-dihydrogalactochitosan, N-Methylformamide, N;N-Dibenzyl Daunomycin, NA17-A Antigen, NA17.A2 Peptide Vaccine, Nab-paclitaxel, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Nadofaragene Firadenovec, Nagrestipen, Namirotene, Namodenoson, NAMPT Inhibitor OT-82, Nanafrocin, Nanatinostat, Nanocell-encapsulated miR-16-based microRNA Mimic, Nanoparticle Albumin-Bound Docetaxel, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404, Nanoparticle Paclitaxel Ointment SOR007, Nanoparticle-based Paclitaxel Suspension, Nanoparticle-encapsulated Doxorubicin Hydrochloride, Nanoscale Coordination Polymer Nanoparticles CPI-100, Nanosomal Docetaxel Lipid Suspension, Napabucasin, Naphthalimide Analogue UNBS5162, Naptumomab Estafenatox, Naquotinib, Naratuximab Emtansine, Narnatumab, Natalizumab, Natural IFN-alpha OPC-18, Natural Killer Cells ZRx101, Navarixin, Navicixizumab, Navitoclax, Navoximod, Navy Bean Powder, Naxitamab, Nazartinib, ncmtRNA Oligonucleotide Andes-1537, Necitumumab, Nedaplatin, NEDD8 Activating Enzyme E1 Inhibitor TAS4464, Nedisertib, Nelarabine, Nelipepimut-S, Nelipepimut-S Plus GM-CSF Vaccine, Nemorubicin, Nemorubicin Hydrochloride, Neoantigen Vaccine GEN-009, Neoantigen-based Glioblastoma Vaccine, Neoantigen-based Melanoma-Poly-ICLC Vaccine, Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine, Neoantigen-based Therapeutic Cancer Vaccine GRT-C903, Neoantigen-based Therapeutic Cancer Vaccine GRT-R904, Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017, Neratinib, Neratinib Maleate, Nesvacumab, NG-nitro-L-arginine, Niacinamide, Niclosamide, Nicotinamide Riboside, Nidanilimab, Nifurtimox, Nilotinib, Nilotinib Hydrochloride Anhydrous, Nilotinib Hydrochloride Monohydrate, Nilutamide, Nimesulide-Hyaluronic Acid Conjugate CA102N, Nimodipine, Nimotuzumab, Nimustine, Nimustine Hydrochloride, Ningetinib Tosylate, Nintedanib, Niraparib, Niraparib Tosylate Monohydrate, Nirogacestat, Nitric Oxide-Releasing Acetylsalicylic Acid Derivative, Nitrogen Mustard Prodrug PR-104, Nitroglycerin Transdermal Patch, Nivolumab, NLRP3 Agonist BMS-986299, Nocodazole, Nogalamycin, Nogapendekin Alfa, Nolatrexed Dihydrochloride, Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201, Norgestrel, North American Ginseng Extract AFX-2, Nortopixantrone, Noscapine, Noscapine Hydrochloride, Not Otherwise Specified, Notch Signaling Inhibitor PF-06650808, Notch Signaling Pathway Inhibitor MK0752, NTRK/ROS1 Inhibitor DS-6051b, Nucleolin Antagonist IPP-204106N, Nucleoside Analog DFP-10917, Nucleotide Analog Prodrug NUC-3373, Nucleotide Analogue GS 9219, Numidargistat, Nurulimab, Nutlin-3a, Nutraceutical TBL-12, NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611, NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301, NY-ESO-1/GLA-SE Vaccine ID-G305, NY-ESO-B, O-Chloroacetylcarbamoylfumagillol, O6-Benzylguanine, Obatoclax Mesylate, Obinutuzumab, Oblimersen Sodium, Ocaratuzumab, Ocrelizumab, Octreotide, Octreotide Acetate, Octreotide Pamoate, Odronextamab, Ofatumumab, Ofranergene Obadenovec, Oglufanide Disodium, Olaparib, Olaptesed Pegol, Olaratumab, Oleandrin, Oleclumab, Oligo-fucoidan, Oligonucleotide SPC2996, Olinvacimab, Olivomycin, Olmutinib, Oltipraz, Olutasidenib, Olvimulogene Nanivacirepvec, Omacetaxine Mepesuccinate, Ombrabulin, Omipalisib, Onalespib, Onalespib Lactate, Onartuzumab, Onatasertib, Oncolytic Adenovirus Ad5-DNX-2401, Oncolytic Adenovirus ORCA-010, Oncolytic Herpes Simplex Virus-1 ONCR-177, Oncolytic HSV-1 C134, Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011, Oncolytic HSV-1 G207, Oncolytic HSV-1 NV1020, Oncolytic HSV-1 rQNestin34.5v.2, Oncolytic HSV-1 rRp450, Oncolytic HSV1716, Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Oncolytic Newcastle Disease Virus MEDI5395, Oncolytic Newcastle Disease Virus MTH-68H, Oncolytic Newcastle Disease Virus Strain PV701, Oncolytic Virus ASP9801, Oncolytic Virus RP1, Ondansetron Hydrochloride, Ontorpacept, Ontuxizumab, Onvansertib, Onvatilimab, Opaganib, OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule, Opioid Growth Factor, Opolimogene Capmilisbac, Oportuzumab Monatox, Oprozomib, Opucolimab, Oral Aminolevulinic Acid Hydrochloride, Oral Azacitidine, Oral Cancer Vaccine V3-OVA, Oral Docetaxel, Oral Fludarabine Phosphate, Oral Hsp90 Inhibitor IPI-493, Oral Ixabepilone, Oral Microencapsulated Diindolylmethane, Oral Milataxel, Oral Myoma Vaccine V3-myoma, Oral Pancreatic Cancer Vaccine V3-P, Oral Picoplatin, Oral Sodium Phenylbutyrate, Oral Topotecan Hydrochloride, Orantinib, Oraxol, Oregovomab, Orelabrutinib, Ormaplatin, Ortataxel, Orteronel, Orvacabtagene Autoleucel, Osilodrostat, Osimertinib, Other, Otlertuzumab, Ovapuldencel-T, Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006, Ovine Submaxillary Mucin, OX40L-expressing Oncolytic Adenovirus DNX-2440, Oxaliplatin, Oxaliplatin Eluting Beads, Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome, Oxcarbazepine, Oxeclosporin, Oxidative Phosphorylation Inhibitor IACS-010759, Oxidative Phosphorylation Inhibitor IM156, Oxidopamine, OxPhos Inhibitor VLX600, Ozarelix, P-cadherin Antagonist PF-03732010, P-cadherin Inhibitor PCA062, P-cadherin-targeting Agent PF-06671008, P-p68 Inhibitor RX-5902, P-TEFb Inhibitor BAY1143572, p300/CBP Bromodomain Inhibitor CCS1477, p38 MAPK Inhibitor LY3007113, p53 Peptide Vaccine MPS-128, p53-HDM2 Interaction Inhibitor MI-773, p53-HDM2 Protein-protein Interaction Inhibitor APG-115, p53/HDM2 Interaction Inhibitor CGM097, p70S6K Inhibitor LY2584702, p70S6K/Akt Inhibitor MSC2363318A, p97 Inhibitor CB-5083, p97 Inhibitor CB-5339, p97 Inhibitor CB-5339 Tosylate, Paclitaxel, Paclitaxel Ceribate, Paclitaxel Injection Concentrate for Nanodispersion, Paclitaxel Liposome, Paclitaxel Poliglumex, Paclitaxel Polymeric Micelle Formulation NANT-008, Paclitaxel PPE Microspheres, Paclitaxel Trevatide, Paclitaxel Vitamin E-Based Emulsion, Paclitaxel-Loaded Polymeric Micelle, Pacmilimab, Pacritinib, Padeliporfin, Padoporfin, PAK4 Inhibitor PF-03758309, PAK4/NAMPT Inhibitor KPT-9274, Palbociclib, Palbociclib Isethionate, Palifosfamide, Palifosfamide Tromethamine, Palladium Pd-103, Palonosetron Hydrochloride, Pamidronate Disodium, Pamidronic Acid, Pamiparib, Pamrevlumab, pan FGFR Inhibitor PRN1371, Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514, Pan-AKT Inhibitor ARQ751, Pan-AKT Kinase Inhibitor GSK690693, Pan-FGFR Inhibitor LY2874455, Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806, pan-HER Kinase Inhibitor AC480, Pan-IDH Mutant Inhibitor AG-881, Pan-KRAS Inhibitor BI 1701963, Pan-Mutant-IDH1 Inhibitor Bay-1436032, Pan-mutation-selective EGFR Inhibitor CLN-081, pan-PI3K Inhibitor CLR457, pan-PI3K/mTOR Inhibitor SF1126, Pan-PIM Inhibitor INCB053914, pan-PIM Kinase Inhibitor AZD1208, pan-PIM Kinase Inhibitor NVP-LGB-321, pan-RAF Inhibitor LXH254, Pan-RAF Inhibitor LY3009120, pan-RAF Kinase Inhibitor CCT3833, pan-RAF Kinase Inhibitor TAK-580, Pan-RAR Agonist/AP-1 Inhibitor LGD 1550, Pan-TRK Inhibitor NOV1601, Pan-TRK Inhibitor ONO-7579, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Pancratistatin, Panitumumab, Panobinostat, Panobinostat Nanoparticle Formulation MTX110, Panulisib, Paricalcitol, PARP 1/2 Inhibitor IMP4297, PARP 1/2 Inhibitor NOV1401, PARP Inhibitor AZD2461, PARP Inhibitor CEP-9722, PARP Inhibitor E7016, PARP Inhibitor NMS-03305293, PARP-1/2 Inhibitor ABT-767, PARP/Tankyrase Inhibitor 2X-121, PARP7 Inhibitor RBN-2397, Parsaclisib, Parsaclisib Hydrochloride, Parsatuzumab, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Parvovirus H-1, Pasireotide, Pasotuxizumab, Patidegib, Patidegib Topical Gel, Patritumab, Patritumab Deruxtecan, Patupilone, Paxalisib, Pazopanib, Pazopanib Hydrochloride, pbi-shRNA STMN1 Lipoplex, PBN Derivative OKN-007, PCNU, PD-1 Directed Probody CX-188, PD-1 Inhibitor, PD-L1 Inhibitor GS-4224, PD-L1 Inhibitor INCB086550, PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480, PD-L1/PD-L2/VISTA Antagonist CA-170, PDK1 Inhibitor AR-12, pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0, PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1, PEG-interleukin-2, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, PEG-Proline-Interferon Alfa-2b, Pegargiminase, Pegaspargase, Pegdinetanib, Pegfilgrastim, Pegilodecakin, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Pegvisomant, Pegvorhyaluronidase Alfa, Pegylated Deoxycytidine Analogue DFP-14927, Pegylated Interferon Alfa, Pegylated Liposomal Belotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Pegylated Liposomal Irinotecan, Pegylated Liposomal Mitomycin C Lipid-based Prodrug, Pegylated Liposomal Mitoxantrone Hydrochloride, Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010, Pegylated Paclitaxel, Pegylated Recombinant Human Arginase I BCT-100, Pegylated Recombinant Human Hyaluronidase PH20, Pegylated Recombinant Interleukin-2 THOR-707, Pegylated Recombinant L-asparaginase Erwinia chrysanthemi, Pegylated SN-38 Conjugate PLX038, Pegzilarginase, Pelabresib, Pelareorep, Peldesine, Pelitinib, Pelitrexol, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Pemigatinib, Pemlimogene Merolisbac, Penberol, Penclomedine, Penicillamine, Pentamethylmelamine, Pentamustine, Pentostatin, Pentoxifylline, PEOX-based Polymer Encapsulated Paclitaxel FID-007, PEP-3-KLH Conjugate Vaccine, Pepinemab, Peplomycin, Peplomycin Sulfate, Peposertib, Peptichemio, Peptide 946 Melanoma Vaccine, Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine, Peretinoin, Perflenapent Emulsion, Perfosfamide, Perifosine, Perillyl Alcohol, Personalized ALL-specific Multi-HLA-binding Peptide Vaccine, Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC, Personalized Cancer Vaccine RO7198457, Personalized Neoantigen DNA Vaccine GNOS-PV01, Personalized Neoantigen DNA Vaccine GNOS-PVO2, Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01, Personalized Neoepitope Yeast Vaccine YE-NEO-001, Personalized Peptide Cancer Vaccine NEO-PV-01, Pertuzumab, Pevonedistat, Pexastimogene Devacirepvec, Pexidartinib, Pexmetinib, PGG Beta-Glucan, PGLA/PEG Copolymer-Based Paclitaxel, PH20 Hyaluronidase-expressing Adenovirus VCN-01, Phaleria macrocarpa Extract DLBS-1425, Pharmacological Ascorbate, Phellodendron amurense Bark Extract, Phenesterin, Phenethyl Isothiocyanate, Phenethyl Isothiocyanate-containing Watercress Juice, Phenyl Acetate, Phenytoin Sodium, Phosphaplatin PT-112, Phosphatidylcholine-Bound Silybin, Phospholipid Ether-drug Conjugate CLR 131, Phosphoramide Mustard, Phosphorodiamidate Morpholino Oligomer AVI-4126, Phosphorus P-32, Photodynamic Compound TLD-1433, Photosensitizer LUZ 11, Phytochlorin Sodium-Polyvinylpyrrolidone Complex, PI3K Alpha/Beta Inhibitor BAY1082439, PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate, PI3K Inhibitor ACP-319, PI3K Inhibitor BGT226, PI3K Inhibitor GDC-0084, PI3K Inhibitor GDC0077, PI3K Inhibitor GSK1059615, PI3K Inhibitor WX-037, PI3K Inhibitor ZSTK474, PI3K p110beta/delta Inhibitor KA2237, PI3K-alpha Inhibitor MEN1611, PI3K-beta Inhibitor GSK2636771, PI3K-beta Inhibitor SAR260301, PI3K-delta Inhibitor AMG 319, PI3K-delta Inhibitor HMPL 689, PI3K-delta Inhibitor INCB050465, PI3K-delta Inhibitor PWT143, PI3K-delta Inhibitor SHC014748M, PI3K-delta Inhibitor YY-20394, PI3K-gamma Inhibitor IPI-549, PI3K/BET Inhibitor LY294002, PI3K/mTOR Kinase Inhibitor DS-7423, PI3K/mTOR Kinase Inhibitor PF-04691502, PI3K/mTOR Kinase Inhibitor VS-5584, PI3K/mTOR Kinase Inhibitor WXFL10030390, PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170, PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901, PI3Ka/mTOR Inhibitor PKI-179, PI3Kalpha Inhibitor AZD8835, PI3Kbeta Inhibitor AZD8186, PI3Kdelta Inhibitor GS-9901, Pibenzimol, Pibrozelesin, Pibrozelesin Hydrobromide, Picibanil, Picoplatin, Picrasinoside H, Picropodophyllin, Pictilisib, Pictilisib Bismesylate, Pidilizumab, Pilaralisib, PIM Kinase Inhibitor LGH447, PIM Kinase Inhibitor SGI-1776, PIM Kinase Inhibitor TP-3654, PIM/FLT3 Kinase Inhibitor SEL24, Pimasertib, Pimitespib, Pimurutamab, Pinatuzumab Vedotin, Pingyangmycin, Pinometostat, Pioglitazone, Pioglitazone Hydrochloride, Pipendoxifene, Piperazinedione, Piperine Extract (Standardized), Pipobroman, Piposulfan, Pirarubicin, Pirarubicin Hydrochloride, Pirfenidone, Piritrexim, Piritrexim Isethionate, Pirotinib, Piroxantrone, Piroxantrone Hydrochloride, Pixantrone, Pixantrone Dimaleate, Pixatimod, PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231, PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521, PKC-beta Inhibitor MS-553, Placebo, Pladienolide Derivative E7107, Plamotamab, Plasmid DNA Vaccine pING-hHER3FL, Platinum, Platinum Acetylacetonate-Titanium Dioxide Nanoparticles, Platinum Compound, Plevitrexed, Plicamycin, Plinabulin, Plitidepsin, Plk1 Inhibitor BI 2536, PLK1 Inhibitor CYC140, PLK1 Inhibitor TAK-960, Plocabulin, Plozalizumab, pNGVL4a-CRT-E6E7L2 DNA Vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2, Pol I Inhibitor CX5461, Polatuzumab Vedotin, Polidocanol, Poliglusam, Polo-like Kinase 1 Inhibitor GSK461364, Polo-like Kinase 1 Inhibitor MK1496, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate, Poly-alendronate Dextran-Guanidine Conjugate, Poly-gamma Glutamic Acid, Polyamine Analog SL11093, Polyamine Analogue PG11047, Polyamine Analogue SBP-101, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Polyandrol, Polyethylene Glycol Recombinant Endostatin, Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, Polymer-encapsulated Luteolin Nanoparticle, Polymeric Camptothecin Prodrug XMT-1001, Polypodium leucotomos Extract, Polysaccharide-K, Polysialic Acid, Polyunsaturated Fatty Acid, Polyvalent Melanoma Vaccine, Pomalidomide, Pomegranate Juice, Pomegranate Liquid Extract, Ponatinib, Ponatinib Hydrochloride, Porcupine Inhibitor CGX1321, Porcupine Inhibitor ETC-1922159, Porcupine Inhibitor RXC004, Porcupine Inhibitor WNT974, Porcupine Inhibitor XNW7201, Porfimer Sodium, Porfiromycin, Poziotinib, PPAR Alpha Antagonist TPST-1120, PR1 Leukemia Peptide Vaccine, Pracinostat, Pralatrexate, Pralsetinib, Praluzatamab Ravtansine, PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701, Pravastatin Sodium, Prednimustine, Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, Prednisone, Prexasertib, Prexigebersen, PRIMA-1 Analog APR-246, Prime Cancer Vaccine MVA-BN-CV301, Prinomastat, PRMT1 Inhibitor GSK3368715, PRMT5 Inhibitor JNJ-64619178, PRMT5 Inhibitor PRT811, Proapoptotic Sulindac Analog CP-461, Procarbazine, Procarbazine Hydrochloride, Procaspase Activating Compound-1 VO-100, Progestational IUD, Prohibitin-Targeting Peptide 1, Prolgolimab, Prostaglandin E2 EP4 Receptor Inhibitor AN0025, Prostaglandin E2 EP4 Receptor Inhibitor E7046, Prostate Cancer Vaccine ONY-P1, Prostate Health Cocktail Dietary Supplement, Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024, Protease-activated Anti-PD-L1 Antibody Prodrug CX-072, Protein Arginine Methyltransferase 5 Inhibitor GSK3326595, Protein Arginine Methyltransferase 5 Inhibitor PF-06939999, Protein Arginine Methyltransferase 5 Inhibitor PRT543, Protein Kinase C Inhibitor IDE196, Protein Phosphatase 2A Inhibitor LB-100, Protein Stabilized Liposomal Docetaxel Nanoparticles, Protein Tyrosine Kinase 2 Inhibitor IN10018, Proxalutamide, PSA/IL-2/GM-CSF Vaccine, PSA/PSMA DNA Plasmid INO-5150, Pseudoisocytidine, PSMA-targeted Docetaxel Nanoparticles BIND-014, PSMA-targeted Tubulysin B-containing Conjugate EC1169, PSMA/CD3 Tri-specific T-cell Activating Construct HPN424, PTEF-b/CDK9 Inhibitor BAY1251152, Pterostilbene, Pumitepa, Puquitinib, Puquitinib Mesylate, Puromycin, Puromycin Hydrochloride, PV-10, PVA Microporous Hydrospheres/Doxorubicin Hydrochloride, Pyrazinamide, Pyrazoloacridine, Pyridyl Cyanoguanidine CHS 828, Pyrotinib, Pyrotinib Dimaleate, Pyroxamide, Pyruvate Kinase Inhibitor TLN-232, Pyruvate Kinase M2 Isoform Activator TP-1454, Qilisheng Immunoregulatory Oral Solution, Quadrivalent Human Papillomavirus (types 6; 11; 16; 18) Recombinant Vaccine, Quarfloxin, Quinacrine Hydrochloride, Quinine, Quisinostat, Quizartinib, R-(-)-Gossypol Acetic Acid, Rabusertib, Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88, Racotumomab, RAD51 Inhibitor CYT-0851, Radgocitabine, Radgocitabine Hydrochloride, Radioactive Iodine, Radiolabeled CC49, Radium Ra 223 Dichloride, Radium Ra 224-labeled Calcium Carbonate Microparticles, Radix Angelicae Sinensis/Radix Astragali Herbal Supplement, Radotinib Hydrochloride, Raf Kinase Inhibitor HM95573, RAF Kinase Inhibitor L-779450, RAF Kinase Inhibitor XL281, Ragifilimab, Ralaniten Acetate, Ralimetinib Mesylate, Raloxifene, Raloxifene Hydrochloride, Raltitrexed, Ramucirumab, Ranibizumab, Ranimustine, Ranolazine, Ranpirnase, RARalpha Agonist IRX5183, Ras Inhibitor, Ras Peptide ASP, Ras Peptide CYS, Ras Peptide VAL, Razoxane, Realgar-Indigo naturalis Formulation, Rebastinib Tosylate, Rebeccamycin, Rebimastat, Receptor Tyrosine Kinase Inhibitor R1530, Recombinant Adenovirus-p53 SCH-58500, Recombinant Anti-WT1 Immunotherapeutic GSK2302024A, Recombinant Bacterial Minicells VAX014, Recombinant Bispecific Single-Chain Antibody rM28, Recombinant CD40-Ligand, Recombinant Erwinia asparaginase JZP-458, Recombinant Erythropoietin, Recombinant Fas Ligand, Recombinant Fractalkine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human 6Ckine, Recombinant Human Adenovirus Type 5 H101, Recombinant Human Angiotensin Converting Enzyme 2 APN01, Recombinant Human Apolipoprotein(a) Kringle V MG1102, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Recombinant Human Endostatin, Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Recombinant Human Papillomavirus 11-valent Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Recombinant Human Plasminogen Kringle 5 Domain ABT 828, Recombinant Human TRAIL-Trimer Fusion Protein SCB-313, Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301, Recombinant Interferon, Recombinant Interferon Alfa, Recombinant Interferon Alfa-1b, Recombinant Interferon Alfa-2a, Recombinant Interferon Alfa-2b, Recombinant Interferon Alpha 2b-like Protein, Recombinant Interferon Beta, Recombinant Interferon Gamma, Recombinant Interleukin-12, Recombinant Interleukin-13, Recombinant Interleukin-18, Recombinant Interleukin-2, Recombinant Interleukin-6, Recombinant KSA Glycoprotein CO17-1A, Recombinant Leukocyte Interleukin, Recombinant Leukoregulin, Recombinant Luteinizing Hormone, Recombinant Macrophage Colony-Stimulating Factor, Recombinant MAGE-3.1 Antigen, Recombinant MIP1-alpha Variant ECI301, Recombinant Modified Vaccinia Ankara-5T4 Vaccine, Recombinant Oncolytic Poliovirus PVS-RIPO, Recombinant Platelet Factor 4, Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A, Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207, Recombinant Super-compound Interferon, Recombinant Thyroglobulin, Recombinant Thyrotropin Alfa, Recombinant Transforming Growth Factor-Beta, Recombinant Transforming Growth Factor-Beta-2, Recombinant Tumor Necrosis Factor-Alpha, Recombinant Tyrosinase-Related Protein-2, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Redaporfin, Refametinib, Regorafenib, Relacorilant, Relatlimab, Relugolix, Remetinostat, Renal Cell Carcinoma Peptides Vaccine IMA901, Reparixin, Repotrectinib, Resiquimod, Resiquimod Topical Gel, Resistant Starch, Resminostat, Resveratrol, Resveratrol Formulation SRT501, RET Inhibitor DS-5010, RET Mutation/Fusion Inhibitor BLU-667, RET/SRC Inhibitor TPX-0046, Retaspimycin, Retaspimycin Hydrochloride, Retelliptine, Retifanlimab, Retinoic Acid Agent Ro 16-9100, Retinoid 9cUAB30, Retinol, Retinyl Acetate, Retinyl Palmitate, Retrovector Encoding Mutant Anti-Cyclin G1, Revdofilimab, Rexinoid NRX 194204, Rezivertinib, RFT5-dgA Immunotoxin IMTOX25, Rhenium Re 188 BMEDA-labeled Liposomes, Rhenium Re-186 Hydroxyethylidene Diphosphonate, Rhenium Re-188 Ethiodized Oil, Rhenium Re-188 Etidronate, Rhizoxin, RhoC Peptide Vaccine RV001V, Ribociclib, Ribociclib/Letrozole, Ribonuclease QBI-139, Ribosome-Inactivating Protein CY503, Ribozyme RPI.4610, Rice Bran, Ricolinostat, Ridaforolimus, Rigosertib, Rigosertib Sodium, Rilimogene Galvacirepvec, Rilimogene Galvacirepvec/Rilimogene Glafolivec, Rilimogene Glafolivec, Rilotumumab, Rindopepimut, Ripertamab, RIPK1 Inhibitor GSK3145095, Ripretinib, Risperidone Formulation in Rumenic Acid, Ritrosulfan, Rituximab, Rituximab and Hyaluronidase Human, Rituximab Conjugate CON-4619, Riviciclib, Rivoceranib, Rivoceranib Mesylate, RNR Inhibitor COH29, Robatumumab, Roblitinib, ROBO1-targeted BiCAR-NKT Cells, Rocakinogene Sifuplasmid, Rocapuldencel-T, Rociletinib, Rodorubicin, Roducitabine, Rofecoxib, Roflumilast, Rogaratinib, Rogletimide, Rolinsatamab Talirine, Romidepsin, Roneparstat, Roniciclib, Ropeginterferon Alfa-2B, Ropidoxuridine, Ropocamptide, Roquinimex, RORgamma Agonist LYC-55716, Rosabulin, Rose Bengal Solution PV-10, Rosiglitazone Maleate, Rosmantuzumab, Rosopatamab, Rosuvastatin, Rovalpituzumab Tesirine, RSK1-4 Inhibitor PMD-026, Rubitecan, Rucaparib, Rucaparib Camsylate, Rucaparib Phosphate, Ruthenium Ru-106, Ruthenium-based Small Molecule Therapeutic BOLD-100, Ruthenium-based Transferrin Targeting Agent NKP-1339, Ruxolitinib, Ruxolitinib Phosphate, Ruxotemitide, S-Adenosylmethionine, S-equol, S1P Receptor Agonist KRP203, Sabarubicin, Sabatolimab, Sacituzumab Govitecan, Sacubitril/Valsartan, Safingol, Sagopilone, Salirasib, Salmonella VNP20009, Sam68 Modulator CWP232291, Samalizumab, Samarium Sm 153-DOTMP, Samotolisib, Samrotamab Vedotin, Samuraciclib, Sapacitabine, Sapanisertib, Sapitinib, Saracatinib, Saracatinib Difumarate, SarCNU, Sardomozide, Sargramostim, Sasanlimab, Satraplatin, Savolitinib, SBIL-2, Scopoletin, SDF-1 Receptor Antagonist PTX-9908, Seclidemstat, Sedoxantrone Trihydrochloride, Selatinib Ditosilate, Selective Androgen Receptor Modulator RAD140, Selective Cytokine Inhibitory Drug CC-1088, Selective Estrogen Receptor Degrader AZD9496, Selective Estrogen Receptor Degrader AZD9833, Selective Estrogen Receptor Degrader LSZ102, Selective Estrogen Receptor Degrader LX-039, Selective Estrogen Receptor Degrader LY3484356, Selective Estrogen Receptor Degrader SRN-927, Selective Estrogen Receptor Modulator CC-8490, Selective Estrogen Receptor Modulator TAS-108, Selective Glucocorticoid Receptor Antagonist CORT125281, Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352, Seliciclib, Selicrelumab, Selinexor, Selitrectinib, Selonsertib, Selpercatinib, Selumetinib, Selumetinib Sulfate, Semaxanib, Semuloparin, Semustine, Seneca Valley Virus-001, Seocalcitol, Sepantronium Bromide, Serabelisib, Serclutamab Talirine, SERD D-0502, SERD G1T48, SERD GDC-9545, SERD SAR439859, SERD SHR9549, SERD ZN-c5, Serdemetan, Sergiolide, Seribantumab, Serine/Threonine Kinase Inhibitor CBP501, Serine/Threonine Kinase Inhibitor XL418, Serplulimab, Sevacizumab, Seviteronel, Shared Anti-Idiotype-AB-S006, Shared Anti-Idiotype-AB-S024A, Shark Cartilage, Shark Cartilage Extract AE-941, Shenqi Fuzheng Injection SQ001, Sho-Saiko-To, Short Chain Fatty Acid HQK-1004, SHP-1 Agonist SC-43, SHP2 Inhibitor JAB-3068, SHP2 Inhibitor RLY-1971, SHP2 Inhibitor RMC-4630, SHP2 Inhibitor TNO155, Shu Yu Wan Formula, Sialyl Tn Antigen, Sialyl Tn-KLH Vaccine, Sibrotuzumab, siG12D LODER, Silatecan AR-67, Silibinin, Silicon Phthalocyanine 4, Silmitasertib Sodium, Siltuximab, Simalikalactone D, Simeprevir, Simlukafusp Alfa, Simmitinib, Simotaxel, Simtuzumab, Simurosertib, Sintilimab, Siplizumab, Sipuleucel-T, Siremadlin, siRNA-transfected Peripheral Blood Mononuclear Cells APN401, Sirolimus, SIRPa-4-1BBL Fusion Protein DSP107, SIRPa-Fc Fusion Protein TTI-621, SIRPa-Fc-CD40L Fusion Protein SL-172154, SIRPa-IgG4-Fc Fusion Protein TTI-622, Sitimagene Ceradenovec, Sitravatinib, Sivifene, Sizofiran, SLC6A8 Inhibitor RGX-202, SLCT Inhibitor GNS561, SMAC Mimetic BI 891065, Smac Mimetic GDC-0152, Smac Mimetic GDC-0917, Smac Mimetic LCL161, SMO Protein Inhibitor ZSP1602, Smoothened Antagonist BMS-833923, Smoothened Antagonist LDE225 Topical, Smoothened Antagonist LEQ506, Smoothened Antagonist TAK-441, SN-38-Loaded Polymeric Micelles NK012, SNS01-T Nanoparticles, Sobuzoxane, Sodium Borocaptate, Sodium Butyrate, Sodium Dichloroacetate, Sodium Iodide I-131, Sodium Metaarsenite, Sodium Phenylbutyrate, Sodium Salicylate, Sodium Selenite, Sodium Stibogluconate, Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108, Sofituzumab Vedotin, Solitomab, Sonepcizumab, Sonidegib, Sonolisib, Sorafenib, Sorafenib Tosylate, Sorghum bicolor Supplement, Sotigalimab, Sotorasib, Sotrastaurin, Sotrastaurin Acetate, Soy Isoflavones, Soy Protein Isolate, Spanlecortemlocel, Sparfosate Sodium, Sparfosic Acid, Spartalizumab, Spebrutinib, Spherical Nucleic Acid Nanoparticle NU-0129, Spirogermanium, Spiromustine, Spiroplatin, Splicing Inhibitor H3B-8800, Spongistatin, Squalamine Lactate, SR-BP1/HSI Inhibitor SR31747A, SR-T100 Gel, Src Kinase Inhibitor AP 23846, Src Kinase Inhibitor KX2-391, Src Kinase Inhibitor KX2-391 Ointment, Src Kinase Inhibitor M475271, Src/Abl Kinase Inhibitor AZD0424, Src/tubulin Inhibitor KX02, SRPK1/ABCG2 Inhibitor SCO-101, ssRNA-based Immunomodulator CV8102, SSTR2-targeting Protein/DM1 Conjugate PEN-221, St. John's Wort, Stallimycin, Staphylococcal Enterotoxin A, Staphylococcal Enterotoxin B, STAT Inhibitor OPB-111077, STAT3 Inhibitor DSP-0337, STAT3 Inhibitor OPB-31121, STAT3 Inhibitor OPB-51602, STAT3 Inhibitor TTI-101, STAT3 Inhibitor WP1066, Staurosporine, STING Agonist BMS-986301, STING Agonist GSK3745417, STING Agonist IMSA101, STING Agonist MK-1454, STING Agonist SB 11285, STING Agonist TAK-676, STING-activating Cyclic Dinucleotide Agonist MIW815, STING-expressing E. coli SYNB1891, Streptonigrin, Streptozocin, Strontium Chloride Sr-89, Submicron Particle Paclitaxel Sterile Suspension, Sugemalimab, Sulfatinib, Sulforaphane, Sulindac, Sulofenur, Sumoylation Inhibitor TAK-981, Sunitinib, Sunitinib Malate, Super Enhancer Inhibitor GZ17-6.02, Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803, Superoxide Dismutase Mimetic GC4711, Suramin, Suramin Sodium, Survivin Antigen, Survivin Antigen Vaccine DPX-Survivac, Survivin mRNA Antagonist EZN-3042, Survivin-expressing CVD908ssb-TXSVN Vaccine, Sustained-release Lipid Inhaled Cisplatin, Sustained-release Mitomycin C Hydrogel Formulation UGN-101, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, Syk Inhibitor HMPL-523, Synchrotope TA2M Plasmid DNA Vaccine, Synchrovax SEM Plasmid DNA Vaccine, Synthetic Alkaloid PM00104, Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2, Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1, Synthetic hTERT DNA Vaccine INO-1400, Synthetic hTERT DNA Vaccine INO-1401, Synthetic Hypericin, Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201, Synthetic Long E6/E7 Peptides Vaccine HPV-01, Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b, Synthetic Plumbagin PCUR-101, T900607, Tabalumab, Tabelecleucel, Tacedinaline, Tafasitamab, Tagraxofusp-erzs, Talabostat, Talabostat Mesylate, Talacotuzumab, Talactoferrin Alfa, Taladegib, Talampanel, Talaporfin Sodium, Talazoparib, Taletrectinib, Talimogene Laherparepvec, Tallimustine, Talmapimod, Talotrexin, Talotrexin Ammonium, Taltobulin, TAM/c-Met Inhibitor RXDX-106, Tamibarotene, Taminadenant, Tamoxifen, Tamoxifen Citrate, Tamrintamab Pamozirine, Tandutinib, Tanespimycin, Tanibirumab, Tankyrase Inhibitor STP1002, Tanomastat, Tapotoclax, Tarenflurbil, Tarextumab, Tariquidar, Tasadenoturev, Taselisib, Tasidotin, Tasisulam, Tasisulam Sodium, Tasquinimod, Taurolidine, Tauromustine, Taurultam, Taurultam Analogue GP-2250, Tavokinogene Telseplasmid, Tavolimab, Taxane Analogue TPI 287, Taxane Compound, Taxol Analogue SID 530, Tazarotene, Tazemetostat, Tebentafusp, Teclistamab, Tecogalan Sodium, Tefinostat, Tegafur, Tegafur-gimeracil-oteracil Potassium, Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation, Tegafur-Uracil, Tegavivint, Teglarinad, Teglarinad Chloride, Telaglenastat, Telaglenastat Hydrochloride, Telapristone, Telapristone Acetate, Telatinib Mesylate, Telisotuzumab, Telisotuzumab Vedotin, Telomerase Inhibitor FJ5002, Telomerase-specific Type 5 Adenovirus OBP-301, Teloxantrone, Teloxantrone Hydrochloride, Telratolimod, Temarotene, Temoporfin, Temozolomide, Temsirolimus, Tenalisib, Tenifatecan, Teniposide, Tepoditamab, Tepotinib, Teprotumumab, Terameprocol, Terfluranol, Tergenpumatucel-L, Teroxirone, Tertomotide, Tesetaxel, Tesevatinib, Tesidolumab, Testolactone, Testosterone Enanthate, Tetanus Toxoid Vaccine, Tetradecanoylphorbol Acetate, Tetrahydrouridine, Tetraphenyl Chlorin Disulfonate, Tetrathiomolybdate, Tezacitabine, Tezacitabine Anhydrous, TGF-beta Receptor 1 Inhibitor PF-06952229, TGF-beta Receptor 1 Kinase Inhibitor SH3051, TGF-beta Receptor 1 Kinase Inhibitor YL-13027, TGFa-PE38 Immunotoxin, TGFbeta Inhibitor LY3200882, TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200, Thalicarpine, Thalidomide, Theliatinib, Theramide, Therapeutic Angiotensin-(1-7), Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907, Therapeutic Cancer Vaccine ATP128, Therapeutic Estradiol, Therapeutic Hydrocortisone, Therapeutic Liver Cancer Peptide Vaccine IMA970A, Thiarabine, Thiodiglycol, Thioguanine, Thioguanine Anhydrous, Thioinosine, Thioredoxin-1 Inhibitor PX-12, Thiotepa, Thioureidobutyronitrile, THL-P, Thorium Th 227 Anetumab, Thorium Th 227 Anetumab Corixetan, Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439, Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497, Threonine Tyrosine Kinase Inhibitor CFI-402257, Thymidylate Synthase Inhibitor CX1106, Thymidylate Synthase Inhibitor DFP-11207, Thymopentin, Thyroid Extract, Tiazofurin, Tidutamab, Tigapotide, Tigatuzumab, TIGIT Inhibitor M6223, TIGIT-targeting Agent MK-7684, Tilarginine, Tilogotamab, Tilsotolimod Sodium, Timonacic, Tin Ethyl Etiopurpurin, Tinostamustine, Tinzaparin Sodium, Tiomolibdate Choline, Tiomolibdate Diammonium, Tipapkinogene Sovacivec, Tipifarnib, Tipiracil, Tipiracil Hydrochloride, Tirabrutinib, Tiragolumab, Tirapazamine, Tirbanibulin, Tisagenlecleucel, Tislelizumab, Tisotumab Vedotin, Tivantinib, Tivozanib, TLC ELL-12, TLR Agonist BDB001, TLR Agonist BSG-001, TLR Agonist CADI-05, TLR-Directed Cationic Lipid-DNA Complex JVRS-100, TLR7 Agonist 852A, TLR7 agonist BNT411, TLR7 Agonist LHC165, TLR7/8/9 Antagonist IMO-8400, TLR8 Agonist DN1508052, TLR9 Agonist AST-008, TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells, Tocilizumab, Tocladesine, Tocotrienol, Tocotrienol-rich Fraction, Tolebrutinib, Toll-like Receptor 7 Agonist DSP-0509, Tolnidamine, Tomaralimab, Tomato-Soy Juice, Tomivosertib, Topical Betulinic Acid, Topical Celecoxib, Topical Fluorouracil, Topical Gemcitabine Hydrochloride, Topical Potassium Dobesilate, Topical Trichloroacetic Acid, Topixantrone, Topoisomerase I Inhibitor Genz-644282, Topoisomerase I Inhibitor LMP400, Topoisomerase I Inhibitor LMP776, Topoisomerase I/II Inhibitor NEV-801, Topoisomerase-1 Inhibitor LMP744, Topoisomerase-II Inhibitor Racemic XK469, Topoisomerase-II-beta Inhibitor Racemic XK469, Topotecan, Topotecan Hydrochloride, Topotecan Hydrochloride Liposomes, Topotecan Sustained-release Episcleral Plaque, Topsalysin, TORC1/2 Kinase Inhibitor DS-3078a, Toremifene, Toremifene Citrate, Toripalimab, Tosedostat, Tositumomab, Total Androgen Blockade, Tovetumab, Tozasertib Lactate, TP40 Immunotoxin, Trabectedin, Trabedersen, TRAIL Receptor Agonist ABBV-621, Trametinib, Trametinib Dimethyl Sulfoxide, Trans Sodium Crocetinate, Transdermal 17beta-Estradiol Gel BHR-200, Transdermal 4-Hydroxytestosterone, Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01, Transferrin Receptor-Targeted Liposomal p53 cDNA, Transferrin-CRM107, Tranylcypromine Sulfate, Trapoxin, Trastuzumab, Trastuzumab Conjugate BI-CON-02, Trastuzumab Deruxtecan, Trastuzumab Duocarmazine, Trastuzumab Emtansine, Trastuzumab Monomethyl Auristatin F, Trastuzumab-TLR 7/8 Agonist BDC-1001, Trastuzumab/Hyaluronidase-oysk, Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502, Trebananib, Tremelimumab, Treosulfan, Tretazicar, Tretinoin, Tretinoin Liposome, Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triapine, Triazene Derivative CB10-277, Triazene Derivative TriN2755, Triazinate, Triaziquone, Tributyrin, Triciribine Phosphate, Trientine Hydrochloride, Triethylenemelamine, Trifluridine, Trifluridine and Tipiracil Hydrochloride, Trigriluzole, Trilaciclib, Trimelamol, Trimeric GITRL-Fc OMP-336B11, Trimethylcolchicinic Acid, Trimetrexate, Trimetrexate Glucuronate, Trioxifene, Triplatin Tetranitrate, Triptolide Analog, Triptorelin, Triptorelin Pamoate, Tris-acryl Gelatin Microspheres, Tritylcysteine, TRK Inhibitor AZD6918, TRK Inhibitor TQB3558, TrkA Inhibitor VMD-928, Trodusquemine, Trofosfamide, Troglitazone, Tropomyosin Receptor Kinase Inhibitor AZD7451, Troriluzole, Troxacitabine, Troxacitabine Nucleotide Prodrug MIV-818, TRPM8 Agonist D-3263, TRPV6 Calcium Channel Inhibitor SOR-C13, TSP-1 Mimetic ABT-510, TSP-1 Mimetic Fusion Protein CVX-045, Tubercidin, Tubulin Binding Agent TTI-237, Tubulin Inhibitor ALB 109564 Dihydrochloride, Tubulin Inhibitor ALB-109564, Tubulin Polymerization Inhibitor AEZS 112, Tubulin Polymerization Inhibitor CKD-516, Tubulin Polymerization Inhibitor VERU-111, Tubulin-Binding Agent SSR97225, Tucatinib, Tucidinostat, Tucotuzumab Celmoleukin, Tyroserleutide, Tyrosinase Peptide, Tyrosinase-KLH, Tyrosinase:146-156 Peptide, Tyrosine Kinase Inhibitor, Tyrosine Kinase Inhibitor OSI-930, Tyrosine Kinase Inhibitor SU5402, Tyrosine Kinase Inhibitor TL-895, Tyrosine Kinase Inhibitor XL228, UAE Inhibitor TAK-243, Ubenimex, Ubidecarenone Nanodispersion BPM31510n, Ublituximab, Ulinastatin, Ulixertinib, Ulocuplumab, Umbralisib, Uncaria tomentosa Extract, Upamostat, Upifitamab, Uproleselan, Uprosertib, Urabrelimab, Uracil Ointment, Urelumab, Uroacitides, Urokinase-Derived Peptide A6, Ursolic Acid, USP14/UCHL5 Inhibitor VLX1570, Utomilumab, Uzansertib, V930 Vaccine, Vaccine-Sensitized Draining Lymph Node Cells, Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules, Vactosertib, Vadacabtagene Leraleucel, Vadastuximab Talirine, Vadimezan, Valecobulin, Valemetostat, Valproic Acid, Valrubicin, Valspodar, Vandetanib, Vandetanib-eluting Radiopaque Bead BTG-002814, Vandortuzumab Vedotin, Vantictumab, Vanucizumab, Vapreotide, Varlilumab, Varlitinib, Varlitinib Tosylate, Vascular Disrupting Agent BNC105, Vascular Disrupting Agent BNC105P, Vascular Disrupting Agent ZD6126, Vatalanib, Vatalanib Succinate, Vecabrutinib, Vector-peptide Conjugated Paclitaxel, Vedolizumab, VEGF Inhibitor PTC299, VEGF/HGF-targeting DARPin MP0250, VEGFR Inhibitor KRN951, VEGFR-2 DNA Vaccine VXM01, VEGFR/FGFR Inhibitor ODM-203, VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593, VEGFR2 Tyrosine Kinase Inhibitor PF-00337210, VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813, Veliparib, Veltuzumab, Vemurafenib, Venetoclax, Verapamil, Verpasep Caltespen, Verubulin, Verubulin Hydrochloride, Vesencumab, Vesigenurtucel-L, VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220, VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820, Viagenpumatucel-L, Vibecotamab, Vibostolimab, Vilaprisan, Vinblastine, Vinblastine Sulfate, Vincristine, Vincristine Liposomal, Vincristine Sulfate, Vincristine Sulfate Liposome, Vindesine, Vinepidine, Vinflunine, Vinflunine Ditartrate, Vinfosiltine, Vinorelbine, Vinorelbine Tartrate, Vinorelbine Tartrate Emulsion, Vinorelbine Tartrate Oral, Vintafolide, Vinzolidine, Vinzolidine Sulfate, Virulizin, Vismodegib, Vistusertib, Vitamin D3 Analogue ILX23-7553, Vitamin E Compound, Vitespen, VLP-encapsulated TLR9 Agonist CMP-001, Vocimagene Amiretrorepvec, Vofatamab, Volasertib, Volociximab, Vonlerolizumab, Vopratelimab, Vorasidenib, Vorinostat, Vorolanib, Vorsetzumab Mafodotin, Vosaroxin, Vosilasarm, Voxtalisib, Vulinacimab, Warfarin Sodium, Wee1 Inhibitor ZN-c3, Wee1 Kinase Inhibitor Debio 0123, White Carrot, Wnt Signaling Inhibitor SM04755, Wnt Signaling Pathway Inhibitor SM08502, Wnt-5a Mimic Hexapeptide Foxy-5, Wobe-Mugos E, WT1 Peptide Vaccine OCV-501, WT1 Peptide Vaccine WT2725, WT1 Protein-derived Peptide Vaccine DSP-7888, WT1-A10/AS01B Immunotherapeutic GSK2130579A, WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401, Xanthohumol, XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410, Xeloda, Xentuzumab, Xevinapant, Xiaoai Jiedu Decoction, XIAP Antisense Oligonucleotide AEG35156, XIAP/cIAP1 Antagonist ASTX660, Xiliertinib, Xisomab 3G3, XPO1 Inhibitor SL-801, Y 90 Monoclonal Antibody CC49, Y 90 Monoclonal Antibody HMFG1, Y 90 Monoclonal Antibody Lym-1, Y 90 Monoclonal Antibody m170, Y 90 Monoclonal Antibody M195, Yang Yin Fu Zheng, Yangzheng Xiaoji Extract, Yiqi-yangyin-jiedu Herbal Decoction, Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8, Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101, Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66, Yttrium Y 90 Basiliximab, Yttrium Y 90 Colloid, Yttrium Y 90 Daclizumab, Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A, Yttrium Y 90 Glass Microspheres, Yttrium Y 90 Monoclonal Antibody B3, Yttrium Y 90 Monoclonal Antibody BrE-3, Yttrium Y 90 Monoclonal Antibody Hu3S193, Yttrium Y 90 Monoclonal Antibody MN-14, Yttrium Y 90 Resin Microspheres, Yttrium Y 90 Tabituximab Barzuxetan, Yttrium Y 90-DOTA-Biotin, Yttrium Y 90-DOTA-di-HSG Peptide IMP-288, Yttrium Y 90-Edotreotide, Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101, Yttrium Y-90 Clivatuzumab Tetraxetan, Yttrium Y-90 Epratuzumab Tetraxetan, Yttrium Y-90 Ibritumomab Tiuxetan, Yttrium Y-90 Tacatuzumab Tetraxetan, Yttrium-90 Polycarbonate Brachytherapy Plaque, Z-Endoxifen Hydrochloride, Zalcitabine, Zalifrelimab, Zalutumumab, Zandelisib, Zanidatamab, Zanolimumab, Zanubrutinib, Zebularine, Zelavespib, Zibotentan, Zinc Finger Nuclease ZFN-603, Zinc Finger Nuclease ZFN-758, Zinostatin, Zinostatin Stimalamer, Zirconium Zr 89 Panitumumab, Ziv-Aflibercept, Zolbetuximab, Zoledronic Acid, Zoptarelin Doxorubicin, Zorifertinib, Zorubicin, Zorubicin Hydrochloride, Zotatifin, Zotiraciclib Citrate, Zuclomiphene Citrate, Unknown, Not Reported",,,CDE:13579886,,string_list,,,,,, Model Primary Diagnosis,"Text term used to describe the histologic diagnosis relevant to the model system, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).","Head and Neck Squamous Cell Carcinoma, Astroblastoma; Other; Other CNS Tumor; NOS Or NEC, Medulloblastoma; Hypercellular Lesion With Marked Atypia, Ependymoma; NOS; Posterior Fossa Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Neuroma; NOS, Precursor Cell Lymphoblastic Leukemia; NOS, Hypercellular Neuroepithelial Tumor With Some Features Of Glioma; Possibly High Grade, Acute Leukemia; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Papillary Glioneuronal Tumor, High-grade serous carcinoma, Myeloid Leukemia; NOS, Choriocarcinoma; NOS, Embryonal Carcinoma; NOS; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Giant Cell Tumor Of Bone; NOS, Adenocarcinoma; Intestinal Type, Not Specified In Data, Neoplasm; Uncertain Whether Benign Or Malignant; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ductal Carcinoma NOS, Renal Cell Carcinoma; NOS, B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Myelodysplastic Syndrome; NOS, Low Grade Fibromyxoid Sarcoma, Benign Cystic Nephroma, Glial Neoplasm, Papillary Adenocarcinoma; NOS, Telangiectatic Osteosarcoma, Ganglioglioma; NOS; Malignant Peripheral Nerve Sheath Tumor; NOS, Central Neurocytoma, Giant Cell Tumor Of Soft Parts; NOS, Giant Cell Tumor Of Bone; Malignant, Sertoli-Leydig Cell Tumor; Poorly Differentiated, Glioma; Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Acute Megakaryoblastic Leukemia, Germinoma; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia; WHO Grade 1, Supratentorial Ependymoma; NOS, Myxoid Liposarcoma, Acute Lymphoblastic Leukemia, Combined Small Cell-Squamous Cell Carcinoma, High Grade Spindle Cell Sarcoma, Medulloblastoma; Group 3 Subtype (WHO Grade 4), Acute Monocytic Leukemia, Neoplasm; NOS, Retinoblastoma; Grade 3, Yolk Sac Tumor; NOS; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Myofibroblastic Tumor; NOS, Sex Cord-Gonadal Stromal Tumor; Mixed Forms, Adamantinomatous Craniopharyngioma, Mesoblastic Nephroma, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Astrocytoma; NOS; High-Grade Glioma; Infant-Type Hemispheric Glioma, Rhabdomyosarcoma; NOS, Mucinous Adenocarcinoma; Endocervical Type, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ganglioglioma; NOS; Glioneuronal And Neuronal Tumors, Dermoid Cyst, Adenocarcinoma Combined With Other Types Of Carcinoma, Precursor Cell Lymphoblastic Lymphoma; NOS, Posterior Fossa Ependymoma; CNS WHO Grade 2, Pituitary Adenoma; NOS, Neoplasm; Malignant; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Sex Cord-Gonadal Stromal Tumor; Incompletely Differentiated, High Grade Follicular Derived Thyroid Carcinoma, Desmoplastic Fibroma, Perineuroma, Diffuse Midline Glioma; H3K27M-Mutant; CNS WHO Grade 4, Ganglioglioma, Pancreatobiliary-Type Carcinoma, Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia, Hemangioblastoma, Colorectal Carcinoma, Acute Myelomonocytic Leukemia, Diffuse Midline Glioma; H3 K27-Altered, T-Lymphoblastic Lymphoma, Lymphangioma; NOS, Neoplasm; Benign, Papillary Intralymphatic Angioendothelioma, Ependymoma; NOS; Supratentorial Ependymoma; ZFTA Fusion-Positive, Unclassified Sarcoma With Round Cell Morphology, Glioma, Medulloblastoma; Classic (Biphasic) Histologic Type; Non-SHH/Non-WNT Molecular Group; CNS WHO Grade 4, Soft Tissue Sarcoma, Xanthogranuloma, Neoplasm; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Bronchio-Alveolar Carcinoma; Mucinous, Hepatocellular Carcinoma; Fibrolamellar, Pancreatic Neuroendocrine Tumor; Nonfunctioning, Myxopapillary Ependymoma, Chondrosarcoma; NOS, Favor Ganglioglioma, Papillary Tumor Of Pineal Region, Acute Myeloid Leukemia With Mutated NPM1, Epithelioid Hemangioendothelioma; NOS, Neuroblastoma; NOS, Chondroid Chordoma, Infiltrating Duct And Lobular Carcinoma, Mitotically Active Glial/ Glioneuronal Neoplasm, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, CPNET, Mycosis Fungoides; Langerhans Cell Histiocytosis; NOS, T-Lymphoblastic Leukemia, Medulloblastoma; NOS; Medulloblastoma; Non-WNT/Non-SHH, Clear Cell Meningioma; Meningioma; Other, Ameloblastic Carcinosarcoma, Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Meningothelial Meningioma, Epithelioid Cell Melanoma, Prostate Cancer, Paraganglioma; Malignant, Small Cell Sarcoma, Cystosarcoma Phyllodes; NOS, Seminoma; NOS, Yolk Sac Tumor; NOS, Intraductal Carcinoma NOS, Adenocarcinoma; Endocervical Type, Neurofibroma; NOS, Astroblastoma; Astroblastoma; MN1-Altered; High-Grade Glioma, Meningothelial Meningioma; Grade 1, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Unknown, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Sarcoma; Ewing Sarcoma, Glioma; Malignant; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Endometrioid Adenocarcinoma; NOS, Pancreas-Adenocarcinoma Ductal Type, Giant Cell Glioblastoma; Glioblastoma; IDH-Wildtype; High-Grade Glioma, Angiomyosarcoma, Carcinoid Tumor, Adenosquamous Carcinoma, Metastatic Neuroblastoma, Clear Cell Sarcoma Of Kidney, Infiltrating Duct Mixed With Other Types Of Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Embryonal Carcinoma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Germ Cell Tumors; CNS Germinoma, Astrocytoma; NOS; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Low Cumulative Sun Damage Melanoma, Supratentorial Ependymoma, Ossifying Fibromyxoid Tumor; NOS, Diffuse Large B-Cell Lymphoma; NOS, Adenocarcinoma With Neuroendocrine Differentiation, Atypical Meningioma, Pineoblastoma, Chronic Myeloid Leukemia; NOS, Atypical Choroid Plexus Papilloma, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFB, Pleomorphic Xanthoastrocytoma; NOS; High-Grade Glioma, Oxyphilic Adenocarcinoma, Favor Pilocytic Astrocytoma; CNS WHO Grade 1, Poorly Differentiated; Intermediate Mitotic-Karyorrhectic Index, Clear Cell Meningioma, Medulloblastoma; Classic Histologic Type; CNS WHO Grade 4, Appearances Consistent With Alveolar Soft Part Sarcoma, Dedifferentiated Liposarcoma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Tubular Adenocarcinoma, Rhabdomyosarcoma; Most Likely An Embryonal Carcinoma, Adenocarcinoma; NOS, Pleuropulmonary Blastoma, Basaloid Squamous Cell Carcinoma, Oligodendroglioma; Anaplastic; NOS, Pilocytic Astrocytoma; WHO Grade 1, Not Applicable, Abdominal Fibromatosis, Hamartoma, Neoplasm; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Choroid Plexus Papilloma; NOS; Choroid Plexus Tumors, Burkitt Lymphoma; NOS, Lymphoepithelial Carcinoma, Bronchiolo-Alveolar Carcinoma; Non-Mucinous, Kidney Clear Cell Renal Carcinoma, Pilocytic Astrocytoma; Low-Grade Glioma, Adenocarcinoma In Situ In Adenomatous Polyp, Neoplasm; Uncertain Whether Benign Or Malignant, Small Blue Cell Tumor. Favor Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma; NOS, Embryonal Tumor With Multi-Layered Rosettes, Chronic Eosinophilic Leukemia, Mixed Glioma, Basal Cell Adenocarcinoma, Olfactory Neuroblastoma, Transitional Cell Carcinoma; NOS, Clear Cell Sarcoma; NOS, Embryonal Rhabdomyosarcoma; High-Grade, Angiocentric Glioma, Diffuse Midline Glioma; H3 K27 Altered; WHO Grade 4, Osteoblastoma; NOS, Malignant Neoplasm With Rhabdomyoblastic Differentiation; High Grade, Myxopapillary Ependymoma (CNS WHO Grade II), Melanoma In Situ, Secretory Carcinoma, Pilocytic Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Rhabdomyosarcoma; Favor Alveolar Type, Adenocarcinoma; Metastatic NOS, Fibrosarcoma; NOS, Glioblastoma, Atypical Choroid Plexus Papilloma; Choroid Plexus Tumors, Ganglioneuroma; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Desmoplastic Melanoma; NOS, Choroid Plexus Carcinoma, Soft Tissue Tumor; Benign, Medulloblastoma; NOS, Glioblastoma; NOS; Medulloblastoma; NOS, Residual Astrocytoma, B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged, Extra Adrenal Paraganglioma, Mucoepidermoid Carcinoma, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Choroid Plexus Papilloma; NOS, Glioma; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, B-Lymphoblastic Leukemia/Lymphoma; NOS, Hodgkin Lymphoma; Nodular Sclerosis; NOS, Fibroma, Craniopharyngioma; NOS; Adamantinomatous Craniopharyngioma, T-Cell/Histiocyte Rich Large B-Cell Lymphoma, Astrocytoma; IDH-Mutant; CNS WHO Grade 4, Acute Erythroid Leukemia, Glioma; Histologically Low Grade, Mucous Adenocarcinoma, Glioma; Malignant; Ganglioglioma; Glioneuronal And Neuronal Tumors, Nodular Melanoma, Synovial Sarcoma; Biphasic, Neoplasm; Metastatic, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Thymoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Posterior Fossa Ependymoma; Group PFA, Desmoplastic/Nodular Medulloblastoma, Papillary Glioneuronal Tumor, Mixed Phenotype Acute Leukemia; T/Myeloid; NOS, Cholangiocarcinoma, Astroblastoma; MN1-Altered. Histologically High-Grade, Sertoli-Leydig Cell Tumor; Poorly Differentiated; With Heterologous Elements, Glioma; Malignant; High-Grade Glioma; Infant-Type Hemispheric Glioma, Juvenile Myelomonocytic Leukemia; NOS, Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry, Myeloid Leukemia With Myelodysplasia-Related Changes, Primary Cutaneous Follicle Center Lymphoma, Choroid Plexus Carcinoma; WHO Grade 3, Infiltrating Duct Carcinoma NOS, T Lymphoblastic Leukemia/Lymphoma, Glioma; Malignant; Other; Other CNS Tumor; NOS Or NEC, Mixed Germ Cell Tumor; Myelodysplastic Syndrome With Excess Blasts, Clear Cell Adenocarcinoma; NOS, Cutaneous T-Cell Lymphoma; NOS, Germinoma, Neoplasm; Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Meningeal Melanocytoma, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Acute Promyelocytic Leukemia; T(15;17)(Q22;Q11-12), Alveolar Soft Part Sarcoma, Astrocytoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Mixed Epithelioid And Spindle Cell Melanoma, CNS Embryonal Tumor; NOS; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Malignant Tumor; Spindle Cell Type, Glioma; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Glioma; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Endometrioid Carcinoma; NOS, Lung Squamous Cell Carcinoma; NOS, Papillary Urothelial Carcinoma; Non-Invasive, Neuroblastoma; Undifferentiated Type, Periosteal Osteosarcoma, Mixed Phenotype Acute Leukemia; B/Myeloid; NOS, Inflammatory Carcinoma, Glioblastoma; NOS, Carcinoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Squamous Cell Carcinoma; NOS, Hypocellular Low Grade Lesion, Glioblastoma Multiforme, Pancreas-Undifferentiated Carcinoma, Differentiating Neuroblastoma, Myxoid Spindle Cell Tumor, Merkel Cell Tumor, Malignant Peripheral Nerve Sheath Tumor; NOS; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Hemangioma; NOS, Acute Myeloid Leukemia With Abnormal Marrow Eosinophils, Well Differentiated Neuroendocrince Tumor; Grade 1, Ganglioglioma; Anaplastic, Ependymoma WHO Grade 2, Synovial Sarcoma; NOS, Thymic Carcinoma; NOS, Tumor Cells; Malignant, Pilomyxoid Astrocytoma, Papillary Carcinoma; Columnar Cell, Plexiform Fibrohistiocytic Tumor, Astrocytoma; NOS; Angiocentric Glioma; Low-Grade Glioma, Carcinoma; Undifferentiated; NOS, Dermatofibrosarcoma Protuberans; NOS, High Grade Glioma With Necrosis; WHO Grade 4, Infiltrating ductular carcinoma, Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Juvenile Myelomonocytic Leukemia; NOS, Infiltrating Duct And Mucinous Carcinoma, Intraductal Papillary Carcinoma, Serous Surface Papillary Carcinoma, Invasive Carcinoma, High Grade Malignant Epithelioid Neoplasm, Favor Pilocytic Astrocytoma With Increased Proliferation Indices, Medulloblastoma; Classic Morphology; CNS WHO Grade 4; NON-WNT/NON-SHH; Group 4 Subtype By Methylation, Composite Hodgkin And Non-Hodgkin Lymphoma, Atypical Teratoid/Rhabdoid Tumor; ATRT; NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor; ATRT-TYR, Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder, Hemangioendothelioma; NOS, Hypercellular Lesion With Atypia, Embryonal Carcinoma; NOS, Subependymoma; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Germ Cell Tumor; Nonseminomatous, Adrenal Cortical Carcinoma, Olfactory Neurocytoma, Large Cell Medulloblastoma; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Nuclear Protein In Testis (NUT)-Associated Carcinoma, Epithelial-Myoepithelial Carcinoma, Squamous Cell Carcinoma; Keratinizing; NOS, Ganglioneuroma; Other; Schwannoma, Glomus Tumor; Malignant, Neoplasm; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Malignant Lymphoma; Non-Hodgkin; NOS, Embryonal Rhabdomyosarcoma; NOS; CNS Embryonal Tumor; NOS, Tenosynovial Giant Cell Tumor; NOS, Histologically Low-Grade Glioma, Chordoma; NOS; Ganglioneuroblastoma, Ependymoma; NOS, Invasive Mammary Carcinoma, Rhabdoid Tumor; Malignant, Medulloblastoma; Classic Histology, Adenocarcinoma In Villous Adenoma, Undifferentiated Sarcoma, Papillary Thyroid Carcinoma, Renal Cell Adenocarcinoma, Hodgkin Lymphoma; NOS, Malignant Histiocytosis, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Solid Pseudopapillary Tumor Of Ovary, Astrocytic Glioma; Histologically Low-Grade; Most Compatible With Pilocytic Astrocytoma, Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst, Myofibromatosis, Small Round Blue Cell Tumor, Meningioma; Atypical; CNS WHO Grade 2, Neoplasm; Uncertain Whether Benign Or Malignant; Adamantinomatous Craniopharyngioma; Craniopharyngioma, Pilocytic Astrocytoma, Lobular And Ductal Carcinoma, Desmoplastic/Nodular Medulloblastoma (Histologically Defined); CNS WHO Grade 4, Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation, Tumor Cells; Malignant; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Malignant Tumor, Brain Tumor, Gastrointestinal Stromal Tumor; Benign, Rasmussen Encephalitis, Medulloblastoma; NOS; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Adenocarcinoma;NOS; Glioblastoma; NOS, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Embryonal Sarcoma, Neoplasm; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Anaplastic Large Cell Lymphoma; T-Cell And Null-Cell Type, Teratoma; NOS, Pleomorphic Xanthoastrocytoma; NOS, Infiltrating duct and lobular carcinoma, Sclerosing Stromal Tumor, Tumor Cells; Uncertain Whether Benign Or Malignant, Acute Myeloid Leukemia; NOS; Juvenile Myelomonocytic Leukemia; NOS, Lobular Carcinoma; NOS, Schwannoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Sarcoma; NOS, CNS Embryonal Tumor With Rhabdoid Features, Glial Neoplasm; Astrocytoma, Pancreas-Adenosquamous Carcinoma, Mesenchymal Lesion, Serous Adenocarcinoma; NOS, Hepatoblastoma; NOS, Astrocytoma; NOS; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Sex Cord-Gonadal Stromal Tumor; NOS, Adenoid Cystic Carcinoma, Embryonal Tumor, Acute Myeloid Leukemia; T(8;21)(Q22;Q22), Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor, Cavernoma, Malignant Tumor; Small Cell Type, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Germinoma, Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma., Neoplasm; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Serous Carcinoma; NOS, Metastatic Secondary Tumors, Yolk Sac Tumor, Morphologically Consistent With Pilocytic Astrocytoma; WHO Grade 1, Neuroendocrine Tumor; NOS, Mixed Germ Cell Tumor; Acute Megakaryoblastic Leukemia, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL, Glioma; Malignant; High-Grade Glioma; Pleomorphic Xanthoastrocytoma, Papillary Glioneuronal Tumor; WHO Grade 1, Central Neuroblastoma, Dysembryoplastic Neuroepithelial Tumor, Mixed Adenocarcinoma And Squamous Cell Carcinoma; Pancreatobiliary-Type Carcinoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Myofibroblastic Tumor, Nephroblastoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Malignant Melanoma; NOS; Meningeal Melanocytic Neoplasms (Includes Melanoma); Other, Carcinoma; Metastatic; NOS, Follicular Carcinoma; Minimally Invasive, Angiomyofibroblastoma, Classic Medulloblastoma; CNS WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Atypical Teratoid/Rhabdoid Tumor; ATRT-MYC, Astroblastoma, Meningothelial Meningioma; Meningioma; Other, Poorly Differentiated Chordoma, Chronic Myelogenous Leukemia, Pleomorphic Sarcoma, Supratentorial Ependymoma CNS WHO Grade 3, Leydig Cell Tumor; NOS, Adenosarcoma, Pigmented Dermatofibrosarcoma Protuberans, Astrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Astrocytoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Astrocytoma; NOS; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Myxofibrosarcoma, Precursor T-Cell Lymphoblastic Leukemia, Neurocytoma, Adrenal Cortical Tumor; NOS, Neoplasm; Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1, Neoplasm; Malignant; CNS Neuroblastoma; FOXR2-Activated; Other CNS Embryonal Tumors, Infiltrating duct and mucinous carcinoma, Adenocarcinoma In Situ; NOS, Mucinous Adenocarcinoma, Retinoblastoma; NOS, Anaplastic Ependymoma, Germ Cell Tumor; Nonseminomatous; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Acute Monoblastic And Monocytic Leukemia, Hemangioblastoma; CNS WHO Grade 1, Alveolar Rhabdomyosarcoma, Medullary Carcinoma; NOS, Adult Granulosa Cell Tumor Of Testis, Medulloblastoma; WHO Grade 4, Craniopharyngioma; Adamantinomatous, High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor), Spindle Cell Rhabdomyosaroma, Diffuse Midline Glioma; H3 K27M-Mutant, Epithelioid Sarcoma; NOS, Myoepithelial Carcinoma, Multiple Myeloma, Triple-Negative Breast Carcinoma, Hepatocellular Carcinoma; NOS; Nephroblastoma; NOS, Neuroblastoma; Schwannian Stroma Poor; Poorly Differentiated; Low MKI; Favorable Histology, Sertoli Cell Tumor; NOS, Ossifying Fibroma, Pleomorphic Liposarcoma, Amelanotic Melanoma, Liposarcoma; NOS, Non-Germinomatous Germ Cell Tumor, Lactotroph Adenoma, Transient Abnormal Myelopoiesis, Favor Posterior Fossa Ependymoma; WHO GRADE 3, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Carcinoma In Situ; NOS, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ependymoma; Anaplastic, Glial Neoplasm; Favor Pilocytic Astrocytoma, Gastrointestinal Stromal Tumor; NOS, Serous Cystadenocarcinoma; NOS, Papillary Lesion With Atypical/High Grade Features, Spinal Ependymoma; WHO Grade 2, Ductal Carcinoma In Situ; NOS, Infiltrating Ductal Carcinoma, Mixed Type Rhabdomyosarcoma, Medulloblastoma; SHH-Activated And TP53-Mutant, Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy, Mesenchymal Chondrosarcoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Cribriform Carcinoma; NOS, Myxopapillary Ependymoma; Anaplastic, Ependymoma; Anaplastic; Supratentorial Ependymoma; NOS Or NEC, Astrocytoma; IDH-Mutant; WHO Grade 2, Meningioangiomatosis, Acute Myeloid Leukemia; NOS; Myeloproliferative Neoplasm; Unclassifiable, Endometrioid carcinoma; NOS, Adenocarcinoma In Situ; Non-Mucinous, Medulloblastoma; NOS; Medulloblastoma; Group 4, Papillary Carcinoma; Follicular Variant, Metaplastic Carcinoma; NOS, Choroid Plexus Carcinoma; Choroid Plexus Tumors, Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation, Low Grade Glioma, Sex Cord Stromal Tumor NOS, Stroma Poor; Poorly Differentiated Neuroblastoma With Low MKI; Favorable Histology, Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid), Melanotic Neuroectodermal Tumor, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Angiocentric Glioma; Low-Grade Glioma, Malignant Lymphoma; NOS, Medulloblastoma WHO Grade 4, Choroid Plexus Papillary Tumor, Follicular Adenocarcinoma; Well Differentiated; Neuroblastoma; NOS, Neuroepithelial Tumor, Myelodysplastic Syndrome With Multilineage Dysplasia, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Mast Cell Leukemia, Ganglioneuroblastoma, Pheochromocytoma; NOS, Papillary Serous Adenocarcinoma, Mixed Germ Cell Tumor, Lymphoid Leukemia; NOS, Ependymoma NOS, Smooth Muscle Tumor Of Uncertain Malignant Potential, Combined Small Cell-Large Carcinoma, Sertoli Leydig Cell Tumor, Anaplastic Large Cell Lymphoma; ALK Positive, Meningioma; Malignant, Rhabdoid Tumor; NOS, Merkel Cell Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Meningioma; Other, Lymphoma; NOS, Gangliocytoma; NOS, Glioblastoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Mucinous Non-Cystic Carcinoma, Mucinous Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Pilocytic Astrocytoma, Ganglioglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, High Grade Carcinosarcoma, Subependymal Giant Cell Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Squamous Cell Carcinoma; Metastatic; NOS, Myeloid Leukemia Associated With Down Syndrome, Meningeal Melanomatosis, Neuroepithelial Tumor With Glioneuronal-Like Features, Squamous Cell Carcinoma; Large Cell; Nonkeratinizing; NOS, Meningiomatosis; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Oligodendroglioma; NOS; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFA, CNS Embryonal Tumor; NOS, Favor Anaplastic Ependymoma, Diffuse Glioma, Adamantinomatous Craniopharyngioma (CNS WHO Grade 1), Medulloblastoma; Classic Variant; WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Glioneuronal Tumor With Focal Increased Atypia, High Grade Neuroepithelial Tumor, Squamous Cell Carcinoma; Small Cell; Nonkeratinizing, Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged, Acute Myeloid Leukemia; Minimal Differentiation, Fibrillary Astrocytoma, Chordoma; NOS, Undifferentiated Leukemia, Myofibroma, Neoplasm; Malignant, Pleomorphic Xanthoastrocytoma; NOS; Low-Grade Glioma, Invasive Ductal Carcinoma, Subependymal Giant Cell Astrocytoma, Embryonal Rhabdomyosarcoma With Anaplastic Features, High-Grade Neuroepithelial Tumor, Low Grade Glioneuronal Tumor, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Acute Myeloid Leukemia Without Maturation, Adenocarcinoma With Mixed Subtypes, B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy, Malignant Peripheral Nerve Sheath Tumor; NOS, Hemangiosarcoma, Paraganglioma; NOS, Medulloblastoma; Nodular/Desmoplastic With Anaplastic/Large Cell Features; Non-WNT/Non-SHH; WHO Grade 4, Signet Ring Cell Carcinoma, Spindle Cell Melanoma; NOS, Lobular Adenocarcinoma, Undiagnosed Spindle Cell Tumor, Pilocytic Astrocytoma; WHO Grade 1; KIAA1549-BRAF Fusion, Meningioma, Hepatosplenic T-Cell Lymphoma; Precursor Cell Lymphoblastic Leukemia; NOS, Mesenchymal Chondrosarcoma, Anaplastic Ganglioglioma, Osteosarcoma; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Ependymoma WHO Grade 3, Lung Adenocarcinoma; NOS, Lymphoproliferative Disorder; NOS, Atypical Lymphoid Infiltrate, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Wildtype, Genital Rhabdomyoma, Chondroblastic Osteosarcoma, Neuroepithelioma; NOS, Malignant Epithelioid And Myxoid Neoplasm, Pancreatoblastoma, Nephroblastoma (Wilms Tumor), Malignant Glioma, Ewing Sarcoma, Atypical Smooth Muscle Neoplasm, Acute Myelomonocytic Leukemia; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Epithelial Tumor; Benign, Favor Teratoma, Malignant Neoplasm Of Prostate, Non-Clear Cell Renal Cell Carcinoma, Meningioma; NOS; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Melanotic Schwannoma; Other, Medulloblastoma; NOS; Medulloblastoma; WNT-Activated, Carcinosarcoma NOS, Plasmacytoma; Extramedullary, Infantile Fibrosarcoma, Glioma; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, CNS Primative Neuroectodermal Tumor (PNET), Infiltrating duct carcinoma; NOS, Precursor B-Cell Lymphoblastic Leukemia, Squamous Cell Carcinoma In Situ; NOS, Acute Myeloid Leukemia; T(16;16)(P 13;Q 11), Papillary Transitional Cell Carcinoma, Atypical Teratoid/Rhabdoid Tumor, Low-Grade Glioneuronal; Neuronal Tumor, Combined Small Cell-Adenocarcinoma, Hepatocellular Carcinoma; NOS, Spindle Cell Carcinoma; NOS, Carcinoma; Diffuse Type, Lentiginous Melanocytic Nevus, Glioma; Malignant; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Solitary Fibrous Tumor; NOS, Glioma; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Granulosa Cell Tumor; Malignant, Ganglioneuroma; Maturing Type; Favorable Histology, Invasive Lobular Carcinoma, Ganglioglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation, Medulloblastoma, Hepatoblastoma, Low Grade Glial/ Glioneuronal Tumor, Atypical Teratoid Rhabdoid Tumor; CNS WHO Grade 4, Oligoastrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Diffuse Glioma; Favor High Grade, Reactive Connective Tissue, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Mutant, Tumor Cells; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Malignant Peripheral Nerve Sheath Tumor; NOS, Melanoma; NOS, Malignant Melanocytic Neoplasm, Chronic Myelogenous Leukemia; BCR/ABL Positive, Vascular Lesion; Consistent With Hemangioma, Small Cell Neuroendocrine Carcinoma, Medullary Carcinoma, Anaplastic Astrocytoma; IDH-Wildtype; Glioblastoma; IDH Wildtype, Rhabdomyosarcoma; Embryonal Subtype, Medulloblastoma By Morphology; NON-WNT By Immunohistochemistry, Glioma; Malignant; Astrocytoma; IDH-Mutant; High-Grade Glioma, Ganglioglioma; NOS, Dysembryoplastic Neuroepithelial Tumor; Angiocentric Glioma; Low-Grade Glioma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Angiomatoid Fibrous Histiocytoma, Micropapillary Carcinoma; NOS, Infiltrating Lobular Carcinoma; NOS, Gastrointestinal Stromal Tumor, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; Group 4, Craniopharyngioma, Sertoli-Leydig Cell Tumor; Intermediate Differentiation; With Heterologous Elements, Acute Myeloid Leukemia; Inv(16)(P13;Q22), Subependymoma, Gliomatosis Cerebri, Infiltrating lobular carcinoma; NOS, Schwannoma; NOS, Oligodendroglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dysplasia, Malignant Rhabdoid Tumor, Blue Nevus; Malignant, Adenocarcinoma; Pancreatobiliary Type, Ependymoma; NOS; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ganglioneuroblastoma; Nodular Type, Granulosa Cell Tumor; Juvenile, Juvenile Granulosa Cell Tumor, Chronic Myeloid Leukemia; BCR-ABL1-Positive, Head & Neck Squamous Cell Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Medulloblastoma; SHH-Activated And TP53-Wildtype, Ganglioglioma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma, Adrenal Cortical Adenoma; NOS, Adenocarcinoma; Pancreatobiliary Type; Pancreatobiliary-Type Carcinoma, Lipoblastomatosis, Central Neurocytoma; Glioneuronal And Neuronal Tumors, Control, HHV8 Positive Diffuse Large B-Cell Lymphoma, Pilocytic Astrocytoma; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Group 4, Large Cell Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1), Central Osteosarcoma; NOS, Chordoma, Pilocytic Astrocytoma; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Pilocytic Astrocytoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dermatofibrosarcoma Protuberans; Fibrosarcomatous, Neuroendocrine Carcinoma; NOS, Glioma; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Oligodendroglioma; NOS, Acute Monoblastic Leukemia, Glioma; Malignant; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Neoplasm, Medulloepithelioma; NOS, Oligodendroglioma; NOS; High-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Not Reported, Aggressive Fibromatosis, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Langerhans Cell Histiocytosis; Disseminated, Glioma; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Oligoastrocytoma; NOS, Undifferentiated Nasopharyngeal Carcinoma, Small Cell Carcinoma; NOS, Chordoma; NOS; Chordoma (Including Poorly Differentiated Chordoma); Other, Mesothelioma; Biphasic; Malignant; B Lymphoblastic Leukemia/Lymphoma; NOS, Central Neurocytoma; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Undifferentiated Small Round Cell Sarcoma, Rhabdomyoma; NOS, Glioblastoma; IDH Wildtype, Neoplasm; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Therapy Related Myeloid Neoplasm, Acute Myeloid Leukemia; NOS, Malignant Tumor; Spindle Cell Type; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Leydig Cell Tumor; Benign, Myelodysplastic Syndrome With Single Lineage Dysplasia, Germinoma; CNS Germ Cell Tumors; CNS Germinoma, Glial Tumor, Synovial Sarcoma; Spindle Cell, Spindle Cell Melanoma; Type B, Familial Adenomatous Polyposis, Giant Cell Glioblastoma, Teratocarcinoma, Adenoma; NOS, Acral Lentiginous Melanoma; Malignant, Carcinoma NOS, Papillary Carcinoma; NOS, Poorly Differentiated Neuroblastoma, Solid Pseudopapillary Neoplasm Of Pancreas, Nasopharyngeal Carcinoma, Adenocarcinoma In Adenomatous Polyposis Coli, Leiomyoma; NOS, Embryonal Rhabdomyosarcoma; NOS, Choroid Plexus Papilloma; NOS; Other CNS Embryonal Tumors; Pineoblastoma, Tumor Cells; Benign, Marginal Zone B-Cell Lymphoma; NOS, Tumor Cells; Malignant; Other; Pineal Parenchymal Tumor Of Intermediate Differentiation, Pinealoma, Atypical Teratoid/Rhabdoid Tumor; INI1/SMARCB1-Altered; WHO Grade 4, Metastatic Signet Ring Cell Carcinoma, Astrocytoma, Desmoplastic Infantile Astrocytoma, Malignant Sarcoma With DICER1 Mutation; Favor Primary Intracranial Sarcoma; DICER1 Mutant, B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy, Colon Adenocarcinoma, Ependymoma; NOS; Supratentorial Ependymoma; NOS Or NEC, Proliferative Dermal Lesion In Congenital Nevus, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; WNT-Activated, Arteriovenous Malformation, Glioma; Malignant, Acinar Cell Carcinoma, Spinal Ependymoma; Histologically Low Grade (CNS WHO Grade 2), Leukemia; NOS, Hemangioblastoma; Other, High-Grade Serous Carcinoma, Medulloblastoma; NOS; Medulloblastoma; Group 3, Schwannian Stroma Poor Peripheral Neuroblastic Tumor; Consistent With Neuroblastoma, Acute Myeloid Leukemia With Mutated CEBPA, Parosteal Osteosarcoma, Epithelioid Mesothelioma; Malignant, Meningioma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Choriocarcinoma Combined With Other Germ Cell Elements, Brain Tumor; Low Grade Glioma, Ganglioglioma; NOS; Diffuse Astrocytoma; MYB- Or MYBL1-Altered; Low-Grade Glioma, Embryonal Tumor With Multilayered Rosettes C19MC-Altered, Neoplasm; Malignant; Uncertain Whether Primary Or Metastatic, Desmoplastic Small Round Cell Tumor, Embryonal Rhabdomyosarcoma, Langerhans Cell Histiocytosis, Glial Neoplasm Showing High-Grade Features, Oligodendroglioma, Malignant Melanoma; NOS, Myxopapillary Ependymoma; Ependymoma, Medulloblastoma; NOS; Medulloblastoma; NOS Or NEC, Neoplasm; Malignant; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Adenocarcinoma, B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1, Hemangioendothelioma; Malignant, Choroid Plexus Neoplasm, Craniopharyngioma; Adamantinomatous; Adamantinomatous Craniopharyngioma, Pinealoblastoma, Large Cell Medulloblastoma; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Spindle Cell Sarcoma, Gliosarcoma, Central Primitive Neuroectodermal Tumor, Astrocytoma; IDH-Mutant; CNS WHO Grade 3, Astrocytoma; Benign, Pleomorphic Rhabdomyosarcoma; Adult Type, Myeloid Sarcoma, Glioma; Malignant; Other; Other Low-Grade B-Cell Lymphomas Of The CNS, Ganglioneuroma, Neoplasm; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Clear Cell Renal Cell Carcinoma, Ependymoma; NOS; Atypical Meningioma, Oligodendroglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Malignant Peripheral Nerve Sheath Tumor, Glioma; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Sertoli-Leydig Cell Tumor Of Intermediate Differentiation; NOS, Desmoplastic Nodular Medulloblastoma, Papillary Microcarcinoma, Craniopharyngioma; NOS, Low Grade Glial Neoplasm, Leiomyosarcoma; NOS, Follicular Adenocarcinoma; NOS",,True,CDE:14714127,,string,,,,,, Model Site of Origin,The text term used to describe the anatomic site of origin associated with the malignant disease model.,"Abdominal Aorta, Abdominal Esophagus, Abdominal Muscle, Abdominal Skin, Abdominal Wall, Abducens Nerve, Accessory Nerve, Acetabulum, Acromioclavicular Joint, Adipose Tissue, Adrenal Cortex, Adrenal Gland, Adrenal Medulla, Ampulla of Vater, Anal Canal, Anal Transitional Zone, Ankle Joint, Ankle Skin, Antecubital Region, Anterior Cranial Fossa, Anterior Mediastinum, Anterior Surface of the Epiglottis, Anterior Wall of the Bladder, Anterior Wall of the Nasopharynx, Antrum Pylori, Anus, Aorta, Aortocaval Lymph Node, Apex of the Tongue, Aponeurosis, Appendage of the Uterus, Appendix, Areola, Arm Skin, Artery, Articular Cartilage, Aryepiglottic Fold, Arytenoid Cartilage, Ascending Colon, Autonomic Nervous System, Axilla, Axillary Artery, Axillary Lymph Node, Axillary Tail of the Breast, Back, Bartholin Gland, Basal Ganglia, Base of the Tongue, Biceps, Biceps Femoris, Bile Canaliculus, Bile Duct, Biliary Tract, Bladder, Bladder Neck, Bladder Trigone, Blood, Blood Vessel, Body of Stomach, Body of the Pancreas, Body of the Penis, Bone, Bone Marrow, Bone of the Extremity, Brachial Lymph Node, Brachial Plexus, Brachialis, Brain, Brain Dura Mater, Brain Stem, Brain Ventricle, Branchial Cleft Remnant, Breast, Broad Ligament, Bronchial Lymph Node, Bronchiole, Bronchus, Buccal Mucosa, Buttock, C1 Vertebra, C2 Vertebra, Calcaneum, Calf, Cardiac Atrium, Cardiac Ventricle, Carina, Carotid Artery, Carotid Body, Carpal Bone, Carpal Region, Cartilage, Cauda Equina, Cecum, Celiac Artery, Celiac Lymph Node, Central Nervous System, Central Portion of the Breast, Cerebellopontine Angle, Cerebellum, Cerebral Cortex, Cerebral Hemisphere, Cerebral Meninges, Cerebral Peduncle, Cerebral White Matter, Ceruminous Gland, Cervical Esophagus, Cervical Gland, Cervical Lymph Node, Cervix Uteri, Cheek, Chest, Chest Wall, Choroid, Choroid Plexus, Choroid Plexus of the Fourth Ventricle, Choroid Plexus of the Lateral Ventricle, Choroid Plexus of the Third Ventricle, Ciliary Body, Clitoris, Coccyx, Cochlear Nerve, Colon, Commissure of the Lip, Common Bile Duct, Concha, Conjunctiva, Connective Tissue, Conus Medullaris, Coracobrachialis, Cornea, Corneoscleral Limbus, Corpus Callosum, Corpus Striatum, Corpus Uteri, Costal Cartilage, Costovertebral Joint, Cowper Gland, Cranial Nerve, Craniopharyngeal Duct, Cricoid Cartilage, Cul-de-sac, Cuneiform Cartilage, Cystic Duct, Descending Colon, Diaphragm, Diaphragmatic Lymph Node, Dome of the Bladder, Duct of Gartner, Ductus Santorini, Duodenum, Dura Mater, Ear, Ear Skin, Ectocervix, Elbow Joint, Elbow Skin, Endocardium, Endocervix, Endocrine Gland, Endometrial Stroma, Endometrium, Ependyma, Epicardium, Epididymis, Epidural Spinal Canal Space, Epiglottis, Epitrochlear Lymph Node, Esophagus, Ethmoid Bone, Ethmoid Sinus, Eustachian Tube, External Acoustic Meatus, External Ear, External Lip, External Lower Lip, External Nose, External Upper Lip, Extrahepatic Bile Duct, Eye, Eyebrow, Eyelid, Facial Bone, Facial Nerve, Fallopian Tube, False Vocal Cord, Falx Cerebelli, Falx Cerebri, Fascia, Female Genitalia, Femoral Artery, Femoral Lymph Node, Femoral Nerve, Femur, Fibrous Tissue, Fibula, Finger, Fingernail, Flank, Floor of Mouth, Foot, Foot Bone, Foot Phalanx, Foot Skin, Forearm, Forehead, Fourth Ventricle, Frontal Bone, Frontal Lobe, Frontal Pole, Frontal Sinus, Fundus of the Stomach, Fundus Uteri, Gallbladder, Gastric Cardia, Gastric Lymph Node, Gastrocnemius Muscle, Gastroesophageal Junction, Gastrointestinal Tract, Gingiva, Gland of Littre, Glans Penis, Globus Pallidus, Glossopharyngeal Nerve, Glottis, Gluteus Maximus, Greater Curvature of the Stomach, Hand, Hand Digit 1, Hand Phalanx, Hand Skin, Hard Palate, Head and Neck Lymph Node, Head of the Pancreas, Head Skin, Heart, Helix, Hematopoietic System, Hepatic, Hepatic Duct, Hepatic Flexure, Hepatic Lymph Node, Hip, Hip Joint, Hippocampus, Humerus, Hymen, Hyoid Bone, Hypoglossal Nerve, Hypopharynx, Hypothalamus, Ileocecal Valve, Ileum, Iliac Artery, Iliac Lymph Node, Iliac Vein, Iliopsoas Muscle, Ilium, Inferior Vena Cava, Infraclavicular Lymph Node, Infraclavicular Region, Infratentorial Brain, Inguinal Lymph Node, Inguinal Region, Inner Canthus, Inner Ear, Intercostal Lymph Node, Intercostal Muscle, Intercostal Nerve, Internal Capsule, Internal Iliac Lymph Node, Internal Mammary Artery, Internal Mammary Lymph Node, Internal Nare, Intervertebral Disc, Intestine, Intra-Abdominal Lymph Node, Intrahepatic Bile Duct, Intraocular Route of Administration, Intrathoracic Lymph Node, Iris, Ischiorectal Fossa, Ischium, Islet of Langerhans, Isthmus Uteri, Jaw Bone, Jaw Joint, Jejunum, Joint, Kidney, Knee Joint, Knee Skin, Labium, Labium Majus, Labium Minus, Lacrimal Gland, Lacrimal Sac, Large Intestine, Laryngeal Cartilage, Larynx, Lateral Ventricle, Lateral Wall of the Bladder, Lateral Wall of the Nasopharynx, Lateral Wall of the Oropharynx, Lateral Wall of the Pharynx, Leg Skin, Lens, Lesser Curvature of the Stomach, Ligament, Lingual Tonsil, Lingula of the Lung, Lip, Liver, Lobule of the Auricle, Lower Extremity, Lower Gingiva, Lower Lobe of the Lung, Lower Third of the Esophagus, Lower-Inner Quadrant of the Breast, Lower-Outer Quadrant of the Breast, Lumbar Nerve, Lumbosacral Plexus, Lung, Lymph Node, Lymph Node of Inguinal Region or Leg, Lymphatic, Main Bronchus, Male Genitalia, Male Prepuce, Mammary Gland, Mandible, Masseter Muscle, Maxilla, Maxillary Sinus, Meckel Diverticulum, Median Nerve, Mediastinal Lymph Node, Mediastinum, Medulla Oblongata, Meibomian Gland, Meninges, Meniscus Lateralis, Meniscus Medialis, Mentum, Mesencephalon, Mesenteric Artery, Mesenteric Lymph Node, Mesentery, Mesonephric Duct, Mesonephros, Mesovarium, Metacarpal Bone, Metatarsal Bone, Middle Cranial Fossa, Middle Ear, Middle Lobe of the Right Lung, Middle Third of the Esophagus, Minor Salivary Gland, Mons Pubis, Mucosa of the Lip, Mucosa of the Lower Lip, Mucosa of the Upper Lip, Muscle, Musculus Latissimus Dorsi, Myocardium, Myometrium, Nasal Bone, Nasal Cartilage, Nasal Cavity, Nasal Septum, Nasal Turbinate, Nasolacrimal Duct, Nasopharynx, Neck Skin, Nerve, Nervous System, Nipple, Nose, Nostril, Obturator Lymph Node, Obturator Nerve, Occipital Bone, Occipital Lobe, Occipital Lymph Node, Oculomotor Muscle, Oculomotor Nerve, Olfactory Nerve, Omentum, Optic Chiasm, Optic Nerve, Optic Tract, Oral Cavity, Orbit, Oropharynx, Other Specified Parts of Pancreas, Outer Canthus, Ovary, Palate, Palatine Tonsil, Palmar Fascia, Pancreas, Pancreatic Duct, Pancreatic Lymph Node, Paraaortic Lymph Node, Paraganglion, Parametrium, Paranasal Sinus, Parasympathetic Nervous System, Parathyroid Gland, Paratracheal Lymph Node, Parietal Bone, Parietal Lobe, Parietal Pleura, Parotid Duct, Parotid Gland, Parotid Gland Lymph Node, Patella, Pectoral Lymph Node, Pectoralis Major, Pelvic Lymph Node, Pelvis, Penis, Pericardium, Perineum, Peripheral Nerve, Peritoneal Cavity, Peritoneum, Pharyngeal Tonsil, Pharynx, Pia Mater, Pineal Gland, Pituitary Gland, Placenta, Plantar Fascia, Plantar Region, Pleura, Pons Varolii, Popliteal Lymph Node, Portal Lymph Node, Postcricoid Region, Posterior Cranial Fossa, Posterior Mediastinum, Posterior Wall of the Bladder, Posterior Wall of the Hypopharynx, Posterior Wall of the Nasopharynx, Posterior Wall of the Oropharynx, Posterior Wall of the Pharynx, Preauricular Lymph Node, Prostate Gland, Prostatic Utricle, Psoas Muscle, Pubic Bone, Pubic Symphysis, Pulmonary, Pulmonary Hilar Lymph Node, Putamen, Pylorus, Pyriform Sinus, Quadriceps Muscle of the Thigh, Radial Artery, Radial Nerve, Radius Bone, Rathke Pouch, Rectosigmoid Colon, Rectosigmoid Region, Rectum, Rectus Abdominis, Renal, Renal Artery, Renal Calyx, Renal Pelvis, Reticuloendothelial System, Retina, Retromolar Trigone, Retroperitoneal Lymph Node, Retroperitoneum, Retropharyngeal Lymph Node, Round Ligament of the Uterus, Sacral Bone, Sacral Lymph Node, Sacral Nerve, Sacral Plexus, Salivary Gland, Scalene Lymph Node, Scalp, Scapula, Sciatic Nerve, Sclera, Scrotum, Sella Turcica, Seminal Vesicle, Shoulder, Shoulder Girdle, Shoulder Joint, Sigmoid Colon, Skeletal Muscle Tissue, Skin, Skin Of The Axilla, Skin of the Face, Skin of the Lip, Skin of the Lower Limb and Hip, Skin of the Scalp and Neck, Skin of the Trunk, Skin of the Upper Limb and Shoulder, Skull, Skullcap, Small Intestine, Spermatic Cord, Sphenoid Bone, Sphenoid Sinus, Sphincter of Oddi, Spinal Cord, Spinal Cord Dura Mater, Spinal Meninges, Spinal Nerve, Spleen, Splenic Flexure, Splenic Hilar Lymph Node, Sternocleidomastoid Muscle, Sternocostal Joint, Stomach, Subclavian Artery, Subcutis, Subglottis, Sublingual Lymph Node, Sublingual Salivary Gland, Submandibular Duct, Submandibular Gland, Submandibular Lymph Node, Superior Vena Cava, Superior Wall of the Nasopharynx, Supraclavicular, Supraclavicular Lymph Node, Supraglottis, Suprasellar Region, Supratentorial Brain, Sympathetic Nervous System, Synovial Bursa, Synovial Fluid, Tail of the Pancreas, Tarsal Bone, Temporal Bone, Temporal Lobe, Tendon, Tendon Sheath, Tentorium Cerebelli, Testis, Thalamus, Thigh, Third Ventricle, Thoracic Duct, Thoracic Esophagus, Thoracic Lymph Node, Thorax, Thymus Gland, Thyroglossal Duct, Thyroid Cartilage, Thyroid Gland, Tibia, Toe, Toenail, Tongue, Tonsillar Fossa, Tonsillar Pillar, Tooth Socket, Trachea, Tracheobronchial Lymph Node, Tragus, Transverse Colon, Trapezius Muscle, Triceps Brachii, Trigeminal Nerve, Trochlear Nerve, True Vocal Cord, Trunk, Tunica Vaginalis, Ulna, Ulnar Artery, Ulnar Nerve, Umbilicus, Uncus, Undescended Testes, Upper Extremity, Upper Gingiva, Upper Lobe of the Lung, Upper Third of the Esophagus, Upper-Inner Quadrant of the Breast, Upper-Outer Quadrant of the Breast, Urachus, Ureter, Ureteric Orifice, Ureteropelvic Junction, Urethra, Uterine Gland, Uterine Ligament, Uterus, Uvea, Uvula, Vagina, Vaginal Fornix, Vagus Nerve, Vallecula, Vas Deferens, Vein, Vena Cava, Vermis, Vertebra, Vertebral Column, Visceral Pleura, Vocal Cord, Vulva, Waldeyer's Tonsillar Ring, Wall of the Pharynx, Wrist Joint, Wrist Skin",,True,,,string,,,,,, @@ -465,7 +465,7 @@ Genomic Reference,Exact version of the human genome reference used in the alignm Genomic Reference URL,Link to human genome sequence; ftp or reference URL will be accepted.,,,,,,string,uri,,,,, Genome Annotation URL,Link to the human genome annotation (GTF) file; ftp or reference URL will be accepted.,,,,,,string,uri,,,,, AccessRequirementKey,The Access Requirement id(s) associated with this object. Provide multiple values as a comma-separated list.,,,,,,string,,,,,, -dataUseModifiers,"A list of data use modifiers that apply to the access requirement. Examples include GRU, IRB, etc.","Pending Annotation, GRU, PS, GSO, RTN, CC, NMDS, NRES, NPU, DUM, POA, NCU, NPUNCU, NPOA, IRB, HMB, PUB, USE, COL, RST, TSM, MOR, IST, GSR, DSR, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:00002002,,string_list,,,,,, +dataUseModifiers,"A list of data use modifiers that apply to the access requirement. Examples include GRU, IRB, etc.","Pending Annotation, DUO:0000042, DUO:0000027, DUO:0000016, DUO:0000029, DUO:0000043, DUO:0000015, DUO:0000004, DUO:0000045, DUO:0000017, DUO:0000011, DUO:0000046, DUO:0000018, DUO:0000044, DUO:0000021, DUO:0000006, DUO:0000019, DUO:0000026, DUO:0000020, DUO:0000012, DUO:0000025, DUO:0000024, DUO:0000028, DUO:0000022, DUO:0000007, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:00002002,,string_list,,,,,, collaborationRequired,"If collaboration is required for the access requirement, provide the PI email address. Provide multiple as a comma-separated list.",,,,,,string,,,,,, diseaseSpecificResearch,The type(s) of disease research allowed by this access requirement. Provide the MONDO ID in format MONDO:id. Provide multiple values as a comma-separated list. MONDO terms can be found here: https://ols.monarchinitiative.org/ontologies/mondo,,,,,,string,,MONDO:\d{7},,,, geographicalRestriction,The specific geographic region(s) to which use is limited by the access requirement.,"AD, AE, AF, AG, AI, AL, AM, AO, AQ, AR, AS, AT, AU, AW, AX, AZ, BA, BB, BD, BE, BF, BG, BH, BI, BJ, BL, BM, BN, BO, BQ, BR, BS, BT, BV, BW, BY, BZ, CA, CC, CD, CF, CG, CH, CI, CK, CL, CM, CN, CO, CR, CU, CV, CW, CX, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, EH, ER, ES, ET, FI, FJ, FK, FM, FO, FR, GA, GB, GD, GE, GF, GG, GH, GI, GL, GM, GN, GP, GQ, GR, GS, GT, GU, GW, GY, HK, HM, HN, HR, HT, HU, ID, IE, IL, IM, IN, IO, IQ, IR, IS, IT, JE, JM, JO, JP, KE, KG, KH, KI, KM, KN, KP, KR, KW, KY, KZ, LA, LB, LC, LI, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MF, MG, MH, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NC, NE, NF, NG, NI, NL, NO, NP, NR, NU, NZ, OM, PA, PE, PF, PG, PH, PK, PL, PM, PN, PR, PS, PT, PW, PY, QA, RE, RO, RS, RU, RW, SA, SB, SC, SD, SE, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SR, SS, ST, SV, SX, SY, SZ, TC, TD, TF, TG, TH, TJ, TK, TL, TM, TN, TO, TR, TT, TV, TW, TZ, UA, UG, UM, US, UY, UZ, VA, VC, VE, VG, VI, VN, VU, WF, WS, YE, YT, ZA, ZM, ZW",,,,,string_list,,,,,, @@ -532,7 +532,7 @@ Study dbGaP Accession Id,A stable unique alphanumeric identifier assigned to a s Study License,Official or legal permission to do or own a specified thing. Studies with data that will be submitted to CDS are required to provide a license. Maps to DUOplus6.,"CC0, CC_BY, CC_BY_NC, CC_BY_ND, CC_BY_SA, CC_BY_NC_ND, CC_BY_NC_SA, Apache_2, MIT, GPL_3, BSD_3_Clause",,,CDE:14902606,,string,,,,,, Study Index Date,"The reference event associated with timepoints in this study. One of Diagnosis Date, Enrollment Date, Collection Date, or Birth Date.","Diagnosis Date , Enrollment Date, Collection Date, Birth Date",,,,,string,,,,,, Study Project Identifier,The Synapse Project identifier (synID) with which this Study is related.,,,,,,string_list,,syn[0-9]+,,,, -Study Data Use Codes,"DUO code - A data item that is used to indicate consent permissions for datasets and/or materials, and relates to the purposes for which datasets and/or material might be removed, stored or used. Available DUO code definitions can be found here: https://mc2-center.github.io/data-models/valid_values/study/#attribute-study-data-use-codes","Pending Annotation, GRU, PS, GSO, RTN, CC, NMDS, NRES, NPU, DUM, POA, NCU, NPUNCU, NPOA, IRB, HMB, PUB, USE, COL, RST, TSM, MOR, IST, GSR, DSR, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:0002001,,string_list,,,,,, +Study Data Use Codes,"DUO code - A data item that is used to indicate consent permissions for datasets and/or materials, and relates to the purposes for which datasets and/or material might be removed, stored or used. Available DUO code definitions can be found here: https://mc2-center.github.io/data-models/valid_values/study/#attribute-study-data-use-codes","Pending Annotation, DUO:0000042, DUO:0000027, DUO:0000016, DUO:0000029, DUO:0000043, DUO:0000015, DUO:0000004, DUO:0000045, DUO:0000017, DUO:0000011, DUO:0000046, DUO:0000018, DUO:0000044, DUO:0000021, DUO:0000006, DUO:0000019, DUO:0000026, DUO:0000020, DUO:0000012, DUO:0000025, DUO:0000024, DUO:0000028, DUO:0000022, DUO:0000007, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:0002001,,string_list,,,,,, Theme,Themes associated with resources derived from consortia activities,,"Theme Name, Theme Display Name, Theme Description",,,,,,,,,True, Theme Name,"Machine readable name of the research theme. (e.g. compuational_resource, drug_resistance_sensitivity).",,,True,,,string,,,,,, Theme Display Name,"Human readable display name of the research theme. (e.g. Computational Resource, Drug Resistance/Sensitivity)",,,True,,,string,,,,,, @@ -592,7 +592,7 @@ Visium Spatial Library Construction Method,Process which results in the creation Visium Slide ID,"For Visium, it is the unique identifier printed on the label of each Visium slide. The serial number starts with V followed by a number which can range between one through five and ends with a dash and a three digit number, such as 123. For CosMx, this refers to the loaded Flow Cell ID. For Xenium, this ID indicates the slide orientation, as it matches the relative location of the ID on the physical Xenium slide.",,,True,,,string,,,,,,HTAN Visium Image Re-orientation,"To ensure good fiducial alignment and tissue spots detection, it is important to correct for this shift in orientation.","True, False",,,,,boolean,,,,,,HTAN Visium Permeabilization Time,Fixed and stained tissue sections are permeabilized for different times. Each Capture Area captures polyadenylated mRNA from the attached tissue section. Measure is provided in minutes.,,,,,,number,,,,,,HTAN -10x Visium RNA Level 2,Alignment workflows downstream of Spatial Transcriptomics RNA-seq Level 1.,,"10xVisiumRNALevel2_id, Filename, 10xVisiumRNALevel1 Key, Biospecimen Key, Study Key, DatasetView Key, File Alias, File Description, File Design, File Level, File Assay, File Species, File Url, File Format, File Data Use Codes, File Longitudinal Group, File Longitudinal Event Type, File Longitudinal Sequence Identifier, File Longitudinal Time Elapsed Unit, File Longitudinal Total Time Elapsed, Visium UMI Tag, Visium Whitelist Spatial Barcode File Link, Visium Spatial Barcode Tag, Visium Applied Hard Trimming, Workflow Version, Workflow Link, Genomic Reference, Genomic Reference URL, Genome Annotation URL, Biospecimen Key, Visium Run ID, Visium Capture Area",,,,,,,,,True,HTAN +10x Visium RNA Level 2,Alignment workflows downstream of Spatial Transcriptomics RNA-seq Level 1.,,"10xVisiumRNALevel2_id, Filename, 10xVisiumRNALevel1 Key, Biospecimen Key, Study Key, DatasetView Key, File Alias, File Description, File Design, File Level, File Assay, File Species, File Url, File Format, File Data Use Codes, File Longitudinal Group, File Longitudinal Event Type, File Longitudinal Sequence Identifier, File Longitudinal Time Elapsed Unit, File Longitudinal Total Time Elapsed, Visium UMI Tag, Visium Whitelist Spatial Barcode File Link, Visium Spatial Barcode Tag, Visium Applied Hard Trimming, Workflow Version, Workflow Link, Genomic Reference, Genomic Reference URL, Genome Annotation URL, Visium Run ID, Visium Capture Area",,,,,,,,,True,HTAN 10xVisiumRNALevel2_id,"Unique row identifier, used as a primary key for record updates. This should be equivalent to the file Synapse Id unless otherwise indicated.",,,True,primary_key,,string,,"^syn\d{7,8}$",,,, Visium UMI Tag,"SAM tag for the UMI field; please provide a valid tag-type pair, consisting of a tag (e.g. UB or UR) and type (e.g. Z) separated by a colon.",,,True,,,string,,,,,,HTAN Visium Whitelist Spatial Barcode File Link,Link to file listing all possible spatial barcodes. URL,,,True,,,string,,,,,,HTAN diff --git a/modules/biospecimen/annotationProperty.csv b/modules/biospecimen/annotationProperty.csv index 2fbc8e92..2af4b968 100644 --- a/modules/biospecimen/annotationProperty.csv +++ b/modules/biospecimen/annotationProperty.csv @@ -35,4 +35,4 @@ Biospecimen Primary Site,Primary site in the body associated with the primary di Biospecimen Primary Diagnosis,"Text term used to describe the histologic diagnosis relevant to the model system, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).","Head and Neck Squamous Cell Carcinoma, Astroblastoma; Other; Other CNS Tumor; NOS Or NEC, Medulloblastoma; Hypercellular Lesion With Marked Atypia, Ependymoma; NOS; Posterior Fossa Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Neuroma; NOS, Precursor Cell Lymphoblastic Leukemia; NOS, Hypercellular Neuroepithelial Tumor With Some Features Of Glioma; Possibly High Grade, Acute Leukemia; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Papillary Glioneuronal Tumor, High-grade serous carcinoma, Myeloid Leukemia; NOS, Choriocarcinoma; NOS, Embryonal Carcinoma; NOS; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Giant Cell Tumor Of Bone; NOS, Adenocarcinoma; Intestinal Type, Not Specified In Data, Neoplasm; Uncertain Whether Benign Or Malignant; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ductal Carcinoma NOS, Renal Cell Carcinoma; NOS, B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Myelodysplastic Syndrome; NOS, Low Grade Fibromyxoid Sarcoma, Benign Cystic Nephroma, Glial Neoplasm, Papillary Adenocarcinoma; NOS, Telangiectatic Osteosarcoma, Ganglioglioma; NOS; Malignant Peripheral Nerve Sheath Tumor; NOS, Central Neurocytoma, Giant Cell Tumor Of Soft Parts; NOS, Giant Cell Tumor Of Bone; Malignant, Sertoli-Leydig Cell Tumor; Poorly Differentiated, Glioma; Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Acute Megakaryoblastic Leukemia, Germinoma; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia; WHO Grade 1, Supratentorial Ependymoma; NOS, Myxoid Liposarcoma, Acute Lymphoblastic Leukemia, Combined Small Cell-Squamous Cell Carcinoma, High Grade Spindle Cell Sarcoma, Medulloblastoma; Group 3 Subtype (WHO Grade 4), Acute Monocytic Leukemia, Neoplasm; NOS, Retinoblastoma; Grade 3, Yolk Sac Tumor; NOS; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Myofibroblastic Tumor; NOS, Sex Cord-Gonadal Stromal Tumor; Mixed Forms, Adamantinomatous Craniopharyngioma, Mesoblastic Nephroma, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Astrocytoma; NOS; High-Grade Glioma; Infant-Type Hemispheric Glioma, Rhabdomyosarcoma; NOS, Mucinous Adenocarcinoma; Endocervical Type, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ganglioglioma; NOS; Glioneuronal And Neuronal Tumors, Dermoid Cyst, Adenocarcinoma Combined With Other Types Of Carcinoma, Precursor Cell Lymphoblastic Lymphoma; NOS, Posterior Fossa Ependymoma; CNS WHO Grade 2, Pituitary Adenoma; NOS, Neoplasm; Malignant; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Sex Cord-Gonadal Stromal Tumor; Incompletely Differentiated, High Grade Follicular Derived Thyroid Carcinoma, Desmoplastic Fibroma, Perineuroma, Diffuse Midline Glioma; H3K27M-Mutant; CNS WHO Grade 4, Ganglioglioma, Pancreatobiliary-Type Carcinoma, Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia, Hemangioblastoma, Colorectal Carcinoma, Acute Myelomonocytic Leukemia, Diffuse Midline Glioma; H3 K27-Altered, T-Lymphoblastic Lymphoma, Lymphangioma; NOS, Neoplasm; Benign, Papillary Intralymphatic Angioendothelioma, Ependymoma; NOS; Supratentorial Ependymoma; ZFTA Fusion-Positive, Unclassified Sarcoma With Round Cell Morphology, Glioma, Medulloblastoma; Classic (Biphasic) Histologic Type; Non-SHH/Non-WNT Molecular Group; CNS WHO Grade 4, Soft Tissue Sarcoma, Xanthogranuloma, Neoplasm; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Bronchio-Alveolar Carcinoma; Mucinous, Hepatocellular Carcinoma; Fibrolamellar, Pancreatic Neuroendocrine Tumor; Nonfunctioning, Myxopapillary Ependymoma, Chondrosarcoma; NOS, Favor Ganglioglioma, Papillary Tumor Of Pineal Region, Acute Myeloid Leukemia With Mutated NPM1, Epithelioid Hemangioendothelioma; NOS, Neuroblastoma; NOS, Chondroid Chordoma, Infiltrating Duct And Lobular Carcinoma, Mitotically Active Glial/ Glioneuronal Neoplasm, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, CPNET, Mycosis Fungoides; Langerhans Cell Histiocytosis; NOS, T-Lymphoblastic Leukemia, Medulloblastoma; NOS; Medulloblastoma; Non-WNT/Non-SHH, Clear Cell Meningioma; Meningioma; Other, Ameloblastic Carcinosarcoma, Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Meningothelial Meningioma, Epithelioid Cell Melanoma, Prostate Cancer, Paraganglioma; Malignant, Small Cell Sarcoma, Cystosarcoma Phyllodes; NOS, Seminoma; NOS, Yolk Sac Tumor; NOS, Intraductal Carcinoma NOS, Adenocarcinoma; Endocervical Type, Neurofibroma; NOS, Astroblastoma; Astroblastoma; MN1-Altered; High-Grade Glioma, Meningothelial Meningioma; Grade 1, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Unknown, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Sarcoma; Ewing Sarcoma, Glioma; Malignant; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Endometrioid Adenocarcinoma; NOS, Pancreas-Adenocarcinoma Ductal Type, Giant Cell Glioblastoma; Glioblastoma; IDH-Wildtype; High-Grade Glioma, Angiomyosarcoma, Carcinoid Tumor, Adenosquamous Carcinoma, Metastatic Neuroblastoma, Clear Cell Sarcoma Of Kidney, Infiltrating Duct Mixed With Other Types Of Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Embryonal Carcinoma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Germ Cell Tumors; CNS Germinoma, Astrocytoma; NOS; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Low Cumulative Sun Damage Melanoma, Supratentorial Ependymoma, Ossifying Fibromyxoid Tumor; NOS, Diffuse Large B-Cell Lymphoma; NOS, Adenocarcinoma With Neuroendocrine Differentiation, Atypical Meningioma, Pineoblastoma, Chronic Myeloid Leukemia; NOS, Atypical Choroid Plexus Papilloma, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFB, Pleomorphic Xanthoastrocytoma; NOS; High-Grade Glioma, Oxyphilic Adenocarcinoma, Favor Pilocytic Astrocytoma; CNS WHO Grade 1, Poorly Differentiated; Intermediate Mitotic-Karyorrhectic Index, Clear Cell Meningioma, Medulloblastoma; Classic Histologic Type; CNS WHO Grade 4, Appearances Consistent With Alveolar Soft Part Sarcoma, Dedifferentiated Liposarcoma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Tubular Adenocarcinoma, Rhabdomyosarcoma; Most Likely An Embryonal Carcinoma, Adenocarcinoma; NOS, Pleuropulmonary Blastoma, Basaloid Squamous Cell Carcinoma, Oligodendroglioma; Anaplastic; NOS, Pilocytic Astrocytoma; WHO Grade 1, Not Applicable, Abdominal Fibromatosis, Hamartoma, Neoplasm; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Choroid Plexus Papilloma; NOS; Choroid Plexus Tumors, Burkitt Lymphoma; NOS, Lymphoepithelial Carcinoma, Bronchiolo-Alveolar Carcinoma; Non-Mucinous, Kidney Clear Cell Renal Carcinoma, Pilocytic Astrocytoma; Low-Grade Glioma, Adenocarcinoma In Situ In Adenomatous Polyp, Neoplasm; Uncertain Whether Benign Or Malignant, Small Blue Cell Tumor. Favor Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma; NOS, Embryonal Tumor With Multi-Layered Rosettes, Chronic Eosinophilic Leukemia, Mixed Glioma, Basal Cell Adenocarcinoma, Olfactory Neuroblastoma, Transitional Cell Carcinoma; NOS, Clear Cell Sarcoma; NOS, Embryonal Rhabdomyosarcoma; High-Grade, Angiocentric Glioma, Diffuse Midline Glioma; H3 K27 Altered; WHO Grade 4, Osteoblastoma; NOS, Malignant Neoplasm With Rhabdomyoblastic Differentiation; High Grade, Myxopapillary Ependymoma (CNS WHO Grade II), Melanoma In Situ, Secretory Carcinoma, Pilocytic Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Rhabdomyosarcoma; Favor Alveolar Type, Adenocarcinoma; Metastatic NOS, Fibrosarcoma; NOS, Glioblastoma, Atypical Choroid Plexus Papilloma; Choroid Plexus Tumors, Ganglioneuroma; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Desmoplastic Melanoma; NOS, Choroid Plexus Carcinoma, Soft Tissue Tumor; Benign, Medulloblastoma; NOS, Glioblastoma; NOS; Medulloblastoma; NOS, Residual Astrocytoma, B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged, Extra Adrenal Paraganglioma, Mucoepidermoid Carcinoma, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Choroid Plexus Papilloma; NOS, Glioma; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, B-Lymphoblastic Leukemia/Lymphoma; NOS, Hodgkin Lymphoma; Nodular Sclerosis; NOS, Fibroma, Craniopharyngioma; NOS; Adamantinomatous Craniopharyngioma, T-Cell/Histiocyte Rich Large B-Cell Lymphoma, Astrocytoma; IDH-Mutant; CNS WHO Grade 4, Acute Erythroid Leukemia, Glioma; Histologically Low Grade, Mucous Adenocarcinoma, Glioma; Malignant; Ganglioglioma; Glioneuronal And Neuronal Tumors, Nodular Melanoma, Synovial Sarcoma; Biphasic, Neoplasm; Metastatic, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Thymoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Posterior Fossa Ependymoma; Group PFA, Desmoplastic/Nodular Medulloblastoma, Papillary Glioneuronal Tumor, Mixed Phenotype Acute Leukemia; T/Myeloid; NOS, Cholangiocarcinoma, Astroblastoma; MN1-Altered. Histologically High-Grade, Sertoli-Leydig Cell Tumor; Poorly Differentiated; With Heterologous Elements, Glioma; Malignant; High-Grade Glioma; Infant-Type Hemispheric Glioma, Juvenile Myelomonocytic Leukemia; NOS, Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry, Myeloid Leukemia With Myelodysplasia-Related Changes, Primary Cutaneous Follicle Center Lymphoma, Choroid Plexus Carcinoma; WHO Grade 3, Infiltrating Duct Carcinoma NOS, T Lymphoblastic Leukemia/Lymphoma, Glioma; Malignant; Other; Other CNS Tumor; NOS Or NEC, Mixed Germ Cell Tumor; Myelodysplastic Syndrome With Excess Blasts, Clear Cell Adenocarcinoma; NOS, Cutaneous T-Cell Lymphoma; NOS, Germinoma, Neoplasm; Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Meningeal Melanocytoma, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Acute Promyelocytic Leukemia; T(15;17)(Q22;Q11-12), Alveolar Soft Part Sarcoma, Astrocytoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Mixed Epithelioid And Spindle Cell Melanoma, CNS Embryonal Tumor; NOS; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Malignant Tumor; Spindle Cell Type, Glioma; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Glioma; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Endometrioid Carcinoma; NOS, Lung Squamous Cell Carcinoma; NOS, Papillary Urothelial Carcinoma; Non-Invasive, Neuroblastoma; Undifferentiated Type, Periosteal Osteosarcoma, Mixed Phenotype Acute Leukemia; B/Myeloid; NOS, Inflammatory Carcinoma, Glioblastoma; NOS, Carcinoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Squamous Cell Carcinoma; NOS, Hypocellular Low Grade Lesion, Glioblastoma Multiforme, Pancreas-Undifferentiated Carcinoma, Differentiating Neuroblastoma, Myxoid Spindle Cell Tumor, Merkel Cell Tumor, Malignant Peripheral Nerve Sheath Tumor; NOS; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Hemangioma; NOS, Acute Myeloid Leukemia With Abnormal Marrow Eosinophils, Well Differentiated Neuroendocrince Tumor; Grade 1, Ganglioglioma; Anaplastic, Ependymoma WHO Grade 2, Synovial Sarcoma; NOS, Thymic Carcinoma; NOS, Tumor Cells; Malignant, Pilomyxoid Astrocytoma, Papillary Carcinoma; Columnar Cell, Plexiform Fibrohistiocytic Tumor, Astrocytoma; NOS; Angiocentric Glioma; Low-Grade Glioma, Carcinoma; Undifferentiated; NOS, Dermatofibrosarcoma Protuberans; NOS, High Grade Glioma With Necrosis; WHO Grade 4, Infiltrating ductular carcinoma, Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Juvenile Myelomonocytic Leukemia; NOS, Infiltrating Duct And Mucinous Carcinoma, Intraductal Papillary Carcinoma, Serous Surface Papillary Carcinoma, Invasive Carcinoma, High Grade Malignant Epithelioid Neoplasm, Favor Pilocytic Astrocytoma With Increased Proliferation Indices, Medulloblastoma; Classic Morphology; CNS WHO Grade 4; NON-WNT/NON-SHH; Group 4 Subtype By Methylation, Composite Hodgkin And Non-Hodgkin Lymphoma, Atypical Teratoid/Rhabdoid Tumor; ATRT; NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor; ATRT-TYR, Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder, Hemangioendothelioma; NOS, Hypercellular Lesion With Atypia, Embryonal Carcinoma; NOS, Subependymoma; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Germ Cell Tumor; Nonseminomatous, Adrenal Cortical Carcinoma, Olfactory Neurocytoma, Large Cell Medulloblastoma; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Nuclear Protein In Testis (NUT)-Associated Carcinoma, Epithelial-Myoepithelial Carcinoma, Squamous Cell Carcinoma; Keratinizing; NOS, Ganglioneuroma; Other; Schwannoma, Glomus Tumor; Malignant, Neoplasm; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Malignant Lymphoma; Non-Hodgkin; NOS, Embryonal Rhabdomyosarcoma; NOS; CNS Embryonal Tumor; NOS, Tenosynovial Giant Cell Tumor; NOS, Histologically Low-Grade Glioma, Chordoma; NOS; Ganglioneuroblastoma, Ependymoma; NOS, Invasive Mammary Carcinoma, Rhabdoid Tumor; Malignant, Medulloblastoma; Classic Histology, Adenocarcinoma In Villous Adenoma, Undifferentiated Sarcoma, Papillary Thyroid Carcinoma, Renal Cell Adenocarcinoma, Hodgkin Lymphoma; NOS, Malignant Histiocytosis, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Solid Pseudopapillary Tumor Of Ovary, Astrocytic Glioma; Histologically Low-Grade; Most Compatible With Pilocytic Astrocytoma, Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst, Myofibromatosis, Small Round Blue Cell Tumor, Meningioma; Atypical; CNS WHO Grade 2, Neoplasm; Uncertain Whether Benign Or Malignant; Adamantinomatous Craniopharyngioma; Craniopharyngioma, Pilocytic Astrocytoma, Lobular And Ductal Carcinoma, Desmoplastic/Nodular Medulloblastoma (Histologically Defined); CNS WHO Grade 4, Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation, Tumor Cells; Malignant; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Malignant Tumor, Brain Tumor, Gastrointestinal Stromal Tumor; Benign, Rasmussen Encephalitis, Medulloblastoma; NOS; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Adenocarcinoma;NOS; Glioblastoma; NOS, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Embryonal Sarcoma, Neoplasm; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Anaplastic Large Cell Lymphoma; T-Cell And Null-Cell Type, Teratoma; NOS, Pleomorphic Xanthoastrocytoma; NOS, Infiltrating duct and lobular carcinoma, Sclerosing Stromal Tumor, Tumor Cells; Uncertain Whether Benign Or Malignant, Acute Myeloid Leukemia; NOS; Juvenile Myelomonocytic Leukemia; NOS, Lobular Carcinoma; NOS, Schwannoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Sarcoma; NOS, CNS Embryonal Tumor With Rhabdoid Features, Glial Neoplasm; Astrocytoma, Pancreas-Adenosquamous Carcinoma, Mesenchymal Lesion, Serous Adenocarcinoma; NOS, Hepatoblastoma; NOS, Astrocytoma; NOS; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Sex Cord-Gonadal Stromal Tumor; NOS, Adenoid Cystic Carcinoma, Embryonal Tumor, Acute Myeloid Leukemia; T(8;21)(Q22;Q22), Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor, Cavernoma, Malignant Tumor; Small Cell Type, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Germinoma, Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma., Neoplasm; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Serous Carcinoma; NOS, Metastatic Secondary Tumors, Yolk Sac Tumor, Morphologically Consistent With Pilocytic Astrocytoma; WHO Grade 1, Neuroendocrine Tumor; NOS, Mixed Germ Cell Tumor; Acute Megakaryoblastic Leukemia, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL, Glioma; Malignant; High-Grade Glioma; Pleomorphic Xanthoastrocytoma, Papillary Glioneuronal Tumor; WHO Grade 1, Central Neuroblastoma, Dysembryoplastic Neuroepithelial Tumor, Mixed Adenocarcinoma And Squamous Cell Carcinoma; Pancreatobiliary-Type Carcinoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Myofibroblastic Tumor, Nephroblastoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Malignant Melanoma; NOS; Meningeal Melanocytic Neoplasms (Includes Melanoma); Other, Carcinoma; Metastatic; NOS, Follicular Carcinoma; Minimally Invasive, Angiomyofibroblastoma, Classic Medulloblastoma; CNS WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Atypical Teratoid/Rhabdoid Tumor; ATRT-MYC, Astroblastoma, Meningothelial Meningioma; Meningioma; Other, Poorly Differentiated Chordoma, Chronic Myelogenous Leukemia, Pleomorphic Sarcoma, Supratentorial Ependymoma CNS WHO Grade 3, Leydig Cell Tumor; NOS, Adenosarcoma, Pigmented Dermatofibrosarcoma Protuberans, Astrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Astrocytoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Astrocytoma; NOS; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Myxofibrosarcoma, Precursor T-Cell Lymphoblastic Leukemia, Neurocytoma, Adrenal Cortical Tumor; NOS, Neoplasm; Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1, Neoplasm; Malignant; CNS Neuroblastoma; FOXR2-Activated; Other CNS Embryonal Tumors, Infiltrating duct and mucinous carcinoma, Adenocarcinoma In Situ; NOS, Mucinous Adenocarcinoma, Retinoblastoma; NOS, Anaplastic Ependymoma, Germ Cell Tumor; Nonseminomatous; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Acute Monoblastic And Monocytic Leukemia, Hemangioblastoma; CNS WHO Grade 1, Alveolar Rhabdomyosarcoma, Medullary Carcinoma; NOS, Adult Granulosa Cell Tumor Of Testis, Medulloblastoma; WHO Grade 4, Craniopharyngioma; Adamantinomatous, High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor), Spindle Cell Rhabdomyosaroma, Diffuse Midline Glioma; H3 K27M-Mutant, Epithelioid Sarcoma; NOS, Myoepithelial Carcinoma, Multiple Myeloma, Triple-Negative Breast Carcinoma, Hepatocellular Carcinoma; NOS; Nephroblastoma; NOS, Neuroblastoma; Schwannian Stroma Poor; Poorly Differentiated; Low MKI; Favorable Histology, Sertoli Cell Tumor; NOS, Ossifying Fibroma, Pleomorphic Liposarcoma, Amelanotic Melanoma, Liposarcoma; NOS, Non-Germinomatous Germ Cell Tumor, Lactotroph Adenoma, Transient Abnormal Myelopoiesis, Favor Posterior Fossa Ependymoma; WHO GRADE 3, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Carcinoma In Situ; NOS, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ependymoma; Anaplastic, Glial Neoplasm; Favor Pilocytic Astrocytoma, Gastrointestinal Stromal Tumor; NOS, Serous Cystadenocarcinoma; NOS, Papillary Lesion With Atypical/High Grade Features, Spinal Ependymoma; WHO Grade 2, Ductal Carcinoma In Situ; NOS, Infiltrating Ductal Carcinoma, Mixed Type Rhabdomyosarcoma, Medulloblastoma; SHH-Activated And TP53-Mutant, Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy, Mesenchymal Chondrosarcoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Cribriform Carcinoma; NOS, Myxopapillary Ependymoma; Anaplastic, Ependymoma; Anaplastic; Supratentorial Ependymoma; NOS Or NEC, Astrocytoma; IDH-Mutant; WHO Grade 2, Meningioangiomatosis, Acute Myeloid Leukemia; NOS; Myeloproliferative Neoplasm; Unclassifiable, Endometrioid carcinoma; NOS, Adenocarcinoma In Situ; Non-Mucinous, Medulloblastoma; NOS; Medulloblastoma; Group 4, Papillary Carcinoma; Follicular Variant, Metaplastic Carcinoma; NOS, Choroid Plexus Carcinoma; Choroid Plexus Tumors, Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation, Low Grade Glioma, Sex Cord Stromal Tumor NOS, Stroma Poor; Poorly Differentiated Neuroblastoma With Low MKI; Favorable Histology, Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid), Melanotic Neuroectodermal Tumor, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Angiocentric Glioma; Low-Grade Glioma, Malignant Lymphoma; NOS, Medulloblastoma WHO Grade 4, Choroid Plexus Papillary Tumor, Follicular Adenocarcinoma; Well Differentiated; Neuroblastoma; NOS, Neuroepithelial Tumor, Myelodysplastic Syndrome With Multilineage Dysplasia, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Mast Cell Leukemia, Ganglioneuroblastoma, Pheochromocytoma; NOS, Papillary Serous Adenocarcinoma, Mixed Germ Cell Tumor, Lymphoid Leukemia; NOS, Ependymoma NOS, Smooth Muscle Tumor Of Uncertain Malignant Potential, Combined Small Cell-Large Carcinoma, Sertoli Leydig Cell Tumor, Anaplastic Large Cell Lymphoma; ALK Positive, Meningioma; Malignant, Rhabdoid Tumor; NOS, Merkel Cell Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Meningioma; Other, Lymphoma; NOS, Gangliocytoma; NOS, Glioblastoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Mucinous Non-Cystic Carcinoma, Mucinous Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Pilocytic Astrocytoma, Ganglioglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, High Grade Carcinosarcoma, Subependymal Giant Cell Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Squamous Cell Carcinoma; Metastatic; NOS, Myeloid Leukemia Associated With Down Syndrome, Meningeal Melanomatosis, Neuroepithelial Tumor With Glioneuronal-Like Features, Squamous Cell Carcinoma; Large Cell; Nonkeratinizing; NOS, Meningiomatosis; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Oligodendroglioma; NOS; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFA, CNS Embryonal Tumor; NOS, Favor Anaplastic Ependymoma, Diffuse Glioma, Adamantinomatous Craniopharyngioma (CNS WHO Grade 1), Medulloblastoma; Classic Variant; WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Glioneuronal Tumor With Focal Increased Atypia, High Grade Neuroepithelial Tumor, Squamous Cell Carcinoma; Small Cell; Nonkeratinizing, Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged, Acute Myeloid Leukemia; Minimal Differentiation, Fibrillary Astrocytoma, Chordoma; NOS, Undifferentiated Leukemia, Myofibroma, Neoplasm; Malignant, Pleomorphic Xanthoastrocytoma; NOS; Low-Grade Glioma, Invasive Ductal Carcinoma, Subependymal Giant Cell Astrocytoma, Embryonal Rhabdomyosarcoma With Anaplastic Features, High-Grade Neuroepithelial Tumor, Low Grade Glioneuronal Tumor, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Acute Myeloid Leukemia Without Maturation, Adenocarcinoma With Mixed Subtypes, B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy, Malignant Peripheral Nerve Sheath Tumor; NOS, Hemangiosarcoma, Paraganglioma; NOS, Medulloblastoma; Nodular/Desmoplastic With Anaplastic/Large Cell Features; Non-WNT/Non-SHH; WHO Grade 4, Signet Ring Cell Carcinoma, Spindle Cell Melanoma; NOS, Lobular Adenocarcinoma, Undiagnosed Spindle Cell Tumor, Pilocytic Astrocytoma; WHO Grade 1; KIAA1549-BRAF Fusion, Meningioma, Hepatosplenic T-Cell Lymphoma; Precursor Cell Lymphoblastic Leukemia; NOS, Mesenchymal Chondrosarcoma, Anaplastic Ganglioglioma, Osteosarcoma; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Ependymoma WHO Grade 3, Lung Adenocarcinoma; NOS, Lymphoproliferative Disorder; NOS, Atypical Lymphoid Infiltrate, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Wildtype, Genital Rhabdomyoma, Chondroblastic Osteosarcoma, Neuroepithelioma; NOS, Malignant Epithelioid And Myxoid Neoplasm, Pancreatoblastoma, Nephroblastoma (Wilms Tumor), Malignant Glioma, Ewing Sarcoma, Atypical Smooth Muscle Neoplasm, Acute Myelomonocytic Leukemia; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Epithelial Tumor; Benign, Favor Teratoma, Malignant Neoplasm Of Prostate, Non-Clear Cell Renal Cell Carcinoma, Meningioma; NOS; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Melanotic Schwannoma; Other, Medulloblastoma; NOS; Medulloblastoma; WNT-Activated, Carcinosarcoma NOS, Plasmacytoma; Extramedullary, Infantile Fibrosarcoma, Glioma; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, CNS Primative Neuroectodermal Tumor (PNET), Infiltrating duct carcinoma; NOS, Precursor B-Cell Lymphoblastic Leukemia, Squamous Cell Carcinoma In Situ; NOS, Acute Myeloid Leukemia; T(16;16)(P 13;Q 11), Papillary Transitional Cell Carcinoma, Atypical Teratoid/Rhabdoid Tumor, Low-Grade Glioneuronal; Neuronal Tumor, Combined Small Cell-Adenocarcinoma, Hepatocellular Carcinoma; NOS, Spindle Cell Carcinoma; NOS, Carcinoma; Diffuse Type, Lentiginous Melanocytic Nevus, Glioma; Malignant; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Solitary Fibrous Tumor; NOS, Glioma; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Granulosa Cell Tumor; Malignant, Ganglioneuroma; Maturing Type; Favorable Histology, Invasive Lobular Carcinoma, Ganglioglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation, Medulloblastoma, Hepatoblastoma, Low Grade Glial/ Glioneuronal Tumor, Atypical Teratoid Rhabdoid Tumor; CNS WHO Grade 4, Oligoastrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Diffuse Glioma; Favor High Grade, Reactive Connective Tissue, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Mutant, Tumor Cells; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Malignant Peripheral Nerve Sheath Tumor; NOS, Melanoma; NOS, Malignant Melanocytic Neoplasm, Chronic Myelogenous Leukemia; BCR/ABL Positive, Vascular Lesion; Consistent With Hemangioma, Small Cell Neuroendocrine Carcinoma, Medullary Carcinoma, Anaplastic Astrocytoma; IDH-Wildtype; Glioblastoma; IDH Wildtype, Rhabdomyosarcoma; Embryonal Subtype, Medulloblastoma By Morphology; NON-WNT By Immunohistochemistry, Glioma; Malignant; Astrocytoma; IDH-Mutant; High-Grade Glioma, Ganglioglioma; NOS, Dysembryoplastic Neuroepithelial Tumor; Angiocentric Glioma; Low-Grade Glioma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Angiomatoid Fibrous Histiocytoma, Micropapillary Carcinoma; NOS, Infiltrating Lobular Carcinoma; NOS, Gastrointestinal Stromal Tumor, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; Group 4, Craniopharyngioma, Sertoli-Leydig Cell Tumor; Intermediate Differentiation; With Heterologous Elements, Acute Myeloid Leukemia; Inv(16)(P13;Q22), Subependymoma, Gliomatosis Cerebri, Infiltrating lobular carcinoma; NOS, Schwannoma; NOS, Oligodendroglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dysplasia, Malignant Rhabdoid Tumor, Blue Nevus; Malignant, Adenocarcinoma; Pancreatobiliary Type, Ependymoma; NOS; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ganglioneuroblastoma; Nodular Type, Granulosa Cell Tumor; Juvenile, Juvenile Granulosa Cell Tumor, Chronic Myeloid Leukemia; BCR-ABL1-Positive, Head & Neck Squamous Cell Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Medulloblastoma; SHH-Activated And TP53-Wildtype, Ganglioglioma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma, Adrenal Cortical Adenoma; NOS, Adenocarcinoma; Pancreatobiliary Type; Pancreatobiliary-Type Carcinoma, Lipoblastomatosis, Central Neurocytoma; Glioneuronal And Neuronal Tumors, Control, HHV8 Positive Diffuse Large B-Cell Lymphoma, Pilocytic Astrocytoma; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Group 4, Large Cell Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1), Central Osteosarcoma; NOS, Chordoma, Pilocytic Astrocytoma; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Pilocytic Astrocytoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dermatofibrosarcoma Protuberans; Fibrosarcomatous, Neuroendocrine Carcinoma; NOS, Glioma; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Oligodendroglioma; NOS, Acute Monoblastic Leukemia, Glioma; Malignant; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Neoplasm, Medulloepithelioma; NOS, Oligodendroglioma; NOS; High-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Not Reported, Aggressive Fibromatosis, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Langerhans Cell Histiocytosis; Disseminated, Glioma; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Oligoastrocytoma; NOS, Undifferentiated Nasopharyngeal Carcinoma, Small Cell Carcinoma; NOS, Chordoma; NOS; Chordoma (Including Poorly Differentiated Chordoma); Other, Mesothelioma; Biphasic; Malignant; B Lymphoblastic Leukemia/Lymphoma; NOS, Central Neurocytoma; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Undifferentiated Small Round Cell Sarcoma, Rhabdomyoma; NOS, Glioblastoma; IDH Wildtype, Neoplasm; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Therapy Related Myeloid Neoplasm, Acute Myeloid Leukemia; NOS, Malignant Tumor; Spindle Cell Type; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Leydig Cell Tumor; Benign, Myelodysplastic Syndrome With Single Lineage Dysplasia, Germinoma; CNS Germ Cell Tumors; CNS Germinoma, Glial Tumor, Synovial Sarcoma; Spindle Cell, Spindle Cell Melanoma; Type B, Familial Adenomatous Polyposis, Giant Cell Glioblastoma, Teratocarcinoma, Adenoma; NOS, Acral Lentiginous Melanoma; Malignant, Carcinoma NOS, Papillary Carcinoma; NOS, Poorly Differentiated Neuroblastoma, Solid Pseudopapillary Neoplasm Of Pancreas, Nasopharyngeal Carcinoma, Adenocarcinoma In Adenomatous Polyposis Coli, Leiomyoma; NOS, Embryonal Rhabdomyosarcoma; NOS, Choroid Plexus Papilloma; NOS; Other CNS Embryonal Tumors; Pineoblastoma, Tumor Cells; Benign, Marginal Zone B-Cell Lymphoma; NOS, Tumor Cells; Malignant; Other; Pineal Parenchymal Tumor Of Intermediate Differentiation, Pinealoma, Atypical Teratoid/Rhabdoid Tumor; INI1/SMARCB1-Altered; WHO Grade 4, Metastatic Signet Ring Cell Carcinoma, Astrocytoma, Desmoplastic Infantile Astrocytoma, Malignant Sarcoma With DICER1 Mutation; Favor Primary Intracranial Sarcoma; DICER1 Mutant, B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy, Colon Adenocarcinoma, Ependymoma; NOS; Supratentorial Ependymoma; NOS Or NEC, Proliferative Dermal Lesion In Congenital Nevus, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; WNT-Activated, Arteriovenous Malformation, Glioma; Malignant, Acinar Cell Carcinoma, Spinal Ependymoma; Histologically Low Grade (CNS WHO Grade 2), Leukemia; NOS, Hemangioblastoma; Other, High-Grade Serous Carcinoma, Medulloblastoma; NOS; Medulloblastoma; Group 3, Schwannian Stroma Poor Peripheral Neuroblastic Tumor; Consistent With Neuroblastoma, Acute Myeloid Leukemia With Mutated CEBPA, Parosteal Osteosarcoma, Epithelioid Mesothelioma; Malignant, Meningioma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Choriocarcinoma Combined With Other Germ Cell Elements, Brain Tumor; Low Grade Glioma, Ganglioglioma; NOS; Diffuse Astrocytoma; MYB- Or MYBL1-Altered; Low-Grade Glioma, Embryonal Tumor With Multilayered Rosettes C19MC-Altered, Neoplasm; Malignant; Uncertain Whether Primary Or Metastatic, Desmoplastic Small Round Cell Tumor, Embryonal Rhabdomyosarcoma, Langerhans Cell Histiocytosis, Glial Neoplasm Showing High-Grade Features, Oligodendroglioma, Malignant Melanoma; NOS, Myxopapillary Ependymoma; Ependymoma, Medulloblastoma; NOS; Medulloblastoma; NOS Or NEC, Neoplasm; Malignant; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Adenocarcinoma, B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1, Hemangioendothelioma; Malignant, Choroid Plexus Neoplasm, Craniopharyngioma; Adamantinomatous; Adamantinomatous Craniopharyngioma, Pinealoblastoma, Large Cell Medulloblastoma; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Spindle Cell Sarcoma, Gliosarcoma, Central Primitive Neuroectodermal Tumor, Astrocytoma; IDH-Mutant; CNS WHO Grade 3, Astrocytoma; Benign, Pleomorphic Rhabdomyosarcoma; Adult Type, Myeloid Sarcoma, Glioma; Malignant; Other; Other Low-Grade B-Cell Lymphomas Of The CNS, Ganglioneuroma, Neoplasm; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Clear Cell Renal Cell Carcinoma, Ependymoma; NOS; Atypical Meningioma, Oligodendroglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Malignant Peripheral Nerve Sheath Tumor, Glioma; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Sertoli-Leydig Cell Tumor Of Intermediate Differentiation; NOS, Desmoplastic Nodular Medulloblastoma, Papillary Microcarcinoma, Craniopharyngioma; NOS, Low Grade Glial Neoplasm, Leiomyosarcoma; NOS, Follicular Adenocarcinoma; NOS",,,CDE:14714127,,string,,,,,, Biospecimen Treatment Response,Text term that describes the treatment response of a model or patient from which this specimen was derived.,"Complete Response, No Evidence of Disease, No Response, Not Applicable, Not Evaluable, Not Reported, Partial Response, Persistent Disease, Progressive Disease, Stable Disease, Unknown",,,CDE:13383448,,string,,,,,, Biospecimen Incidence Type,Text term describing a change in disease status associated with the collection of this specimen. ,"Primary, Progression, Recurrence, Metastasis, Remission, No Disease",,,CDE:0002002,,string,,,,,, -Biospecimen Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string_list,,,,,, +Biospecimen Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string_list,,,,,, diff --git a/modules/individual/annotationProperty.csv b/modules/individual/annotationProperty.csv index cedaea9f..7b67c96a 100644 --- a/modules/individual/annotationProperty.csv +++ b/modules/individual/annotationProperty.csv @@ -18,7 +18,7 @@ Individual Primary Tumor Stage,Extent of the primary cancer based on evidence ob Individual Tumor Lymph Node Stage,Extent of the regional lymph node involvement for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.,"N0, N0 (i+), N0 (i-), N0 (mol+), N0 (mol-), N1, N1a, N1b, N1bI, N1bII, N1bIII, N1bIV, N1c, N1mi, N2, N2a, N2b, N2c, N3, N3a, N3b, N3c, N4, NX, Unknown, Not Reported",,,CDE:3440330,,string,,,,,, Individual Days To Recurrence,Number of days between the date used for index and the date the patient's disease recurred,,,,,,number,,,,,, Individual Days to Last Known Disease Status,"Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days.",,,,,,number,,,,,, -Individual Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, +Individual Treatment Type,Text term that describes the kind of treatment administered.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, Individual Days to Treatment,Number of days between the date used for index and the date the treatment started.,,,,,,number,,,,,, Individual Therapeutic Agent,Text identification of the individual agent(s) used as part of a treatment regimen.,"10-Deacetyltaxol, 11C Topotecan, 11D10 AluGel Anti-Idiotype Monoclonal Antibody, 12-Allyldeoxoartemisinin, 13-Deoxydoxorubicin, 14C BMS-275183, 17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521, 2-Deoxy-D-glucose, 2-Ethylhydrazide, 2-Fluoroadenine, 2-Fluorofucose-containing SGN-2FF, 2-Hydroxyestradiol, 2-Hydroxyestrone, 2-Hydroxyflutamide Depot, 2-Hydroxyoleic Acid, 2-Methoxyestradiol, 2-Methoxyestradiol Nanocrystal Colloidal Dispersion, 2-Methoxyestrone, 2-O; 3-O Desulfated Heparin, 2;6-Diaminopurine, 2;6-Dimethoxyquinone, 2'-F-ara-deoxyuridine, 3'-C-ethynylcytidine, 3'-dA Phosphoramidate NUC-7738, 4-Nitroestrone 3-Methyl Ether, 4-Thio-2-deoxycytidine, 4'-Iodo-4'-Deoxydoxorubicin, 5-Aza-4'-thio-2'-deoxycytidine, 5-Fluoro-2-Deoxycytidine, 6-Phosphofructo-2-kinase/fructose-2;6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158, 7-Cyanoquinocarcinol, 7-Ethyl-10-Hydroxycamptothecin, 7-Hydroxystaurosporine, 8-Azaguanine, 9-Ethyl 6-Mercaptopurine, 9H-Purine-6Thio-98D, A2A Receptor Antagonist EOS100850, Abagovomab, Abarelix, Abemaciclib, Abemaciclib Mesylate, Abexinostat, Abexinostat Tosylate, Abiraterone, Abiraterone Acetate, Abituzumab, Acai Berry Juice, Acalabrutinib, Acalisib, Aceglatone, Acetylcysteine, Acitretin, Acivicin, Aclacinomycin B, Aclarubicin, Acodazole, Acodazole Hydrochloride, Acolbifene Hydrochloride, Acridine, Acridine Carboxamide, Acronine, Actinium Ac 225 Lintuzumab, Actinium Ac 225-FPI-1434, Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591, Actinomycin C2, Actinomycin C3, Actinomycin F1, Activin Type 2B Receptor Fc Fusion Protein STM 434, Acyclic Nucleoside Phosphonate Prodrug ABI-1968, Ad-RTS-hIL-12, Adagloxad Simolenin, Adavosertib, Adecatumumab, Adenosine A2A Receptor Antagonist AZD4635, Adenosine A2A Receptor Antagonist CS3005, Adenosine A2A Receptor Antagonist NIR178, Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999, Adenosine A2A/A2B Receptor Antagonist AB928, Adenosine A2B Receptor Antagonist PBF-1129, Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201, Adenoviral Brachyury Vaccine ETBX-051, Adenoviral Cancer Vaccine PF-06936308, Adenoviral MUC1 Vaccine ETBX-061, Adenoviral PSA Vaccine ETBX-071, Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001, Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901, Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE, Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918, Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931, Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3, Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001, Aderbasib, ADH-1, AE37 Peptide/GM-CSF Vaccine, AEE788, Aerosol Gemcitabine, Aerosolized Aldesleukin, Aerosolized Liposomal Rubitecan, Afatinib, Afatinib Dimaleate, Afimoxifene, Afuresertib, Agatolimod Sodium, Agerafenib, Aglatimagene Besadenovec, Agonistic Anti-CD40 Monoclonal Antibody ADC-1013, Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Agonistic Anti-OX40 Monoclonal Antibody MEDI6469, AKR1C3-activated Prodrug OBI-3424, AKT 1/2 Inhibitor BAY1125976, AKT Inhibitor ARQ 092, Akt Inhibitor LY2780301, Akt Inhibitor MK2206, Akt Inhibitor SR13668, Akt/ERK Inhibitor ONC201, Alacizumab Pegol, Alanosine, Albumin-binding Cisplatin Prodrug BTP-114, Aldesleukin, Aldoxorubicin, Alectinib, Alefacept, Alemtuzumab, Alestramustine, Alflutinib Mesylate, Algenpantucel-L, Alisertib, Alitretinoin, ALK Inhibitor, ALK Inhibitor ASP3026, ALK Inhibitor PLB 1003, ALK Inhibitor RO5424802, ALK Inhibitor TAE684, ALK Inhibitor WX-0593, ALK-2 Inhibitor TP-0184, ALK-FAK Inhibitor CEP-37440, ALK/c-Met Inhibitor TQ-B3139, ALK/FAK/Pyk2 Inhibitor CT-707, ALK/ROS1/Met Inhibitor TQ-B3101, ALK/TRK Inhibitor TSR-011, Alkotinib, Allodepleted T Cell Immunotherapeutic ATIR101, Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715, Allogeneic Anti-BCMA-CAR T-cells PBCAR269A, Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells, Allogeneic Anti-CD19 CAR T-cells ALLO-501A, Allogeneic Anti-CD19 Universal CAR-T Cells CTA101, Allogeneic Anti-CD19-CAR T-cells PBCAR0191, Allogeneic Anti-CD20 CAR T-cells LUCAR-20S, Allogeneic Anti-CD20-CAR T-cells PBCAR20A, Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22, Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100, Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001, Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Allogeneic Cellular Vaccine 1650-G, Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120, Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130, Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine, Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo, Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2, Allogeneic Irradiated Melanoma Cell Vaccine CSF470, Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307, Allogeneic Melanoma Vaccine AGI-101H, Allogeneic Natural Killer Cell Line MG4101, Allogeneic Natural Killer Cell Line NK-92, Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01, Allogeneic Renal Cell Carcinoma Vaccine MGN1601, Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19, Allosteric ErbB Inhibitor BDTX-189, Allovectin-7, Almurtide, Alobresib, Alofanib, Alpelisib, Alpha Galactosylceramide, Alpha V Beta 1 Inhibitor ATN-161, Alpha V Beta 8 Antagonist PF-06940434, alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801, Alpha-Gal AGI-134, Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H, Alpha-Thioguanine Deoxyriboside, Alpha-tocopheryloxyacetic Acid, Alsevalimab, Altiratinib, Altretamine, Alvespimycin, Alvespimycin Hydrochloride, Alvocidib, Alvocidib Hydrochloride, Alvocidib Prodrug TP-1287, Amatuximab, Ambamustine, Ambazone, Amblyomin-X, Amcasertib, Ametantrone, Amifostine, Amino Acid Injection, Aminocamptothecin, Aminocamptothecin Colloidal Dispersion, Aminoflavone Prodrug AFP464, Aminopterin, Aminopterin Sodium, Amivantamab, Amolimogene Bepiplasmid, Amonafide L-Malate, Amrubicin, Amrubicin Hydrochloride, Amsacrine, Amsacrine Lactate, Amsilarotene, Amustaline, Amustaline Dihydrochloride, Amuvatinib, Amuvatinib Hydrochloride, Anakinra, Anastrozole, Anaxirone, Ancitabine, Ancitabine Hydrochloride, Andecaliximab, Androgen Antagonist APC-100, Androgen Receptor Antagonist BAY 1161116, Androgen Receptor Antagonist SHR3680, Androgen Receptor Antagonist TAS3681, Androgen Receptor Antagonist TRC253, Androgen Receptor Antisense Oligonucleotide AZD5312, Androgen Receptor Antisense Oligonucleotide EZN-4176, Androgen Receptor Degrader ARV-110, Androgen Receptor Degrader CC-94676, Androgen Receptor Downregulator AZD3514, Androgen Receptor Inhibitor EPI-7386, Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118, Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10, Andrographolide, Androstane Steroid HE3235, Anetumab Ravtansine, Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241, Angiogenesis Inhibitor GT-111, Angiogenesis Inhibitor JI-101, Angiogenesis/Heparanase Inhibitor PG545, Angiopoietin-2-specific Fusion Protein PF-04856884, Anhydrous Enol-oxaloacetate, Anhydrovinblastine, Aniline Mustard, Anlotinib Hydrochloride, Annamycin, Annamycin Liposomal, Annonaceous Acetogenins, Ansamitomicin P-3, Anthramycin, Anthrapyrazole, Anti c-KIT Antibody-drug Conjugate LOP628, Anti-5T4 Antibody-drug Conjugate ASN004, Anti-5T4 Antibody-Drug Conjugate PF-06263507, Anti-5T4 Antibody-drug Conjugate SYD1875, Anti-A33 Monoclonal Antibody KRN330, Anti-A5B1 Integrin Monoclonal Antibody PF-04605412, Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087, Anti-AG7 Antibody Drug Conjugate AbGn-107, Anti-AGS-16 Monoclonal Antibody AGS-16M18, Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME, Anti-AGS-8 Monoclonal Antibody AGS-8M4, Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B, Anti-alpha5beta1 Integrin Antibody MINT1526A, Anti-ANG2 Monoclonal Antibody MEDI-3617, Anti-angiopoietin Monoclonal Antibody AMG 780, Anti-APRIL Monoclonal Antibody BION-1301, Anti-AXL Fusion Protein AVB-S6-500, Anti-AXL/PBD Antibody-drug Conjugate ADCT-601, Anti-B7-H3 Antibody DS-5573a, Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a, Anti-B7-H4 Monoclonal Antibody FPA150, Anti-B7H3 Antibody-drug Conjugate MGC018, Anti-BCMA Antibody SEA-BCMA, Anti-BCMA Antibody-drug Conjugate AMG 224, Anti-BCMA Antibody-drug Conjugate CC-99712, Anti-BCMA Antibody-drug Conjugate GSK2857916, Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA, Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459, Anti-BCMA/CD3 BiTE Antibody AMG 420, Anti-BCMA/CD3 BiTE Antibody AMG 701, Anti-BCMA/CD3 BiTE Antibody REGN5458, Anti-BCMA/PBD ADC MEDI2228, Anti-BTLA Monoclonal Antibody TAB004, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, Anti-c-fms Monoclonal Antibody AMG 820, Anti-c-KIT Monoclonal Antibody CDX 0158, Anti-c-Met Antibody-drug Conjugate HTI-1066, Anti-c-Met Antibody-drug Conjugate TR1801, Anti-c-Met Monoclonal Antibody ABT-700, Anti-c-Met Monoclonal Antibody ARGX-111, Anti-c-Met Monoclonal Antibody HLX55, Anti-c-MET Monoclonal Antibody LY2875358, Anti-C-met Monoclonal Antibody SAIT301, Anti-C4.4a Antibody-Drug Conjugate BAY1129980, Anti-C5aR Monoclonal Antibody IPH5401, Anti-CA19-9 Monoclonal Antibody 5B1, Anti-CA6-DM4 Immunoconjugate SAR566658, Anti-CCR7 Antibody-drug Conjugate JBH492, Anti-CD117 Monoclonal Antibody JSP191, Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1, Anti-CD123 ADC IMGN632, Anti-CD123 Monoclonal Antibody CSL360, Anti-CD123 Monoclonal Antibody KHK2823, Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404, Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A, Anti-CD123/CD3 Bispecific Antibody APVO436, Anti-CD123/CD3 Bispecific Antibody JNJ-63709178, Anti-CD123/CD3 BiTE Antibody SAR440234, Anti-CD137 Agonistic Monoclonal Antibody ADG106, Anti-CD137 Agonistic Monoclonal Antibody AGEN2373, Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017, Anti-CD137 Agonistic Monoclonal Antibody CTX-471, Anti-CD137 Agonistic Monoclonal Antibody LVGN6051, Anti-CD157 Monoclonal Antibody MEN1112, Anti-CD166 Probody-drug Conjugate CX-2009, Anti-CD19 Antibody-drug Conjugate SGN-CD19B, Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003, Anti-CD19 iCAR NK Cells, Anti-CD19 Monoclonal Antibody DI-B4, Anti-CD19 Monoclonal Antibody MDX-1342, Anti-CD19 Monoclonal Antibody MEDI-551, Anti-CD19 Monoclonal Antibody XmAb5574, Anti-CD19-DM4 Immunoconjugate SAR3419, Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL, Anti-CD19/CD22 CAR NK Cells, Anti-CD19/CD3 BiTE Antibody AMG 562, Anti-CD19/CD3 Tetravalent Antibody AFM11, Anti-CD20 Monoclonal Antibody B001, Anti-CD20 Monoclonal Antibody BAT4306F, Anti-CD20 Monoclonal Antibody MIL62, Anti-CD20 Monoclonal Antibody PRO131921, Anti-CD20 Monoclonal Antibody SCT400, Anti-CD20 Monoclonal Antibody TL011, Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002, Anti-CD20-engineered Toxin Body MT-3724, Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323, Anti-CD20/CD3 Monoclonal Antibody REGN1979, Anti-CD20/CD3 Monoclonal Antibody XmAb13676, Anti-CD205 Antibody-drug Conjugate OBT076, Anti-CD22 ADC TRPH-222, Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S, Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A, Anti-CD25 Monoclonal Antibody RO7296682, Anti-CD25-PBD Antibody-drug Conjugate ADCT-301, Anti-CD26 Monoclonal Antibody YS110, Anti-CD27 Agonistic Monoclonal Antibody MK-5890, Anti-CD27L Antibody-Drug Conjugate AMG 172, Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1), Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135, Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119, Anti-CD3/CD20 Bispecific Antibody GEN3013, Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424, Anti-CD3/CD7-Ricin Toxin A Immunotoxin, Anti-CD30 Monoclonal Antibody MDX-1401, Anti-CD30 Monoclonal Antibody XmAb2513, Anti-CD30/CD16A Monoclonal Antibody AFM13, Anti-CD30/DM1 Antibody-drug Conjugate F0002, Anti-CD32B Monoclonal Antibody BI-1206, Anti-CD33 Antibody-drug Conjugate IMGN779, Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564, Anti-CD33 Monoclonal Antibody BI 836858, Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633, Anti-CD33/CD3 Bispecific Antibody GEM 333, Anti-CD33/CD3 Bispecific Antibody JNJ-67571244, Anti-CD33/CD3 BiTE Antibody AMG 330, Anti-CD33/CD3 BiTE Antibody AMG 673, Anti-CD352 Antibody-drug Conjugate SGN-CD352A, Anti-CD37 Antibody-Drug Conjugate IMGN529, Anti-CD37 Bispecific Monoclonal Antibody GEN3009, Anti-CD37 MMAE Antibody-drug Conjugate AGS67E, Anti-CD37 Monoclonal Antibody BI 836826, Anti-CD38 Antibody-drug Conjugate STI-6129, Anti-CD38 Monoclonal Antibody MOR03087, Anti-CD38 Monoclonal Antibody SAR442085, Anti-CD38 Monoclonal Antibody TAK-079, Anti-CD38-targeted IgG4-attenuated IFNa TAK-573, Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257, Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342, Anti-CD39 Monoclonal Antibody SRF617, Anti-CD39 Monoclonal Antibody TTX-030, Anti-CD40 Agonist Monoclonal Antibody ABBV-927, Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Anti-CD40 Monoclonal Antibody Chi Lob 7/4, Anti-CD40 Monoclonal Antibody SEA-CD40, Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042, Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428, Anti-CD40L Fc-Fusion Protein BMS-986004, Anti-CD44 Monoclonal Antibody RO5429083, Anti-CD45 Monoclonal Antibody AHN-12, Anti-CD46 Antibody-drug Conjugate FOR46, Anti-CD47 ADC SGN-CD47M, Anti-CD47 Monoclonal Antibody AO-176, Anti-CD47 Monoclonal Antibody CC-90002, Anti-CD47 Monoclonal Antibody Hu5F9-G4, Anti-CD47 Monoclonal Antibody IBI188, Anti-CD47 Monoclonal Antibody IMC-002, Anti-CD47 Monoclonal Antibody SHR-1603, Anti-CD47 Monoclonal Antibody SRF231, Anti-CD47 Monoclonal Antibody TJC4, Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801, Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A, Anti-CD52 Monoclonal Antibody ALLO-647, Anti-CD70 Antibody-Drug Conjugate MDX-1203, Anti-CD70 Antibody-drug Conjugate SGN-CD70A, Anti-CD70 CAR-expressing T Lymphocytes, Anti-CD70 Monoclonal Antibody MDX-1411, Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029, Anti-CD73 Monoclonal Antibody BMS-986179, Anti-CD73 Monoclonal Antibody CPI-006, Anti-CD73 Monoclonal Antibody NZV930, Anti-CD73 Monoclonal Antibody TJ4309, Anti-CD74 Antibody-drug Conjugate STRO-001, Anti-CD98 Monoclonal Antibody IGN523, Anti-CDH6 Antibody-drug Conjugate HKT288, Anti-CEA BiTE Monoclonal Antibody AMG211, Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody, Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2, Anti-CEACAM1 Monoclonal Antibody CM-24, Anti-CEACAM5 Antibody-Drug Conjugate SAR408701, Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47, Anti-CEACAM6 Antibody BAY1834942, Anti-claudin18.2 Monoclonal Antibody AB011, Anti-Claudin18.2 Monoclonal Antibody TST001, Anti-CLDN6 Monoclonal Antibody ASP1650, Anti-CLEC12A/CD3 Bispecific Antibody MCLA117, Anti-CLEVER-1 Monoclonal Antibody FP-1305, Anti-CSF1 Monoclonal Antibody PD-0360324, Anti-CSF1R Monoclonal Antibody IMC-CS4, Anti-CSF1R Monoclonal Antibody SNDX-6352, Anti-CTGF Monoclonal Antibody FG-3019, Anti-CTLA-4 Monoclonal Antibody ADG116, Anti-CTLA-4 Monoclonal Antibody ADU-1604, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Anti-CTLA-4 Monoclonal Antibody BCD-145, Anti-CTLA-4 Monoclonal Antibody HBM4003, Anti-CTLA-4 Monoclonal Antibody MK-1308, Anti-CTLA-4 Monoclonal Antibody ONC-392, Anti-CTLA-4 Monoclonal Antibody REGN4659, Anti-CTLA-4 Probody BMS-986288, Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217, Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841, Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015, Anti-CTLA4 Antibody Fc Fusion Protein KN044, Anti-CTLA4 Monoclonal Antibody BMS-986218, Anti-CXCR4 Monoclonal Antibody PF-06747143, Anti-Denatured Collagen Monoclonal Antibody TRC093, Anti-DKK-1 Monoclonal Antibody LY2812176, Anti-DKK1 Monoclonal Antibody BHQ880, Anti-DLL3/CD3 BiTE Antibody AMG 757, Anti-DLL4 Monoclonal Antibody MEDI0639, Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83, Anti-DR5 Agonist Monoclonal Antibody TRA-8, Anti-DR5 Agonistic Antibody DS-8273a, Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Anti-EGFR Monoclonal Antibody CPGJ 602, Anti-EGFR Monoclonal Antibody EMD 55900, Anti-EGFR Monoclonal Antibody GC1118, Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX, Anti-EGFR Monoclonal Antibody HLX-07, Anti-EGFR Monoclonal Antibody Mixture MM-151, Anti-EGFR Monoclonal Antibody RO5083945, Anti-EGFR Monoclonal Antibody SCT200, Anti-EGFR Monoclonal Antibody SYN004, Anti-EGFR TAP Antibody-drug Conjugate IMGN289, Anti-EGFR/c-Met Bispecific Antibody EMB-01, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, Anti-EGFR/CD16A Bispecific Antibody AFM24, Anti-EGFR/DM1 Antibody-drug Conjugate AVID100, Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013, Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321, Anti-EGFRvIII Antibody Drug Conjugate AMG 595, Anti-EGFRvIII Immunotoxin MR1-1, Anti-EGFRvIII/CD3 BiTE Antibody AMG 596, Anti-EGP-2 Immunotoxin MOC31-PE, Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F, Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F, Anti-Ep-CAM Monoclonal Antibody ING-1, Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310, Anti-EphA2 Monoclonal Antibody DS-8895a, Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547, Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111, Anti-ErbB3 Antibody ISU104, Anti-ErbB3 Monoclonal Antibody AV-203, Anti-ErbB3 Monoclonal Antibody CDX-3379, Anti-ErbB3 Monoclonal Antibody REGN1400, Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141, Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A, Anti-FAP/Interleukin-2 Fusion Protein RO6874281, Anti-FCRH5/CD3 BiTE Antibody BFCR4350A, Anti-FGFR2 Antibody BAY1179470, Anti-FGFR3 Antibody-drug Conjugate LY3076226, Anti-FGFR4 Monoclonal Antibody U3-1784, Anti-FLT3 Antibody-drug Conjugate AGS62P1, Anti-FLT3 Monoclonal Antibody 4G8-SDIEM, Anti-FLT3 Monoclonal Antibody IMC-EB10, Anti-FLT3/CD3 BiTE Antibody AMG 427, Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002, Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202, Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012, Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962, Anti-GARP Monoclonal Antibody ABBV-151, Anti-GCC Antibody-Drug Conjugate MLN0264, Anti-GCC Antibody-Drug Conjugate TAK-164, Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody, Anti-GD2 Monoclonal Antibody hu14.18K322A, Anti-GD2 Monoclonal Antibody MORAb-028, Anti-GD3 Antibody-drug Conjugate PF-06688992, Anti-GITR Agonistic Monoclonal Antibody ASP1951, Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Anti-GITR Agonistic Monoclonal Antibody INCAGN01876, Anti-GITR Monoclonal Antibody GWN 323, Anti-GITR Monoclonal Antibody MK-4166, Anti-Globo H Monoclonal Antibody OBI-888, Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999, Anti-Glypican 3/CD3 Bispecific Antibody ERY974, Anti-GnRH Vaccine PEP223, Anti-gpA33/CD3 Monoclonal Antibody MGD007, Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a, Anti-gremlin-1 Monoclonal Antibody UCB6114, Anti-GRP78 Monoclonal Antibody PAT-SM6, Anti-HA Epitope Monoclonal Antibody MEDI8852, Anti-HB-EGF Monoclonal Antibody KHK2866, Anti-HBEGF Monoclonal Antibody U3-1565, Anti-hepcidin Monoclonal Antibody LY2787106, Anti-HER-2 Bispecific Antibody KN026, Anti-HER2 ADC DS-8201a, Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702, Anti-HER2 Antibody-drug Conjugate A166, Anti-HER2 Antibody-drug Conjugate ARX788, Anti-HER2 Antibody-drug Conjugate BAT8001, Anti-HER2 Antibody-drug Conjugate DP303c, Anti-HER2 Antibody-drug Conjugate MEDI4276, Anti-HER2 Antibody-drug Conjugate RC48, Anti-HER2 Bi-specific Monoclonal Antibody ZW25, Anti-HER2 Bispecific Antibody-drug Conjugate ZW49, Anti-HER2 Immune Stimulator-antibody Conjugate NJH395, Anti-HER2 Monoclonal Antibody B002, Anti-HER2 Monoclonal Antibody CT-P6, Anti-HER2 Monoclonal Antibody HLX22, Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343, Anti-HER2-DM1 ADC B003, Anti-HER2-DM1 Antibody-drug Conjugate GQ1001, Anti-HER2-vc0101 ADC PF-06804103, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302, Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522, Anti-HER2/MMAE Antibody-drug Conjugate MRG002, Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A, Anti-HER3 Antibody-drug Conjugate U3 1402, Anti-HER3 Monoclonal Antibody GSK2849330, Anti-HGF Monoclonal Antibody TAK-701, Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968, Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1, Anti-HLA-DR Monoclonal Antibody IMMU-114, Anti-HLA-G Antibody TTX-080, Anti-human GITR Monoclonal Antibody AMG 228, Anti-human GITR Monoclonal Antibody TRX518, Anti-ICAM-1 Monoclonal Antibody BI-505, Anti-ICOS Agonist Antibody GSK3359609, Anti-ICOS Agonist Monoclonal Antibody BMS-986226, Anti-ICOS Monoclonal Antibody KY1044, Anti-ICOS Monoclonal Antibody MEDI-570, Anti-IGF-1R Monoclonal Antibody AVE1642, Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, Anti-IL-1 alpha Monoclonal Antibody MABp1, Anti-IL-13 Humanized Monoclonal Antibody TNX-650, Anti-IL-15 Monoclonal Antibody AMG 714, Anti-IL-8 Monoclonal Antibody BMS-986253, Anti-IL-8 Monoclonal Antibody HuMax-IL8, Anti-ILDR2 Monoclonal Antibody BAY 1905254, Anti-ILT4 Monoclonal Antibody MK-4830, Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A, Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388, Anti-IRF4 Antisense Oligonucleotide ION251, Anti-KIR Monoclonal Antibody IPH 2101, Anti-KSP/Anti-VEGF siRNAs ALN-VSP02, Anti-LAG-3 Monoclonal Antibody IBI-110, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG-3 Monoclonal Antibody LAG525, Anti-LAG-3 Monoclonal Antibody REGN3767, Anti-LAG-3/PD-L1 Bispecific Antibody FS118, Anti-LAG3 Monoclonal Antibody BI 754111, Anti-LAG3 Monoclonal Antibody MK-4280, Anti-LAG3 Monoclonal Antibody TSR-033, Anti-LAMP1 Antibody-drug Conjugate SAR428926, Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181, Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102, Anti-LGR5 Monoclonal Antibody BNC101, Anti-LIF Monoclonal Antibody MSC-1, Anti-LILRB4 Monoclonal Antibody IO-202, Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A, Anti-Ly6E Antibody-Drug Conjugate RG 7841, Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C, Anti-Melanin Monoclonal Antibody PTI-6D2, Anti-mesothelin Antibody-drug Conjugate BMS-986148, Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100, Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A, Anti-mesothelin/MMAE Antibody-drug Conjugate RC88, Anti-Met Monoclonal Antibody Mixture Sym015, Anti-Met/EGFR Monoclonal Antibody LY3164530, Anti-MMP-9 Monoclonal Antibody GS-5745, Anti-MUC1 Monoclonal Antibody BTH1704, Anti-MUC16/CD3 Bispecific Antibody REGN4018, Anti-MUC16/CD3 BiTE Antibody REGN4018, Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A, Anti-MUC17/CD3 BiTE Antibody AMG 199, Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062, Anti-myostatin Monoclonal Antibody LY2495655, Anti-NaPi2b Antibody-drug Conjugate XMT-1592, Anti-NaPi2b Monoclonal Antibody XMT-1535, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A, Anti-nf-P2X7 Antibody Ointment BIL-010t, Anti-NRP1 Antibody ASP1948, Anti-Nucleolin Aptamer AS1411, Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A, Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso, Anti-OFA Immunotherapeutic BB-MPI-03, Anti-OX40 Agonist Monoclonal Antibody ABBV-368, Anti-OX40 Agonist Monoclonal Antibody BGB-A445, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Anti-OX40 Antibody BMS 986178, Anti-OX40 Hexavalent Agonist Antibody INBRX-106, Anti-OX40 Monoclonal Antibody GSK3174998, Anti-OX40 Monoclonal Antibody IBI101, Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256, Anti-PD-1 Checkpoint Inhibitor PF-06801591, Anti-PD-1 Fusion Protein AMP-224, Anti-PD-1 Monoclonal Antibody 609A, Anti-PD-1 Monoclonal Antibody AK105, Anti-PD-1 Monoclonal Antibody AMG 404, Anti-PD-1 Monoclonal Antibody BAT1306, Anti-PD-1 Monoclonal Antibody BCD-100, Anti-PD-1 Monoclonal Antibody BI 754091, Anti-PD-1 Monoclonal Antibody CS1003, Anti-PD-1 Monoclonal Antibody F520, Anti-PD-1 Monoclonal Antibody GLS-010, Anti-PD-1 Monoclonal Antibody HLX10, Anti-PD-1 Monoclonal Antibody HX008, Anti-PD-1 Monoclonal Antibody JTX-4014, Anti-PD-1 Monoclonal Antibody LZM009, Anti-PD-1 Monoclonal Antibody MEDI0680, Anti-PD-1 Monoclonal Antibody MGA012, Anti-PD-1 Monoclonal Antibody SCT-I10A, Anti-PD-1 Monoclonal Antibody Sym021, Anti-PD-1 Monoclonal Antibody TSR-042, Anti-PD-1/Anti-CTLA4 DART Protein MGD019, Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315, Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669, Anti-PD-1/Anti-LAG-3 DART Protein MGD013, Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318, Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172, Anti-PD-1/CD47 Infusion Protein HX009, Anti-PD-1/CTLA-4 Bispecific Antibody AK104, Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752, Anti-PD-1/TIM-3 Bispecific Antibody RO7121661, Anti-PD-1/VEGF Bispecific Antibody AK112, Anti-PD-L1 Monoclonal Antibody A167, Anti-PD-L1 Monoclonal Antibody BCD-135, Anti-PD-L1 Monoclonal Antibody BGB-A333, Anti-PD-L1 Monoclonal Antibody CBT-502, Anti-PD-L1 Monoclonal Antibody CK-301, Anti-PD-L1 Monoclonal Antibody CS1001, Anti-PD-L1 Monoclonal Antibody FAZ053, Anti-PD-L1 Monoclonal Antibody GR1405, Anti-PD-L1 Monoclonal Antibody HLX20, Anti-PD-L1 Monoclonal Antibody IMC-001, Anti-PD-L1 Monoclonal Antibody LY3300054, Anti-PD-L1 Monoclonal Antibody MDX-1105, Anti-PD-L1 Monoclonal Antibody MSB2311, Anti-PD-L1 Monoclonal Antibody RC98, Anti-PD-L1 Monoclonal Antibody SHR-1316, Anti-PD-L1 Monoclonal Antibody TG-1501, Anti-PD-L1 Monoclonal Antibody ZKAB001, Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105, Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046, Anti-PD-L1/CD137 Bispecific Antibody MCLA-145, Anti-PD-L1/IL-15 Fusion Protein KD033, Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244, Anti-PD1 Monoclonal Antibody AGEN2034, Anti-PD1/CTLA4 Bispecific Antibody XmAb20717, Anti-PGF Monoclonal Antibody RO5323441, Anti-PKN3 siRNA Atu027, Anti-PLGF Monoclonal Antibody TB-403, Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Anti-PRAME Immunotherapeutic GSK2302032A, Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Anti-PRL-3 Monoclonal Antibody PRL3-zumab, Anti-prolactin Receptor Antibody LFA102, Anti-PSCA Monoclonal Antibody AGS-1C4D4, Anti-PSMA Monoclonal Antibody MDX1201-A488, Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704, Anti-PSMA Monoclonal Antibody-MMAE Conjugate, Anti-PSMA/CD28 Bispecific Antibody REGN5678, Anti-PSMA/CD3 Bispecific Antibody CCW702, Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081, Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414, Anti-PSMA/PBD ADC MEDI3726, Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020, Anti-PVRIG Monoclonal Antibody COM701, Anti-RANKL Monoclonal Antibody GB-223, Anti-RANKL Monoclonal Antibody JMT103, Anti-Ribonucleoprotein Antibody ATRC-101, Anti-ROR1 ADC VLS-101, Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002, Anti-S15 Monoclonal Antibody NC318, Anti-sCLU Monoclonal Antibody AB-16B5, Anti-SIRPa Monoclonal Antibody CC-95251, Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E, Anti-TAG-72 Monoclonal Antibody scFV CC-49/218, Anti-TF Monoclonal Antibody ALT-836, Anti-TGF-beta Monoclonal Antibody NIS793, Anti-TGF-beta Monoclonal Antibody SAR-439459, Anti-TGF-beta RII Monoclonal Antibody IMC-TR1, Anti-TIGIT Monoclonal Antibody AB154, Anti-TIGIT Monoclonal Antibody BGB-A1217, Anti-TIGIT Monoclonal Antibody BMS-986207, Anti-TIGIT Monoclonal Antibody COM902, Anti-TIGIT Monoclonal Antibody OMP-313M32, Anti-TIGIT Monoclonal Antibody SGN-TGT, Anti-TIM-3 Antibody BMS-986258, Anti-TIM-3 Monoclonal Antibody BGB-A425, Anti-TIM-3 Monoclonal Antibody INCAGN02390, Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM-3 Monoclonal Antibody Sym023, Anti-TIM-3 Monoclonal Antibody TSR-022, Anti-TIM3 Monoclonal Antibody LY3321367, Anti-TIM3 Monoclonal Antibody SHR-1702, Anti-Tissue Factor Monoclonal Antibody MORAb-066, Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711, Anti-TROP2 Antibody-drug Conjugate BAT8003, Anti-TROP2 Antibody-drug Conjugate SKB264, Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a, Anti-TWEAK Monoclonal Antibody RG7212, Anti-VEGF Anticalin PRS-050-PEG40, Anti-VEGF Monoclonal Antibody hPV19, Anti-VEGF/ANG2 Nanobody BI 836880, Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T, Anti-VEGFC Monoclonal Antibody VGX-100, Anti-VEGFR2 Monoclonal Antibody HLX06, Anti-VEGFR2 Monoclonal Antibody MSB0254, Anti-VEGFR3 Monoclonal Antibody IMC-3C5, Anti-VISTA Monoclonal Antibody JNJ 61610588, Antiangiogenic Drug Combination TL-118, Antibody-drug Conjugate ABBV-011, Antibody-drug Conjugate ABBV-085, Antibody-drug Conjugate ABBV-155, Antibody-drug Conjugate ABBV-176, Antibody-drug Conjugate ABBV-838, Antibody-drug Conjugate ADC XMT-1536, Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014, Antibody-Drug Conjugate DFRF4539A, Antibody-drug Conjugate MEDI7247, Antibody-drug Conjugate PF-06647263, Antibody-drug Conjugate PF-06664178, Antibody-drug Conjugate SC-002, Antibody-drug Conjugate SC-003, Antibody-drug Conjugate SC-004, Antibody-drug Conjugate SC-005, Antibody-drug Conjugate SC-006, Antibody-drug Conjugate SC-007, Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008, Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV, Antimetabolite FF-10502, Antineoplastic Agent Combination SM-88, Antineoplastic Vaccine, Antineoplastic Vaccine GV-1301, Antineoplaston A10, Antineoplaston AS2-1, Antisense Oligonucleotide GTI-2040, Antisense Oligonucleotide QR-313, Antitumor B Key Active Component-alpha, Antrodia cinnamomea Supplement, Antroquinonol Capsule, Apalutamide, Apatorsen, Apaziquone, APC8015F, APE1/Ref-1 Redox Inhibitor APX3330, Aphidicoline Glycinate, Apilimod Dimesylate Capsule, Apitolisib, Apolizumab, Apomab, Apomine, Apoptosis Inducer BZL101, Apoptosis Inducer GCS-100, Apoptosis Inducer MPC-2130, Apricoxib, Aprinocarsen, Aprutumab, Aprutumab Ixadotin, AR Antagonist BMS-641988, Arabinoxylan Compound MGN3, Aranose, ARC Fusion Protein SL-279252, Archexin, Arcitumomab, Arfolitixorin, Arginase Inhibitor INCB001158, Arginine Butyrate, Arnebia Indigo Jade Pearl Topical Cream, Arsenic Trioxide, Arsenic Trioxide Capsule Formulation ORH 2014, Artemether Sublingual Spray, Artemisinin Dimer, Artesunate, Arugula Seed Powder, Aryl Hydrocarbon Receptor Antagonist BAY2416964, Aryl Hydrocarbon Receptor Inhibitor IK-175, Asaley, Asciminib, Ascrinvacumab, Ashwagandha Root Powder Extract, ASP4132, Aspacytarabine, Asparaginase, Asparaginase Erwinia chrysanthemi, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astuprotimut-R, Asulacrine, Asulacrine Isethionate, Asunercept, At 211 Monoclonal Antibody 81C6, Atamestane, Atezolizumab, Atiprimod, Atiprimod Dihydrochloride, Atiprimod Dimaleate, ATM Inhibitor M 3541, ATM Kinase Inhibitor AZD0156, ATM Kinase Inhibitor AZD1390, Atorvastatin Calcium, Atorvastatin Sodium, ATR Inhibitor RP-3500, ATR Kinase Inhibitor BAY1895344, ATR Kinase Inhibitor M1774, ATR Kinase Inhibitor M6620, ATR Kinase Inhibitor VX-803, Atrasentan Hydrochloride, Attenuated Listeria monocytogenes CRS-100, Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Attenuated Measles Virus Encoding SCD Transgene TMV-018, Atuveciclib, Audencel, Auranofin, Aurora A Kinase Inhibitor LY3295668, Aurora A Kinase Inhibitor LY3295668 Erbumine, Aurora A Kinase Inhibitor MK5108, Aurora A Kinase Inhibitor TAS-119, Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076, Aurora B Serine/Threonine Kinase Inhibitor TAK-901, Aurora B/C Kinase Inhibitor GSK1070916A, Aurora kinase A/B inhibitor TT-00420, Aurora Kinase Inhibitor AMG 900, Aurora Kinase Inhibitor BI 811283, Aurora Kinase Inhibitor MLN8054, Aurora Kinase Inhibitor PF-03814735, Aurora Kinase Inhibitor SNS-314, Aurora Kinase Inhibitor TTP607, Aurora Kinase/VEGFR2 Inhibitor CYC116, Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707, Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055, Autologous Anti-BCMA CAR T-cells PHE885, Autologous Anti-BCMA CAR-transduced T-cells KITE-585, Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11, Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053, Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Autologous Anti-CD123 CAR-T Cells, Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx, Autologous Anti-CD19 CAR T-cells IM19, Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19, Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19, Autologous Anti-CD19 CAR-CD28 T-cells ET019002, Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01, Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19, Autologous Anti-CD19 T-cell Receptor T cells ET190L1, Autologous Anti-CD19 TAC-T cells TAC01-CD19, Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells, Autologous Anti-CD19/CD22 CAR T-cells AUTO3, Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells, Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1, Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s, Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes, Autologous Anti-FLT3 CAR T Cells AMG 553, Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202, Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1, Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100, Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes, Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794, Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes, Autologous Anti-PSMA CAR-T Cells P-PSMA-101, Autologous AXL-targeted CAR T-cells CCT301-38, Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B, Autologous BCMA-targeted CAR T Cells CC-98633, Autologous BCMA-targeted CAR T Cells LCAR-B4822M, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022, Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006, Autologous CD123-4SCAR-expressing T-cells 4SCAR123, Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1, Autologous CD19-targeted CAR T Cells CC-97540, Autologous CD19-targeted CAR T Cells JWCAR029, Autologous CD19-targeted CAR-T Cells GC007F, Autologous CD19/PD-1 Bispecific CAR-T Cells, Autologous CD20-4SCAR-expressing T-cells 4SCAR20, Autologous CD22-4SCAR-expressing T-cells 4SCAR22, Autologous CD38-4SCAR-expressing T-cells 4SCAR38, Autologous Clonal Neoantigen T Cells ATL001, Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19, Autologous Deep IL-15 Primed T-cells TRQ15-01, Autologous Dendritic Cell Vaccine ACT2001, Autologous Dendritic Cell-based Immunotherapeutic AV0113, Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa, Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells, Autologous Genetically-modified MAGE-A4 C1032 T Cells, Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858, Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439, Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001, Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718, Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous Mesenchymal Stem Cells Apceth_101, Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11, Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC, Autologous Multi-lineage Potential Cells, Autologous Nectin-4/FAP-targeted CAR-T Cells, Autologous NKG2D CAR T-cells CYAD-02, Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01, Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine, Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001, Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101, Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601, Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201, Autologous ROR2-targeted CAR T-cells CCT301-59, Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1, Autologous TCR-engineered T-cells IMA201, Autologous TCR-engineered T-cells IMA202, Autologous TCR-engineered T-cells IMA203, Autologous TCRm-expressing T-cells ET140203, Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG, Autologous Tumor Infiltrating Lymphocytes LN-144, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T, Avadomide, Avadomide Hydrochloride, Avapritinib, Avdoralimab, Avelumab, Aviscumine, Avitinib Maleate, Axalimogene Filolisbac, Axatilimab, Axicabtagene Ciloleucel, Axitinib, AXL Inhibitor DS-1205c, AXL Inhibitor SLC-391, AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M, AXL/ FLT3/VEGFR2 Inhibitor KC1036, Axl/Mer Inhibitor INCB081776, Axl/Mer Inhibitor PF-07265807, Azacitidine, Azapicyl, Azaribine, Azaserine, Azathioprine, Azimexon, Azintuxizumab Vedotin, Aziridinylbenzoquinone RH1, Azotomycin, Azurin:50-77 Cell Penetrating Peptide p28, B-Raf/VEGFR-2 Inhibitor RAF265, Babaodan Capsule, Bacillus Calmette-Guerin Substrain Connaught Live Antigen, Bactobolin, Bafetinib, Balixafortide, Balstilimab, Baltaleucel-T, Banoxantrone, Barasertib, Bardoxolone, Bardoxolone Methyl, Baricitinib, Batabulin, Batabulin Sodium, Batimastat, Bavituximab, Bazedoxifene, Bazlitoran, BC-819 Plasmid/Polyethylenimine Complex, BCG Solution, BCG Tokyo-172 Strain Solution, BCG Vaccine, Bcl-2 Inhibitor APG 2575, Bcl-2 Inhibitor BCL201, Bcl-2 Inhibitor BGB-11417, Bcl-2 Inhibitor LP-108, Bcl-2 Inhibitor S65487, Bcl-Xs Adenovirus Vaccine, BCMA x CD3 T-cell Engaging Antibody CC-93269, BCMA-CD19 Compound CAR T Cells, BCMA/CD3e Tri-specific T-cell Activating Construct HPN217, Bcr-Abl Kinase Inhibitor K0706, Bcr-Abl Kinase Inhibitor PF-114, BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351, Beauvericin, Becatecarin, Belagenpumatucel-L, Belantamab Mafodotin, Belapectin, Belimumab, Belinostat, Belotecan Hydrochloride, Belvarafenib, Belzutifan, Bemarituzumab, Bemcentinib, Bempegaldesleukin, Benaxibine, Bendamustine, Bendamustine Hydrochloride, Bendamustine-containing Nanoparticle-based Formulation RXDX-107, Benzaldehyde Dimethane Sulfonate, Benzoylphenylurea, Berberine Chloride, Bermekimab, Bersanlimab, Berubicin Hydrochloride, Berzosertib, BET Bromodomain Inhibitor ZEN-3694, BET Inhibitor ABBV-744, BET Inhibitor BAY1238097, BET inhibitor BI 894999, BET Inhibitor BMS-986158, BET Inhibitor CC-90010, BET Inhibitor CPI-0610, BET Inhibitor FT-1101, BET Inhibitor GS-5829, BET Inhibitor GSK2820151, BET Inhibitor INCB054329, BET Inhibitor INCB057643, BET Inhibitor RO6870810, BET-bromodomain Inhibitor ODM-207, Beta Alethine, Beta-Carotene, Beta-elemene, Beta-Glucan, Beta-Glucan MM-10-001, Beta-lapachone Prodrug ARQ 761, Beta-Thioguanine Deoxyriboside, Betaglucin Gel, Betulinic Acid, Bevacizumab, Bexarotene, Bexmarilimab, BF-200 Gel Formulation, BH3 Mimetic ABT-737, Bi-functional Alkylating Agent VAL-083, Bicalutamide, Bimiralisib, Binetrakin, Binimetinib, Bintrafusp Alfa, Birabresib, Birinapant, Bis(choline)tetrathiomolybdate, Bisantrene, Bisantrene Hydrochloride, Bisnafide, Bisnafide Dimesylate, Bispecific Antibody 2B1, Bispecific Antibody AGEN1223, Bispecific Antibody AMG 509, Bispecific Antibody GS-1423, Bispecific Antibody MDX-H210, Bispecific Antibody MDX447, Bisthianostat, BiTE Antibody AMG 910, Bivalent BRD4 Inhibitor AZD5153, Bizalimogene Ralaplasmid, Bizelesin, BL22 Immunotoxin, Black Cohosh, Black Raspberry Nectar, Bleomycin, Bleomycin A2, Bleomycin B2, Bleomycin Sulfate, Blinatumomab, Blueberry Powder Supplement, BMI1 Inhibitor PTC596, BMS-184476, BMS-188797, BMS-214662, BMS-275183, Boanmycin Hydrochloride, Bomedemstat, Boronophenylalanine-Fructose Complex, Bortezomib, Bosutinib, Bosutinib Monohydrate, Botanical Agent BEL-X-HG, Botanical Agent LEAC-102, Bovine Cartilage, Bozitinib, BP-Cx1-Platinum Complex BP-C1, BR96-Doxorubicin Immunoconjugate, Brachyury-expressing Yeast Vaccine GI-6301, BRAF Inhibitor, BRAF Inhibitor ARQ 736, BRAF Inhibitor BGB-3245, BRAF Inhibitor PLX8394, BRAF(V600E) Kinase Inhibitor ABM-1310, BRAF(V600E) Kinase Inhibitor RO5212054, BRAF/EGFR Inhibitor BGB-283, BRAFV600/PI3K Inhibitor ASN003, BRD4 Inhibitor PLX2853, BRD4 Inhibitor PLX51107, Breflate, Brentuximab, Brentuximab Vedotin, Brequinar, Brequinar Sodium, Briciclib Sodium, Brigatinib, Brilanestrant, Brimonidine Tartrate Nanoemulsion OCU-300, Brivanib, Brivanib Alaninate, Brivudine, Brivudine Phosphoramidate, Broad-Spectrum Human Papillomavirus Vaccine V505, Broccoli Sprout/Broccoli Seed Extract Supplement, Bromacrylide, Bromebric Acid, Bromocriptine Mesylate, Brontictuzumab, Brostacillin Hydrochloride, Brostallicin, Broxuridine, Bruceanol A, Bruceanol B, Bruceanol C, Bruceanol D, Bruceanol E, Bruceanol F, Bruceanol G, Bruceanol H, Bruceantin, Bryostatin 1, BTK Inhibitor ARQ 531, BTK Inhibitor CT-1530, BTK Inhibitor DTRMWXHS-12, BTK Inhibitor HZ-A-018, BTK Inhibitor ICP-022, BTK Inhibitor LOXO-305, BTK Inhibitor M7583, BTK inhibitor TG-1701, Budigalimab, Budotitane, Bufalin, Buparlisib, Burixafor, Burixafor Hydrobromide, Burosumab, Buserelin, Bushen Culuan Decoction, Bushen-Jianpi Decoction, Busulfan, Buthionine Sulfoximine, BXQ-350 Nanovesicle Formulation, c-Kit Inhibitor PLX9486, c-Met Inhibitor ABN401, c-Met Inhibitor AL2846, c-Met Inhibitor AMG 208, c-Met Inhibitor AMG 337, c-Met Inhibitor GST-HG161, c-Met Inhibitor HS-10241, c-Met Inhibitor JNJ-38877605, c-Met Inhibitor MK2461, c-Met Inhibitor MK8033, c-Met Inhibitor MSC2156119J, C-myb Antisense Oligonucleotide G4460, c-raf Antisense Oligonucleotide ISIS 5132, C-VISA BikDD:Liposome, C/EBP Beta Antagonist ST101, CAB-ROR2-ADC BA3021, Cabazitaxel, Cabiralizumab, Cabozantinib, Cabozantinib S-malate, Cactinomycin, Caffeic Acid Phenethyl Ester, CAIX Inhibitor DTP348, CAIX Inhibitor SLC-0111, Calaspargase Pegol-mknl, Calcitriol, Calcium Release-activated Channel Inhibitor CM4620, Calcium Release-activated Channels Inhibitor RP4010, Calcium Saccharate, Calculus bovis/Moschus/Olibanum/Myrrha Capsule, Calicheamicin Gamma 1I, Camidanlumab Tesirine, Camptothecin, Camptothecin Analogue TLC388, Camptothecin Glycoconjugate BAY 38-3441, Camptothecin Sodium, Camptothecin-20(S)-O-Propionate Hydrate, Camrelizumab, Camsirubicin, Cancell, Cancer Peptide Vaccine S-588410, Canerpaturev, Canertinib Dihydrochloride, Canfosfamide, Canfosfamide Hydrochloride, Cannabidiol, Cantrixil, Cantuzumab Ravtansine, Capecitabine, Capecitabine Rapidly Disintegrating Tablet, Capivasertib, Capmatinib, Captopril, CAR T-Cells AMG 119, Caracemide, Carbendazim, Carbetimer, Carbogen, Carbon C 14-pamiparib, Carboplatin, Carboquone, Carboxyamidotriazole, Carboxyamidotriazole Orotate, Carboxyphenyl Retinamide, Carfilzomib, Caricotamide/Tretazicar, Carlumab, Carmofur, Carmustine, Carmustine Implant, Carmustine in Ethanol, Carmustine Sustained-Release Implant Wafer, Carotuximab, Carubicin, Carubicin Hydrochloride, Carzelesin, Carzinophilin, Cathelicidin LL-37, Cationic Liposome-Encapsulated Paclitaxel, Cationic Peptide Cream Cypep-1, Catumaxomab, CBP/beta-catenin Antagonist PRI-724, CBP/beta-catenin Modulator E7386, CCR2 Antagonist CCX872-B, CCR2 Antagonist PF-04136309, CCR2/CCR5 Antagonist BMS-813160, CCR4 Inhibitor FLX475, CD11b Agonist GB1275, CD123-CD33 Compound CAR T Cells, CD123-specific Targeting Module TM123, CD20-CD19 Compound CAR T Cells, CD28/ICOS Antagonist ALPN-101, CD4-specific Telomerase Peptide Vaccine UCPVax, CD40 Agonist Monoclonal Antibody CP-870;893, CD40 Agonistic Monoclonal Antibody APX005M, CD44 Targeted Agent SPL-108, CD44v6-specific CAR T-cells, CD47 Antagonist ALX148, CD73 Inhibitor AB680, CD73 Inhibitor LY3475070, CD80-Fc Fusion Protein ALPN-202, CD80-Fc Fusion Protein FPT155, CDC7 Inhibitor TAK-931, CDC7 Kinase Inhibitor BMS-863233, CDC7 Kinase Inhibitor LY3143921 Hydrate, CDC7 Kinase Inhibitor NMS-1116354, CDK Inhibitor AT7519, CDK Inhibitor R547, CDK Inhibitor SNS-032, CDK/JAK2/FLT3 Inhibitor TG02 Citrate, CDK1 Inhibitor BEY1107, CDK1/2/4 Inhibitor AG-024322, CDK2 Inhibitor PF-07104091, CDK2/4/6/FLT3 Inhibitor FN-1501, CDK2/5/9 Inhibitor CYC065, CDK4 Inhibitor P1446A-05, CDK4/6 Inhibitor, CDK4/6 Inhibitor BPI-16350, CDK4/6 Inhibitor CS3002, CDK4/6 Inhibitor FCN-437, CDK4/6 Inhibitor G1T38, CDK4/6 Inhibitor HS-10342, CDK4/6 Inhibitor SHR6390, CDK4/6 Inhibitor TQB3616, CDK7 Inhibitor CT7001, CDK7 Inhibitor SY-1365, CDK7 Inhibitor SY-5609, CDK8/19 Inhibitor SEL 120, CDK9 Inhibitor AZD4573, CEA-MUC-1-TRICOM Vaccine CV301, CEA-targeting Agent RG6123, CEBPA-targeting saRNA MTL-CEBPA Liposome, Cedazuridine, Cedazuridine/Azacitidine Combination Agent ASTX030, Cedazuridine/Decitabine Combination Agent ASTX727, Cedefingol, Cediranib, Cediranib Maleate, Celecoxib, Cell Cycle Checkpoint/DNA Repair Antagonist IC83, Cemadotin, Cemadotin Hydrochloride, Cemiplimab, Cenersen, Cenisertib, CENP-E Inhibitor GSK-923295, Ceralasertib, Ceramide Nanoliposome, Cerdulatinib, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282, Cereblon Modulator CC-90009, Cergutuzumab Amunaleukin, Ceritinib, Cesalin, cEt KRAS Antisense Oligonucleotide AZD4785, Cetrelimab, Cetuximab, Cetuximab Sarotalocan, Cetuximab-IR700 Conjugate RM-1929, Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY), Cevipabulin, Cevipabulin Fumarate, Cevipabulin Succinate, Cevostamab, cFMS Tyrosine Kinase Inhibitor ARRY-382, Chaparrin, Chaparrinone, Checkpoint Kinase Inhibitor AZD7762, Checkpoint Kinase Inhibitor XL844, Chemotherapy, Chiauranib, Chimeric Monoclonal Antibody 81C6, ChiNing Decoction, Chk1 Inhibitor CCT245737, Chk1 Inhibitor GDC-0425, Chk1 Inhibitor GDC-0575, CHK1 Inhibitor MK-8776, CHK1 Inhibitor PF-477736, Chlorambucil, Chlorodihydropyrimidine, Chloroquine, Chloroquinoxaline Sulfonamide, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, Chlorozotocin, Choline Kinase Alpha Inhibitor TCD-717, CHP-NY-ESO-1 Peptide Vaccine IMF-001, Chromomycin A3, Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement, Cibisatamab, Ciclopirox Prodrug CPX-POM, Cidan Herbal Capsule, Ciforadenant, Cilengitide, Ciltacabtagene Autoleucel, Cimetidine, Cinacalcet Hydrochloride, Cinobufagin, Cinobufotalin, Cinrebafusp Alfa, Cintirorgon, Cintredekin Besudotox, Cirmtuzumab, cis-Urocanic Acid, Cisplatin, Cisplatin Liposomal, Cisplatin-E Therapeutic Implant, Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6, Citarinostat, Citatuzumab Bogatox, Cixutumumab, CK1alpha/CDK7/CDK9 Inhibitor BTX-A51, CK2-targeting Synthetic Peptide CIGB-300, CL 246738, Cladribine, Clanfenur, Clarithromycin, Class 1/4 Histone Deacetylase Inhibitor OKI-179, Clinical Trial, Clinical Trial Agent, Clioquinol, Clivatuzumab, Clodronate Disodium, Clodronic Acid, Clofarabine, Clomesone, Clomiphene, Clomiphene Citrate, Clostridium Novyi-NT Spores, Cobimetinib, Cobolimab, Cobomarsen, Codrituzumab, Coenzyme Q10, Cofetuzumab Pelidotin, Colchicine-Site Binding Agent ABT-751, Cold Contaminant-free Iobenguane I-131, Colloidal Gold-Bound Tumor Necrosis Factor, Colorectal Cancer Peptide Vaccine PolyPEPI1018, Colorectal Tumor-Associated Peptides Vaccine IMA910, Coltuximab Ravtansine, Combretastatin, Combretastatin A-1, Combretastatin A1 Diphosphate, Commensal Bacterial Strain Formulation VE800, Compound Kushen Injection, Conatumumab, Conbercept, Concentrated Lingzhi Mushroom Extract, Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011, Copanlisib, Copanlisib Hydrochloride, Copper Cu 64-ATSM, Copper Cu 67 Tyr3-octreotate, Copper Gluconate, Cord Blood Derived CAR T-Cells, Cord Blood-derived Expanded Natural Killer Cells PNK-007, Cordycepin, Cordycepin Triphosphate, Coriolus Versicolor Extract, Corticorelin Acetate, Cortisone Acetate, Cosibelimab, Cositecan, Coxsackievirus A21, Coxsackievirus V937, CpG Oligodeoxynucleotide GNKG168, Crenolanib, Crenolanib Besylate, Crizotinib, Crolibulin, Cryptophycin, Cryptophycin 52, Crystalline Genistein Formulation AXP107-11, CSF-1R Inhibitor BLZ945, CSF1R Inhibitor ABSK021, CSF1R Inhibitor DCC-3014, CSF1R Inhibitor PLX73086, CT2584 HMS, CTLA-4-directed Probody BMS-986249, Curcumin, Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110, Cusatuzumab, Custirsen Sodium, CXC Chemokine Receptor 2 Antagonist AZD5069, CXCR1/2 Inhibitor SX-682, CXCR2 Antagonist QBM076, CXCR4 Antagonist BL-8040, CXCR4 Antagonist USL311, CXCR4 Inhibitor Q-122, CXCR4 Peptide Antagonist LY2510924, CXCR4/E-selectin Antagonist GMI-1359, Cyclin-dependent Kinase 8/19 Inhibitor BCD 115, Cyclin-dependent Kinase Inhibitor PF-06873600, Cyclodextrin-Based Polymer-Camptothecin CRLX101, Cyclodisone, Cycloleucine, Cyclopentenyl Cytosine, Cyclophosphamide, Cyclophosphamide Anhydrous, Cyclosporine, CYL-02 Plasmid DNA, CYP11A1 inhibitor ODM-208, CYP11A1 Inhibitor ODM-209, CYP17 Inhibitor CFG920, CYP17 Lyase Inhibitor ASN001, CYP17/Androgen Receptor Inhibitor ODM 204, CYP17/CYP11B2 Inhibitor LAE001, Cyproterone, Cyproterone Acetate, Cytarabine, Cytarabine Monophosphate Prodrug MB07133, Cytarabine-asparagine Prodrug BST-236, Cytidine Analog RX-3117, Cytochlor, Cytokine-based Biologic Agent IRX-2, D-methionine Formulation MRX-1024, DAB389 Epidermal Growth Factor, Dabrafenib, Dabrafenib Mesylate, Dacarbazine, Dacetuzumab, DACH Polymer Platinate AP5346, DACH-Platin Micelle NC-4016, Daclizumab, Dacomitinib, Dacplatinum, Dactinomycin, Dactolisib, Dactolisib Tosylate, Dalantercept, Dalotuzumab, Daniquidone, Danusertib, Danvatirsen, Daporinad, Daratumumab, Daratumumab and Hyaluronidase-fihj, Daratumumab/rHuPH20, Darinaparsin, Darleukin, Darolutamide, Daromun, Dasatinib, Daunorubicin, Daunorubicin Citrate, Daunorubicin Hydrochloride, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Decitabine and Cedazuridine, Defactinib, Defactinib Hydrochloride, Deferoxamine, Deferoxamine Mesylate, Degarelix, Degarelix Acetate, Delanzomib, Delolimogene Mupadenorepvec, Demcizumab, Demecolcine, Demplatin Pegraglumer, Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466, Dendritic Cell Vaccine, Dendritic Cell-Autologous Lung Tumor Vaccine, Dendritic Cell-targeting Lentiviral Vector ID-LV305, Denenicokin, Dengue Virus Adjuvant PV-001-DV, Denibulin, Denibulin Hydrochloride, Denileukin Diftitox, Denintuzumab Mafodotin, Denosumab, Deoxycytidine Analogue TAS-109, Deoxycytidine Analogue TAS-109 Hydrochloride, Depatuxizumab, Depatuxizumab Mafodotin, Derazantinib, Deslorelin, Deslorelin Acetate, Detirelix, Detorubicin, Deuteporfin, Deuterated Enzalutamide, Devimistat, Dexamethason, Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, Dexanabinol, Dexrazoxane, Dexrazoxane Hydrochloride, Dezaguanine, Dezaguanine Mesylate, Dezapelisib, DHA-Paclitaxel, DHEA Mustard, DI-Leu16-IL2 Immunocytokine, Dianhydrogalactitol, Diarylsulfonylurea Compound ILX-295501, Diazepinomicin, Diaziquone, Diazooxonorleucine, Dibrospidium Chloride, Dichloroallyl Lawsone, Dicycloplatin, Didox, Dienogest, Diethylnorspermine, Digitoxin, Digoxin, Dihydro-5-Azacytidine, Dihydrolenperone, Dihydroorotate Dehydrogenase Inhibitor AG-636, Dihydroorotate Dehydrogenase Inhibitor BAY2402234, Diindolylmethane, Dilpacimab, Dimethylmyleran, Dinaciclib, Dinutuximab, Dioscorea nipponica Makino Extract DNE3, Diphencyprone, Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777, Ditiocarb, DKK1-Neutralizing Monoclonal Antibody DKN-01, DM-CHOC-PEN, DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015, DNA Interference Oligonucleotide PNT2258, DNA Minor Groove Binding Agent SG2000, DNA Plasmid Encoding Interleukin-12 INO-9012, DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151, DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, DNA Vaccine VB10.16, DNA-dependent Protein Kinase Inhibitor VX-984, DNA-PK inhibitor AZD7648, DNA-PK/PI3K-delta Inhibitor BR101801, DNA-PK/TOR Kinase Inhibitor CC-115, DNMT1 Inhibitor NTX-301, DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98, Docetaxel, Docetaxel Anhydrous, Docetaxel Emulsion ANX-514, Docetaxel Formulation CKD-810, Docetaxel Lipid Microspheres, Docetaxel Nanoparticle CPC634, Docetaxel Polymeric Micelles, Docetaxel-loaded Nanopharmaceutical CRLX301, Docetaxel-PNP, Docetaxel/Ritonavir, Dociparstat sodium, Dolastatin 10, Dolastatin 15, Domatinostat, Donafenib, Dopamine-Somatostatin Chimeric Molecule BIM-23A760, Dostarlimab, Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703, Dovitinib, Dovitinib Lactate, Doxazosin, Doxercalciferol, Doxifluridine, Doxorubicin, Doxorubicin Hydrochloride, Doxorubicin Prodrug L-377;202, Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370, Doxorubicin-Eluting Beads, Doxorubicin-HPMA Conjugate, Doxorubicin-loaded EGFR-targeting Nanocells, Doxorubicin-Magnetic Targeted Carrier Complex, DPT/BCG/Measles/Serratia/Pneumococcus Vaccine, DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine, DPX-E7 HPV Vaccine, DR5 HexaBody Agonist GEN1029, DR5-targeting Tetrameric Nanobody Agonist TAS266, Dromostanolone Propionate, Drozitumab, DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555, Dual IGF-1R/InsR Inhibitor BMS-754807, Dual Variable Domain Immunoglobulin ABT-165, Dual-affinity B7-H3/CD3-targeted Protein MGD009, Dubermatinib, Duborimycin, Dulanermin, Duligotuzumab, Dupilumab, Durvalumab, Dusigitumab, dUTPase/DPD Inhibitor TAS-114, Duvelisib, Duvortuxizumab, Dynemicin, Dynemicin A, E2F1 Pathway Activator ARQ 171, EBNA-1 inhibitor VK-2019, Echinomycin, Ecromeximab, Edatrexate, Edelfosine, Edicotinib, Edodekin alfa, Edotecarin, Edrecolomab, EED Inhibitor MAK683, Efatutazone, Efatutazone Dihydrochloride, Efizonerimod, Eflornithine, Eflornithine Hydrochloride, Eftilagimod Alpha, Eftozanermin Alfa, Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205, Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621, EGb761, EGFR Antagonist Hemay022, EGFR Antisense DNA BB-401, EGFR Inhibitor AZD3759, EGFR Inhibitor BIBX 1382, EGFR Inhibitor DBPR112, EGFR Inhibitor PD-168393, EGFR Inhibitor TY-9591, EGFR Mutant-selective Inhibitor TQB3804, EGFR Mutant-specific Inhibitor BPI-7711, EGFR Mutant-specific Inhibitor CK-101, EGFR Mutant-specific Inhibitor D-0316, EGFR Mutant-specific Inhibitor ZN-e4, EGFR T790M Antagonist BPI-15086, EGFR T790M Inhibitor HS-10296, EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR/FLT3/Abl Inhibitor SKLB1028, EGFR/HER1/HER2 Inhibitor PKI166, EGFR/HER2 Inhibitor AP32788, EGFR/HER2 Inhibitor AV-412, EGFR/HER2 Inhibitor DZD9008, EGFR/HER2 Kinase Inhibitor TAK-285, EGFR/TGFb Fusion Monoclonal Antibody BCA101, EGFR/VEGFR/RET Inhibitor HA121-28, Eicosapentaenoic Acid, eIF4E Antisense Oligonucleotide ISIS 183750, Elacestrant, Elacytarabine, Elagolix, Elbasvir/Grazoprevir, Elesclomol, Elesclomol Sodium, Elgemtumab, Elinafide, Elisidepsin, Elliptinium, Elliptinium Acetate, Elmustine, Elotuzumab, Elpamotide, Elsamitrucin, Eltanexor, Emactuzumab, Emapalumab, Emepepimut-S, Emibetuzumab, Emitefur, Emofolin Sodium, Empesertib, Enadenotucirev, Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A, Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641, Enasidenib, Enasidenib Mesylate, Enavatuzumab, Encapsulated Rapamycin, Encelimab, Enclomiphene, Enclomiphene Citrate, Encorafenib, Endothelin B Receptor Blocker ENB 003, Endothelin Receptor Type A Antagonist YM598, Enfortumab Vedotin, Engineered Human Umbilical Vein Endothelial Cells AB-205, Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240, Engineered Toxin Body Targeting CD38 TAK-169, Engineered Toxin Body Targeting HER2 MT-5111, Eniluracil/5-FU Combination Tablet, Enloplatin, Enoblituzumab, Enobosarm, Enoticumab, Enpromate, Ensartinib, Ensituximab, Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride, Enterococcus gallinarum Strain MRx0518, Entinostat, Entolimod, Entospletinib, Entrectinib, Envafolimab, Enzalutamide, Enzastaurin, Enzastaurin Hydrochloride, EP2/EP4 Antagonist TPST-1495, EP4 Antagonist INV-1120, EP4 Antagonist ONO-4578, Epacadostat, Epcoritamab, EphA2-targeting Bicycle Toxin Conjugate BT5528, Epipodophyllotoxin Analog GL331, Epipropidine, Epirubicin, Epirubicin Hydrochloride, Epitinib Succinate, Epitiostanol, Epothilone Analog UTD1, Epothilone KOS-1584, Epratuzumab, Epratuzumab-cys-tesirine, ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471, ERa36 Modulator Icaritin, Erastin Analogue PRLX 93936, Erbulozole, Erdafitinib, Eribulin, Eribulin Mesylate, ERK 1/2 Inhibitor ASTX029, ERK Inhibitor CC-90003, ERK Inhibitor GDC-0994, ERK Inhibitor LTT462, ERK Inhibitor MK-8353, ERK1/2 Inhibitor ASN007, ERK1/2 Inhibitor HH2710, ERK1/2 Inhibitor JSI-1187, ERK1/2 Inhibitor KO-947, ERK1/2 Inhibitor LY3214996, Erlotinib, Erlotinib Hydrochloride, Ertumaxomab, Erythrocyte-encapsulated L-asparaginase Suspension, Esorubicin, Esorubicin Hydrochloride, Esperamicin A1, Essiac, Esterified Estrogens, Estradiol Valerate, Estramustine, Estramustine Phosphate Sodium, Estrogen Receptor Agonist GTx-758, Estrogens; Conjugated, Etalocib, Etanercept, Etanidazole, Etaracizumab, Etarotene, Ethaselen, Ethinyl Estradiol, Ethyleneimine, Ethylnitrosourea, Etidronate-Cytarabine Conjugate MBC-11, Etigilimab, Etirinotecan Pegol, Etoglucid, Etoposide, Etoposide Phosphate, Etoposide Toniribate, Etoprine, Etoricoxib, Ets-family Transcription Factor Inhibitor TK216, Everolimus, Everolimus Tablets for Oral Suspension, Evofosfamide, Ex Vivo-expanded Autologous T Cells IMA101, Exatecan Mesylate, Exatecan Mesylate Anhydrous, Exemestane, Exicorilant, Exisulind, Extended Release Flucytosine, Extended Release Metformin Hydrochloride, Extended-release Onapristone, Ezabenlimab, EZH1/2 Inhibitor DS-3201, EZH1/2 Inhibitor HH2853, EZH2 inhibitor CPI-0209, EZH2 Inhibitor CPI-1205, EZH2 Inhibitor PF-06821497, EZH2 Inhibitor SHR2554, F16-IL2 Fusion Protein, FACT Complex-targeting Curaxin CBL0137, Factor VII-targeting Immunoconjugate Protein ICON-1, Factor VIIa Inhibitor PCI-27483, Fadraciclib, Fadrozole Hydrochloride, FAK Inhibitor GSK2256098, FAK Inhibitor PF-00562271, FAK Inhibitor VS-4718, FAK/ALK/ROS1 Inhibitor APG-2449, Falimarev, Famitinib, FAP/4-1BB-targeting DARPin MP0310, FAP/4-1BB-targeting Fusion Protein RO7122290, Farletuzumab, Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778;123, Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells, Fas Receptor Agonist APO010, Fascin Inhibitor NP-G2-044, FASN Inhibitor TVB-2640, Favezelimab, Fazarabine, Fc-engineered Anti-CD40 Agonist Antibody 2141-V11, Febuxostat, Fedratinib, Fedratinib Hydrochloride, Feladilimab, Felzartamab, Fenebrutinib, Fenretinide, Fenretinide Lipid Matrix, Fenretinide Phospholipid Suspension ST-001, FGF Receptor Antagonist HGS1036, FGF/FGFR Pathway Inhibitor E7090, FGFR Inhibitor ASP5878, FGFR Inhibitor AZD4547, FGFR Inhibitor CPL304110, FGFR Inhibitor Debio 1347, FGFR Inhibitor TAS-120, FGFR/CSF-1R Inhibitor 3D185, FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999, FGFR1/2/3 Inhibitor HMPL-453, FGFR2 Inhibitor RLY-4008, FGFR4 Antagonist INCB062079, FGFR4 Inhibitor BLU 9931, FGFR4 Inhibitor FGF401, FGFR4 Inhibitor H3B-6527, FGFR4 Inhibitor ICP-105, Fianlimab, Fibromun, Ficlatuzumab, Figitumumab, Filanesib, Filgotinib, Filgrastim, Fimaporfin A, Fimepinostat, Firtecan Pegol, Fisogatinib, Flanvotumab, Flotetuzumab, Floxuridine, FLT3 Inhibitor FF-10101 Succinate, FLT3 Inhibitor HM43239, FLT3 Inhibitor SKI-G-801, Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01, FLT3 Tyrosine Kinase Inhibitor TTT-3002, FLT3/ABL/Aurora Kinase Inhibitor KW-2449, FLT3/CDK4/6 Inhibitor FLX925, FLT3/FGFR Dual Kinase Inhibitor MAX-40279, FLT3/KIT Kinase Inhibitor AKN-028, FLT3/KIT/CSF1R Inhibitor NMS-03592088, Flt3/MerTK Inhibitor MRX-2843, Fludarabine, Fludarabine Phosphate, Flumatinib, Flumatinib Mesylate, Fluorine F 18 Ara-G, Fluorodopan, Fluorouracil, Fluorouracil Implant, Fluorouracil-E Therapeutic Implant, Fluoxymesterone, Flutamide, Fluvastatin, Fluvastatin Sodium, Fluzoparib, FMS Inhibitor JNJ-40346527, Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate, Folate Receptor Targeted Epothilone BMS753493, Folate Receptor-Targeted Tubulysin Conjugate EC1456, Folate Receptor-Targeted Vinca Alkaloid EC0489, Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225, Folate-FITC, Folic Acid, Folitixorin, Foretinib, Foritinib Succinate, Formestane, Forodesine Hydrochloride, Fosaprepitant, Fosbretabulin, Fosbretabulin Disodium, Fosbretabulin Tromethamine, Fosgemcitabine Palabenamide, Fosifloxuridine Nafalbenamide, Foslinanib, Foslinanib Disodium, Fosquidone, Fostriecin, Fotemustine, Fotretamine, FPV Vaccine CV301, FPV-Brachyury-TRICOM Vaccine, Fresolimumab, Fruquintinib, Fulvestrant, Fumagillin-Derived Polymer Conjugate XMT-1107, Fursultiamine, Futibatinib, Futuximab, Futuximab/Modotuximab Mixture, G Protein-coupled Estrogen Receptor Agonist LNS8801, G-Quadruplex Stabilizer BMVC, Galamustine, Galarubicin, Galectin Inhibitor GR-MD-02, Galectin-1 Inhibitor OTX008, Galeterone, Galiximab, Gallium-based Bone Resorption Inhibitor AP-002, Galocitabine, Galunisertib, Gamboge Resin Extract TSB-9-W1, Gamma-delta Tocotrienol, Gamma-Secretase Inhibitor LY3039478, Gamma-Secretase Inhibitor RO4929097, Gandotinib, Ganetespib, Ganglioside GD2, Ganglioside GM2, Ganitumab, Ganoderma lucidum Spores Powder Capsule, Garlic, Gastrin Immunotoxin, Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360, Gataparsen Sodium, Gatipotuzumab, GBM Antigens and Alloantigens Immunotherapeutic Vaccine, Gedatolisib, Gefitinib, Geldanamycin, Gelonin, Gemcitabine, Gemcitabine Elaidate, Gemcitabine Hydrochloride, Gemcitabine Hydrochloride Emulsion, Gemcitabine Prodrug LY2334737, Gemcitabine-Phosphoramidate Hydrochloride NUC-1031, Gemcitabine-Releasing Intravesical System, Gemtuzumab Ozogamicin, Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum, Genistein, Gentuximab, Geranylgeranyltransferase I Inhibitor, GI-4000 Vaccine, Giloralimab, Gilteritinib, Gilteritinib Fumarate, Gimatecan, Gimeracil, Ginsenoside Rg3 Capsule, Giredestrant, Girentuximab, Girodazole, GITR Agonist MEDI1873, Givinostat, Glasdegib, Glasdegib Maleate, Glaucarubolone, Glecaprevir/Pibrentasvir, Glembatumumab Vedotin, Glesatinib, Glioblastoma Cancer Vaccine ERC1671, Glioblastoma Multiforme Multipeptide Vaccine IMA950, Glioma Lysate Vaccine GBM6-AD, Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701, Globo H-DT Vaccine OBI-833, Glofitamab, Glucarpidase, Glucocorticoid Receptor Antagonist ORIC-101, Glufosfamide, Glumetinib, Glutaminase Inhibitor CB-839, Glutaminase Inhibitor CB-839 Hydrochloride, Glutaminase Inhibitor IPN60090, Glutamine Antagonist DRP-104, Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101, Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01, Glycooptimized Trastuzumab-GEX, GM-CSF-encoding Oncolytic Adenovirus CGTG-102, Gold Sodium Thiomalate, Golnerminogene Pradenovec, Golotimod, Golvatinib, Gonadotropin-releasing Hormone Analog, Goserelin, Goserelin Acetate, Goserelin Acetate Extended-release Microspheres LY01005, Gossypol, Gossypol Acetic Acid, Grapiprant, Green Tea Extract-based Antioxidant Supplement, GS/pan-Notch Inhibitor AL101, GS/pan-Notch Inhibitor BMS-986115, GSK-3 Inhibitor 9-ING-41, GSK-3 Inhibitor LY2090314, Guadecitabine, Guanabenz Acetate, Guselkumab, Gusperimus Trihydrochloride, Gutolactone, H-ras Antisense Oligodeoxynucleotide ISIS 2503, H1299 Tumor Cell Lysate Vaccine, HAAH Lambda phage Vaccine SNS-301, Hafnium Oxide-containing Nanoparticles NBTXR3, Halichondrin Analogue E7130, Halichondrin B, Halofuginone, Halofuginone Hydrobromide, HCV DNA Vaccine INO-8000, HDAC Class I/IIb Inhibitor HG146, HDAC Inhibitor AR-42, HDAC inhibitor CG200745, HDAC Inhibitor CHR-2845, HDAC Inhibitor CKD-581, HDAC Inhibitor CXD101, HDAC Inhibitor MPT0E028, HDAC Inhibitor OBP-801, HDAC/EGFR/HER2 Inhibitor CUDC-101, HDAC6 Inhibitor KA2507, HDAC8 Inhibitor NBM-BMX, HDM2 Inhibitor HDM201, HDM2 Inhibitor MK-8242, Hedgehog Inhibitor IPI-609, Hematoporphyrin Derivative, Hemiasterlin Analog E7974, Henatinib Maleate, Heparan Sulfate Glycosaminoglycan Mimetic M402, Heparin Derivative SST0001, HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131, HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901, HER2 Inhibitor CP-724;714, HER2 Inhibitor DZD1516, HER2 Inhibitor TAS0728, HER2 Tri-specific Natural Killer Cell Engager DF1001, HER2-directed TLR8 Agonist SBT6050, HER2-targeted DARPin MP0274, HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302, HER2-targeting Antibody Fc Fragment FS102, Herba Scutellaria Barbata, Herbimycin, Heterodimeric Interleukin-15, Hexamethylene Bisacetamide, Hexaminolevulinate, Hexylresorcinol, HIF-1alpha Inhibitor PX-478, HIF-2alpha Inhibitor PT2385, HIF-2alpha Inhibitor PT2977, HIF2a RNAi ARO-HIF2, Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126, Histrelin Acetate, HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001, HLA-A*2402-Restricted Multipeptide Vaccine S-488410, HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201, HM2/MMAE Antibody-Drug Conjugate ALT-P7, Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine, Holmium Ho 166 Poly(L-Lactic Acid) Microspheres, Hormone Therapy, HPPH, HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202, HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, HPV E6/E7 DNA Vaccine GX-188E, HPV E6/E7-encoding Arenavirus Vaccine HB-201, HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C, HPV-16 E6 Peptides Vaccine/Candida albicans Extract, HPV-6-targeting Immunotherapeutic Vaccine INO-3106, HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101, HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN, HPV6/11-targeted DNA Plasmid Vaccine INO-3107, Hsp90 Antagonist KW-2478, Hsp90 Inhibitor AB-010, Hsp90 Inhibitor BIIB021, Hsp90 Inhibitor BIIB028, Hsp90 Inhibitor Debio 0932, Hsp90 Inhibitor DS-2248, Hsp90 Inhibitor HSP990, Hsp90 Inhibitor MPC-3100, Hsp90 Inhibitor PU-H71, Hsp90 Inhibitor SNX-5422 Mesylate, Hsp90 Inhibitor SNX-5542 Mesylate, Hsp90 Inhibitor TQB3474, Hsp90 Inhibitor XL888, Hsp90-targeted Photosensitizer HS-201, HSP90-targeted SN-38 Conjugate PEN-866, HSP90alpha/beta Inhibitor TAS-116, hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301, hTERT Vaccine V934/V935, hTERT-encoding DNA Vaccine INVAC-1, Hu14.18-IL2 Fusion Protein EMD 273063, HuaChanSu, Huaier Extract Granule, Huang Lian, huBC1-huIL12 Fusion Protein AS1409, Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736, Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104, Human MOAB LICO 28a32, Human Monoclonal Antibody 216, Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307, Human Papillomavirus 16 E7 Peptide/Padre 965.10, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Hycanthone, Hydralazine Hydrochloride, Hydrocortisone Sodium Succinate, Hydroxychloroquine, Hydroxyprogesterone Caproate, Hydroxytyrosol, Hydroxyurea, Hypericin, Hypoxia-activated Prodrug TH-4000, I 131 Antiferritin Immunoglobulin, I 131 Monoclonal Antibody A33, I 131 Monoclonal Antibody CC49, I 131 Monoclonal Antibody F19, I 131 Monoclonal Antibody Lym-1, Iadademstat, Ianalumab, IAP Inhibitor APG-1387, IAP Inhibitor AT-406, IAP Inhibitor HGS1029, Ibandronate Sodium, Iberdomide, Iboctadekin, Ibritumomab Tiuxetan, Ibrutinib, Icotinib Hydrochloride, Icrucumab, ICT-121 Dendritic Cell Vaccine, Idarubicin, Idarubicin Hydrochloride, Idarubicin-Eluting Beads, Idasanutlin, Idecabtagene Vicleucel, Idelalisib, Idetrexed, IDH1 Mutant Inhibitor LY3410738, IDH1(R132) Inhibitor IDH305, IDH1R132H-Specific Peptide Vaccine PEPIDH1M, Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020, IDO Peptide Vaccine IO102, IDO-1 Inhibitor LY3381916, IDO/TDO Inhibitor HTI-1090, IDO/TDO Inhibitor LY-01013, IDO1 Inhibitor KHK2455, IDO1 Inhibitor MK-7162, IDO1 Inhibitor PF-06840003, IDO1/TDO2 Inhibitor DN1406131, IDO1/TDO2 Inhibitor M4112, Idronoxil, Idronoxil Suppository NOX66, Ieramilimab, Ifabotuzumab, Ifetroban, Ifosfamide, IGF-1R Inhibitor, IGF-1R Inhibitor PL225B, IGF-1R/IR Inhibitor KW-2450, IGF-methotrexate Conjugate, IL-10 Immunomodulator MK-1966, IL-12-expressing HSV-1 NSC 733972, IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051, IL-12sc; IL-15sushi; IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000, IL-2 Recombinant Fusion Protein ALT-801, IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1, IL4-Pseudomonas Exotoxin Fusion Protein MDNA55, Ilginatinib, Ilixadencel, Iloprost, Ilorasertib, Imalumab, Imaradenant, Imatinib, Imatinib Mesylate, Imetelstat, Imetelstat Sodium, Imexon, Imgatuzumab, Imidazole Mustard, Imidazole-Pyrazole, Imifoplatin, Imipramine Blue, Imiquimod, Immediate-release Onapristone, Immediate-release Tablet Afuresertib, Immune Checkpoint Inhibitor ASP8374, Immunoconjugate RO5479599, Immunocytokine NHS-IL12, Immunocytokine NHS-IL2-LT, Immunomodulator LAM-003, Immunomodulator OHR/AVR118, Immunomodulatory Agent CC-11006, Immunomodulatory Oligonucleotide HYB2055, Immunotherapeutic Combination Product CMB305, Immunotherapeutic GSK1572932A, Immunotherapy Regimen MKC-1106-MT, Immunotoxin CMD-193, IMT-1012 Immunotherapeutic Vaccine, Inactivated Oncolytic Virus Particle GEN0101, Inalimarev, Incyclinide, Indatuximab Ravtansine, Indibulin, Indicine-N-Oxide, Indisulam, Individualized MVA-based Vaccine TG4050, Indocyanine Green-labeled Polymeric Micelles ONM-100, Indole-3-Carbinol, Indomethacin, Indoximod, Indoximod Prodrug NLG802, Indusatumab Vedotin, Inebilizumab, Inecalcitol, Infigratinib, Infigratinib Mesylate, Infliximab, Ingenol Mebutate, Ingenol Mebutate Gel, Iniparib, iNKT Cell Agonist ABX196, Innate Immunostimulator rBBX-01, INO-1001, Inodiftagene Vixteplasmid, iNOS Dimerization Inhibitor ASP9853, Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01, Inosine Monophosphate Dehydrogenase Inhibitor AVN944, Inositol, Inotuzumab Ozogamicin, Inproquone, Integrin alpha-2 Inhibitor E7820, Integrin Receptor Antagonist GLPG0187, Interferon, Interferon Alfa-2B, Interferon Alfa-N1, Interferon Alfa-N3, Interferon Alfacon-1, Interferon Beta-1A, Interferon Gamma-1b, Interferon-gamma-expressing Adenovirus Vaccine ASN-002, Interleukin Therapy, Interleukin-12-Fc Fusion Protein DF6002, Interleukin-15 Agonist Fusion Protein SHR1501, Interleukin-15 Fusion Protein BJ-001, Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306, Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101, Interleukin-2 Liposome, Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230, Intetumumab, Intiquinatine, Intoplicine, Inulin, Iobenguane I-131, Iodine I 124 Monoclonal Antibody A33, Iodine I 124 Monoclonal Antibody M5A, Iodine I 125-Anti-EGFR-425 Monoclonal Antibody, Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP, Iodine I 131 Apamistamab, Iodine I 131 Derlotuximab Biotin, Iodine I 131 Ethiodized Oil, Iodine I 131 IPA, Iodine I 131 MIP-1095, Iodine I 131 Monoclonal Antibody 81C6, Iodine I 131 Monoclonal Antibody BC8, Iodine I 131 Monoclonal Antibody CC49-deltaCH2, Iodine I 131 Monoclonal Antibody F16SIP, Iodine I 131 Monoclonal Antibody G-250, Iodine I 131 Monoclonal Antibody muJ591, Iodine I 131 Omburtamab, Iodine I 131 Rituximab, Iodine I 131 Tenatumomab, Iodine I 131 TM-601, Iodine I 131 Tositumomab, Iodine I-131, Ioflubenzamide I-131, Ionomycin, Ipafricept, Ipatasertib, Ipilimumab, Ipomeanol, Iproplatin, iPSC-derived CD16-expressing Natural Killer Cells FT516, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596, iPSC-derived Natural Killer Cells FT500, IRAK4 Inhibitor CA-4948, Iratumumab, Iridium Ir 192, Irinotecan, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Irinotecan-Eluting Beads, Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet, Irofulven, Iroplact, Irosustat, Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130, Isatuximab, Iso-fludelone, Isobrucein B, Isocoumarin NM-3, Isotretinoin, Ispinesib, Ispinesib Mesylate, ISS 1018 CpG Oligodeoxynucleotide, Istiratumab, Itacitinib, Itacitinib Adipate, ITK Inhibitor CPI-818, Itraconazole, Itraconazole Dispersion In Polymer Matrix, Ivaltinostat, Ivosidenib, Ivuxolimab, Ixabepilone, Ixazomib, Ixazomib Citrate, JAK Inhibitor, JAK Inhibitor INCB047986, JAK1 Inhibitor AZD4205, JAK1 Inhibitor INCB052793, JAK2 Inhibitor AZD1480, JAK2 Inhibitor BMS-911543, JAK2 Inhibitor XL019, JAK2/Src Inhibitor NS-018, Jin Fu Kang, JNK Inhibitor CC-401, Kanglaite, Kanitinib, Ketoconazole, Ketotrexate, KRAS G12C Inhibitor GDC-6036, KRAS G12C Inhibitor LY3499446, KRAS G12C Inhibitor MRTX849, KRAS Mutant-targeting AMG 510, KRAS-MAPK Signaling Pathway Inhibitor JAB-3312, KRASG12C Inhibitor JNJ-74699157, KRN5500, KSP Inhibitor AZD4877, KSP Inhibitor SB-743921, Kunecatechins Ointment, L-Gossypol, L-methylfolate, Labetuzumab Govitecan, Lactoferrin-derived Lytic Peptide LTX-315, Lacutamab, Ladiratuzumab Vedotin, Ladirubicin, Laetrile, LAIR-2 Fusion Protein NC410, Landogrozumab, Laniquidar, Lanreotide Acetate, Lapachone, Lapatinib, Lapatinib Ditosylate, Laprituximab Emtansine, Lapuleucel-T, Laromustine, Larotaxel, Larotinib Mesylate, Larotrectinib, Larotrectinib Sulfate, Lavendustin A, Lazertinib, Lead Pb 212 TCMC-trastuzumab, Lefitolimod, Leflunomide, Lenalidomide, Lenalidomide Analog KPG-121, Lentinan, Lenvatinib, Lenvatinib Mesylate, Lenzilumab, Lerociclib, Lestaurtinib, Letetresgene Autoleucel, Letolizumab, Letrozole, Leucovorin, Leucovorin Calcium, Leuprolide, Leuprolide Acetate, Leuprolide Mesylate Injectable Suspension, Leurubicin, Levetiracetam, Levoleucovorin Calcium, Levothyroxine, Levothyroxine Sodium, Lexatumumab, Lexibulin, Liarozole, Liarozole Fumarate, Liarozole Hydrochloride, Licartin, Licorice, Lifastuzumab Vedotin, Lifileucel, Lifirafenib, Light-activated AU-011, Light-Emitting Oncolytic Vaccinia Virus GL-ONC1, Lilotomab, Limonene; (+)-, Limonene; (+/-)-, Linifanib, Linoleyl Carbonate-Paclitaxel, Linperlisib, Linrodostat, Linsitinib, Lintuzumab, Liothyronine I-131, Liothyronine Sodium, Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1, Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191, Lipid Nanoparticle Encapsulated OX40L mRNA-2416, Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006, Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752, Liposomal Bcl-2 Antisense Oligonucleotide BP1002, Liposomal c-raf Antisense Oligonucleotide, Liposomal Curcumin, Liposomal Cytarabine, Liposomal Daunorubicin Citrate, Liposomal Docetaxel, Liposomal Eribulin Mesylate, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Liposomal Irinotecan, Liposomal Mitoxantrone Hydrochloride, Liposomal MUC1/PET-lipid A Vaccine ONT-10, Liposomal NDDP, Liposomal Rhenium Re 186, Liposomal SN-38, Liposomal Topotecan FF-10850, Liposomal Vinorelbine, Liposomal Vinorelbine Tartrate, Liposome, Liposome-encapsulated Daunorubicin-Cytarabine, Liposome-Encapsulated Doxorubicin Citrate, Liposome-encapsulated miR-34 Mimic MRX34, Liposome-encapsulated OSI-7904, Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94, Liposome-encapsulated TAAs mRNA Vaccine W_ova1, Lirilumab, Lisavanbulin, Lisocabtagene Maraleucel, Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142, Litronesib, Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809, Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207, Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623, Liver X Receptor beta Agonist RGX-104, Lm-tLLO-neoantigens Vaccine ADXS-NEO, LMB-1 Immunotoxin, LMB-2 Immunotoxin, LMB-7 Immunotoxin, LMB-9 Immunotoxin, LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164, LMP-2:340-349 Peptide Vaccine, LMP-2:419-427 Peptide Vaccine, LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes, LMP7 Inhibitor M3258, Lobaplatin, Lodapolimab, Lometrexol, Lometrexol Sodium, Lomustine, Lonafarnib, Loncastuximab Tesirine, Long Peptide Vaccine 7, Long-acting Release Pasireotide, Lontucirev, Lorlatinib, Lorukafusp alfa, Lorvotuzumab Mertansine, Losatuxizumab Vedotin, Losoxantrone, Losoxantrone Hydrochloride, Lovastatin, LOXL2 Inhibitor PAT-1251, LRP5 Antagonist BI 905681, LRP5/6 Antagonist BI 905677, LSD1 Inhibitor CC-90011, LSD1 Inhibitor GSK2879552, LSD1 Inhibitor IMG-7289, LSD1 Inhibitor RO7051790, LSD1 Inhibitor SYHA1807, Lucanthone, Lucatumumab, Lucitanib, Luminespib, Luminespib Mesylate, Lumretuzumab, Lung-targeted Immunomodulator QBKPN, Lupartumab Amadotin, Lurbinectedin, Lurtotecan, Lurtotecan Liposome, Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1, Lutetium Lu 177 DOTA-biotin, Lutetium Lu 177 DOTA-N3-CTT1403, Lutetium Lu 177 DOTA-Tetulomab, Lutetium Lu 177 Dotatate, Lutetium Lu 177 Lilotomab-satetraxetan, Lutetium Lu 177 Monoclonal Antibody CC49, Lutetium Lu 177 Monoclonal Antibody J591, Lutetium Lu 177 PP-F11N, Lutetium Lu 177 Satoreotide Tetraxetan, Lutetium Lu 177-DOTA-EB-TATE, Lutetium Lu 177-DTPA-omburtamab, Lutetium Lu 177-Edotreotide, Lutetium Lu 177-NeoB, Lutetium Lu 177-PSMA-617, Lutetium Lu-177 Capromab, Lutetium Lu-177 Girentuximab, Lutetium Lu-177 PSMA-R2, Lutetium Lu-177 Rituximab, LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1, Lyophilized Black Raspberry Lozenge, Lyophilized Black Raspberry Saliva Substitute, Lysine-specific Demethylase 1 Inhibitor INCB059872, Lyso-Thermosensitive Liposome Doxorubicin, Maackia amurensis Seed Lectin, Macimorelin, Macitentan, Macrocycle-bridged STING Agonist E7766, Maekmoondong-tang, Mafosfamide, MAGE-10.A2, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, MAGE-A3 Multipeptide Vaccine GL-0817, MAGE-A3 Peptide Vaccine, MAGE-A3-specific Immunotherapeutic GSK 2132231A, MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201, Magnesium Valproate, Magrolimab, MALT1 Inhibitor JNJ-67856633, Manelimab, Mannosulfan, Mannosylerythritol Lipid, Mapatumumab, Maraba Oncolytic Virus Expressing Mutant HPV E6/E7, Marcellomycin, MARCKS Protein Inhibitor BIO-11006, Margetuximab, Marimastat, Marizomib, Masitinib Mesylate, Masoprocol, MAT2A Inhibitor AG-270, Matrix Metalloproteinase Inhibitor MMI270, Matuzumab, Mavelertinib, Mavorixafor, Maytansine, MCL-1 Inhibitor ABBV-467, MCL-1 Inhibitor AMG 176, MCL-1 inhibitor AMG 397, Mcl-1 Inhibitor AZD5991, Mcl-1 Inhibitor MIK665, MDM2 Antagonist ASTX295, MDM2 Antagonist RO5045337, MDM2 Antagonist RO6839921, MDM2 Inhibitor AMG-232, MDM2 Inhibitor AMGMDS3, MDM2 Inhibitor BI 907828, MDM2 Inhibitor KRT-232, MDM2/MDMX Inhibitor ALRN-6924, MDR Modulator CBT-1, Mechlorethamine, Mechlorethamine Hydrochloride, Mechlorethamine Hydrochloride Gel, Medorubicin, Medroxyprogesterone, Medroxyprogesterone Acetate, Megestrol Acetate, MEK 1/2 Inhibitor AS703988/MSC2015103B, MEK 1/2 Inhibitor FCN-159, MEK Inhibitor AZD8330, MEK Inhibitor CI-1040, MEK inhibitor CS3006, MEK Inhibitor GDC-0623, MEK Inhibitor HL-085, MEK Inhibitor PD0325901, MEK Inhibitor RO4987655, MEK Inhibitor SHR 7390, MEK Inhibitor TAK-733, MEK Inhibitor WX-554, MEK-1/MEKK-1 Inhibitor E6201, MEK/Aurora Kinase Inhibitor BI 847325, Melanoma Monoclonal Antibody hIgG2A, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Melapuldencel-T, MELK Inhibitor OTS167, Melphalan, Melphalan Flufenamide, Melphalan Hydrochloride, Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex, Membrane-Disrupting Peptide EP-100, Menatetrenone, Menin-MLL Interaction Inhibitor SNDX-5613, Menogaril, Merbarone, Mercaptopurine, Mercaptopurine Anhydrous, Mercaptopurine Oral Suspension, Merestinib, Mesna, Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536, MET Kinase Inhibitor OMO-1, MET Tyrosine Kinase Inhibitor BMS-777607, MET Tyrosine Kinase Inhibitor EMD 1204831, MET Tyrosine Kinase Inhibitor PF-04217903, MET Tyrosine Kinase Inhibitor SAR125844, MET Tyrosine Kinase Inhibitor SGX523, MET x MET Bispecific Antibody REGN5093, Metamelfalan, MetAP2 Inhibitor APL-1202, MetAP2 Inhibitor SDX-7320, Metarrestin, Metatinib Tromethamine, Metformin, Metformin Hydrochloride, Methanol Extraction Residue of BCG, Methazolamide, Methionine Aminopeptidase 2 Inhibitor M8891, Methionine Aminopeptidase 2 Inhibitor PPI-2458, Methotrexate, Methotrexate Sodium, Methotrexate-E Therapeutic Implant, Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles, Methoxsalen, Methoxyamine, Methoxyamine Hydrochloride, Methyl-5-Aminolevulinate Hydrochloride Cream, Methylcantharidimide, Methylmercaptopurine Riboside, Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, Methylselenocysteine, Methyltestosterone, Metoprine, Mevociclib, Mezagitamab, Mibefradil, Mibefradil Dihydrochloride, Micellar Nanoparticle-encapsulated Epirubicin, Micro Needle Array-Doxorubicin, Microbiome GEN-001, Microbiome-derived Peptide Vaccine EO2401, Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300, Microtubule Inhibitor SCB01A, Midostaurin, Mifamurtide, Mifepristone, Milademetan Tosylate, Milataxel, Milatuzumab, Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110, Milciclib Maleate, Milk Thistle, Miltefosine, Minretumomab, Mipsagargin, Miptenalimab, Mirabegron, Miransertib, Mirdametinib, Mirvetuximab Soravtansine, Mirzotamab Clezutoclax, Misonidazole, Mistletoe Extract, Mitazalimab, Mitindomide, Mitobronitol, Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101, Mitoclomine, Mitoflaxone, Mitoguazone, Mitoguazone Dihydrochloride, Mitolactol, Mitomycin, Mitomycin A, Mitomycin B, Mitomycin C Analog KW-2149, Mitosis Inhibitor T 1101 Tosylate, Mitotane, Mitotenamine, Mitoxantrone, Mitoxantrone Hydrochloride, Mitozolomide, Mivavotinib, Mivebresib, Mivobulin, Mivobulin Isethionate, Mixed Bacteria Vaccine, MK0731, MKC-1, MKNK1 Inhibitor BAY 1143269, MMP Inhibitor S-3304, MNK1/2 Inhibitor ETC-1907206, Mobocertinib, Mocetinostat, Modakafusp Alfa, Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208, Modified Vitamin D Binding Protein Macrophage Activator EF-022, Modotuximab, MOF Compound RiMO-301, Mofarotene, Mogamulizumab, Molibresib, Molibresib Besylate, Momelotinib, Monalizumab, Monocarboxylate Transporter 1 Inhibitor AZD3965, Monoclonal Antibody 105AD7 Anti-idiotype Vaccine, Monoclonal Antibody 11D10, Monoclonal Antibody 11D10 Anti-Idiotype Vaccine, Monoclonal Antibody 14G2A, Monoclonal Antibody 1F5, Monoclonal Antibody 3622W94, Monoclonal Antibody 3F8, Monoclonal Antibody 3H1 Anti-Idiotype Vaccine, Monoclonal Antibody 4B5 Anti-Idiotype Vaccine, Monoclonal Antibody 7C11, Monoclonal Antibody 81C6, Monoclonal Antibody A1G4 Anti-Idiotype Vaccine, Monoclonal Antibody A27.15, Monoclonal Antibody A33, Monoclonal Antibody AbGn-7, Monoclonal Antibody AK002, Monoclonal Antibody ASP1948, Monoclonal Antibody CAL, Monoclonal Antibody CC49-delta CH2, Monoclonal Antibody CEP-37250/KHK2804, Monoclonal Antibody D6.12, Monoclonal Antibody E2.3, Monoclonal Antibody F19, Monoclonal Antibody GD2 Anti-Idiotype Vaccine, Monoclonal Antibody HeFi-1, Monoclonal Antibody Hu3S193, Monoclonal Antibody HuAFP31, Monoclonal Antibody HuHMFG1, Monoclonal Antibody huJ591, Monoclonal Antibody HuPAM4, Monoclonal Antibody IMMU-14, Monoclonal Antibody L6, Monoclonal Antibody Lym-1, Monoclonal Antibody m170, Monoclonal Antibody Me1-14 F(ab')2, Monoclonal Antibody muJ591, Monoclonal Antibody MX35 F(ab')2, Monoclonal Antibody NEO-201, Monoclonal Antibody R24, Monoclonal Antibody RAV12, Monoclonal Antibody SGN-14, Monoclonal Antibody TRK-950, Monoclonal Microbial EDP1503, Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100, Monomethyl Auristatin E, Morinda Citrifolia Fruit Extract, Morpholinodoxorubicin, Mosedipimod, Mosunetuzumab, Motesanib, Motesanib Diphosphate, Motexafin Gadolinium, Motexafin Lutetium, Motixafortide, Motolimod, MOv-gamma Chimeric Receptor Gene, Moxetumomab Pasudotox, Mps1 Inhibitor BAY 1217389, Mps1 Inhibitor BOS172722, mRNA-based Personalized Cancer Vaccine mRNA-4157, mRNA-based Personalized Cancer Vaccine NCI-4650, mRNA-based TriMix Melanoma Vaccine ECI-006, mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902, mRNA-derived KRAS-targeted Vaccine V941, mRNA-derived Lung Cancer Vaccine BI 1361849, mRNA-Derived Prostate Cancer Vaccine CV9103, mRNA-derived Prostate Cancer Vaccine CV9104, MTF-1 Inhibitor APTO-253 HCl, mTOR Inhibitor GDC-0349, mTOR Kinase Inhibitor AZD8055, mTOR Kinase Inhibitor CC-223, mTOR Kinase Inhibitor OSI-027, mTOR Kinase Inhibitor PP242, mTOR1/2 Kinase Inhibitor ME-344, mTORC 1/2 Inhibitor LXI-15029, mTORC1/2 Kinase Inhibitor BI 860585, mTORC1/mTORC2/DHFR Inhibitor ABTL0812, MUC-1/WT1 Peptide-primed Autologous Dendritic Cells, MUC1-targeted Peptide GO-203-2C, Mucoadhesive Paclitaxel Formulation, Multi-AGC Kinase Inhibitor AT13148, Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200, Multi-epitope HER2 Peptide Vaccine H2NVAC, Multi-epitope HER2 Peptide Vaccine TPIV100, Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107, Multi-kinase Inhibitor TPX-0022, Multi-kinase Inhibitor XL092, Multi-mode Kinase Inhibitor EOC317, Multi-neo-epitope Vaccine OSE 2101, Multifunctional/Multitargeted Anticancer Agent OMN54, Multikinase Inhibitor 4SC-203, Multikinase Inhibitor AEE788, Multikinase Inhibitor AT9283, Multikinase Inhibitor SAR103168, Multipeptide Vaccine S-588210, Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327, Muparfostat, Mureletecan, Murizatoclax, Muscadine Grape Extract, Mutant IDH1 Inhibitor DS-1001, Mutant p53 Activator COTI-2, Mutant-selective EGFR Inhibitor PF-06459988, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-BN Smallpox Vaccine, MVA-FCU1 TG4023, MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1, MYC-targeting siRNA DCR-MYC, Mycobacterium tuberculosis Arabinomannan Z-100, Mycobacterium w, Mycophenolic Acid, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea, N-dihydrogalactochitosan, N-Methylformamide, N;N-Dibenzyl Daunomycin, NA17-A Antigen, NA17.A2 Peptide Vaccine, Nab-paclitaxel, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Nadofaragene Firadenovec, Nagrestipen, Namirotene, Namodenoson, NAMPT Inhibitor OT-82, Nanafrocin, Nanatinostat, Nanocell-encapsulated miR-16-based microRNA Mimic, Nanoparticle Albumin-Bound Docetaxel, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404, Nanoparticle Paclitaxel Ointment SOR007, Nanoparticle-based Paclitaxel Suspension, Nanoparticle-encapsulated Doxorubicin Hydrochloride, Nanoscale Coordination Polymer Nanoparticles CPI-100, Nanosomal Docetaxel Lipid Suspension, Napabucasin, Naphthalimide Analogue UNBS5162, Naptumomab Estafenatox, Naquotinib, Naratuximab Emtansine, Narnatumab, Natalizumab, Natural IFN-alpha OPC-18, Natural Killer Cells ZRx101, Navarixin, Navicixizumab, Navitoclax, Navoximod, Navy Bean Powder, Naxitamab, Nazartinib, ncmtRNA Oligonucleotide Andes-1537, Necitumumab, Nedaplatin, NEDD8 Activating Enzyme E1 Inhibitor TAS4464, Nedisertib, Nelarabine, Nelipepimut-S, Nelipepimut-S Plus GM-CSF Vaccine, Nemorubicin, Nemorubicin Hydrochloride, Neoantigen Vaccine GEN-009, Neoantigen-based Glioblastoma Vaccine, Neoantigen-based Melanoma-Poly-ICLC Vaccine, Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine, Neoantigen-based Therapeutic Cancer Vaccine GRT-C903, Neoantigen-based Therapeutic Cancer Vaccine GRT-R904, Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017, Neratinib, Neratinib Maleate, Nesvacumab, NG-nitro-L-arginine, Niacinamide, Niclosamide, Nicotinamide Riboside, Nidanilimab, Nifurtimox, Nilotinib, Nilotinib Hydrochloride Anhydrous, Nilotinib Hydrochloride Monohydrate, Nilutamide, Nimesulide-Hyaluronic Acid Conjugate CA102N, Nimodipine, Nimotuzumab, Nimustine, Nimustine Hydrochloride, Ningetinib Tosylate, Nintedanib, Niraparib, Niraparib Tosylate Monohydrate, Nirogacestat, Nitric Oxide-Releasing Acetylsalicylic Acid Derivative, Nitrogen Mustard Prodrug PR-104, Nitroglycerin Transdermal Patch, Nivolumab, NLRP3 Agonist BMS-986299, Nocodazole, Nogalamycin, Nogapendekin Alfa, Nolatrexed Dihydrochloride, Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201, Norgestrel, North American Ginseng Extract AFX-2, Nortopixantrone, Noscapine, Noscapine Hydrochloride, Not Otherwise Specified, Notch Signaling Inhibitor PF-06650808, Notch Signaling Pathway Inhibitor MK0752, NTRK/ROS1 Inhibitor DS-6051b, Nucleolin Antagonist IPP-204106N, Nucleoside Analog DFP-10917, Nucleotide Analog Prodrug NUC-3373, Nucleotide Analogue GS 9219, Numidargistat, Nurulimab, Nutlin-3a, Nutraceutical TBL-12, NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611, NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301, NY-ESO-1/GLA-SE Vaccine ID-G305, NY-ESO-B, O-Chloroacetylcarbamoylfumagillol, O6-Benzylguanine, Obatoclax Mesylate, Obinutuzumab, Oblimersen Sodium, Ocaratuzumab, Ocrelizumab, Octreotide, Octreotide Acetate, Octreotide Pamoate, Odronextamab, Ofatumumab, Ofranergene Obadenovec, Oglufanide Disodium, Olaparib, Olaptesed Pegol, Olaratumab, Oleandrin, Oleclumab, Oligo-fucoidan, Oligonucleotide SPC2996, Olinvacimab, Olivomycin, Olmutinib, Oltipraz, Olutasidenib, Olvimulogene Nanivacirepvec, Omacetaxine Mepesuccinate, Ombrabulin, Omipalisib, Onalespib, Onalespib Lactate, Onartuzumab, Onatasertib, Oncolytic Adenovirus Ad5-DNX-2401, Oncolytic Adenovirus ORCA-010, Oncolytic Herpes Simplex Virus-1 ONCR-177, Oncolytic HSV-1 C134, Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011, Oncolytic HSV-1 G207, Oncolytic HSV-1 NV1020, Oncolytic HSV-1 rQNestin34.5v.2, Oncolytic HSV-1 rRp450, Oncolytic HSV1716, Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Oncolytic Newcastle Disease Virus MEDI5395, Oncolytic Newcastle Disease Virus MTH-68H, Oncolytic Newcastle Disease Virus Strain PV701, Oncolytic Virus ASP9801, Oncolytic Virus RP1, Ondansetron Hydrochloride, Ontorpacept, Ontuxizumab, Onvansertib, Onvatilimab, Opaganib, OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule, Opioid Growth Factor, Opolimogene Capmilisbac, Oportuzumab Monatox, Oprozomib, Opucolimab, Oral Aminolevulinic Acid Hydrochloride, Oral Azacitidine, Oral Cancer Vaccine V3-OVA, Oral Docetaxel, Oral Fludarabine Phosphate, Oral Hsp90 Inhibitor IPI-493, Oral Ixabepilone, Oral Microencapsulated Diindolylmethane, Oral Milataxel, Oral Myoma Vaccine V3-myoma, Oral Pancreatic Cancer Vaccine V3-P, Oral Picoplatin, Oral Sodium Phenylbutyrate, Oral Topotecan Hydrochloride, Orantinib, Oraxol, Oregovomab, Orelabrutinib, Ormaplatin, Ortataxel, Orteronel, Orvacabtagene Autoleucel, Osilodrostat, Osimertinib, Other, Otlertuzumab, Ovapuldencel-T, Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006, Ovine Submaxillary Mucin, OX40L-expressing Oncolytic Adenovirus DNX-2440, Oxaliplatin, Oxaliplatin Eluting Beads, Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome, Oxcarbazepine, Oxeclosporin, Oxidative Phosphorylation Inhibitor IACS-010759, Oxidative Phosphorylation Inhibitor IM156, Oxidopamine, OxPhos Inhibitor VLX600, Ozarelix, P-cadherin Antagonist PF-03732010, P-cadherin Inhibitor PCA062, P-cadherin-targeting Agent PF-06671008, P-p68 Inhibitor RX-5902, P-TEFb Inhibitor BAY1143572, p300/CBP Bromodomain Inhibitor CCS1477, p38 MAPK Inhibitor LY3007113, p53 Peptide Vaccine MPS-128, p53-HDM2 Interaction Inhibitor MI-773, p53-HDM2 Protein-protein Interaction Inhibitor APG-115, p53/HDM2 Interaction Inhibitor CGM097, p70S6K Inhibitor LY2584702, p70S6K/Akt Inhibitor MSC2363318A, p97 Inhibitor CB-5083, p97 Inhibitor CB-5339, p97 Inhibitor CB-5339 Tosylate, Paclitaxel, Paclitaxel Ceribate, Paclitaxel Injection Concentrate for Nanodispersion, Paclitaxel Liposome, Paclitaxel Poliglumex, Paclitaxel Polymeric Micelle Formulation NANT-008, Paclitaxel PPE Microspheres, Paclitaxel Trevatide, Paclitaxel Vitamin E-Based Emulsion, Paclitaxel-Loaded Polymeric Micelle, Pacmilimab, Pacritinib, Padeliporfin, Padoporfin, PAK4 Inhibitor PF-03758309, PAK4/NAMPT Inhibitor KPT-9274, Palbociclib, Palbociclib Isethionate, Palifosfamide, Palifosfamide Tromethamine, Palladium Pd-103, Palonosetron Hydrochloride, Pamidronate Disodium, Pamidronic Acid, Pamiparib, Pamrevlumab, pan FGFR Inhibitor PRN1371, Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514, Pan-AKT Inhibitor ARQ751, Pan-AKT Kinase Inhibitor GSK690693, Pan-FGFR Inhibitor LY2874455, Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806, pan-HER Kinase Inhibitor AC480, Pan-IDH Mutant Inhibitor AG-881, Pan-KRAS Inhibitor BI 1701963, Pan-Mutant-IDH1 Inhibitor Bay-1436032, Pan-mutation-selective EGFR Inhibitor CLN-081, pan-PI3K Inhibitor CLR457, pan-PI3K/mTOR Inhibitor SF1126, Pan-PIM Inhibitor INCB053914, pan-PIM Kinase Inhibitor AZD1208, pan-PIM Kinase Inhibitor NVP-LGB-321, pan-RAF Inhibitor LXH254, Pan-RAF Inhibitor LY3009120, pan-RAF Kinase Inhibitor CCT3833, pan-RAF Kinase Inhibitor TAK-580, Pan-RAR Agonist/AP-1 Inhibitor LGD 1550, Pan-TRK Inhibitor NOV1601, Pan-TRK Inhibitor ONO-7579, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Pancratistatin, Panitumumab, Panobinostat, Panobinostat Nanoparticle Formulation MTX110, Panulisib, Paricalcitol, PARP 1/2 Inhibitor IMP4297, PARP 1/2 Inhibitor NOV1401, PARP Inhibitor AZD2461, PARP Inhibitor CEP-9722, PARP Inhibitor E7016, PARP Inhibitor NMS-03305293, PARP-1/2 Inhibitor ABT-767, PARP/Tankyrase Inhibitor 2X-121, PARP7 Inhibitor RBN-2397, Parsaclisib, Parsaclisib Hydrochloride, Parsatuzumab, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Parvovirus H-1, Pasireotide, Pasotuxizumab, Patidegib, Patidegib Topical Gel, Patritumab, Patritumab Deruxtecan, Patupilone, Paxalisib, Pazopanib, Pazopanib Hydrochloride, pbi-shRNA STMN1 Lipoplex, PBN Derivative OKN-007, PCNU, PD-1 Directed Probody CX-188, PD-1 Inhibitor, PD-L1 Inhibitor GS-4224, PD-L1 Inhibitor INCB086550, PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480, PD-L1/PD-L2/VISTA Antagonist CA-170, PDK1 Inhibitor AR-12, pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0, PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1, PEG-interleukin-2, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, PEG-Proline-Interferon Alfa-2b, Pegargiminase, Pegaspargase, Pegdinetanib, Pegfilgrastim, Pegilodecakin, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Pegvisomant, Pegvorhyaluronidase Alfa, Pegylated Deoxycytidine Analogue DFP-14927, Pegylated Interferon Alfa, Pegylated Liposomal Belotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Pegylated Liposomal Irinotecan, Pegylated Liposomal Mitomycin C Lipid-based Prodrug, Pegylated Liposomal Mitoxantrone Hydrochloride, Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010, Pegylated Paclitaxel, Pegylated Recombinant Human Arginase I BCT-100, Pegylated Recombinant Human Hyaluronidase PH20, Pegylated Recombinant Interleukin-2 THOR-707, Pegylated Recombinant L-asparaginase Erwinia chrysanthemi, Pegylated SN-38 Conjugate PLX038, Pegzilarginase, Pelabresib, Pelareorep, Peldesine, Pelitinib, Pelitrexol, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Pemigatinib, Pemlimogene Merolisbac, Penberol, Penclomedine, Penicillamine, Pentamethylmelamine, Pentamustine, Pentostatin, Pentoxifylline, PEOX-based Polymer Encapsulated Paclitaxel FID-007, PEP-3-KLH Conjugate Vaccine, Pepinemab, Peplomycin, Peplomycin Sulfate, Peposertib, Peptichemio, Peptide 946 Melanoma Vaccine, Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine, Peretinoin, Perflenapent Emulsion, Perfosfamide, Perifosine, Perillyl Alcohol, Personalized ALL-specific Multi-HLA-binding Peptide Vaccine, Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC, Personalized Cancer Vaccine RO7198457, Personalized Neoantigen DNA Vaccine GNOS-PV01, Personalized Neoantigen DNA Vaccine GNOS-PVO2, Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01, Personalized Neoepitope Yeast Vaccine YE-NEO-001, Personalized Peptide Cancer Vaccine NEO-PV-01, Pertuzumab, Pevonedistat, Pexastimogene Devacirepvec, Pexidartinib, Pexmetinib, PGG Beta-Glucan, PGLA/PEG Copolymer-Based Paclitaxel, PH20 Hyaluronidase-expressing Adenovirus VCN-01, Phaleria macrocarpa Extract DLBS-1425, Pharmacological Ascorbate, Phellodendron amurense Bark Extract, Phenesterin, Phenethyl Isothiocyanate, Phenethyl Isothiocyanate-containing Watercress Juice, Phenyl Acetate, Phenytoin Sodium, Phosphaplatin PT-112, Phosphatidylcholine-Bound Silybin, Phospholipid Ether-drug Conjugate CLR 131, Phosphoramide Mustard, Phosphorodiamidate Morpholino Oligomer AVI-4126, Phosphorus P-32, Photodynamic Compound TLD-1433, Photosensitizer LUZ 11, Phytochlorin Sodium-Polyvinylpyrrolidone Complex, PI3K Alpha/Beta Inhibitor BAY1082439, PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate, PI3K Inhibitor ACP-319, PI3K Inhibitor BGT226, PI3K Inhibitor GDC-0084, PI3K Inhibitor GDC0077, PI3K Inhibitor GSK1059615, PI3K Inhibitor WX-037, PI3K Inhibitor ZSTK474, PI3K p110beta/delta Inhibitor KA2237, PI3K-alpha Inhibitor MEN1611, PI3K-beta Inhibitor GSK2636771, PI3K-beta Inhibitor SAR260301, PI3K-delta Inhibitor AMG 319, PI3K-delta Inhibitor HMPL 689, PI3K-delta Inhibitor INCB050465, PI3K-delta Inhibitor PWT143, PI3K-delta Inhibitor SHC014748M, PI3K-delta Inhibitor YY-20394, PI3K-gamma Inhibitor IPI-549, PI3K/BET Inhibitor LY294002, PI3K/mTOR Kinase Inhibitor DS-7423, PI3K/mTOR Kinase Inhibitor PF-04691502, PI3K/mTOR Kinase Inhibitor VS-5584, PI3K/mTOR Kinase Inhibitor WXFL10030390, PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170, PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901, PI3Ka/mTOR Inhibitor PKI-179, PI3Kalpha Inhibitor AZD8835, PI3Kbeta Inhibitor AZD8186, PI3Kdelta Inhibitor GS-9901, Pibenzimol, Pibrozelesin, Pibrozelesin Hydrobromide, Picibanil, Picoplatin, Picrasinoside H, Picropodophyllin, Pictilisib, Pictilisib Bismesylate, Pidilizumab, Pilaralisib, PIM Kinase Inhibitor LGH447, PIM Kinase Inhibitor SGI-1776, PIM Kinase Inhibitor TP-3654, PIM/FLT3 Kinase Inhibitor SEL24, Pimasertib, Pimitespib, Pimurutamab, Pinatuzumab Vedotin, Pingyangmycin, Pinometostat, Pioglitazone, Pioglitazone Hydrochloride, Pipendoxifene, Piperazinedione, Piperine Extract (Standardized), Pipobroman, Piposulfan, Pirarubicin, Pirarubicin Hydrochloride, Pirfenidone, Piritrexim, Piritrexim Isethionate, Pirotinib, Piroxantrone, Piroxantrone Hydrochloride, Pixantrone, Pixantrone Dimaleate, Pixatimod, PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231, PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521, PKC-beta Inhibitor MS-553, Placebo, Pladienolide Derivative E7107, Plamotamab, Plasmid DNA Vaccine pING-hHER3FL, Platinum, Platinum Acetylacetonate-Titanium Dioxide Nanoparticles, Platinum Compound, Plevitrexed, Plicamycin, Plinabulin, Plitidepsin, Plk1 Inhibitor BI 2536, PLK1 Inhibitor CYC140, PLK1 Inhibitor TAK-960, Plocabulin, Plozalizumab, pNGVL4a-CRT-E6E7L2 DNA Vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2, Pol I Inhibitor CX5461, Polatuzumab Vedotin, Polidocanol, Poliglusam, Polo-like Kinase 1 Inhibitor GSK461364, Polo-like Kinase 1 Inhibitor MK1496, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate, Poly-alendronate Dextran-Guanidine Conjugate, Poly-gamma Glutamic Acid, Polyamine Analog SL11093, Polyamine Analogue PG11047, Polyamine Analogue SBP-101, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Polyandrol, Polyethylene Glycol Recombinant Endostatin, Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, Polymer-encapsulated Luteolin Nanoparticle, Polymeric Camptothecin Prodrug XMT-1001, Polypodium leucotomos Extract, Polysaccharide-K, Polysialic Acid, Polyunsaturated Fatty Acid, Polyvalent Melanoma Vaccine, Pomalidomide, Pomegranate Juice, Pomegranate Liquid Extract, Ponatinib, Ponatinib Hydrochloride, Porcupine Inhibitor CGX1321, Porcupine Inhibitor ETC-1922159, Porcupine Inhibitor RXC004, Porcupine Inhibitor WNT974, Porcupine Inhibitor XNW7201, Porfimer Sodium, Porfiromycin, Poziotinib, PPAR Alpha Antagonist TPST-1120, PR1 Leukemia Peptide Vaccine, Pracinostat, Pralatrexate, Pralsetinib, Praluzatamab Ravtansine, PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701, Pravastatin Sodium, Prednimustine, Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, Prednisone, Prexasertib, Prexigebersen, PRIMA-1 Analog APR-246, Prime Cancer Vaccine MVA-BN-CV301, Prinomastat, PRMT1 Inhibitor GSK3368715, PRMT5 Inhibitor JNJ-64619178, PRMT5 Inhibitor PRT811, Proapoptotic Sulindac Analog CP-461, Procarbazine, Procarbazine Hydrochloride, Procaspase Activating Compound-1 VO-100, Progestational IUD, Prohibitin-Targeting Peptide 1, Prolgolimab, Prostaglandin E2 EP4 Receptor Inhibitor AN0025, Prostaglandin E2 EP4 Receptor Inhibitor E7046, Prostate Cancer Vaccine ONY-P1, Prostate Health Cocktail Dietary Supplement, Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024, Protease-activated Anti-PD-L1 Antibody Prodrug CX-072, Protein Arginine Methyltransferase 5 Inhibitor GSK3326595, Protein Arginine Methyltransferase 5 Inhibitor PF-06939999, Protein Arginine Methyltransferase 5 Inhibitor PRT543, Protein Kinase C Inhibitor IDE196, Protein Phosphatase 2A Inhibitor LB-100, Protein Stabilized Liposomal Docetaxel Nanoparticles, Protein Tyrosine Kinase 2 Inhibitor IN10018, Proxalutamide, PSA/IL-2/GM-CSF Vaccine, PSA/PSMA DNA Plasmid INO-5150, Pseudoisocytidine, PSMA-targeted Docetaxel Nanoparticles BIND-014, PSMA-targeted Tubulysin B-containing Conjugate EC1169, PSMA/CD3 Tri-specific T-cell Activating Construct HPN424, PTEF-b/CDK9 Inhibitor BAY1251152, Pterostilbene, Pumitepa, Puquitinib, Puquitinib Mesylate, Puromycin, Puromycin Hydrochloride, PV-10, PVA Microporous Hydrospheres/Doxorubicin Hydrochloride, Pyrazinamide, Pyrazoloacridine, Pyridyl Cyanoguanidine CHS 828, Pyrotinib, Pyrotinib Dimaleate, Pyroxamide, Pyruvate Kinase Inhibitor TLN-232, Pyruvate Kinase M2 Isoform Activator TP-1454, Qilisheng Immunoregulatory Oral Solution, Quadrivalent Human Papillomavirus (types 6; 11; 16; 18) Recombinant Vaccine, Quarfloxin, Quinacrine Hydrochloride, Quinine, Quisinostat, Quizartinib, R-(-)-Gossypol Acetic Acid, Rabusertib, Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88, Racotumomab, RAD51 Inhibitor CYT-0851, Radgocitabine, Radgocitabine Hydrochloride, Radioactive Iodine, Radiolabeled CC49, Radium Ra 223 Dichloride, Radium Ra 224-labeled Calcium Carbonate Microparticles, Radix Angelicae Sinensis/Radix Astragali Herbal Supplement, Radotinib Hydrochloride, Raf Kinase Inhibitor HM95573, RAF Kinase Inhibitor L-779450, RAF Kinase Inhibitor XL281, Ragifilimab, Ralaniten Acetate, Ralimetinib Mesylate, Raloxifene, Raloxifene Hydrochloride, Raltitrexed, Ramucirumab, Ranibizumab, Ranimustine, Ranolazine, Ranpirnase, RARalpha Agonist IRX5183, Ras Inhibitor, Ras Peptide ASP, Ras Peptide CYS, Ras Peptide VAL, Razoxane, Realgar-Indigo naturalis Formulation, Rebastinib Tosylate, Rebeccamycin, Rebimastat, Receptor Tyrosine Kinase Inhibitor R1530, Recombinant Adenovirus-p53 SCH-58500, Recombinant Anti-WT1 Immunotherapeutic GSK2302024A, Recombinant Bacterial Minicells VAX014, Recombinant Bispecific Single-Chain Antibody rM28, Recombinant CD40-Ligand, Recombinant Erwinia asparaginase JZP-458, Recombinant Erythropoietin, Recombinant Fas Ligand, Recombinant Fractalkine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human 6Ckine, Recombinant Human Adenovirus Type 5 H101, Recombinant Human Angiotensin Converting Enzyme 2 APN01, Recombinant Human Apolipoprotein(a) Kringle V MG1102, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Recombinant Human Endostatin, Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Recombinant Human Papillomavirus 11-valent Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Recombinant Human Plasminogen Kringle 5 Domain ABT 828, Recombinant Human TRAIL-Trimer Fusion Protein SCB-313, Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301, Recombinant Interferon, Recombinant Interferon Alfa, Recombinant Interferon Alfa-1b, Recombinant Interferon Alfa-2a, Recombinant Interferon Alfa-2b, Recombinant Interferon Alpha 2b-like Protein, Recombinant Interferon Beta, Recombinant Interferon Gamma, Recombinant Interleukin-12, Recombinant Interleukin-13, Recombinant Interleukin-18, Recombinant Interleukin-2, Recombinant Interleukin-6, Recombinant KSA Glycoprotein CO17-1A, Recombinant Leukocyte Interleukin, Recombinant Leukoregulin, Recombinant Luteinizing Hormone, Recombinant Macrophage Colony-Stimulating Factor, Recombinant MAGE-3.1 Antigen, Recombinant MIP1-alpha Variant ECI301, Recombinant Modified Vaccinia Ankara-5T4 Vaccine, Recombinant Oncolytic Poliovirus PVS-RIPO, Recombinant Platelet Factor 4, Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A, Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207, Recombinant Super-compound Interferon, Recombinant Thyroglobulin, Recombinant Thyrotropin Alfa, Recombinant Transforming Growth Factor-Beta, Recombinant Transforming Growth Factor-Beta-2, Recombinant Tumor Necrosis Factor-Alpha, Recombinant Tyrosinase-Related Protein-2, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Redaporfin, Refametinib, Regorafenib, Relacorilant, Relatlimab, Relugolix, Remetinostat, Renal Cell Carcinoma Peptides Vaccine IMA901, Reparixin, Repotrectinib, Resiquimod, Resiquimod Topical Gel, Resistant Starch, Resminostat, Resveratrol, Resveratrol Formulation SRT501, RET Inhibitor DS-5010, RET Mutation/Fusion Inhibitor BLU-667, RET/SRC Inhibitor TPX-0046, Retaspimycin, Retaspimycin Hydrochloride, Retelliptine, Retifanlimab, Retinoic Acid Agent Ro 16-9100, Retinoid 9cUAB30, Retinol, Retinyl Acetate, Retinyl Palmitate, Retrovector Encoding Mutant Anti-Cyclin G1, Revdofilimab, Rexinoid NRX 194204, Rezivertinib, RFT5-dgA Immunotoxin IMTOX25, Rhenium Re 188 BMEDA-labeled Liposomes, Rhenium Re-186 Hydroxyethylidene Diphosphonate, Rhenium Re-188 Ethiodized Oil, Rhenium Re-188 Etidronate, Rhizoxin, RhoC Peptide Vaccine RV001V, Ribociclib, Ribociclib/Letrozole, Ribonuclease QBI-139, Ribosome-Inactivating Protein CY503, Ribozyme RPI.4610, Rice Bran, Ricolinostat, Ridaforolimus, Rigosertib, Rigosertib Sodium, Rilimogene Galvacirepvec, Rilimogene Galvacirepvec/Rilimogene Glafolivec, Rilimogene Glafolivec, Rilotumumab, Rindopepimut, Ripertamab, RIPK1 Inhibitor GSK3145095, Ripretinib, Risperidone Formulation in Rumenic Acid, Ritrosulfan, Rituximab, Rituximab and Hyaluronidase Human, Rituximab Conjugate CON-4619, Riviciclib, Rivoceranib, Rivoceranib Mesylate, RNR Inhibitor COH29, Robatumumab, Roblitinib, ROBO1-targeted BiCAR-NKT Cells, Rocakinogene Sifuplasmid, Rocapuldencel-T, Rociletinib, Rodorubicin, Roducitabine, Rofecoxib, Roflumilast, Rogaratinib, Rogletimide, Rolinsatamab Talirine, Romidepsin, Roneparstat, Roniciclib, Ropeginterferon Alfa-2B, Ropidoxuridine, Ropocamptide, Roquinimex, RORgamma Agonist LYC-55716, Rosabulin, Rose Bengal Solution PV-10, Rosiglitazone Maleate, Rosmantuzumab, Rosopatamab, Rosuvastatin, Rovalpituzumab Tesirine, RSK1-4 Inhibitor PMD-026, Rubitecan, Rucaparib, Rucaparib Camsylate, Rucaparib Phosphate, Ruthenium Ru-106, Ruthenium-based Small Molecule Therapeutic BOLD-100, Ruthenium-based Transferrin Targeting Agent NKP-1339, Ruxolitinib, Ruxolitinib Phosphate, Ruxotemitide, S-Adenosylmethionine, S-equol, S1P Receptor Agonist KRP203, Sabarubicin, Sabatolimab, Sacituzumab Govitecan, Sacubitril/Valsartan, Safingol, Sagopilone, Salirasib, Salmonella VNP20009, Sam68 Modulator CWP232291, Samalizumab, Samarium Sm 153-DOTMP, Samotolisib, Samrotamab Vedotin, Samuraciclib, Sapacitabine, Sapanisertib, Sapitinib, Saracatinib, Saracatinib Difumarate, SarCNU, Sardomozide, Sargramostim, Sasanlimab, Satraplatin, Savolitinib, SBIL-2, Scopoletin, SDF-1 Receptor Antagonist PTX-9908, Seclidemstat, Sedoxantrone Trihydrochloride, Selatinib Ditosilate, Selective Androgen Receptor Modulator RAD140, Selective Cytokine Inhibitory Drug CC-1088, Selective Estrogen Receptor Degrader AZD9496, Selective Estrogen Receptor Degrader AZD9833, Selective Estrogen Receptor Degrader LSZ102, Selective Estrogen Receptor Degrader LX-039, Selective Estrogen Receptor Degrader LY3484356, Selective Estrogen Receptor Degrader SRN-927, Selective Estrogen Receptor Modulator CC-8490, Selective Estrogen Receptor Modulator TAS-108, Selective Glucocorticoid Receptor Antagonist CORT125281, Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352, Seliciclib, Selicrelumab, Selinexor, Selitrectinib, Selonsertib, Selpercatinib, Selumetinib, Selumetinib Sulfate, Semaxanib, Semuloparin, Semustine, Seneca Valley Virus-001, Seocalcitol, Sepantronium Bromide, Serabelisib, Serclutamab Talirine, SERD D-0502, SERD G1T48, SERD GDC-9545, SERD SAR439859, SERD SHR9549, SERD ZN-c5, Serdemetan, Sergiolide, Seribantumab, Serine/Threonine Kinase Inhibitor CBP501, Serine/Threonine Kinase Inhibitor XL418, Serplulimab, Sevacizumab, Seviteronel, Shared Anti-Idiotype-AB-S006, Shared Anti-Idiotype-AB-S024A, Shark Cartilage, Shark Cartilage Extract AE-941, Shenqi Fuzheng Injection SQ001, Sho-Saiko-To, Short Chain Fatty Acid HQK-1004, SHP-1 Agonist SC-43, SHP2 Inhibitor JAB-3068, SHP2 Inhibitor RLY-1971, SHP2 Inhibitor RMC-4630, SHP2 Inhibitor TNO155, Shu Yu Wan Formula, Sialyl Tn Antigen, Sialyl Tn-KLH Vaccine, Sibrotuzumab, siG12D LODER, Silatecan AR-67, Silibinin, Silicon Phthalocyanine 4, Silmitasertib Sodium, Siltuximab, Simalikalactone D, Simeprevir, Simlukafusp Alfa, Simmitinib, Simotaxel, Simtuzumab, Simurosertib, Sintilimab, Siplizumab, Sipuleucel-T, Siremadlin, siRNA-transfected Peripheral Blood Mononuclear Cells APN401, Sirolimus, SIRPa-4-1BBL Fusion Protein DSP107, SIRPa-Fc Fusion Protein TTI-621, SIRPa-Fc-CD40L Fusion Protein SL-172154, SIRPa-IgG4-Fc Fusion Protein TTI-622, Sitimagene Ceradenovec, Sitravatinib, Sivifene, Sizofiran, SLC6A8 Inhibitor RGX-202, SLCT Inhibitor GNS561, SMAC Mimetic BI 891065, Smac Mimetic GDC-0152, Smac Mimetic GDC-0917, Smac Mimetic LCL161, SMO Protein Inhibitor ZSP1602, Smoothened Antagonist BMS-833923, Smoothened Antagonist LDE225 Topical, Smoothened Antagonist LEQ506, Smoothened Antagonist TAK-441, SN-38-Loaded Polymeric Micelles NK012, SNS01-T Nanoparticles, Sobuzoxane, Sodium Borocaptate, Sodium Butyrate, Sodium Dichloroacetate, Sodium Iodide I-131, Sodium Metaarsenite, Sodium Phenylbutyrate, Sodium Salicylate, Sodium Selenite, Sodium Stibogluconate, Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108, Sofituzumab Vedotin, Solitomab, Sonepcizumab, Sonidegib, Sonolisib, Sorafenib, Sorafenib Tosylate, Sorghum bicolor Supplement, Sotigalimab, Sotorasib, Sotrastaurin, Sotrastaurin Acetate, Soy Isoflavones, Soy Protein Isolate, Spanlecortemlocel, Sparfosate Sodium, Sparfosic Acid, Spartalizumab, Spebrutinib, Spherical Nucleic Acid Nanoparticle NU-0129, Spirogermanium, Spiromustine, Spiroplatin, Splicing Inhibitor H3B-8800, Spongistatin, Squalamine Lactate, SR-BP1/HSI Inhibitor SR31747A, SR-T100 Gel, Src Kinase Inhibitor AP 23846, Src Kinase Inhibitor KX2-391, Src Kinase Inhibitor KX2-391 Ointment, Src Kinase Inhibitor M475271, Src/Abl Kinase Inhibitor AZD0424, Src/tubulin Inhibitor KX02, SRPK1/ABCG2 Inhibitor SCO-101, ssRNA-based Immunomodulator CV8102, SSTR2-targeting Protein/DM1 Conjugate PEN-221, St. John's Wort, Stallimycin, Staphylococcal Enterotoxin A, Staphylococcal Enterotoxin B, STAT Inhibitor OPB-111077, STAT3 Inhibitor DSP-0337, STAT3 Inhibitor OPB-31121, STAT3 Inhibitor OPB-51602, STAT3 Inhibitor TTI-101, STAT3 Inhibitor WP1066, Staurosporine, STING Agonist BMS-986301, STING Agonist GSK3745417, STING Agonist IMSA101, STING Agonist MK-1454, STING Agonist SB 11285, STING Agonist TAK-676, STING-activating Cyclic Dinucleotide Agonist MIW815, STING-expressing E. coli SYNB1891, Streptonigrin, Streptozocin, Strontium Chloride Sr-89, Submicron Particle Paclitaxel Sterile Suspension, Sugemalimab, Sulfatinib, Sulforaphane, Sulindac, Sulofenur, Sumoylation Inhibitor TAK-981, Sunitinib, Sunitinib Malate, Super Enhancer Inhibitor GZ17-6.02, Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803, Superoxide Dismutase Mimetic GC4711, Suramin, Suramin Sodium, Survivin Antigen, Survivin Antigen Vaccine DPX-Survivac, Survivin mRNA Antagonist EZN-3042, Survivin-expressing CVD908ssb-TXSVN Vaccine, Sustained-release Lipid Inhaled Cisplatin, Sustained-release Mitomycin C Hydrogel Formulation UGN-101, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, Syk Inhibitor HMPL-523, Synchrotope TA2M Plasmid DNA Vaccine, Synchrovax SEM Plasmid DNA Vaccine, Synthetic Alkaloid PM00104, Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2, Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1, Synthetic hTERT DNA Vaccine INO-1400, Synthetic hTERT DNA Vaccine INO-1401, Synthetic Hypericin, Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201, Synthetic Long E6/E7 Peptides Vaccine HPV-01, Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b, Synthetic Plumbagin PCUR-101, T900607, Tabalumab, Tabelecleucel, Tacedinaline, Tafasitamab, Tagraxofusp-erzs, Talabostat, Talabostat Mesylate, Talacotuzumab, Talactoferrin Alfa, Taladegib, Talampanel, Talaporfin Sodium, Talazoparib, Taletrectinib, Talimogene Laherparepvec, Tallimustine, Talmapimod, Talotrexin, Talotrexin Ammonium, Taltobulin, TAM/c-Met Inhibitor RXDX-106, Tamibarotene, Taminadenant, Tamoxifen, Tamoxifen Citrate, Tamrintamab Pamozirine, Tandutinib, Tanespimycin, Tanibirumab, Tankyrase Inhibitor STP1002, Tanomastat, Tapotoclax, Tarenflurbil, Tarextumab, Tariquidar, Tasadenoturev, Taselisib, Tasidotin, Tasisulam, Tasisulam Sodium, Tasquinimod, Taurolidine, Tauromustine, Taurultam, Taurultam Analogue GP-2250, Tavokinogene Telseplasmid, Tavolimab, Taxane Analogue TPI 287, Taxane Compound, Taxol Analogue SID 530, Tazarotene, Tazemetostat, Tebentafusp, Teclistamab, Tecogalan Sodium, Tefinostat, Tegafur, Tegafur-gimeracil-oteracil Potassium, Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation, Tegafur-Uracil, Tegavivint, Teglarinad, Teglarinad Chloride, Telaglenastat, Telaglenastat Hydrochloride, Telapristone, Telapristone Acetate, Telatinib Mesylate, Telisotuzumab, Telisotuzumab Vedotin, Telomerase Inhibitor FJ5002, Telomerase-specific Type 5 Adenovirus OBP-301, Teloxantrone, Teloxantrone Hydrochloride, Telratolimod, Temarotene, Temoporfin, Temozolomide, Temsirolimus, Tenalisib, Tenifatecan, Teniposide, Tepoditamab, Tepotinib, Teprotumumab, Terameprocol, Terfluranol, Tergenpumatucel-L, Teroxirone, Tertomotide, Tesetaxel, Tesevatinib, Tesidolumab, Testolactone, Testosterone Enanthate, Tetanus Toxoid Vaccine, Tetradecanoylphorbol Acetate, Tetrahydrouridine, Tetraphenyl Chlorin Disulfonate, Tetrathiomolybdate, Tezacitabine, Tezacitabine Anhydrous, TGF-beta Receptor 1 Inhibitor PF-06952229, TGF-beta Receptor 1 Kinase Inhibitor SH3051, TGF-beta Receptor 1 Kinase Inhibitor YL-13027, TGFa-PE38 Immunotoxin, TGFbeta Inhibitor LY3200882, TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200, Thalicarpine, Thalidomide, Theliatinib, Theramide, Therapeutic Angiotensin-(1-7), Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907, Therapeutic Cancer Vaccine ATP128, Therapeutic Estradiol, Therapeutic Hydrocortisone, Therapeutic Liver Cancer Peptide Vaccine IMA970A, Thiarabine, Thiodiglycol, Thioguanine, Thioguanine Anhydrous, Thioinosine, Thioredoxin-1 Inhibitor PX-12, Thiotepa, Thioureidobutyronitrile, THL-P, Thorium Th 227 Anetumab, Thorium Th 227 Anetumab Corixetan, Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439, Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497, Threonine Tyrosine Kinase Inhibitor CFI-402257, Thymidylate Synthase Inhibitor CX1106, Thymidylate Synthase Inhibitor DFP-11207, Thymopentin, Thyroid Extract, Tiazofurin, Tidutamab, Tigapotide, Tigatuzumab, TIGIT Inhibitor M6223, TIGIT-targeting Agent MK-7684, Tilarginine, Tilogotamab, Tilsotolimod Sodium, Timonacic, Tin Ethyl Etiopurpurin, Tinostamustine, Tinzaparin Sodium, Tiomolibdate Choline, Tiomolibdate Diammonium, Tipapkinogene Sovacivec, Tipifarnib, Tipiracil, Tipiracil Hydrochloride, Tirabrutinib, Tiragolumab, Tirapazamine, Tirbanibulin, Tisagenlecleucel, Tislelizumab, Tisotumab Vedotin, Tivantinib, Tivozanib, TLC ELL-12, TLR Agonist BDB001, TLR Agonist BSG-001, TLR Agonist CADI-05, TLR-Directed Cationic Lipid-DNA Complex JVRS-100, TLR7 Agonist 852A, TLR7 agonist BNT411, TLR7 Agonist LHC165, TLR7/8/9 Antagonist IMO-8400, TLR8 Agonist DN1508052, TLR9 Agonist AST-008, TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells, Tocilizumab, Tocladesine, Tocotrienol, Tocotrienol-rich Fraction, Tolebrutinib, Toll-like Receptor 7 Agonist DSP-0509, Tolnidamine, Tomaralimab, Tomato-Soy Juice, Tomivosertib, Topical Betulinic Acid, Topical Celecoxib, Topical Fluorouracil, Topical Gemcitabine Hydrochloride, Topical Potassium Dobesilate, Topical Trichloroacetic Acid, Topixantrone, Topoisomerase I Inhibitor Genz-644282, Topoisomerase I Inhibitor LMP400, Topoisomerase I Inhibitor LMP776, Topoisomerase I/II Inhibitor NEV-801, Topoisomerase-1 Inhibitor LMP744, Topoisomerase-II Inhibitor Racemic XK469, Topoisomerase-II-beta Inhibitor Racemic XK469, Topotecan, Topotecan Hydrochloride, Topotecan Hydrochloride Liposomes, Topotecan Sustained-release Episcleral Plaque, Topsalysin, TORC1/2 Kinase Inhibitor DS-3078a, Toremifene, Toremifene Citrate, Toripalimab, Tosedostat, Tositumomab, Total Androgen Blockade, Tovetumab, Tozasertib Lactate, TP40 Immunotoxin, Trabectedin, Trabedersen, TRAIL Receptor Agonist ABBV-621, Trametinib, Trametinib Dimethyl Sulfoxide, Trans Sodium Crocetinate, Transdermal 17beta-Estradiol Gel BHR-200, Transdermal 4-Hydroxytestosterone, Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01, Transferrin Receptor-Targeted Liposomal p53 cDNA, Transferrin-CRM107, Tranylcypromine Sulfate, Trapoxin, Trastuzumab, Trastuzumab Conjugate BI-CON-02, Trastuzumab Deruxtecan, Trastuzumab Duocarmazine, Trastuzumab Emtansine, Trastuzumab Monomethyl Auristatin F, Trastuzumab-TLR 7/8 Agonist BDC-1001, Trastuzumab/Hyaluronidase-oysk, Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502, Trebananib, Tremelimumab, Treosulfan, Tretazicar, Tretinoin, Tretinoin Liposome, Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triapine, Triazene Derivative CB10-277, Triazene Derivative TriN2755, Triazinate, Triaziquone, Tributyrin, Triciribine Phosphate, Trientine Hydrochloride, Triethylenemelamine, Trifluridine, Trifluridine and Tipiracil Hydrochloride, Trigriluzole, Trilaciclib, Trimelamol, Trimeric GITRL-Fc OMP-336B11, Trimethylcolchicinic Acid, Trimetrexate, Trimetrexate Glucuronate, Trioxifene, Triplatin Tetranitrate, Triptolide Analog, Triptorelin, Triptorelin Pamoate, Tris-acryl Gelatin Microspheres, Tritylcysteine, TRK Inhibitor AZD6918, TRK Inhibitor TQB3558, TrkA Inhibitor VMD-928, Trodusquemine, Trofosfamide, Troglitazone, Tropomyosin Receptor Kinase Inhibitor AZD7451, Troriluzole, Troxacitabine, Troxacitabine Nucleotide Prodrug MIV-818, TRPM8 Agonist D-3263, TRPV6 Calcium Channel Inhibitor SOR-C13, TSP-1 Mimetic ABT-510, TSP-1 Mimetic Fusion Protein CVX-045, Tubercidin, Tubulin Binding Agent TTI-237, Tubulin Inhibitor ALB 109564 Dihydrochloride, Tubulin Inhibitor ALB-109564, Tubulin Polymerization Inhibitor AEZS 112, Tubulin Polymerization Inhibitor CKD-516, Tubulin Polymerization Inhibitor VERU-111, Tubulin-Binding Agent SSR97225, Tucatinib, Tucidinostat, Tucotuzumab Celmoleukin, Tyroserleutide, Tyrosinase Peptide, Tyrosinase-KLH, Tyrosinase:146-156 Peptide, Tyrosine Kinase Inhibitor, Tyrosine Kinase Inhibitor OSI-930, Tyrosine Kinase Inhibitor SU5402, Tyrosine Kinase Inhibitor TL-895, Tyrosine Kinase Inhibitor XL228, UAE Inhibitor TAK-243, Ubenimex, Ubidecarenone Nanodispersion BPM31510n, Ublituximab, Ulinastatin, Ulixertinib, Ulocuplumab, Umbralisib, Uncaria tomentosa Extract, Upamostat, Upifitamab, Uproleselan, Uprosertib, Urabrelimab, Uracil Ointment, Urelumab, Uroacitides, Urokinase-Derived Peptide A6, Ursolic Acid, USP14/UCHL5 Inhibitor VLX1570, Utomilumab, Uzansertib, V930 Vaccine, Vaccine-Sensitized Draining Lymph Node Cells, Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules, Vactosertib, Vadacabtagene Leraleucel, Vadastuximab Talirine, Vadimezan, Valecobulin, Valemetostat, Valproic Acid, Valrubicin, Valspodar, Vandetanib, Vandetanib-eluting Radiopaque Bead BTG-002814, Vandortuzumab Vedotin, Vantictumab, Vanucizumab, Vapreotide, Varlilumab, Varlitinib, Varlitinib Tosylate, Vascular Disrupting Agent BNC105, Vascular Disrupting Agent BNC105P, Vascular Disrupting Agent ZD6126, Vatalanib, Vatalanib Succinate, Vecabrutinib, Vector-peptide Conjugated Paclitaxel, Vedolizumab, VEGF Inhibitor PTC299, VEGF/HGF-targeting DARPin MP0250, VEGFR Inhibitor KRN951, VEGFR-2 DNA Vaccine VXM01, VEGFR/FGFR Inhibitor ODM-203, VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593, VEGFR2 Tyrosine Kinase Inhibitor PF-00337210, VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813, Veliparib, Veltuzumab, Vemurafenib, Venetoclax, Verapamil, Verpasep Caltespen, Verubulin, Verubulin Hydrochloride, Vesencumab, Vesigenurtucel-L, VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220, VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820, Viagenpumatucel-L, Vibecotamab, Vibostolimab, Vilaprisan, Vinblastine, Vinblastine Sulfate, Vincristine, Vincristine Liposomal, Vincristine Sulfate, Vincristine Sulfate Liposome, Vindesine, Vinepidine, Vinflunine, Vinflunine Ditartrate, Vinfosiltine, Vinorelbine, Vinorelbine Tartrate, Vinorelbine Tartrate Emulsion, Vinorelbine Tartrate Oral, Vintafolide, Vinzolidine, Vinzolidine Sulfate, Virulizin, Vismodegib, Vistusertib, Vitamin D3 Analogue ILX23-7553, Vitamin E Compound, Vitespen, VLP-encapsulated TLR9 Agonist CMP-001, Vocimagene Amiretrorepvec, Vofatamab, Volasertib, Volociximab, Vonlerolizumab, Vopratelimab, Vorasidenib, Vorinostat, Vorolanib, Vorsetzumab Mafodotin, Vosaroxin, Vosilasarm, Voxtalisib, Vulinacimab, Warfarin Sodium, Wee1 Inhibitor ZN-c3, Wee1 Kinase Inhibitor Debio 0123, White Carrot, Wnt Signaling Inhibitor SM04755, Wnt Signaling Pathway Inhibitor SM08502, Wnt-5a Mimic Hexapeptide Foxy-5, Wobe-Mugos E, WT1 Peptide Vaccine OCV-501, WT1 Peptide Vaccine WT2725, WT1 Protein-derived Peptide Vaccine DSP-7888, WT1-A10/AS01B Immunotherapeutic GSK2130579A, WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401, Xanthohumol, XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410, Xeloda, Xentuzumab, Xevinapant, Xiaoai Jiedu Decoction, XIAP Antisense Oligonucleotide AEG35156, XIAP/cIAP1 Antagonist ASTX660, Xiliertinib, Xisomab 3G3, XPO1 Inhibitor SL-801, Y 90 Monoclonal Antibody CC49, Y 90 Monoclonal Antibody HMFG1, Y 90 Monoclonal Antibody Lym-1, Y 90 Monoclonal Antibody m170, Y 90 Monoclonal Antibody M195, Yang Yin Fu Zheng, Yangzheng Xiaoji Extract, Yiqi-yangyin-jiedu Herbal Decoction, Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8, Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101, Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66, Yttrium Y 90 Basiliximab, Yttrium Y 90 Colloid, Yttrium Y 90 Daclizumab, Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A, Yttrium Y 90 Glass Microspheres, Yttrium Y 90 Monoclonal Antibody B3, Yttrium Y 90 Monoclonal Antibody BrE-3, Yttrium Y 90 Monoclonal Antibody Hu3S193, Yttrium Y 90 Monoclonal Antibody MN-14, Yttrium Y 90 Resin Microspheres, Yttrium Y 90 Tabituximab Barzuxetan, Yttrium Y 90-DOTA-Biotin, Yttrium Y 90-DOTA-di-HSG Peptide IMP-288, Yttrium Y 90-Edotreotide, Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101, Yttrium Y-90 Clivatuzumab Tetraxetan, Yttrium Y-90 Epratuzumab Tetraxetan, Yttrium Y-90 Ibritumomab Tiuxetan, Yttrium Y-90 Tacatuzumab Tetraxetan, Yttrium-90 Polycarbonate Brachytherapy Plaque, Z-Endoxifen Hydrochloride, Zalcitabine, Zalifrelimab, Zalutumumab, Zandelisib, Zanidatamab, Zanolimumab, Zanubrutinib, Zebularine, Zelavespib, Zibotentan, Zinc Finger Nuclease ZFN-603, Zinc Finger Nuclease ZFN-758, Zinostatin, Zinostatin Stimalamer, Zirconium Zr 89 Panitumumab, Ziv-Aflibercept, Zolbetuximab, Zoledronic Acid, Zoptarelin Doxorubicin, Zorifertinib, Zorubicin, Zorubicin Hydrochloride, Zotatifin, Zotiraciclib Citrate, Zuclomiphene Citrate, Unknown, Not Reported",,,CDE:13579886,,string,,,,,, Individual Metastasis Stage,Extent of the distant metastasis for the cancer based on evidence obtained from clinical assessment parameters determined prior to treatment.,"M0, M1, M1a, M1b, M1c, MX, cM0 (i+), Unknown, Not Reported",,,CDE:3440331,,string,,,,,, diff --git a/modules/model/annotationProperty.csv b/modules/model/annotationProperty.csv index 84c246a2..e1d5e8e7 100644 --- a/modules/model/annotationProperty.csv +++ b/modules/model/annotationProperty.csv @@ -13,7 +13,7 @@ Model Source,"The reference organism from which the model was derived, if applic Model Acquisition Type,"The method by which the model was obtained. If applicable, please provide a link to the supplier of the model source.",,,,,,string,,,,,, Model Graft Source,"If the model is an allograft or xenograft, as indicated by Model Type, please provide a unique identifier associated with the source of the graft material (e.g., RRID, Individual Key, Model Key, Biospecimen Key)",,,,,,string,,,,,, Model Genotype,"The relevant genotype information associated with the model, including markers, background, etc.",,,,,,string,,,,,, -Model Treatment Type,Text term that describes the kind of treatment applied to the model.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, +Model Treatment Type,Text term that describes the kind of treatment applied to the model.,"3-Dimensional Conformal Radiation Therapy, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Brachytherapy, Cellular Therapy, Chemotherapy, Concurrent Chemoradiation, Control, Conventional Radiotherapy, Electron Beam Radiation Therapy, External Beam Radiation Therapy, High-Dose Rate Brachytherapy, Hormone Therapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Low-Dose Rate Brachytherapy, Not Reported, Organ Transplantation, Palliative Care, Pharmacotherapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Radiation Therapy, Radiofrequency Ablation, Radiopharmaceutical, Stem Cell Transplant, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Surgical Procedure, Targeted Molecular Therapy, Unknown",,,CDE:14737565,,string,,,,,, Model Therapeutic Agent,Text identification of the individual agent(s) used as part of an experimental protocol performed using the model.,"10-Deacetyltaxol, 11C Topotecan, 11D10 AluGel Anti-Idiotype Monoclonal Antibody, 12-Allyldeoxoartemisinin, 13-Deoxydoxorubicin, 14C BMS-275183, 17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521, 2-Deoxy-D-glucose, 2-Ethylhydrazide, 2-Fluoroadenine, 2-Fluorofucose-containing SGN-2FF, 2-Hydroxyestradiol, 2-Hydroxyestrone, 2-Hydroxyflutamide Depot, 2-Hydroxyoleic Acid, 2-Methoxyestradiol, 2-Methoxyestradiol Nanocrystal Colloidal Dispersion, 2-Methoxyestrone, 2-O; 3-O Desulfated Heparin, 2;6-Diaminopurine, 2;6-Dimethoxyquinone, 2'-F-ara-deoxyuridine, 3'-C-ethynylcytidine, 3'-dA Phosphoramidate NUC-7738, 4-Nitroestrone 3-Methyl Ether, 4-Thio-2-deoxycytidine, 4'-Iodo-4'-Deoxydoxorubicin, 5-Aza-4'-thio-2'-deoxycytidine, 5-Fluoro-2-Deoxycytidine, 6-Phosphofructo-2-kinase/fructose-2;6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158, 7-Cyanoquinocarcinol, 7-Ethyl-10-Hydroxycamptothecin, 7-Hydroxystaurosporine, 8-Azaguanine, 9-Ethyl 6-Mercaptopurine, 9H-Purine-6Thio-98D, A2A Receptor Antagonist EOS100850, Abagovomab, Abarelix, Abemaciclib, Abemaciclib Mesylate, Abexinostat, Abexinostat Tosylate, Abiraterone, Abiraterone Acetate, Abituzumab, Acai Berry Juice, Acalabrutinib, Acalisib, Aceglatone, Acetylcysteine, Acitretin, Acivicin, Aclacinomycin B, Aclarubicin, Acodazole, Acodazole Hydrochloride, Acolbifene Hydrochloride, Acridine, Acridine Carboxamide, Acronine, Actinium Ac 225 Lintuzumab, Actinium Ac 225-FPI-1434, Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591, Actinomycin C2, Actinomycin C3, Actinomycin F1, Activin Type 2B Receptor Fc Fusion Protein STM 434, Acyclic Nucleoside Phosphonate Prodrug ABI-1968, Ad-RTS-hIL-12, Adagloxad Simolenin, Adavosertib, Adecatumumab, Adenosine A2A Receptor Antagonist AZD4635, Adenosine A2A Receptor Antagonist CS3005, Adenosine A2A Receptor Antagonist NIR178, Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999, Adenosine A2A/A2B Receptor Antagonist AB928, Adenosine A2B Receptor Antagonist PBF-1129, Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201, Adenoviral Brachyury Vaccine ETBX-051, Adenoviral Cancer Vaccine PF-06936308, Adenoviral MUC1 Vaccine ETBX-061, Adenoviral PSA Vaccine ETBX-071, Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001, Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901, Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE, Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918, Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931, Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3, Adenovirus-mediated Human Interleukin-12 INXN-2001 Plus Activator Ligand INXN-1001, Aderbasib, ADH-1, AE37 Peptide/GM-CSF Vaccine, AEE788, Aerosol Gemcitabine, Aerosolized Aldesleukin, Aerosolized Liposomal Rubitecan, Afatinib, Afatinib Dimaleate, Afimoxifene, Afuresertib, Agatolimod Sodium, Agerafenib, Aglatimagene Besadenovec, Agonistic Anti-CD40 Monoclonal Antibody ADC-1013, Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Agonistic Anti-OX40 Monoclonal Antibody MEDI6469, AKR1C3-activated Prodrug OBI-3424, AKT 1/2 Inhibitor BAY1125976, AKT Inhibitor ARQ 092, Akt Inhibitor LY2780301, Akt Inhibitor MK2206, Akt Inhibitor SR13668, Akt/ERK Inhibitor ONC201, Alacizumab Pegol, Alanosine, Albumin-binding Cisplatin Prodrug BTP-114, Aldesleukin, Aldoxorubicin, Alectinib, Alefacept, Alemtuzumab, Alestramustine, Alflutinib Mesylate, Algenpantucel-L, Alisertib, Alitretinoin, ALK Inhibitor, ALK Inhibitor ASP3026, ALK Inhibitor PLB 1003, ALK Inhibitor RO5424802, ALK Inhibitor TAE684, ALK Inhibitor WX-0593, ALK-2 Inhibitor TP-0184, ALK-FAK Inhibitor CEP-37440, ALK/c-Met Inhibitor TQ-B3139, ALK/FAK/Pyk2 Inhibitor CT-707, ALK/ROS1/Met Inhibitor TQ-B3101, ALK/TRK Inhibitor TSR-011, Alkotinib, Allodepleted T Cell Immunotherapeutic ATIR101, Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715, Allogeneic Anti-BCMA-CAR T-cells PBCAR269A, Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells, Allogeneic Anti-CD19 CAR T-cells ALLO-501A, Allogeneic Anti-CD19 Universal CAR-T Cells CTA101, Allogeneic Anti-CD19-CAR T-cells PBCAR0191, Allogeneic Anti-CD20 CAR T-cells LUCAR-20S, Allogeneic Anti-CD20-CAR T-cells PBCAR20A, Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22, Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100, Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001, Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Allogeneic Cellular Vaccine 1650-G, Allogeneic CRISPR-Cas9 Engineered Anti-BCMA T Cells CTX120, Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130, Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Allogeneic GM-CSF-secreting Lethally Irradiated Prostate Cancer Vaccine, Allogeneic GM-CSF-secreting Lethally Irradiated Whole Melanoma Cell Vaccine, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo, Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo, Allogeneic IL13-Zetakine/HyTK-Expressing-Glucocorticoid Resistant Cytotoxic T Lymphocytes GRm13Z40-2, Allogeneic Irradiated Melanoma Cell Vaccine CSF470, Allogeneic Large Multivalent Immunogen Melanoma Vaccine LP2307, Allogeneic Melanoma Vaccine AGI-101H, Allogeneic Natural Killer Cell Line MG4101, Allogeneic Natural Killer Cell Line NK-92, Allogeneic Plasmacytoid Dendritic Cells Expressing Lung Tumor Antigens PDC*lung01, Allogeneic Renal Cell Carcinoma Vaccine MGN1601, Allogeneic Third-party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T-cells CTL 19, Allosteric ErbB Inhibitor BDTX-189, Allovectin-7, Almurtide, Alobresib, Alofanib, Alpelisib, Alpha Galactosylceramide, Alpha V Beta 1 Inhibitor ATN-161, Alpha V Beta 8 Antagonist PF-06940434, alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801, Alpha-Gal AGI-134, Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H, Alpha-Thioguanine Deoxyriboside, Alpha-tocopheryloxyacetic Acid, Alsevalimab, Altiratinib, Altretamine, Alvespimycin, Alvespimycin Hydrochloride, Alvocidib, Alvocidib Hydrochloride, Alvocidib Prodrug TP-1287, Amatuximab, Ambamustine, Ambazone, Amblyomin-X, Amcasertib, Ametantrone, Amifostine, Amino Acid Injection, Aminocamptothecin, Aminocamptothecin Colloidal Dispersion, Aminoflavone Prodrug AFP464, Aminopterin, Aminopterin Sodium, Amivantamab, Amolimogene Bepiplasmid, Amonafide L-Malate, Amrubicin, Amrubicin Hydrochloride, Amsacrine, Amsacrine Lactate, Amsilarotene, Amustaline, Amustaline Dihydrochloride, Amuvatinib, Amuvatinib Hydrochloride, Anakinra, Anastrozole, Anaxirone, Ancitabine, Ancitabine Hydrochloride, Andecaliximab, Androgen Antagonist APC-100, Androgen Receptor Antagonist BAY 1161116, Androgen Receptor Antagonist SHR3680, Androgen Receptor Antagonist TAS3681, Androgen Receptor Antagonist TRC253, Androgen Receptor Antisense Oligonucleotide AZD5312, Androgen Receptor Antisense Oligonucleotide EZN-4176, Androgen Receptor Degrader ARV-110, Androgen Receptor Degrader CC-94676, Androgen Receptor Downregulator AZD3514, Androgen Receptor Inhibitor EPI-7386, Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118, Androgen Receptor/Glucocorticoid Receptor Antagonist CB-03-10, Andrographolide, Androstane Steroid HE3235, Anetumab Ravtansine, Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241, Angiogenesis Inhibitor GT-111, Angiogenesis Inhibitor JI-101, Angiogenesis/Heparanase Inhibitor PG545, Angiopoietin-2-specific Fusion Protein PF-04856884, Anhydrous Enol-oxaloacetate, Anhydrovinblastine, Aniline Mustard, Anlotinib Hydrochloride, Annamycin, Annamycin Liposomal, Annonaceous Acetogenins, Ansamitomicin P-3, Anthramycin, Anthrapyrazole, Anti c-KIT Antibody-drug Conjugate LOP628, Anti-5T4 Antibody-drug Conjugate ASN004, Anti-5T4 Antibody-Drug Conjugate PF-06263507, Anti-5T4 Antibody-drug Conjugate SYD1875, Anti-A33 Monoclonal Antibody KRN330, Anti-A5B1 Integrin Monoclonal Antibody PF-04605412, Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087, Anti-AG7 Antibody Drug Conjugate AbGn-107, Anti-AGS-16 Monoclonal Antibody AGS-16M18, Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME, Anti-AGS-8 Monoclonal Antibody AGS-8M4, Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B, Anti-alpha5beta1 Integrin Antibody MINT1526A, Anti-ANG2 Monoclonal Antibody MEDI-3617, Anti-angiopoietin Monoclonal Antibody AMG 780, Anti-APRIL Monoclonal Antibody BION-1301, Anti-AXL Fusion Protein AVB-S6-500, Anti-AXL/PBD Antibody-drug Conjugate ADCT-601, Anti-B7-H3 Antibody DS-5573a, Anti-B7-H3/DXd Antibody-drug Conjugate DS-7300a, Anti-B7-H4 Monoclonal Antibody FPA150, Anti-B7H3 Antibody-drug Conjugate MGC018, Anti-BCMA Antibody SEA-BCMA, Anti-BCMA Antibody-drug Conjugate AMG 224, Anti-BCMA Antibody-drug Conjugate CC-99712, Anti-BCMA Antibody-drug Conjugate GSK2857916, Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA, Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459, Anti-BCMA/CD3 BiTE Antibody AMG 420, Anti-BCMA/CD3 BiTE Antibody AMG 701, Anti-BCMA/CD3 BiTE Antibody REGN5458, Anti-BCMA/PBD ADC MEDI2228, Anti-BTLA Monoclonal Antibody TAB004, Anti-BTN3A Agonistic Monoclonal Antibody ICT01, Anti-c-fms Monoclonal Antibody AMG 820, Anti-c-KIT Monoclonal Antibody CDX 0158, Anti-c-Met Antibody-drug Conjugate HTI-1066, Anti-c-Met Antibody-drug Conjugate TR1801, Anti-c-Met Monoclonal Antibody ABT-700, Anti-c-Met Monoclonal Antibody ARGX-111, Anti-c-Met Monoclonal Antibody HLX55, Anti-c-MET Monoclonal Antibody LY2875358, Anti-C-met Monoclonal Antibody SAIT301, Anti-C4.4a Antibody-Drug Conjugate BAY1129980, Anti-C5aR Monoclonal Antibody IPH5401, Anti-CA19-9 Monoclonal Antibody 5B1, Anti-CA6-DM4 Immunoconjugate SAR566658, Anti-CCR7 Antibody-drug Conjugate JBH492, Anti-CD117 Monoclonal Antibody JSP191, Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1, Anti-CD123 ADC IMGN632, Anti-CD123 Monoclonal Antibody CSL360, Anti-CD123 Monoclonal Antibody KHK2823, Anti-CD123 x Anti-CD3 Bispecific Antibody XmAb1404, Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A, Anti-CD123/CD3 Bispecific Antibody APVO436, Anti-CD123/CD3 Bispecific Antibody JNJ-63709178, Anti-CD123/CD3 BiTE Antibody SAR440234, Anti-CD137 Agonistic Monoclonal Antibody ADG106, Anti-CD137 Agonistic Monoclonal Antibody AGEN2373, Anti-CD137 Agonistic Monoclonal Antibody ATOR-1017, Anti-CD137 Agonistic Monoclonal Antibody CTX-471, Anti-CD137 Agonistic Monoclonal Antibody LVGN6051, Anti-CD157 Monoclonal Antibody MEN1112, Anti-CD166 Probody-drug Conjugate CX-2009, Anti-CD19 Antibody-drug Conjugate SGN-CD19B, Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003, Anti-CD19 iCAR NK Cells, Anti-CD19 Monoclonal Antibody DI-B4, Anti-CD19 Monoclonal Antibody MDX-1342, Anti-CD19 Monoclonal Antibody MEDI-551, Anti-CD19 Monoclonal Antibody XmAb5574, Anti-CD19-DM4 Immunoconjugate SAR3419, Anti-CD19/Anti-CD22 Bispecific Immunotoxin DT2219ARL, Anti-CD19/CD22 CAR NK Cells, Anti-CD19/CD3 BiTE Antibody AMG 562, Anti-CD19/CD3 Tetravalent Antibody AFM11, Anti-CD20 Monoclonal Antibody B001, Anti-CD20 Monoclonal Antibody BAT4306F, Anti-CD20 Monoclonal Antibody MIL62, Anti-CD20 Monoclonal Antibody PRO131921, Anti-CD20 Monoclonal Antibody SCT400, Anti-CD20 Monoclonal Antibody TL011, Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002, Anti-CD20-engineered Toxin Body MT-3724, Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323, Anti-CD20/CD3 Monoclonal Antibody REGN1979, Anti-CD20/CD3 Monoclonal Antibody XmAb13676, Anti-CD205 Antibody-drug Conjugate OBT076, Anti-CD22 ADC TRPH-222, Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S, Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A, Anti-CD25 Monoclonal Antibody RO7296682, Anti-CD25-PBD Antibody-drug Conjugate ADCT-301, Anti-CD26 Monoclonal Antibody YS110, Anti-CD27 Agonistic Monoclonal Antibody MK-5890, Anti-CD27L Antibody-Drug Conjugate AMG 172, Anti-CD3 Immunotoxin A-dmDT390-bisFv(UCHT1), Anti-CD3/Anti-5T4 Bispecific Antibody GEN1044, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957, Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody PF-06863135, Anti-CD3/Anti-CD20 Trifunctional Bispecific Monoclonal Antibody FBTA05, Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564, Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119, Anti-CD3/CD20 Bispecific Antibody GEN3013, Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424, Anti-CD3/CD7-Ricin Toxin A Immunotoxin, Anti-CD30 Monoclonal Antibody MDX-1401, Anti-CD30 Monoclonal Antibody XmAb2513, Anti-CD30/CD16A Monoclonal Antibody AFM13, Anti-CD30/DM1 Antibody-drug Conjugate F0002, Anti-CD32B Monoclonal Antibody BI-1206, Anti-CD33 Antibody-drug Conjugate IMGN779, Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564, Anti-CD33 Monoclonal Antibody BI 836858, Anti-CD33 Monoclonal Antibody-DM4 Conjugate AVE9633, Anti-CD33/CD3 Bispecific Antibody GEM 333, Anti-CD33/CD3 Bispecific Antibody JNJ-67571244, Anti-CD33/CD3 BiTE Antibody AMG 330, Anti-CD33/CD3 BiTE Antibody AMG 673, Anti-CD352 Antibody-drug Conjugate SGN-CD352A, Anti-CD37 Antibody-Drug Conjugate IMGN529, Anti-CD37 Bispecific Monoclonal Antibody GEN3009, Anti-CD37 MMAE Antibody-drug Conjugate AGS67E, Anti-CD37 Monoclonal Antibody BI 836826, Anti-CD38 Antibody-drug Conjugate STI-6129, Anti-CD38 Monoclonal Antibody MOR03087, Anti-CD38 Monoclonal Antibody SAR442085, Anti-CD38 Monoclonal Antibody TAK-079, Anti-CD38-targeted IgG4-attenuated IFNa TAK-573, Anti-CD38/CD28xCD3 Tri-specific Monoclonal Antibody SAR442257, Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342, Anti-CD39 Monoclonal Antibody SRF617, Anti-CD39 Monoclonal Antibody TTX-030, Anti-CD40 Agonist Monoclonal Antibody ABBV-927, Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Anti-CD40 Monoclonal Antibody Chi Lob 7/4, Anti-CD40 Monoclonal Antibody SEA-CD40, Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042, Anti-CD40/Anti-TAA Bispecific Monoclonal Antibody ABBV-428, Anti-CD40L Fc-Fusion Protein BMS-986004, Anti-CD44 Monoclonal Antibody RO5429083, Anti-CD45 Monoclonal Antibody AHN-12, Anti-CD46 Antibody-drug Conjugate FOR46, Anti-CD47 ADC SGN-CD47M, Anti-CD47 Monoclonal Antibody AO-176, Anti-CD47 Monoclonal Antibody CC-90002, Anti-CD47 Monoclonal Antibody Hu5F9-G4, Anti-CD47 Monoclonal Antibody IBI188, Anti-CD47 Monoclonal Antibody IMC-002, Anti-CD47 Monoclonal Antibody SHR-1603, Anti-CD47 Monoclonal Antibody SRF231, Anti-CD47 Monoclonal Antibody TJC4, Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801, Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A, Anti-CD52 Monoclonal Antibody ALLO-647, Anti-CD70 Antibody-Drug Conjugate MDX-1203, Anti-CD70 Antibody-drug Conjugate SGN-CD70A, Anti-CD70 CAR-expressing T Lymphocytes, Anti-CD70 Monoclonal Antibody MDX-1411, Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029, Anti-CD73 Monoclonal Antibody BMS-986179, Anti-CD73 Monoclonal Antibody CPI-006, Anti-CD73 Monoclonal Antibody NZV930, Anti-CD73 Monoclonal Antibody TJ4309, Anti-CD74 Antibody-drug Conjugate STRO-001, Anti-CD98 Monoclonal Antibody IGN523, Anti-CDH6 Antibody-drug Conjugate HKT288, Anti-CEA BiTE Monoclonal Antibody AMG211, Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody, Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2, Anti-CEACAM1 Monoclonal Antibody CM-24, Anti-CEACAM5 Antibody-Drug Conjugate SAR408701, Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47, Anti-CEACAM6 Antibody BAY1834942, Anti-claudin18.2 Monoclonal Antibody AB011, Anti-Claudin18.2 Monoclonal Antibody TST001, Anti-CLDN6 Monoclonal Antibody ASP1650, Anti-CLEC12A/CD3 Bispecific Antibody MCLA117, Anti-CLEVER-1 Monoclonal Antibody FP-1305, Anti-CSF1 Monoclonal Antibody PD-0360324, Anti-CSF1R Monoclonal Antibody IMC-CS4, Anti-CSF1R Monoclonal Antibody SNDX-6352, Anti-CTGF Monoclonal Antibody FG-3019, Anti-CTLA-4 Monoclonal Antibody ADG116, Anti-CTLA-4 Monoclonal Antibody ADU-1604, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Anti-CTLA-4 Monoclonal Antibody BCD-145, Anti-CTLA-4 Monoclonal Antibody HBM4003, Anti-CTLA-4 Monoclonal Antibody MK-1308, Anti-CTLA-4 Monoclonal Antibody ONC-392, Anti-CTLA-4 Monoclonal Antibody REGN4659, Anti-CTLA-4 Probody BMS-986288, Anti-CTLA-4/Anti-PD-1 Monoclonal Antibody Combination BCD-217, Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841, Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015, Anti-CTLA4 Antibody Fc Fusion Protein KN044, Anti-CTLA4 Monoclonal Antibody BMS-986218, Anti-CXCR4 Monoclonal Antibody PF-06747143, Anti-Denatured Collagen Monoclonal Antibody TRC093, Anti-DKK-1 Monoclonal Antibody LY2812176, Anti-DKK1 Monoclonal Antibody BHQ880, Anti-DLL3/CD3 BiTE Antibody AMG 757, Anti-DLL4 Monoclonal Antibody MEDI0639, Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83, Anti-DR5 Agonist Monoclonal Antibody TRA-8, Anti-DR5 Agonistic Antibody DS-8273a, Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Anti-EGFR Monoclonal Antibody CPGJ 602, Anti-EGFR Monoclonal Antibody EMD 55900, Anti-EGFR Monoclonal Antibody GC1118, Anti-EGFR Monoclonal Antibody GT-MAB 5.2-GEX, Anti-EGFR Monoclonal Antibody HLX-07, Anti-EGFR Monoclonal Antibody Mixture MM-151, Anti-EGFR Monoclonal Antibody RO5083945, Anti-EGFR Monoclonal Antibody SCT200, Anti-EGFR Monoclonal Antibody SYN004, Anti-EGFR TAP Antibody-drug Conjugate IMGN289, Anti-EGFR/c-Met Bispecific Antibody EMB-01, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, Anti-EGFR/CD16A Bispecific Antibody AFM24, Anti-EGFR/DM1 Antibody-drug Conjugate AVID100, Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013, Anti-EGFR/PBD Antibody-drug Conjugate ABBV-321, Anti-EGFRvIII Antibody Drug Conjugate AMG 595, Anti-EGFRvIII Immunotoxin MR1-1, Anti-EGFRvIII/CD3 BiTE Antibody AMG 596, Anti-EGP-2 Immunotoxin MOC31-PE, Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F, Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F, Anti-Ep-CAM Monoclonal Antibody ING-1, Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310, Anti-EphA2 Monoclonal Antibody DS-8895a, Anti-EphA2 Monoclonal Antibody-MMAF Immunoconjugate MEDI-547, Anti-ErbB2/Anti-ErbB3 Bispecific Monoclonal Antibody MM-111, Anti-ErbB3 Antibody ISU104, Anti-ErbB3 Monoclonal Antibody AV-203, Anti-ErbB3 Monoclonal Antibody CDX-3379, Anti-ErbB3 Monoclonal Antibody REGN1400, Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141, Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A, Anti-FAP/Interleukin-2 Fusion Protein RO6874281, Anti-FCRH5/CD3 BiTE Antibody BFCR4350A, Anti-FGFR2 Antibody BAY1179470, Anti-FGFR3 Antibody-drug Conjugate LY3076226, Anti-FGFR4 Monoclonal Antibody U3-1784, Anti-FLT3 Antibody-drug Conjugate AGS62P1, Anti-FLT3 Monoclonal Antibody 4G8-SDIEM, Anti-FLT3 Monoclonal Antibody IMC-EB10, Anti-FLT3/CD3 BiTE Antibody AMG 427, Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002, Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202, Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012, Anti-Ganglioside GM2 Monoclonal Antibody BIW-8962, Anti-GARP Monoclonal Antibody ABBV-151, Anti-GCC Antibody-Drug Conjugate MLN0264, Anti-GCC Antibody-Drug Conjugate TAK-164, Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody, Anti-GD2 Monoclonal Antibody hu14.18K322A, Anti-GD2 Monoclonal Antibody MORAb-028, Anti-GD3 Antibody-drug Conjugate PF-06688992, Anti-GITR Agonistic Monoclonal Antibody ASP1951, Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Anti-GITR Agonistic Monoclonal Antibody INCAGN01876, Anti-GITR Monoclonal Antibody GWN 323, Anti-GITR Monoclonal Antibody MK-4166, Anti-Globo H Monoclonal Antibody OBI-888, Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999, Anti-Glypican 3/CD3 Bispecific Antibody ERY974, Anti-GnRH Vaccine PEP223, Anti-gpA33/CD3 Monoclonal Antibody MGD007, Anti-GPR20/DXd Antibody-drug Conjugate DS-6157a, Anti-gremlin-1 Monoclonal Antibody UCB6114, Anti-GRP78 Monoclonal Antibody PAT-SM6, Anti-HA Epitope Monoclonal Antibody MEDI8852, Anti-HB-EGF Monoclonal Antibody KHK2866, Anti-HBEGF Monoclonal Antibody U3-1565, Anti-hepcidin Monoclonal Antibody LY2787106, Anti-HER-2 Bispecific Antibody KN026, Anti-HER2 ADC DS-8201a, Anti-HER2 Antibody Conjugated Natural Killer Cells ACE1702, Anti-HER2 Antibody-drug Conjugate A166, Anti-HER2 Antibody-drug Conjugate ARX788, Anti-HER2 Antibody-drug Conjugate BAT8001, Anti-HER2 Antibody-drug Conjugate DP303c, Anti-HER2 Antibody-drug Conjugate MEDI4276, Anti-HER2 Antibody-drug Conjugate RC48, Anti-HER2 Bi-specific Monoclonal Antibody ZW25, Anti-HER2 Bispecific Antibody-drug Conjugate ZW49, Anti-HER2 Immune Stimulator-antibody Conjugate NJH395, Anti-HER2 Monoclonal Antibody B002, Anti-HER2 Monoclonal Antibody CT-P6, Anti-HER2 Monoclonal Antibody HLX22, Anti-HER2 Monoclonal Antibody/Anti-CD137Anticalin Bispecific Fusion Protein PRS-343, Anti-HER2-DM1 ADC B003, Anti-HER2-DM1 Antibody-drug Conjugate GQ1001, Anti-HER2-vc0101 ADC PF-06804103, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A, Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302, Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128, Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522, Anti-HER2/MMAE Antibody-drug Conjugate MRG002, Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A, Anti-HER3 Antibody-drug Conjugate U3 1402, Anti-HER3 Monoclonal Antibody GSK2849330, Anti-HGF Monoclonal Antibody TAK-701, Anti-HIF-1alpha LNA Antisense Oligonucleotide EZN-2968, Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1, Anti-HLA-DR Monoclonal Antibody IMMU-114, Anti-HLA-G Antibody TTX-080, Anti-human GITR Monoclonal Antibody AMG 228, Anti-human GITR Monoclonal Antibody TRX518, Anti-ICAM-1 Monoclonal Antibody BI-505, Anti-ICOS Agonist Antibody GSK3359609, Anti-ICOS Agonist Monoclonal Antibody BMS-986226, Anti-ICOS Monoclonal Antibody KY1044, Anti-ICOS Monoclonal Antibody MEDI-570, Anti-IGF-1R Monoclonal Antibody AVE1642, Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, Anti-IL-1 alpha Monoclonal Antibody MABp1, Anti-IL-13 Humanized Monoclonal Antibody TNX-650, Anti-IL-15 Monoclonal Antibody AMG 714, Anti-IL-8 Monoclonal Antibody BMS-986253, Anti-IL-8 Monoclonal Antibody HuMax-IL8, Anti-ILDR2 Monoclonal Antibody BAY 1905254, Anti-ILT4 Monoclonal Antibody MK-4830, Anti-integrin Beta-6/MMAE Antibody-drug Conjugate SGN-B6A, Anti-Integrin Monoclonal Antibody-DM4 Immunoconjugate IMGN388, Anti-IRF4 Antisense Oligonucleotide ION251, Anti-KIR Monoclonal Antibody IPH 2101, Anti-KSP/Anti-VEGF siRNAs ALN-VSP02, Anti-LAG-3 Monoclonal Antibody IBI-110, Anti-LAG-3 Monoclonal Antibody INCAGN02385, Anti-LAG-3 Monoclonal Antibody LAG525, Anti-LAG-3 Monoclonal Antibody REGN3767, Anti-LAG-3/PD-L1 Bispecific Antibody FS118, Anti-LAG3 Monoclonal Antibody BI 754111, Anti-LAG3 Monoclonal Antibody MK-4280, Anti-LAG3 Monoclonal Antibody TSR-033, Anti-LAMP1 Antibody-drug Conjugate SAR428926, Anti-latent TGF-beta 1 Monoclonal Antibody SRK-181, Anti-Lewis B/Lewis Y Monoclonal Antibody GNX102, Anti-LGR5 Monoclonal Antibody BNC101, Anti-LIF Monoclonal Antibody MSC-1, Anti-LILRB4 Monoclonal Antibody IO-202, Anti-LIV-1 Monoclonal Antibody-MMAE Conjugate SGN-LIV1A, Anti-Ly6E Antibody-Drug Conjugate RG 7841, Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C, Anti-Melanin Monoclonal Antibody PTI-6D2, Anti-mesothelin Antibody-drug Conjugate BMS-986148, Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100, Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A, Anti-mesothelin/MMAE Antibody-drug Conjugate RC88, Anti-Met Monoclonal Antibody Mixture Sym015, Anti-Met/EGFR Monoclonal Antibody LY3164530, Anti-MMP-9 Monoclonal Antibody GS-5745, Anti-MUC1 Monoclonal Antibody BTH1704, Anti-MUC16/CD3 Bispecific Antibody REGN4018, Anti-MUC16/CD3 BiTE Antibody REGN4018, Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A, Anti-MUC17/CD3 BiTE Antibody AMG 199, Anti-Myeloma Monoclonal Antibody-DM4 Immunoconjugate BT-062, Anti-myostatin Monoclonal Antibody LY2495655, Anti-NaPi2b Antibody-drug Conjugate XMT-1592, Anti-NaPi2b Monoclonal Antibody XMT-1535, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A, Anti-nf-P2X7 Antibody Ointment BIL-010t, Anti-NRP1 Antibody ASP1948, Anti-Nucleolin Aptamer AS1411, Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A, Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso, Anti-OFA Immunotherapeutic BB-MPI-03, Anti-OX40 Agonist Monoclonal Antibody ABBV-368, Anti-OX40 Agonist Monoclonal Antibody BGB-A445, Anti-OX40 Agonist Monoclonal Antibody PF-04518600, Anti-OX40 Antibody BMS 986178, Anti-OX40 Hexavalent Agonist Antibody INBRX-106, Anti-OX40 Monoclonal Antibody GSK3174998, Anti-OX40 Monoclonal Antibody IBI101, Anti-PD-1 Antibody-interleukin-21 Mutein Fusion Protein AMG 256, Anti-PD-1 Checkpoint Inhibitor PF-06801591, Anti-PD-1 Fusion Protein AMP-224, Anti-PD-1 Monoclonal Antibody 609A, Anti-PD-1 Monoclonal Antibody AK105, Anti-PD-1 Monoclonal Antibody AMG 404, Anti-PD-1 Monoclonal Antibody BAT1306, Anti-PD-1 Monoclonal Antibody BCD-100, Anti-PD-1 Monoclonal Antibody BI 754091, Anti-PD-1 Monoclonal Antibody CS1003, Anti-PD-1 Monoclonal Antibody F520, Anti-PD-1 Monoclonal Antibody GLS-010, Anti-PD-1 Monoclonal Antibody HLX10, Anti-PD-1 Monoclonal Antibody HX008, Anti-PD-1 Monoclonal Antibody JTX-4014, Anti-PD-1 Monoclonal Antibody LZM009, Anti-PD-1 Monoclonal Antibody MEDI0680, Anti-PD-1 Monoclonal Antibody MGA012, Anti-PD-1 Monoclonal Antibody SCT-I10A, Anti-PD-1 Monoclonal Antibody Sym021, Anti-PD-1 Monoclonal Antibody TSR-042, Anti-PD-1/Anti-CTLA4 DART Protein MGD019, Anti-PD-1/Anti-HER2 Bispecific Antibody IBI315, Anti-PD-1/Anti-LAG-3 Bispecific Antibody RO7247669, Anti-PD-1/Anti-LAG-3 DART Protein MGD013, Anti-PD-1/Anti-PD-L1 Bispecific Antibody IBI318, Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172, Anti-PD-1/CD47 Infusion Protein HX009, Anti-PD-1/CTLA-4 Bispecific Antibody AK104, Anti-PD-1/CTLA-4 Bispecific Antibody MEDI5752, Anti-PD-1/TIM-3 Bispecific Antibody RO7121661, Anti-PD-1/VEGF Bispecific Antibody AK112, Anti-PD-L1 Monoclonal Antibody A167, Anti-PD-L1 Monoclonal Antibody BCD-135, Anti-PD-L1 Monoclonal Antibody BGB-A333, Anti-PD-L1 Monoclonal Antibody CBT-502, Anti-PD-L1 Monoclonal Antibody CK-301, Anti-PD-L1 Monoclonal Antibody CS1001, Anti-PD-L1 Monoclonal Antibody FAZ053, Anti-PD-L1 Monoclonal Antibody GR1405, Anti-PD-L1 Monoclonal Antibody HLX20, Anti-PD-L1 Monoclonal Antibody IMC-001, Anti-PD-L1 Monoclonal Antibody LY3300054, Anti-PD-L1 Monoclonal Antibody MDX-1105, Anti-PD-L1 Monoclonal Antibody MSB2311, Anti-PD-L1 Monoclonal Antibody RC98, Anti-PD-L1 Monoclonal Antibody SHR-1316, Anti-PD-L1 Monoclonal Antibody TG-1501, Anti-PD-L1 Monoclonal Antibody ZKAB001, Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105, Anti-PD-L1/Anti-4-1BB Bispecific Monoclonal Antibody GEN1046, Anti-PD-L1/CD137 Bispecific Antibody MCLA-145, Anti-PD-L1/IL-15 Fusion Protein KD033, Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244, Anti-PD1 Monoclonal Antibody AGEN2034, Anti-PD1/CTLA4 Bispecific Antibody XmAb20717, Anti-PGF Monoclonal Antibody RO5323441, Anti-PKN3 siRNA Atu027, Anti-PLGF Monoclonal Antibody TB-403, Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Anti-PRAME Immunotherapeutic GSK2302032A, Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C, Anti-PRL-3 Monoclonal Antibody PRL3-zumab, Anti-prolactin Receptor Antibody LFA102, Anti-PSCA Monoclonal Antibody AGS-1C4D4, Anti-PSMA Monoclonal Antibody MDX1201-A488, Anti-PSMA Monoclonal Antibody MLN591-DM1 Immunoconjugate MLN2704, Anti-PSMA Monoclonal Antibody-MMAE Conjugate, Anti-PSMA/CD28 Bispecific Antibody REGN5678, Anti-PSMA/CD3 Bispecific Antibody CCW702, Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081, Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414, Anti-PSMA/PBD ADC MEDI3726, Anti-PTK7/Auristatin-0101 Antibody-drug Conjugate PF-06647020, Anti-PVRIG Monoclonal Antibody COM701, Anti-RANKL Monoclonal Antibody GB-223, Anti-RANKL Monoclonal Antibody JMT103, Anti-Ribonucleoprotein Antibody ATRC-101, Anti-ROR1 ADC VLS-101, Anti-ROR1/PNU-159682 Derivative Antibody-drug Conjugate NBE-002, Anti-S15 Monoclonal Antibody NC318, Anti-sCLU Monoclonal Antibody AB-16B5, Anti-SIRPa Monoclonal Antibody CC-95251, Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E, Anti-TAG-72 Monoclonal Antibody scFV CC-49/218, Anti-TF Monoclonal Antibody ALT-836, Anti-TGF-beta Monoclonal Antibody NIS793, Anti-TGF-beta Monoclonal Antibody SAR-439459, Anti-TGF-beta RII Monoclonal Antibody IMC-TR1, Anti-TIGIT Monoclonal Antibody AB154, Anti-TIGIT Monoclonal Antibody BGB-A1217, Anti-TIGIT Monoclonal Antibody BMS-986207, Anti-TIGIT Monoclonal Antibody COM902, Anti-TIGIT Monoclonal Antibody OMP-313M32, Anti-TIGIT Monoclonal Antibody SGN-TGT, Anti-TIM-3 Antibody BMS-986258, Anti-TIM-3 Monoclonal Antibody BGB-A425, Anti-TIM-3 Monoclonal Antibody INCAGN02390, Anti-TIM-3 Monoclonal Antibody MBG453, Anti-TIM-3 Monoclonal Antibody Sym023, Anti-TIM-3 Monoclonal Antibody TSR-022, Anti-TIM3 Monoclonal Antibody LY3321367, Anti-TIM3 Monoclonal Antibody SHR-1702, Anti-Tissue Factor Monoclonal Antibody MORAb-066, Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711, Anti-TROP2 Antibody-drug Conjugate BAT8003, Anti-TROP2 Antibody-drug Conjugate SKB264, Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a, Anti-TWEAK Monoclonal Antibody RG7212, Anti-VEGF Anticalin PRS-050-PEG40, Anti-VEGF Monoclonal Antibody hPV19, Anti-VEGF/ANG2 Nanobody BI 836880, Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T, Anti-VEGFC Monoclonal Antibody VGX-100, Anti-VEGFR2 Monoclonal Antibody HLX06, Anti-VEGFR2 Monoclonal Antibody MSB0254, Anti-VEGFR3 Monoclonal Antibody IMC-3C5, Anti-VISTA Monoclonal Antibody JNJ 61610588, Antiangiogenic Drug Combination TL-118, Antibody-drug Conjugate ABBV-011, Antibody-drug Conjugate ABBV-085, Antibody-drug Conjugate ABBV-155, Antibody-drug Conjugate ABBV-176, Antibody-drug Conjugate ABBV-838, Antibody-drug Conjugate ADC XMT-1536, Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014, Antibody-Drug Conjugate DFRF4539A, Antibody-drug Conjugate MEDI7247, Antibody-drug Conjugate PF-06647263, Antibody-drug Conjugate PF-06664178, Antibody-drug Conjugate SC-002, Antibody-drug Conjugate SC-003, Antibody-drug Conjugate SC-004, Antibody-drug Conjugate SC-005, Antibody-drug Conjugate SC-006, Antibody-drug Conjugate SC-007, Antibody-like CD95 Receptor/Fc-fusion Protein CAN-008, Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV, Antimetabolite FF-10502, Antineoplastic Agent Combination SM-88, Antineoplastic Vaccine, Antineoplastic Vaccine GV-1301, Antineoplaston A10, Antineoplaston AS2-1, Antisense Oligonucleotide GTI-2040, Antisense Oligonucleotide QR-313, Antitumor B Key Active Component-alpha, Antrodia cinnamomea Supplement, Antroquinonol Capsule, Apalutamide, Apatorsen, Apaziquone, APC8015F, APE1/Ref-1 Redox Inhibitor APX3330, Aphidicoline Glycinate, Apilimod Dimesylate Capsule, Apitolisib, Apolizumab, Apomab, Apomine, Apoptosis Inducer BZL101, Apoptosis Inducer GCS-100, Apoptosis Inducer MPC-2130, Apricoxib, Aprinocarsen, Aprutumab, Aprutumab Ixadotin, AR Antagonist BMS-641988, Arabinoxylan Compound MGN3, Aranose, ARC Fusion Protein SL-279252, Archexin, Arcitumomab, Arfolitixorin, Arginase Inhibitor INCB001158, Arginine Butyrate, Arnebia Indigo Jade Pearl Topical Cream, Arsenic Trioxide, Arsenic Trioxide Capsule Formulation ORH 2014, Artemether Sublingual Spray, Artemisinin Dimer, Artesunate, Arugula Seed Powder, Aryl Hydrocarbon Receptor Antagonist BAY2416964, Aryl Hydrocarbon Receptor Inhibitor IK-175, Asaley, Asciminib, Ascrinvacumab, Ashwagandha Root Powder Extract, ASP4132, Aspacytarabine, Asparaginase, Asparaginase Erwinia chrysanthemi, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Astuprotimut-R, Asulacrine, Asulacrine Isethionate, Asunercept, At 211 Monoclonal Antibody 81C6, Atamestane, Atezolizumab, Atiprimod, Atiprimod Dihydrochloride, Atiprimod Dimaleate, ATM Inhibitor M 3541, ATM Kinase Inhibitor AZD0156, ATM Kinase Inhibitor AZD1390, Atorvastatin Calcium, Atorvastatin Sodium, ATR Inhibitor RP-3500, ATR Kinase Inhibitor BAY1895344, ATR Kinase Inhibitor M1774, ATR Kinase Inhibitor M6620, ATR Kinase Inhibitor VX-803, Atrasentan Hydrochloride, Attenuated Listeria monocytogenes CRS-100, Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001, Attenuated Measles Virus Encoding SCD Transgene TMV-018, Atuveciclib, Audencel, Auranofin, Aurora A Kinase Inhibitor LY3295668, Aurora A Kinase Inhibitor LY3295668 Erbumine, Aurora A Kinase Inhibitor MK5108, Aurora A Kinase Inhibitor TAS-119, Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076, Aurora B Serine/Threonine Kinase Inhibitor TAK-901, Aurora B/C Kinase Inhibitor GSK1070916A, Aurora kinase A/B inhibitor TT-00420, Aurora Kinase Inhibitor AMG 900, Aurora Kinase Inhibitor BI 811283, Aurora Kinase Inhibitor MLN8054, Aurora Kinase Inhibitor PF-03814735, Aurora Kinase Inhibitor SNS-314, Aurora Kinase Inhibitor TTP607, Aurora Kinase/VEGFR2 Inhibitor CYC116, Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707, Autologous AFP Specific T Cell Receptor Transduced T Cells C-TCR055, Autologous Anti-BCMA CAR T-cells PHE885, Autologous Anti-BCMA CAR-transduced T-cells KITE-585, Autologous Anti-BCMA CD8+ CAR T-cells Descartes-11, Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells C-CAR088, Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053, Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Autologous Anti-CD123 CAR-T Cells, Autologous Anti-CD19 CAR T-cells 19(T2)28z1xx, Autologous Anti-CD19 CAR T-cells IM19, Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19, Autologous Anti-CD19 CAR-4-1BB-CD3zeta-expressing T-cells CNCT19, Autologous Anti-CD19 CAR-CD28 T-cells ET019002, Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01, Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells AUTO1, Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19, Autologous Anti-CD19 T-cell Receptor T cells ET190L1, Autologous Anti-CD19 TAC-T cells TAC01-CD19, Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells, Autologous Anti-CD19/CD22 CAR T-cells AUTO3, Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells, Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1, Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s, Autologous Anti-EGFR CAR-transduced CXCR 5-modified T-lymphocytes, Autologous Anti-FLT3 CAR T Cells AMG 553, Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202, Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1, Autologous Anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T-cells AIC100, Autologous Anti-kappa Light Chain CAR-CD28-expressing T-lymphocytes, Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794, Autologous Anti-PD-1 Antibody-activated Tumor-infiltrating Lymphocytes, Autologous Anti-PSMA CAR-T Cells P-PSMA-101, Autologous AXL-targeted CAR T-cells CCT301-38, Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B, Autologous BCMA-targeted CAR T Cells CC-98633, Autologous BCMA-targeted CAR T Cells LCAR-B4822M, Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528, Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Autologous Bispecific CD19/CD22-targeted CAR-T Cells GC022, Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005, Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006, Autologous CD123-4SCAR-expressing T-cells 4SCAR123, Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1, Autologous CD19-targeted CAR T Cells CC-97540, Autologous CD19-targeted CAR T Cells JWCAR029, Autologous CD19-targeted CAR-T Cells GC007F, Autologous CD19/PD-1 Bispecific CAR-T Cells, Autologous CD20-4SCAR-expressing T-cells 4SCAR20, Autologous CD22-4SCAR-expressing T-cells 4SCAR22, Autologous CD38-4SCAR-expressing T-cells 4SCAR38, Autologous Clonal Neoantigen T Cells ATL001, Autologous CRISPR-edited Anti-CD19 CAR T Cells XYF19, Autologous Deep IL-15 Primed T-cells TRQ15-01, Autologous Dendritic Cell Vaccine ACT2001, Autologous Dendritic Cell-based Immunotherapeutic AV0113, Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa, Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells, Autologous Genetically-modified MAGE-A4 C1032 T Cells, Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858, Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439, Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001, Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718, Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous Mesenchymal Stem Cells Apceth_101, Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11, Autologous Monocyte-derived Lysate-pulsed Dendritic Cell Vaccine PV-001-DC, Autologous Multi-lineage Potential Cells, Autologous Nectin-4/FAP-targeted CAR-T Cells, Autologous NKG2D CAR T-cells CYAD-02, Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01, Autologous Pancreatic Adenocarcinoma Lysate and mRNA-loaded Dendritic Cell Vaccine, Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001, Autologous Prostate Cancer Antigen-expressing Dendritic Cell Vaccine BPX-101, Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601, Autologous Rapamycin-resistant Th1/Tc1 Cells RAPA-201, Autologous ROR2-targeted CAR T-cells CCT301-59, Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1, Autologous TCR-engineered T-cells IMA201, Autologous TCR-engineered T-cells IMA202, Autologous TCR-engineered T-cells IMA203, Autologous TCRm-expressing T-cells ET140203, Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG, Autologous Tumor Infiltrating Lymphocytes LN-144, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Autologous Universal CAR-expressing T-lymphocytes UniCAR02-T, Avadomide, Avadomide Hydrochloride, Avapritinib, Avdoralimab, Avelumab, Aviscumine, Avitinib Maleate, Axalimogene Filolisbac, Axatilimab, Axicabtagene Ciloleucel, Axitinib, AXL Inhibitor DS-1205c, AXL Inhibitor SLC-391, AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M, AXL/ FLT3/VEGFR2 Inhibitor KC1036, Axl/Mer Inhibitor INCB081776, Axl/Mer Inhibitor PF-07265807, Azacitidine, Azapicyl, Azaribine, Azaserine, Azathioprine, Azimexon, Azintuxizumab Vedotin, Aziridinylbenzoquinone RH1, Azotomycin, Azurin:50-77 Cell Penetrating Peptide p28, B-Raf/VEGFR-2 Inhibitor RAF265, Babaodan Capsule, Bacillus Calmette-Guerin Substrain Connaught Live Antigen, Bactobolin, Bafetinib, Balixafortide, Balstilimab, Baltaleucel-T, Banoxantrone, Barasertib, Bardoxolone, Bardoxolone Methyl, Baricitinib, Batabulin, Batabulin Sodium, Batimastat, Bavituximab, Bazedoxifene, Bazlitoran, BC-819 Plasmid/Polyethylenimine Complex, BCG Solution, BCG Tokyo-172 Strain Solution, BCG Vaccine, Bcl-2 Inhibitor APG 2575, Bcl-2 Inhibitor BCL201, Bcl-2 Inhibitor BGB-11417, Bcl-2 Inhibitor LP-108, Bcl-2 Inhibitor S65487, Bcl-Xs Adenovirus Vaccine, BCMA x CD3 T-cell Engaging Antibody CC-93269, BCMA-CD19 Compound CAR T Cells, BCMA/CD3e Tri-specific T-cell Activating Construct HPN217, Bcr-Abl Kinase Inhibitor K0706, Bcr-Abl Kinase Inhibitor PF-114, BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351, Beauvericin, Becatecarin, Belagenpumatucel-L, Belantamab Mafodotin, Belapectin, Belimumab, Belinostat, Belotecan Hydrochloride, Belvarafenib, Belzutifan, Bemarituzumab, Bemcentinib, Bempegaldesleukin, Benaxibine, Bendamustine, Bendamustine Hydrochloride, Bendamustine-containing Nanoparticle-based Formulation RXDX-107, Benzaldehyde Dimethane Sulfonate, Benzoylphenylurea, Berberine Chloride, Bermekimab, Bersanlimab, Berubicin Hydrochloride, Berzosertib, BET Bromodomain Inhibitor ZEN-3694, BET Inhibitor ABBV-744, BET Inhibitor BAY1238097, BET inhibitor BI 894999, BET Inhibitor BMS-986158, BET Inhibitor CC-90010, BET Inhibitor CPI-0610, BET Inhibitor FT-1101, BET Inhibitor GS-5829, BET Inhibitor GSK2820151, BET Inhibitor INCB054329, BET Inhibitor INCB057643, BET Inhibitor RO6870810, BET-bromodomain Inhibitor ODM-207, Beta Alethine, Beta-Carotene, Beta-elemene, Beta-Glucan, Beta-Glucan MM-10-001, Beta-lapachone Prodrug ARQ 761, Beta-Thioguanine Deoxyriboside, Betaglucin Gel, Betulinic Acid, Bevacizumab, Bexarotene, Bexmarilimab, BF-200 Gel Formulation, BH3 Mimetic ABT-737, Bi-functional Alkylating Agent VAL-083, Bicalutamide, Bimiralisib, Binetrakin, Binimetinib, Bintrafusp Alfa, Birabresib, Birinapant, Bis(choline)tetrathiomolybdate, Bisantrene, Bisantrene Hydrochloride, Bisnafide, Bisnafide Dimesylate, Bispecific Antibody 2B1, Bispecific Antibody AGEN1223, Bispecific Antibody AMG 509, Bispecific Antibody GS-1423, Bispecific Antibody MDX-H210, Bispecific Antibody MDX447, Bisthianostat, BiTE Antibody AMG 910, Bivalent BRD4 Inhibitor AZD5153, Bizalimogene Ralaplasmid, Bizelesin, BL22 Immunotoxin, Black Cohosh, Black Raspberry Nectar, Bleomycin, Bleomycin A2, Bleomycin B2, Bleomycin Sulfate, Blinatumomab, Blueberry Powder Supplement, BMI1 Inhibitor PTC596, BMS-184476, BMS-188797, BMS-214662, BMS-275183, Boanmycin Hydrochloride, Bomedemstat, Boronophenylalanine-Fructose Complex, Bortezomib, Bosutinib, Bosutinib Monohydrate, Botanical Agent BEL-X-HG, Botanical Agent LEAC-102, Bovine Cartilage, Bozitinib, BP-Cx1-Platinum Complex BP-C1, BR96-Doxorubicin Immunoconjugate, Brachyury-expressing Yeast Vaccine GI-6301, BRAF Inhibitor, BRAF Inhibitor ARQ 736, BRAF Inhibitor BGB-3245, BRAF Inhibitor PLX8394, BRAF(V600E) Kinase Inhibitor ABM-1310, BRAF(V600E) Kinase Inhibitor RO5212054, BRAF/EGFR Inhibitor BGB-283, BRAFV600/PI3K Inhibitor ASN003, BRD4 Inhibitor PLX2853, BRD4 Inhibitor PLX51107, Breflate, Brentuximab, Brentuximab Vedotin, Brequinar, Brequinar Sodium, Briciclib Sodium, Brigatinib, Brilanestrant, Brimonidine Tartrate Nanoemulsion OCU-300, Brivanib, Brivanib Alaninate, Brivudine, Brivudine Phosphoramidate, Broad-Spectrum Human Papillomavirus Vaccine V505, Broccoli Sprout/Broccoli Seed Extract Supplement, Bromacrylide, Bromebric Acid, Bromocriptine Mesylate, Brontictuzumab, Brostacillin Hydrochloride, Brostallicin, Broxuridine, Bruceanol A, Bruceanol B, Bruceanol C, Bruceanol D, Bruceanol E, Bruceanol F, Bruceanol G, Bruceanol H, Bruceantin, Bryostatin 1, BTK Inhibitor ARQ 531, BTK Inhibitor CT-1530, BTK Inhibitor DTRMWXHS-12, BTK Inhibitor HZ-A-018, BTK Inhibitor ICP-022, BTK Inhibitor LOXO-305, BTK Inhibitor M7583, BTK inhibitor TG-1701, Budigalimab, Budotitane, Bufalin, Buparlisib, Burixafor, Burixafor Hydrobromide, Burosumab, Buserelin, Bushen Culuan Decoction, Bushen-Jianpi Decoction, Busulfan, Buthionine Sulfoximine, BXQ-350 Nanovesicle Formulation, c-Kit Inhibitor PLX9486, c-Met Inhibitor ABN401, c-Met Inhibitor AL2846, c-Met Inhibitor AMG 208, c-Met Inhibitor AMG 337, c-Met Inhibitor GST-HG161, c-Met Inhibitor HS-10241, c-Met Inhibitor JNJ-38877605, c-Met Inhibitor MK2461, c-Met Inhibitor MK8033, c-Met Inhibitor MSC2156119J, C-myb Antisense Oligonucleotide G4460, c-raf Antisense Oligonucleotide ISIS 5132, C-VISA BikDD:Liposome, C/EBP Beta Antagonist ST101, CAB-ROR2-ADC BA3021, Cabazitaxel, Cabiralizumab, Cabozantinib, Cabozantinib S-malate, Cactinomycin, Caffeic Acid Phenethyl Ester, CAIX Inhibitor DTP348, CAIX Inhibitor SLC-0111, Calaspargase Pegol-mknl, Calcitriol, Calcium Release-activated Channel Inhibitor CM4620, Calcium Release-activated Channels Inhibitor RP4010, Calcium Saccharate, Calculus bovis/Moschus/Olibanum/Myrrha Capsule, Calicheamicin Gamma 1I, Camidanlumab Tesirine, Camptothecin, Camptothecin Analogue TLC388, Camptothecin Glycoconjugate BAY 38-3441, Camptothecin Sodium, Camptothecin-20(S)-O-Propionate Hydrate, Camrelizumab, Camsirubicin, Cancell, Cancer Peptide Vaccine S-588410, Canerpaturev, Canertinib Dihydrochloride, Canfosfamide, Canfosfamide Hydrochloride, Cannabidiol, Cantrixil, Cantuzumab Ravtansine, Capecitabine, Capecitabine Rapidly Disintegrating Tablet, Capivasertib, Capmatinib, Captopril, CAR T-Cells AMG 119, Caracemide, Carbendazim, Carbetimer, Carbogen, Carbon C 14-pamiparib, Carboplatin, Carboquone, Carboxyamidotriazole, Carboxyamidotriazole Orotate, Carboxyphenyl Retinamide, Carfilzomib, Caricotamide/Tretazicar, Carlumab, Carmofur, Carmustine, Carmustine Implant, Carmustine in Ethanol, Carmustine Sustained-Release Implant Wafer, Carotuximab, Carubicin, Carubicin Hydrochloride, Carzelesin, Carzinophilin, Cathelicidin LL-37, Cationic Liposome-Encapsulated Paclitaxel, Cationic Peptide Cream Cypep-1, Catumaxomab, CBP/beta-catenin Antagonist PRI-724, CBP/beta-catenin Modulator E7386, CCR2 Antagonist CCX872-B, CCR2 Antagonist PF-04136309, CCR2/CCR5 Antagonist BMS-813160, CCR4 Inhibitor FLX475, CD11b Agonist GB1275, CD123-CD33 Compound CAR T Cells, CD123-specific Targeting Module TM123, CD20-CD19 Compound CAR T Cells, CD28/ICOS Antagonist ALPN-101, CD4-specific Telomerase Peptide Vaccine UCPVax, CD40 Agonist Monoclonal Antibody CP-870;893, CD40 Agonistic Monoclonal Antibody APX005M, CD44 Targeted Agent SPL-108, CD44v6-specific CAR T-cells, CD47 Antagonist ALX148, CD73 Inhibitor AB680, CD73 Inhibitor LY3475070, CD80-Fc Fusion Protein ALPN-202, CD80-Fc Fusion Protein FPT155, CDC7 Inhibitor TAK-931, CDC7 Kinase Inhibitor BMS-863233, CDC7 Kinase Inhibitor LY3143921 Hydrate, CDC7 Kinase Inhibitor NMS-1116354, CDK Inhibitor AT7519, CDK Inhibitor R547, CDK Inhibitor SNS-032, CDK/JAK2/FLT3 Inhibitor TG02 Citrate, CDK1 Inhibitor BEY1107, CDK1/2/4 Inhibitor AG-024322, CDK2 Inhibitor PF-07104091, CDK2/4/6/FLT3 Inhibitor FN-1501, CDK2/5/9 Inhibitor CYC065, CDK4 Inhibitor P1446A-05, CDK4/6 Inhibitor, CDK4/6 Inhibitor BPI-16350, CDK4/6 Inhibitor CS3002, CDK4/6 Inhibitor FCN-437, CDK4/6 Inhibitor G1T38, CDK4/6 Inhibitor HS-10342, CDK4/6 Inhibitor SHR6390, CDK4/6 Inhibitor TQB3616, CDK7 Inhibitor CT7001, CDK7 Inhibitor SY-1365, CDK7 Inhibitor SY-5609, CDK8/19 Inhibitor SEL 120, CDK9 Inhibitor AZD4573, CEA-MUC-1-TRICOM Vaccine CV301, CEA-targeting Agent RG6123, CEBPA-targeting saRNA MTL-CEBPA Liposome, Cedazuridine, Cedazuridine/Azacitidine Combination Agent ASTX030, Cedazuridine/Decitabine Combination Agent ASTX727, Cedefingol, Cediranib, Cediranib Maleate, Celecoxib, Cell Cycle Checkpoint/DNA Repair Antagonist IC83, Cemadotin, Cemadotin Hydrochloride, Cemiplimab, Cenersen, Cenisertib, CENP-E Inhibitor GSK-923295, Ceralasertib, Ceramide Nanoliposome, Cerdulatinib, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480, Cereblon E3 Ubiquitin Ligase Modulating Agent CC-99282, Cereblon Modulator CC-90009, Cergutuzumab Amunaleukin, Ceritinib, Cesalin, cEt KRAS Antisense Oligonucleotide AZD4785, Cetrelimab, Cetuximab, Cetuximab Sarotalocan, Cetuximab-IR700 Conjugate RM-1929, Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY), Cevipabulin, Cevipabulin Fumarate, Cevipabulin Succinate, Cevostamab, cFMS Tyrosine Kinase Inhibitor ARRY-382, Chaparrin, Chaparrinone, Checkpoint Kinase Inhibitor AZD7762, Checkpoint Kinase Inhibitor XL844, Chemotherapy, Chiauranib, Chimeric Monoclonal Antibody 81C6, ChiNing Decoction, Chk1 Inhibitor CCT245737, Chk1 Inhibitor GDC-0425, Chk1 Inhibitor GDC-0575, CHK1 Inhibitor MK-8776, CHK1 Inhibitor PF-477736, Chlorambucil, Chlorodihydropyrimidine, Chloroquine, Chloroquinoxaline Sulfonamide, Chlorotoxin, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, Chlorozotocin, Choline Kinase Alpha Inhibitor TCD-717, CHP-NY-ESO-1 Peptide Vaccine IMF-001, Chromomycin A3, Chrysanthemum morifolium/Ganoderma lucidum/Glycyrrhiza glabra/Isatis indigotica/Panax pseudoginseng/Rabdosia rubescens/Scutellaria baicalensis/Serona repens Supplement, Cibisatamab, Ciclopirox Prodrug CPX-POM, Cidan Herbal Capsule, Ciforadenant, Cilengitide, Ciltacabtagene Autoleucel, Cimetidine, Cinacalcet Hydrochloride, Cinobufagin, Cinobufotalin, Cinrebafusp Alfa, Cintirorgon, Cintredekin Besudotox, Cirmtuzumab, cis-Urocanic Acid, Cisplatin, Cisplatin Liposomal, Cisplatin-E Therapeutic Implant, Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6, Citarinostat, Citatuzumab Bogatox, Cixutumumab, CK1alpha/CDK7/CDK9 Inhibitor BTX-A51, CK2-targeting Synthetic Peptide CIGB-300, CL 246738, Cladribine, Clanfenur, Clarithromycin, Class 1/4 Histone Deacetylase Inhibitor OKI-179, Clinical Trial, Clinical Trial Agent, Clioquinol, Clivatuzumab, Clodronate Disodium, Clodronic Acid, Clofarabine, Clomesone, Clomiphene, Clomiphene Citrate, Clostridium Novyi-NT Spores, Cobimetinib, Cobolimab, Cobomarsen, Codrituzumab, Coenzyme Q10, Cofetuzumab Pelidotin, Colchicine-Site Binding Agent ABT-751, Cold Contaminant-free Iobenguane I-131, Colloidal Gold-Bound Tumor Necrosis Factor, Colorectal Cancer Peptide Vaccine PolyPEPI1018, Colorectal Tumor-Associated Peptides Vaccine IMA910, Coltuximab Ravtansine, Combretastatin, Combretastatin A-1, Combretastatin A1 Diphosphate, Commensal Bacterial Strain Formulation VE800, Compound Kushen Injection, Conatumumab, Conbercept, Concentrated Lingzhi Mushroom Extract, Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011, Copanlisib, Copanlisib Hydrochloride, Copper Cu 64-ATSM, Copper Cu 67 Tyr3-octreotate, Copper Gluconate, Cord Blood Derived CAR T-Cells, Cord Blood-derived Expanded Natural Killer Cells PNK-007, Cordycepin, Cordycepin Triphosphate, Coriolus Versicolor Extract, Corticorelin Acetate, Cortisone Acetate, Cosibelimab, Cositecan, Coxsackievirus A21, Coxsackievirus V937, CpG Oligodeoxynucleotide GNKG168, Crenolanib, Crenolanib Besylate, Crizotinib, Crolibulin, Cryptophycin, Cryptophycin 52, Crystalline Genistein Formulation AXP107-11, CSF-1R Inhibitor BLZ945, CSF1R Inhibitor ABSK021, CSF1R Inhibitor DCC-3014, CSF1R Inhibitor PLX73086, CT2584 HMS, CTLA-4-directed Probody BMS-986249, Curcumin, Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110, Cusatuzumab, Custirsen Sodium, CXC Chemokine Receptor 2 Antagonist AZD5069, CXCR1/2 Inhibitor SX-682, CXCR2 Antagonist QBM076, CXCR4 Antagonist BL-8040, CXCR4 Antagonist USL311, CXCR4 Inhibitor Q-122, CXCR4 Peptide Antagonist LY2510924, CXCR4/E-selectin Antagonist GMI-1359, Cyclin-dependent Kinase 8/19 Inhibitor BCD 115, Cyclin-dependent Kinase Inhibitor PF-06873600, Cyclodextrin-Based Polymer-Camptothecin CRLX101, Cyclodisone, Cycloleucine, Cyclopentenyl Cytosine, Cyclophosphamide, Cyclophosphamide Anhydrous, Cyclosporine, CYL-02 Plasmid DNA, CYP11A1 inhibitor ODM-208, CYP11A1 Inhibitor ODM-209, CYP17 Inhibitor CFG920, CYP17 Lyase Inhibitor ASN001, CYP17/Androgen Receptor Inhibitor ODM 204, CYP17/CYP11B2 Inhibitor LAE001, Cyproterone, Cyproterone Acetate, Cytarabine, Cytarabine Monophosphate Prodrug MB07133, Cytarabine-asparagine Prodrug BST-236, Cytidine Analog RX-3117, Cytochlor, Cytokine-based Biologic Agent IRX-2, D-methionine Formulation MRX-1024, DAB389 Epidermal Growth Factor, Dabrafenib, Dabrafenib Mesylate, Dacarbazine, Dacetuzumab, DACH Polymer Platinate AP5346, DACH-Platin Micelle NC-4016, Daclizumab, Dacomitinib, Dacplatinum, Dactinomycin, Dactolisib, Dactolisib Tosylate, Dalantercept, Dalotuzumab, Daniquidone, Danusertib, Danvatirsen, Daporinad, Daratumumab, Daratumumab and Hyaluronidase-fihj, Daratumumab/rHuPH20, Darinaparsin, Darleukin, Darolutamide, Daromun, Dasatinib, Daunorubicin, Daunorubicin Citrate, Daunorubicin Hydrochloride, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Decitabine and Cedazuridine, Defactinib, Defactinib Hydrochloride, Deferoxamine, Deferoxamine Mesylate, Degarelix, Degarelix Acetate, Delanzomib, Delolimogene Mupadenorepvec, Demcizumab, Demecolcine, Demplatin Pegraglumer, Dendrimer-conjugated Bcl-2/Bcl-XL Inhibitor AZD0466, Dendritic Cell Vaccine, Dendritic Cell-Autologous Lung Tumor Vaccine, Dendritic Cell-targeting Lentiviral Vector ID-LV305, Denenicokin, Dengue Virus Adjuvant PV-001-DV, Denibulin, Denibulin Hydrochloride, Denileukin Diftitox, Denintuzumab Mafodotin, Denosumab, Deoxycytidine Analogue TAS-109, Deoxycytidine Analogue TAS-109 Hydrochloride, Depatuxizumab, Depatuxizumab Mafodotin, Derazantinib, Deslorelin, Deslorelin Acetate, Detirelix, Detorubicin, Deuteporfin, Deuterated Enzalutamide, Devimistat, Dexamethason, Dexamethasone, Dexamethasone Phosphate, Dexamethasone Sodium Phosphate, Dexanabinol, Dexrazoxane, Dexrazoxane Hydrochloride, Dezaguanine, Dezaguanine Mesylate, Dezapelisib, DHA-Paclitaxel, DHEA Mustard, DI-Leu16-IL2 Immunocytokine, Dianhydrogalactitol, Diarylsulfonylurea Compound ILX-295501, Diazepinomicin, Diaziquone, Diazooxonorleucine, Dibrospidium Chloride, Dichloroallyl Lawsone, Dicycloplatin, Didox, Dienogest, Diethylnorspermine, Digitoxin, Digoxin, Dihydro-5-Azacytidine, Dihydrolenperone, Dihydroorotate Dehydrogenase Inhibitor AG-636, Dihydroorotate Dehydrogenase Inhibitor BAY2402234, Diindolylmethane, Dilpacimab, Dimethylmyleran, Dinaciclib, Dinutuximab, Dioscorea nipponica Makino Extract DNE3, Diphencyprone, Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777, Ditiocarb, DKK1-Neutralizing Monoclonal Antibody DKN-01, DM-CHOC-PEN, DM4-Conjugated Anti-Cripto Monoclonal Antibody BIIB015, DNA Interference Oligonucleotide PNT2258, DNA Minor Groove Binding Agent SG2000, DNA Plasmid Encoding Interleukin-12 INO-9012, DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151, DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, DNA Vaccine VB10.16, DNA-dependent Protein Kinase Inhibitor VX-984, DNA-PK inhibitor AZD7648, DNA-PK/PI3K-delta Inhibitor BR101801, DNA-PK/TOR Kinase Inhibitor CC-115, DNMT1 Inhibitor NTX-301, DNMT1 Mixed-Backbone Antisense Oligonucleotide MG 98, Docetaxel, Docetaxel Anhydrous, Docetaxel Emulsion ANX-514, Docetaxel Formulation CKD-810, Docetaxel Lipid Microspheres, Docetaxel Nanoparticle CPC634, Docetaxel Polymeric Micelles, Docetaxel-loaded Nanopharmaceutical CRLX301, Docetaxel-PNP, Docetaxel/Ritonavir, Dociparstat sodium, Dolastatin 10, Dolastatin 15, Domatinostat, Donafenib, Dopamine-Somatostatin Chimeric Molecule BIM-23A760, Dostarlimab, Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703, Dovitinib, Dovitinib Lactate, Doxazosin, Doxercalciferol, Doxifluridine, Doxorubicin, Doxorubicin Hydrochloride, Doxorubicin Prodrug L-377;202, Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370, Doxorubicin-Eluting Beads, Doxorubicin-HPMA Conjugate, Doxorubicin-loaded EGFR-targeting Nanocells, Doxorubicin-Magnetic Targeted Carrier Complex, DPT/BCG/Measles/Serratia/Pneumococcus Vaccine, DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine, DPX-E7 HPV Vaccine, DR5 HexaBody Agonist GEN1029, DR5-targeting Tetrameric Nanobody Agonist TAS266, Dromostanolone Propionate, Drozitumab, DTRMWXHS-12/Everolimus/Pomalidomide Combination Agent DTRM-555, Dual IGF-1R/InsR Inhibitor BMS-754807, Dual Variable Domain Immunoglobulin ABT-165, Dual-affinity B7-H3/CD3-targeted Protein MGD009, Dubermatinib, Duborimycin, Dulanermin, Duligotuzumab, Dupilumab, Durvalumab, Dusigitumab, dUTPase/DPD Inhibitor TAS-114, Duvelisib, Duvortuxizumab, Dynemicin, Dynemicin A, E2F1 Pathway Activator ARQ 171, EBNA-1 inhibitor VK-2019, Echinomycin, Ecromeximab, Edatrexate, Edelfosine, Edicotinib, Edodekin alfa, Edotecarin, Edrecolomab, EED Inhibitor MAK683, Efatutazone, Efatutazone Dihydrochloride, Efizonerimod, Eflornithine, Eflornithine Hydrochloride, Eftilagimod Alpha, Eftozanermin Alfa, Eg5 Kinesin-Related Motor Protein Inhibitor 4SC-205, Eg5 Kinesin-Related Motor Protein Inhibitor ARQ 621, EGb761, EGFR Antagonist Hemay022, EGFR Antisense DNA BB-401, EGFR Inhibitor AZD3759, EGFR Inhibitor BIBX 1382, EGFR Inhibitor DBPR112, EGFR Inhibitor PD-168393, EGFR Inhibitor TY-9591, EGFR Mutant-selective Inhibitor TQB3804, EGFR Mutant-specific Inhibitor BPI-7711, EGFR Mutant-specific Inhibitor CK-101, EGFR Mutant-specific Inhibitor D-0316, EGFR Mutant-specific Inhibitor ZN-e4, EGFR T790M Antagonist BPI-15086, EGFR T790M Inhibitor HS-10296, EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR/FLT3/Abl Inhibitor SKLB1028, EGFR/HER1/HER2 Inhibitor PKI166, EGFR/HER2 Inhibitor AP32788, EGFR/HER2 Inhibitor AV-412, EGFR/HER2 Inhibitor DZD9008, EGFR/HER2 Kinase Inhibitor TAK-285, EGFR/TGFb Fusion Monoclonal Antibody BCA101, EGFR/VEGFR/RET Inhibitor HA121-28, Eicosapentaenoic Acid, eIF4E Antisense Oligonucleotide ISIS 183750, Elacestrant, Elacytarabine, Elagolix, Elbasvir/Grazoprevir, Elesclomol, Elesclomol Sodium, Elgemtumab, Elinafide, Elisidepsin, Elliptinium, Elliptinium Acetate, Elmustine, Elotuzumab, Elpamotide, Elsamitrucin, Eltanexor, Emactuzumab, Emapalumab, Emepepimut-S, Emibetuzumab, Emitefur, Emofolin Sodium, Empesertib, Enadenotucirev, Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A, Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641, Enasidenib, Enasidenib Mesylate, Enavatuzumab, Encapsulated Rapamycin, Encelimab, Enclomiphene, Enclomiphene Citrate, Encorafenib, Endothelin B Receptor Blocker ENB 003, Endothelin Receptor Type A Antagonist YM598, Enfortumab Vedotin, Engineered Human Umbilical Vein Endothelial Cells AB-205, Engineered Red Blood Cells Co-expressing 4-1BBL and IL-15TP RTX-240, Engineered Toxin Body Targeting CD38 TAK-169, Engineered Toxin Body Targeting HER2 MT-5111, Eniluracil/5-FU Combination Tablet, Enloplatin, Enoblituzumab, Enobosarm, Enoticumab, Enpromate, Ensartinib, Ensituximab, Enteric-Coated TRPM8 Agonist D-3263 Hydrochloride, Enterococcus gallinarum Strain MRx0518, Entinostat, Entolimod, Entospletinib, Entrectinib, Envafolimab, Enzalutamide, Enzastaurin, Enzastaurin Hydrochloride, EP2/EP4 Antagonist TPST-1495, EP4 Antagonist INV-1120, EP4 Antagonist ONO-4578, Epacadostat, Epcoritamab, EphA2-targeting Bicycle Toxin Conjugate BT5528, Epipodophyllotoxin Analog GL331, Epipropidine, Epirubicin, Epirubicin Hydrochloride, Epitinib Succinate, Epitiostanol, Epothilone Analog UTD1, Epothilone KOS-1584, Epratuzumab, Epratuzumab-cys-tesirine, ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471, ERa36 Modulator Icaritin, Erastin Analogue PRLX 93936, Erbulozole, Erdafitinib, Eribulin, Eribulin Mesylate, ERK 1/2 Inhibitor ASTX029, ERK Inhibitor CC-90003, ERK Inhibitor GDC-0994, ERK Inhibitor LTT462, ERK Inhibitor MK-8353, ERK1/2 Inhibitor ASN007, ERK1/2 Inhibitor HH2710, ERK1/2 Inhibitor JSI-1187, ERK1/2 Inhibitor KO-947, ERK1/2 Inhibitor LY3214996, Erlotinib, Erlotinib Hydrochloride, Ertumaxomab, Erythrocyte-encapsulated L-asparaginase Suspension, Esorubicin, Esorubicin Hydrochloride, Esperamicin A1, Essiac, Esterified Estrogens, Estradiol Valerate, Estramustine, Estramustine Phosphate Sodium, Estrogen Receptor Agonist GTx-758, Estrogens; Conjugated, Etalocib, Etanercept, Etanidazole, Etaracizumab, Etarotene, Ethaselen, Ethinyl Estradiol, Ethyleneimine, Ethylnitrosourea, Etidronate-Cytarabine Conjugate MBC-11, Etigilimab, Etirinotecan Pegol, Etoglucid, Etoposide, Etoposide Phosphate, Etoposide Toniribate, Etoprine, Etoricoxib, Ets-family Transcription Factor Inhibitor TK216, Everolimus, Everolimus Tablets for Oral Suspension, Evofosfamide, Ex Vivo-expanded Autologous T Cells IMA101, Exatecan Mesylate, Exatecan Mesylate Anhydrous, Exemestane, Exicorilant, Exisulind, Extended Release Flucytosine, Extended Release Metformin Hydrochloride, Extended-release Onapristone, Ezabenlimab, EZH1/2 Inhibitor DS-3201, EZH1/2 Inhibitor HH2853, EZH2 inhibitor CPI-0209, EZH2 Inhibitor CPI-1205, EZH2 Inhibitor PF-06821497, EZH2 Inhibitor SHR2554, F16-IL2 Fusion Protein, FACT Complex-targeting Curaxin CBL0137, Factor VII-targeting Immunoconjugate Protein ICON-1, Factor VIIa Inhibitor PCI-27483, Fadraciclib, Fadrozole Hydrochloride, FAK Inhibitor GSK2256098, FAK Inhibitor PF-00562271, FAK Inhibitor VS-4718, FAK/ALK/ROS1 Inhibitor APG-2449, Falimarev, Famitinib, FAP/4-1BB-targeting DARPin MP0310, FAP/4-1BB-targeting Fusion Protein RO7122290, Farletuzumab, Farnesyltransferase/Geranylgeranyltransferase Inhibitor L-778;123, Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells, Fas Receptor Agonist APO010, Fascin Inhibitor NP-G2-044, FASN Inhibitor TVB-2640, Favezelimab, Fazarabine, Fc-engineered Anti-CD40 Agonist Antibody 2141-V11, Febuxostat, Fedratinib, Fedratinib Hydrochloride, Feladilimab, Felzartamab, Fenebrutinib, Fenretinide, Fenretinide Lipid Matrix, Fenretinide Phospholipid Suspension ST-001, FGF Receptor Antagonist HGS1036, FGF/FGFR Pathway Inhibitor E7090, FGFR Inhibitor ASP5878, FGFR Inhibitor AZD4547, FGFR Inhibitor CPL304110, FGFR Inhibitor Debio 1347, FGFR Inhibitor TAS-120, FGFR/CSF-1R Inhibitor 3D185, FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999, FGFR1/2/3 Inhibitor HMPL-453, FGFR2 Inhibitor RLY-4008, FGFR4 Antagonist INCB062079, FGFR4 Inhibitor BLU 9931, FGFR4 Inhibitor FGF401, FGFR4 Inhibitor H3B-6527, FGFR4 Inhibitor ICP-105, Fianlimab, Fibromun, Ficlatuzumab, Figitumumab, Filanesib, Filgotinib, Filgrastim, Fimaporfin A, Fimepinostat, Firtecan Pegol, Fisogatinib, Flanvotumab, Flotetuzumab, Floxuridine, FLT3 Inhibitor FF-10101 Succinate, FLT3 Inhibitor HM43239, FLT3 Inhibitor SKI-G-801, Flt3 Ligand/Anti-CTLA-4 Antibody/IL-12 Engineered Oncolytic Vaccinia Virus RIVAL-01, FLT3 Tyrosine Kinase Inhibitor TTT-3002, FLT3/ABL/Aurora Kinase Inhibitor KW-2449, FLT3/CDK4/6 Inhibitor FLX925, FLT3/FGFR Dual Kinase Inhibitor MAX-40279, FLT3/KIT Kinase Inhibitor AKN-028, FLT3/KIT/CSF1R Inhibitor NMS-03592088, Flt3/MerTK Inhibitor MRX-2843, Fludarabine, Fludarabine Phosphate, Flumatinib, Flumatinib Mesylate, Fluorine F 18 Ara-G, Fluorodopan, Fluorouracil, Fluorouracil Implant, Fluorouracil-E Therapeutic Implant, Fluoxymesterone, Flutamide, Fluvastatin, Fluvastatin Sodium, Fluzoparib, FMS Inhibitor JNJ-40346527, Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate, Folate Receptor Targeted Epothilone BMS753493, Folate Receptor-Targeted Tubulysin Conjugate EC1456, Folate Receptor-Targeted Vinca Alkaloid EC0489, Folate Receptor-Targeted Vinca Alkaloid/Mitomycin C EC0225, Folate-FITC, Folic Acid, Folitixorin, Foretinib, Foritinib Succinate, Formestane, Forodesine Hydrochloride, Fosaprepitant, Fosbretabulin, Fosbretabulin Disodium, Fosbretabulin Tromethamine, Fosgemcitabine Palabenamide, Fosifloxuridine Nafalbenamide, Foslinanib, Foslinanib Disodium, Fosquidone, Fostriecin, Fotemustine, Fotretamine, FPV Vaccine CV301, FPV-Brachyury-TRICOM Vaccine, Fresolimumab, Fruquintinib, Fulvestrant, Fumagillin-Derived Polymer Conjugate XMT-1107, Fursultiamine, Futibatinib, Futuximab, Futuximab/Modotuximab Mixture, G Protein-coupled Estrogen Receptor Agonist LNS8801, G-Quadruplex Stabilizer BMVC, Galamustine, Galarubicin, Galectin Inhibitor GR-MD-02, Galectin-1 Inhibitor OTX008, Galeterone, Galiximab, Gallium-based Bone Resorption Inhibitor AP-002, Galocitabine, Galunisertib, Gamboge Resin Extract TSB-9-W1, Gamma-delta Tocotrienol, Gamma-Secretase Inhibitor LY3039478, Gamma-Secretase Inhibitor RO4929097, Gandotinib, Ganetespib, Ganglioside GD2, Ganglioside GM2, Ganitumab, Ganoderma lucidum Spores Powder Capsule, Garlic, Gastrin Immunotoxin, Gastrin/cholecystokinin Type B Receptor Inhibitor Z-360, Gataparsen Sodium, Gatipotuzumab, GBM Antigens and Alloantigens Immunotherapeutic Vaccine, Gedatolisib, Gefitinib, Geldanamycin, Gelonin, Gemcitabine, Gemcitabine Elaidate, Gemcitabine Hydrochloride, Gemcitabine Hydrochloride Emulsion, Gemcitabine Prodrug LY2334737, Gemcitabine-Phosphoramidate Hydrochloride NUC-1031, Gemcitabine-Releasing Intravesical System, Gemtuzumab Ozogamicin, Genetically Modified Interleukin-12 Transgene-encoding Bifidobacterium longum, Genistein, Gentuximab, Geranylgeranyltransferase I Inhibitor, GI-4000 Vaccine, Giloralimab, Gilteritinib, Gilteritinib Fumarate, Gimatecan, Gimeracil, Ginsenoside Rg3 Capsule, Giredestrant, Girentuximab, Girodazole, GITR Agonist MEDI1873, Givinostat, Glasdegib, Glasdegib Maleate, Glaucarubolone, Glecaprevir/Pibrentasvir, Glembatumumab Vedotin, Glesatinib, Glioblastoma Cancer Vaccine ERC1671, Glioblastoma Multiforme Multipeptide Vaccine IMA950, Glioma Lysate Vaccine GBM6-AD, Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701, Globo H-DT Vaccine OBI-833, Glofitamab, Glucarpidase, Glucocorticoid Receptor Antagonist ORIC-101, Glufosfamide, Glumetinib, Glutaminase Inhibitor CB-839, Glutaminase Inhibitor CB-839 Hydrochloride, Glutaminase Inhibitor IPN60090, Glutamine Antagonist DRP-104, Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101, Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01, Glycooptimized Trastuzumab-GEX, GM-CSF-encoding Oncolytic Adenovirus CGTG-102, Gold Sodium Thiomalate, Golnerminogene Pradenovec, Golotimod, Golvatinib, Gonadotropin-releasing Hormone Analog, Goserelin, Goserelin Acetate, Goserelin Acetate Extended-release Microspheres LY01005, Gossypol, Gossypol Acetic Acid, Grapiprant, Green Tea Extract-based Antioxidant Supplement, GS/pan-Notch Inhibitor AL101, GS/pan-Notch Inhibitor BMS-986115, GSK-3 Inhibitor 9-ING-41, GSK-3 Inhibitor LY2090314, Guadecitabine, Guanabenz Acetate, Guselkumab, Gusperimus Trihydrochloride, Gutolactone, H-ras Antisense Oligodeoxynucleotide ISIS 2503, H1299 Tumor Cell Lysate Vaccine, HAAH Lambda phage Vaccine SNS-301, Hafnium Oxide-containing Nanoparticles NBTXR3, Halichondrin Analogue E7130, Halichondrin B, Halofuginone, Halofuginone Hydrobromide, HCV DNA Vaccine INO-8000, HDAC Class I/IIb Inhibitor HG146, HDAC Inhibitor AR-42, HDAC inhibitor CG200745, HDAC Inhibitor CHR-2845, HDAC Inhibitor CKD-581, HDAC Inhibitor CXD101, HDAC Inhibitor MPT0E028, HDAC Inhibitor OBP-801, HDAC/EGFR/HER2 Inhibitor CUDC-101, HDAC6 Inhibitor KA2507, HDAC8 Inhibitor NBM-BMX, HDM2 Inhibitor HDM201, HDM2 Inhibitor MK-8242, Hedgehog Inhibitor IPI-609, Hematoporphyrin Derivative, Hemiasterlin Analog E7974, Henatinib Maleate, Heparan Sulfate Glycosaminoglycan Mimetic M402, Heparin Derivative SST0001, HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131, HER2 ECD+TM Virus-like Replicon Particles Vaccine AVX901, HER2 Inhibitor CP-724;714, HER2 Inhibitor DZD1516, HER2 Inhibitor TAS0728, HER2 Tri-specific Natural Killer Cell Engager DF1001, HER2-directed TLR8 Agonist SBT6050, HER2-targeted DARPin MP0274, HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302, HER2-targeting Antibody Fc Fragment FS102, Herba Scutellaria Barbata, Herbimycin, Heterodimeric Interleukin-15, Hexamethylene Bisacetamide, Hexaminolevulinate, Hexylresorcinol, HIF-1alpha Inhibitor PX-478, HIF-2alpha Inhibitor PT2385, HIF-2alpha Inhibitor PT2977, HIF2a RNAi ARO-HIF2, Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126, Histrelin Acetate, HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001, HLA-A*2402-Restricted Multipeptide Vaccine S-488410, HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201, HM2/MMAE Antibody-Drug Conjugate ALT-P7, Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine, Holmium Ho 166 Poly(L-Lactic Acid) Microspheres, Hormone Therapy, HPPH, HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202, HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, HPV E6/E7 DNA Vaccine GX-188E, HPV E6/E7-encoding Arenavirus Vaccine HB-201, HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C, HPV-16 E6 Peptides Vaccine/Candida albicans Extract, HPV-6-targeting Immunotherapeutic Vaccine INO-3106, HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101, HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN, HPV6/11-targeted DNA Plasmid Vaccine INO-3107, Hsp90 Antagonist KW-2478, Hsp90 Inhibitor AB-010, Hsp90 Inhibitor BIIB021, Hsp90 Inhibitor BIIB028, Hsp90 Inhibitor Debio 0932, Hsp90 Inhibitor DS-2248, Hsp90 Inhibitor HSP990, Hsp90 Inhibitor MPC-3100, Hsp90 Inhibitor PU-H71, Hsp90 Inhibitor SNX-5422 Mesylate, Hsp90 Inhibitor SNX-5542 Mesylate, Hsp90 Inhibitor TQB3474, Hsp90 Inhibitor XL888, Hsp90-targeted Photosensitizer HS-201, HSP90-targeted SN-38 Conjugate PEN-866, HSP90alpha/beta Inhibitor TAS-116, hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301, hTERT Vaccine V934/V935, hTERT-encoding DNA Vaccine INVAC-1, Hu14.18-IL2 Fusion Protein EMD 273063, HuaChanSu, Huaier Extract Granule, Huang Lian, huBC1-huIL12 Fusion Protein AS1409, Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736, Human MHC Non-Restricted Cytotoxic T-Cell Line TALL-104, Human MOAB LICO 28a32, Human Monoclonal Antibody 216, Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307, Human Papillomavirus 16 E7 Peptide/Padre 965.10, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Hycanthone, Hydralazine Hydrochloride, Hydrocortisone Sodium Succinate, Hydroxychloroquine, Hydroxyprogesterone Caproate, Hydroxytyrosol, Hydroxyurea, Hypericin, Hypoxia-activated Prodrug TH-4000, I 131 Antiferritin Immunoglobulin, I 131 Monoclonal Antibody A33, I 131 Monoclonal Antibody CC49, I 131 Monoclonal Antibody F19, I 131 Monoclonal Antibody Lym-1, Iadademstat, Ianalumab, IAP Inhibitor APG-1387, IAP Inhibitor AT-406, IAP Inhibitor HGS1029, Ibandronate Sodium, Iberdomide, Iboctadekin, Ibritumomab Tiuxetan, Ibrutinib, Icotinib Hydrochloride, Icrucumab, ICT-121 Dendritic Cell Vaccine, Idarubicin, Idarubicin Hydrochloride, Idarubicin-Eluting Beads, Idasanutlin, Idecabtagene Vicleucel, Idelalisib, Idetrexed, IDH1 Mutant Inhibitor LY3410738, IDH1(R132) Inhibitor IDH305, IDH1R132H-Specific Peptide Vaccine PEPIDH1M, Idiotype-Pulsed Autologous Dendritic Cell Vaccine APC8020, IDO Peptide Vaccine IO102, IDO-1 Inhibitor LY3381916, IDO/TDO Inhibitor HTI-1090, IDO/TDO Inhibitor LY-01013, IDO1 Inhibitor KHK2455, IDO1 Inhibitor MK-7162, IDO1 Inhibitor PF-06840003, IDO1/TDO2 Inhibitor DN1406131, IDO1/TDO2 Inhibitor M4112, Idronoxil, Idronoxil Suppository NOX66, Ieramilimab, Ifabotuzumab, Ifetroban, Ifosfamide, IGF-1R Inhibitor, IGF-1R Inhibitor PL225B, IGF-1R/IR Inhibitor KW-2450, IGF-methotrexate Conjugate, IL-10 Immunomodulator MK-1966, IL-12-expressing HSV-1 NSC 733972, IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051, IL-12sc; IL-15sushi; IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000, IL-2 Recombinant Fusion Protein ALT-801, IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1, IL4-Pseudomonas Exotoxin Fusion Protein MDNA55, Ilginatinib, Ilixadencel, Iloprost, Ilorasertib, Imalumab, Imaradenant, Imatinib, Imatinib Mesylate, Imetelstat, Imetelstat Sodium, Imexon, Imgatuzumab, Imidazole Mustard, Imidazole-Pyrazole, Imifoplatin, Imipramine Blue, Imiquimod, Immediate-release Onapristone, Immediate-release Tablet Afuresertib, Immune Checkpoint Inhibitor ASP8374, Immunoconjugate RO5479599, Immunocytokine NHS-IL12, Immunocytokine NHS-IL2-LT, Immunomodulator LAM-003, Immunomodulator OHR/AVR118, Immunomodulatory Agent CC-11006, Immunomodulatory Oligonucleotide HYB2055, Immunotherapeutic Combination Product CMB305, Immunotherapeutic GSK1572932A, Immunotherapy Regimen MKC-1106-MT, Immunotoxin CMD-193, IMT-1012 Immunotherapeutic Vaccine, Inactivated Oncolytic Virus Particle GEN0101, Inalimarev, Incyclinide, Indatuximab Ravtansine, Indibulin, Indicine-N-Oxide, Indisulam, Individualized MVA-based Vaccine TG4050, Indocyanine Green-labeled Polymeric Micelles ONM-100, Indole-3-Carbinol, Indomethacin, Indoximod, Indoximod Prodrug NLG802, Indusatumab Vedotin, Inebilizumab, Inecalcitol, Infigratinib, Infigratinib Mesylate, Infliximab, Ingenol Mebutate, Ingenol Mebutate Gel, Iniparib, iNKT Cell Agonist ABX196, Innate Immunostimulator rBBX-01, INO-1001, Inodiftagene Vixteplasmid, iNOS Dimerization Inhibitor ASP9853, Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01, Inosine Monophosphate Dehydrogenase Inhibitor AVN944, Inositol, Inotuzumab Ozogamicin, Inproquone, Integrin alpha-2 Inhibitor E7820, Integrin Receptor Antagonist GLPG0187, Interferon, Interferon Alfa-2B, Interferon Alfa-N1, Interferon Alfa-N3, Interferon Alfacon-1, Interferon Beta-1A, Interferon Gamma-1b, Interferon-gamma-expressing Adenovirus Vaccine ASN-002, Interleukin Therapy, Interleukin-12-Fc Fusion Protein DF6002, Interleukin-15 Agonist Fusion Protein SHR1501, Interleukin-15 Fusion Protein BJ-001, Interleukin-15/Interleukin-15 Receptor Alpha Complex-Fc Fusion Protein XmAb24306, Interleukin-15/Interleukin-15 Receptor Alpha Sushi+ Domain Fusion Protein SO-C101, Interleukin-2 Liposome, Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230, Intetumumab, Intiquinatine, Intoplicine, Inulin, Iobenguane I-131, Iodine I 124 Monoclonal Antibody A33, Iodine I 124 Monoclonal Antibody M5A, Iodine I 125-Anti-EGFR-425 Monoclonal Antibody, Iodine I 131 Anti-Fibronectin Antibody Fragment L19-SIP, Iodine I 131 Apamistamab, Iodine I 131 Derlotuximab Biotin, Iodine I 131 Ethiodized Oil, Iodine I 131 IPA, Iodine I 131 MIP-1095, Iodine I 131 Monoclonal Antibody 81C6, Iodine I 131 Monoclonal Antibody BC8, Iodine I 131 Monoclonal Antibody CC49-deltaCH2, Iodine I 131 Monoclonal Antibody F16SIP, Iodine I 131 Monoclonal Antibody G-250, Iodine I 131 Monoclonal Antibody muJ591, Iodine I 131 Omburtamab, Iodine I 131 Rituximab, Iodine I 131 Tenatumomab, Iodine I 131 TM-601, Iodine I 131 Tositumomab, Iodine I-131, Ioflubenzamide I-131, Ionomycin, Ipafricept, Ipatasertib, Ipilimumab, Ipomeanol, Iproplatin, iPSC-derived CD16-expressing Natural Killer Cells FT516, iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596, iPSC-derived Natural Killer Cells FT500, IRAK4 Inhibitor CA-4948, Iratumumab, Iridium Ir 192, Irinotecan, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Irinotecan-Eluting Beads, Irinotecan/P-glycoprotein Inhibitor HM30181AK Combination Tablet, Irofulven, Iroplact, Irosustat, Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130, Isatuximab, Iso-fludelone, Isobrucein B, Isocoumarin NM-3, Isotretinoin, Ispinesib, Ispinesib Mesylate, ISS 1018 CpG Oligodeoxynucleotide, Istiratumab, Itacitinib, Itacitinib Adipate, ITK Inhibitor CPI-818, Itraconazole, Itraconazole Dispersion In Polymer Matrix, Ivaltinostat, Ivosidenib, Ivuxolimab, Ixabepilone, Ixazomib, Ixazomib Citrate, JAK Inhibitor, JAK Inhibitor INCB047986, JAK1 Inhibitor AZD4205, JAK1 Inhibitor INCB052793, JAK2 Inhibitor AZD1480, JAK2 Inhibitor BMS-911543, JAK2 Inhibitor XL019, JAK2/Src Inhibitor NS-018, Jin Fu Kang, JNK Inhibitor CC-401, Kanglaite, Kanitinib, Ketoconazole, Ketotrexate, KRAS G12C Inhibitor GDC-6036, KRAS G12C Inhibitor LY3499446, KRAS G12C Inhibitor MRTX849, KRAS Mutant-targeting AMG 510, KRAS-MAPK Signaling Pathway Inhibitor JAB-3312, KRASG12C Inhibitor JNJ-74699157, KRN5500, KSP Inhibitor AZD4877, KSP Inhibitor SB-743921, Kunecatechins Ointment, L-Gossypol, L-methylfolate, Labetuzumab Govitecan, Lactoferrin-derived Lytic Peptide LTX-315, Lacutamab, Ladiratuzumab Vedotin, Ladirubicin, Laetrile, LAIR-2 Fusion Protein NC410, Landogrozumab, Laniquidar, Lanreotide Acetate, Lapachone, Lapatinib, Lapatinib Ditosylate, Laprituximab Emtansine, Lapuleucel-T, Laromustine, Larotaxel, Larotinib Mesylate, Larotrectinib, Larotrectinib Sulfate, Lavendustin A, Lazertinib, Lead Pb 212 TCMC-trastuzumab, Lefitolimod, Leflunomide, Lenalidomide, Lenalidomide Analog KPG-121, Lentinan, Lenvatinib, Lenvatinib Mesylate, Lenzilumab, Lerociclib, Lestaurtinib, Letetresgene Autoleucel, Letolizumab, Letrozole, Leucovorin, Leucovorin Calcium, Leuprolide, Leuprolide Acetate, Leuprolide Mesylate Injectable Suspension, Leurubicin, Levetiracetam, Levoleucovorin Calcium, Levothyroxine, Levothyroxine Sodium, Lexatumumab, Lexibulin, Liarozole, Liarozole Fumarate, Liarozole Hydrochloride, Licartin, Licorice, Lifastuzumab Vedotin, Lifileucel, Lifirafenib, Light-activated AU-011, Light-Emitting Oncolytic Vaccinia Virus GL-ONC1, Lilotomab, Limonene; (+)-, Limonene; (+/-)-, Linifanib, Linoleyl Carbonate-Paclitaxel, Linperlisib, Linrodostat, Linsitinib, Lintuzumab, Liothyronine I-131, Liothyronine Sodium, Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1, Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191, Lipid Nanoparticle Encapsulated OX40L mRNA-2416, Lipid Nanoparticle Encapsulating Glutathione S-transferase P siRNA NBF-006, Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752, Liposomal Bcl-2 Antisense Oligonucleotide BP1002, Liposomal c-raf Antisense Oligonucleotide, Liposomal Curcumin, Liposomal Cytarabine, Liposomal Daunorubicin Citrate, Liposomal Docetaxel, Liposomal Eribulin Mesylate, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Liposomal Irinotecan, Liposomal Mitoxantrone Hydrochloride, Liposomal MUC1/PET-lipid A Vaccine ONT-10, Liposomal NDDP, Liposomal Rhenium Re 186, Liposomal SN-38, Liposomal Topotecan FF-10850, Liposomal Vinorelbine, Liposomal Vinorelbine Tartrate, Liposome, Liposome-encapsulated Daunorubicin-Cytarabine, Liposome-Encapsulated Doxorubicin Citrate, Liposome-encapsulated miR-34 Mimic MRX34, Liposome-encapsulated OSI-7904, Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94, Liposome-encapsulated TAAs mRNA Vaccine W_ova1, Lirilumab, Lisavanbulin, Lisocabtagene Maraleucel, Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142, Litronesib, Live-attenuated Double-deleted Listeria monocytogenes Bacteria JNJ-64041809, Live-Attenuated Listeria Encoding Human Mesothelin Vaccine CRS-207, Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623, Liver X Receptor beta Agonist RGX-104, Lm-tLLO-neoantigens Vaccine ADXS-NEO, LMB-1 Immunotoxin, LMB-2 Immunotoxin, LMB-7 Immunotoxin, LMB-9 Immunotoxin, LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164, LMP-2:340-349 Peptide Vaccine, LMP-2:419-427 Peptide Vaccine, LMP2-specific T Cell Receptor-transduced Autologous T-lymphocytes, LMP7 Inhibitor M3258, Lobaplatin, Lodapolimab, Lometrexol, Lometrexol Sodium, Lomustine, Lonafarnib, Loncastuximab Tesirine, Long Peptide Vaccine 7, Long-acting Release Pasireotide, Lontucirev, Lorlatinib, Lorukafusp alfa, Lorvotuzumab Mertansine, Losatuxizumab Vedotin, Losoxantrone, Losoxantrone Hydrochloride, Lovastatin, LOXL2 Inhibitor PAT-1251, LRP5 Antagonist BI 905681, LRP5/6 Antagonist BI 905677, LSD1 Inhibitor CC-90011, LSD1 Inhibitor GSK2879552, LSD1 Inhibitor IMG-7289, LSD1 Inhibitor RO7051790, LSD1 Inhibitor SYHA1807, Lucanthone, Lucatumumab, Lucitanib, Luminespib, Luminespib Mesylate, Lumretuzumab, Lung-targeted Immunomodulator QBKPN, Lupartumab Amadotin, Lurbinectedin, Lurtotecan, Lurtotecan Liposome, Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1, Lutetium Lu 177 DOTA-biotin, Lutetium Lu 177 DOTA-N3-CTT1403, Lutetium Lu 177 DOTA-Tetulomab, Lutetium Lu 177 Dotatate, Lutetium Lu 177 Lilotomab-satetraxetan, Lutetium Lu 177 Monoclonal Antibody CC49, Lutetium Lu 177 Monoclonal Antibody J591, Lutetium Lu 177 PP-F11N, Lutetium Lu 177 Satoreotide Tetraxetan, Lutetium Lu 177-DOTA-EB-TATE, Lutetium Lu 177-DTPA-omburtamab, Lutetium Lu 177-Edotreotide, Lutetium Lu 177-NeoB, Lutetium Lu 177-PSMA-617, Lutetium Lu-177 Capromab, Lutetium Lu-177 Girentuximab, Lutetium Lu-177 PSMA-R2, Lutetium Lu-177 Rituximab, LV.IL-2/B7.1-Transduced AML Blast Vaccine RFUSIN2-AML1, Lyophilized Black Raspberry Lozenge, Lyophilized Black Raspberry Saliva Substitute, Lysine-specific Demethylase 1 Inhibitor INCB059872, Lyso-Thermosensitive Liposome Doxorubicin, Maackia amurensis Seed Lectin, Macimorelin, Macitentan, Macrocycle-bridged STING Agonist E7766, Maekmoondong-tang, Mafosfamide, MAGE-10.A2, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, MAGE-A3 Multipeptide Vaccine GL-0817, MAGE-A3 Peptide Vaccine, MAGE-A3-specific Immunotherapeutic GSK 2132231A, MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201, Magnesium Valproate, Magrolimab, MALT1 Inhibitor JNJ-67856633, Manelimab, Mannosulfan, Mannosylerythritol Lipid, Mapatumumab, Maraba Oncolytic Virus Expressing Mutant HPV E6/E7, Marcellomycin, MARCKS Protein Inhibitor BIO-11006, Margetuximab, Marimastat, Marizomib, Masitinib Mesylate, Masoprocol, MAT2A Inhibitor AG-270, Matrix Metalloproteinase Inhibitor MMI270, Matuzumab, Mavelertinib, Mavorixafor, Maytansine, MCL-1 Inhibitor ABBV-467, MCL-1 Inhibitor AMG 176, MCL-1 inhibitor AMG 397, Mcl-1 Inhibitor AZD5991, Mcl-1 Inhibitor MIK665, MDM2 Antagonist ASTX295, MDM2 Antagonist RO5045337, MDM2 Antagonist RO6839921, MDM2 Inhibitor AMG-232, MDM2 Inhibitor AMGMDS3, MDM2 Inhibitor BI 907828, MDM2 Inhibitor KRT-232, MDM2/MDMX Inhibitor ALRN-6924, MDR Modulator CBT-1, Mechlorethamine, Mechlorethamine Hydrochloride, Mechlorethamine Hydrochloride Gel, Medorubicin, Medroxyprogesterone, Medroxyprogesterone Acetate, Megestrol Acetate, MEK 1/2 Inhibitor AS703988/MSC2015103B, MEK 1/2 Inhibitor FCN-159, MEK Inhibitor AZD8330, MEK Inhibitor CI-1040, MEK inhibitor CS3006, MEK Inhibitor GDC-0623, MEK Inhibitor HL-085, MEK Inhibitor PD0325901, MEK Inhibitor RO4987655, MEK Inhibitor SHR 7390, MEK Inhibitor TAK-733, MEK Inhibitor WX-554, MEK-1/MEKK-1 Inhibitor E6201, MEK/Aurora Kinase Inhibitor BI 847325, Melanoma Monoclonal Antibody hIgG2A, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Melapuldencel-T, MELK Inhibitor OTS167, Melphalan, Melphalan Flufenamide, Melphalan Hydrochloride, Melphalan Hydrochloride/Sulfobutyl Ether Beta-Cyclodextrin Complex, Membrane-Disrupting Peptide EP-100, Menatetrenone, Menin-MLL Interaction Inhibitor SNDX-5613, Menogaril, Merbarone, Mercaptopurine, Mercaptopurine Anhydrous, Mercaptopurine Oral Suspension, Merestinib, Mesna, Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536, MET Kinase Inhibitor OMO-1, MET Tyrosine Kinase Inhibitor BMS-777607, MET Tyrosine Kinase Inhibitor EMD 1204831, MET Tyrosine Kinase Inhibitor PF-04217903, MET Tyrosine Kinase Inhibitor SAR125844, MET Tyrosine Kinase Inhibitor SGX523, MET x MET Bispecific Antibody REGN5093, Metamelfalan, MetAP2 Inhibitor APL-1202, MetAP2 Inhibitor SDX-7320, Metarrestin, Metatinib Tromethamine, Metformin, Metformin Hydrochloride, Methanol Extraction Residue of BCG, Methazolamide, Methionine Aminopeptidase 2 Inhibitor M8891, Methionine Aminopeptidase 2 Inhibitor PPI-2458, Methotrexate, Methotrexate Sodium, Methotrexate-E Therapeutic Implant, Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles, Methoxsalen, Methoxyamine, Methoxyamine Hydrochloride, Methyl-5-Aminolevulinate Hydrochloride Cream, Methylcantharidimide, Methylmercaptopurine Riboside, Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, Methylselenocysteine, Methyltestosterone, Metoprine, Mevociclib, Mezagitamab, Mibefradil, Mibefradil Dihydrochloride, Micellar Nanoparticle-encapsulated Epirubicin, Micro Needle Array-Doxorubicin, Microbiome GEN-001, Microbiome-derived Peptide Vaccine EO2401, Microparticle-encapsulated CYP1B1-encoding DNA Vaccine ZYC300, Microtubule Inhibitor SCB01A, Midostaurin, Mifamurtide, Mifepristone, Milademetan Tosylate, Milataxel, Milatuzumab, Milatuzumab-Doxorubicin Antibody-Drug Conjugate IMMU-110, Milciclib Maleate, Milk Thistle, Miltefosine, Minretumomab, Mipsagargin, Miptenalimab, Mirabegron, Miransertib, Mirdametinib, Mirvetuximab Soravtansine, Mirzotamab Clezutoclax, Misonidazole, Mistletoe Extract, Mitazalimab, Mitindomide, Mitobronitol, Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101, Mitoclomine, Mitoflaxone, Mitoguazone, Mitoguazone Dihydrochloride, Mitolactol, Mitomycin, Mitomycin A, Mitomycin B, Mitomycin C Analog KW-2149, Mitosis Inhibitor T 1101 Tosylate, Mitotane, Mitotenamine, Mitoxantrone, Mitoxantrone Hydrochloride, Mitozolomide, Mivavotinib, Mivebresib, Mivobulin, Mivobulin Isethionate, Mixed Bacteria Vaccine, MK0731, MKC-1, MKNK1 Inhibitor BAY 1143269, MMP Inhibitor S-3304, MNK1/2 Inhibitor ETC-1907206, Mobocertinib, Mocetinostat, Modakafusp Alfa, Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208, Modified Vitamin D Binding Protein Macrophage Activator EF-022, Modotuximab, MOF Compound RiMO-301, Mofarotene, Mogamulizumab, Molibresib, Molibresib Besylate, Momelotinib, Monalizumab, Monocarboxylate Transporter 1 Inhibitor AZD3965, Monoclonal Antibody 105AD7 Anti-idiotype Vaccine, Monoclonal Antibody 11D10, Monoclonal Antibody 11D10 Anti-Idiotype Vaccine, Monoclonal Antibody 14G2A, Monoclonal Antibody 1F5, Monoclonal Antibody 3622W94, Monoclonal Antibody 3F8, Monoclonal Antibody 3H1 Anti-Idiotype Vaccine, Monoclonal Antibody 4B5 Anti-Idiotype Vaccine, Monoclonal Antibody 7C11, Monoclonal Antibody 81C6, Monoclonal Antibody A1G4 Anti-Idiotype Vaccine, Monoclonal Antibody A27.15, Monoclonal Antibody A33, Monoclonal Antibody AbGn-7, Monoclonal Antibody AK002, Monoclonal Antibody ASP1948, Monoclonal Antibody CAL, Monoclonal Antibody CC49-delta CH2, Monoclonal Antibody CEP-37250/KHK2804, Monoclonal Antibody D6.12, Monoclonal Antibody E2.3, Monoclonal Antibody F19, Monoclonal Antibody GD2 Anti-Idiotype Vaccine, Monoclonal Antibody HeFi-1, Monoclonal Antibody Hu3S193, Monoclonal Antibody HuAFP31, Monoclonal Antibody HuHMFG1, Monoclonal Antibody huJ591, Monoclonal Antibody HuPAM4, Monoclonal Antibody IMMU-14, Monoclonal Antibody L6, Monoclonal Antibody Lym-1, Monoclonal Antibody m170, Monoclonal Antibody Me1-14 F(ab')2, Monoclonal Antibody muJ591, Monoclonal Antibody MX35 F(ab')2, Monoclonal Antibody NEO-201, Monoclonal Antibody R24, Monoclonal Antibody RAV12, Monoclonal Antibody SGN-14, Monoclonal Antibody TRK-950, Monoclonal Microbial EDP1503, Monoclonal T-cell Receptor Anti-CD3 scFv Fusion Protein IMCgp100, Monomethyl Auristatin E, Morinda Citrifolia Fruit Extract, Morpholinodoxorubicin, Mosedipimod, Mosunetuzumab, Motesanib, Motesanib Diphosphate, Motexafin Gadolinium, Motexafin Lutetium, Motixafortide, Motolimod, MOv-gamma Chimeric Receptor Gene, Moxetumomab Pasudotox, Mps1 Inhibitor BAY 1217389, Mps1 Inhibitor BOS172722, mRNA-based Personalized Cancer Vaccine mRNA-4157, mRNA-based Personalized Cancer Vaccine NCI-4650, mRNA-based TriMix Melanoma Vaccine ECI-006, mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902, mRNA-derived KRAS-targeted Vaccine V941, mRNA-derived Lung Cancer Vaccine BI 1361849, mRNA-Derived Prostate Cancer Vaccine CV9103, mRNA-derived Prostate Cancer Vaccine CV9104, MTF-1 Inhibitor APTO-253 HCl, mTOR Inhibitor GDC-0349, mTOR Kinase Inhibitor AZD8055, mTOR Kinase Inhibitor CC-223, mTOR Kinase Inhibitor OSI-027, mTOR Kinase Inhibitor PP242, mTOR1/2 Kinase Inhibitor ME-344, mTORC 1/2 Inhibitor LXI-15029, mTORC1/2 Kinase Inhibitor BI 860585, mTORC1/mTORC2/DHFR Inhibitor ABTL0812, MUC-1/WT1 Peptide-primed Autologous Dendritic Cells, MUC1-targeted Peptide GO-203-2C, Mucoadhesive Paclitaxel Formulation, Multi-AGC Kinase Inhibitor AT13148, Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200, Multi-epitope HER2 Peptide Vaccine H2NVAC, Multi-epitope HER2 Peptide Vaccine TPIV100, Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107, Multi-kinase Inhibitor TPX-0022, Multi-kinase Inhibitor XL092, Multi-mode Kinase Inhibitor EOC317, Multi-neo-epitope Vaccine OSE 2101, Multifunctional/Multitargeted Anticancer Agent OMN54, Multikinase Inhibitor 4SC-203, Multikinase Inhibitor AEE788, Multikinase Inhibitor AT9283, Multikinase Inhibitor SAR103168, Multipeptide Vaccine S-588210, Multitargeted Tyrosine Kinase Inhibitor JNJ-26483327, Muparfostat, Mureletecan, Murizatoclax, Muscadine Grape Extract, Mutant IDH1 Inhibitor DS-1001, Mutant p53 Activator COTI-2, Mutant-selective EGFR Inhibitor PF-06459988, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, MVA-BN Smallpox Vaccine, MVA-FCU1 TG4023, MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1, MYC-targeting siRNA DCR-MYC, Mycobacterium tuberculosis Arabinomannan Z-100, Mycobacterium w, Mycophenolic Acid, N-(5-tert-butyl-3-isoxazolyl)-N-(4-(4-pyridinyl)oxyphenyl) Urea, N-dihydrogalactochitosan, N-Methylformamide, N;N-Dibenzyl Daunomycin, NA17-A Antigen, NA17.A2 Peptide Vaccine, Nab-paclitaxel, Nab-paclitaxel/Rituximab-coated Nanoparticle AR160, Nadofaragene Firadenovec, Nagrestipen, Namirotene, Namodenoson, NAMPT Inhibitor OT-82, Nanafrocin, Nanatinostat, Nanocell-encapsulated miR-16-based microRNA Mimic, Nanoparticle Albumin-Bound Docetaxel, Nanoparticle Albumin-Bound Rapamycin, Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404, Nanoparticle Paclitaxel Ointment SOR007, Nanoparticle-based Paclitaxel Suspension, Nanoparticle-encapsulated Doxorubicin Hydrochloride, Nanoscale Coordination Polymer Nanoparticles CPI-100, Nanosomal Docetaxel Lipid Suspension, Napabucasin, Naphthalimide Analogue UNBS5162, Naptumomab Estafenatox, Naquotinib, Naratuximab Emtansine, Narnatumab, Natalizumab, Natural IFN-alpha OPC-18, Natural Killer Cells ZRx101, Navarixin, Navicixizumab, Navitoclax, Navoximod, Navy Bean Powder, Naxitamab, Nazartinib, ncmtRNA Oligonucleotide Andes-1537, Necitumumab, Nedaplatin, NEDD8 Activating Enzyme E1 Inhibitor TAS4464, Nedisertib, Nelarabine, Nelipepimut-S, Nelipepimut-S Plus GM-CSF Vaccine, Nemorubicin, Nemorubicin Hydrochloride, Neoantigen Vaccine GEN-009, Neoantigen-based Glioblastoma Vaccine, Neoantigen-based Melanoma-Poly-ICLC Vaccine, Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine, Neoantigen-based Therapeutic Cancer Vaccine GRT-C903, Neoantigen-based Therapeutic Cancer Vaccine GRT-R904, Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017, Neratinib, Neratinib Maleate, Nesvacumab, NG-nitro-L-arginine, Niacinamide, Niclosamide, Nicotinamide Riboside, Nidanilimab, Nifurtimox, Nilotinib, Nilotinib Hydrochloride Anhydrous, Nilotinib Hydrochloride Monohydrate, Nilutamide, Nimesulide-Hyaluronic Acid Conjugate CA102N, Nimodipine, Nimotuzumab, Nimustine, Nimustine Hydrochloride, Ningetinib Tosylate, Nintedanib, Niraparib, Niraparib Tosylate Monohydrate, Nirogacestat, Nitric Oxide-Releasing Acetylsalicylic Acid Derivative, Nitrogen Mustard Prodrug PR-104, Nitroglycerin Transdermal Patch, Nivolumab, NLRP3 Agonist BMS-986299, Nocodazole, Nogalamycin, Nogapendekin Alfa, Nolatrexed Dihydrochloride, Non-Small Cell Lung Cancer mRNA-Derived Vaccine CV9201, Norgestrel, North American Ginseng Extract AFX-2, Nortopixantrone, Noscapine, Noscapine Hydrochloride, Not Otherwise Specified, Notch Signaling Inhibitor PF-06650808, Notch Signaling Pathway Inhibitor MK0752, NTRK/ROS1 Inhibitor DS-6051b, Nucleolin Antagonist IPP-204106N, Nucleoside Analog DFP-10917, Nucleotide Analog Prodrug NUC-3373, Nucleotide Analogue GS 9219, Numidargistat, Nurulimab, Nutlin-3a, Nutraceutical TBL-12, NY-ESO-1 Plasmid DNA Cancer Vaccine pPJV7611, NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301, NY-ESO-1/GLA-SE Vaccine ID-G305, NY-ESO-B, O-Chloroacetylcarbamoylfumagillol, O6-Benzylguanine, Obatoclax Mesylate, Obinutuzumab, Oblimersen Sodium, Ocaratuzumab, Ocrelizumab, Octreotide, Octreotide Acetate, Octreotide Pamoate, Odronextamab, Ofatumumab, Ofranergene Obadenovec, Oglufanide Disodium, Olaparib, Olaptesed Pegol, Olaratumab, Oleandrin, Oleclumab, Oligo-fucoidan, Oligonucleotide SPC2996, Olinvacimab, Olivomycin, Olmutinib, Oltipraz, Olutasidenib, Olvimulogene Nanivacirepvec, Omacetaxine Mepesuccinate, Ombrabulin, Omipalisib, Onalespib, Onalespib Lactate, Onartuzumab, Onatasertib, Oncolytic Adenovirus Ad5-DNX-2401, Oncolytic Adenovirus ORCA-010, Oncolytic Herpes Simplex Virus-1 ONCR-177, Oncolytic HSV-1 C134, Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011, Oncolytic HSV-1 G207, Oncolytic HSV-1 NV1020, Oncolytic HSV-1 rQNestin34.5v.2, Oncolytic HSV-1 rRp450, Oncolytic HSV1716, Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Oncolytic Newcastle Disease Virus MEDI5395, Oncolytic Newcastle Disease Virus MTH-68H, Oncolytic Newcastle Disease Virus Strain PV701, Oncolytic Virus ASP9801, Oncolytic Virus RP1, Ondansetron Hydrochloride, Ontorpacept, Ontuxizumab, Onvansertib, Onvatilimab, Opaganib, OPCs/Green Tea/Spirullina/Curcumin/Antrodia Camphorate/Fermented Soymilk Extract Capsule, Opioid Growth Factor, Opolimogene Capmilisbac, Oportuzumab Monatox, Oprozomib, Opucolimab, Oral Aminolevulinic Acid Hydrochloride, Oral Azacitidine, Oral Cancer Vaccine V3-OVA, Oral Docetaxel, Oral Fludarabine Phosphate, Oral Hsp90 Inhibitor IPI-493, Oral Ixabepilone, Oral Microencapsulated Diindolylmethane, Oral Milataxel, Oral Myoma Vaccine V3-myoma, Oral Pancreatic Cancer Vaccine V3-P, Oral Picoplatin, Oral Sodium Phenylbutyrate, Oral Topotecan Hydrochloride, Orantinib, Oraxol, Oregovomab, Orelabrutinib, Ormaplatin, Ortataxel, Orteronel, Orvacabtagene Autoleucel, Osilodrostat, Osimertinib, Other, Otlertuzumab, Ovapuldencel-T, Ovarian Cancer Stem Cell/hTERT/Survivin mRNAs-loaded Autologous Dendritic Cell Vaccine DC-006, Ovine Submaxillary Mucin, OX40L-expressing Oncolytic Adenovirus DNX-2440, Oxaliplatin, Oxaliplatin Eluting Beads, Oxaliplatin-Encapsulated Transferrin-Conjugated N-glutaryl Phosphatidylethanolamine Liposome, Oxcarbazepine, Oxeclosporin, Oxidative Phosphorylation Inhibitor IACS-010759, Oxidative Phosphorylation Inhibitor IM156, Oxidopamine, OxPhos Inhibitor VLX600, Ozarelix, P-cadherin Antagonist PF-03732010, P-cadherin Inhibitor PCA062, P-cadherin-targeting Agent PF-06671008, P-p68 Inhibitor RX-5902, P-TEFb Inhibitor BAY1143572, p300/CBP Bromodomain Inhibitor CCS1477, p38 MAPK Inhibitor LY3007113, p53 Peptide Vaccine MPS-128, p53-HDM2 Interaction Inhibitor MI-773, p53-HDM2 Protein-protein Interaction Inhibitor APG-115, p53/HDM2 Interaction Inhibitor CGM097, p70S6K Inhibitor LY2584702, p70S6K/Akt Inhibitor MSC2363318A, p97 Inhibitor CB-5083, p97 Inhibitor CB-5339, p97 Inhibitor CB-5339 Tosylate, Paclitaxel, Paclitaxel Ceribate, Paclitaxel Injection Concentrate for Nanodispersion, Paclitaxel Liposome, Paclitaxel Poliglumex, Paclitaxel Polymeric Micelle Formulation NANT-008, Paclitaxel PPE Microspheres, Paclitaxel Trevatide, Paclitaxel Vitamin E-Based Emulsion, Paclitaxel-Loaded Polymeric Micelle, Pacmilimab, Pacritinib, Padeliporfin, Padoporfin, PAK4 Inhibitor PF-03758309, PAK4/NAMPT Inhibitor KPT-9274, Palbociclib, Palbociclib Isethionate, Palifosfamide, Palifosfamide Tromethamine, Palladium Pd-103, Palonosetron Hydrochloride, Pamidronate Disodium, Pamidronic Acid, Pamiparib, Pamrevlumab, pan FGFR Inhibitor PRN1371, Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514, Pan-AKT Inhibitor ARQ751, Pan-AKT Kinase Inhibitor GSK690693, Pan-FGFR Inhibitor LY2874455, Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806, pan-HER Kinase Inhibitor AC480, Pan-IDH Mutant Inhibitor AG-881, Pan-KRAS Inhibitor BI 1701963, Pan-Mutant-IDH1 Inhibitor Bay-1436032, Pan-mutation-selective EGFR Inhibitor CLN-081, pan-PI3K Inhibitor CLR457, pan-PI3K/mTOR Inhibitor SF1126, Pan-PIM Inhibitor INCB053914, pan-PIM Kinase Inhibitor AZD1208, pan-PIM Kinase Inhibitor NVP-LGB-321, pan-RAF Inhibitor LXH254, Pan-RAF Inhibitor LY3009120, pan-RAF Kinase Inhibitor CCT3833, pan-RAF Kinase Inhibitor TAK-580, Pan-RAR Agonist/AP-1 Inhibitor LGD 1550, Pan-TRK Inhibitor NOV1601, Pan-TRK Inhibitor ONO-7579, Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Pancratistatin, Panitumumab, Panobinostat, Panobinostat Nanoparticle Formulation MTX110, Panulisib, Paricalcitol, PARP 1/2 Inhibitor IMP4297, PARP 1/2 Inhibitor NOV1401, PARP Inhibitor AZD2461, PARP Inhibitor CEP-9722, PARP Inhibitor E7016, PARP Inhibitor NMS-03305293, PARP-1/2 Inhibitor ABT-767, PARP/Tankyrase Inhibitor 2X-121, PARP7 Inhibitor RBN-2397, Parsaclisib, Parsaclisib Hydrochloride, Parsatuzumab, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Parvovirus H-1, Pasireotide, Pasotuxizumab, Patidegib, Patidegib Topical Gel, Patritumab, Patritumab Deruxtecan, Patupilone, Paxalisib, Pazopanib, Pazopanib Hydrochloride, pbi-shRNA STMN1 Lipoplex, PBN Derivative OKN-007, PCNU, PD-1 Directed Probody CX-188, PD-1 Inhibitor, PD-L1 Inhibitor GS-4224, PD-L1 Inhibitor INCB086550, PD-L1/4-1BB/HSA Trispecific Fusion Protein NM21-1480, PD-L1/PD-L2/VISTA Antagonist CA-170, PDK1 Inhibitor AR-12, pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0, PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1, PEG-interleukin-2, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1, PEG-Proline-Interferon Alfa-2b, Pegargiminase, Pegaspargase, Pegdinetanib, Pegfilgrastim, Pegilodecakin, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Pegvisomant, Pegvorhyaluronidase Alfa, Pegylated Deoxycytidine Analogue DFP-14927, Pegylated Interferon Alfa, Pegylated Liposomal Belotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Pegylated Liposomal Irinotecan, Pegylated Liposomal Mitomycin C Lipid-based Prodrug, Pegylated Liposomal Mitoxantrone Hydrochloride, Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010, Pegylated Paclitaxel, Pegylated Recombinant Human Arginase I BCT-100, Pegylated Recombinant Human Hyaluronidase PH20, Pegylated Recombinant Interleukin-2 THOR-707, Pegylated Recombinant L-asparaginase Erwinia chrysanthemi, Pegylated SN-38 Conjugate PLX038, Pegzilarginase, Pelabresib, Pelareorep, Peldesine, Pelitinib, Pelitrexol, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Pemigatinib, Pemlimogene Merolisbac, Penberol, Penclomedine, Penicillamine, Pentamethylmelamine, Pentamustine, Pentostatin, Pentoxifylline, PEOX-based Polymer Encapsulated Paclitaxel FID-007, PEP-3-KLH Conjugate Vaccine, Pepinemab, Peplomycin, Peplomycin Sulfate, Peposertib, Peptichemio, Peptide 946 Melanoma Vaccine, Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine, Peretinoin, Perflenapent Emulsion, Perfosfamide, Perifosine, Perillyl Alcohol, Personalized ALL-specific Multi-HLA-binding Peptide Vaccine, Personalized and Adjusted Neoantigen Peptide Vaccine PANDA-VAC, Personalized Cancer Vaccine RO7198457, Personalized Neoantigen DNA Vaccine GNOS-PV01, Personalized Neoantigen DNA Vaccine GNOS-PVO2, Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01, Personalized Neoepitope Yeast Vaccine YE-NEO-001, Personalized Peptide Cancer Vaccine NEO-PV-01, Pertuzumab, Pevonedistat, Pexastimogene Devacirepvec, Pexidartinib, Pexmetinib, PGG Beta-Glucan, PGLA/PEG Copolymer-Based Paclitaxel, PH20 Hyaluronidase-expressing Adenovirus VCN-01, Phaleria macrocarpa Extract DLBS-1425, Pharmacological Ascorbate, Phellodendron amurense Bark Extract, Phenesterin, Phenethyl Isothiocyanate, Phenethyl Isothiocyanate-containing Watercress Juice, Phenyl Acetate, Phenytoin Sodium, Phosphaplatin PT-112, Phosphatidylcholine-Bound Silybin, Phospholipid Ether-drug Conjugate CLR 131, Phosphoramide Mustard, Phosphorodiamidate Morpholino Oligomer AVI-4126, Phosphorus P-32, Photodynamic Compound TLD-1433, Photosensitizer LUZ 11, Phytochlorin Sodium-Polyvinylpyrrolidone Complex, PI3K Alpha/Beta Inhibitor BAY1082439, PI3K Alpha/mTOR Inhibitor PWT33597 Mesylate, PI3K Inhibitor ACP-319, PI3K Inhibitor BGT226, PI3K Inhibitor GDC-0084, PI3K Inhibitor GDC0077, PI3K Inhibitor GSK1059615, PI3K Inhibitor WX-037, PI3K Inhibitor ZSTK474, PI3K p110beta/delta Inhibitor KA2237, PI3K-alpha Inhibitor MEN1611, PI3K-beta Inhibitor GSK2636771, PI3K-beta Inhibitor SAR260301, PI3K-delta Inhibitor AMG 319, PI3K-delta Inhibitor HMPL 689, PI3K-delta Inhibitor INCB050465, PI3K-delta Inhibitor PWT143, PI3K-delta Inhibitor SHC014748M, PI3K-delta Inhibitor YY-20394, PI3K-gamma Inhibitor IPI-549, PI3K/BET Inhibitor LY294002, PI3K/mTOR Kinase Inhibitor DS-7423, PI3K/mTOR Kinase Inhibitor PF-04691502, PI3K/mTOR Kinase Inhibitor VS-5584, PI3K/mTOR Kinase Inhibitor WXFL10030390, PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170, PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901, PI3Ka/mTOR Inhibitor PKI-179, PI3Kalpha Inhibitor AZD8835, PI3Kbeta Inhibitor AZD8186, PI3Kdelta Inhibitor GS-9901, Pibenzimol, Pibrozelesin, Pibrozelesin Hydrobromide, Picibanil, Picoplatin, Picrasinoside H, Picropodophyllin, Pictilisib, Pictilisib Bismesylate, Pidilizumab, Pilaralisib, PIM Kinase Inhibitor LGH447, PIM Kinase Inhibitor SGI-1776, PIM Kinase Inhibitor TP-3654, PIM/FLT3 Kinase Inhibitor SEL24, Pimasertib, Pimitespib, Pimurutamab, Pinatuzumab Vedotin, Pingyangmycin, Pinometostat, Pioglitazone, Pioglitazone Hydrochloride, Pipendoxifene, Piperazinedione, Piperine Extract (Standardized), Pipobroman, Piposulfan, Pirarubicin, Pirarubicin Hydrochloride, Pirfenidone, Piritrexim, Piritrexim Isethionate, Pirotinib, Piroxantrone, Piroxantrone Hydrochloride, Pixantrone, Pixantrone Dimaleate, Pixatimod, PKA Regulatory Subunit RIalpha Mixed-Backbone Antisense Oligonucleotide GEM 231, PKC-alpha Antisense Oligodeoxynucleotide ISIS 3521, PKC-beta Inhibitor MS-553, Placebo, Pladienolide Derivative E7107, Plamotamab, Plasmid DNA Vaccine pING-hHER3FL, Platinum, Platinum Acetylacetonate-Titanium Dioxide Nanoparticles, Platinum Compound, Plevitrexed, Plicamycin, Plinabulin, Plitidepsin, Plk1 Inhibitor BI 2536, PLK1 Inhibitor CYC140, PLK1 Inhibitor TAK-960, Plocabulin, Plozalizumab, pNGVL4a-CRT-E6E7L2 DNA Vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2, Pol I Inhibitor CX5461, Polatuzumab Vedotin, Polidocanol, Poliglusam, Polo-like Kinase 1 Inhibitor GSK461364, Polo-like Kinase 1 Inhibitor MK1496, Polo-like Kinase 1 Inhibitor NMS-1286937, Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate, Poly-alendronate Dextran-Guanidine Conjugate, Poly-gamma Glutamic Acid, Polyamine Analog SL11093, Polyamine Analogue PG11047, Polyamine Analogue SBP-101, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Polyandrol, Polyethylene Glycol Recombinant Endostatin, Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, Polymer-encapsulated Luteolin Nanoparticle, Polymeric Camptothecin Prodrug XMT-1001, Polypodium leucotomos Extract, Polysaccharide-K, Polysialic Acid, Polyunsaturated Fatty Acid, Polyvalent Melanoma Vaccine, Pomalidomide, Pomegranate Juice, Pomegranate Liquid Extract, Ponatinib, Ponatinib Hydrochloride, Porcupine Inhibitor CGX1321, Porcupine Inhibitor ETC-1922159, Porcupine Inhibitor RXC004, Porcupine Inhibitor WNT974, Porcupine Inhibitor XNW7201, Porfimer Sodium, Porfiromycin, Poziotinib, PPAR Alpha Antagonist TPST-1120, PR1 Leukemia Peptide Vaccine, Pracinostat, Pralatrexate, Pralsetinib, Praluzatamab Ravtansine, PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701, Pravastatin Sodium, Prednimustine, Prednisolone, Prednisolone Acetate, Prednisolone Sodium Phosphate, Prednisone, Prexasertib, Prexigebersen, PRIMA-1 Analog APR-246, Prime Cancer Vaccine MVA-BN-CV301, Prinomastat, PRMT1 Inhibitor GSK3368715, PRMT5 Inhibitor JNJ-64619178, PRMT5 Inhibitor PRT811, Proapoptotic Sulindac Analog CP-461, Procarbazine, Procarbazine Hydrochloride, Procaspase Activating Compound-1 VO-100, Progestational IUD, Prohibitin-Targeting Peptide 1, Prolgolimab, Prostaglandin E2 EP4 Receptor Inhibitor AN0025, Prostaglandin E2 EP4 Receptor Inhibitor E7046, Prostate Cancer Vaccine ONY-P1, Prostate Health Cocktail Dietary Supplement, Prostatic Acid Phosphatase-Sargramostim Fusion Protein PA2024, Protease-activated Anti-PD-L1 Antibody Prodrug CX-072, Protein Arginine Methyltransferase 5 Inhibitor GSK3326595, Protein Arginine Methyltransferase 5 Inhibitor PF-06939999, Protein Arginine Methyltransferase 5 Inhibitor PRT543, Protein Kinase C Inhibitor IDE196, Protein Phosphatase 2A Inhibitor LB-100, Protein Stabilized Liposomal Docetaxel Nanoparticles, Protein Tyrosine Kinase 2 Inhibitor IN10018, Proxalutamide, PSA/IL-2/GM-CSF Vaccine, PSA/PSMA DNA Plasmid INO-5150, Pseudoisocytidine, PSMA-targeted Docetaxel Nanoparticles BIND-014, PSMA-targeted Tubulysin B-containing Conjugate EC1169, PSMA/CD3 Tri-specific T-cell Activating Construct HPN424, PTEF-b/CDK9 Inhibitor BAY1251152, Pterostilbene, Pumitepa, Puquitinib, Puquitinib Mesylate, Puromycin, Puromycin Hydrochloride, PV-10, PVA Microporous Hydrospheres/Doxorubicin Hydrochloride, Pyrazinamide, Pyrazoloacridine, Pyridyl Cyanoguanidine CHS 828, Pyrotinib, Pyrotinib Dimaleate, Pyroxamide, Pyruvate Kinase Inhibitor TLN-232, Pyruvate Kinase M2 Isoform Activator TP-1454, Qilisheng Immunoregulatory Oral Solution, Quadrivalent Human Papillomavirus (types 6; 11; 16; 18) Recombinant Vaccine, Quarfloxin, Quinacrine Hydrochloride, Quinine, Quisinostat, Quizartinib, R-(-)-Gossypol Acetic Acid, Rabusertib, Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus SM-88, Racotumomab, RAD51 Inhibitor CYT-0851, Radgocitabine, Radgocitabine Hydrochloride, Radioactive Iodine, Radiolabeled CC49, Radium Ra 223 Dichloride, Radium Ra 224-labeled Calcium Carbonate Microparticles, Radix Angelicae Sinensis/Radix Astragali Herbal Supplement, Radotinib Hydrochloride, Raf Kinase Inhibitor HM95573, RAF Kinase Inhibitor L-779450, RAF Kinase Inhibitor XL281, Ragifilimab, Ralaniten Acetate, Ralimetinib Mesylate, Raloxifene, Raloxifene Hydrochloride, Raltitrexed, Ramucirumab, Ranibizumab, Ranimustine, Ranolazine, Ranpirnase, RARalpha Agonist IRX5183, Ras Inhibitor, Ras Peptide ASP, Ras Peptide CYS, Ras Peptide VAL, Razoxane, Realgar-Indigo naturalis Formulation, Rebastinib Tosylate, Rebeccamycin, Rebimastat, Receptor Tyrosine Kinase Inhibitor R1530, Recombinant Adenovirus-p53 SCH-58500, Recombinant Anti-WT1 Immunotherapeutic GSK2302024A, Recombinant Bacterial Minicells VAX014, Recombinant Bispecific Single-Chain Antibody rM28, Recombinant CD40-Ligand, Recombinant Erwinia asparaginase JZP-458, Recombinant Erythropoietin, Recombinant Fas Ligand, Recombinant Fractalkine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human 6Ckine, Recombinant Human Adenovirus Type 5 H101, Recombinant Human Angiotensin Converting Enzyme 2 APN01, Recombinant Human Apolipoprotein(a) Kringle V MG1102, Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Recombinant Human Endostatin, Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Recombinant Human Papillomavirus 11-valent Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Recombinant Human Plasminogen Kringle 5 Domain ABT 828, Recombinant Human TRAIL-Trimer Fusion Protein SCB-313, Recombinant Humanized Anti-HER-2 Bispecific Monoclonal Antibody MBS301, Recombinant Interferon, Recombinant Interferon Alfa, Recombinant Interferon Alfa-1b, Recombinant Interferon Alfa-2a, Recombinant Interferon Alfa-2b, Recombinant Interferon Alpha 2b-like Protein, Recombinant Interferon Beta, Recombinant Interferon Gamma, Recombinant Interleukin-12, Recombinant Interleukin-13, Recombinant Interleukin-18, Recombinant Interleukin-2, Recombinant Interleukin-6, Recombinant KSA Glycoprotein CO17-1A, Recombinant Leukocyte Interleukin, Recombinant Leukoregulin, Recombinant Luteinizing Hormone, Recombinant Macrophage Colony-Stimulating Factor, Recombinant MAGE-3.1 Antigen, Recombinant MIP1-alpha Variant ECI301, Recombinant Modified Vaccinia Ankara-5T4 Vaccine, Recombinant Oncolytic Poliovirus PVS-RIPO, Recombinant Platelet Factor 4, Recombinant PRAME Protein Plus AS15 Adjuvant GSK2302025A, Recombinant Saccharomyces Cerevisia-CEA(610D)-Expressing Vaccine GI-6207, Recombinant Super-compound Interferon, Recombinant Thyroglobulin, Recombinant Thyrotropin Alfa, Recombinant Transforming Growth Factor-Beta, Recombinant Transforming Growth Factor-Beta-2, Recombinant Tumor Necrosis Factor-Alpha, Recombinant Tyrosinase-Related Protein-2, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Redaporfin, Refametinib, Regorafenib, Relacorilant, Relatlimab, Relugolix, Remetinostat, Renal Cell Carcinoma Peptides Vaccine IMA901, Reparixin, Repotrectinib, Resiquimod, Resiquimod Topical Gel, Resistant Starch, Resminostat, Resveratrol, Resveratrol Formulation SRT501, RET Inhibitor DS-5010, RET Mutation/Fusion Inhibitor BLU-667, RET/SRC Inhibitor TPX-0046, Retaspimycin, Retaspimycin Hydrochloride, Retelliptine, Retifanlimab, Retinoic Acid Agent Ro 16-9100, Retinoid 9cUAB30, Retinol, Retinyl Acetate, Retinyl Palmitate, Retrovector Encoding Mutant Anti-Cyclin G1, Revdofilimab, Rexinoid NRX 194204, Rezivertinib, RFT5-dgA Immunotoxin IMTOX25, Rhenium Re 188 BMEDA-labeled Liposomes, Rhenium Re-186 Hydroxyethylidene Diphosphonate, Rhenium Re-188 Ethiodized Oil, Rhenium Re-188 Etidronate, Rhizoxin, RhoC Peptide Vaccine RV001V, Ribociclib, Ribociclib/Letrozole, Ribonuclease QBI-139, Ribosome-Inactivating Protein CY503, Ribozyme RPI.4610, Rice Bran, Ricolinostat, Ridaforolimus, Rigosertib, Rigosertib Sodium, Rilimogene Galvacirepvec, Rilimogene Galvacirepvec/Rilimogene Glafolivec, Rilimogene Glafolivec, Rilotumumab, Rindopepimut, Ripertamab, RIPK1 Inhibitor GSK3145095, Ripretinib, Risperidone Formulation in Rumenic Acid, Ritrosulfan, Rituximab, Rituximab and Hyaluronidase Human, Rituximab Conjugate CON-4619, Riviciclib, Rivoceranib, Rivoceranib Mesylate, RNR Inhibitor COH29, Robatumumab, Roblitinib, ROBO1-targeted BiCAR-NKT Cells, Rocakinogene Sifuplasmid, Rocapuldencel-T, Rociletinib, Rodorubicin, Roducitabine, Rofecoxib, Roflumilast, Rogaratinib, Rogletimide, Rolinsatamab Talirine, Romidepsin, Roneparstat, Roniciclib, Ropeginterferon Alfa-2B, Ropidoxuridine, Ropocamptide, Roquinimex, RORgamma Agonist LYC-55716, Rosabulin, Rose Bengal Solution PV-10, Rosiglitazone Maleate, Rosmantuzumab, Rosopatamab, Rosuvastatin, Rovalpituzumab Tesirine, RSK1-4 Inhibitor PMD-026, Rubitecan, Rucaparib, Rucaparib Camsylate, Rucaparib Phosphate, Ruthenium Ru-106, Ruthenium-based Small Molecule Therapeutic BOLD-100, Ruthenium-based Transferrin Targeting Agent NKP-1339, Ruxolitinib, Ruxolitinib Phosphate, Ruxotemitide, S-Adenosylmethionine, S-equol, S1P Receptor Agonist KRP203, Sabarubicin, Sabatolimab, Sacituzumab Govitecan, Sacubitril/Valsartan, Safingol, Sagopilone, Salirasib, Salmonella VNP20009, Sam68 Modulator CWP232291, Samalizumab, Samarium Sm 153-DOTMP, Samotolisib, Samrotamab Vedotin, Samuraciclib, Sapacitabine, Sapanisertib, Sapitinib, Saracatinib, Saracatinib Difumarate, SarCNU, Sardomozide, Sargramostim, Sasanlimab, Satraplatin, Savolitinib, SBIL-2, Scopoletin, SDF-1 Receptor Antagonist PTX-9908, Seclidemstat, Sedoxantrone Trihydrochloride, Selatinib Ditosilate, Selective Androgen Receptor Modulator RAD140, Selective Cytokine Inhibitory Drug CC-1088, Selective Estrogen Receptor Degrader AZD9496, Selective Estrogen Receptor Degrader AZD9833, Selective Estrogen Receptor Degrader LSZ102, Selective Estrogen Receptor Degrader LX-039, Selective Estrogen Receptor Degrader LY3484356, Selective Estrogen Receptor Degrader SRN-927, Selective Estrogen Receptor Modulator CC-8490, Selective Estrogen Receptor Modulator TAS-108, Selective Glucocorticoid Receptor Antagonist CORT125281, Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352, Seliciclib, Selicrelumab, Selinexor, Selitrectinib, Selonsertib, Selpercatinib, Selumetinib, Selumetinib Sulfate, Semaxanib, Semuloparin, Semustine, Seneca Valley Virus-001, Seocalcitol, Sepantronium Bromide, Serabelisib, Serclutamab Talirine, SERD D-0502, SERD G1T48, SERD GDC-9545, SERD SAR439859, SERD SHR9549, SERD ZN-c5, Serdemetan, Sergiolide, Seribantumab, Serine/Threonine Kinase Inhibitor CBP501, Serine/Threonine Kinase Inhibitor XL418, Serplulimab, Sevacizumab, Seviteronel, Shared Anti-Idiotype-AB-S006, Shared Anti-Idiotype-AB-S024A, Shark Cartilage, Shark Cartilage Extract AE-941, Shenqi Fuzheng Injection SQ001, Sho-Saiko-To, Short Chain Fatty Acid HQK-1004, SHP-1 Agonist SC-43, SHP2 Inhibitor JAB-3068, SHP2 Inhibitor RLY-1971, SHP2 Inhibitor RMC-4630, SHP2 Inhibitor TNO155, Shu Yu Wan Formula, Sialyl Tn Antigen, Sialyl Tn-KLH Vaccine, Sibrotuzumab, siG12D LODER, Silatecan AR-67, Silibinin, Silicon Phthalocyanine 4, Silmitasertib Sodium, Siltuximab, Simalikalactone D, Simeprevir, Simlukafusp Alfa, Simmitinib, Simotaxel, Simtuzumab, Simurosertib, Sintilimab, Siplizumab, Sipuleucel-T, Siremadlin, siRNA-transfected Peripheral Blood Mononuclear Cells APN401, Sirolimus, SIRPa-4-1BBL Fusion Protein DSP107, SIRPa-Fc Fusion Protein TTI-621, SIRPa-Fc-CD40L Fusion Protein SL-172154, SIRPa-IgG4-Fc Fusion Protein TTI-622, Sitimagene Ceradenovec, Sitravatinib, Sivifene, Sizofiran, SLC6A8 Inhibitor RGX-202, SLCT Inhibitor GNS561, SMAC Mimetic BI 891065, Smac Mimetic GDC-0152, Smac Mimetic GDC-0917, Smac Mimetic LCL161, SMO Protein Inhibitor ZSP1602, Smoothened Antagonist BMS-833923, Smoothened Antagonist LDE225 Topical, Smoothened Antagonist LEQ506, Smoothened Antagonist TAK-441, SN-38-Loaded Polymeric Micelles NK012, SNS01-T Nanoparticles, Sobuzoxane, Sodium Borocaptate, Sodium Butyrate, Sodium Dichloroacetate, Sodium Iodide I-131, Sodium Metaarsenite, Sodium Phenylbutyrate, Sodium Salicylate, Sodium Selenite, Sodium Stibogluconate, Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108, Sofituzumab Vedotin, Solitomab, Sonepcizumab, Sonidegib, Sonolisib, Sorafenib, Sorafenib Tosylate, Sorghum bicolor Supplement, Sotigalimab, Sotorasib, Sotrastaurin, Sotrastaurin Acetate, Soy Isoflavones, Soy Protein Isolate, Spanlecortemlocel, Sparfosate Sodium, Sparfosic Acid, Spartalizumab, Spebrutinib, Spherical Nucleic Acid Nanoparticle NU-0129, Spirogermanium, Spiromustine, Spiroplatin, Splicing Inhibitor H3B-8800, Spongistatin, Squalamine Lactate, SR-BP1/HSI Inhibitor SR31747A, SR-T100 Gel, Src Kinase Inhibitor AP 23846, Src Kinase Inhibitor KX2-391, Src Kinase Inhibitor KX2-391 Ointment, Src Kinase Inhibitor M475271, Src/Abl Kinase Inhibitor AZD0424, Src/tubulin Inhibitor KX02, SRPK1/ABCG2 Inhibitor SCO-101, ssRNA-based Immunomodulator CV8102, SSTR2-targeting Protein/DM1 Conjugate PEN-221, St. John's Wort, Stallimycin, Staphylococcal Enterotoxin A, Staphylococcal Enterotoxin B, STAT Inhibitor OPB-111077, STAT3 Inhibitor DSP-0337, STAT3 Inhibitor OPB-31121, STAT3 Inhibitor OPB-51602, STAT3 Inhibitor TTI-101, STAT3 Inhibitor WP1066, Staurosporine, STING Agonist BMS-986301, STING Agonist GSK3745417, STING Agonist IMSA101, STING Agonist MK-1454, STING Agonist SB 11285, STING Agonist TAK-676, STING-activating Cyclic Dinucleotide Agonist MIW815, STING-expressing E. coli SYNB1891, Streptonigrin, Streptozocin, Strontium Chloride Sr-89, Submicron Particle Paclitaxel Sterile Suspension, Sugemalimab, Sulfatinib, Sulforaphane, Sulindac, Sulofenur, Sumoylation Inhibitor TAK-981, Sunitinib, Sunitinib Malate, Super Enhancer Inhibitor GZ17-6.02, Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803, Superoxide Dismutase Mimetic GC4711, Suramin, Suramin Sodium, Survivin Antigen, Survivin Antigen Vaccine DPX-Survivac, Survivin mRNA Antagonist EZN-3042, Survivin-expressing CVD908ssb-TXSVN Vaccine, Sustained-release Lipid Inhaled Cisplatin, Sustained-release Mitomycin C Hydrogel Formulation UGN-101, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, Syk Inhibitor HMPL-523, Synchrotope TA2M Plasmid DNA Vaccine, Synchrovax SEM Plasmid DNA Vaccine, Synthetic Alkaloid PM00104, Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2, Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1, Synthetic hTERT DNA Vaccine INO-1400, Synthetic hTERT DNA Vaccine INO-1401, Synthetic Hypericin, Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201, Synthetic Long E6/E7 Peptides Vaccine HPV-01, Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b, Synthetic Plumbagin PCUR-101, T900607, Tabalumab, Tabelecleucel, Tacedinaline, Tafasitamab, Tagraxofusp-erzs, Talabostat, Talabostat Mesylate, Talacotuzumab, Talactoferrin Alfa, Taladegib, Talampanel, Talaporfin Sodium, Talazoparib, Taletrectinib, Talimogene Laherparepvec, Tallimustine, Talmapimod, Talotrexin, Talotrexin Ammonium, Taltobulin, TAM/c-Met Inhibitor RXDX-106, Tamibarotene, Taminadenant, Tamoxifen, Tamoxifen Citrate, Tamrintamab Pamozirine, Tandutinib, Tanespimycin, Tanibirumab, Tankyrase Inhibitor STP1002, Tanomastat, Tapotoclax, Tarenflurbil, Tarextumab, Tariquidar, Tasadenoturev, Taselisib, Tasidotin, Tasisulam, Tasisulam Sodium, Tasquinimod, Taurolidine, Tauromustine, Taurultam, Taurultam Analogue GP-2250, Tavokinogene Telseplasmid, Tavolimab, Taxane Analogue TPI 287, Taxane Compound, Taxol Analogue SID 530, Tazarotene, Tazemetostat, Tebentafusp, Teclistamab, Tecogalan Sodium, Tefinostat, Tegafur, Tegafur-gimeracil-oteracil Potassium, Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation, Tegafur-Uracil, Tegavivint, Teglarinad, Teglarinad Chloride, Telaglenastat, Telaglenastat Hydrochloride, Telapristone, Telapristone Acetate, Telatinib Mesylate, Telisotuzumab, Telisotuzumab Vedotin, Telomerase Inhibitor FJ5002, Telomerase-specific Type 5 Adenovirus OBP-301, Teloxantrone, Teloxantrone Hydrochloride, Telratolimod, Temarotene, Temoporfin, Temozolomide, Temsirolimus, Tenalisib, Tenifatecan, Teniposide, Tepoditamab, Tepotinib, Teprotumumab, Terameprocol, Terfluranol, Tergenpumatucel-L, Teroxirone, Tertomotide, Tesetaxel, Tesevatinib, Tesidolumab, Testolactone, Testosterone Enanthate, Tetanus Toxoid Vaccine, Tetradecanoylphorbol Acetate, Tetrahydrouridine, Tetraphenyl Chlorin Disulfonate, Tetrathiomolybdate, Tezacitabine, Tezacitabine Anhydrous, TGF-beta Receptor 1 Inhibitor PF-06952229, TGF-beta Receptor 1 Kinase Inhibitor SH3051, TGF-beta Receptor 1 Kinase Inhibitor YL-13027, TGFa-PE38 Immunotoxin, TGFbeta Inhibitor LY3200882, TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein AVID200, Thalicarpine, Thalidomide, Theliatinib, Theramide, Therapeutic Angiotensin-(1-7), Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907, Therapeutic Cancer Vaccine ATP128, Therapeutic Estradiol, Therapeutic Hydrocortisone, Therapeutic Liver Cancer Peptide Vaccine IMA970A, Thiarabine, Thiodiglycol, Thioguanine, Thioguanine Anhydrous, Thioinosine, Thioredoxin-1 Inhibitor PX-12, Thiotepa, Thioureidobutyronitrile, THL-P, Thorium Th 227 Anetumab, Thorium Th 227 Anetumab Corixetan, Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439, Thorium Th 227 Anti-PSMA Monoclonal Antibody BAY 2315497, Threonine Tyrosine Kinase Inhibitor CFI-402257, Thymidylate Synthase Inhibitor CX1106, Thymidylate Synthase Inhibitor DFP-11207, Thymopentin, Thyroid Extract, Tiazofurin, Tidutamab, Tigapotide, Tigatuzumab, TIGIT Inhibitor M6223, TIGIT-targeting Agent MK-7684, Tilarginine, Tilogotamab, Tilsotolimod Sodium, Timonacic, Tin Ethyl Etiopurpurin, Tinostamustine, Tinzaparin Sodium, Tiomolibdate Choline, Tiomolibdate Diammonium, Tipapkinogene Sovacivec, Tipifarnib, Tipiracil, Tipiracil Hydrochloride, Tirabrutinib, Tiragolumab, Tirapazamine, Tirbanibulin, Tisagenlecleucel, Tislelizumab, Tisotumab Vedotin, Tivantinib, Tivozanib, TLC ELL-12, TLR Agonist BDB001, TLR Agonist BSG-001, TLR Agonist CADI-05, TLR-Directed Cationic Lipid-DNA Complex JVRS-100, TLR7 Agonist 852A, TLR7 agonist BNT411, TLR7 Agonist LHC165, TLR7/8/9 Antagonist IMO-8400, TLR8 Agonist DN1508052, TLR9 Agonist AST-008, TM4SF1-CAR/EpCAM-CAR-expressing Autologous T Cells, Tocilizumab, Tocladesine, Tocotrienol, Tocotrienol-rich Fraction, Tolebrutinib, Toll-like Receptor 7 Agonist DSP-0509, Tolnidamine, Tomaralimab, Tomato-Soy Juice, Tomivosertib, Topical Betulinic Acid, Topical Celecoxib, Topical Fluorouracil, Topical Gemcitabine Hydrochloride, Topical Potassium Dobesilate, Topical Trichloroacetic Acid, Topixantrone, Topoisomerase I Inhibitor Genz-644282, Topoisomerase I Inhibitor LMP400, Topoisomerase I Inhibitor LMP776, Topoisomerase I/II Inhibitor NEV-801, Topoisomerase-1 Inhibitor LMP744, Topoisomerase-II Inhibitor Racemic XK469, Topoisomerase-II-beta Inhibitor Racemic XK469, Topotecan, Topotecan Hydrochloride, Topotecan Hydrochloride Liposomes, Topotecan Sustained-release Episcleral Plaque, Topsalysin, TORC1/2 Kinase Inhibitor DS-3078a, Toremifene, Toremifene Citrate, Toripalimab, Tosedostat, Tositumomab, Total Androgen Blockade, Tovetumab, Tozasertib Lactate, TP40 Immunotoxin, Trabectedin, Trabedersen, TRAIL Receptor Agonist ABBV-621, Trametinib, Trametinib Dimethyl Sulfoxide, Trans Sodium Crocetinate, Transdermal 17beta-Estradiol Gel BHR-200, Transdermal 4-Hydroxytestosterone, Transferrin Receptor-Targeted Anti-RRM2 siRNA CALAA-01, Transferrin Receptor-Targeted Liposomal p53 cDNA, Transferrin-CRM107, Tranylcypromine Sulfate, Trapoxin, Trastuzumab, Trastuzumab Conjugate BI-CON-02, Trastuzumab Deruxtecan, Trastuzumab Duocarmazine, Trastuzumab Emtansine, Trastuzumab Monomethyl Auristatin F, Trastuzumab-TLR 7/8 Agonist BDC-1001, Trastuzumab/Hyaluronidase-oysk, Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502, Trebananib, Tremelimumab, Treosulfan, Tretazicar, Tretinoin, Tretinoin Liposome, Triamcinolone Acetonide, Triamcinolone Hexacetonide, Triapine, Triazene Derivative CB10-277, Triazene Derivative TriN2755, Triazinate, Triaziquone, Tributyrin, Triciribine Phosphate, Trientine Hydrochloride, Triethylenemelamine, Trifluridine, Trifluridine and Tipiracil Hydrochloride, Trigriluzole, Trilaciclib, Trimelamol, Trimeric GITRL-Fc OMP-336B11, Trimethylcolchicinic Acid, Trimetrexate, Trimetrexate Glucuronate, Trioxifene, Triplatin Tetranitrate, Triptolide Analog, Triptorelin, Triptorelin Pamoate, Tris-acryl Gelatin Microspheres, Tritylcysteine, TRK Inhibitor AZD6918, TRK Inhibitor TQB3558, TrkA Inhibitor VMD-928, Trodusquemine, Trofosfamide, Troglitazone, Tropomyosin Receptor Kinase Inhibitor AZD7451, Troriluzole, Troxacitabine, Troxacitabine Nucleotide Prodrug MIV-818, TRPM8 Agonist D-3263, TRPV6 Calcium Channel Inhibitor SOR-C13, TSP-1 Mimetic ABT-510, TSP-1 Mimetic Fusion Protein CVX-045, Tubercidin, Tubulin Binding Agent TTI-237, Tubulin Inhibitor ALB 109564 Dihydrochloride, Tubulin Inhibitor ALB-109564, Tubulin Polymerization Inhibitor AEZS 112, Tubulin Polymerization Inhibitor CKD-516, Tubulin Polymerization Inhibitor VERU-111, Tubulin-Binding Agent SSR97225, Tucatinib, Tucidinostat, Tucotuzumab Celmoleukin, Tyroserleutide, Tyrosinase Peptide, Tyrosinase-KLH, Tyrosinase:146-156 Peptide, Tyrosine Kinase Inhibitor, Tyrosine Kinase Inhibitor OSI-930, Tyrosine Kinase Inhibitor SU5402, Tyrosine Kinase Inhibitor TL-895, Tyrosine Kinase Inhibitor XL228, UAE Inhibitor TAK-243, Ubenimex, Ubidecarenone Nanodispersion BPM31510n, Ublituximab, Ulinastatin, Ulixertinib, Ulocuplumab, Umbralisib, Uncaria tomentosa Extract, Upamostat, Upifitamab, Uproleselan, Uprosertib, Urabrelimab, Uracil Ointment, Urelumab, Uroacitides, Urokinase-Derived Peptide A6, Ursolic Acid, USP14/UCHL5 Inhibitor VLX1570, Utomilumab, Uzansertib, V930 Vaccine, Vaccine-Sensitized Draining Lymph Node Cells, Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules, Vactosertib, Vadacabtagene Leraleucel, Vadastuximab Talirine, Vadimezan, Valecobulin, Valemetostat, Valproic Acid, Valrubicin, Valspodar, Vandetanib, Vandetanib-eluting Radiopaque Bead BTG-002814, Vandortuzumab Vedotin, Vantictumab, Vanucizumab, Vapreotide, Varlilumab, Varlitinib, Varlitinib Tosylate, Vascular Disrupting Agent BNC105, Vascular Disrupting Agent BNC105P, Vascular Disrupting Agent ZD6126, Vatalanib, Vatalanib Succinate, Vecabrutinib, Vector-peptide Conjugated Paclitaxel, Vedolizumab, VEGF Inhibitor PTC299, VEGF/HGF-targeting DARPin MP0250, VEGFR Inhibitor KRN951, VEGFR-2 DNA Vaccine VXM01, VEGFR/FGFR Inhibitor ODM-203, VEGFR/PDGFR Tyrosine Kinase Inhibitor TAK-593, VEGFR2 Tyrosine Kinase Inhibitor PF-00337210, VEGFR2/PDGFR/c-Kit/Flt-3 Inhibitor SU014813, Veliparib, Veltuzumab, Vemurafenib, Venetoclax, Verapamil, Verpasep Caltespen, Verubulin, Verubulin Hydrochloride, Vesencumab, Vesigenurtucel-L, VGEF Mixed-Backbone Antisense Oligonucleotide GEM 220, VGEFR/c-kit/PDGFR Tyrosine Kinase Inhibitor XL820, Viagenpumatucel-L, Vibecotamab, Vibostolimab, Vilaprisan, Vinblastine, Vinblastine Sulfate, Vincristine, Vincristine Liposomal, Vincristine Sulfate, Vincristine Sulfate Liposome, Vindesine, Vinepidine, Vinflunine, Vinflunine Ditartrate, Vinfosiltine, Vinorelbine, Vinorelbine Tartrate, Vinorelbine Tartrate Emulsion, Vinorelbine Tartrate Oral, Vintafolide, Vinzolidine, Vinzolidine Sulfate, Virulizin, Vismodegib, Vistusertib, Vitamin D3 Analogue ILX23-7553, Vitamin E Compound, Vitespen, VLP-encapsulated TLR9 Agonist CMP-001, Vocimagene Amiretrorepvec, Vofatamab, Volasertib, Volociximab, Vonlerolizumab, Vopratelimab, Vorasidenib, Vorinostat, Vorolanib, Vorsetzumab Mafodotin, Vosaroxin, Vosilasarm, Voxtalisib, Vulinacimab, Warfarin Sodium, Wee1 Inhibitor ZN-c3, Wee1 Kinase Inhibitor Debio 0123, White Carrot, Wnt Signaling Inhibitor SM04755, Wnt Signaling Pathway Inhibitor SM08502, Wnt-5a Mimic Hexapeptide Foxy-5, Wobe-Mugos E, WT1 Peptide Vaccine OCV-501, WT1 Peptide Vaccine WT2725, WT1 Protein-derived Peptide Vaccine DSP-7888, WT1-A10/AS01B Immunotherapeutic GSK2130579A, WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401, Xanthohumol, XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410, Xeloda, Xentuzumab, Xevinapant, Xiaoai Jiedu Decoction, XIAP Antisense Oligonucleotide AEG35156, XIAP/cIAP1 Antagonist ASTX660, Xiliertinib, Xisomab 3G3, XPO1 Inhibitor SL-801, Y 90 Monoclonal Antibody CC49, Y 90 Monoclonal Antibody HMFG1, Y 90 Monoclonal Antibody Lym-1, Y 90 Monoclonal Antibody m170, Y 90 Monoclonal Antibody M195, Yang Yin Fu Zheng, Yangzheng Xiaoji Extract, Yiqi-yangyin-jiedu Herbal Decoction, Yttrium Y 90 Anti-CD19 Monoclonal Antibody BU12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12, Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8, Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101, Yttrium Y 90 Anti-CEA Monoclonal Antibody cT84.66, Yttrium Y 90 Basiliximab, Yttrium Y 90 Colloid, Yttrium Y 90 Daclizumab, Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A, Yttrium Y 90 Glass Microspheres, Yttrium Y 90 Monoclonal Antibody B3, Yttrium Y 90 Monoclonal Antibody BrE-3, Yttrium Y 90 Monoclonal Antibody Hu3S193, Yttrium Y 90 Monoclonal Antibody MN-14, Yttrium Y 90 Resin Microspheres, Yttrium Y 90 Tabituximab Barzuxetan, Yttrium Y 90-DOTA-Biotin, Yttrium Y 90-DOTA-di-HSG Peptide IMP-288, Yttrium Y 90-Edotreotide, Yttrium Y 90-labeled Anti-FZD10 Monoclonal Antibody OTSA101, Yttrium Y-90 Clivatuzumab Tetraxetan, Yttrium Y-90 Epratuzumab Tetraxetan, Yttrium Y-90 Ibritumomab Tiuxetan, Yttrium Y-90 Tacatuzumab Tetraxetan, Yttrium-90 Polycarbonate Brachytherapy Plaque, Z-Endoxifen Hydrochloride, Zalcitabine, Zalifrelimab, Zalutumumab, Zandelisib, Zanidatamab, Zanolimumab, Zanubrutinib, Zebularine, Zelavespib, Zibotentan, Zinc Finger Nuclease ZFN-603, Zinc Finger Nuclease ZFN-758, Zinostatin, Zinostatin Stimalamer, Zirconium Zr 89 Panitumumab, Ziv-Aflibercept, Zolbetuximab, Zoledronic Acid, Zoptarelin Doxorubicin, Zorifertinib, Zorubicin, Zorubicin Hydrochloride, Zotatifin, Zotiraciclib Citrate, Zuclomiphene Citrate, Unknown, Not Reported",,,CDE:13579886,,string_list,,,,,, Model Primary Diagnosis,"Text term used to describe the histologic diagnosis relevant to the model system, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).","Head and Neck Squamous Cell Carcinoma, Astroblastoma; Other; Other CNS Tumor; NOS Or NEC, Medulloblastoma; Hypercellular Lesion With Marked Atypia, Ependymoma; NOS; Posterior Fossa Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Neuroma; NOS, Precursor Cell Lymphoblastic Leukemia; NOS, Hypercellular Neuroepithelial Tumor With Some Features Of Glioma; Possibly High Grade, Acute Leukemia; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Papillary Glioneuronal Tumor, High-grade serous carcinoma, Myeloid Leukemia; NOS, Choriocarcinoma; NOS, Embryonal Carcinoma; NOS; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Giant Cell Tumor Of Bone; NOS, Adenocarcinoma; Intestinal Type, Not Specified In Data, Neoplasm; Uncertain Whether Benign Or Malignant; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ductal Carcinoma NOS, Renal Cell Carcinoma; NOS, B Lymphoblastic Leukemia/Lymphoma With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Myelodysplastic Syndrome; NOS, Low Grade Fibromyxoid Sarcoma, Benign Cystic Nephroma, Glial Neoplasm, Papillary Adenocarcinoma; NOS, Telangiectatic Osteosarcoma, Ganglioglioma; NOS; Malignant Peripheral Nerve Sheath Tumor; NOS, Central Neurocytoma, Giant Cell Tumor Of Soft Parts; NOS, Giant Cell Tumor Of Bone; Malignant, Sertoli-Leydig Cell Tumor; Poorly Differentiated, Glioma; Malignant; Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Acute Megakaryoblastic Leukemia, Germinoma; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Dysembryoplastic Neuroepithelial Tumor With Adjacent Cortical Dysplasia; WHO Grade 1, Supratentorial Ependymoma; NOS, Myxoid Liposarcoma, Acute Lymphoblastic Leukemia, Combined Small Cell-Squamous Cell Carcinoma, High Grade Spindle Cell Sarcoma, Medulloblastoma; Group 3 Subtype (WHO Grade 4), Acute Monocytic Leukemia, Neoplasm; NOS, Retinoblastoma; Grade 3, Yolk Sac Tumor; NOS; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Myofibroblastic Tumor; NOS, Sex Cord-Gonadal Stromal Tumor; Mixed Forms, Adamantinomatous Craniopharyngioma, Mesoblastic Nephroma, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Astrocytoma; NOS; High-Grade Glioma; Infant-Type Hemispheric Glioma, Rhabdomyosarcoma; NOS, Mucinous Adenocarcinoma; Endocervical Type, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ganglioglioma; NOS; Glioneuronal And Neuronal Tumors, Dermoid Cyst, Adenocarcinoma Combined With Other Types Of Carcinoma, Precursor Cell Lymphoblastic Lymphoma; NOS, Posterior Fossa Ependymoma; CNS WHO Grade 2, Pituitary Adenoma; NOS, Neoplasm; Malignant; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Sex Cord-Gonadal Stromal Tumor; Incompletely Differentiated, High Grade Follicular Derived Thyroid Carcinoma, Desmoplastic Fibroma, Perineuroma, Diffuse Midline Glioma; H3K27M-Mutant; CNS WHO Grade 4, Ganglioglioma, Pancreatobiliary-Type Carcinoma, Paratesticular Rhabdomyosarcoma With Diffuse Anaplasia, Hemangioblastoma, Colorectal Carcinoma, Acute Myelomonocytic Leukemia, Diffuse Midline Glioma; H3 K27-Altered, T-Lymphoblastic Lymphoma, Lymphangioma; NOS, Neoplasm; Benign, Papillary Intralymphatic Angioendothelioma, Ependymoma; NOS; Supratentorial Ependymoma; ZFTA Fusion-Positive, Unclassified Sarcoma With Round Cell Morphology, Glioma, Medulloblastoma; Classic (Biphasic) Histologic Type; Non-SHH/Non-WNT Molecular Group; CNS WHO Grade 4, Soft Tissue Sarcoma, Xanthogranuloma, Neoplasm; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Bronchio-Alveolar Carcinoma; Mucinous, Hepatocellular Carcinoma; Fibrolamellar, Pancreatic Neuroendocrine Tumor; Nonfunctioning, Myxopapillary Ependymoma, Chondrosarcoma; NOS, Favor Ganglioglioma, Papillary Tumor Of Pineal Region, Acute Myeloid Leukemia With Mutated NPM1, Epithelioid Hemangioendothelioma; NOS, Neuroblastoma; NOS, Chondroid Chordoma, Infiltrating Duct And Lobular Carcinoma, Mitotically Active Glial/ Glioneuronal Neoplasm, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, CPNET, Mycosis Fungoides; Langerhans Cell Histiocytosis; NOS, T-Lymphoblastic Leukemia, Medulloblastoma; NOS; Medulloblastoma; Non-WNT/Non-SHH, Clear Cell Meningioma; Meningioma; Other, Ameloblastic Carcinosarcoma, Dysembryoplastic Neuroepithelial Tumor; Glioneuronal And Neuronal Tumors, Meningothelial Meningioma, Epithelioid Cell Melanoma, Prostate Cancer, Paraganglioma; Malignant, Small Cell Sarcoma, Cystosarcoma Phyllodes; NOS, Seminoma; NOS, Yolk Sac Tumor; NOS, Intraductal Carcinoma NOS, Adenocarcinoma; Endocervical Type, Neurofibroma; NOS, Astroblastoma; Astroblastoma; MN1-Altered; High-Grade Glioma, Meningothelial Meningioma; Grade 1, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Unknown, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Sarcoma; Ewing Sarcoma, Glioma; Malignant; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Endometrioid Adenocarcinoma; NOS, Pancreas-Adenocarcinoma Ductal Type, Giant Cell Glioblastoma; Glioblastoma; IDH-Wildtype; High-Grade Glioma, Angiomyosarcoma, Carcinoid Tumor, Adenosquamous Carcinoma, Metastatic Neuroblastoma, Clear Cell Sarcoma Of Kidney, Infiltrating Duct Mixed With Other Types Of Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Embryonal Carcinoma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Neoplasm; Uncertain Whether Benign Or Malignant; CNS Germ Cell Tumors; CNS Germinoma, Astrocytoma; NOS; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Low Cumulative Sun Damage Melanoma, Supratentorial Ependymoma, Ossifying Fibromyxoid Tumor; NOS, Diffuse Large B-Cell Lymphoma; NOS, Adenocarcinoma With Neuroendocrine Differentiation, Atypical Meningioma, Pineoblastoma, Chronic Myeloid Leukemia; NOS, Atypical Choroid Plexus Papilloma, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFB, Pleomorphic Xanthoastrocytoma; NOS; High-Grade Glioma, Oxyphilic Adenocarcinoma, Favor Pilocytic Astrocytoma; CNS WHO Grade 1, Poorly Differentiated; Intermediate Mitotic-Karyorrhectic Index, Clear Cell Meningioma, Medulloblastoma; Classic Histologic Type; CNS WHO Grade 4, Appearances Consistent With Alveolar Soft Part Sarcoma, Dedifferentiated Liposarcoma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Tubular Adenocarcinoma, Rhabdomyosarcoma; Most Likely An Embryonal Carcinoma, Adenocarcinoma; NOS, Pleuropulmonary Blastoma, Basaloid Squamous Cell Carcinoma, Oligodendroglioma; Anaplastic; NOS, Pilocytic Astrocytoma; WHO Grade 1, Not Applicable, Abdominal Fibromatosis, Hamartoma, Neoplasm; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Choroid Plexus Papilloma; NOS; Choroid Plexus Tumors, Burkitt Lymphoma; NOS, Lymphoepithelial Carcinoma, Bronchiolo-Alveolar Carcinoma; Non-Mucinous, Kidney Clear Cell Renal Carcinoma, Pilocytic Astrocytoma; Low-Grade Glioma, Adenocarcinoma In Situ In Adenomatous Polyp, Neoplasm; Uncertain Whether Benign Or Malignant, Small Blue Cell Tumor. Favor Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma; NOS, Embryonal Tumor With Multi-Layered Rosettes, Chronic Eosinophilic Leukemia, Mixed Glioma, Basal Cell Adenocarcinoma, Olfactory Neuroblastoma, Transitional Cell Carcinoma; NOS, Clear Cell Sarcoma; NOS, Embryonal Rhabdomyosarcoma; High-Grade, Angiocentric Glioma, Diffuse Midline Glioma; H3 K27 Altered; WHO Grade 4, Osteoblastoma; NOS, Malignant Neoplasm With Rhabdomyoblastic Differentiation; High Grade, Myxopapillary Ependymoma (CNS WHO Grade II), Melanoma In Situ, Secretory Carcinoma, Pilocytic Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Rhabdomyosarcoma; Favor Alveolar Type, Adenocarcinoma; Metastatic NOS, Fibrosarcoma; NOS, Glioblastoma, Atypical Choroid Plexus Papilloma; Choroid Plexus Tumors, Ganglioneuroma; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Desmoplastic Melanoma; NOS, Choroid Plexus Carcinoma, Soft Tissue Tumor; Benign, Medulloblastoma; NOS, Glioblastoma; NOS; Medulloblastoma; NOS, Residual Astrocytoma, B Lymphoblastic Leukemia/Lymphoma With T(V;11q23); MLL Rearranged, Extra Adrenal Paraganglioma, Mucoepidermoid Carcinoma, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Choroid Plexus Papilloma; NOS, Glioma; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, B-Lymphoblastic Leukemia/Lymphoma; NOS, Hodgkin Lymphoma; Nodular Sclerosis; NOS, Fibroma, Craniopharyngioma; NOS; Adamantinomatous Craniopharyngioma, T-Cell/Histiocyte Rich Large B-Cell Lymphoma, Astrocytoma; IDH-Mutant; CNS WHO Grade 4, Acute Erythroid Leukemia, Glioma; Histologically Low Grade, Mucous Adenocarcinoma, Glioma; Malignant; Ganglioglioma; Glioneuronal And Neuronal Tumors, Nodular Melanoma, Synovial Sarcoma; Biphasic, Neoplasm; Metastatic, Neoplasm; Uncertain Whether Benign Or Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Thymoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Ependymoma; Posterior Fossa Ependymoma; Group PFA, Desmoplastic/Nodular Medulloblastoma, Papillary Glioneuronal Tumor, Mixed Phenotype Acute Leukemia; T/Myeloid; NOS, Cholangiocarcinoma, Astroblastoma; MN1-Altered. Histologically High-Grade, Sertoli-Leydig Cell Tumor; Poorly Differentiated; With Heterologous Elements, Glioma; Malignant; High-Grade Glioma; Infant-Type Hemispheric Glioma, Juvenile Myelomonocytic Leukemia; NOS, Embryonal Neoplasm With INI-1 Loss By Immunohistochemistry, Myeloid Leukemia With Myelodysplasia-Related Changes, Primary Cutaneous Follicle Center Lymphoma, Choroid Plexus Carcinoma; WHO Grade 3, Infiltrating Duct Carcinoma NOS, T Lymphoblastic Leukemia/Lymphoma, Glioma; Malignant; Other; Other CNS Tumor; NOS Or NEC, Mixed Germ Cell Tumor; Myelodysplastic Syndrome With Excess Blasts, Clear Cell Adenocarcinoma; NOS, Cutaneous T-Cell Lymphoma; NOS, Germinoma, Neoplasm; Malignant; ATRT; NOS Or NEC; Atypical Teratoid/Rhabdoid Tumor, Meningeal Melanocytoma, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Acute Promyelocytic Leukemia; T(15;17)(Q22;Q11-12), Alveolar Soft Part Sarcoma, Astrocytoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Mixed Epithelioid And Spindle Cell Melanoma, CNS Embryonal Tumor; NOS; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Malignant Tumor; Spindle Cell Type, Glioma; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Glioma; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Endometrioid Carcinoma; NOS, Lung Squamous Cell Carcinoma; NOS, Papillary Urothelial Carcinoma; Non-Invasive, Neuroblastoma; Undifferentiated Type, Periosteal Osteosarcoma, Mixed Phenotype Acute Leukemia; B/Myeloid; NOS, Inflammatory Carcinoma, Glioblastoma; NOS, Carcinoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Squamous Cell Carcinoma; NOS, Hypocellular Low Grade Lesion, Glioblastoma Multiforme, Pancreas-Undifferentiated Carcinoma, Differentiating Neuroblastoma, Myxoid Spindle Cell Tumor, Merkel Cell Tumor, Malignant Peripheral Nerve Sheath Tumor; NOS; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Hemangioma; NOS, Acute Myeloid Leukemia With Abnormal Marrow Eosinophils, Well Differentiated Neuroendocrince Tumor; Grade 1, Ganglioglioma; Anaplastic, Ependymoma WHO Grade 2, Synovial Sarcoma; NOS, Thymic Carcinoma; NOS, Tumor Cells; Malignant, Pilomyxoid Astrocytoma, Papillary Carcinoma; Columnar Cell, Plexiform Fibrohistiocytic Tumor, Astrocytoma; NOS; Angiocentric Glioma; Low-Grade Glioma, Carcinoma; Undifferentiated; NOS, Dermatofibrosarcoma Protuberans; NOS, High Grade Glioma With Necrosis; WHO Grade 4, Infiltrating ductular carcinoma, Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Juvenile Myelomonocytic Leukemia; NOS, Infiltrating Duct And Mucinous Carcinoma, Intraductal Papillary Carcinoma, Serous Surface Papillary Carcinoma, Invasive Carcinoma, High Grade Malignant Epithelioid Neoplasm, Favor Pilocytic Astrocytoma With Increased Proliferation Indices, Medulloblastoma; Classic Morphology; CNS WHO Grade 4; NON-WNT/NON-SHH; Group 4 Subtype By Methylation, Composite Hodgkin And Non-Hodgkin Lymphoma, Atypical Teratoid/Rhabdoid Tumor; ATRT; NOS Or NEC, Atypical Teratoid/Rhabdoid Tumor; ATRT-TYR, Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorder, Hemangioendothelioma; NOS, Hypercellular Lesion With Atypia, Embryonal Carcinoma; NOS, Subependymoma; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Germ Cell Tumor; Nonseminomatous, Adrenal Cortical Carcinoma, Olfactory Neurocytoma, Large Cell Medulloblastoma; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Nuclear Protein In Testis (NUT)-Associated Carcinoma, Epithelial-Myoepithelial Carcinoma, Squamous Cell Carcinoma; Keratinizing; NOS, Ganglioneuroma; Other; Schwannoma, Glomus Tumor; Malignant, Neoplasm; Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Malignant Lymphoma; Non-Hodgkin; NOS, Embryonal Rhabdomyosarcoma; NOS; CNS Embryonal Tumor; NOS, Tenosynovial Giant Cell Tumor; NOS, Histologically Low-Grade Glioma, Chordoma; NOS; Ganglioneuroblastoma, Ependymoma; NOS, Invasive Mammary Carcinoma, Rhabdoid Tumor; Malignant, Medulloblastoma; Classic Histology, Adenocarcinoma In Villous Adenoma, Undifferentiated Sarcoma, Papillary Thyroid Carcinoma, Renal Cell Adenocarcinoma, Hodgkin Lymphoma; NOS, Malignant Histiocytosis, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Solid Pseudopapillary Tumor Of Ovary, Astrocytic Glioma; Histologically Low-Grade; Most Compatible With Pilocytic Astrocytoma, Inflammatory Myofibroblastic Tumor With An Associated Odontogenic Keratocyst, Myofibromatosis, Small Round Blue Cell Tumor, Meningioma; Atypical; CNS WHO Grade 2, Neoplasm; Uncertain Whether Benign Or Malignant; Adamantinomatous Craniopharyngioma; Craniopharyngioma, Pilocytic Astrocytoma, Lobular And Ductal Carcinoma, Desmoplastic/Nodular Medulloblastoma (Histologically Defined); CNS WHO Grade 4, Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation, Tumor Cells; Malignant; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Malignant Tumor, Brain Tumor, Gastrointestinal Stromal Tumor; Benign, Rasmussen Encephalitis, Medulloblastoma; NOS; Diffuse Hemispheric Glioma; H3 G34-Mutant; High-Grade Glioma, Adenocarcinoma;NOS; Glioblastoma; NOS, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Embryonal Sarcoma, Neoplasm; Malignant; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Anaplastic Large Cell Lymphoma; T-Cell And Null-Cell Type, Teratoma; NOS, Pleomorphic Xanthoastrocytoma; NOS, Infiltrating duct and lobular carcinoma, Sclerosing Stromal Tumor, Tumor Cells; Uncertain Whether Benign Or Malignant, Acute Myeloid Leukemia; NOS; Juvenile Myelomonocytic Leukemia; NOS, Lobular Carcinoma; NOS, Schwannoma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Sarcoma; NOS, CNS Embryonal Tumor With Rhabdoid Features, Glial Neoplasm; Astrocytoma, Pancreas-Adenosquamous Carcinoma, Mesenchymal Lesion, Serous Adenocarcinoma; NOS, Hepatoblastoma; NOS, Astrocytoma; NOS; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Sex Cord-Gonadal Stromal Tumor; NOS, Adenoid Cystic Carcinoma, Embryonal Tumor, Acute Myeloid Leukemia; T(8;21)(Q22;Q22), Spindled And Epithelioid Tumor With Features Of Intracranial Mesenchymal Tumor, Cavernoma, Malignant Tumor; Small Cell Type, Mixed Germ Cell Tumor; CNS Germ Cell Tumors; CNS Germinoma, Low Grade Neoplasm. Features Suggestive Of Pilocytic Astrocytoma., Neoplasm; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Serous Carcinoma; NOS, Metastatic Secondary Tumors, Yolk Sac Tumor, Morphologically Consistent With Pilocytic Astrocytoma; WHO Grade 1, Neuroendocrine Tumor; NOS, Mixed Germ Cell Tumor; Acute Megakaryoblastic Leukemia, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia With T(9;11)(P22;Q23); MLLT3-MLL, Glioma; Malignant; High-Grade Glioma; Pleomorphic Xanthoastrocytoma, Papillary Glioneuronal Tumor; WHO Grade 1, Central Neuroblastoma, Dysembryoplastic Neuroepithelial Tumor, Mixed Adenocarcinoma And Squamous Cell Carcinoma; Pancreatobiliary-Type Carcinoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Myofibroblastic Tumor, Nephroblastoma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; SHH-Activated And TP53-Wildtype, Malignant Melanoma; NOS; Meningeal Melanocytic Neoplasms (Includes Melanoma); Other, Carcinoma; Metastatic; NOS, Follicular Carcinoma; Minimally Invasive, Angiomyofibroblastoma, Classic Medulloblastoma; CNS WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Atypical Teratoid/Rhabdoid Tumor; ATRT-MYC, Astroblastoma, Meningothelial Meningioma; Meningioma; Other, Poorly Differentiated Chordoma, Chronic Myelogenous Leukemia, Pleomorphic Sarcoma, Supratentorial Ependymoma CNS WHO Grade 3, Leydig Cell Tumor; NOS, Adenosarcoma, Pigmented Dermatofibrosarcoma Protuberans, Astrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Astrocytoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Astrocytoma; NOS; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Myxofibrosarcoma, Precursor T-Cell Lymphoblastic Leukemia, Neurocytoma, Adrenal Cortical Tumor; NOS, Neoplasm; Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Acute Myeloid Leukemia (Megakaryoblastic) With T(1;22)(P13;Q13); RBM15-MKL1, Neoplasm; Malignant; CNS Neuroblastoma; FOXR2-Activated; Other CNS Embryonal Tumors, Infiltrating duct and mucinous carcinoma, Adenocarcinoma In Situ; NOS, Mucinous Adenocarcinoma, Retinoblastoma; NOS, Anaplastic Ependymoma, Germ Cell Tumor; Nonseminomatous; CNS Germ Cell Tumors; CNS Non-Germinomatous Germ Cell Tumor, Acute Monoblastic And Monocytic Leukemia, Hemangioblastoma; CNS WHO Grade 1, Alveolar Rhabdomyosarcoma, Medullary Carcinoma; NOS, Adult Granulosa Cell Tumor Of Testis, Medulloblastoma; WHO Grade 4, Craniopharyngioma; Adamantinomatous, High Grade Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomyoblastic Differentiation (Malignant Triton Tumor), Spindle Cell Rhabdomyosaroma, Diffuse Midline Glioma; H3 K27M-Mutant, Epithelioid Sarcoma; NOS, Myoepithelial Carcinoma, Multiple Myeloma, Triple-Negative Breast Carcinoma, Hepatocellular Carcinoma; NOS; Nephroblastoma; NOS, Neuroblastoma; Schwannian Stroma Poor; Poorly Differentiated; Low MKI; Favorable Histology, Sertoli Cell Tumor; NOS, Ossifying Fibroma, Pleomorphic Liposarcoma, Amelanotic Melanoma, Liposarcoma; NOS, Non-Germinomatous Germ Cell Tumor, Lactotroph Adenoma, Transient Abnormal Myelopoiesis, Favor Posterior Fossa Ependymoma; WHO GRADE 3, Dysembryoplastic Neuroepithelial Tumor; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Carcinoma In Situ; NOS, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Ependymoma; Anaplastic, Glial Neoplasm; Favor Pilocytic Astrocytoma, Gastrointestinal Stromal Tumor; NOS, Serous Cystadenocarcinoma; NOS, Papillary Lesion With Atypical/High Grade Features, Spinal Ependymoma; WHO Grade 2, Ductal Carcinoma In Situ; NOS, Infiltrating Ductal Carcinoma, Mixed Type Rhabdomyosarcoma, Medulloblastoma; SHH-Activated And TP53-Mutant, Precursor B-Cell Acute Lymphoblastic Leukemia With Hyperdiploidy, Mesenchymal Chondrosarcoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Cribriform Carcinoma; NOS, Myxopapillary Ependymoma; Anaplastic, Ependymoma; Anaplastic; Supratentorial Ependymoma; NOS Or NEC, Astrocytoma; IDH-Mutant; WHO Grade 2, Meningioangiomatosis, Acute Myeloid Leukemia; NOS; Myeloproliferative Neoplasm; Unclassifiable, Endometrioid carcinoma; NOS, Adenocarcinoma In Situ; Non-Mucinous, Medulloblastoma; NOS; Medulloblastoma; Group 4, Papillary Carcinoma; Follicular Variant, Metaplastic Carcinoma; NOS, Choroid Plexus Carcinoma; Choroid Plexus Tumors, Poorly Differentiated Sertoli-Leydig Cell Tumor With Heterologous Rhabdomyosarcomatous Differentiation, Low Grade Glioma, Sex Cord Stromal Tumor NOS, Stroma Poor; Poorly Differentiated Neuroblastoma With Low MKI; Favorable Histology, Residual Low Grade Neuroendocrine Tumor (Typical Carcinoid), Melanotic Neuroectodermal Tumor, Ependymoma; NOS; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Angiocentric Glioma; Low-Grade Glioma, Malignant Lymphoma; NOS, Medulloblastoma WHO Grade 4, Choroid Plexus Papillary Tumor, Follicular Adenocarcinoma; Well Differentiated; Neuroblastoma; NOS, Neuroepithelial Tumor, Myelodysplastic Syndrome With Multilineage Dysplasia, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Mast Cell Leukemia, Ganglioneuroblastoma, Pheochromocytoma; NOS, Papillary Serous Adenocarcinoma, Mixed Germ Cell Tumor, Lymphoid Leukemia; NOS, Ependymoma NOS, Smooth Muscle Tumor Of Uncertain Malignant Potential, Combined Small Cell-Large Carcinoma, Sertoli Leydig Cell Tumor, Anaplastic Large Cell Lymphoma; ALK Positive, Meningioma; Malignant, Rhabdoid Tumor; NOS, Merkel Cell Carcinoma, Neoplasm; Uncertain Whether Benign Or Malignant; Meningioma; Other, Lymphoma; NOS, Gangliocytoma; NOS, Glioblastoma; NOS; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Mucinous Non-Cystic Carcinoma, Mucinous Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Pilocytic Astrocytoma, Ganglioglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, High Grade Carcinosarcoma, Subependymal Giant Cell Astrocytoma; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Squamous Cell Carcinoma; Metastatic; NOS, Myeloid Leukemia Associated With Down Syndrome, Meningeal Melanomatosis, Neuroepithelial Tumor With Glioneuronal-Like Features, Squamous Cell Carcinoma; Large Cell; Nonkeratinizing; NOS, Meningiomatosis; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Oligodendroglioma; NOS; Low-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Ependymoma; NOS; Posterior Fossa Ependymoma; Group PFA, CNS Embryonal Tumor; NOS, Favor Anaplastic Ependymoma, Diffuse Glioma, Adamantinomatous Craniopharyngioma (CNS WHO Grade 1), Medulloblastoma; Classic Variant; WHO Grade 4, Neoplasm; Uncertain Whether Benign Or Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Glioneuronal Tumor With Focal Increased Atypia, High Grade Neuroepithelial Tumor, Squamous Cell Carcinoma; Small Cell; Nonkeratinizing, Mixed Phenotype Acute Leukemia With T(V;11q23); MLL Rearranged, Acute Myeloid Leukemia; Minimal Differentiation, Fibrillary Astrocytoma, Chordoma; NOS, Undifferentiated Leukemia, Myofibroma, Neoplasm; Malignant, Pleomorphic Xanthoastrocytoma; NOS; Low-Grade Glioma, Invasive Ductal Carcinoma, Subependymal Giant Cell Astrocytoma, Embryonal Rhabdomyosarcoma With Anaplastic Features, High-Grade Neuroepithelial Tumor, Low Grade Glioneuronal Tumor, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Acute Myeloid Leukemia Without Maturation, Adenocarcinoma With Mixed Subtypes, B Lymphoblastic Leukemia/Lymphoma With Hyperdiploidy, Malignant Peripheral Nerve Sheath Tumor; NOS, Hemangiosarcoma, Paraganglioma; NOS, Medulloblastoma; Nodular/Desmoplastic With Anaplastic/Large Cell Features; Non-WNT/Non-SHH; WHO Grade 4, Signet Ring Cell Carcinoma, Spindle Cell Melanoma; NOS, Lobular Adenocarcinoma, Undiagnosed Spindle Cell Tumor, Pilocytic Astrocytoma; WHO Grade 1; KIAA1549-BRAF Fusion, Meningioma, Hepatosplenic T-Cell Lymphoma; Precursor Cell Lymphoblastic Leukemia; NOS, Mesenchymal Chondrosarcoma, Anaplastic Ganglioglioma, Osteosarcoma; NOS, Oligoastrocytoma; NOS; Glioneuronal And Neuronal Tumors; Glioneuronal And Neuronal Tumors; NOS Or NEC, Ependymoma WHO Grade 3, Lung Adenocarcinoma; NOS, Lymphoproliferative Disorder; NOS, Atypical Lymphoid Infiltrate, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Wildtype, Genital Rhabdomyoma, Chondroblastic Osteosarcoma, Neuroepithelioma; NOS, Malignant Epithelioid And Myxoid Neoplasm, Pancreatoblastoma, Nephroblastoma (Wilms Tumor), Malignant Glioma, Ewing Sarcoma, Atypical Smooth Muscle Neoplasm, Acute Myelomonocytic Leukemia; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Epithelial Tumor; Benign, Favor Teratoma, Malignant Neoplasm Of Prostate, Non-Clear Cell Renal Cell Carcinoma, Meningioma; NOS; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Melanotic Schwannoma; Other, Medulloblastoma; NOS; Medulloblastoma; WNT-Activated, Carcinosarcoma NOS, Plasmacytoma; Extramedullary, Infantile Fibrosarcoma, Glioma; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, CNS Primative Neuroectodermal Tumor (PNET), Infiltrating duct carcinoma; NOS, Precursor B-Cell Lymphoblastic Leukemia, Squamous Cell Carcinoma In Situ; NOS, Acute Myeloid Leukemia; T(16;16)(P 13;Q 11), Papillary Transitional Cell Carcinoma, Atypical Teratoid/Rhabdoid Tumor, Low-Grade Glioneuronal; Neuronal Tumor, Combined Small Cell-Adenocarcinoma, Hepatocellular Carcinoma; NOS, Spindle Cell Carcinoma; NOS, Carcinoma; Diffuse Type, Lentiginous Melanocytic Nevus, Glioma; Malignant; Embryonal Tumor With Multilayered Rosettes; C19MC Altered; Other CNS Embryonal Tumors, Solitary Fibrous Tumor; NOS, Glioma; Malignant; Medulloblastoma; Medulloblastoma; Non-WNT/Non-SHH, Granulosa Cell Tumor; Malignant, Ganglioneuroma; Maturing Type; Favorable Histology, Invasive Lobular Carcinoma, Ganglioglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Bland Myofibroblastic Proliferation With Associated Florid Lymphoplasmacytic Inflammation, Medulloblastoma, Hepatoblastoma, Low Grade Glial/ Glioneuronal Tumor, Atypical Teratoid Rhabdoid Tumor; CNS WHO Grade 4, Oligoastrocytoma; NOS; Other; Other CNS Tumor; NOS Or NEC, Diffuse Glioma; Favor High Grade, Reactive Connective Tissue, Medulloblastoma; NOS; Medulloblastoma; SHH-Activated And TP53-Mutant, Tumor Cells; Malignant; Medulloblastoma; Medulloblastoma; NOS Or NEC, Glioma; Malignant; Malignant Peripheral Nerve Sheath Tumor; NOS, Melanoma; NOS, Malignant Melanocytic Neoplasm, Chronic Myelogenous Leukemia; BCR/ABL Positive, Vascular Lesion; Consistent With Hemangioma, Small Cell Neuroendocrine Carcinoma, Medullary Carcinoma, Anaplastic Astrocytoma; IDH-Wildtype; Glioblastoma; IDH Wildtype, Rhabdomyosarcoma; Embryonal Subtype, Medulloblastoma By Morphology; NON-WNT By Immunohistochemistry, Glioma; Malignant; Astrocytoma; IDH-Mutant; High-Grade Glioma, Ganglioglioma; NOS, Dysembryoplastic Neuroepithelial Tumor; Angiocentric Glioma; Low-Grade Glioma, Neoplasm; Uncertain Whether Benign Or Malignant; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Angiomatoid Fibrous Histiocytoma, Micropapillary Carcinoma; NOS, Infiltrating Lobular Carcinoma; NOS, Gastrointestinal Stromal Tumor, Desmoplastic Nodular Medulloblastoma; Medulloblastoma; Medulloblastoma; Group 4, Craniopharyngioma, Sertoli-Leydig Cell Tumor; Intermediate Differentiation; With Heterologous Elements, Acute Myeloid Leukemia; Inv(16)(P13;Q22), Subependymoma, Gliomatosis Cerebri, Infiltrating lobular carcinoma; NOS, Schwannoma; NOS, Oligodendroglioma; NOS; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dysplasia, Malignant Rhabdoid Tumor, Blue Nevus; Malignant, Adenocarcinoma; Pancreatobiliary Type, Ependymoma; NOS; Choroid Plexus Tumors; Choroid Plexus Papilloma, Ganglioneuroblastoma; Nodular Type, Granulosa Cell Tumor; Juvenile, Juvenile Granulosa Cell Tumor, Chronic Myeloid Leukemia; BCR-ABL1-Positive, Head & Neck Squamous Cell Carcinoma, Astrocytoma; NOS; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Medulloblastoma; SHH-Activated And TP53-Wildtype, Ganglioglioma; NOS; Ependymoma; Supratentorial Ependymoma; NOS Or NEC, Intraductal Papillary Mucinous Neoplasm With An Associated Invasive Carcinoma, Adrenal Cortical Adenoma; NOS, Adenocarcinoma; Pancreatobiliary Type; Pancreatobiliary-Type Carcinoma, Lipoblastomatosis, Central Neurocytoma; Glioneuronal And Neuronal Tumors, Control, HHV8 Positive Diffuse Large B-Cell Lymphoma, Pilocytic Astrocytoma; Low-Grade Glioma; Pleomorphic Xanthoastrocytoma, Neoplasm; Uncertain Whether Benign Or Malignant; Medulloblastoma; Medulloblastoma; Group 4, Large Cell Medulloblastoma, B Lymphoblastic Leukemia/Lymphoma With T(12;21)(P13;Q22); TEL-AML1 (ETV6-RUNX1), Central Osteosarcoma; NOS, Chordoma, Pilocytic Astrocytoma; Diffuse Leptomeningeal Glioneuronal Tumor; Glioneuronal And Neuronal Tumors, Pilocytic Astrocytoma; Low-Grade Glioma; Low-Grade Glioma; NOS Or NEC, Dermatofibrosarcoma Protuberans; Fibrosarcomatous, Neuroendocrine Carcinoma; NOS, Glioma; Malignant; Diffuse Pediatric-Type High-Grade Glioma; H3-Wildtype And IDH-Wildtype; High-Grade Glioma, Oligodendroglioma; NOS, Acute Monoblastic Leukemia, Glioma; Malignant; Low-Grade Glioma; Polymorphous Low-Grade Neuroepithelial Tumor Of The Young, Neoplasm, Medulloepithelioma; NOS, Oligodendroglioma; NOS; High-Grade Glioma; Oligodendroglioma; IDH-Mutant; And 1p/19q-Codeleted, Not Reported, Aggressive Fibromatosis, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Langerhans Cell Histiocytosis; Disseminated, Glioma; Malignant; Low-Grade Glioma; Pilocytic Astrocytoma, Oligoastrocytoma; NOS, Undifferentiated Nasopharyngeal Carcinoma, Small Cell Carcinoma; NOS, Chordoma; NOS; Chordoma (Including Poorly Differentiated Chordoma); Other, Mesothelioma; Biphasic; Malignant; B Lymphoblastic Leukemia/Lymphoma; NOS, Central Neurocytoma; Low-Grade Glioma; Subependymal Giant Cell Astrocytoma, Undifferentiated Small Round Cell Sarcoma, Rhabdomyoma; NOS, Glioblastoma; IDH Wildtype, Neoplasm; Malignant; Astrocytoma; IDH-Mutant; Low-Grade Glioma, Therapy Related Myeloid Neoplasm, Acute Myeloid Leukemia; NOS, Malignant Tumor; Spindle Cell Type; CNS Sarcoma; CNS Sarcoma; NOS Or NEC, Leydig Cell Tumor; Benign, Myelodysplastic Syndrome With Single Lineage Dysplasia, Germinoma; CNS Germ Cell Tumors; CNS Germinoma, Glial Tumor, Synovial Sarcoma; Spindle Cell, Spindle Cell Melanoma; Type B, Familial Adenomatous Polyposis, Giant Cell Glioblastoma, Teratocarcinoma, Adenoma; NOS, Acral Lentiginous Melanoma; Malignant, Carcinoma NOS, Papillary Carcinoma; NOS, Poorly Differentiated Neuroblastoma, Solid Pseudopapillary Neoplasm Of Pancreas, Nasopharyngeal Carcinoma, Adenocarcinoma In Adenomatous Polyposis Coli, Leiomyoma; NOS, Embryonal Rhabdomyosarcoma; NOS, Choroid Plexus Papilloma; NOS; Other CNS Embryonal Tumors; Pineoblastoma, Tumor Cells; Benign, Marginal Zone B-Cell Lymphoma; NOS, Tumor Cells; Malignant; Other; Pineal Parenchymal Tumor Of Intermediate Differentiation, Pinealoma, Atypical Teratoid/Rhabdoid Tumor; INI1/SMARCB1-Altered; WHO Grade 4, Metastatic Signet Ring Cell Carcinoma, Astrocytoma, Desmoplastic Infantile Astrocytoma, Malignant Sarcoma With DICER1 Mutation; Favor Primary Intracranial Sarcoma; DICER1 Mutant, B Lymphoblastic Leukemia/Lymphoma With Hypodiploidy, Colon Adenocarcinoma, Ependymoma; NOS; Supratentorial Ependymoma; NOS Or NEC, Proliferative Dermal Lesion In Congenital Nevus, Neoplasm; Malignant; Medulloblastoma; Medulloblastoma; WNT-Activated, Arteriovenous Malformation, Glioma; Malignant, Acinar Cell Carcinoma, Spinal Ependymoma; Histologically Low Grade (CNS WHO Grade 2), Leukemia; NOS, Hemangioblastoma; Other, High-Grade Serous Carcinoma, Medulloblastoma; NOS; Medulloblastoma; Group 3, Schwannian Stroma Poor Peripheral Neuroblastic Tumor; Consistent With Neuroblastoma, Acute Myeloid Leukemia With Mutated CEBPA, Parosteal Osteosarcoma, Epithelioid Mesothelioma; Malignant, Meningioma; NOS, Neoplasm; Uncertain Whether Benign Or Malignant; ATRT-SHH; Atypical Teratoid/Rhabdoid Tumor, Choriocarcinoma Combined With Other Germ Cell Elements, Brain Tumor; Low Grade Glioma, Ganglioglioma; NOS; Diffuse Astrocytoma; MYB- Or MYBL1-Altered; Low-Grade Glioma, Embryonal Tumor With Multilayered Rosettes C19MC-Altered, Neoplasm; Malignant; Uncertain Whether Primary Or Metastatic, Desmoplastic Small Round Cell Tumor, Embryonal Rhabdomyosarcoma, Langerhans Cell Histiocytosis, Glial Neoplasm Showing High-Grade Features, Oligodendroglioma, Malignant Melanoma; NOS, Myxopapillary Ependymoma; Ependymoma, Medulloblastoma; NOS; Medulloblastoma; NOS Or NEC, Neoplasm; Malignant; CNS Embryonal Tumor; NOS Or NEC; Other CNS Embryonal Tumors, Adenocarcinoma, B Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34;Q11.2); BCR-ABL1, Hemangioendothelioma; Malignant, Choroid Plexus Neoplasm, Craniopharyngioma; Adamantinomatous; Adamantinomatous Craniopharyngioma, Pinealoblastoma, Large Cell Medulloblastoma; Embryonal Tumor With Multilayered Rosettes; NOS; Other CNS Embryonal Tumors, Spindle Cell Sarcoma, Gliosarcoma, Central Primitive Neuroectodermal Tumor, Astrocytoma; IDH-Mutant; CNS WHO Grade 3, Astrocytoma; Benign, Pleomorphic Rhabdomyosarcoma; Adult Type, Myeloid Sarcoma, Glioma; Malignant; Other; Other Low-Grade B-Cell Lymphomas Of The CNS, Ganglioneuroma, Neoplasm; Malignant; High-Grade Glioma; High-Grade Glioma; NOS Or NEC, Clear Cell Renal Cell Carcinoma, Ependymoma; NOS; Atypical Meningioma, Oligodendroglioma; NOS; Other; Other CNS Tumor; NOS Or NEC, Malignant Peripheral Nerve Sheath Tumor, Glioma; Malignant; Diffuse Midline Glioma; H3 K27-Altered; High-Grade Glioma, Sertoli-Leydig Cell Tumor Of Intermediate Differentiation; NOS, Desmoplastic Nodular Medulloblastoma, Papillary Microcarcinoma, Craniopharyngioma; NOS, Low Grade Glial Neoplasm, Leiomyosarcoma; NOS, Follicular Adenocarcinoma; NOS",,True,CDE:14714127,,string,,,,,, Model Site of Origin,The text term used to describe the anatomic site of origin associated with the malignant disease model.,"Abdominal Aorta, Abdominal Esophagus, Abdominal Muscle, Abdominal Skin, Abdominal Wall, Abducens Nerve, Accessory Nerve, Acetabulum, Acromioclavicular Joint, Adipose Tissue, Adrenal Cortex, Adrenal Gland, Adrenal Medulla, Ampulla of Vater, Anal Canal, Anal Transitional Zone, Ankle Joint, Ankle Skin, Antecubital Region, Anterior Cranial Fossa, Anterior Mediastinum, Anterior Surface of the Epiglottis, Anterior Wall of the Bladder, Anterior Wall of the Nasopharynx, Antrum Pylori, Anus, Aorta, Aortocaval Lymph Node, Apex of the Tongue, Aponeurosis, Appendage of the Uterus, Appendix, Areola, Arm Skin, Artery, Articular Cartilage, Aryepiglottic Fold, Arytenoid Cartilage, Ascending Colon, Autonomic Nervous System, Axilla, Axillary Artery, Axillary Lymph Node, Axillary Tail of the Breast, Back, Bartholin Gland, Basal Ganglia, Base of the Tongue, Biceps, Biceps Femoris, Bile Canaliculus, Bile Duct, Biliary Tract, Bladder, Bladder Neck, Bladder Trigone, Blood, Blood Vessel, Body of Stomach, Body of the Pancreas, Body of the Penis, Bone, Bone Marrow, Bone of the Extremity, Brachial Lymph Node, Brachial Plexus, Brachialis, Brain, Brain Dura Mater, Brain Stem, Brain Ventricle, Branchial Cleft Remnant, Breast, Broad Ligament, Bronchial Lymph Node, Bronchiole, Bronchus, Buccal Mucosa, Buttock, C1 Vertebra, C2 Vertebra, Calcaneum, Calf, Cardiac Atrium, Cardiac Ventricle, Carina, Carotid Artery, Carotid Body, Carpal Bone, Carpal Region, Cartilage, Cauda Equina, Cecum, Celiac Artery, Celiac Lymph Node, Central Nervous System, Central Portion of the Breast, Cerebellopontine Angle, Cerebellum, Cerebral Cortex, Cerebral Hemisphere, Cerebral Meninges, Cerebral Peduncle, Cerebral White Matter, Ceruminous Gland, Cervical Esophagus, Cervical Gland, Cervical Lymph Node, Cervix Uteri, Cheek, Chest, Chest Wall, Choroid, Choroid Plexus, Choroid Plexus of the Fourth Ventricle, Choroid Plexus of the Lateral Ventricle, Choroid Plexus of the Third Ventricle, Ciliary Body, Clitoris, Coccyx, Cochlear Nerve, Colon, Commissure of the Lip, Common Bile Duct, Concha, Conjunctiva, Connective Tissue, Conus Medullaris, Coracobrachialis, Cornea, Corneoscleral Limbus, Corpus Callosum, Corpus Striatum, Corpus Uteri, Costal Cartilage, Costovertebral Joint, Cowper Gland, Cranial Nerve, Craniopharyngeal Duct, Cricoid Cartilage, Cul-de-sac, Cuneiform Cartilage, Cystic Duct, Descending Colon, Diaphragm, Diaphragmatic Lymph Node, Dome of the Bladder, Duct of Gartner, Ductus Santorini, Duodenum, Dura Mater, Ear, Ear Skin, Ectocervix, Elbow Joint, Elbow Skin, Endocardium, Endocervix, Endocrine Gland, Endometrial Stroma, Endometrium, Ependyma, Epicardium, Epididymis, Epidural Spinal Canal Space, Epiglottis, Epitrochlear Lymph Node, Esophagus, Ethmoid Bone, Ethmoid Sinus, Eustachian Tube, External Acoustic Meatus, External Ear, External Lip, External Lower Lip, External Nose, External Upper Lip, Extrahepatic Bile Duct, Eye, Eyebrow, Eyelid, Facial Bone, Facial Nerve, Fallopian Tube, False Vocal Cord, Falx Cerebelli, Falx Cerebri, Fascia, Female Genitalia, Femoral Artery, Femoral Lymph Node, Femoral Nerve, Femur, Fibrous Tissue, Fibula, Finger, Fingernail, Flank, Floor of Mouth, Foot, Foot Bone, Foot Phalanx, Foot Skin, Forearm, Forehead, Fourth Ventricle, Frontal Bone, Frontal Lobe, Frontal Pole, Frontal Sinus, Fundus of the Stomach, Fundus Uteri, Gallbladder, Gastric Cardia, Gastric Lymph Node, Gastrocnemius Muscle, Gastroesophageal Junction, Gastrointestinal Tract, Gingiva, Gland of Littre, Glans Penis, Globus Pallidus, Glossopharyngeal Nerve, Glottis, Gluteus Maximus, Greater Curvature of the Stomach, Hand, Hand Digit 1, Hand Phalanx, Hand Skin, Hard Palate, Head and Neck Lymph Node, Head of the Pancreas, Head Skin, Heart, Helix, Hematopoietic System, Hepatic, Hepatic Duct, Hepatic Flexure, Hepatic Lymph Node, Hip, Hip Joint, Hippocampus, Humerus, Hymen, Hyoid Bone, Hypoglossal Nerve, Hypopharynx, Hypothalamus, Ileocecal Valve, Ileum, Iliac Artery, Iliac Lymph Node, Iliac Vein, Iliopsoas Muscle, Ilium, Inferior Vena Cava, Infraclavicular Lymph Node, Infraclavicular Region, Infratentorial Brain, Inguinal Lymph Node, Inguinal Region, Inner Canthus, Inner Ear, Intercostal Lymph Node, Intercostal Muscle, Intercostal Nerve, Internal Capsule, Internal Iliac Lymph Node, Internal Mammary Artery, Internal Mammary Lymph Node, Internal Nare, Intervertebral Disc, Intestine, Intra-Abdominal Lymph Node, Intrahepatic Bile Duct, Intraocular Route of Administration, Intrathoracic Lymph Node, Iris, Ischiorectal Fossa, Ischium, Islet of Langerhans, Isthmus Uteri, Jaw Bone, Jaw Joint, Jejunum, Joint, Kidney, Knee Joint, Knee Skin, Labium, Labium Majus, Labium Minus, Lacrimal Gland, Lacrimal Sac, Large Intestine, Laryngeal Cartilage, Larynx, Lateral Ventricle, Lateral Wall of the Bladder, Lateral Wall of the Nasopharynx, Lateral Wall of the Oropharynx, Lateral Wall of the Pharynx, Leg Skin, Lens, Lesser Curvature of the Stomach, Ligament, Lingual Tonsil, Lingula of the Lung, Lip, Liver, Lobule of the Auricle, Lower Extremity, Lower Gingiva, Lower Lobe of the Lung, Lower Third of the Esophagus, Lower-Inner Quadrant of the Breast, Lower-Outer Quadrant of the Breast, Lumbar Nerve, Lumbosacral Plexus, Lung, Lymph Node, Lymph Node of Inguinal Region or Leg, Lymphatic, Main Bronchus, Male Genitalia, Male Prepuce, Mammary Gland, Mandible, Masseter Muscle, Maxilla, Maxillary Sinus, Meckel Diverticulum, Median Nerve, Mediastinal Lymph Node, Mediastinum, Medulla Oblongata, Meibomian Gland, Meninges, Meniscus Lateralis, Meniscus Medialis, Mentum, Mesencephalon, Mesenteric Artery, Mesenteric Lymph Node, Mesentery, Mesonephric Duct, Mesonephros, Mesovarium, Metacarpal Bone, Metatarsal Bone, Middle Cranial Fossa, Middle Ear, Middle Lobe of the Right Lung, Middle Third of the Esophagus, Minor Salivary Gland, Mons Pubis, Mucosa of the Lip, Mucosa of the Lower Lip, Mucosa of the Upper Lip, Muscle, Musculus Latissimus Dorsi, Myocardium, Myometrium, Nasal Bone, Nasal Cartilage, Nasal Cavity, Nasal Septum, Nasal Turbinate, Nasolacrimal Duct, Nasopharynx, Neck Skin, Nerve, Nervous System, Nipple, Nose, Nostril, Obturator Lymph Node, Obturator Nerve, Occipital Bone, Occipital Lobe, Occipital Lymph Node, Oculomotor Muscle, Oculomotor Nerve, Olfactory Nerve, Omentum, Optic Chiasm, Optic Nerve, Optic Tract, Oral Cavity, Orbit, Oropharynx, Other Specified Parts of Pancreas, Outer Canthus, Ovary, Palate, Palatine Tonsil, Palmar Fascia, Pancreas, Pancreatic Duct, Pancreatic Lymph Node, Paraaortic Lymph Node, Paraganglion, Parametrium, Paranasal Sinus, Parasympathetic Nervous System, Parathyroid Gland, Paratracheal Lymph Node, Parietal Bone, Parietal Lobe, Parietal Pleura, Parotid Duct, Parotid Gland, Parotid Gland Lymph Node, Patella, Pectoral Lymph Node, Pectoralis Major, Pelvic Lymph Node, Pelvis, Penis, Pericardium, Perineum, Peripheral Nerve, Peritoneal Cavity, Peritoneum, Pharyngeal Tonsil, Pharynx, Pia Mater, Pineal Gland, Pituitary Gland, Placenta, Plantar Fascia, Plantar Region, Pleura, Pons Varolii, Popliteal Lymph Node, Portal Lymph Node, Postcricoid Region, Posterior Cranial Fossa, Posterior Mediastinum, Posterior Wall of the Bladder, Posterior Wall of the Hypopharynx, Posterior Wall of the Nasopharynx, Posterior Wall of the Oropharynx, Posterior Wall of the Pharynx, Preauricular Lymph Node, Prostate Gland, Prostatic Utricle, Psoas Muscle, Pubic Bone, Pubic Symphysis, Pulmonary, Pulmonary Hilar Lymph Node, Putamen, Pylorus, Pyriform Sinus, Quadriceps Muscle of the Thigh, Radial Artery, Radial Nerve, Radius Bone, Rathke Pouch, Rectosigmoid Colon, Rectosigmoid Region, Rectum, Rectus Abdominis, Renal, Renal Artery, Renal Calyx, Renal Pelvis, Reticuloendothelial System, Retina, Retromolar Trigone, Retroperitoneal Lymph Node, Retroperitoneum, Retropharyngeal Lymph Node, Round Ligament of the Uterus, Sacral Bone, Sacral Lymph Node, Sacral Nerve, Sacral Plexus, Salivary Gland, Scalene Lymph Node, Scalp, Scapula, Sciatic Nerve, Sclera, Scrotum, Sella Turcica, Seminal Vesicle, Shoulder, Shoulder Girdle, Shoulder Joint, Sigmoid Colon, Skeletal Muscle Tissue, Skin, Skin Of The Axilla, Skin of the Face, Skin of the Lip, Skin of the Lower Limb and Hip, Skin of the Scalp and Neck, Skin of the Trunk, Skin of the Upper Limb and Shoulder, Skull, Skullcap, Small Intestine, Spermatic Cord, Sphenoid Bone, Sphenoid Sinus, Sphincter of Oddi, Spinal Cord, Spinal Cord Dura Mater, Spinal Meninges, Spinal Nerve, Spleen, Splenic Flexure, Splenic Hilar Lymph Node, Sternocleidomastoid Muscle, Sternocostal Joint, Stomach, Subclavian Artery, Subcutis, Subglottis, Sublingual Lymph Node, Sublingual Salivary Gland, Submandibular Duct, Submandibular Gland, Submandibular Lymph Node, Superior Vena Cava, Superior Wall of the Nasopharynx, Supraclavicular, Supraclavicular Lymph Node, Supraglottis, Suprasellar Region, Supratentorial Brain, Sympathetic Nervous System, Synovial Bursa, Synovial Fluid, Tail of the Pancreas, Tarsal Bone, Temporal Bone, Temporal Lobe, Tendon, Tendon Sheath, Tentorium Cerebelli, Testis, Thalamus, Thigh, Third Ventricle, Thoracic Duct, Thoracic Esophagus, Thoracic Lymph Node, Thorax, Thymus Gland, Thyroglossal Duct, Thyroid Cartilage, Thyroid Gland, Tibia, Toe, Toenail, Tongue, Tonsillar Fossa, Tonsillar Pillar, Tooth Socket, Trachea, Tracheobronchial Lymph Node, Tragus, Transverse Colon, Trapezius Muscle, Triceps Brachii, Trigeminal Nerve, Trochlear Nerve, True Vocal Cord, Trunk, Tunica Vaginalis, Ulna, Ulnar Artery, Ulnar Nerve, Umbilicus, Uncus, Undescended Testes, Upper Extremity, Upper Gingiva, Upper Lobe of the Lung, Upper Third of the Esophagus, Upper-Inner Quadrant of the Breast, Upper-Outer Quadrant of the Breast, Urachus, Ureter, Ureteric Orifice, Ureteropelvic Junction, Urethra, Uterine Gland, Uterine Ligament, Uterus, Uvea, Uvula, Vagina, Vaginal Fornix, Vagus Nerve, Vallecula, Vas Deferens, Vein, Vena Cava, Vermis, Vertebra, Vertebral Column, Visceral Pleura, Vocal Cord, Vulva, Waldeyer's Tonsillar Ring, Wall of the Pharynx, Wrist Joint, Wrist Skin",,True,,,string,,,,,, diff --git a/modules/shared/annotationProperty.csv b/modules/shared/annotationProperty.csv index fe928d50..afa41bce 100644 --- a/modules/shared/annotationProperty.csv +++ b/modules/shared/annotationProperty.csv @@ -46,7 +46,7 @@ Genomic Reference,Exact version of the human genome reference used in the alignm Genomic Reference URL,Link to human genome sequence; ftp or reference URL will be accepted.,,,,,,string,uri,,,,, Genome Annotation URL,Link to the human genome annotation (GTF) file; ftp or reference URL will be accepted.,,,,,,string,uri,,,,, AccessRequirementKey,The Access Requirement id(s) associated with this object. Provide multiple values as a comma-separated list.,,,,,,string,,,,,, -dataUseModifiers,"A list of data use modifiers that apply to the access requirement. Examples include GRU, IRB, etc.","DUO:0000042, DUO:0000027, DUO:0000016, DUO:0000029, DUO:0000043, DUO:0000015, DUO:0000004, DUO:0000045, DUO:0000017, DUO:0000011, DUO:0000046, DUO:0000018, DUO:0000044, DUO:0000021, DUO:0000006, DUO:0000019, DUO:0000026, DUO:0000020, DUO:0000012, DUO:0000025, DUO:0000024, DUO:0000028, DUO:0000022, DUO:0000007, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7, Pending Annotation",,,CDE:00002002,,string_list,,,,,, +dataUseModifiers,"A list of data use modifiers that apply to the access requirement. Examples include GRU, IRB, etc.","Pending Annotation, DUO:0000042, DUO:0000027, DUO:0000016, DUO:0000029, DUO:0000043, DUO:0000015, DUO:0000004, DUO:0000045, DUO:0000017, DUO:0000011, DUO:0000046, DUO:0000018, DUO:0000044, DUO:0000021, DUO:0000006, DUO:0000019, DUO:0000026, DUO:0000020, DUO:0000012, DUO:0000025, DUO:0000024, DUO:0000028, DUO:0000022, DUO:0000007, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:00002002,,string_list,,,,,, collaborationRequired,"If collaboration is required for the access requirement, provide the PI email address. Provide multiple as a comma-separated list.",,,,,,string,,,,,, diseaseSpecificResearch,The type(s) of disease research allowed by this access requirement. Provide the MONDO ID in format MONDO:id. Provide multiple values as a comma-separated list. MONDO terms can be found here: https://ols.monarchinitiative.org/ontologies/mondo,,,,,,string,,MONDO:\d{7},,,, geographicalRestriction,The specific geographic region(s) to which use is limited by the access requirement.,"AD, AE, AF, AG, AI, AL, AM, AO, AQ, AR, AS, AT, AU, AW, AX, AZ, BA, BB, BD, BE, BF, BG, BH, BI, BJ, BL, BM, BN, BO, BQ, BR, BS, BT, BV, BW, BY, BZ, CA, CC, CD, CF, CG, CH, CI, CK, CL, CM, CN, CO, CR, CU, CV, CW, CX, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, EH, ER, ES, ET, FI, FJ, FK, FM, FO, FR, GA, GB, GD, GE, GF, GG, GH, GI, GL, GM, GN, GP, GQ, GR, GS, GT, GU, GW, GY, HK, HM, HN, HR, HT, HU, ID, IE, IL, IM, IN, IO, IQ, IR, IS, IT, JE, JM, JO, JP, KE, KG, KH, KI, KM, KN, KP, KR, KW, KY, KZ, LA, LB, LC, LI, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MF, MG, MH, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NC, NE, NF, NG, NI, NL, NO, NP, NR, NU, NZ, OM, PA, PE, PF, PG, PH, PK, PL, PM, PN, PR, PS, PT, PW, PY, QA, RE, RO, RS, RU, RW, SA, SB, SC, SD, SE, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SR, SS, ST, SV, SX, SY, SZ, TC, TD, TF, TG, TH, TJ, TK, TL, TM, TN, TO, TR, TT, TV, TW, TZ, UA, UG, UM, US, UY, UZ, VA, VC, VE, VG, VI, VN, VU, WF, WS, YE, YT, ZA, ZM, ZW",,,,,string_list,,,,,, diff --git a/modules/shared/treatmentType.csv b/modules/shared/treatmentType.csv index a0c77e57..338d2421 100644 --- a/modules/shared/treatmentType.csv +++ b/modules/shared/treatmentType.csv @@ -6,6 +6,7 @@ Brachytherapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,, Cellular Therapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, Chemotherapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, Concurrent Chemoradiation,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, +Control,,,,FALSE,,Treatment Type,,MC2,,,,,, Conventional Radiotherapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, Electron Beam Radiation Therapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, External Beam Radiation Therapy,,,,FALSE,,Treatment Type,,CDS v5.0.4/Treatment-treatment_type,,,,,, diff --git a/modules/study/annotationProperty.csv b/modules/study/annotationProperty.csv index 12f5194b..fb5756ba 100644 --- a/modules/study/annotationProperty.csv +++ b/modules/study/annotationProperty.csv @@ -12,4 +12,4 @@ Study dbGaP Accession Id,A stable unique alphanumeric identifier assigned to a s Study License,Official or legal permission to do or own a specified thing. Studies with data that will be submitted to CDS are required to provide a license. Maps to DUOplus6.,"CC0, CC_BY, CC_BY_NC, CC_BY_ND, CC_BY_SA, CC_BY_NC_ND, CC_BY_NC_SA, Apache_2, MIT, GPL_3, BSD_3_Clause",,,CDE:14902606,,string,,,,,, Study Index Date,"The reference event associated with timepoints in this study. One of Diagnosis Date, Enrollment Date, Collection Date, or Birth Date.","Diagnosis Date , Enrollment Date, Collection Date, Birth Date",,,,,string,,,,,, Study Project Identifier,The Synapse Project identifier (synID) with which this Study is related.,,,,,,string_list,,syn[0-9]+,,,, -Study Data Use Codes,"DUO code - A data item that is used to indicate consent permissions for datasets and/or materials, and relates to the purposes for which datasets and/or material might be removed, stored or used. Available DUO code definitions can be found here: https://mc2-center.github.io/data-models/valid_values/study/#attribute-study-data-use-codes","Pending Annotation, GRU, PS, GSO, RTN, CC, NMDS, NRES, NPU, DUM, POA, NCU, NPUNCU, NPOA, IRB, HMB, PUB, USE, COL, RST, TSM, MOR, IST, GSR, DSR, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:0002001,,string_list,,,,,, +Study Data Use Codes,"DUO code - A data item that is used to indicate consent permissions for datasets and/or materials, and relates to the purposes for which datasets and/or material might be removed, stored or used. Available DUO code definitions can be found here: https://mc2-center.github.io/data-models/valid_values/study/#attribute-study-data-use-codes","Pending Annotation, DUO:0000042, DUO:0000027, DUO:0000016, DUO:0000029, DUO:0000043, DUO:0000015, DUO:0000004, DUO:0000045, DUO:0000017, DUO:0000011, DUO:0000046, DUO:0000018, DUO:0000044, DUO:0000021, DUO:0000006, DUO:0000019, DUO:0000026, DUO:0000020, DUO:0000012, DUO:0000025, DUO:0000024, DUO:0000028, DUO:0000022, DUO:0000007, DUOPlus1, DUOPlus2, DUOPlus3, DUOPlus4, DUOPlus5, DUOPlus6, DUOPlus7",,,CDE:0002001,,string_list,,,,,, diff --git a/modules/visiumRNALevel2/annotationProperty.csv b/modules/visiumRNALevel2/annotationProperty.csv index 41f21300..2b1f8ab1 100644 --- a/modules/visiumRNALevel2/annotationProperty.csv +++ b/modules/visiumRNALevel2/annotationProperty.csv @@ -1,5 +1,5 @@ Attribute,Description,Valid Values,DependsOn,Required,Properties,Validation Rules,columnType,Format,Pattern,Minimum,Maximum,IsTemplate,Source -10x Visium RNA Level 2,Alignment workflows downstream of Spatial Transcriptomics RNA-seq Level 1.,,"10xVisiumRNALevel2_id, Filename, 10xVisiumRNALevel1 Key, Biospecimen Key, Study Key, DatasetView Key, File Alias, File Description, File Design, File Level, File Assay, File Species, File Url, File Format, File Data Use Codes, File Longitudinal Group, File Longitudinal Event Type, File Longitudinal Sequence Identifier, File Longitudinal Time Elapsed Unit, File Longitudinal Total Time Elapsed, Visium UMI Tag, Visium Whitelist Spatial Barcode File Link, Visium Spatial Barcode Tag, Visium Applied Hard Trimming, Workflow Version, Workflow Link, Genomic Reference, Genomic Reference URL, Genome Annotation URL, Biospecimen Key, Visium Run ID, Visium Capture Area",,,,,,,,,True,HTAN +10x Visium RNA Level 2,Alignment workflows downstream of Spatial Transcriptomics RNA-seq Level 1.,,"10xVisiumRNALevel2_id, Filename, 10xVisiumRNALevel1 Key, Biospecimen Key, Study Key, DatasetView Key, File Alias, File Description, File Design, File Level, File Assay, File Species, File Url, File Format, File Data Use Codes, File Longitudinal Group, File Longitudinal Event Type, File Longitudinal Sequence Identifier, File Longitudinal Time Elapsed Unit, File Longitudinal Total Time Elapsed, Visium UMI Tag, Visium Whitelist Spatial Barcode File Link, Visium Spatial Barcode Tag, Visium Applied Hard Trimming, Workflow Version, Workflow Link, Genomic Reference, Genomic Reference URL, Genome Annotation URL, Visium Run ID, Visium Capture Area",,,,,,,,,True,HTAN 10xVisiumRNALevel2_id,"Unique row identifier, used as a primary key for record updates. This should be equivalent to the file Synapse Id unless otherwise indicated.",,,True,primary_key,,string,,"^syn\d{7,8}$",,,, Visium UMI Tag,"SAM tag for the UMI field; please provide a valid tag-type pair, consisting of a tag (e.g. UB or UR) and type (e.g. Z) separated by a colon.",,,True,,,string,,,,,,HTAN Visium Whitelist Spatial Barcode File Link,Link to file listing all possible spatial barcodes. URL,,,True,,,string,,,,,,HTAN diff --git a/nav.yml b/nav.yml index bbb8b95c..13a91fe1 100644 --- a/nav.yml +++ b/nav.yml @@ -1,14 +1,45 @@ -Home: +Home: - index.md Data Models: - - Dataset Data Model: model/dataset.md - - Dataset Sharing Plan: model/DataDSP.md - - Education Resource Data Model: model/education.md - - File Data Model: model/file.md - - Grant Data Model: model/grant.md - - Person Data Model: model/person.md - - Publication Data Model: model/publication.md - - Study Data Model: model/study.md - - Tool Data Model: model/tool.md + - Sample Data Model: + - Biospecimen: model/biospecimen.md + - Individual: model/individual.md + - Model: model/model.md + - Administrative Data Model: + - Grant: model/grant.md + - Study: model/study.md + - Person: model/person.md + - Resource Sharing Data Model: + - Dataset: model/dataset.md + - Dataset Sharing Plan: model/DataDSP.md + - Education Resource: model/education.md + - File: model/file.md + - Publication: model/publication.md + - Tool: model/tool.md + - Imaging Data Model: + - Imaging Channel: model/imagingChannel.md + - Imaging Level 1: model/imagingLevel1.md + - Imaging Level 2: model/imagingLevel2.md + - Imaging Level 3 (Image): model/imagingLevel3Image.md + - Imaging Level 3 (Segments): model/imagingLevel3Segments.md + - Imaging Level 4: model/imagingLevel4.md + - NanoString GeoMx Data Model: + - GeoMx Auxiliary Files: model/geomxAux.md + - GeoMx Imaging: model/geomxImaging.md + - GeoMx Level 1: model/geomxLevel1.md + - GeoMx Level 2: model/geomxLevel2.md + - GeoMx Level 3: model/geomxLevel3.md + - GeoMx ROI Segment Annotation: model/geomxRoi.md + - Sequencing Data Model: + - Sequencing Level 1: model/sequencingLevel1.md + - Sequencing Level 2: model/sequencingLevel2.md + - Sequencing Level 3: model/sequencingLevel3.md + - Sequencing RNA Level 1: model/sequencingRNALevel1.md + - 10x Visium Data Model: + - Visium Auxiliary Files: model/visiumRNAAux.md + - Visium RNA Level 1: model/visiumRNALevel1.md + - Visium RNA Level 2: model/visiumRNALevel2.md + - Visium RNA Level 3: model/visiumRNALevel3.md + - Visium RNA Level 4: model/visiumRNALevel4.md Standard Terms: {} Contributing to the Data Model: contributing.md diff --git a/scripts/hooks.py b/scripts/hooks.py index 0f5c797d..170bf82a 100644 --- a/scripts/hooks.py +++ b/scripts/hooks.py @@ -1,3 +1,4 @@ +import json from os.path import getsize, isfile, join import pandas as pd @@ -16,6 +17,52 @@ "publication": "Publication", "study": "Study", "tool": "Tool", + "biospecimen": "Biospecimen", + "individual": "Individual", + "model": "Model", + "imagingChannel": "Imaging Channel", + "imagingLevel1": "Imaging Level 1", + "imagingLevel2": "Imaging Level 2", + "imagingLevel3Image": "Imaging Level 3 (Image)", + "imagingLevel3Segments": "Imaging Level 3 (Segments)", + "imagingLevel4": "Imaging Level 4", + "geomxAux": "NanoString GeoMx Auxiliary Files", + "geomxImaging": "NanoString GeoMx Imaging", + "geomxLevel1": "NanoString GeoMx Level 1", + "geomxLevel2": "NanoString GeoMx Level 2", + "geomxLevel3": "NanoString GeoMx Level 3", + "geomxRoi": "NanoString GeoMx ROI Segment Annotation", + "sequencingLevel1": "Sequencing Level 1", + "sequencingLevel2": "Sequencing Level 2", + "sequencingLevel3": "Sequencing Level 3", + "sequencingRNALevel1": "Sequencing RNA Level 1", + "visiumRNAAux": "10x Visium Auxiliary Files", + "visiumRNALevel1": "10x Visium RNA Level 1", + "visiumRNALevel2": "10x Visium RNA Level 2", + "visiumRNALevel3": "10x Visium RNA Level 3", + "visiumRNALevel4": "10x Visium RNA Level 4", +} + +# Each model's exported JSON Schema is the authoritative list of which +# attributes actually belong to its manifest (resolved from DependsOn when +# the schema was generated) - map module folder -> json_schemas/.json. +# Only listed where it differs from the module folder name itself. +SCHEMA_COMPONENT = { + "dataset": "DatasetView", + "sharingPlans": "DataDSP", + "education": "EducationalResource", + "file": "FileView", + "grant": "GrantView", + "person": "PersonView", + "publication": "PublicationView", + "tool": "ToolView", + "geomxAux": "NanoStringGeoMxAuxiliaryFiles", + "geomxImaging": "NanoStringGeoMxDSPImaging", + "geomxLevel1": "NanoStringGeoMxDSPLevel1", + "geomxLevel2": "NanoStringGeoMxDSPLevel2", + "geomxLevel3": "NanoStringGeoMxDSPLevel3", + "geomxRoi": "NanoStringGeoMXROISegmentAnnotation", + "visiumRNAAux": "VisiumAuxiliaryFiles", } # Columns to render for the full field reference tables. @@ -23,28 +70,89 @@ "Attribute", "Description", "Required", - "Validation Rules", + "Column Type", + "Format", + "Pattern", + "Standard Terms", "Examples", ] MAPPING_FILENAME = "mapping.yaml" NAVIGATION_FILENAME = "nav.yml" +MODEL_CSV_FILENAME = "mc2.model.csv" +SCHEMA_DIR = "json_schemas" ANNOTATIONS_FILENAME = "annotationProperty.csv" EXAMPLE_FILENAME = "exampleColumn.csv" REFERENCE_FILENAME = "reference.csv" # --- Helper Functions --- -def _create_markdown_link(attribute: str, model: str) -> str: +def _create_markdown_link(attribute: str, model: str, text: str = None) -> str: """Create markdown link to list of valid values for the given attribute.""" link_prefix = f"../valid_values/{model}.md#attribute" slug = attribute.lower().replace(" ", "-") - return f"[{attribute}]({link_prefix}-{slug})" + return f"[{text or attribute}]({link_prefix}-{slug})" + + +def _format_technical_column(col: pd.Series, escape_backslashes: bool = False) -> pd.Series: + """Format a technical metadata column, replacing empty strings with '_None_'.""" + if escape_backslashes: + col = col.str.replace(r"\\", r"\\\\", regex=True) + return col.replace("", "_None_") -def _format_validation_rules(col: pd.Series) -> pd.Series: - """Format validation rules, replacing empty strings with '_None_'.""" - return col.str.replace(r"\\", r"\\\\", regex=True).replace("", "_None_") +def _get_model_attributes(model: str) -> list: + """Get the ordered list of attribute display names that make up a + model's manifest. + + DependsOn (in the module's own annotationProperty.csv) is the live, + hand-edited source of truth, but the exported JSON Schema is used to + cross-check it, since either can drift independently: DependsOn can + gain attributes a schema hasn't been regenerated for yet, while an + un-regenerated schema can still list attributes since removed from + DependsOn (e.g. Study.json still has ~15 access-requirement fields that + were moved out to the governance model but never regenerated away). + Attributes must appear in DependsOn; the schema, when available, is + used to filter out anything no longer current. + """ + annotations_file = join("modules", model, ANNOTATIONS_FILENAME) + annotation_df = pd.read_csv( + annotations_file, quoting=1, dtype=str, keep_default_na=False + ) + # The manifest/root row is the one with a non-empty DependsOn - the + # only reliable signal (it isn't always the first row, e.g. person's + # "Person View" row, and IsTemplate isn't consistently set either, + # e.g. visiumRNALevel1's root row). + root = annotation_df[annotation_df["DependsOn"].str.strip() != ""].iloc[0] + depends_on = [a.strip() for a in root["DependsOn"].split(",") if a.strip()] + + component = SCHEMA_COMPONENT.get(model, model[0].upper() + model[1:]) + schema_file = join(SCHEMA_DIR, f"{component}.json") + if not isfile(schema_file): + return depends_on + + with open(schema_file) as f: + schema = json.load(f) + schema_titles = {prop.get("title", key) for key, prop in schema["properties"].items()} + return [a for a in depends_on if a in schema_titles] + + +def _load_attribute_owners() -> dict: + """Reverse-lookup: which model's valid-values page a given attribute's + standard-terms anchor actually lives on. + + Attributes are often shared across models via DependsOn (e.g. "File + Assay" is used by several imaging/sequencing/spatial modules), but its + anchor is only ever generated on the one model mapping.yaml lists it + under. + """ + with open(join("modules", MAPPING_FILENAME)) as f: + mapping = yaml.safe_load(f) + return { + attribute["name"]: owning_model + for owning_model, attributes in mapping.items() + for attribute in attributes + } # --- Core logic functions --- @@ -54,55 +162,87 @@ def generate_linked_table(model: str): Desired markdown look: render model reference table so that - it is known which attributes require valid values - clicking on attribute will direct to valid values table + + The attribute list comes from the model's JSON Schema (its DependsOn- + resolved manifest), and every attribute's metadata is looked up from the + fully collated mc2.model.csv, since attributes referenced via DependsOn + (e.g. "Study Key") are often defined in a different module's file than + the one requesting them. """ parent = join("modules", model) - annotations_file = join(parent, ANNOTATIONS_FILENAME) example_file = join(parent, EXAMPLE_FILENAME) reference_file = join(parent, REFERENCE_FILENAME) - # Read both annotation properties and examples - annotation_df = pd.read_csv(annotations_file, quoting=1).fillna("") - examples_df = pd.read_csv(example_file, quoting=1).fillna("") - - # First select only the columns we want from annotation_df - table = annotation_df[[ - "Attribute", - "Description", - "Required", - "Validation Rules", - "Valid Values", - ]] + model_df = ( + pd.read_csv(MODEL_CSV_FILENAME, quoting=1, dtype=str, keep_default_na=False) + .drop_duplicates(subset="Attribute", keep="first") + .set_index("Attribute") + ) - # Then add the Example column and rename it to Examples + table = pd.DataFrame({"Attribute": _get_model_attributes(model)}) table = table.merge( - examples_df[["Attribute", "Example"]], - on="Attribute", + model_df[["Description", "Required", "Valid Values", "columnType", "Format", "Pattern"]], + left_on="Attribute", + right_index=True, how="left", - ).rename(columns={"Example": "Examples"}) + ).fillna("").rename(columns={"columnType": "Column Type"}) + + # Normalize Required to explicit True/False (rather than blank/NaN). + table["Required"] = table["Required"].apply( + lambda v: "True" if str(v).strip() == "True" else "False" + ) + + # Add the Example column and rename it to Examples, if example data + # exists for this model. Some newer modules don't yet have curated + # examples, in which case the column is left blank. + if isfile(example_file): + examples_df = pd.read_csv(example_file, quoting=1).fillna("") + table = table.merge( + examples_df[["Attribute", "Example"]], + on="Attribute", + how="left", + ).rename(columns={"Example": "Examples"}) + else: + table["Examples"] = "" + table["Examples"] = table["Examples"].fillna("") - # If attribute has a list of valid values, create a link. - table["Attribute"] = table.apply( + # If an attribute has a list of standard terms, link to its anchor on + # whichever model's valid-values page actually owns it. + attribute_owners = _load_attribute_owners() + table["Standard Terms"] = table.apply( lambda row: ( - _create_markdown_link(row["Attribute"], model) + _create_markdown_link( + row["Attribute"], attribute_owners.get(row["Attribute"], model), text="View" + ) if row["Valid Values"] - else row["Attribute"] + else "None" ), axis=1, ) # Fix any remaining rendering issues, then output table as CSV. - table["Validation Rules"] = _format_validation_rules(table["Validation Rules"]) + table["Column Type"] = _format_technical_column(table["Column Type"]) + table["Format"] = _format_technical_column(table["Format"]) + table["Pattern"] = _format_technical_column(table["Pattern"], escape_backslashes=True) table[COLS_TO_RENDER].to_csv(reference_file, index=False) def generate_valid_values_markdown(model: str): - """Generate docs page for standard terms of the given data model.""" + """Generate docs page for standard terms of the given data model. + + Some models have no attributes with a controlled list of standard terms + (i.e. no entry in mapping.yaml). Skip writing a page for those, so they + don't show up as an empty, un-linked orphan page in the built site. + """ dest_parent_dir = join("docs", "valid_values") - with open(join("modules", MAPPING_FILENAME)) as f, \ - open(join(dest_parent_dir, f"{model}.md"), "w") as md: + with open(join("modules", MAPPING_FILENAME)) as f: mapping = yaml.safe_load(f) + if not mapping.get(model): + return + + with open(join(dest_parent_dir, f"{model}.md"), "w") as md: # Create a section in the docs page for each attribute that has a list # of standard terms. for attribute in mapping.get(model, {}): diff --git a/templates/Biospecimen.csv b/templates/Biospecimen.csv new file mode 100644 index 00000000..356b45f3 --- /dev/null +++ b/templates/Biospecimen.csv @@ -0,0 +1,2 @@ +Component,Biospecimen_id,Study Key,Individual Key,Model Key,Parent Biospecimen Key,Biospecimen Type Category,Biospecimen Type,Biospecimen Tumor Status,Biospecimen Acquisition Method,Biospecimen Incidence Type,Biospecimen Stain,Biospecimen Species,Biospecimen Sex,Biospecimen Age at Collection,Biospecimen Age at Collection Unit,Biospecimen Disease Type,Biospecimen Primary Site,Biospecimen Primary Diagnosis,Biospecimen Site of Origin,Biospecimen Tumor Subtype,Biospecimen Tumor Grade,Biospecimen Known Metastasis Sites,Biospecimen Tumor Morphology,Biospecimen Composition,Biospecimen Preservation Method,Biospecimen Fixative,Biospecimen Embedding Medium,Biospecimen Anatomic Site,Biospecimen Site of Resection or Biopsy,Biospecimen Timepoint Type,Biospecimen Timepoint Offset,Biospecimen Collection Site,Biospecimen Treatment Type,Biospecimen Therapeutic Agent,Biospecimen Treatment Response,Biospecimen Last Known Disease Status,Biospecimen BioSample Identifier,Biospecimen Description +Biospecimen,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/ImagingChannel.csv b/templates/ImagingChannel.csv new file mode 100644 index 00000000..6d5279d4 --- /dev/null +++ b/templates/ImagingChannel.csv @@ -0,0 +1,2 @@ +Component,ImagingChannel_id,Study Key,Channel Identifier,Channel Name,Channel Passed QC,Channel Cycle Number,Channel Sub-cycle Number,Channel Antibody Role,Channel Target Name,Channel Antibody Name,Channel Resource ID,Channel Fluorophore,Channel Antibody Clone,Channel Antibody Lot,Channel Antibody Vendor,Channel Antibody Catalog Number,Channel Excitation Wavelength,Channel Emission Wavelength,Channel Excitation Bandwidth,Channel Emission Bandwidth,Channel Metal Symbol,Channel Metal Isotope,Channel Oligo Barcode Upper Strand,Channel Oligo Barcode Lower Strand,Channel Probe Dilution Ratio,Channel Probe Concentration +ImagingChannel,,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/ImagingLevel1.csv b/templates/ImagingLevel1.csv new file mode 100644 index 00000000..6397d6a8 --- /dev/null +++ b/templates/ImagingLevel1.csv @@ -0,0 +1,2 @@ +Component,ImagingLevel1_id,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Image Assay Type,Image Protocol Link,Image Platform Model,Image Platform Manufacturer,Image Software,ImagingChannel Key +ImagingLevel1,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/ImagingLevel2.csv b/templates/ImagingLevel2.csv new file mode 100644 index 00000000..385bd48a --- /dev/null +++ b/templates/ImagingLevel2.csv @@ -0,0 +1,2 @@ +Component,ImagingLevel2_id,Filename,ImagingLevel1 Key,ImagingChannel Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Image Assay Type,Image Protocol Link,Image Platform Model,Image Platform Manufacturer,Image Software,Image Objective,Image Nominal Magnification,Image Lense Aperture,Image Working Distance,Image Working Distance Unit,Image Immersion Type,Image Pyramidal,Image Z stack,Image Timeseries,Image FOV Index,Image FOV Size X,Image FOV Size X Unit,Image FOV Size Y,Image FOV Size Y Unit,Image Frame Averaging,Image Identifier,Image Dimension Order,Image Physical Size X,Image Physical Size X Unit,Image Physical Size Y,Image Physical Size Y Unit,Image Physical Size Z,Image Physical Size Z Unit,Image Pixels BigEndian,Image Plane Count,Image Channel Size,Image Number of Timepoints,Image X Pixels,Image Y Pixels,Image Z Pixels,Image Pixel Type +ImagingLevel2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/ImagingLevel3Image.csv b/templates/ImagingLevel3Image.csv new file mode 100644 index 00000000..42a3844d --- /dev/null +++ b/templates/ImagingLevel3Image.csv @@ -0,0 +1,2 @@ +Component,ImagingLevel3Image_id,Filename,ImagingChannel Key,ImagingLevel2 Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Image Assay Type,Image Protocol Link,Image Platform Model,Image Platform Manufacturer,Image Software,Image Objective,Image Nominal Magnification,Image Lense Aperture,Image Working Distance,Image Working Distance Unit,Image Immersion Type,Image Pyramidal,Image Z stack,Image Timeseries,Image FOV Index,Image FOV Size X,Image FOV Size X Unit,Image FOV Size Y,Image FOV Size Y Unit,Image Frame Averaging,Image Identifier,Image Dimension Order,Image Physical Size X,Image Physical Size X Unit,Image Physical Size Y,Image Physical Size Y Unit,Image Physical Size Z,Image Physical Size Z Unit,Image Pixels BigEndian,Image Plane Count,Image Channel Size,Image Number of Timepoints,Image X Pixels,Image Y Pixels,Image Z Pixels,Image Pixel Type +ImagingLevel3Image,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/ImagingLevel3Segments.csv b/templates/ImagingLevel3Segments.csv new file mode 100644 index 00000000..4266be51 --- /dev/null +++ b/templates/ImagingLevel3Segments.csv @@ -0,0 +1,2 @@ +Component,ImagingLevel3Segments_id,Filename,ImagingLevel2 Key,ImagingLevel3Image Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Image Segmentation Data Type,Image Parameter file,Software and Version,Image Object Class,Image Object Class Description,Image Number of Objects +ImagingLevel3Segments,,,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/ImagingLevel4.csv b/templates/ImagingLevel4.csv new file mode 100644 index 00000000..218591d4 --- /dev/null +++ b/templates/ImagingLevel4.csv @@ -0,0 +1,2 @@ +Component,ImagingLevel4_id,Filename,ImagingLevel2 Key,ImagingLevel3Image Key,ImagingLevel3Segments Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Image Parameter file,Image Software,Image Number of Objects,Image Number of Features,Image Object Class,Image Summary Statistic +ImagingLevel4,,,,,,,,,,,,,,,,,,,,,,,,,,,, \ No newline at end of file diff --git a/templates/Individual.csv b/templates/Individual.csv new file mode 100644 index 00000000..a6448f1a --- /dev/null +++ b/templates/Individual.csv @@ -0,0 +1,2 @@ +Component,Individual_id,Study Key,Individual dbGaP Subject Id,Individual Sex,Individual Gender,Individual Age at Diagnosis,Individual Disease Type,Individual Primary Diagnosis,Individual Primary Site,Individual Primary Tumor Stage,Individual Site of Origin,Individual Tumor Subtype,Individual Tumor Grade,Individual Tumor Lymph Node Stage,Individual Known Metastasis Sites,Individual Metastasis Stage,Individual Treatment Type,Individual Therapeutic Agent,Individual Days to Treatment,Individual Treatment Response,Individual Days to Last Followup,Individual Recurrence Status,Individual Days To Recurrence,Individual Days to Last Known Disease Status,Individual Last Known Disease Status,Individual Vital Status +Individual,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/Model.csv b/templates/Model.csv new file mode 100644 index 00000000..aae59123 --- /dev/null +++ b/templates/Model.csv @@ -0,0 +1,2 @@ +Component,Model_id,Study Key,Individual Key,Model Age,Model Age Unit,Model Sex,Model Disease Type,Model Primary Diagnosis,Model Primary Site,Model Site of Origin,Model Tumor Subtype,Model Species,Model Type,Model Method,Model Source,Model Acquisition Type,Model Graft Source,Model Genotype,Model Treatment Type,Model Therapeutic Agent,Model Days to Treatment,Model Treatment Response +Model,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/NanoStringGeoMXROISegmentAnnotation.csv b/templates/NanoStringGeoMXROISegmentAnnotation.csv new file mode 100644 index 00000000..d7a62f29 --- /dev/null +++ b/templates/NanoStringGeoMXROISegmentAnnotation.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMXROISegmentAnnotation_id,Biospecimen Key,GeoMx Scan name,GeoMx ROI Name,GeoMx AOI Name,GeoMx Tags,GeoMx ROI X Coordinate,GeoMx ROI Y Coordinate,GeoMx AOI X Coordinate,GeoMx AOI Y Coordinate,GeoMx QC status,GeoMx Scan Height,GeoMx Scan Width,GeoMx Scan Offset X,GeoMx Scan Offset Y,GeoMx Binding Density,GeoMx Positive norm factor,GeoMx Surface area,GeoMx Nuclei count,GeoMx Tissue Stain,GeoMx Slide name,NGS Raw Reads,NGS Stitched Reads,NGS Aligned Reads,NGS Deduplicated Reads,NGS Trimmed Reads,NGS Sequencing Coverage,NGS MapQ30,GeoMx Negative count mean,GeoMx No Template Control count,GeoMx Excluded Outlier Probes,GeoMx Limit of Quantification +NanoStringGeoMXROISegmentAnnotation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/NanoStringGeoMxAuxiliaryFiles.csv b/templates/NanoStringGeoMxAuxiliaryFiles.csv new file mode 100644 index 00000000..801bca53 --- /dev/null +++ b/templates/NanoStringGeoMxAuxiliaryFiles.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMxAuxiliaryFiles_id,Synapse ID of GeoMx DSP ROI Segment Annotation File,Synapse ID of GeoMx DSP PKC File,Synapse ID of GeoMx Lab Worksheet File,Synapse ID of GeoMx DSP Config File +NanoStringGeoMxAuxiliaryFiles,,,,, diff --git a/templates/NanoStringGeoMxDSPImaging.csv b/templates/NanoStringGeoMxDSPImaging.csv new file mode 100644 index 00000000..64b5b4e1 --- /dev/null +++ b/templates/NanoStringGeoMxDSPImaging.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMxDSPImaging_id,Filename,NanoStringGeoMxDSPLevel1 Key,NanoStringGeoMxDSPLevel2 Key,NanoStringGeoMxAuxiliaryFiles Key,NanoStringGeoMXROISegmentAnnotation Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,GeoMx Imaging Channel Names,GeoMx Imaging AOI Coordinates,ImagingChannel Key,Image Assay Type,Image Protocol Link,Image Platform Model,Image Platform Manufacturer,Image Software,Image Objective,Image Nominal Magnification,Image Lense Aperture,Image Working Distance,Image Working Distance Unit,Image Immersion Type,Image Pyramidal,Image Z stack,Image Timeseries,Image FOV Index,Image FOV Size X,Image FOV Size X Unit,Image FOV Size Y,Image FOV Size Y Unit,Image Frame Averaging,Image Identifier,Image Dimension Order,Image Physical Size X,Image Physical Size X Unit,Image Physical Size Y,Image Physical Size Y Unit,Image Physical Size Z,Image Physical Size Z Unit,Image Pixels BigEndian,Image Plane Count,Image Channel Size,Image Number of Timepoints,Image X Pixels,Image Y Pixels,Image Z Pixels,Image Pixel Type +NanoStringGeoMxDSPImaging,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/NanoStringGeoMxDSPLevel1.csv b/templates/NanoStringGeoMxDSPLevel1.csv new file mode 100644 index 00000000..6769122c --- /dev/null +++ b/templates/NanoStringGeoMxDSPLevel1.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMxDSPLevel1_id,Filename,NanoStringGeoMxAuxiliaryFiles Key,NanoStringGeoMXROISegmentAnnotation Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,GeoMx DSP Assay Type,NGS Library Strategy,NGS Library Source Material,NGS Library Source Molecule,NGS Library Selection Method,NGS Library Layout,NGS Sequencing Platform,NGS Sequencing Design Description,NGS Read Length,NGS Raw Reads,NGS Unique Bases,NGS Sequencing Coverage,NGS Library Preparation Kit Name,NGS Library Preparation Kit Vendor,NGS Library Preparation Kit Version,NGS Read Indicator,NGS Library Preparation Days from Index,NGS Sequencing Library Construction Days from Index +NanoStringGeoMxDSPLevel1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/NanoStringGeoMxDSPLevel2.csv b/templates/NanoStringGeoMxDSPLevel2.csv new file mode 100644 index 00000000..5cf6dd6d --- /dev/null +++ b/templates/NanoStringGeoMxDSPLevel2.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMxDSPLevel2_id,Filename,NanoStringGeoMxDSPLevel1 Key,NanoStringGeoMxAuxiliaryFiles Key,NanoStringGeoMXROISegmentAnnotation Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,GeoMx DSP Assay Type,NGS Library Strategy,NGS Library Source Material,NGS Library Source Molecule,NGS Library Selection Method,NGS Library Layout,NGS Sequencing Platform,NGS Sequencing Design Description,NGS Raw Reads,NGS Stitched Reads,NGS Aligned Reads,NGS Deduplicated Reads,NGS Trimmed Reads,NGS MapQ30,NGS Unique Bases,NGS Read Length,NGS Sequencing Coverage,Genomic Reference,Software and Version +NanoStringGeoMxDSPLevel2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/NanoStringGeoMxDSPLevel3.csv b/templates/NanoStringGeoMxDSPLevel3.csv new file mode 100644 index 00000000..626ad489 --- /dev/null +++ b/templates/NanoStringGeoMxDSPLevel3.csv @@ -0,0 +1,2 @@ +Component,NanoStringGeoMxDSPLevel3_id,Filename,NanoStringGeoMxDSPLevel1 Key,NanoStringGeoMxDSPLevel2 Key,NanoStringGeoMxAuxiliaryFiles Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,NGS Unique Probe Count,NGS Unique Target Count,NGS Matrix Type,Software and Version,Workflow Type,Workflow Parameter Description,Workflow Link +NanoStringGeoMxDSPLevel3,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/SequencingLevel1.csv b/templates/SequencingLevel1.csv new file mode 100644 index 00000000..66d04a51 --- /dev/null +++ b/templates/SequencingLevel1.csv @@ -0,0 +1,2 @@ +Component,SequencingLevel1_id,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,NGS Library Strategy,NGS Library Source Material,NGS Library Source Molecule,NGS Library Selection Method,NGS Library Layout,NGS Sequencing Platform,NGS Sequencing Design Description,NGS Read Length,NGS Raw Reads,NGS Unique Bases,NGS Sequencing Coverage,NGS Library Preparation Kit Name,NGS Library Preparation Kit Vendor,NGS Library Preparation Kit Version,NGS Read Indicator,NGS Library Preparation Days from Index,NGS Sequencing Library Construction Days from Index +SequencingLevel1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/SequencingLevel2.csv b/templates/SequencingLevel2.csv new file mode 100644 index 00000000..b184fed7 --- /dev/null +++ b/templates/SequencingLevel2.csv @@ -0,0 +1,2 @@ +Component,SequencingLevel2_id,SequencingLevel1 Key,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,NGS Library Strategy,NGS Library Source Material,NGS Library Source Molecule,NGS Library Selection Method,NGS Library Layout,NGS Sequencing Platform,NGS Sequencing Design Description,NGS Raw Reads,NGS Stitched Reads,NGS Aligned Reads,NGS Deduplicated Reads,NGS Trimmed Reads,NGS MapQ30,NGS Unique Bases,NGS Read Length,NGS Sequencing Coverage,Genomic Reference,Software and Version +SequencingLevel2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/SequencingLevel3.csv b/templates/SequencingLevel3.csv new file mode 100644 index 00000000..4edf693a --- /dev/null +++ b/templates/SequencingLevel3.csv @@ -0,0 +1,2 @@ +Component,SequencingLevel3_id,SequencingLevel2 Key,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,NGS Unique Probe Count,NGS Unique Target Count,NGS Matrix Type,Software and Version,Workflow Type,Workflow Parameter Description,Workflow Link +SequencingLevel3,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/SequencingRNALevel1.csv b/templates/SequencingRNALevel1.csv new file mode 100644 index 00000000..ceec4582 --- /dev/null +++ b/templates/SequencingRNALevel1.csv @@ -0,0 +1,2 @@ +Component,SequencingRNALevel1_id,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,NGS Library Strategy,NGS Library Source Material,NGS Library Source Molecule,NGS Library Selection Method,NGS Library Layout,NGS Sequencing Platform,NGS Sequencing Design Description,NGS Read Length,NGS Raw Reads,NGS Unique Bases,NGS Sequencing Coverage,NGS Library Preparation Kit Name,NGS Library Preparation Kit Vendor,NGS Library Preparation Kit Version,NGS Read Indicator,NGS Library Preparation Days from Index,NGS Sequencing Library Construction Days from Index,NGS RNA End Bias,NGS RNA Reverse Transcription Primer,NGS RNA RIN,NGS RNA DV200 +SequencingRNALevel1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/VisiumAuxiliaryFiles.csv b/templates/VisiumAuxiliaryFiles.csv new file mode 100644 index 00000000..de7df9af --- /dev/null +++ b/templates/VisiumAuxiliaryFiles.csv @@ -0,0 +1,2 @@ +Component,10xVisiumAuxiliaryFiles_id,Filename,10xVisiumRNALevel1 Key,10xVisiumRNALevel2 Key,10xVisiumRNALevel3 Key,10xVisiumRNALevel4 Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Visium Run ID,Visium File Type,Visium Slide ID,Visium Capture Area,Workflow Version,Workflow Link +VisiumAuxiliaryFiles,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/VisiumRNALevel1.csv b/templates/VisiumRNALevel1.csv new file mode 100644 index 00000000..60170c5b --- /dev/null +++ b/templates/VisiumRNALevel1.csv @@ -0,0 +1,2 @@ +Component,10xVisiumRNALevel1_id,Filename,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Visium Run ID,NGS Read Indicator,Visium Spatial Read1,Visium Spatial Read2,Visium Spatial Library Construction Method,NGS Library Preparation Days from Index,NGS Sequencing Library Construction Days from Index,NGS RNA End Bias,NGS RNA Reverse Transcription Primer,NGS Sequencing Platform,Visium Capture Area,Image Protocol Link,Visium Slide Version,Visium Slide ID,Visium Image Re-orientation,Visium Permeabilization Time,NGS RNA RIN,NGS RNA DV200 +VisiumRNALevel1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/VisiumRNALevel2.csv b/templates/VisiumRNALevel2.csv new file mode 100644 index 00000000..ae94d629 --- /dev/null +++ b/templates/VisiumRNALevel2.csv @@ -0,0 +1,2 @@ +Component,10xVisiumRNALevel2_id,Filename,10xVisiumRNALevel1 Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Visium UMI Tag,Visium Whitelist Spatial Barcode File Link,Visium Spatial Barcode Tag,Visium Applied Hard Trimming,Workflow Version,Workflow Link,Genomic Reference,Genomic Reference URL,Genome Annotation URL,Visium Run ID,Visium Capture Area +VisiumRNALevel2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/VisiumRNALevel3.csv b/templates/VisiumRNALevel3.csv new file mode 100644 index 00000000..af1a8d9c --- /dev/null +++ b/templates/VisiumRNALevel3.csv @@ -0,0 +1,2 @@ +Component,10xVisiumRNALevel3_id,Filename,10xVisiumRNALevel2 Key,10xVisiumAuxiliaryFiles Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Visium Run ID,Visium File Type,Workflow Version,Workflow Link,Visium Capture Area,Visium Spots under tissue,Visium Mean Reads per Spatial Spot,Visium Median Number Genes per Spatial Spot,NGS Sequencing Coverage,Visium Proportion Reads Mapped,Visium Proportion Reads Mapped to Transcriptome,Visium Median UMI Counts per Spot +VisiumRNALevel3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, diff --git a/templates/VisiumRNALevel4.csv b/templates/VisiumRNALevel4.csv new file mode 100644 index 00000000..99dce924 --- /dev/null +++ b/templates/VisiumRNALevel4.csv @@ -0,0 +1,2 @@ +Component,10xVisiumRNALevel4_id,Filename,10xVisiumRNALevel3 Key,Biospecimen Key,Study Key,DatasetView Key,File Alias,File Description,File Design,File Level,File Assay,File Species,File Url,File Format,File Data Use Codes,File Longitudinal Group,File Longitudinal Event Type,File Longitudinal Sequence Identifier,File Longitudinal Time Elapsed Unit,File Longitudinal Total Time Elapsed,Visium Run ID,Workflow Version,Workflow Link,Visium Workflow Type,Visium Workflow Parameters Description +VisiumRNALevel4,,,,,,,,,,,,,,,,,,,,,,,,,